id,race,sex,age,bmi,treatment arm,adherence,serious adverse effect,bowel obstruction,bowel perforation,chemotherapy cycles,histology,performance status,KRAS biomarker,adverse effect: thrombosis,adverse effect: hypersensitivity,adverse effect: diarrhea,adverse effect: infection,adverse effect: infarction,target_label,linearized,summary
0,other,female,57,20.97,FOLFOX,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: other, sex: female, age: 57, bmi: 20.97, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 57-year-old female of a race categorized as ""other"" with a BMI of 20.97. She is undergoing treatment with the FOLFOX chemotherapy regimen and has completed 12 cycles. Her cancer histology is well-differentiated, and she has a fully active performance status. Additionally, her KRAS biomarker status is wild-type."
1,white,male,69,29.14,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 69, bmi: 29.14, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type",The patient is a 69-year-old white male with a BMI of 29.14. He is receiving treatment in the FOLFOX + Cetuximab treatment arm and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer cells. The patient has a fully active performance status and has a wild-type KRAS biomarker.
2,white,female,65,49.27,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 65, bmi: 49.27, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 65-year-old white female with a BMI of 49.27. She is receiving treatment in the FOLFOX + Cetuximab treatment arm and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cancer cells. Despite her age, she has a fully active performance status. Additionally, her KRAS biomarker status is wild-type."
3,white,male,44,31.57,FOLFOX,No,No,No,No,12,well differentiated,fully active,mutant,No,No,No,No,No,0,"race: white, sex: male, age: 44, bmi: 31.57, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 44-year-old white male with a BMI of 31.57. He is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cells, and his performance status is fully active. The KRAS biomarker analysis indicates a mutant status."
4,white,male,40,16.78,FOLFOX + Cetuximab,Yes,No,No,No,12,poorly differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 40, bmi: 16.78, treatment arm: FOLFOX + Cetuximab, adherence: Yes, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 40-year-old white male with a low BMI of 16.78. He is receiving treatment in the FOLFOX + Cetuximab treatment arm and has been adherent to the treatment. He has completed 12 cycles of chemotherapy. His histology shows poorly differentiated cancer cells. Despite this, his performance status is fully active. The KRAS biomarker analysis indicates that he has a wild-type KRAS status."
5,white,female,67,22.7,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,fully active,mutant,No,No,No,No,No,0,"race: white, sex: female, age: 67, bmi: 22.7, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant",The patient is a 67-year-old white female with a BMI of 22.7. She is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. The histology shows well-differentiated cancer cells. The patient has a fully active performance status. The KRAS biomarker indicates a mutant status.
6,white,male,64,26.04,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 64, bmi: 26.04, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 64-year-old white male with a BMI of 26.04. He is receiving treatment in the FOLFOX + Cetuximab treatment arm and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cells, and he has a fully active performance status. Additionally, his KRAS biomarker is wild-type."
7,white,male,35,26.56,FOLFIRI,No,No,No,No,12,well differentiated,fully active,mutant,No,No,No,No,No,0,"race: white, sex: male, age: 35, bmi: 26.56, treatment arm: FOLFIRI, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant",The patient is a 35-year-old white male with a BMI of 26.56. He is receiving the FOLFIRI treatment arm and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer cells. The patient has a fully active performance status. The KRAS biomarker analysis indicates a mutant status.
8,white,male,54,28.93,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,fully active,interminate,No,No,No,No,No,0,"race: white, sex: male, age: 54, bmi: 28.93, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: interminate","The patient is a 54-year-old white male with a BMI of 28.93. He is receiving treatment in the FOLFOX + Cetuximab treatment arm and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cells, and he has a fully active performance status. The KRAS biomarker status is indeterminate."
9,white,male,44,27.86,FOLFOX,No,No,No,No,5,well differentiated,symptoms but ambulatory,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 44, bmi: 27.86, treatment arm: FOLFOX, chemotherapy cycles: 5, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type","The patient is a 44-year-old white male with a BMI of 27.86. He is receiving the FOLFOX treatment regimen and has completed 5 cycles of chemotherapy. His histology shows well-differentiated cancer cells. Despite experiencing symptoms, he is still able to be ambulatory. The KRAS biomarker analysis indicates that he has a wild-type KRAS status."
10,white,female,76,25.24,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,fully active,mutant,No,No,No,No,No,0,"race: white, sex: female, age: 76, bmi: 25.24, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 76-year-old white female with a BMI of 25.24. She is receiving treatment in the FOLFOX + Cetuximab treatment arm and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cancer cells. Despite her age, she has a fully active performance status. The patient's KRAS biomarker indicates a mutant status."
11,white,female,72,35.44,FOLFOX,No,No,No,No,12,poorly differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 72, bmi: 35.44, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 72-year-old white female with a BMI of 35.44. She is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. Her histology shows poorly differentiated cancer cells. Despite her age, she has a fully active performance status. Additionally, her KRAS biomarker indicates that it is wild-type."
12,white,female,49,32.81,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,Yes,No,No,0,"race: white, sex: female, age: 49, bmi: 32.81, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type, adverse effect: diarrhea: Yes","The patient is a 49-year-old white female with a BMI of 32.81 who is receiving treatment with FOLFOX + Cetuximab. She has completed 12 cycles of chemotherapy. Her cancer histology is well-differentiated, and she has a fully active performance status. The KRAS biomarker testing showed that she has a wild-type KRAS status. She is experiencing diarrhea as an adverse effect of the treatment."
13,white,female,51,25.77,FOLFOX + Cetuximab,Yes,Yes,No,No,12,well differentiated,fully active,wild-type,Yes,No,Yes,No,No,1,"race: white, sex: female, age: 51, bmi: 25.77, treatment arm: FOLFOX + Cetuximab, adherence: Yes, serious adverse effect: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type, adverse effect: thrombosis: Yes, adverse effect: diarrhea: Yes","The patient is a 51-year-old white female with a BMI of 25.77. She is receiving treatment with FOLFOX + Cetuximab and has been adherent to the treatment. She experienced a serious adverse effect during the treatment, specifically thrombosis and diarrhea. She completed 12 cycles of chemotherapy. Her histology shows well-differentiated cells, and her performance status is fully active. Her KRAS biomarker is wild-type."
14,white,male,52,29.45,FOLFOX,No,No,No,Yes,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 52, bmi: 29.45, treatment arm: FOLFOX, bowel perforation: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 52-year-old white male with a BMI of 29.45. He is receiving the FOLFOX treatment arm for his condition. He has experienced a bowel perforation and has undergone 12 cycles of chemotherapy. The histology shows that the cancer is well-differentiated. Despite these challenges, the patient has a fully active performance status. Additionally, the KRAS biomarker indicates that he has a wild-type status."
15,white,female,65,26.25,FOLFOX + Cetuximab,No,No,No,No,12,poorly differentiated,fully active,mutant,No,No,No,No,No,0,"race: white, sex: female, age: 65, bmi: 26.25, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 65-year-old white female with a BMI of 26.25. She is receiving treatment with FOLFOX + Cetuximab and is scheduled for 12 chemotherapy cycles. Her cancer histology is poorly differentiated, and she has a fully active performance status. The KRAS biomarker testing revealed a mutant status."
16,white,male,64,30.26,FOLFOX,Yes,No,No,No,12,poorly differentiated,symptoms but ambulatory,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 64, bmi: 30.26, treatment arm: FOLFOX, adherence: Yes, chemotherapy cycles: 12, histology: poorly differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type","The patient is a 64-year-old white male with a BMI of 30.26. He is receiving treatment with the FOLFOX chemotherapy regimen and has been adherent to the treatment. He has completed 12 cycles of chemotherapy. The histology of his cancer is poorly differentiated. Despite experiencing symptoms, he is still able to be ambulatory. The KRAS biomarker testing revealed that he has a wild-type KRAS status."
17,white,female,76,26.14,FOLFOX + Cetuximab,No,No,No,No,12,poorly differentiated,fully active,mutant,No,No,No,No,No,0,"race: white, sex: female, age: 76, bmi: 26.14, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 76-year-old white female with a BMI of 26.14. She is receiving treatment in the FOLFOX + Cetuximab treatment arm and has completed 12 cycles of chemotherapy. Her histology shows poorly differentiated cancer cells. Despite her age, she has a fully active performance status. The KRAS biomarker analysis indicates a mutant status."
18,white,male,60,30.37,FOLFOX,No,No,No,No,12,poorly differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 60, bmi: 30.37, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 60-year-old white male with a BMI of 30.37. He is receiving the FOLFOX treatment arm and has completed 12 cycles of chemotherapy. His histology shows poorly differentiated cancer cells. Despite this, he has a fully active performance status. The KRAS biomarker analysis indicates that he has a wild-type KRAS status."
19,white,female,49,26.84,FOLFIRI (KRAS mutant),No,No,No,No,12,well differentiated,symptoms but ambulatory,mutant,No,No,No,No,No,0,"race: white, sex: female, age: 49, bmi: 26.84, treatment arm: FOLFIRI (KRAS mutant), chemotherapy cycles: 12, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: mutant","The patient is a 49-year-old white female with a BMI of 26.84. She is receiving treatment with the FOLFIRI regimen for KRAS mutant cancer. She has undergone 12 cycles of chemotherapy. The histology of her cancer is well-differentiated. Despite experiencing symptoms, she is still able to be ambulatory."
20,white,female,56,37.11,FOLFOX,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 56, bmi: 37.11, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 56-year-old white female with a BMI of 37.11. She is undergoing treatment with the FOLFOX chemotherapy regimen and has completed 12 cycles. Her cancer histology is well-differentiated, and she has a fully active performance status. The KRAS biomarker testing indicates that she has a wild-type KRAS status."
21,white,male,61,22.14,FOLFOX + Cetuximab,Yes,No,No,No,12,well differentiated,fully active,mutant,No,Yes,No,No,No,0,"race: white, sex: male, age: 61, bmi: 22.14, treatment arm: FOLFOX + Cetuximab, adherence: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant, adverse effect: hypersensitivity: Yes","The patient is a 61-year-old white male with a BMI of 22.14. He is receiving treatment with FOLFOX + Cetuximab and has been adherent to the treatment. He has completed 12 cycles of chemotherapy. His histology shows well-differentiated cells, and his performance status is fully active. The KRAS biomarker is mutant in this patient. He has experienced hypersensitivity as an adverse effect."
22,white,male,75,26.09,FOLFIRI,Yes,No,Yes,No,12,poorly differentiated,symptoms but ambulatory,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 75, bmi: 26.09, treatment arm: FOLFIRI, adherence: Yes, bowel obstruction: Yes, chemotherapy cycles: 12, histology: poorly differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type","The patient is a 75-year-old white male with a BMI of 26.09. He is receiving the FOLFIRI treatment regimen and has been adherent to the treatment. He is currently experiencing a bowel obstruction and has completed 12 cycles of chemotherapy. The histology shows poorly differentiated cancer cells. Despite experiencing symptoms, the patient is still able to ambulate. The KRAS biomarker indicates that the cancer is wild-type."
23,white,female,55,29.34,FOLFOX,No,No,No,No,12,well differentiated,fully active,wild-type,No,Yes,No,No,No,0,"race: white, sex: female, age: 55, bmi: 29.34, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type, adverse effect: hypersensitivity: Yes","The patient is a 55-year-old white female with a BMI of 29.34. She is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cells, and she has a fully active performance status. The KRAS biomarker indicates that she is wild-type. The patient has experienced a hypersensitivity adverse effect."
24,white,female,58,26.7,FOLFOX + Cetuximab,Yes,Yes,No,No,12,well differentiated,fully active,mutant,No,No,No,No,No,0,"race: white, sex: female, age: 58, bmi: 26.7, treatment arm: FOLFOX + Cetuximab, adherence: Yes, serious adverse effect: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 58-year-old white female with a BMI of 26.7. She is receiving treatment with FOLFOX + Cetuximab and has been adherent to the treatment. She experienced a serious adverse effect during the course of her 12 chemotherapy cycles. Her histology shows that the cancer is well-differentiated. Despite the adverse effect, her performance status remains fully active. The KRAS biomarker analysis revealed a mutant status."
25,white,male,60,30.91,FOLFIRI (KRAS mutant),No,Yes,No,No,12,poorly differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 60, bmi: 30.91, treatment arm: FOLFIRI (KRAS mutant), serious adverse effect: Yes, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 60-year-old white male with a BMI of 30.91. He is receiving the FOLFIRI treatment regimen for his KRAS mutant status. Unfortunately, he is experiencing a serious adverse effect. He has completed 12 cycles of chemotherapy. His histology shows poorly differentiated cells. Despite these challenges, his performance status is fully active. It is worth noting that his KRAS biomarker is wild-type."
26,white,male,72,23.57,FOLFOX,No,No,Yes,No,12,poorly differentiated,fully active,wild-type,No,No,No,No,No,1,"race: white, sex: male, age: 72, bmi: 23.57, treatment arm: FOLFOX, bowel obstruction: Yes, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 72-year-old white male with a BMI of 23.57. He is receiving the FOLFOX treatment regimen and has experienced a bowel obstruction. He has completed 12 cycles of chemotherapy. The histology of his cancer is poorly differentiated. Despite these challenges, his performance status is fully active. His KRAS biomarker status is wild-type."
27,white,female,43,37.75,FOLFOX + Cetuximab,Yes,Yes,No,No,12,well differentiated,symptoms but ambulatory,wild-type,No,No,No,Yes,No,0,"race: white, sex: female, age: 43, bmi: 37.75, treatment arm: FOLFOX + Cetuximab, adherence: Yes, serious adverse effect: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type, adverse effect: infection: Yes","The patient is a 43-year-old white female with a BMI of 37.75 who is undergoing treatment with FOLFOX + Cetuximab. She has been adherent to her treatment and has completed 12 cycles of chemotherapy. The patient's histology shows well-differentiated cancer, and she has a performance status of experiencing symptoms but still able to be ambulatory. Her KRAS biomarker is wild-type. The patient has experienced a serious adverse effect in the form of an infection."
28,white,female,42,39.62,FOLFOX,No,Yes,No,No,12,well differentiated,symptoms but ambulatory,wild-type,No,No,Yes,No,No,0,"race: white, sex: female, age: 42, bmi: 39.62, treatment arm: FOLFOX, serious adverse effect: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type, adverse effect: diarrhea: Yes","The patient is a 42-year-old white female with a BMI of 39.62 who is receiving the FOLFOX treatment regimen. She has experienced a serious adverse effect during her chemotherapy cycles, which total 12. Her histology shows well-differentiated cells, and her performance status indicates that she has symptoms but is still ambulatory. The KRAS biomarker testing revealed that she has a wild-type KRAS status. Additionally, she has experienced diarrhea as an adverse effect of the treatment."
29,white,male,49,22.12,FOLFOX,No,No,Yes,No,12,well differentiated,fully active,mutant,No,No,No,No,No,0,"race: white, sex: male, age: 49, bmi: 22.12, treatment arm: FOLFOX, bowel obstruction: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant",The patient is a 49-year-old white male with a BMI of 22.12. He is receiving the FOLFOX treatment regimen and has experienced a bowel obstruction. He has completed 12 cycles of chemotherapy. The histology shows well-differentiated cancer cells. The patient has a fully active performance status. The KRAS biomarker indicates a mutant status.
30,white,male,72,27.55,FOLFOX + Cetuximab,No,No,No,No,12,poorly differentiated,fully active,wild-type,No,No,No,No,No,1,"race: white, sex: male, age: 72, bmi: 27.55, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 72-year-old white male with a BMI of 27.55. He is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. His cancer histology is poorly differentiated. Despite his age, he has a fully active performance status. The KRAS biomarker testing revealed that he has a wild-type KRAS status."
31,white,male,62,24.59,FOLFOX + Cetuximab,No,Yes,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 62, bmi: 24.59, treatment arm: FOLFOX + Cetuximab, serious adverse effect: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 62-year-old white male with a BMI of 24.59. He is receiving treatment with FOLFOX + Cetuximab and has experienced a serious adverse effect. He has completed 12 cycles of chemotherapy. His histology shows well-differentiated cells, and his performance status is fully active. The KRAS biomarker indicates that he has a wild-type gene."
32,white,female,37,20.57,FOLFOX + Cetuximab,Yes,No,Yes,No,12,well differentiated,symptoms but ambulatory,mutant,No,No,No,No,No,1,"race: white, sex: female, age: 37, bmi: 20.57, treatment arm: FOLFOX + Cetuximab, adherence: Yes, bowel obstruction: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: mutant","The patient is a 37-year-old white female with a BMI of 20.57. She is receiving treatment with FOLFOX + Cetuximab and has been adherent to the treatment. She has experienced a bowel obstruction and has completed 12 cycles of chemotherapy. The histology shows well-differentiated cells. Despite experiencing symptoms, she is still able to be ambulatory. The KRAS biomarker indicates a mutant status."
33,white,male,58,24.78,FOLFOX,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 58, bmi: 24.78, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 58-year-old white male with a BMI of 24.78. He is undergoing treatment with the FOLFOX chemotherapy regimen and has completed 12 cycles. His cancer histology is well-differentiated, and he has a fully active performance status. The KRAS biomarker testing revealed that he has a wild-type KRAS status."
34,white,male,60,32.72,FOLFOX,Yes,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 60, bmi: 32.72, treatment arm: FOLFOX, adherence: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type",The patient is a 60-year-old white male with a BMI of 32.72. He is receiving the FOLFOX treatment regimen and has been adherent to the treatment. He has completed 12 cycles of chemotherapy. The histology shows well-differentiated cancer cells. The patient has a fully active performance status. His KRAS biomarker status is wild-type.
35,white,female,47,19.96,FOLFOX,No,No,No,No,2,well differentiated,fully active,mutant,No,No,No,No,No,0,"race: white, sex: female, age: 47, bmi: 19.96, treatment arm: FOLFOX, chemotherapy cycles: 2, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 47-year-old white female with a BMI of 19.96. She is receiving the FOLFOX treatment regimen and has completed 2 cycles of chemotherapy. Her cancer histology is well-differentiated, and she has a fully active performance status. The KRAS biomarker testing revealed a mutant status."
36,white,female,41,23.29,FOLFOX,No,No,No,No,9,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 41, bmi: 23.29, treatment arm: FOLFOX, chemotherapy cycles: 9, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type",The patient is a 41-year-old white female with a BMI of 23.29. She is receiving treatment in the FOLFOX chemotherapy arm and has completed 9 cycles of chemotherapy. The histology of her cancer is well-differentiated. She has a fully active performance status. The KRAS biomarker testing indicates that she has a wild-type KRAS status.
37,white,male,43,36.1,FOLFOX,No,No,No,No,12,well differentiated,symptoms but ambulatory,wild-type,No,No,Yes,No,No,1,"race: white, sex: male, age: 43, bmi: 36.1, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type, adverse effect: diarrhea: Yes","The patient is a 43-year-old white male with a BMI of 36.1 who is receiving the FOLFOX treatment regimen for 12 chemotherapy cycles. His cancer histology is well differentiated, and he has symptoms but is still ambulatory. The KRAS biomarker shows that he is wild-type. The patient is experiencing diarrhea as an adverse effect of the treatment."
38,white,male,56,28.54,FOLFOX,No,Yes,No,No,12,well differentiated,fully active,mutant,No,No,No,No,No,0,"race: white, sex: male, age: 56, bmi: 28.54, treatment arm: FOLFOX, serious adverse effect: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 56-year-old white male with a BMI of 28.54. He is undergoing treatment with the FOLFOX chemotherapy regimen and has experienced a serious adverse effect. He has completed 12 cycles of chemotherapy. The histology of his cancer is well-differentiated. Despite the adverse effect, his performance status is fully active. The patient's KRAS biomarker status is mutant."
39,white,female,71,26.27,FOLFOX + Cetuximab,No,No,No,No,12,poorly differentiated,symptoms but ambulatory,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 71, bmi: 26.27, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: poorly differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type","The patient is a 71-year-old white female with a BMI of 26.27. She is receiving treatment in the FOLFOX + Cetuximab treatment arm and has completed 12 cycles of chemotherapy. Her histology shows poorly differentiated cancer cells. Despite experiencing symptoms, she is still able to be ambulatory. Additionally, her KRAS biomarker indicates that it is wild-type."
40,white,female,62,34.49,FOLFOX,No,No,No,No,12,well differentiated,symptoms but ambulatory,mutant,No,No,No,No,No,0,"race: white, sex: female, age: 62, bmi: 34.49, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: mutant","The patient is a 62-year-old white female with a BMI of 34.49. She is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cancer cells. Despite experiencing symptoms, she is still able to be ambulatory. The KRAS biomarker analysis indicates a mutant status."
41,white,male,60,19.24,FOLFOX + Cetuximab,No,No,Yes,No,12,poorly differentiated,fully active,mutant,No,No,No,No,No,0,"race: white, sex: male, age: 60, bmi: 19.24, treatment arm: FOLFOX + Cetuximab, bowel obstruction: Yes, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 60-year-old white male with a BMI of 19.24. He is receiving treatment in the FOLFOX + Cetuximab treatment arm. He has a bowel obstruction and has completed 12 cycles of chemotherapy. The histology shows poorly differentiated cancer cells. Despite these challenges, his performance status is fully active. The KRAS biomarker indicates a mutant status."
42,white,female,51,28.37,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,Yes,No,No,0,"race: white, sex: female, age: 51, bmi: 28.37, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type, adverse effect: diarrhea: Yes","The patient is a 51-year-old white female with a BMI of 28.37. She is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cancer, and she has a fully active performance status. The KRAS biomarker indicates that she is wild-type. The patient is experiencing diarrhea as an adverse effect of the treatment."
43,white,male,40,24.13,FOLFOX,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 40, bmi: 24.13, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 40-year-old white male with a BMI of 24.13. He is receiving the FOLFOX treatment arm for his cancer, with a planned 12 cycles of chemotherapy. His cancer histology is well-differentiated, and he has a fully active performance status. The KRAS biomarker testing showed that he has a wild-type KRAS status."
44,white,female,47,37.04,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 47, bmi: 37.04, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type",The patient is a 47-year-old white female with a BMI of 37.04. She is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cancer cells. The patient has a fully active performance status. Her KRAS biomarker is wild-type.
45,white,male,76,27.89,FOLFOX + Cetuximab,No,Yes,No,No,9,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 76, bmi: 27.89, treatment arm: FOLFOX + Cetuximab, serious adverse effect: Yes, chemotherapy cycles: 9, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","This patient is a 76-year-old white male with a BMI of 27.89. He is receiving treatment with FOLFOX + Cetuximab and has experienced a serious adverse effect. He has completed 9 cycles of chemotherapy. His histology shows well-differentiated cancer cells. Despite his age, he has a fully active performance status. Additionally, his KRAS biomarker status is wild-type."
46,white,male,34,25.52,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,fully active,mutant,No,No,No,No,No,0,"race: white, sex: male, age: 34, bmi: 25.52, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant",The patient is a 34-year-old white male with a BMI of 25.52. He is receiving treatment in the FOLFOX + Cetuximab treatment arm and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer cells. The patient has a fully active performance status. The KRAS biomarker analysis indicates a mutant status.
47,white,male,42,25.94,FOLFOX + Cetuximab,No,No,Yes,No,12,well differentiated,fully active,mutant,No,No,No,No,No,0,"race: white, sex: male, age: 42, bmi: 25.94, treatment arm: FOLFOX + Cetuximab, bowel obstruction: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 42-year-old white male with a BMI of 25.94. He is receiving treatment with FOLFOX + Cetuximab for his well-differentiated histology. He has experienced a bowel obstruction and has completed 12 cycles of chemotherapy. Despite the bowel obstruction, his performance status is fully active. Additionally, the KRAS biomarker testing revealed a mutant status."
48,white,female,56,35,FOLFOX + Cetuximab,No,No,No,No,7,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 56, bmi: 35.0, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 7, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 56-year-old white female with a BMI of 35.0. She is currently receiving treatment with FOLFOX + Cetuximab and has completed 7 cycles of chemotherapy. Her cancer histology is well-differentiated, and she has a fully active performance status. The KRAS biomarker testing showed that she has a wild-type KRAS status."
49,white,male,61,28.28,FOLFOX,No,No,No,No,12,well differentiated,fully active,mutant,No,No,No,No,No,0,"race: white, sex: male, age: 61, bmi: 28.28, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant",The patient is a 61-year-old white male with a BMI of 28.28. He is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. His cancer histology is well differentiated. The patient has a fully active performance status. The KRAS biomarker testing revealed a mutant result.
50,black,female,51,22.04,FOLFOX + Cetuximab,No,No,Yes,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: black, sex: female, age: 51, bmi: 22.04, treatment arm: FOLFOX + Cetuximab, bowel obstruction: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 51-year-old Black female with a BMI of 22.04. She is receiving treatment with FOLFOX + Cetuximab for her condition. She has experienced a bowel obstruction and has completed 12 cycles of chemotherapy. Her histology shows that the cancer is well-differentiated. Despite the challenges, her performance status is fully active. Additionally, her KRAS biomarker indicates that it is wild-type."
51,white,female,66,32.41,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,fully active,mutant,No,No,No,No,No,0,"race: white, sex: female, age: 66, bmi: 32.41, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 66-year-old white female with a BMI of 32.41. She is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cancer cells. Despite her age, she has a fully active performance status. The KRAS biomarker analysis revealed a mutant status."
52,white,female,61,34.48,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,symptoms but ambulatory,wild-type,No,No,No,No,No,1,"race: white, sex: female, age: 61, bmi: 34.48, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type","The patient is a 61-year-old white female with a BMI of 34.48. She is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. The histology shows well-differentiated cells. Despite experiencing symptoms, the patient is still able to walk around (ambulatory). The KRAS biomarker indicates that the patient has a wild-type KRAS gene."
53,white,male,67,33.38,FOLFOX + Cetuximab,No,No,No,No,12,poorly differentiated,fully active,mutant,No,No,No,No,No,0,"race: white, sex: male, age: 67, bmi: 33.38, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 67-year-old white male with a BMI of 33.38. He is receiving treatment in the FOLFOX + Cetuximab treatment arm and has completed 12 cycles of chemotherapy. His histology shows poorly differentiated cancer cells. Despite this, his performance status is fully active. The KRAS biomarker analysis indicates a mutant status."
54,white,female,57,23.95,FOLFOX + Cetuximab,No,Yes,No,No,12,poorly differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 57, bmi: 23.95, treatment arm: FOLFOX + Cetuximab, serious adverse effect: Yes, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 57-year-old white female with a BMI of 23.95. She is receiving treatment with FOLFOX + Cetuximab and has experienced a serious adverse effect. She has completed 12 cycles of chemotherapy. The histology of her cancer is poorly differentiated. Despite this, her performance status is fully active. Additionally, her KRAS biomarker is wild-type."
55,white,male,47,29.24,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,fully active,mutant,No,No,No,No,No,0,"race: white, sex: male, age: 47, bmi: 29.24, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 47-year-old white male with a BMI of 29.24. He is receiving treatment in the FOLFOX + Cetuximab treatment arm and is scheduled for 12 chemotherapy cycles. His histology shows well-differentiated cells, and he has a fully active performance status. The KRAS biomarker analysis indicates a mutant status."
56,other,female,34,26.38,FOLFOX + Cetuximab,No,No,Yes,No,1,well differentiated,in bed less than 50% of the time,wild-type,No,No,Yes,No,No,0,"race: other, sex: female, age: 34, bmi: 26.38, treatment arm: FOLFOX + Cetuximab, bowel obstruction: Yes, chemotherapy cycles: 1, histology: well differentiated, performance status: in bed less than 50% of the time, KRAS biomarker: wild-type, adverse effect: diarrhea: Yes","The patient is a 34-year-old female of a race categorized as ""other"" with a BMI of 26.38. She is currently receiving treatment in the FOLFOX + Cetuximab treatment arm. The patient is experiencing a bowel obstruction and has completed one cycle of chemotherapy. Histologically, the patient's cancer is well-differentiated. Her performance status indicates that she is in bed less than 50% of the time. The KRAS biomarker analysis shows that she has a wild-type KRAS status. Additionally, the patient is experiencing diarrhea as an adverse effect."
57,white,female,50,26.2,FOLFOX + Cetuximab,No,No,No,No,2,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 50, bmi: 26.2, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 2, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 50-year-old white female with a BMI of 26.2. She is currently receiving treatment in the FOLFOX + Cetuximab treatment arm and has completed 2 cycles of chemotherapy. Her histology shows well-differentiated cancer cells. Despite her cancer diagnosis, she has a fully active performance status. Additionally, her KRAS biomarker indicates that it is wild-type."
58,white,female,65,24.24,FOLFOX,No,Yes,No,No,12,well differentiated,symptoms but ambulatory,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 65, bmi: 24.24, treatment arm: FOLFOX, serious adverse effect: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type","The patient is a 65-year-old white female with a BMI of 24.24. She is receiving the FOLFOX treatment arm and has experienced a serious adverse effect. She has completed 12 cycles of chemotherapy. The histology shows that the cancer is well-differentiated. Despite experiencing symptoms, she is still able to be ambulatory. The KRAS biomarker indicates that she has a wild-type status."
59,white,female,37,32.9,FOLFOX,No,No,No,No,12,well differentiated,fully active,mutant,No,No,No,No,No,0,"race: white, sex: female, age: 37, bmi: 32.9, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 37-year-old white female with a BMI of 32.9. She is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. Her cancer histology is well-differentiated. Despite her cancer diagnosis, she has a fully active performance status. The KRAS biomarker testing revealed a mutation in the KRAS gene."
60,white,female,42,22.79,FOLFOX + Cetuximab,No,No,No,No,12,poorly differentiated,symptoms but ambulatory,wild-type,No,No,Yes,No,No,0,"race: white, sex: female, age: 42, bmi: 22.79, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: poorly differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type, adverse effect: diarrhea: Yes","The patient is a 42-year-old white female with a BMI of 22.79. She is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. Her cancer histology is poorly differentiated. Despite experiencing symptoms, she is still able to be ambulatory. The KRAS biomarker testing showed that she has a wild-type result. The patient is experiencing diarrhea as an adverse effect of the treatment."
61,white,male,60,36.8,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,fully active,wild-type,No,Yes,Yes,No,No,0,"race: white, sex: male, age: 60, bmi: 36.8, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type, adverse effect: hypersensitivity: Yes, adverse effect: diarrhea: Yes","The patient is a 60-year-old white male with a BMI of 36.8. He is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. His cancer histology is well-differentiated, and he has a fully active performance status. The KRAS biomarker shows that he is wild-type. The patient has experienced hypersensitivity and diarrhea as adverse effects during treatment."
62,white,female,43,20.41,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,Yes,No,0,"race: white, sex: female, age: 43, bmi: 20.41, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type, adverse effect: infection: Yes","The patient is a 43-year-old white female with a BMI of 20.41. She is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cells, and she has a fully active performance status. The KRAS biomarker indicates she has a wild-type status. The patient has experienced an infection as an adverse effect during her treatment."
63,white,male,72,27.02,FOLFOX + Cetuximab,No,No,Yes,No,10,well differentiated,symptoms but ambulatory,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 72, bmi: 27.02, treatment arm: FOLFOX + Cetuximab, bowel obstruction: Yes, chemotherapy cycles: 10, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type","The patient is a 72-year-old white male with a BMI of 27.02. He is receiving treatment in the FOLFOX + Cetuximab treatment arm. He has a bowel obstruction and has completed 10 cycles of chemotherapy. The histology shows well-differentiated cells. Despite experiencing symptoms, the patient is still able to be ambulatory. His KRAS biomarker is wild-type."
64,white,female,55,33.77,FOLFOX,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 55, bmi: 33.77, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type",The patient is a 55-year-old white female with a BMI of 33.77. She is receiving treatment with the FOLFOX regimen and has completed 12 cycles of chemotherapy. The histology of her cancer is well-differentiated. She has a fully active performance status. The KRAS biomarker testing showed that she has a wild-type KRAS status.
65,white,female,49,33.87,FOLFOX,No,Yes,No,No,12,well differentiated,fully active,mutant,No,Yes,Yes,No,No,0,"race: white, sex: female, age: 49, bmi: 33.87, treatment arm: FOLFOX, serious adverse effect: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant, adverse effect: hypersensitivity: Yes, adverse effect: diarrhea: Yes","The patient is a 49-year-old white female with a BMI of 33.87 who is receiving the FOLFOX treatment regimen. She has experienced a serious adverse effect during her 12 chemotherapy cycles. Her histology shows well-differentiated cells, and she has a fully active performance status. The patient's KRAS biomarker is mutant. She has also experienced adverse effects including hypersensitivity and diarrhea."
66,black,female,52,33.32,FOLFOX,No,No,No,No,12,well differentiated,symptoms but ambulatory,mutant,No,No,Yes,No,No,0,"race: black, sex: female, age: 52, bmi: 33.32, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: mutant, adverse effect: diarrhea: Yes","The patient is a 52-year-old Black female with a BMI of 33.32 who is undergoing treatment with the FOLFOX chemotherapy regimen. She has completed 12 cycles of chemotherapy and has well-differentiated histology. Despite experiencing symptoms, she is still able to be ambulatory. The KRAS biomarker testing showed a mutant result. The patient is experiencing diarrhea as an adverse effect of the treatment."
67,white,female,64,23.06,FOLFIRI + Cetuximab,No,No,No,No,11,well differentiated,fully active,interminate,No,No,No,No,No,1,"race: white, sex: female, age: 64, bmi: 23.06, treatment arm: FOLFIRI + Cetuximab, chemotherapy cycles: 11, histology: well differentiated, performance status: fully active, KRAS biomarker: interminate","The patient is a 64-year-old white female with a BMI of 23.06. She is currently receiving treatment in the FOLFIRI + Cetuximab treatment arm and has completed 11 cycles of chemotherapy. Her histology shows well-differentiated cancer cells. Despite her cancer diagnosis, she maintains a fully active performance status. The KRAS biomarker status is indeterminate for this patient."
68,white,male,69,35.19,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,symptoms but ambulatory,mutant,No,No,Yes,No,No,1,"race: white, sex: male, age: 69, bmi: 35.19, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: mutant, adverse effect: diarrhea: Yes","The patient is a 69-year-old white male with a BMI of 35.19. He is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer. Despite experiencing symptoms, he is still able to ambulate. The KRAS biomarker testing revealed a mutant status. The patient is experiencing diarrhea as an adverse effect of the treatment."
69,white,male,75,28.52,FOLFOX,No,No,No,No,8,well differentiated,fully active,interminate,No,No,No,No,No,0,"race: white, sex: male, age: 75, bmi: 28.52, treatment arm: FOLFOX, chemotherapy cycles: 8, histology: well differentiated, performance status: fully active, KRAS biomarker: interminate",The patient is a 75-year-old white male with a BMI of 28.52. He is receiving the FOLFOX treatment regimen and has completed 8 cycles of chemotherapy. His histology shows well-differentiated cancer cells. The patient has a fully active performance status. The KRAS biomarker status is indeterminate.
70,white,male,73,31.14,FOLFIRI,No,No,No,No,5,well differentiated,symptoms but ambulatory,mutant,No,No,Yes,No,No,0,"race: white, sex: male, age: 73, bmi: 31.14, treatment arm: FOLFIRI, chemotherapy cycles: 5, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: mutant, adverse effect: diarrhea: Yes","The patient is a 73-year-old white male with a BMI of 31.14. He is currently receiving the FOLFIRI treatment regimen and has completed 5 cycles of chemotherapy. His histology shows well-differentiated cancer cells. Despite experiencing symptoms, he is still able to ambulate. The KRAS biomarker testing revealed a mutant status. The patient is experiencing diarrhea as an adverse effect of the treatment."
71,white,female,50,24.49,FOLFOX + Cetuximab,No,Yes,No,No,10,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 50, bmi: 24.49, treatment arm: FOLFOX + Cetuximab, serious adverse effect: Yes, chemotherapy cycles: 10, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 50-year-old white female with a BMI of 24.49. She is receiving treatment with FOLFOX + Cetuximab and has experienced a serious adverse effect. She has completed 10 cycles of chemotherapy. Her histology shows that the cancer is well-differentiated. Despite undergoing treatment, her performance status is fully active. Additionally, her KRAS biomarker indicates that it is wild-type."
72,white,male,58,19.08,FOLFOX,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 58, bmi: 19.08, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type",The patient is a 58-year-old white male with a BMI of 19.08. He is receiving treatment with the FOLFOX chemotherapy regimen and has completed 12 cycles. The histology shows well-differentiated cancer cells. The patient has a fully active performance status and the KRAS biomarker is wild-type.
73,white,male,45,27.87,FOLFOX,No,No,No,No,12,well differentiated,fully active,mutant,No,No,No,No,No,0,"race: white, sex: male, age: 45, bmi: 27.87, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 45-year-old white male with a BMI of 27.87. He is undergoing treatment with the FOLFOX chemotherapy regimen and is scheduled for 12 cycles. The histology of his cancer is well-differentiated. Despite his diagnosis, he has a fully active performance status. Additionally, the KRAS biomarker testing revealed a mutant status."
74,other,female,59,25.96,FOLFOX + Cetuximab,Yes,No,Yes,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: other, sex: female, age: 59, bmi: 25.96, treatment arm: FOLFOX + Cetuximab, adherence: Yes, bowel obstruction: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 59-year-old female of a race categorized as ""other"" with a BMI of 25.96. She is currently undergoing treatment in the FOLFOX + Cetuximab treatment arm and has been adherent to her treatment regimen. She has experienced a bowel obstruction and has completed 12 cycles of chemotherapy. The histology of her cancer is well-differentiated, and her performance status is fully active. Additionally, her KRAS biomarker status is wild-type."
75,black,female,38,29.68,FOLFOX,No,No,No,No,12,poorly differentiated,fully active,wild-type,No,No,No,No,No,0,"race: black, sex: female, age: 38, bmi: 29.68, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 38-year-old Black female with a BMI of 29.68. She is receiving the FOLFOX treatment regimen and is scheduled for 12 chemotherapy cycles. Her histology shows poorly differentiated cells. Despite this, her performance status is fully active. Additionally, her KRAS biomarker indicates that it is wild-type."
76,other,female,52,26.76,FOLFOX,No,No,No,No,12,well differentiated,symptoms but ambulatory,mutant,No,No,No,No,No,0,"race: other, sex: female, age: 52, bmi: 26.76, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: mutant","The patient is a 52-year-old female of a race categorized as ""other"" with a BMI of 26.76. She is undergoing treatment with the FOLFOX chemotherapy regimen and has completed 12 cycles. The histology of her cancer is well-differentiated. Despite experiencing symptoms, she is still able to ambulate. The KRAS biomarker testing revealed a mutation in the patient."
77,other,male,50,23.78,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,symptoms but ambulatory,wild-type,No,No,No,No,No,0,"race: other, sex: male, age: 50, bmi: 23.78, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type","The patient is a 50-year-old male of a race categorized as ""other"" with a BMI of 23.78. He is receiving treatment in the FOLFOX + Cetuximab treatment arm and is scheduled for 12 chemotherapy cycles. The histology indicates well-differentiated cancer. Despite experiencing symptoms, the patient is still able to be ambulatory. Additionally, the KRAS biomarker shows that it is wild-type."
78,white,male,54,31.9,FOLFOX,No,No,No,No,11,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 54, bmi: 31.9, treatment arm: FOLFOX, chemotherapy cycles: 11, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type",The patient is a 54-year-old white male with a BMI of 31.9. He is receiving treatment with the FOLFOX chemotherapy regimen and has completed 11 cycles so far. The histology of his cancer is well-differentiated. He has a fully active performance status. The KRAS biomarker testing showed that he has a wild-type KRAS status.
79,white,male,67,25.86,FOLFOX,No,No,No,No,12,well differentiated,symptoms but ambulatory,mutant,No,No,No,No,No,0,"race: white, sex: male, age: 67, bmi: 25.86, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: mutant","The patient is a 67-year-old white male with a BMI of 25.86. He is receiving treatment with the FOLFOX regimen and has completed 12 cycles of chemotherapy. His cancer histology is well differentiated. Despite experiencing symptoms, he is still able to walk around (ambulatory). The KRAS biomarker analysis shows a mutation in the KRAS gene."
80,white,female,46,25.8,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,fully active,mutant,No,Yes,Yes,No,No,0,"race: white, sex: female, age: 46, bmi: 25.8, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant, adverse effect: hypersensitivity: Yes, adverse effect: diarrhea: Yes","The patient is a 46-year-old white female with a BMI of 25.8. She is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. Her cancer histology is well-differentiated, and she has a fully active performance status. The KRAS biomarker testing showed a mutant result. She has experienced adverse effects of hypersensitivity and diarrhea during her treatment."
81,white,male,58,26.19,FOLFOX,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 58, bmi: 26.19, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 58-year-old white male with a BMI of 26.19. He is undergoing treatment with the FOLFOX chemotherapy regimen and has completed 12 cycles. The histology shows that the cancer is well-differentiated. The patient has a fully active performance status, and the KRAS biomarker indicates that it is wild-type."
82,white,female,58,32.41,FOLFOX + Cetuximab,No,No,No,No,5,well differentiated,fully active,wild-type,No,No,No,Yes,No,0,"race: white, sex: female, age: 58, bmi: 32.41, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 5, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type, adverse effect: infection: Yes","The patient is a 58-year-old white female with a BMI of 32.41. She is receiving treatment with FOLFOX + Cetuximab and has completed 5 cycles of chemotherapy. Her histology shows well-differentiated cells, and she has a fully active performance status. The KRAS biomarker analysis indicates that she has a wild-type KRAS status. The patient has experienced an infection as an adverse effect during her treatment."
83,white,male,65,39.12,FOLFOX,No,No,No,No,1,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 65, bmi: 39.12, treatment arm: FOLFOX, chemotherapy cycles: 1, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 65-year-old white male with a BMI of 39.12. He is receiving treatment with the FOLFOX chemotherapy regimen and has completed one cycle so far. His cancer histology is well-differentiated. Despite his age, he has a fully active performance status. Additionally, his KRAS biomarker status is wild-type."
84,white,male,59,27.46,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 59, bmi: 27.46, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type",The patient is a 59-year-old white male with a BMI of 27.46. He is receiving treatment in the FOLFOX + Cetuximab treatment arm and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer cells. The patient has a fully active performance status and his KRAS biomarker is wild-type.
85,white,male,42,28.22,FOLFOX,Yes,No,No,No,12,well differentiated,fully active,mutant,No,No,No,No,No,0,"race: white, sex: male, age: 42, bmi: 28.22, treatment arm: FOLFOX, adherence: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 42-year-old white male with a BMI of 28.22. He is receiving treatment in the FOLFOX arm and has been adherent to the chemotherapy regimen for 12 cycles. His histology shows well-differentiated cancer, and he has a fully active performance status. The KRAS biomarker analysis indicates a mutant status."
86,white,male,44,35.79,FOLFOX,No,No,No,No,12,well differentiated,symptoms but ambulatory,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 44, bmi: 35.79, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type","The patient is a 44-year-old white male with a BMI of 35.79. He is receiving the FOLFOX treatment arm and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cells. Despite experiencing symptoms, he is still able to walk around (ambulatory). His KRAS biomarker is wild-type."
87,white,male,62,32.66,FOLFOX + Cetuximab,Yes,No,No,No,10,poorly differentiated,symptoms but ambulatory,wild-type,No,No,No,Yes,No,0,"race: white, sex: male, age: 62, bmi: 32.66, treatment arm: FOLFOX + Cetuximab, adherence: Yes, chemotherapy cycles: 10, histology: poorly differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type, adverse effect: infection: Yes","The patient is a 62-year-old white male with a BMI of 32.66 who is receiving treatment with FOLFOX + Cetuximab. He has been adherent to his treatment and has completed 10 chemotherapy cycles. His histology shows poorly differentiated cancer cells. Despite experiencing symptoms, he is still able to be ambulatory. His KRAS biomarker is wild-type. The patient has developed an infection as an adverse effect of the treatment."
88,white,female,70,19.17,FOLFIRI (KRAS mutant),No,No,Yes,No,12,well differentiated,symptoms but ambulatory,mutant,No,No,No,No,No,0,"race: white, sex: female, age: 70, bmi: 19.17, treatment arm: FOLFIRI (KRAS mutant), bowel obstruction: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: mutant","The patient is a 70-year-old white female with a BMI of 19.17. She is receiving treatment with the FOLFIRI regimen for her KRAS mutant status. She has a bowel obstruction and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cells. Despite experiencing symptoms, she is still able to be ambulatory."
89,white,male,45,31.56,FOLFOX + Cetuximab,No,No,No,No,12,poorly differentiated,fully active,wild-type,No,Yes,No,No,No,0,"race: white, sex: male, age: 45, bmi: 31.56, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type, adverse effect: hypersensitivity: Yes","The patient is a 45-year-old white male with a BMI of 31.56. He is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. His cancer histology is poorly differentiated, and he has a fully active performance status. The KRAS biomarker testing showed that he has a wild-type KRAS status. The patient has experienced a hypersensitivity adverse effect during treatment."
90,white,male,60,25.21,FOLFOX,No,Yes,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 60, bmi: 25.21, treatment arm: FOLFOX, serious adverse effect: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","This patient is a 60-year-old white male with a BMI of 25.21. He is receiving the FOLFOX treatment regimen and has experienced a serious adverse effect. He has completed 12 cycles of chemotherapy. The histology shows that the cancer is well differentiated. Despite the treatment, his performance status is fully active. Additionally, the KRAS biomarker indicates that he has a wild-type mutation."
91,white,female,42,36.04,FOLFOX + Cetuximab,Yes,No,No,No,12,poorly differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 42, bmi: 36.04, treatment arm: FOLFOX + Cetuximab, adherence: Yes, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 42-year-old white female with a BMI of 36.04. She is receiving treatment with FOLFOX + Cetuximab and has been adherent to the treatment. She has completed 12 cycles of chemotherapy. The histology of her cancer is poorly differentiated. Despite this, her performance status is fully active. Her KRAS biomarker status is wild-type."
92,white,male,44,36.72,FOLFOX + Cetuximab,Yes,No,No,No,12,poorly differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 44, bmi: 36.72, treatment arm: FOLFOX + Cetuximab, adherence: Yes, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 44-year-old white male with a BMI of 36.72. He is receiving treatment in the FOLFOX + Cetuximab treatment arm and has been adherent to the treatment. He has completed 12 cycles of chemotherapy. His histology shows poorly differentiated cells. Despite this, his performance status is fully active. The KRAS biomarker analysis indicates that he has a wild-type KRAS status."
93,white,female,34,22.98,FOLFOX,Yes,No,No,No,12,poorly differentiated,fully active,mutant,No,No,No,No,No,0,"race: white, sex: female, age: 34, bmi: 22.98, treatment arm: FOLFOX, adherence: Yes, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 34-year-old white female with a BMI of 22.98. She is receiving the FOLFOX treatment regimen and has been adherent to her chemotherapy. She has completed 12 cycles of chemotherapy. Her histology shows poorly differentiated cancer cells. Despite this, her performance status is fully active. Additionally, she has a mutant KRAS biomarker."
94,white,female,65,22.86,FOLFOX + Cetuximab,Yes,No,No,No,12,poorly differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 65, bmi: 22.86, treatment arm: FOLFOX + Cetuximab, adherence: Yes, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 65-year-old white female with a BMI of 22.86. She is receiving treatment in the FOLFOX + Cetuximab treatment arm and has been adherent to her chemotherapy regimen, completing 12 cycles. Her histology shows poorly differentiated cancer cells, and she has a fully active performance status. Additionally, her KRAS biomarker indicates that she has a wild-type mutation."
95,white,male,63,31.28,FOLFOX,Yes,No,No,Yes,12,well differentiated,fully active,mutant,No,No,No,No,No,1,"race: white, sex: male, age: 63, bmi: 31.28, treatment arm: FOLFOX, adherence: Yes, bowel perforation: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 63-year-old white male with a BMI of 31.28. He is receiving treatment in the FOLFOX treatment arm and has been adherent to the prescribed regimen. The patient has experienced a bowel perforation and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cells, and he has a fully active performance status. The KRAS biomarker analysis indicates a mutant status."
96,white,female,43,27.6,FOLFOX,No,No,No,No,12,well differentiated,fully active,mutant,No,No,Yes,Yes,No,0,"race: white, sex: female, age: 43, bmi: 27.6, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant, adverse effect: diarrhea: Yes, adverse effect: infection: Yes","The patient is a 43-year-old white female with a BMI of 27.6. She is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cancer cells. Despite experiencing adverse effects such as diarrhea and infection, her performance status is fully active. Additionally, the KRAS biomarker testing revealed a mutant status."
97,white,female,70,32.05,FOLFOX,No,Yes,No,No,12,well differentiated,fully active,mutant,No,No,No,No,No,0,"race: white, sex: female, age: 70, bmi: 32.05, treatment arm: FOLFOX, serious adverse effect: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 70-year-old white female with a BMI of 32.05. She is receiving the FOLFOX treatment regimen and has experienced a serious adverse effect. She has completed 12 cycles of chemotherapy. The histology of her cancer is well-differentiated. Despite her age, she has a fully active performance status. Additionally, the KRAS biomarker testing revealed a mutant status."
98,white,male,47,30.07,FOLFOX,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 47, bmi: 30.07, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type",The patient is a 47-year-old white male with a BMI of 30.07. He is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer cells. The patient has a fully active performance status and has a wild-type KRAS biomarker.
99,black,female,72,28.76,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: black, sex: female, age: 72, bmi: 28.76, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 72-year-old Black female with a BMI of 28.76. She is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cancer, and she has a fully active performance status. The KRAS biomarker indicates that she has a wild-type status."
100,white,male,56,28.27,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,symptoms but ambulatory,interminate,No,No,No,No,No,0,"race: white, sex: male, age: 56, bmi: 28.27, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: interminate","The patient is a 56-year-old white male with a BMI of 28.27. He is receiving treatment in the FOLFOX + Cetuximab treatment arm and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer cells. Despite experiencing symptoms, he is still able to walk around (ambulatory). The KRAS biomarker status is indeterminate for this patient."
101,white,male,39,23.41,FOLFOX,No,No,No,No,12,poorly differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 39, bmi: 23.41, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 39-year-old white male with a BMI of 23.41. He is receiving treatment with the FOLFOX chemotherapy regimen and has completed 12 cycles. His cancer histology is poorly differentiated. Despite this, his performance status is fully active. Additionally, his KRAS biomarker status is wild-type."
102,black,male,60,22.99,FOLFOX + Cetuximab,No,No,Yes,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: black, sex: male, age: 60, bmi: 22.99, treatment arm: FOLFOX + Cetuximab, bowel obstruction: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type",The patient is a 60-year-old Black male with a BMI of 22.99. He is receiving treatment with FOLFOX + Cetuximab for bowel obstruction. He has completed 12 cycles of chemotherapy. The histology shows well-differentiated cells. The patient has a fully active performance status. His KRAS biomarker is wild-type.
103,white,male,35,29.57,FOLFOX,Yes,No,Yes,No,12,well differentiated,fully active,mutant,No,No,No,No,No,0,"race: white, sex: male, age: 35, bmi: 29.57, treatment arm: FOLFOX, adherence: Yes, bowel obstruction: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 35-year-old white male with a BMI of 29.57. He is receiving treatment in the FOLFOX treatment arm and has been adherent to his treatment. He has experienced a bowel obstruction and has completed 12 cycles of chemotherapy. The histology shows well-differentiated cells. Despite the bowel obstruction, the patient's performance status is fully active. The KRAS biomarker analysis indicates a mutant status."
104,white,female,63,34.95,FOLFOX + Cetuximab,No,No,Yes,No,12,well differentiated,fully active,mutant,No,No,No,No,No,0,"race: white, sex: female, age: 63, bmi: 34.95, treatment arm: FOLFOX + Cetuximab, bowel obstruction: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 63-year-old white female with a BMI of 34.95. She is receiving treatment in the FOLFOX + Cetuximab treatment arm for her condition. She has a bowel obstruction and has completed 12 cycles of chemotherapy. The histology of her condition is well differentiated. Despite her bowel obstruction, her performance status is fully active. Additionally, the KRAS biomarker indicates that she has a mutant status."
105,white,female,48,27.38,FOLFOX,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 48, bmi: 27.38, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type",The patient is a 48-year-old white female with a BMI of 27.38. She is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cancer cells. The patient has a fully active performance status and her KRAS biomarker is wild-type.
106,white,male,54,29.37,FOLFOX + Cetuximab,No,No,No,No,12,poorly differentiated,symptoms but ambulatory,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 54, bmi: 29.37, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: poorly differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type","The patient is a 54-year-old white male with a BMI of 29.37. He is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. His histology shows poorly differentiated cancer cells. Despite experiencing symptoms, he is still able to move around. His KRAS biomarker is wild-type."
107,white,male,44,27.56,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 44, bmi: 27.56, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 44-year-old white male with a BMI of 27.56. He is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. His cancer histology is well-differentiated, and he has a fully active performance status. The KRAS biomarker testing showed that he has a wild-type KRAS status."
108,white,male,65,27.46,FOLFOX,No,No,No,No,12,well differentiated,fully active,wild-type,Yes,No,No,No,No,0,"race: white, sex: male, age: 65, bmi: 27.46, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type, adverse effect: thrombosis: Yes","The patient is a 65-year-old white male with a BMI of 27.46. He is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cells, and he has a fully active performance status. The KRAS biomarker testing revealed a wild-type result. The patient has experienced an adverse effect of thrombosis."
109,black,female,38,23.67,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: black, sex: female, age: 38, bmi: 23.67, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 38-year-old Black female with a BMI of 23.67. She is receiving treatment in the FOLFOX + Cetuximab treatment arm and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cancer cells. The patient has a fully active performance status. Additionally, her KRAS biomarker indicates that it is wild-type."
110,black,female,45,26.84,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: black, sex: female, age: 45, bmi: 26.84, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type",The patient is a 45-year-old Black female with a BMI of 26.84. She is receiving treatment in the FOLFOX + Cetuximab treatment arm and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cancer cells. The patient has a fully active performance status and her KRAS biomarker is wild-type.
111,white,male,64,27.02,FOLFOX + Cetuximab,No,Yes,Yes,No,12,well differentiated,symptoms but ambulatory,mutant,No,Yes,No,No,No,0,"race: white, sex: male, age: 64, bmi: 27.02, treatment arm: FOLFOX + Cetuximab, serious adverse effect: Yes, bowel obstruction: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: mutant, adverse effect: hypersensitivity: Yes","The patient is a 64-year-old white male with a BMI of 27.02. He is receiving treatment with FOLFOX + Cetuximab and has experienced a serious adverse effect, specifically a bowel obstruction. He has completed 12 cycles of chemotherapy and has well-differentiated histology. Despite experiencing symptoms, he is still able to be ambulatory. The patient's KRAS biomarker is mutant, and he has also experienced a hypersensitivity adverse effect."
112,white,male,76,21.72,FOLFIRI,No,No,No,No,12,well differentiated,symptoms but ambulatory,wild-type,No,No,Yes,No,No,0,"race: white, sex: male, age: 76, bmi: 21.72, treatment arm: FOLFIRI, chemotherapy cycles: 12, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type, adverse effect: diarrhea: Yes","The patient is a 76-year-old white male with a BMI of 21.72. He is receiving the FOLFIRI treatment regimen and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer. Despite experiencing symptoms, he is still able to be ambulatory. The KRAS biomarker indicates that he has a wild-type status. He is also experiencing diarrhea as an adverse effect of the treatment."
113,white,female,51,31.98,FOLFOX,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 51, bmi: 31.98, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type",The patient is a 51-year-old white female with a BMI of 31.98. She is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cancer cells. The patient has a fully active performance status and her KRAS biomarker is wild-type.
114,white,male,67,32.72,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,fully active,mutant,No,No,No,No,No,0,"race: white, sex: male, age: 67, bmi: 32.72, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 67-year-old white male with a BMI of 32.72. He is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. His cancer histology is well differentiated. Despite his age, he has a fully active performance status. The KRAS biomarker testing revealed a mutant status."
115,white,female,57,44.06,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,Yes,No,0,"race: white, sex: female, age: 57, bmi: 44.06, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type, adverse effect: infection: Yes","The patient is a 57-year-old white female with a BMI of 44.06. She is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cancer cells. Despite her high BMI, she has a fully active performance status. The KRAS biomarker testing revealed that she has a wild-type KRAS gene. Unfortunately, she has experienced an infection as an adverse effect of her treatment."
116,white,female,59,21.51,FOLFOX,No,No,Yes,No,12,poorly differentiated,fully active,mutant,No,No,No,No,No,0,"race: white, sex: female, age: 59, bmi: 21.51, treatment arm: FOLFOX, bowel obstruction: Yes, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 59-year-old white female with a BMI of 21.51. She is receiving treatment with the FOLFOX regimen for her bowel obstruction. She has completed 12 cycles of chemotherapy. The histology of her cancer is poorly differentiated. Despite her condition, she has a fully active performance status. Additionally, the KRAS biomarker testing showed that she has a mutant KRAS status."
117,white,female,67,33.76,FOLFOX,No,No,No,No,11,poorly differentiated,symptoms but ambulatory,mutant,No,No,No,No,Yes,0,"race: white, sex: female, age: 67, bmi: 33.76, treatment arm: FOLFOX, chemotherapy cycles: 11, histology: poorly differentiated, performance status: symptoms but ambulatory, KRAS biomarker: mutant, adverse effect: infarction: Yes","The patient is a 67-year-old white female with a BMI of 33.76. She is receiving the FOLFOX treatment regimen and has completed 11 cycles of chemotherapy. Her cancer histology is poorly differentiated, and she has symptoms but is still able to be ambulatory. The KRAS biomarker testing showed a mutant result. Additionally, the patient experienced an infarction as an adverse effect."
118,white,female,44,26.95,FOLFOX + Cetuximab,No,No,No,No,8,poorly differentiated,fully active,wild-type,No,No,No,No,No,1,"race: white, sex: female, age: 44, bmi: 26.95, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 8, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 44-year-old white female with a BMI of 26.95. She is receiving treatment with FOLFOX + Cetuximab and has completed 8 cycles of chemotherapy. Her cancer histology is poorly differentiated. Despite her diagnosis, she has a fully active performance status. The KRAS biomarker testing revealed that she has a wild-type KRAS status."
119,white,male,69,31.25,FOLFOX,No,No,No,No,4,poorly differentiated,fully active,mutant,No,No,No,No,No,0,"race: white, sex: male, age: 69, bmi: 31.25, treatment arm: FOLFOX, chemotherapy cycles: 4, histology: poorly differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 69-year-old white male with a BMI of 31.25. He is receiving the FOLFOX treatment regimen and has completed 4 cycles of chemotherapy. His cancer histology is poorly differentiated. Despite his age, he has a fully active performance status. The KRAS biomarker testing revealed a mutant status."
120,white,female,57,22.58,FOLFOX,No,Yes,Yes,No,12,well differentiated,fully active,mutant,No,No,No,No,No,0,"race: white, sex: female, age: 57, bmi: 22.58, treatment arm: FOLFOX, serious adverse effect: Yes, bowel obstruction: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 57-year-old white female with a BMI of 22.58. She is undergoing treatment with the FOLFOX chemotherapy regimen and has experienced a serious adverse effect, specifically a bowel obstruction. She has completed 12 cycles of chemotherapy. The histology of her condition is well-differentiated. Despite the adverse effects, her performance status is fully active. Additionally, the KRAS biomarker analysis has shown a mutant status."
121,white,male,49,29.95,FOLFOX + Cetuximab,Yes,No,No,No,12,poorly differentiated,symptoms but ambulatory,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 49, bmi: 29.95, treatment arm: FOLFOX + Cetuximab, adherence: Yes, chemotherapy cycles: 12, histology: poorly differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type","The patient is a 49-year-old white male with a BMI of 29.95. He is receiving treatment in the FOLFOX + Cetuximab treatment arm and has been adherent to the treatment. He has completed 12 cycles of chemotherapy. His histology shows poorly differentiated cancer cells. Despite experiencing symptoms, he is still able to be ambulatory. The KRAS biomarker analysis indicates that he has a wild-type KRAS status."
122,white,female,67,26.65,FOLFOX + Cetuximab,No,No,No,No,12,poorly differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 67, bmi: 26.65, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 67-year-old white female with a BMI of 26.65. She is undergoing treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. The histology of her cancer is poorly differentiated. Despite her cancer diagnosis, her performance status is fully active. Additionally, her KRAS biomarker status is wild-type."
123,white,female,53,28.48,FOLFOX,No,No,No,No,12,poorly differentiated,symptoms but ambulatory,wild-type,No,No,Yes,No,No,0,"race: white, sex: female, age: 53, bmi: 28.48, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: poorly differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type, adverse effect: diarrhea: Yes","The patient is a 53-year-old white female with a BMI of 28.48. She is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. Her histology shows poorly differentiated cancer cells. Despite experiencing symptoms, she is still able to be ambulatory. The KRAS biomarker testing revealed a wild-type result. The patient is currently experiencing diarrhea as an adverse effect of the treatment."
124,white,female,67,17.26,FOLFOX,Yes,No,No,Yes,10,well differentiated,fully active,interminate,No,No,No,No,No,0,"race: white, sex: female, age: 67, bmi: 17.26, treatment arm: FOLFOX, adherence: Yes, bowel perforation: Yes, chemotherapy cycles: 10, histology: well differentiated, performance status: fully active, KRAS biomarker: interminate","The patient is a 67-year-old white female with a BMI of 17.26. She is undergoing treatment with the FOLFOX regimen and has been adherent to the treatment. She experienced a bowel perforation during the course of her treatment. She has completed 10 cycles of chemotherapy. The histology of her cancer is well-differentiated. Despite the bowel perforation, her performance status is fully active. The KRAS biomarker status is indeterminate."
125,white,female,75,27.06,FOLFIRI + Cetuximab,No,No,Yes,No,0,well differentiated,fully active,interminate,No,No,No,No,No,0,"race: white, sex: female, age: 75, bmi: 27.06, treatment arm: FOLFIRI + Cetuximab, bowel obstruction: Yes, chemotherapy cycles: 0, histology: well differentiated, performance status: fully active, KRAS biomarker: interminate","This patient is a 75-year-old white female with a BMI of 27.06. She is enrolled in the FOLFIRI + Cetuximab treatment arm for her cancer. She is currently experiencing a bowel obstruction. She has not started any chemotherapy cycles yet. The histology of her cancer is well-differentiated. Despite her condition, her performance status is fully active. Her KRAS biomarker status is indeterminate."
126,white,female,54,25.31,FOLFOX + Cetuximab,No,No,Yes,No,3,poorly differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 54, bmi: 25.31, treatment arm: FOLFOX + Cetuximab, bowel obstruction: Yes, chemotherapy cycles: 3, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type","This patient is a 54-year-old white female with a BMI of 25.31. She is receiving treatment in the FOLFOX + Cetuximab treatment arm. She has experienced a bowel obstruction and has completed 3 cycles of chemotherapy. The histology of her cancer is poorly differentiated. Despite her condition, her performance status is fully active. Her KRAS biomarker status is wild-type."
127,black,female,38,37.2,FOLFOX,Yes,No,No,No,12,well differentiated,symptoms but ambulatory,wild-type,No,No,No,No,No,0,"race: black, sex: female, age: 38, bmi: 37.2, treatment arm: FOLFOX, adherence: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type","This patient is a 38-year-old Black female with a BMI of 37.2. She is receiving the FOLFOX treatment regimen and has been adherent to her chemotherapy cycles, completing a total of 12 cycles. Her histology shows well-differentiated cancer. Despite experiencing symptoms, she is still able to be ambulatory. The KRAS biomarker analysis indicates that she has a wild-type status."
128,white,female,60,20.2,FOLFIRI,No,No,No,No,12,poorly differentiated,fully active,wild-type,No,No,No,No,No,1,"race: white, sex: female, age: 60, bmi: 20.2, treatment arm: FOLFIRI, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 60-year-old white female with a BMI of 20.2. She is receiving the FOLFIRI treatment regimen and has completed 12 cycles of chemotherapy. Her cancer histology is poorly differentiated. Despite her cancer diagnosis, she has a fully active performance status. The KRAS biomarker testing revealed that she has a wild-type KRAS status."
129,white,male,75,35.33,FOLFOX,No,No,No,No,12,well differentiated,fully active,wild-type,No,Yes,No,No,No,0,"race: white, sex: male, age: 75, bmi: 35.33, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type, adverse effect: hypersensitivity: Yes","The patient is a 75-year-old white male with a BMI of 35.33. He is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cells, and he has a fully active performance status. The KRAS biomarker indicates that he is wild-type. The patient has experienced hypersensitivity as an adverse effect."
130,white,male,41,30.67,FOLFOX + Cetuximab,Yes,No,No,No,10,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 41, bmi: 30.67, treatment arm: FOLFOX + Cetuximab, adherence: Yes, chemotherapy cycles: 10, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type",The patient is a 41-year-old white male with a BMI of 30.67. He is currently receiving treatment in the FOLFOX + Cetuximab treatment arm and has been adherent to the treatment. He has completed 10 cycles of chemotherapy. His histology shows well-differentiated cancer cells. The patient has a fully active performance status. His KRAS biomarker is wild-type.
131,white,male,36,31.73,FOLFOX + Cetuximab,No,Yes,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 36, bmi: 31.73, treatment arm: FOLFOX + Cetuximab, serious adverse effect: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","This patient is a 36-year-old white male with a BMI of 31.73. He is receiving treatment in the FOLFOX + Cetuximab treatment arm. Unfortunately, he has experienced a serious adverse effect. He has completed 12 cycles of chemotherapy. His histology shows that the cancer is well-differentiated. Despite the treatment, his performance status is fully active. Additionally, his KRAS biomarker is wild-type."
132,white,male,71,24.89,FOLFOX + Cetuximab,No,No,Yes,No,12,well differentiated,fully active,mutant,No,No,Yes,No,No,0,"race: white, sex: male, age: 71, bmi: 24.89, treatment arm: FOLFOX + Cetuximab, bowel obstruction: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant, adverse effect: diarrhea: Yes","This patient is a 71-year-old white male with a BMI of 24.89. He is receiving treatment with FOLFOX + Cetuximab for his well-differentiated histology. He has experienced a bowel obstruction and has completed 12 cycles of chemotherapy. Despite the adverse effect of diarrhea, his performance status is fully active. Additionally, his KRAS biomarker is mutant."
133,white,male,76,30.3,FOLFIRI (KRAS mutant),No,No,Yes,Yes,12,well differentiated,fully active,wild-type,No,No,No,No,No,1,"race: white, sex: male, age: 76, bmi: 30.3, treatment arm: FOLFIRI (KRAS mutant), bowel obstruction: Yes, bowel perforation: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","This patient is a 76-year-old white male with a BMI of 30.3. He is receiving the FOLFIRI treatment regimen for his KRAS mutant status. He has experienced both a bowel obstruction and perforation. He has completed 12 cycles of chemotherapy. His cancer histology is well differentiated. Despite his medical challenges, his performance status is fully active. His KRAS biomarker is wild-type."
134,other,female,65,21.79,FOLFOX,No,No,No,No,12,well differentiated,fully active,wild-type,No,Yes,No,No,No,0,"race: other, sex: female, age: 65, bmi: 21.79, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type, adverse effect: hypersensitivity: Yes","The patient is a 65-year-old female of a race categorized as ""other"" with a BMI of 21.79. She is undergoing treatment with the FOLFOX chemotherapy regimen and has completed 12 cycles. The histology of her cancer is well-differentiated. She has a fully active performance status and her KRAS biomarker is wild-type. The patient has experienced a hypersensitivity adverse effect."
135,white,male,47,24.71,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 47, bmi: 24.71, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 47-year-old white male with a BMI of 24.71. He is receiving treatment in the FOLFOX + Cetuximab treatment arm and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cells, and he has a fully active performance status. The KRAS biomarker analysis indicates that he has a wild-type KRAS status."
136,black,female,72,27.51,FOLFOX + Cetuximab,No,No,No,Yes,12,poorly differentiated,fully active,wild-type,No,No,No,No,No,0,"race: black, sex: female, age: 72, bmi: 27.51, treatment arm: FOLFOX + Cetuximab, bowel perforation: Yes, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 72-year-old Black female with a BMI of 27.51. She is receiving treatment with FOLFOX + Cetuximab for her cancer. She experienced a bowel perforation and has completed 12 cycles of chemotherapy. The histology of her cancer is poorly differentiated. Despite these challenges, her performance status is fully active. Her KRAS biomarker status is wild-type."
137,white,male,67,35.59,FOLFOX + Cetuximab,No,Yes,No,No,12,poorly differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 67, bmi: 35.59, treatment arm: FOLFOX + Cetuximab, serious adverse effect: Yes, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 67-year-old white male with a BMI of 35.59. He is receiving treatment with FOLFOX + Cetuximab and has experienced a serious adverse effect. He has completed 12 cycles of chemotherapy. His histology shows poorly differentiated cancer cells. Despite this, his performance status is fully active. The KRAS biomarker indicates that he has a wild-type gene."
138,white,male,42,27.08,FOLFIRI (KRAS mutant),Yes,Yes,No,No,12,poorly differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 42, bmi: 27.08, treatment arm: FOLFIRI (KRAS mutant), adherence: Yes, serious adverse effect: Yes, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 42-year-old white male with a BMI of 27.08. He is receiving the FOLFIRI treatment regimen for his KRAS mutant status. He has been adherent to the treatment. However, he has experienced a serious adverse effect. He has completed 12 cycles of chemotherapy. His histology shows poorly differentiated cells. Despite this, his performance status is fully active. His KRAS biomarker is wild-type."
139,white,female,64,25.97,FOLFOX,Yes,Yes,No,No,12,poorly differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 64, bmi: 25.97, treatment arm: FOLFOX, adherence: Yes, serious adverse effect: Yes, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 64-year-old white female with a BMI of 25.97. She is receiving the FOLFOX treatment regimen and has been adherent to the treatment. She experienced a serious adverse effect during the treatment. The patient completed 12 cycles of chemotherapy. The histology of her cancer is poorly differentiated. Despite this, her performance status is fully active. The KRAS biomarker analysis showed that she has a wild-type KRAS status."
140,white,female,48,30.75,FOLFOX,No,No,No,No,10,well differentiated,symptoms but ambulatory,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 48, bmi: 30.75, treatment arm: FOLFOX, chemotherapy cycles: 10, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type","The patient is a 48-year-old white female with a BMI of 30.75. She is undergoing treatment with the FOLFOX chemotherapy regimen and has completed 10 cycles so far. Her histology shows well-differentiated cancer cells. Despite experiencing symptoms, she is still able to be ambulatory. The KRAS biomarker analysis indicates that she has the wild-type variant."
141,white,male,45,29.57,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,in bed less than 50% of the time,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 45, bmi: 29.57, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: in bed less than 50% of the time, KRAS biomarker: wild-type","The patient is a 45-year-old white male with a BMI of 29.57. He is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. His cancer histology is well-differentiated, and he has a performance status of being in bed less than 50% of the time. His KRAS biomarker status is wild-type."
142,white,male,43,25.77,FOLFOX + Cetuximab,Yes,No,No,No,12,poorly differentiated,symptoms but ambulatory,mutant,No,No,Yes,No,No,0,"race: white, sex: male, age: 43, bmi: 25.77, treatment arm: FOLFOX + Cetuximab, adherence: Yes, chemotherapy cycles: 12, histology: poorly differentiated, performance status: symptoms but ambulatory, KRAS biomarker: mutant, adverse effect: diarrhea: Yes","The patient is a 43-year-old white male with a BMI of 25.77. He is receiving treatment in the FOLFOX + Cetuximab treatment arm and has been adherent to the treatment. He has completed 12 chemotherapy cycles. The histology of his cancer is poorly differentiated. Despite experiencing symptoms, he is still able to be ambulatory. The KRAS biomarker testing revealed a mutant status. The patient has experienced diarrhea as an adverse effect of the treatment."
143,white,female,43,23.84,FOLFOX + Cetuximab,No,No,Yes,No,12,well differentiated,fully active,mutant,No,No,No,No,No,0,"race: white, sex: female, age: 43, bmi: 23.84, treatment arm: FOLFOX + Cetuximab, bowel obstruction: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 43-year-old white female with a BMI of 23.84. She is receiving the FOLFOX + Cetuximab treatment regimen for her cancer. She has experienced a bowel obstruction and has completed 12 cycles of chemotherapy. The histology of her cancer is well-differentiated. Despite her condition, her performance status is fully active. Additionally, the KRAS biomarker testing revealed a mutant status."
144,white,female,70,22.66,FOLFOX,No,No,No,No,8,well differentiated,symptoms but ambulatory,mutant,No,No,No,No,No,1,"race: white, sex: female, age: 70, bmi: 22.66, treatment arm: FOLFOX, chemotherapy cycles: 8, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: mutant","The patient is a 70-year-old white female with a BMI of 22.66. She is receiving the FOLFOX treatment regimen and has completed 8 cycles of chemotherapy. Her cancer histology is well-differentiated. Despite experiencing symptoms, she is still able to walk around (ambulatory). The KRAS biomarker testing revealed a mutant status."
145,white,female,41,38.98,FOLFOX,No,No,Yes,No,10,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 41, bmi: 38.98, treatment arm: FOLFOX, bowel obstruction: Yes, chemotherapy cycles: 10, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 41-year-old white female with a BMI of 38.98. She is undergoing treatment with the FOLFOX regimen and has experienced a bowel obstruction. She has completed 10 cycles of chemotherapy. The histology of her cancer is well-differentiated. Despite the bowel obstruction, her performance status is fully active. Her KRAS biomarker status is wild-type."
146,white,male,67,29.1,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,fully active,mutant,No,Yes,No,No,No,1,"race: white, sex: male, age: 67, bmi: 29.1, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant, adverse effect: hypersensitivity: Yes","The patient is a 67-year-old white male with a BMI of 29.1. He is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer, and he has a fully active performance status. The KRAS biomarker indicates a mutant status. The patient has experienced a hypersensitivity adverse effect."
147,white,male,49,26.89,FOLFOX,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,1,"race: white, sex: male, age: 49, bmi: 26.89, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type",The patient is a 49-year-old white male with a BMI of 26.89. He is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer cells. The patient has a fully active performance status and his KRAS biomarker is wild-type.
148,white,female,51,25.3,FOLFOX,Yes,No,No,No,12,poorly differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 51, bmi: 25.3, treatment arm: FOLFOX, adherence: Yes, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 51-year-old white female with a BMI of 25.3. She is receiving treatment in the FOLFOX chemotherapy arm and has been adherent to her treatment. She has completed 12 cycles of chemotherapy. The histology of her cancer is poorly differentiated. Despite this, her performance status is fully active. Her KRAS biomarker status is wild-type."
149,white,female,54,25.96,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,Yes,No,No,0,"race: white, sex: female, age: 54, bmi: 25.96, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type, adverse effect: diarrhea: Yes","The patient is a 54-year-old white female with a BMI of 25.96. She is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cancer, and she has a fully active performance status. The KRAS biomarker indicates that she is wild-type. She is experiencing diarrhea as an adverse effect of her treatment."
150,white,male,75,27.77,FOLFOX,No,No,Yes,No,12,well differentiated,fully active,mutant,No,No,No,No,No,0,"race: white, sex: male, age: 75, bmi: 27.77, treatment arm: FOLFOX, bowel obstruction: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 75-year-old white male with a BMI of 27.77. He is receiving the FOLFOX treatment regimen for his cancer. He has experienced a bowel obstruction and has completed 12 cycles of chemotherapy. The histology of his cancer is well-differentiated. Despite his age, he has a fully active performance status. The KRAS biomarker testing revealed a mutant status."
151,other,male,40,24.68,FOLFOX + Cetuximab,No,No,No,No,11,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: other, sex: male, age: 40, bmi: 24.68, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 11, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 40-year-old male of a race categorized as ""other"" with a BMI of 24.68. He is currently undergoing treatment in the FOLFOX + Cetuximab treatment arm and has completed 11 cycles of chemotherapy. The histology indicates that the cancer cells are well-differentiated. The patient has a fully active performance status and the KRAS biomarker shows that it is wild-type."
152,white,male,66,36.24,FOLFOX,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 66, bmi: 36.24, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type",The patient is a 66-year-old white male with a BMI of 36.24. He is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. His cancer histology is well differentiated. The patient has a fully active performance status and has a wild-type KRAS biomarker.
153,white,female,55,22.89,FOLFOX,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 55, bmi: 22.89, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type",The patient is a 55-year-old white female with a BMI of 22.89. She is undergoing treatment with the FOLFOX chemotherapy regimen and has completed 12 cycles. The histology of her cancer is well-differentiated. She has a fully active performance status. The KRAS biomarker testing shows that she has a wild-type KRAS status.
154,white,male,64,36.4,FOLFOX,No,No,Yes,No,12,well differentiated,fully active,wild-type,No,Yes,No,No,No,1,"race: white, sex: male, age: 64, bmi: 36.4, treatment arm: FOLFOX, bowel obstruction: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type, adverse effect: hypersensitivity: Yes","The patient is a 64-year-old white male with a BMI of 36.4. He is receiving treatment with FOLFOX for his well-differentiated histology. He has experienced a bowel obstruction and has completed 12 cycles of chemotherapy. Despite this, his performance status is fully active. The patient has a wild-type KRAS biomarker. He has also experienced a hypersensitivity adverse effect."
155,white,female,58,31.62,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 58, bmi: 31.62, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 58-year-old white female with a BMI of 31.62. She is receiving treatment in the FOLFOX + Cetuximab treatment arm and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cancer cells. Despite her cancer diagnosis, she has a fully active performance status. Additionally, her KRAS biomarker indicates that it is wild-type."
156,white,female,40,20.39,FOLFOX + Cetuximab,Yes,No,No,No,9,well differentiated,symptoms but ambulatory,mutant,No,No,No,No,No,1,"race: white, sex: female, age: 40, bmi: 20.39, treatment arm: FOLFOX + Cetuximab, adherence: Yes, chemotherapy cycles: 9, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: mutant","The patient is a 40-year-old white female with a BMI of 20.39. She is receiving treatment with FOLFOX + Cetuximab and has been adherent to the treatment. She has completed 9 cycles of chemotherapy. The histology shows well-differentiated cancer. Despite experiencing symptoms, she is still able to be ambulatory. The KRAS biomarker indicates that she has a mutant status."
157,white,male,74,29.6,FOLFOX,No,No,No,No,9,well differentiated,fully active,mutant,No,No,No,No,No,1,"race: white, sex: male, age: 74, bmi: 29.6, treatment arm: FOLFOX, chemotherapy cycles: 9, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 74-year-old white male with a BMI of 29.6. He is receiving treatment with the FOLFOX chemotherapy regimen and has completed 9 cycles so far. His cancer histology is well differentiated. Despite his age, he has a fully active performance status. The KRAS biomarker testing revealed a mutant status."
158,white,male,60,23.34,FOLFOX + Cetuximab,No,No,No,No,11,poorly differentiated,fully active,wild-type,No,No,Yes,Yes,No,0,"race: white, sex: male, age: 60, bmi: 23.34, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 11, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type, adverse effect: diarrhea: Yes, adverse effect: infection: Yes","The patient is a 60-year-old white male with a BMI of 23.34. He is currently receiving treatment with FOLFOX + Cetuximab and has completed 11 cycles of chemotherapy. His cancer histology is poorly differentiated. Despite experiencing adverse effects such as diarrhea and infection, his performance status is fully active. Additionally, his KRAS biomarker status is wild-type."
159,white,male,56,23.99,FOLFIRI (KRAS mutant),Yes,No,Yes,No,12,poorly differentiated,fully active,mutant,No,No,No,No,No,0,"race: white, sex: male, age: 56, bmi: 23.99, treatment arm: FOLFIRI (KRAS mutant), adherence: Yes, bowel obstruction: Yes, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 56-year-old white male with a BMI of 23.99. He is receiving treatment with the FOLFIRI regimen for his KRAS mutant status. The patient has been adherent to the treatment and has experienced a bowel obstruction. He has completed 12 cycles of chemotherapy. Histologically, the patient's cancer is poorly differentiated. Despite these challenges, the patient has a fully active performance status."
160,white,male,51,25,FOLFOX,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 51, bmi: 25.0, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type",The patient is a 51-year-old white male with a BMI of 25.0. He is receiving treatment with the FOLFOX chemotherapy regimen and has completed 12 cycles. The histology of his cancer is well-differentiated. He has a fully active performance status. His KRAS biomarker status is wild-type.
161,white,female,53,22.65,FOLFOX + Cetuximab,No,No,No,No,1,well differentiated,fully active,mutant,No,No,No,No,No,0,"race: white, sex: female, age: 53, bmi: 22.65, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 1, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant",The patient is a 53-year-old white female with a BMI of 22.65. She is receiving treatment in the FOLFOX + Cetuximab treatment arm and has completed 1 cycle of chemotherapy. Her histology shows well-differentiated cells. The patient has a fully active performance status. The KRAS biomarker analysis indicates a mutant status.
162,white,female,59,24.45,FOLFOX + Cetuximab,Yes,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,Yes,No,0,"race: white, sex: female, age: 59, bmi: 24.45, treatment arm: FOLFOX + Cetuximab, adherence: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type, adverse effect: infection: Yes",The patient is a 59-year-old white female with a BMI of 24.45. She is receiving treatment with FOLFOX + Cetuximab and has been adherent to the treatment. She has completed 12 chemotherapy cycles. The histology shows well-differentiated cancer cells. The patient has a fully active performance status. Her KRAS biomarker is wild-type. She has experienced an infection as an adverse effect during her treatment.
163,white,female,59,21.57,FOLFOX,No,No,Yes,No,5,well differentiated,fully active,mutant,No,No,No,No,No,1,"race: white, sex: female, age: 59, bmi: 21.57, treatment arm: FOLFOX, bowel obstruction: Yes, chemotherapy cycles: 5, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 59-year-old white female with a BMI of 21.57. She is receiving the FOLFOX treatment regimen and has experienced a bowel obstruction. She has completed 5 cycles of chemotherapy. The histology shows that the cancer is well-differentiated. Despite the bowel obstruction, her performance status is fully active. The KRAS biomarker testing revealed a mutant result."
164,black,female,64,31.68,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,fully active,mutant,No,No,No,No,No,0,"race: black, sex: female, age: 64, bmi: 31.68, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 64-year-old Black female with a BMI of 31.68. She is receiving treatment with FOLFOX and Cetuximab and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cancer cells. Despite her cancer diagnosis, she has a fully active performance status. The KRAS biomarker testing revealed a mutant status."
165,white,male,61,37.27,FOLFIRI + Cetuximab,No,No,No,No,11,poorly differentiated,symptoms but ambulatory,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 61, bmi: 37.27, treatment arm: FOLFIRI + Cetuximab, chemotherapy cycles: 11, histology: poorly differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type","The patient is a 61-year-old white male with a BMI of 37.27. He is receiving treatment with FOLFIRI + Cetuximab and has completed 11 cycles of chemotherapy. His histology shows poorly differentiated cancer cells. Despite experiencing symptoms, he is still able to walk around (ambulatory). The KRAS biomarker analysis indicates that he has a wild-type KRAS gene."
166,white,male,48,26.1,FOLFOX + Cetuximab,No,Yes,No,No,4,well differentiated,symptoms but ambulatory,mutant,No,No,No,No,No,1,"race: white, sex: male, age: 48, bmi: 26.1, treatment arm: FOLFOX + Cetuximab, serious adverse effect: Yes, chemotherapy cycles: 4, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: mutant","The patient is a 48-year-old white male with a BMI of 26.1. He is receiving treatment with FOLFOX + Cetuximab and has experienced a serious adverse effect. He has completed 4 cycles of chemotherapy. His histology shows well-differentiated cells. Despite experiencing symptoms, he is still able to be ambulatory. The KRAS biomarker analysis indicates a mutant status."
167,black,male,42,34.94,FOLFIRI,Yes,No,No,No,12,poorly differentiated,symptoms but ambulatory,wild-type,No,No,No,No,No,0,"race: black, sex: male, age: 42, bmi: 34.94, treatment arm: FOLFIRI, adherence: Yes, chemotherapy cycles: 12, histology: poorly differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type","The patient is a 42-year-old Black male with a BMI of 34.94. He is receiving the FOLFIRI treatment regimen and has been adherent to the treatment. He has completed 12 cycles of chemotherapy. The histology of his cancer is poorly differentiated. Despite experiencing symptoms, he is still able to ambulate. His KRAS biomarker status is wild-type."
168,white,female,53,25.94,FOLFOX,Yes,Yes,Yes,Yes,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 53, bmi: 25.94, treatment arm: FOLFOX, adherence: Yes, serious adverse effect: Yes, bowel obstruction: Yes, bowel perforation: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 53-year-old white female with a BMI of 25.94. She is receiving the FOLFOX treatment regimen and has been adherent to her treatment. Unfortunately, she has experienced serious adverse effects in the form of bowel obstruction and perforation. Despite these challenges, she has completed 12 cycles of chemotherapy. Her cancer histology is well-differentiated, and she has a fully active performance status. The KRAS biomarker analysis indicates that she has a wild-type KRAS status."
169,white,female,68,27.7,FOLFOX,No,Yes,Yes,No,12,well differentiated,symptoms but ambulatory,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 68, bmi: 27.7, treatment arm: FOLFOX, serious adverse effect: Yes, bowel obstruction: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type","The patient is a 68-year-old white female with a BMI of 27.7. She is receiving the FOLFOX treatment regimen and has experienced a serious adverse effect in the form of a bowel obstruction. She has completed 12 cycles of chemotherapy. The histology shows that the cancer is well-differentiated. Despite experiencing symptoms, the patient is still able to be ambulatory. The KRAS biomarker indicates that the cancer is wild-type."
170,white,male,60,25.93,FOLFOX,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 60, bmi: 25.93, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type",The patient is a 60-year-old white male with a BMI of 25.93. He is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. The histology shows well-differentiated cancer cells. The patient has a fully active performance status and the KRAS biomarker is wild-type.
171,white,male,40,29.9,FOLFOX + Cetuximab,No,No,Yes,No,12,well differentiated,symptoms but ambulatory,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 40, bmi: 29.9, treatment arm: FOLFOX + Cetuximab, bowel obstruction: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type","This patient is a 40-year-old white male with a BMI of 29.9. He is receiving treatment with FOLFOX + Cetuximab for his cancer. He has a bowel obstruction and has completed 12 cycles of chemotherapy. The histology of his cancer is well-differentiated. Despite experiencing symptoms, he is still able to be ambulatory. His KRAS biomarker status is wild-type."
172,white,female,54,32.14,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 54, bmi: 32.14, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type",The patient is a 54-year-old white female with a BMI of 32.14. She is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. Her cancer histology is well differentiated. She has a fully active performance status and her KRAS biomarker is wild-type.
173,white,male,48,39.55,FOLFOX + Cetuximab,No,No,No,No,10,poorly differentiated,symptoms but ambulatory,wild-type,Yes,No,No,No,No,0,"race: white, sex: male, age: 48, bmi: 39.55, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 10, histology: poorly differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type, adverse effect: thrombosis: Yes","The patient is a 48-year-old white male with a BMI of 39.55. He is receiving treatment with FOLFOX + Cetuximab and has completed 10 cycles of chemotherapy. His cancer histology is poorly differentiated, and he has symptoms but is still able to be ambulatory. The KRAS biomarker shows that he is wild-type. Additionally, the patient has experienced a thrombosis as an adverse effect."
174,white,female,60,25.95,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 60, bmi: 25.95, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 60-year-old white female with a BMI of 25.95. She is receiving treatment with FOLFOX + Cetuximab and is scheduled for 12 chemotherapy cycles. Her cancer histology is well-differentiated, and she has a fully active performance status. The KRAS biomarker testing revealed that she has a wild-type KRAS status."
175,white,female,71,28.54,FOLFOX + Cetuximab,No,No,No,No,12,poorly differentiated,symptoms but ambulatory,mutant,Yes,No,No,Yes,No,0,"race: white, sex: female, age: 71, bmi: 28.54, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: poorly differentiated, performance status: symptoms but ambulatory, KRAS biomarker: mutant, adverse effect: thrombosis: Yes, adverse effect: infection: Yes","The patient is a 71-year-old white female with a BMI of 28.54. She is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. Her cancer histology is poorly differentiated, and she has symptoms but is still ambulatory. The KRAS biomarker is mutant in her case. She has experienced adverse effects of thrombosis and infection during her treatment."
176,white,female,63,37.85,FOLFOX,No,No,No,No,12,well differentiated,symptoms but ambulatory,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 63, bmi: 37.85, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type","The patient is a 63-year-old white female with a BMI of 37.85. She is receiving the FOLFOX treatment arm and is scheduled for 12 chemotherapy cycles. The histology indicates that the cancer is well-differentiated. Despite experiencing symptoms, the patient is still able to be ambulatory. The KRAS biomarker shows that it is wild-type."
177,white,male,34,28.13,FOLFOX + Cetuximab,Yes,No,No,No,9,poorly differentiated,fully active,wild-type,No,No,No,Yes,No,1,"race: white, sex: male, age: 34, bmi: 28.13, treatment arm: FOLFOX + Cetuximab, adherence: Yes, chemotherapy cycles: 9, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type, adverse effect: infection: Yes","The patient is a 34-year-old white male with a BMI of 28.13. He is receiving treatment in the FOLFOX + Cetuximab treatment arm and has been adherent to the treatment. He has completed 9 cycles of chemotherapy. His histology shows poorly differentiated cancer cells. Despite this, his performance status is fully active. His KRAS biomarker is wild-type. The patient has experienced an infection as an adverse effect of the treatment."
178,black,female,67,43.08,FOLFOX + Cetuximab,No,No,No,No,11,well differentiated,fully active,mutant,No,No,No,No,No,0,"race: black, sex: female, age: 67, bmi: 43.08, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 11, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 67-year-old Black female with a BMI of 43.08. She is receiving treatment with FOLFOX + Cetuximab and has completed 11 cycles of chemotherapy. The histology shows well-differentiated cancer cells. Despite her age, she has a fully active performance status. The KRAS biomarker analysis indicates a mutant status."
179,white,male,63,30.08,FOLFOX + Cetuximab,No,No,Yes,No,12,well differentiated,fully active,wild-type,No,Yes,No,No,No,0,"race: white, sex: male, age: 63, bmi: 30.08, treatment arm: FOLFOX + Cetuximab, bowel obstruction: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type, adverse effect: hypersensitivity: Yes","The patient is a 63-year-old white male with a BMI of 30.08. He is receiving treatment with FOLFOX + Cetuximab for his well-differentiated histology. He has experienced a bowel obstruction and has completed 12 cycles of chemotherapy. Despite the adverse effect of hypersensitivity, the patient's performance status remains fully active. Additionally, his KRAS biomarker is wild-type."
180,white,female,56,28.4,FOLFOX + Cetuximab,Yes,No,No,No,12,well differentiated,fully active,wild-type,No,No,Yes,No,No,0,"race: white, sex: female, age: 56, bmi: 28.4, treatment arm: FOLFOX + Cetuximab, adherence: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type, adverse effect: diarrhea: Yes",The patient is a 56-year-old white female with a BMI of 28.4. She is receiving treatment with FOLFOX + Cetuximab and has been adherent to the treatment. She has completed 12 cycles of chemotherapy. The histology shows well-differentiated cancer cells. The patient has a fully active performance status. Her KRAS biomarker is wild-type. She is experiencing diarrhea as an adverse effect of the treatment.
181,black,female,46,27.13,FOLFOX,No,No,No,No,11,well differentiated,fully active,interminate,No,No,No,No,No,0,"race: black, sex: female, age: 46, bmi: 27.13, treatment arm: FOLFOX, chemotherapy cycles: 11, histology: well differentiated, performance status: fully active, KRAS biomarker: interminate","The patient is a 46-year-old Black female with a BMI of 27.13. She is currently receiving treatment in the FOLFOX chemotherapy arm and has completed 11 cycles of chemotherapy. The histology of her cancer is well-differentiated. Despite undergoing treatment, her performance status is fully active. The KRAS biomarker status is indeterminate."
182,white,male,53,26.38,FOLFOX + Cetuximab,Yes,No,No,No,12,poorly differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 53, bmi: 26.38, treatment arm: FOLFOX + Cetuximab, adherence: Yes, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 53-year-old white male with a BMI of 26.38. He is receiving treatment in the FOLFOX + Cetuximab treatment arm and has been adherent to the treatment. He has completed 12 chemotherapy cycles. The histology of his cancer is poorly differentiated. Despite this, his performance status is fully active. His KRAS biomarker status is wild-type."
183,white,male,42,27.22,FOLFOX,No,No,No,No,12,poorly differentiated,fully active,mutant,No,No,No,No,No,1,"race: white, sex: male, age: 42, bmi: 27.22, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 42-year-old white male with a BMI of 27.22. He is receiving the FOLFOX treatment arm and has completed 12 cycles of chemotherapy. The histology shows poorly differentiated cancer cells. Despite this, the patient has a fully active performance status. The KRAS biomarker analysis indicates a mutant status."
184,white,female,53,27.27,FOLFOX,No,No,No,No,12,well differentiated,fully active,mutant,No,No,No,No,No,0,"race: white, sex: female, age: 53, bmi: 27.27, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant",The patient is a 53-year-old white female with a BMI of 27.27. She is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. Her cancer histology is well-differentiated. She has a fully active performance status. The KRAS biomarker testing revealed a mutant status.
185,white,male,60,26.22,FOLFOX,No,No,No,No,12,well differentiated,symptoms but ambulatory,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 60, bmi: 26.22, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type","The patient is a 60-year-old white male with a BMI of 26.22. He is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. His cancer histology is well-differentiated. Despite experiencing symptoms, he is still able to be ambulatory. The KRAS biomarker analysis shows that he has a wild-type KRAS status."
186,white,female,43,18.25,FOLFOX,No,No,No,No,4,well differentiated,fully active,wild-type,No,No,Yes,No,No,0,"race: white, sex: female, age: 43, bmi: 18.25, treatment arm: FOLFOX, chemotherapy cycles: 4, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type, adverse effect: diarrhea: Yes",The patient is a 43-year-old white female with a BMI of 18.25. She is receiving the FOLFOX treatment arm and has completed 4 cycles of chemotherapy. The histology shows well-differentiated cancer cells. The patient has a fully active performance status and her KRAS biomarker is wild-type. She is experiencing diarrhea as an adverse effect of the treatment.
187,other,male,66,26.23,FOLFOX,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: other, sex: male, age: 66, bmi: 26.23, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 66-year-old male of a race categorized as ""other"" with a BMI of 26.23. He is undergoing treatment with the FOLFOX chemotherapy regimen and has completed 12 cycles. The histology of his condition is well-differentiated. Despite his age, he has a fully active performance status. Additionally, his KRAS biomarker status is wild-type."
188,white,male,60,28.64,FOLFOX,No,No,No,No,9,well differentiated,fully active,wild-type,No,No,No,No,No,1,"race: white, sex: male, age: 60, bmi: 28.64, treatment arm: FOLFOX, chemotherapy cycles: 9, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type",The patient is a 60-year-old white male with a BMI of 28.64. He is receiving the FOLFOX treatment regimen and has completed 9 cycles of chemotherapy. His histology shows well-differentiated cancer cells. The patient has a fully active performance status. His KRAS biomarker status is wild-type.
189,white,female,64,21.64,FOLFOX + Cetuximab,No,No,No,No,6,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 64, bmi: 21.64, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 6, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 64-year-old white female with a BMI of 21.64. She is receiving treatment in the FOLFOX + Cetuximab treatment arm and has completed 6 cycles of chemotherapy. Her histology shows well-differentiated cells, and she has a fully active performance status. Additionally, her KRAS biomarker is wild-type."
190,white,female,55,33.99,FOLFIRI,No,No,No,No,12,well differentiated,symptoms but ambulatory,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 55, bmi: 33.99, treatment arm: FOLFIRI, chemotherapy cycles: 12, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type","The patient is a 55-year-old white female with a BMI of 33.99. She is receiving treatment with the FOLFIRI chemotherapy regimen and has completed 12 cycles. Her cancer histology is well-differentiated. Despite experiencing symptoms, she is still able to be ambulatory. The KRAS biomarker analysis shows that she has a wild-type KRAS status."
191,white,female,37,44.6,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 37, bmi: 44.6, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 37-year-old white female with a BMI of 44.6. She is receiving treatment in the FOLFOX + Cetuximab treatment arm and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cancer cells. Despite her high BMI, her performance status is fully active. Additionally, her KRAS biomarker indicates that it is wild-type."
192,white,male,65,24.31,FOLFIRI (KRAS mutant),No,No,No,No,0,well differentiated,fully active,interminate,No,No,No,No,No,0,"race: white, sex: male, age: 65, bmi: 24.31, treatment arm: FOLFIRI (KRAS mutant), chemotherapy cycles: 0, histology: well differentiated, performance status: fully active, KRAS biomarker: interminate","The patient is a 65-year-old white male with a BMI of 24.31. He is in the FOLFIRI treatment arm for his KRAS mutant status. He has not started chemotherapy cycles yet. His histology shows well-differentiated cells, and his performance status is fully active. The KRAS biomarker status is indeterminate."
193,white,female,76,33.72,FOLFOX,Yes,Yes,No,No,12,poorly differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 76, bmi: 33.72, treatment arm: FOLFOX, adherence: Yes, serious adverse effect: Yes, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 76-year-old white female with a BMI of 33.72. She is receiving the FOLFOX treatment regimen and has been adherent to the treatment. However, she experienced a serious adverse effect during the course of her 12 chemotherapy cycles. The histology of her cancer is poorly differentiated. Despite these challenges, her performance status is fully active. Additionally, her KRAS biomarker status is wild-type."
194,white,male,53,28.85,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,fully active,mutant,No,No,Yes,No,No,0,"race: white, sex: male, age: 53, bmi: 28.85, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant, adverse effect: diarrhea: Yes","The patient is a 53-year-old white male with a BMI of 28.85 who is undergoing treatment with FOLFOX + Cetuximab for colorectal cancer. He has completed 12 cycles of chemotherapy. His cancer histology is well-differentiated, and he has a fully active performance status. The KRAS biomarker testing showed a mutant result. The patient is experiencing diarrhea as an adverse effect of the treatment."
195,white,female,49,21.4,FOLFOX,No,No,No,No,12,well differentiated,fully active,interminate,No,No,No,No,No,0,"race: white, sex: female, age: 49, bmi: 21.4, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: interminate",The patient is a 49-year-old white female with a BMI of 21.4. She is undergoing treatment with the FOLFOX regimen and has completed 12 cycles of chemotherapy. The histology shows well-differentiated cancer cells. The patient has a fully active performance status. The KRAS biomarker status is indeterminate.
196,white,female,34,24.97,FOLFOX,No,No,No,No,12,poorly differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 34, bmi: 24.97, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 34-year-old white female with a BMI of 24.97. She is receiving treatment in the FOLFOX chemotherapy arm and is scheduled for 12 cycles. The histology of her cancer is poorly differentiated. Despite her diagnosis, she has a fully active performance status. Additionally, her KRAS biomarker indicates that it is wild-type."
197,other,male,49,40.3,FOLFOX + Cetuximab,No,No,No,No,12,poorly differentiated,symptoms but ambulatory,wild-type,No,No,No,No,No,0,"race: other, sex: male, age: 49, bmi: 40.3, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: poorly differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type","The patient is a 49-year-old male of a race other than Caucasian, with a BMI of 40.3. He is receiving treatment in the FOLFOX + Cetuximab treatment arm and has completed 12 cycles of chemotherapy. The histology of his cancer is poorly differentiated. Despite experiencing symptoms, he is still able to be ambulatory. His KRAS biomarker status is wild-type."
198,white,female,68,34.64,FOLFOX,No,Yes,No,No,12,well differentiated,fully active,wild-type,Yes,No,No,No,No,0,"race: white, sex: female, age: 68, bmi: 34.64, treatment arm: FOLFOX, serious adverse effect: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type, adverse effect: thrombosis: Yes","This patient is a 68-year-old white female with a BMI of 34.64 who is undergoing treatment with the FOLFOX chemotherapy regimen. She has experienced a serious adverse effect during treatment. She has completed 12 cycles of chemotherapy and her histology shows well-differentiated cells. Despite the serious adverse effect, her performance status is fully active. Her KRAS biomarker is wild-type. Additionally, she has experienced an adverse effect of thrombosis."
199,white,female,51,25.01,FOLFOX + Cetuximab,No,Yes,No,No,9,well differentiated,fully active,mutant,No,No,No,No,No,0,"race: white, sex: female, age: 51, bmi: 25.01, treatment arm: FOLFOX + Cetuximab, serious adverse effect: Yes, chemotherapy cycles: 9, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 51-year-old white female with a BMI of 25.01. She is receiving treatment with FOLFOX + Cetuximab and has experienced a serious adverse effect. She has completed 9 cycles of chemotherapy. Her histology shows well-differentiated cells, and her performance status is fully active. The KRAS biomarker indicates a mutant status."
200,white,female,74,28.84,FOLFIRI,No,No,No,No,2,well differentiated,fully active,interminate,No,No,No,No,No,0,"race: white, sex: female, age: 74, bmi: 28.84, treatment arm: FOLFIRI, chemotherapy cycles: 2, histology: well differentiated, performance status: fully active, KRAS biomarker: interminate","The patient is a 74-year-old white female with a BMI of 28.84. She is currently receiving the FOLFIRI treatment regimen and has completed 2 cycles of chemotherapy. Her cancer histology is well-differentiated, and she has a fully active performance status. The KRAS biomarker status is indeterminate for this patient."
201,white,female,70,26.85,FOLFOX + Cetuximab,No,No,Yes,No,1,well differentiated,fully active,wild-type,No,No,No,Yes,No,1,"race: white, sex: female, age: 70, bmi: 26.85, treatment arm: FOLFOX + Cetuximab, bowel obstruction: Yes, chemotherapy cycles: 1, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type, adverse effect: infection: Yes","The patient is a 70-year-old white female with a BMI of 26.85. She is currently receiving treatment with FOLFOX + Cetuximab for her well-differentiated histology. She has experienced a bowel obstruction and has completed one cycle of chemotherapy. Despite this, her performance status is fully active. The KRAS biomarker shows that she is wild-type. Additionally, she has developed an infection as an adverse effect of her treatment."
202,black,female,66,36.4,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,symptoms but ambulatory,wild-type,No,No,No,No,No,0,"race: black, sex: female, age: 66, bmi: 36.4, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type","The patient is a 66-year-old Black female with a BMI of 36.4. She is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. The histology shows well-differentiated cancer. Despite experiencing symptoms, the patient is still able to walk around (ambulatory). The KRAS biomarker indicates that the cancer is wild-type."
203,white,female,58,30.52,FOLFOX + Cetuximab,No,No,Yes,Yes,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 58, bmi: 30.52, treatment arm: FOLFOX + Cetuximab, bowel obstruction: Yes, bowel perforation: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","This patient is a 58-year-old white female with a BMI of 30.52. She is receiving treatment in the FOLFOX + Cetuximab treatment arm. She has experienced both a bowel obstruction and a bowel perforation. The patient has completed 12 cycles of chemotherapy. The histology of her cancer is well differentiated. Despite her bowel issues, her performance status is fully active. Her KRAS biomarker status is wild-type."
204,white,female,43,24.87,FOLFOX,No,Yes,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 43, bmi: 24.87, treatment arm: FOLFOX, serious adverse effect: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 43-year-old white female with a BMI of 24.87. She is receiving the FOLFOX treatment regimen and has experienced a serious adverse effect. She has completed 12 cycles of chemotherapy. The histology shows that the cancer is well-differentiated. Despite the treatment, her performance status is fully active. The KRAS biomarker analysis indicates that she has a wild-type KRAS status."
205,white,female,57,36.96,FOLFOX,Yes,No,No,No,3,poorly differentiated,symptoms but ambulatory,wild-type,No,No,No,No,No,1,"race: white, sex: female, age: 57, bmi: 36.96, treatment arm: FOLFOX, adherence: Yes, chemotherapy cycles: 3, histology: poorly differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type","The patient is a 57-year-old white female with a BMI of 36.96. She is receiving treatment in the FOLFOX arm and has been adherent to the chemotherapy regimen for 3 cycles. The histology of her cancer is poorly differentiated. Despite experiencing symptoms, she is still able to be ambulatory. Her KRAS biomarker shows that it is wild-type."
206,white,male,41,27.43,FOLFOX,No,No,No,No,12,poorly differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 41, bmi: 27.43, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 41-year-old white male with a BMI of 27.43. He is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. His histology shows poorly differentiated cancer cells. Despite this, his performance status is fully active. Additionally, his KRAS biomarker indicates that it is wild-type."
207,other,male,63,22.83,FOLFOX + Cetuximab,No,No,Yes,Yes,12,well differentiated,symptoms but ambulatory,wild-type,No,No,No,No,No,0,"race: other, sex: male, age: 63, bmi: 22.83, treatment arm: FOLFOX + Cetuximab, bowel obstruction: Yes, bowel perforation: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type","The patient is a 63-year-old male of a race categorized as ""other"" with a BMI of 22.83. He is receiving treatment in the FOLFOX + Cetuximab treatment arm. The patient has experienced both a bowel obstruction and a bowel perforation. He has completed 12 cycles of chemotherapy. The histology indicates well-differentiated cancer. Despite experiencing symptoms, the patient is still ambulatory. The KRAS biomarker shows that the patient has a wild-type status."
208,white,female,71,20.81,FOLFOX,No,No,Yes,No,12,poorly differentiated,symptoms but ambulatory,mutant,No,No,No,No,No,0,"race: white, sex: female, age: 71, bmi: 20.81, treatment arm: FOLFOX, bowel obstruction: Yes, chemotherapy cycles: 12, histology: poorly differentiated, performance status: symptoms but ambulatory, KRAS biomarker: mutant","The patient is a 71-year-old white female with a BMI of 20.81. She is receiving the FOLFOX treatment arm for her bowel obstruction. She has undergone 12 cycles of chemotherapy. The histology shows poorly differentiated cells. Despite experiencing symptoms, she is still able to ambulate. The KRAS biomarker indicates a mutant status."
209,white,male,44,28.15,FOLFOX,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 44, bmi: 28.15, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 44-year-old white male with a BMI of 28.15. He is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. His cancer histology is well-differentiated, and he has a fully active performance status. The KRAS biomarker testing indicates that he has a wild-type KRAS status."
210,white,female,50,53.84,FOLFOX,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 50, bmi: 53.84, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 50-year-old white female with a high BMI of 53.84. She is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. Her cancer histology is well-differentiated, and she has a fully active performance status. The KRAS biomarker analysis shows that she has a wild-type KRAS status."
211,white,female,60,32.64,FOLFOX + Cetuximab,No,Yes,No,No,12,poorly differentiated,fully active,mutant,No,No,No,No,No,0,"race: white, sex: female, age: 60, bmi: 32.64, treatment arm: FOLFOX + Cetuximab, serious adverse effect: Yes, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 60-year-old white female with a BMI of 32.64. She is receiving treatment with FOLFOX + Cetuximab and has experienced a serious adverse effect. She has undergone 12 cycles of chemotherapy. Her histology shows poorly differentiated cells. Despite this, her performance status is fully active. Additionally, the KRAS biomarker indicates a mutant status."
212,white,male,62,34.57,FOLFOX,No,No,No,No,12,well differentiated,symptoms but ambulatory,wild-type,No,No,No,No,No,1,"race: white, sex: male, age: 62, bmi: 34.57, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type","The patient is a 62-year-old white male with a BMI of 34.57. He is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer cells. Despite experiencing symptoms, he is still able to walk around (ambulatory). The KRAS biomarker analysis indicates that he has a wild-type KRAS gene."
213,white,male,41,29.02,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,fully active,interminate,No,No,No,No,No,0,"race: white, sex: male, age: 41, bmi: 29.02, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: interminate",The patient is a 41-year-old white male with a BMI of 29.02. He is receiving treatment in the FOLFOX + Cetuximab treatment arm and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer cells. The patient has a fully active performance status and his KRAS biomarker status is indeterminate.
214,black,male,74,21.14,FOLFOX,No,No,Yes,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: black, sex: male, age: 74, bmi: 21.14, treatment arm: FOLFOX, bowel obstruction: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 74-year-old Black male with a BMI of 21.14. He is receiving treatment with the FOLFOX regimen for his bowel obstruction. He has completed 12 cycles of chemotherapy. The histology of his cancer is well-differentiated. Despite his condition, his performance status is fully active. His KRAS biomarker status is wild-type."
215,white,male,76,31.73,FOLFOX + Cetuximab,Yes,No,No,No,12,poorly differentiated,fully active,wild-type,No,No,Yes,No,No,0,"race: white, sex: male, age: 76, bmi: 31.73, treatment arm: FOLFOX + Cetuximab, adherence: Yes, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type, adverse effect: diarrhea: Yes","The patient is a 76-year-old white male with a BMI of 31.73. He is receiving treatment with FOLFOX + Cetuximab and has been adherent to the treatment. He has completed 12 chemotherapy cycles. His histology shows poorly differentiated cancer cells. Despite this, his performance status is fully active. His KRAS biomarker is wild-type. He is experiencing diarrhea as an adverse effect of the treatment."
216,white,male,69,26.76,FOLFOX,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 69, bmi: 26.76, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type",The patient is a 69-year-old white male with a BMI of 26.76. He is undergoing treatment with the FOLFOX chemotherapy regimen and has completed 12 cycles. His histology shows well-differentiated cancer cells. The patient has a fully active performance status and his KRAS biomarker is wild-type.
217,white,male,54,20.98,FOLFOX,No,No,Yes,No,12,well differentiated,fully active,mutant,No,No,No,No,No,0,"race: white, sex: male, age: 54, bmi: 20.98, treatment arm: FOLFOX, bowel obstruction: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 54-year-old white male with a BMI of 20.98. He is receiving treatment with the FOLFOX regimen and has experienced a bowel obstruction. He has completed 12 cycles of chemotherapy. The histology of his cancer is well-differentiated. Despite the bowel obstruction, his performance status is fully active. The KRAS biomarker testing revealed a mutant status."
218,white,female,37,25.87,FOLFOX + Cetuximab,No,Yes,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 37, bmi: 25.87, treatment arm: FOLFOX + Cetuximab, serious adverse effect: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 37-year-old white female with a BMI of 25.87. She is receiving treatment with FOLFOX + Cetuximab and has experienced a serious adverse effect. She has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cells. Despite the adverse effect, her performance status is fully active. The KRAS biomarker indicates that she has a wild-type gene."
219,other,female,63,23.64,FOLFOX + Cetuximab,No,Yes,Yes,No,12,well differentiated,fully active,mutant,No,No,No,No,No,0,"race: other, sex: female, age: 63, bmi: 23.64, treatment arm: FOLFOX + Cetuximab, serious adverse effect: Yes, bowel obstruction: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 63-year-old female of a race categorized as ""other"" with a BMI of 23.64. She is receiving treatment with FOLFOX + Cetuximab and has experienced a serious adverse effect, specifically a bowel obstruction. She has completed 12 cycles of chemotherapy and her histology shows well-differentiated cells. Despite the adverse effects, her performance status is fully active. Additionally, the KRAS biomarker analysis indicates a mutant status."
220,white,male,58,46.04,FOLFOX + Cetuximab,No,No,No,No,0,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 58, bmi: 46.04, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 0, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type",The patient is a 58-year-old white male with a BMI of 46.04. He is enrolled in the FOLFOX + Cetuximab treatment arm and has not started chemotherapy cycles yet. His histology shows well-differentiated cancer cells. The patient has a fully active performance status. His KRAS biomarker indicates that it is wild-type.
221,white,female,71,24.88,FOLFOX + Cetuximab,No,No,No,No,0,poorly differentiated,fully active,interminate,No,No,No,No,No,0,"race: white, sex: female, age: 71, bmi: 24.88, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 0, histology: poorly differentiated, performance status: fully active, KRAS biomarker: interminate","The patient is a 71-year-old white female with a BMI of 24.88. She is enrolled in the treatment arm receiving FOLFOX + Cetuximab for her poorly differentiated histology. She has not started any chemotherapy cycles yet. Despite her age, she has a fully active performance status. Her KRAS biomarker status is indeterminate."
222,white,female,50,36.47,FOLFOX,No,Yes,No,No,12,poorly differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 50, bmi: 36.47, treatment arm: FOLFOX, serious adverse effect: Yes, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type","This patient is a 50-year-old white female with a BMI of 36.47. She is receiving the FOLFOX treatment regimen and has experienced a serious adverse effect. She has completed 12 cycles of chemotherapy. The histology of her cancer is poorly differentiated. Despite this, her performance status is fully active. Additionally, her KRAS biomarker is wild-type."
223,white,male,44,37.72,FOLFOX,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 44, bmi: 37.72, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 44-year-old white male with a BMI of 37.72. He is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer cells. Despite his cancer diagnosis, he has a fully active performance status. Additionally, the KRAS biomarker analysis indicates that he has a wild-type KRAS gene."
224,white,male,54,27.16,FOLFIRI + Cetuximab,No,No,No,No,12,poorly differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 54, bmi: 27.16, treatment arm: FOLFIRI + Cetuximab, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 54-year-old white male with a BMI of 27.16. He is receiving treatment in the FOLFIRI + Cetuximab treatment arm and has completed 12 cycles of chemotherapy. His histology shows poorly differentiated cancer cells. Despite this, his performance status is fully active. Additionally, his KRAS biomarker status is wild-type."
225,white,female,41,25.09,FOLFOX,No,No,No,No,6,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 41, bmi: 25.09, treatment arm: FOLFOX, chemotherapy cycles: 6, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type",The patient is a 41-year-old white female with a BMI of 25.09. She is receiving the FOLFOX treatment regimen and has completed 6 cycles of chemotherapy. The histology shows well-differentiated cancer cells. The patient has a fully active performance status. The KRAS biomarker indicates that she has a wild-type mutation.
226,white,female,49,26.54,FOLFOX + Cetuximab,No,Yes,No,No,9,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 49, bmi: 26.54, treatment arm: FOLFOX + Cetuximab, serious adverse effect: Yes, chemotherapy cycles: 9, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 49-year-old white female with a BMI of 26.54. She is receiving treatment with FOLFOX + Cetuximab and has experienced a serious adverse effect. She has completed 9 cycles of chemotherapy. The histology shows that the cancer is well-differentiated. Despite the treatment, her performance status is fully active. The KRAS biomarker indicates that she has a wild-type mutation."
227,other,male,72,22.19,FOLFOX,Yes,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: other, sex: male, age: 72, bmi: 22.19, treatment arm: FOLFOX, adherence: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 72-year-old male of a race categorized as ""other"" with a BMI of 22.19. He is undergoing treatment with the FOLFOX regimen and has been adherent to the treatment. He has completed 12 cycles of chemotherapy. The histology of his cancer is well-differentiated. Despite his age, he has a fully active performance status. Additionally, his KRAS biomarker status is wild-type."
228,white,female,65,41.3,FOLFOX,No,No,No,No,3,well differentiated,symptoms but ambulatory,wild-type,No,No,No,Yes,No,0,"race: white, sex: female, age: 65, bmi: 41.3, treatment arm: FOLFOX, chemotherapy cycles: 3, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type, adverse effect: infection: Yes","The patient is a 65-year-old white female with a BMI of 41.3 who is undergoing treatment with the FOLFOX chemotherapy regimen. She has completed 3 cycles of chemotherapy. Her cancer histology is well differentiated. Despite experiencing symptoms, she is still able to ambulate. The KRAS biomarker testing revealed that she has a wild-type KRAS status. The patient has developed an infection as an adverse effect of the treatment."
229,other,male,59,33.09,FOLFOX,Yes,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: other, sex: male, age: 59, bmi: 33.09, treatment arm: FOLFOX, adherence: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 59-year-old male of a race categorized as ""other"" with a BMI of 33.09. He is receiving treatment with the FOLFOX regimen and has been adherent to the treatment. He has completed 12 cycles of chemotherapy. The histology of his cancer is well-differentiated. The patient has a fully active performance status. His KRAS biomarker status is wild-type."
230,other,male,71,24.69,FOLFOX + Cetuximab,No,No,No,No,7,well differentiated,fully active,mutant,No,No,Yes,No,No,0,"race: other, sex: male, age: 71, bmi: 24.69, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 7, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant, adverse effect: diarrhea: Yes","The patient is a 71-year-old male of a race categorized as ""other"" with a BMI of 24.69. He is currently undergoing treatment with FOLFOX + Cetuximab and has completed 7 cycles of chemotherapy. His histology shows well-differentiated cells, and he has a fully active performance status. The KRAS biomarker testing revealed a mutant status. The patient has experienced diarrhea as an adverse effect of the treatment."
231,white,female,47,20.84,FOLFOX + Cetuximab,No,No,No,No,4,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 47, bmi: 20.84, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 4, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type",The patient is a 47-year-old white female with a BMI of 20.84. She is receiving treatment with FOLFOX + Cetuximab and has completed 4 cycles of chemotherapy. Her histology shows well-differentiated cancer cells. The patient has a fully active performance status and her KRAS biomarker is wild-type.
232,black,female,61,23.19,FOLFIRI (KRAS mutant),No,Yes,Yes,No,9,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: black, sex: female, age: 61, bmi: 23.19, treatment arm: FOLFIRI (KRAS mutant), serious adverse effect: Yes, bowel obstruction: Yes, chemotherapy cycles: 9, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 61-year-old Black female with a BMI of 23.19. She is receiving the FOLFIRI treatment regimen for her KRAS mutant status. Unfortunately, she is experiencing a serious adverse effect and has developed a bowel obstruction. She has completed 9 cycles of chemotherapy and her histology shows well-differentiated cells. Despite these challenges, her performance status is fully active. Her KRAS biomarker is wild-type."
233,white,male,71,27.91,FOLFOX + Cetuximab,No,No,No,No,0,poorly differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 71, bmi: 27.91, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 0, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 71-year-old white male with a BMI of 27.91. He is enrolled in the FOLFOX + Cetuximab treatment arm but has not started chemotherapy cycles yet. His cancer histology is poorly differentiated. Despite this, his performance status is fully active. The KRAS biomarker analysis shows that he has a wild-type KRAS status."
234,white,female,43,56.6,FOLFOX,No,No,No,No,12,well differentiated,fully active,mutant,No,No,No,No,No,0,"race: white, sex: female, age: 43, bmi: 56.6, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 43-year-old white female with a BMI of 56.6. She is receiving the FOLFOX treatment arm and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cancer cells. Despite her high BMI, her performance status is fully active. The KRAS biomarker analysis indicates a mutant status."
235,white,female,41,18.99,FOLFOX,No,No,No,No,5,well differentiated,fully active,mutant,No,No,No,No,No,0,"race: white, sex: female, age: 41, bmi: 18.99, treatment arm: FOLFOX, chemotherapy cycles: 5, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 41-year-old white female with a BMI of 18.99. She is receiving the FOLFOX treatment arm and has completed 5 cycles of chemotherapy. Her histology shows well-differentiated cancer cells. Despite her cancer diagnosis, she has a fully active performance status. The KRAS biomarker analysis indicates that she has a mutant KRAS status."
236,white,female,46,30.52,FOLFOX + Cetuximab,No,No,No,No,12,poorly differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 46, bmi: 30.52, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 46-year-old white female with a BMI of 30.52. She is receiving treatment with FOLFOX + Cetuximab and is scheduled for 12 cycles of chemotherapy. The histology indicates poorly differentiated cancer. Despite this, her performance status is fully active. Additionally, the KRAS biomarker shows that she has a wild-type status."
237,white,female,56,19.76,FOLFIRI (KRAS mutant),No,Yes,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 56, bmi: 19.76, treatment arm: FOLFIRI (KRAS mutant), serious adverse effect: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 56-year-old white female with a BMI of 19.76. She is receiving the FOLFIRI treatment regimen for her KRAS mutant status. Unfortunately, she has experienced a serious adverse effect. She has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cells, and her performance status is fully active. It is important to note that her KRAS biomarker is wild-type."
238,white,female,34,29.98,FOLFOX,No,No,No,No,2,well differentiated,fully active,wild-type,No,No,No,Yes,No,0,"race: white, sex: female, age: 34, bmi: 29.98, treatment arm: FOLFOX, chemotherapy cycles: 2, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type, adverse effect: infection: Yes","The patient is a 34-year-old white female with a BMI of 29.98. She is receiving the FOLFOX treatment regimen and has completed 2 cycles of chemotherapy. Her histology shows well-differentiated cells, and she has a fully active performance status. The KRAS biomarker testing indicates she has a wild-type mutation. The patient has experienced an infection as an adverse effect of the treatment."
239,white,male,72,29.49,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 72, bmi: 29.49, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 72-year-old white male with a BMI of 29.49. He is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. His cancer histology is well-differentiated, and he has a fully active performance status. The KRAS biomarker testing showed that he has a wild-type KRAS status."
240,white,female,53,22.14,FOLFOX + Cetuximab,No,No,No,No,6,well differentiated,fully active,wild-type,No,No,Yes,No,No,0,"race: white, sex: female, age: 53, bmi: 22.14, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 6, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type, adverse effect: diarrhea: Yes","The patient is a 53-year-old white female with a BMI of 22.14. She is receiving treatment with FOLFOX + Cetuximab and has completed 6 cycles of chemotherapy. Her histology shows well-differentiated cancer, and she has a fully active performance status. The KRAS biomarker testing indicates she has a wild-type KRAS status. She is experiencing diarrhea as an adverse effect of the treatment."
241,black,female,51,27.73,FOLFOX,No,No,Yes,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: black, sex: female, age: 51, bmi: 27.73, treatment arm: FOLFOX, bowel obstruction: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 51-year-old Black female with a BMI of 27.73. She is receiving the FOLFOX treatment regimen and has experienced a bowel obstruction. She has completed 12 cycles of chemotherapy. The histology of her cancer is well-differentiated. Despite the bowel obstruction, her performance status is fully active. The KRAS biomarker analysis indicates that she has a wild-type KRAS gene."
242,black,female,59,21.7,FOLFOX,No,Yes,Yes,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: black, sex: female, age: 59, bmi: 21.7, treatment arm: FOLFOX, serious adverse effect: Yes, bowel obstruction: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 59-year-old Black female with a BMI of 21.7. She is receiving the FOLFOX treatment arm for her well-differentiated histology. She has experienced a serious adverse effect and is currently dealing with a bowel obstruction. Despite these challenges, her performance status is fully active. She has completed 12 cycles of chemotherapy. The KRAS biomarker shows that she has a wild-type status."
243,white,male,76,28,FOLFOX + Cetuximab,No,Yes,No,Yes,3,well differentiated,fully active,wild-type,No,No,Yes,No,No,1,"race: white, sex: male, age: 76, bmi: 28.0, treatment arm: FOLFOX + Cetuximab, serious adverse effect: Yes, bowel perforation: Yes, chemotherapy cycles: 3, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type, adverse effect: diarrhea: Yes","The patient is a 76-year-old white male with a BMI of 28.0. He is receiving treatment with FOLFOX + Cetuximab and has experienced a serious adverse effect in the form of a bowel perforation after completing 3 cycles of chemotherapy. The histology shows well-differentiated cancer, and the patient has a fully active performance status. His KRAS biomarker is wild-type. Additionally, he has experienced diarrhea as an adverse effect of the treatment."
244,white,male,51,26.59,FOLFOX + Cetuximab,Yes,No,No,No,12,poorly differentiated,fully active,wild-type,No,No,Yes,No,No,0,"race: white, sex: male, age: 51, bmi: 26.59, treatment arm: FOLFOX + Cetuximab, adherence: Yes, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type, adverse effect: diarrhea: Yes","The patient is a 51-year-old white male with a BMI of 26.59. He is receiving treatment in the FOLFOX + Cetuximab treatment arm and has been adherent to the treatment. He has completed 12 chemotherapy cycles. His histology shows poorly differentiated cancer cells. Despite this, his performance status is fully active. His KRAS biomarker is wild-type. The patient has experienced diarrhea as an adverse effect of the treatment."
245,white,male,71,27.55,FOLFOX + Cetuximab,No,No,No,No,1,well differentiated,symptoms but ambulatory,interminate,No,No,No,No,No,0,"race: white, sex: male, age: 71, bmi: 27.55, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 1, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: interminate","The patient is a 71-year-old white male with a BMI of 27.55. He is currently receiving treatment in the FOLFOX + Cetuximab treatment arm and has completed 1 cycle of chemotherapy. His histology shows well-differentiated cells. Despite experiencing symptoms, he is still able to walk around (ambulatory). The KRAS biomarker status is indeterminate for this patient."
246,white,male,46,27.34,FOLFOX,Yes,No,No,No,12,poorly differentiated,symptoms but ambulatory,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 46, bmi: 27.34, treatment arm: FOLFOX, adherence: Yes, chemotherapy cycles: 12, histology: poorly differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type","The patient is a 46-year-old white male with a BMI of 27.34. He is receiving the FOLFOX treatment regimen and has been adherent to the treatment. He has completed 12 cycles of chemotherapy. His histology shows poorly differentiated cancer cells. Despite experiencing symptoms, he is still able to be ambulatory. The KRAS biomarker analysis indicates that he has a wild-type KRAS status."
247,white,male,37,24.7,FOLFOX + Cetuximab,Yes,No,Yes,No,12,poorly differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 37, bmi: 24.7, treatment arm: FOLFOX + Cetuximab, adherence: Yes, bowel obstruction: Yes, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 37-year-old white male with a BMI of 24.7. He is receiving treatment with FOLFOX + Cetuximab and has been adherent to the treatment regimen. He is currently experiencing a bowel obstruction. The patient has completed 12 cycles of chemotherapy. His histology shows poorly differentiated cancer cells. Despite the bowel obstruction, his performance status is fully active. The KRAS biomarker analysis indicates that he has a wild-type KRAS gene."
248,white,male,47,35.76,FOLFIRI (KRAS mutant),No,No,No,No,12,well differentiated,fully active,mutant,No,No,No,No,No,0,"race: white, sex: male, age: 47, bmi: 35.76, treatment arm: FOLFIRI (KRAS mutant), chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 47-year-old white male with a BMI of 35.76. He is receiving FOLFIRI treatment for his KRAS mutant status and has completed 12 cycles of chemotherapy. His cancer histology is well-differentiated, and he has a fully active performance status."
249,white,male,55,26.54,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 55, bmi: 26.54, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type",The patient is a 55-year-old white male with a BMI of 26.54. He is receiving treatment in the FOLFOX + Cetuximab treatment arm and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer cells. The patient has a fully active performance status and has a wild-type KRAS biomarker.
250,white,male,62,27.89,FOLFOX,No,No,No,No,5,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 62, bmi: 27.89, treatment arm: FOLFOX, chemotherapy cycles: 5, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type",The patient is a 62-year-old white male with a BMI of 27.89. He is receiving the FOLFOX treatment regimen and has completed 5 cycles of chemotherapy. His histology shows well-differentiated cancer cells. The patient has a fully active performance status and his KRAS biomarker is wild-type.
251,white,female,76,24.75,FOLFOX + Cetuximab,No,Yes,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 76, bmi: 24.75, treatment arm: FOLFOX + Cetuximab, serious adverse effect: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","This patient is a 76-year-old white female with a BMI of 24.75. She is undergoing treatment with FOLFOX + Cetuximab and has experienced a serious adverse effect. She has completed 12 cycles of chemotherapy. Her histology shows that the cancer is well-differentiated. Despite her age, she has a fully active performance status. Additionally, her KRAS biomarker is wild-type."
252,white,male,52,35.95,FOLFOX,No,No,No,No,10,poorly differentiated,fully active,wild-type,No,No,No,Yes,No,1,"race: white, sex: male, age: 52, bmi: 35.95, treatment arm: FOLFOX, chemotherapy cycles: 10, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type, adverse effect: infection: Yes","The patient is a 52-year-old white male with a BMI of 35.95. He is receiving the FOLFOX treatment arm and has completed 10 cycles of chemotherapy. His histology shows poorly differentiated cancer cells. Despite this, his performance status is fully active. The KRAS biomarker analysis indicates that he has a wild-type KRAS gene. The patient has experienced an adverse effect in the form of an infection."
253,white,female,74,27.58,FOLFOX,No,No,No,No,6,poorly differentiated,fully active,wild-type,No,No,No,No,No,1,"race: white, sex: female, age: 74, bmi: 27.58, treatment arm: FOLFOX, chemotherapy cycles: 6, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 74-year-old white female with a BMI of 27.58. She is receiving treatment with the FOLFOX chemotherapy regimen and has completed 6 cycles. The histology of her cancer is poorly differentiated. Despite her age, she has a fully active performance status. Additionally, her KRAS biomarker status is wild-type."
254,white,male,45,31.78,FOLFOX,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,Yes,No,No,1,"race: white, sex: male, age: 45, bmi: 31.78, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type, adverse effect: diarrhea: Yes","The patient is a 45-year-old white male with a BMI of 31.78. He is receiving the FOLFOX treatment arm and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cells, and he has a fully active performance status. The KRAS biomarker indicates he is wild-type. The patient is experiencing diarrhea as an adverse effect."
255,white,male,51,30.86,FOLFOX + Cetuximab,Yes,No,Yes,No,10,poorly differentiated,symptoms but ambulatory,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 51, bmi: 30.86, treatment arm: FOLFOX + Cetuximab, adherence: Yes, bowel obstruction: Yes, chemotherapy cycles: 10, histology: poorly differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type","The patient is a 51-year-old white male with a BMI of 30.86. He is receiving treatment with FOLFOX + Cetuximab and has been adherent to the treatment. He is currently experiencing a bowel obstruction and has completed 10 cycles of chemotherapy. The histology of his cancer is poorly differentiated. Despite experiencing symptoms, he is still able to be ambulatory. His KRAS biomarker is wild-type."
256,white,female,76,28.92,FOLFOX + Cetuximab,No,No,No,No,1,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 76, bmi: 28.92, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 1, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 76-year-old white female with a BMI of 28.92. She is receiving treatment with FOLFOX + Cetuximab and has completed one cycle of chemotherapy. Her histology shows well-differentiated cells. Despite her age, she has a fully active performance status. The KRAS biomarker analysis indicates that she has a wild-type KRAS gene."
257,black,female,54,31.3,FOLFOX + Cetuximab,No,Yes,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: black, sex: female, age: 54, bmi: 31.3, treatment arm: FOLFOX + Cetuximab, serious adverse effect: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 54-year-old Black female with a BMI of 31.3. She is receiving treatment with FOLFOX + Cetuximab and has experienced a serious adverse effect. She has completed 12 cycles of chemotherapy. The histology shows that the cancer is well-differentiated. Despite the treatment, her performance status is fully active. The KRAS biomarker indicates that she has a wild-type status."
258,white,female,45,37.19,FOLFOX,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 45, bmi: 37.19, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 45-year-old white female with a BMI of 37.19. She is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cancer cells. Despite her cancer diagnosis, she is fully active with a good performance status. The KRAS biomarker analysis indicates that she has a wild-type KRAS gene."
259,white,male,75,25.28,FOLFOX,No,No,No,No,5,poorly differentiated,fully active,mutant,No,No,No,No,No,0,"race: white, sex: male, age: 75, bmi: 25.28, treatment arm: FOLFOX, chemotherapy cycles: 5, histology: poorly differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 75-year-old white male with a BMI of 25.28. He is receiving the FOLFOX treatment regimen and has completed 5 cycles of chemotherapy. His histology shows poorly differentiated cancer cells. Despite this, his performance status is fully active. The KRAS biomarker analysis indicates a mutant status."
260,white,male,66,30.77,FOLFIRI,Yes,No,No,No,12,poorly differentiated,fully active,wild-type,No,No,No,No,No,1,"race: white, sex: male, age: 66, bmi: 30.77, treatment arm: FOLFIRI, adherence: Yes, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 66-year-old white male with a BMI of 30.77. He is receiving treatment in the FOLFIRI chemotherapy arm and has been adherent to the treatment. He has completed 12 cycles of chemotherapy. The histology of his cancer is poorly differentiated. Despite this, his performance status is fully active. The KRAS biomarker analysis shows that he has a wild-type KRAS status."
261,white,male,48,30.13,FOLFOX,No,Yes,No,No,12,poorly differentiated,fully active,mutant,No,No,No,No,No,0,"race: white, sex: male, age: 48, bmi: 30.13, treatment arm: FOLFOX, serious adverse effect: Yes, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 48-year-old white male with a BMI of 30.13. He is receiving the FOLFOX treatment regimen and has experienced a serious adverse effect. He has undergone 12 cycles of chemotherapy. The histology of his condition is poorly differentiated. Despite this, his performance status is fully active. Additionally, the KRAS biomarker is identified as mutant in this patient."
262,white,male,56,28.54,FOLFOX,No,Yes,Yes,No,4,poorly differentiated,fully active,wild-type,No,No,Yes,No,No,1,"race: white, sex: male, age: 56, bmi: 28.54, treatment arm: FOLFOX, serious adverse effect: Yes, bowel obstruction: Yes, chemotherapy cycles: 4, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type, adverse effect: diarrhea: Yes","The patient is a 56-year-old white male with a BMI of 28.54 who is receiving the FOLFOX treatment regimen. He has experienced a serious adverse effect in the form of a bowel obstruction after completing 4 cycles of chemotherapy. The histology of his cancer is poorly differentiated, but his performance status is fully active. His KRAS biomarker status is wild-type. Additionally, he has also experienced diarrhea as an adverse effect of the treatment."
263,white,male,57,39.33,FOLFOX,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 57, bmi: 39.33, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 57-year-old white male with a BMI of 39.33. He is undergoing treatment with the FOLFOX chemotherapy regimen and has completed 12 cycles. His cancer histology is well-differentiated, and he has a fully active performance status. The KRAS biomarker analysis indicates that he has a wild-type KRAS status."
264,other,female,55,22.04,FOLFOX,No,No,No,No,2,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: other, sex: female, age: 55, bmi: 22.04, treatment arm: FOLFOX, chemotherapy cycles: 2, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 55-year-old female of a race categorized as ""other"" with a BMI of 22.04. She is currently undergoing treatment with the FOLFOX chemotherapy regimen and has completed 2 cycles so far. The histology of her cancer is well-differentiated. In terms of performance status, she is fully active. Additionally, the KRAS biomarker testing revealed that she has a wild-type KRAS status."
265,white,male,56,27.95,FOLFOX,No,No,No,No,1,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 56, bmi: 27.95, treatment arm: FOLFOX, chemotherapy cycles: 1, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type",The patient is a 56-year-old white male with a BMI of 27.95. He is receiving treatment with the FOLFOX chemotherapy regimen and has completed one cycle so far. His cancer histology is well-differentiated. The patient has a fully active performance status. His KRAS biomarker status is wild-type.
266,white,female,42,24.54,FOLFIRI,No,No,No,No,0,well differentiated,symptoms but ambulatory,wild-type,No,No,No,No,No,1,"race: white, sex: female, age: 42, bmi: 24.54, treatment arm: FOLFIRI, chemotherapy cycles: 0, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type","The patient is a 42-year-old white female with a BMI of 24.54. She is enrolled in the FOLFIRI treatment arm but has not started chemotherapy cycles yet. Her histology shows well-differentiated cancer cells. Despite experiencing symptoms, she is still able to be ambulatory. The KRAS biomarker analysis indicates that she has a wild-type KRAS status."
267,white,male,50,24.26,FOLFOX,No,Yes,No,No,1,well differentiated,symptoms but ambulatory,mutant,No,No,Yes,Yes,No,1,"race: white, sex: male, age: 50, bmi: 24.26, treatment arm: FOLFOX, serious adverse effect: Yes, chemotherapy cycles: 1, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: mutant, adverse effect: diarrhea: Yes, adverse effect: infection: Yes","The patient is a 50-year-old white male with a BMI of 24.26 who is receiving the FOLFOX treatment regimen. He has experienced a serious adverse effect after one cycle of chemotherapy, with well-differentiated histology. Despite experiencing symptoms, he is still able to be ambulatory. The patient's KRAS biomarker is mutant. He has also experienced adverse effects of diarrhea and infection."
268,white,male,55,26.05,FOLFOX,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 55, bmi: 26.05, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type",The patient is a 55-year-old white male with a BMI of 26.05. He is receiving the FOLFOX treatment regimen and is scheduled for 12 cycles of chemotherapy. The histology shows well-differentiated cancer cells. The patient has a fully active performance status. The KRAS biomarker analysis indicates that the patient has a wild-type KRAS gene.
269,white,male,64,24.64,FOLFIRI,No,No,No,No,12,well differentiated,fully active,mutant,No,No,Yes,No,No,1,"race: white, sex: male, age: 64, bmi: 24.64, treatment arm: FOLFIRI, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant, adverse effect: diarrhea: Yes","The patient is a 64-year-old white male with a BMI of 24.64. He is receiving the FOLFIRI treatment regimen and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer cells. Despite his age, he has a fully active performance status. The KRAS biomarker testing revealed a mutant status. The patient is experiencing diarrhea as an adverse effect of the treatment."
270,white,female,65,32.09,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,fully active,mutant,No,No,No,No,No,0,"race: white, sex: female, age: 65, bmi: 32.09, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 65-year-old white female with a BMI of 32.09. She is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cancer cells. Despite her age, she has a fully active performance status. The KRAS biomarker testing revealed a mutant result."
271,white,male,62,26.13,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 62, bmi: 26.13, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type",The patient is a 62-year-old white male with a BMI of 26.13. He is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer cells. The patient has a fully active performance status and his KRAS biomarker is wild-type.
272,white,male,45,27.74,FOLFOX,No,No,No,No,12,well differentiated,fully active,mutant,No,No,No,No,No,0,"race: white, sex: male, age: 45, bmi: 27.74, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 45-year-old white male with a BMI of 27.74. He is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. His cancer histology is well-differentiated, and he has a fully active performance status. The patient's KRAS biomarker status is mutant."
273,white,male,42,23.65,FOLFOX + Cetuximab,No,No,Yes,No,12,well differentiated,symptoms but ambulatory,mutant,No,No,No,No,No,0,"race: white, sex: male, age: 42, bmi: 23.65, treatment arm: FOLFOX + Cetuximab, bowel obstruction: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: mutant","The patient is a 42-year-old white male with a BMI of 23.65. He is receiving treatment with FOLFOX + Cetuximab for his well-differentiated histology. He has experienced a bowel obstruction and has completed 12 cycles of chemotherapy. Despite experiencing symptoms, he is still able to be ambulatory. The patient's KRAS biomarker is mutant."
274,white,female,74,22.02,FOLFOX + Cetuximab,No,No,No,No,12,poorly differentiated,fully active,wild-type,No,No,No,No,No,1,"race: white, sex: female, age: 74, bmi: 22.02, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 74-year-old white female with a BMI of 22.02. She is receiving treatment in the FOLFOX + Cetuximab treatment arm and has completed 12 cycles of chemotherapy. Her histology shows poorly differentiated cancer cells. Despite this, her performance status is fully active. Additionally, her KRAS biomarker indicates that it is wild-type."
275,black,female,45,31.95,FOLFOX,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: black, sex: female, age: 45, bmi: 31.95, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 45-year-old Black female with a BMI of 31.95. She is receiving the FOLFOX treatment arm and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cells, and she has a fully active performance status. The KRAS biomarker indicates that she has a wild-type status."
276,white,male,50,23.67,FOLFOX,No,Yes,No,No,12,poorly differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 50, bmi: 23.67, treatment arm: FOLFOX, serious adverse effect: Yes, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 50-year-old white male with a BMI of 23.67. He is receiving the FOLFOX treatment regimen and has experienced a serious adverse effect. He has completed 12 cycles of chemotherapy. The histology of his cancer is poorly differentiated. Despite this, his performance status is fully active. His KRAS biomarker status is wild-type."
277,other,male,62,25.01,FOLFIRI (KRAS mutant),Yes,No,Yes,Yes,2,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: other, sex: male, age: 62, bmi: 25.01, treatment arm: FOLFIRI (KRAS mutant), adherence: Yes, bowel obstruction: Yes, bowel perforation: Yes, chemotherapy cycles: 2, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 62-year-old male of a race categorized as ""other"" with a BMI of 25.01. He is currently receiving treatment in the FOLFIRI treatment arm for his KRAS mutant status. Despite experiencing bowel obstruction and perforation, he has maintained good adherence to his treatment. He has completed two cycles of chemotherapy. The histology of his cancer is well-differentiated. Despite the bowel issues, his performance status is fully active. It is noted that his KRAS biomarker is wild-type."
278,white,female,41,24.66,FOLFIRI + Cetuximab,No,No,No,No,12,well differentiated,symptoms but ambulatory,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 41, bmi: 24.66, treatment arm: FOLFIRI + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type","The patient is a 41-year-old white female with a BMI of 24.66. She is receiving treatment with FOLFIRI + Cetuximab and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cancer. Despite experiencing symptoms, she is still able to be ambulatory. Additionally, her KRAS biomarker indicates that it is wild-type."
279,white,female,65,27.68,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,fully active,interminate,No,No,No,No,No,0,"race: white, sex: female, age: 65, bmi: 27.68, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: interminate","The patient is a 65-year-old white female with a BMI of 27.68. She is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cells, and she has a fully active performance status. The KRAS biomarker status is indeterminate for this patient."
280,white,male,68,48.98,FOLFIRI (KRAS mutant),No,No,No,No,12,well differentiated,fully active,mutant,No,No,No,No,No,0,"race: white, sex: male, age: 68, bmi: 48.98, treatment arm: FOLFIRI (KRAS mutant), chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 68-year-old white male with a high BMI of 48.98. He is undergoing treatment with the FOLFIRI regimen for his KRAS mutant status. He has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer cells. Despite his age and BMI, his performance status is fully active."
281,white,female,62,26.32,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 62, bmi: 26.32, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 62-year-old white female with a BMI of 26.32. She is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. Her cancer histology is well-differentiated, and she has a fully active performance status. The KRAS biomarker analysis shows that she has a wild-type KRAS status."
282,white,female,50,23.5,FOLFIRI (KRAS mutant),No,Yes,No,No,12,poorly differentiated,fully active,wild-type,No,No,No,No,No,1,"race: white, sex: female, age: 50, bmi: 23.5, treatment arm: FOLFIRI (KRAS mutant), serious adverse effect: Yes, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 50-year-old white female with a BMI of 23.5. She is receiving the FOLFIRI treatment regimen for her KRAS mutant status. Unfortunately, she has experienced a serious adverse effect. She has completed 12 cycles of chemotherapy. Her histology shows poorly differentiated cells. Despite these challenges, her performance status is fully active. It is worth noting that her KRAS biomarker is wild-type."
283,white,male,57,28.28,FOLFOX + Cetuximab,No,No,No,No,0,well differentiated,fully active,interminate,No,No,No,No,No,0,"race: white, sex: male, age: 57, bmi: 28.28, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 0, histology: well differentiated, performance status: fully active, KRAS biomarker: interminate","The patient is a 57-year-old white male with a BMI of 28.28. He is enrolled in the treatment arm receiving FOLFOX + Cetuximab but has not started chemotherapy cycles yet. His histology shows well-differentiated cancer, and he has a fully active performance status. The KRAS biomarker status is intermediate."
284,white,male,38,25.73,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,fully active,mutant,No,No,No,No,No,0,"race: white, sex: male, age: 38, bmi: 25.73, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 38-year-old white male with a BMI of 25.73. He is receiving treatment in the FOLFOX + Cetuximab treatment arm and is scheduled for 12 chemotherapy cycles. His histology shows well-differentiated cells, and he has a fully active performance status. The KRAS biomarker analysis indicates a mutant status."
285,white,female,64,27.47,FOLFOX,No,No,No,No,12,well differentiated,fully active,mutant,No,No,No,No,No,0,"race: white, sex: female, age: 64, bmi: 27.47, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 64-year-old white female with a BMI of 27.47. She is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cells, and she has a fully active performance status. The KRAS biomarker analysis indicates a mutant status."
286,white,female,66,29.4,FOLFOX,No,No,No,No,12,poorly differentiated,fully active,wild-type,No,Yes,Yes,No,No,0,"race: white, sex: female, age: 66, bmi: 29.4, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type, adverse effect: hypersensitivity: Yes, adverse effect: diarrhea: Yes","The patient is a 66-year-old white female with a BMI of 29.4. She is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. Her cancer histology is poorly differentiated, and she has a fully active performance status. The KRAS biomarker testing showed that she has a wild-type KRAS status. The patient has experienced adverse effects including hypersensitivity and diarrhea."
287,white,male,43,37.15,FOLFOX + Cetuximab,No,No,No,No,4,well differentiated,fully active,wild-type,No,No,Yes,No,No,0,"race: white, sex: male, age: 43, bmi: 37.15, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 4, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type, adverse effect: diarrhea: Yes","The patient is a 43-year-old white male with a BMI of 37.15. He is receiving treatment with FOLFOX + Cetuximab and has completed 4 cycles of chemotherapy. His histology shows well-differentiated cells, and he has a fully active performance status. The KRAS biomarker is wild-type. The patient is experiencing diarrhea as an adverse effect of the treatment."
288,white,female,74,33.15,FOLFIRI,No,No,Yes,No,12,well differentiated,symptoms but ambulatory,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 74, bmi: 33.15, treatment arm: FOLFIRI, bowel obstruction: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type","The patient is a 74-year-old white female with a BMI of 33.15. She is receiving the FOLFIRI treatment regimen and has experienced a bowel obstruction. She has completed 12 cycles of chemotherapy. The histology indicates that the cancer is well-differentiated. Despite experiencing symptoms, she is still able to walk around. The KRAS biomarker shows that she has a wild-type mutation."
289,white,female,49,26.45,FOLFOX,Yes,No,No,No,12,poorly differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 49, bmi: 26.45, treatment arm: FOLFOX, adherence: Yes, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 49-year-old white female with a BMI of 26.45. She is receiving the FOLFOX treatment regimen and has been adherent to her chemotherapy cycles, completing a total of 12 cycles. Her cancer histology is poorly differentiated. Despite her diagnosis, she has a fully active performance status. Additionally, her KRAS biomarker status is wild-type."
290,white,male,62,27.18,FOLFOX,No,No,No,No,7,well differentiated,symptoms but ambulatory,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 62, bmi: 27.18, treatment arm: FOLFOX, chemotherapy cycles: 7, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type","The patient is a 62-year-old white male with a BMI of 27.18. He is undergoing treatment with the FOLFOX chemotherapy regimen and has completed 7 cycles so far. His cancer histology is well-differentiated. Despite experiencing symptoms, he is still able to be ambulatory. The KRAS biomarker analysis shows that he has a wild-type KRAS status."
291,white,female,43,28.22,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,1,"race: white, sex: female, age: 43, bmi: 28.22, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type",The patient is a 43-year-old white female with a BMI of 28.22. She is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cancer cells. The patient has a fully active performance status and her KRAS biomarker is wild-type.
292,white,male,45,22.95,FOLFOX,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 45, bmi: 22.95, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 45-year-old white male with a BMI of 22.95. He is receiving treatment with the FOLFOX chemotherapy regimen and has completed 12 cycles. His cancer histology is well-differentiated, and he has a fully active performance status. The KRAS biomarker testing revealed that he has a wild-type KRAS status."
293,white,male,69,29.19,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,fully active,wild-type,Yes,No,No,No,No,0,"race: white, sex: male, age: 69, bmi: 29.19, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type, adverse effect: thrombosis: Yes","The patient is a 69-year-old white male with a BMI of 29.19. He is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. His cancer histology is well-differentiated, and he has a fully active performance status. The KRAS biomarker testing showed that he has a wild-type KRAS status. The patient has experienced an adverse effect of thrombosis."
294,other,male,61,27.02,FOLFOX,No,No,No,No,12,well differentiated,fully active,mutant,No,No,No,No,No,0,"race: other, sex: male, age: 61, bmi: 27.02, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 61-year-old male of a race other than specified, with a BMI of 27.02. He is undergoing treatment with the FOLFOX chemotherapy regimen and has completed 12 cycles. The histology of his cancer is well-differentiated. Despite his age, he has a fully active performance status. The KRAS biomarker testing revealed a mutant status."
295,white,female,40,30.79,FOLFOX,No,No,No,No,12,poorly differentiated,fully active,wild-type,No,No,No,No,No,1,"race: white, sex: female, age: 40, bmi: 30.79, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 40-year-old white female with a BMI of 30.79. She is receiving the FOLFOX treatment arm and has completed 12 cycles of chemotherapy. Her histology shows poorly differentiated cells. Despite this, her performance status is fully active. Additionally, her KRAS biomarker is wild-type."
296,white,female,59,26.33,FOLFOX + Cetuximab,No,No,No,No,4,well differentiated,symptoms but ambulatory,wild-type,Yes,No,No,No,No,1,"race: white, sex: female, age: 59, bmi: 26.33, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 4, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type, adverse effect: thrombosis: Yes","The patient is a 59-year-old white female with a BMI of 26.33. She is receiving treatment with FOLFOX + Cetuximab and has completed 4 cycles of chemotherapy. Her cancer histology is well-differentiated, and she has symptoms but is still able to be ambulatory. The KRAS biomarker shows that she is wild-type. Additionally, she has experienced an adverse effect of thrombosis."
297,white,male,72,35.96,FOLFOX,No,Yes,No,No,12,well differentiated,fully active,mutant,No,No,Yes,No,No,0,"race: white, sex: male, age: 72, bmi: 35.96, treatment arm: FOLFOX, serious adverse effect: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant, adverse effect: diarrhea: Yes","The patient is a 72-year-old white male with a BMI of 35.96. He is receiving the FOLFOX treatment regimen and has experienced a serious adverse effect. He has completed 12 cycles of chemotherapy. The histology shows that the cancer is well-differentiated. Despite the serious adverse effect, the patient's performance status is fully active. The KRAS biomarker testing revealed a mutant status. Additionally, the patient has experienced diarrhea as an adverse effect of the treatment."
298,white,male,61,27.14,FOLFOX,No,No,No,No,12,well differentiated,fully active,mutant,No,No,No,No,No,1,"race: white, sex: male, age: 61, bmi: 27.14, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 61-year-old white male with a BMI of 27.14. He is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. The histology shows well-differentiated cells, and his performance status is fully active. The KRAS biomarker analysis indicates a mutant status."
299,white,female,54,24.88,FOLFOX,No,Yes,Yes,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 54, bmi: 24.88, treatment arm: FOLFOX, serious adverse effect: Yes, bowel obstruction: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 54-year-old white female with a BMI of 24.88. She is receiving the FOLFOX treatment regimen and has experienced a serious adverse effect, specifically a bowel obstruction. She has completed 12 cycles of chemotherapy. The histology of her condition is well-differentiated. Despite the adverse effect, her performance status is fully active. Additionally, her KRAS biomarker status is wild-type."
300,white,female,48,39.54,FOLFOX + Cetuximab,No,Yes,No,No,12,poorly differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 48, bmi: 39.54, treatment arm: FOLFOX + Cetuximab, serious adverse effect: Yes, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 48-year-old white female with a BMI of 39.54. She is undergoing treatment with FOLFOX + Cetuximab and has experienced a serious adverse effect. She has completed 12 cycles of chemotherapy. The histology of her condition is poorly differentiated. Despite this, her performance status is fully active. Her KRAS biomarker status is wild-type."
301,white,male,50,28.33,FOLFOX,Yes,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 50, bmi: 28.33, treatment arm: FOLFOX, adherence: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type",The patient is a 50-year-old white male with a BMI of 28.33. He is receiving the FOLFOX treatment regimen and has been adherent to the treatment. He has completed 12 cycles of chemotherapy. The histology shows well-differentiated cancer cells. The patient has a fully active performance status. The KRAS biomarker is wild-type.
302,white,male,48,30.14,FOLFOX + Cetuximab,No,Yes,Yes,No,2,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 48, bmi: 30.14, treatment arm: FOLFOX + Cetuximab, serious adverse effect: Yes, bowel obstruction: Yes, chemotherapy cycles: 2, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","This patient is a 48-year-old white male with a BMI of 30.14. He is receiving treatment with FOLFOX + Cetuximab for his cancer. Unfortunately, he has experienced a serious adverse effect in the form of a bowel obstruction after completing 2 cycles of chemotherapy. The histology of his cancer is well differentiated, and his performance status is fully active. His KRAS biomarker status is wild-type."
303,other,male,62,29.4,FOLFOX,Yes,No,No,No,12,poorly differentiated,fully active,wild-type,No,No,No,No,No,0,"race: other, sex: male, age: 62, bmi: 29.4, treatment arm: FOLFOX, adherence: Yes, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 62-year-old male of a race categorized as ""other"" with a BMI of 29.4. He is receiving treatment in the FOLFOX chemotherapy arm and has been adherent to the treatment. He has completed 12 cycles of chemotherapy. The histology of his cancer is poorly differentiated. Despite this, his performance status is fully active. Additionally, the KRAS biomarker testing indicates that he has a wild-type KRAS status."
304,white,male,60,31.47,FOLFOX + Cetuximab,No,No,No,No,12,poorly differentiated,fully active,wild-type,No,Yes,No,No,No,0,"race: white, sex: male, age: 60, bmi: 31.47, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type, adverse effect: hypersensitivity: Yes","The patient is a 60-year-old white male with a BMI of 31.47. He is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. His histology shows poorly differentiated cancer cells. Despite this, his performance status is fully active. The KRAS biomarker indicates that he has a wild-type gene. The patient has experienced a hypersensitivity adverse effect."
305,white,male,40,26.5,FOLFOX + Cetuximab,No,No,No,No,12,poorly differentiated,fully active,mutant,No,No,No,No,No,1,"race: white, sex: male, age: 40, bmi: 26.5, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 40-year-old white male with a BMI of 26.5. He is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. His histology shows poorly differentiated cancer cells. Despite this, his performance status is fully active. Additionally, the KRAS biomarker analysis indicates a mutant status."
306,white,female,63,28.21,FOLFOX,No,Yes,No,No,12,poorly differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 63, bmi: 28.21, treatment arm: FOLFOX, serious adverse effect: Yes, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 63-year-old white female with a BMI of 28.21. She is undergoing treatment with the FOLFOX chemotherapy regimen and has experienced a serious adverse effect. She has completed 12 cycles of chemotherapy. The histology of her cancer is poorly differentiated. Despite these challenges, her performance status is fully active. The KRAS biomarker testing revealed that she has a wild-type KRAS status."
307,white,male,40,23.99,FOLFOX + Cetuximab,No,No,No,No,2,well differentiated,fully active,wild-type,No,No,No,No,No,1,"race: white, sex: male, age: 40, bmi: 23.99, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 2, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type",The patient is a 40-year-old white male with a BMI of 23.99. He is currently receiving treatment with FOLFOX + Cetuximab and has completed 2 cycles of chemotherapy. His histology shows well-differentiated cancer cells. The patient has a fully active performance status and his KRAS biomarker is wild-type.
308,white,female,41,25.72,FOLFOX,Yes,No,Yes,No,10,poorly differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 41, bmi: 25.72, treatment arm: FOLFOX, adherence: Yes, bowel obstruction: Yes, chemotherapy cycles: 10, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 41-year-old white female with a BMI of 25.72. She is receiving treatment with FOLFOX and has been adherent to the treatment. She has experienced a bowel obstruction and has completed 10 cycles of chemotherapy. The histology of her cancer is poorly differentiated. Despite these challenges, her performance status is fully active. Her KRAS biomarker status is wild-type."
309,white,female,41,33.83,FOLFOX + Cetuximab,Yes,Yes,No,No,12,well differentiated,fully active,mutant,No,No,No,No,No,0,"race: white, sex: female, age: 41, bmi: 33.83, treatment arm: FOLFOX + Cetuximab, adherence: Yes, serious adverse effect: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 41-year-old white female with a BMI of 33.83. She is receiving treatment in the FOLFOX + Cetuximab treatment arm and has been adherent to her treatment. She experienced a serious adverse effect during her chemotherapy cycles, which totaled 12. Her histology shows well-differentiated cells, and her performance status is fully active. Additionally, the KRAS biomarker indicates a mutant status."
310,black,male,52,24.62,FOLFOX,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: black, sex: male, age: 52, bmi: 24.62, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type",The patient is a 52-year-old Black male with a BMI of 24.62. He is receiving the FOLFOX treatment arm and has completed 12 cycles of chemotherapy. The histology shows well-differentiated cancer cells. The patient has a fully active performance status. The KRAS biomarker is wild-type.
311,white,male,58,30.34,FOLFOX + Cetuximab,No,Yes,No,No,2,well differentiated,fully active,wild-type,No,No,No,No,No,1,"race: white, sex: male, age: 58, bmi: 30.34, treatment arm: FOLFOX + Cetuximab, serious adverse effect: Yes, chemotherapy cycles: 2, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 58-year-old white male with a BMI of 30.34. He is receiving treatment with FOLFOX + Cetuximab and has experienced a serious adverse effect. He has completed 2 cycles of chemotherapy. His histology shows well-differentiated cells, and his performance status is fully active. The KRAS biomarker indicates that he has a wild-type mutation."
312,white,male,67,42.05,FOLFOX,No,Yes,No,No,2,well differentiated,symptoms but ambulatory,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 67, bmi: 42.05, treatment arm: FOLFOX, serious adverse effect: Yes, chemotherapy cycles: 2, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type","The patient is a 67-year-old white male with a BMI of 42.05. He is receiving the FOLFOX treatment arm and has experienced a serious adverse effect. He has completed 2 cycles of chemotherapy. His histology shows well-differentiated cancer cells. Despite experiencing symptoms, he is still able to be ambulatory. The KRAS biomarker indicates that he has a wild-type gene."
313,white,male,38,29.86,FOLFIRI + Cetuximab,No,Yes,No,No,1,well differentiated,fully active,wild-type,No,No,No,Yes,Yes,1,"race: white, sex: male, age: 38, bmi: 29.86, treatment arm: FOLFIRI + Cetuximab, serious adverse effect: Yes, chemotherapy cycles: 1, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type, adverse effect: infection: Yes, adverse effect: infarction: Yes","The patient is a 38-year-old white male with a BMI of 29.86. He is receiving treatment with FOLFIRI + Cetuximab and has experienced a serious adverse effect. He has completed one cycle of chemotherapy. His histology shows well-differentiated cells, and he has a fully active performance status. The KRAS biomarker indicates he is wild-type. The patient has experienced adverse effects including infection and infarction."
314,white,male,74,21.46,FOLFOX,Yes,No,No,No,12,poorly differentiated,symptoms but ambulatory,wild-type,No,No,Yes,No,No,0,"race: white, sex: male, age: 74, bmi: 21.46, treatment arm: FOLFOX, adherence: Yes, chemotherapy cycles: 12, histology: poorly differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type, adverse effect: diarrhea: Yes","The patient is a 74-year-old white male with a BMI of 21.46. He is receiving the FOLFOX treatment regimen and has adhered to the treatment. He has completed 12 cycles of chemotherapy. The histology of his cancer is poorly differentiated. Despite experiencing symptoms, he is still able to move around. His KRAS biomarker is wild-type. He has also experienced diarrhea as an adverse effect of the treatment."
315,other,female,48,26.21,FOLFIRI,No,No,No,No,12,poorly differentiated,symptoms but ambulatory,wild-type,No,No,No,No,No,0,"race: other, sex: female, age: 48, bmi: 26.21, treatment arm: FOLFIRI, chemotherapy cycles: 12, histology: poorly differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type","The patient is a 48-year-old female of a race categorized as ""other"" with a BMI of 26.21. She is undergoing treatment with the FOLFIRI chemotherapy regimen and has completed 12 cycles. The histology of her cancer is poorly differentiated. Despite experiencing symptoms, she is still able to ambulate, indicating a relatively good performance status. Additionally, her KRAS biomarker status is wild-type."
316,white,male,44,22.66,FOLFOX + Cetuximab,No,No,No,No,10,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 44, bmi: 22.66, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 10, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type",The patient is a 44-year-old white male with a BMI of 22.66. He is receiving treatment in the FOLFOX + Cetuximab treatment arm and has completed 10 cycles of chemotherapy. His histology shows well-differentiated cancer cells. The patient has a fully active performance status and his KRAS biomarker is wild-type.
317,black,female,57,37.02,FOLFOX + Cetuximab,No,Yes,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: black, sex: female, age: 57, bmi: 37.02, treatment arm: FOLFOX + Cetuximab, serious adverse effect: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 57-year-old Black female with a BMI of 37.02. She is receiving treatment with FOLFOX + Cetuximab and has experienced a serious adverse effect. She has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cells. Despite these challenges, her performance status is fully active. Additionally, her KRAS biomarker indicates that it is wild-type."
318,white,female,46,36.84,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,symptoms but ambulatory,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 46, bmi: 36.84, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type","The patient is a 46-year-old white female with a BMI of 36.84. She is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cancer cells. Despite experiencing symptoms, she is still able to walk around (ambulatory). The KRAS biomarker analysis indicates that she has a wild-type KRAS gene."
319,white,male,52,36.37,FOLFOX,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 52, bmi: 36.37, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type",The patient is a 52-year-old white male with a BMI of 36.37. He is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cells. The patient has a fully active performance status and his KRAS biomarker is wild-type.
320,white,male,71,27.93,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 71, bmi: 27.93, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 71-year-old white male with a BMI of 27.93. He is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer cells. Despite his age, the patient has a fully active performance status. Additionally, his KRAS biomarker indicates that he has a wild-type gene."
321,white,female,49,28.58,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 49, bmi: 28.58, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 49-year-old white female with a BMI of 28.58. She is receiving treatment in the FOLFOX + Cetuximab treatment arm and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cancer, and she has a fully active performance status. Additionally, her KRAS biomarker is wild-type."
322,white,female,74,22.54,FOLFOX + Cetuximab,No,No,No,No,1,well differentiated,symptoms but ambulatory,wild-type,No,No,Yes,No,No,0,"race: white, sex: female, age: 74, bmi: 22.54, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 1, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type, adverse effect: diarrhea: Yes","The patient is a 74-year-old white female with a BMI of 22.54. She is receiving treatment with FOLFOX + Cetuximab and has completed one cycle of chemotherapy. Her histology shows well-differentiated cancer, and she has symptoms but is still able to be ambulatory. The KRAS biomarker indicates that she has a wild-type gene. She is experiencing diarrhea as an adverse effect of the treatment."
323,other,male,40,22.86,FOLFOX + Cetuximab,No,No,Yes,No,8,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: other, sex: male, age: 40, bmi: 22.86, treatment arm: FOLFOX + Cetuximab, bowel obstruction: Yes, chemotherapy cycles: 8, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 40-year-old male of a race categorized as ""other"" with a BMI of 22.86. He is receiving treatment in the FOLFOX + Cetuximab treatment arm. The patient has experienced a bowel obstruction and has completed 8 cycles of chemotherapy. His histology shows well-differentiated cells, and he has a fully active performance status. Additionally, the KRAS biomarker indicates that he has a wild-type status."
324,white,female,66,25.09,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 66, bmi: 25.09, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 66-year-old white female with a BMI of 25.09. She is receiving treatment in the FOLFOX + Cetuximab treatment arm and is scheduled for 12 chemotherapy cycles. The histology indicates that the cancer is well-differentiated. Despite the diagnosis, the patient has a fully active performance status. Additionally, the KRAS biomarker testing revealed that the patient has a wild-type KRAS status."
325,white,female,74,26.66,FOLFOX,No,No,No,No,12,well differentiated,symptoms but ambulatory,mutant,No,No,No,No,No,1,"race: white, sex: female, age: 74, bmi: 26.66, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: mutant","The patient is a 74-year-old white female with a BMI of 26.66. She is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cancer cells. Despite experiencing symptoms, she is still able to be ambulatory. The KRAS biomarker testing revealed a mutant status."
326,white,female,65,24.46,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,fully active,mutant,No,No,No,No,No,0,"race: white, sex: female, age: 65, bmi: 24.46, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant",The patient is a 65-year-old white female with a BMI of 24.46. She is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cancer cells. The patient has a fully active performance status. The KRAS biomarker analysis indicates a mutant status.
327,black,female,47,36.92,FOLFOX + Cetuximab,No,Yes,No,No,12,poorly differentiated,fully active,wild-type,No,No,No,No,No,0,"race: black, sex: female, age: 47, bmi: 36.92, treatment arm: FOLFOX + Cetuximab, serious adverse effect: Yes, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 47-year-old Black female with a BMI of 36.92. She is receiving treatment with FOLFOX + Cetuximab and has experienced a serious adverse effect. She has undergone 12 cycles of chemotherapy. The histology of her condition is poorly differentiated. Despite this, her performance status is fully active. Additionally, her KRAS biomarker is wild-type."
328,white,male,68,44.42,FOLFOX,No,No,No,No,12,well differentiated,fully active,mutant,No,No,No,No,No,0,"race: white, sex: male, age: 68, bmi: 44.42, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 68-year-old white male with a BMI of 44.42. He is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer cells. Despite his age, he has a fully active performance status. The KRAS biomarker analysis indicates a mutant status."
329,white,female,53,22.72,FOLFOX + Cetuximab,Yes,No,Yes,No,0,well differentiated,fully active,interminate,No,No,No,No,No,0,"race: white, sex: female, age: 53, bmi: 22.72, treatment arm: FOLFOX + Cetuximab, adherence: Yes, bowel obstruction: Yes, chemotherapy cycles: 0, histology: well differentiated, performance status: fully active, KRAS biomarker: interminate","The patient is a 53-year-old white female with a BMI of 22.72. She is currently enrolled in the treatment arm receiving FOLFOX + Cetuximab. She is adherent to her treatment regimen. The patient has a history of bowel obstruction. She has not yet started any chemotherapy cycles. Histologically, her cancer is well-differentiated. Despite the bowel obstruction, her performance status is fully active. The KRAS biomarker status is indeterminate for this patient."
330,white,female,75,28.32,FOLFOX,No,No,No,No,12,well differentiated,symptoms but ambulatory,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 75, bmi: 28.32, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type","The patient is a 75-year-old white female with a BMI of 28.32. She is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cancer cells. Despite experiencing symptoms, she is still able to walk around (ambulatory). The KRAS biomarker analysis indicates that she has the wild-type variant."
331,white,female,75,29.94,FOLFOX,Yes,No,Yes,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 75, bmi: 29.94, treatment arm: FOLFOX, adherence: Yes, bowel obstruction: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 75-year-old white female with a BMI of 29.94. She is receiving the FOLFOX treatment regimen and has been adherent to the treatment. She has experienced a bowel obstruction. The patient has completed 12 cycles of chemotherapy. The histology shows well-differentiated cancer cells. Despite the bowel obstruction, her performance status is fully active. The KRAS biomarker analysis indicates that she has a wild-type KRAS status."
332,white,female,41,34.22,FOLFOX + Cetuximab,Yes,No,Yes,No,3,well differentiated,in bed less than 50% of the time,wild-type,No,Yes,No,No,No,0,"race: white, sex: female, age: 41, bmi: 34.22, treatment arm: FOLFOX + Cetuximab, adherence: Yes, bowel obstruction: Yes, chemotherapy cycles: 3, histology: well differentiated, performance status: in bed less than 50% of the time, KRAS biomarker: wild-type, adverse effect: hypersensitivity: Yes",The patient is a 41-year-old white female with a BMI of 34.22. She is currently receiving treatment in the FOLFOX + Cetuximab treatment arm and has been adherent to her medication. She is experiencing a bowel obstruction and has completed 3 cycles of chemotherapy. The histology shows that the cancer is well-differentiated. The patient's performance status indicates that she is in bed less than 50% of the time. Her KRAS biomarker is wild-type. She has experienced a hypersensitivity adverse effect.
333,white,male,65,26.37,FOLFOX,No,No,Yes,Yes,12,well differentiated,symptoms but ambulatory,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 65, bmi: 26.37, treatment arm: FOLFOX, bowel obstruction: Yes, bowel perforation: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type","The patient is a 65-year-old white male with a BMI of 26.37. He is receiving treatment with FOLFOX chemotherapy. He has experienced both a bowel obstruction and perforation. The patient has completed 12 cycles of chemotherapy and has well-differentiated histology. Despite experiencing symptoms, he is still able to be ambulatory. His KRAS biomarker status is wild-type."
334,white,female,48,35.02,FOLFOX,No,Yes,No,No,10,well differentiated,fully active,mutant,No,No,No,Yes,No,1,"race: white, sex: female, age: 48, bmi: 35.02, treatment arm: FOLFOX, serious adverse effect: Yes, chemotherapy cycles: 10, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant, adverse effect: infection: Yes","This patient is a 48-year-old white female with a BMI of 35.02. She is receiving the FOLFOX treatment regimen and has experienced a serious adverse effect. She has completed 10 cycles of chemotherapy. The histology of her cancer is well differentiated. Despite the serious adverse effect, her performance status is fully active. The KRAS biomarker testing revealed a mutant status. Additionally, she has developed an infection as an adverse effect of her treatment."
335,white,male,64,29.07,FOLFOX,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 64, bmi: 29.07, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 64-year-old white male with a BMI of 29.07. He is receiving treatment with the FOLFOX chemotherapy regimen and has completed 12 cycles. His cancer histology is well-differentiated, and he has a fully active performance status. The KRAS biomarker analysis shows that he has a wild-type KRAS status."
336,white,female,64,27.82,FOLFOX,No,No,No,No,12,well differentiated,fully active,interminate,No,No,No,No,No,0,"race: white, sex: female, age: 64, bmi: 27.82, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: interminate","The patient is a 64-year-old white female with a BMI of 27.82. She is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cancer cells. Despite her cancer diagnosis, she has a fully active performance status. The KRAS biomarker status is indeterminate for this patient."
337,white,male,62,27.03,FOLFIRI (KRAS mutant),No,No,No,No,12,well differentiated,symptoms but ambulatory,mutant,No,No,No,No,No,0,"race: white, sex: male, age: 62, bmi: 27.03, treatment arm: FOLFIRI (KRAS mutant), chemotherapy cycles: 12, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: mutant","The patient is a 62-year-old white male with a BMI of 27.03. He is receiving treatment with the FOLFIRI regimen for his KRAS mutant status. He has completed 12 cycles of chemotherapy. His cancer histology is well differentiated. Despite experiencing symptoms, he is still able to be ambulatory."
338,white,male,69,29.59,FOLFOX,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 69, bmi: 29.59, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type",The patient is a 69-year-old white male with a BMI of 29.59. He is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer cells. The patient has a fully active performance status. His KRAS biomarker status is wild-type.
339,white,male,35,22.68,FOLFOX + Cetuximab,No,No,No,No,4,well differentiated,symptoms but ambulatory,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 35, bmi: 22.68, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 4, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type","The patient is a 35-year-old white male with a BMI of 22.68. He is receiving treatment with FOLFOX + Cetuximab and has completed 4 cycles of chemotherapy. His histology shows well-differentiated cancer cells. Despite experiencing symptoms, he is still able to walk around (ambulatory). The KRAS biomarker analysis indicates that he has a wild-type KRAS status."
340,white,male,56,20.27,FOLFIRI (KRAS mutant),No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 56, bmi: 20.27, treatment arm: FOLFIRI (KRAS mutant), chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type",The patient is a 56-year-old white male with a BMI of 20.27. He is receiving treatment in the FOLFIRI chemotherapy arm for KRAS mutant status. He has completed 12 cycles of chemotherapy. The histology shows well-differentiated cancer cells. The patient has a fully active performance status and the KRAS biomarker is wild-type.
341,black,male,66,25.3,FOLFOX,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: black, sex: male, age: 66, bmi: 25.3, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 66-year-old Black male with a BMI of 25.3. He is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer cells. Despite his age, he has a fully active performance status. The KRAS biomarker analysis indicates that he has a wild-type KRAS gene."
342,white,male,76,22.94,FOLFOX,No,Yes,No,No,12,poorly differentiated,symptoms but ambulatory,wild-type,No,No,No,No,No,1,"race: white, sex: male, age: 76, bmi: 22.94, treatment arm: FOLFOX, serious adverse effect: Yes, chemotherapy cycles: 12, histology: poorly differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type","The patient is a 76-year-old white male with a BMI of 22.94. He is undergoing treatment with the FOLFOX chemotherapy regimen and has experienced a serious adverse effect. He has completed 12 cycles of chemotherapy. The histology of his cancer is poorly differentiated. Despite experiencing symptoms, he is still able to be ambulatory. His KRAS biomarker status is wild-type."
343,white,female,63,34.65,FOLFOX + Cetuximab,No,Yes,No,No,12,well differentiated,fully active,mutant,No,No,No,Yes,No,0,"race: white, sex: female, age: 63, bmi: 34.65, treatment arm: FOLFOX + Cetuximab, serious adverse effect: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant, adverse effect: infection: Yes","The patient is a 63-year-old white female with a BMI of 34.65. She is receiving treatment with FOLFOX + Cetuximab and has experienced a serious adverse effect. She has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cells, and she has a fully active performance status. The KRAS biomarker testing revealed a mutant status. Additionally, she has experienced an infection as an adverse effect."
344,other,male,42,23.31,FOLFOX + Cetuximab,Yes,No,No,No,12,poorly differentiated,fully active,wild-type,No,No,No,No,No,0,"race: other, sex: male, age: 42, bmi: 23.31, treatment arm: FOLFOX + Cetuximab, adherence: Yes, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 42-year-old male of a race categorized as ""other"" with a BMI of 23.31. He is undergoing treatment in the FOLFOX + Cetuximab treatment arm and has been adherent to the treatment. He has completed 12 cycles of chemotherapy. The histology of his condition is poorly differentiated. Despite this, his performance status is fully active. Additionally, the KRAS biomarker analysis indicates that he has a wild-type KRAS status."
345,white,female,42,27.58,FOLFOX + Cetuximab,No,Yes,No,No,12,well differentiated,symptoms but ambulatory,wild-type,No,No,Yes,No,No,0,"race: white, sex: female, age: 42, bmi: 27.58, treatment arm: FOLFOX + Cetuximab, serious adverse effect: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type, adverse effect: diarrhea: Yes","The patient is a 42-year-old white female with a BMI of 27.58 who is receiving treatment with FOLFOX + Cetuximab. She experienced a serious adverse effect during the treatment. She has undergone 12 cycles of chemotherapy. The histology shows that the cancer is well-differentiated. Despite experiencing symptoms, she is still able to be ambulatory. Her KRAS biomarker is wild-type. Additionally, she has experienced diarrhea as an adverse effect of the treatment."
346,white,female,62,26.12,FOLFIRI,No,No,No,No,12,poorly differentiated,fully active,mutant,No,No,No,No,No,0,"race: white, sex: female, age: 62, bmi: 26.12, treatment arm: FOLFIRI, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 62-year-old white female with a BMI of 26.12. She is receiving the FOLFIRI treatment regimen and has completed 12 cycles of chemotherapy. Her cancer histology is poorly differentiated. Despite her diagnosis, she has a fully active performance status. The KRAS biomarker testing revealed a mutant status."
347,black,male,52,22.5,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,symptoms but ambulatory,wild-type,No,No,No,No,No,0,"race: black, sex: male, age: 52, bmi: 22.5, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type","The patient is a 52-year-old Black male with a BMI of 22.5. He is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer. Despite experiencing symptoms, he is still able to walk around (ambulatory). His KRAS biomarker status is wild-type."
348,white,male,76,28.15,FOLFOX + Cetuximab,Yes,Yes,Yes,Yes,12,well differentiated,symptoms but ambulatory,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 76, bmi: 28.15, treatment arm: FOLFOX + Cetuximab, adherence: Yes, serious adverse effect: Yes, bowel obstruction: Yes, bowel perforation: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type","The patient is a 76-year-old white male with a BMI of 28.15. He is receiving treatment in the FOLFOX + Cetuximab treatment arm and has been adherent to the treatment. Unfortunately, he experienced serious adverse effects in the form of bowel obstruction and perforation. He has completed 12 cycles of chemotherapy and has well-differentiated histology. Despite experiencing symptoms, he is still ambulatory. His KRAS biomarker status is wild-type."
349,white,female,50,23.6,FOLFOX + Cetuximab,No,No,No,Yes,5,well differentiated,symptoms but ambulatory,wild-type,No,No,Yes,No,No,0,"race: white, sex: female, age: 50, bmi: 23.6, treatment arm: FOLFOX + Cetuximab, bowel perforation: Yes, chemotherapy cycles: 5, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type, adverse effect: diarrhea: Yes","This patient is a 50-year-old white female with a BMI of 23.6. She is receiving treatment with FOLFOX + Cetuximab and has experienced a bowel perforation. She has completed 5 cycles of chemotherapy. The histology of her cancer is well-differentiated, and her performance status is symptomatic but she is still able to be ambulatory. Her KRAS biomarker is wild-type. She is experiencing diarrhea as an adverse effect of her treatment."
350,white,male,64,31.94,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 64, bmi: 31.94, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 64-year-old white male with a BMI of 31.94. He is receiving treatment in the FOLFOX + Cetuximab treatment arm and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer cells. Despite his age, he has a fully active performance status. Additionally, his KRAS biomarker indicates that he has a wild-type gene."
351,white,male,69,26.1,FOLFOX,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 69, bmi: 26.1, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type",The patient is a 69-year-old white male with a BMI of 26.1. He is undergoing treatment with the FOLFOX chemotherapy regimen and has completed 12 cycles. His cancer histology is well differentiated. The patient has a fully active performance status and his KRAS biomarker is wild-type.
352,white,female,62,34.87,FOLFOX,No,No,No,No,5,poorly differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 62, bmi: 34.87, treatment arm: FOLFOX, chemotherapy cycles: 5, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 62-year-old white female with a BMI of 34.87. She is receiving the FOLFOX treatment regimen and has completed 5 cycles of chemotherapy. The histology of her cancer is poorly differentiated. Despite her cancer diagnosis, she has a fully active performance status. Her KRAS biomarker status is wild-type."
353,white,female,60,47.51,FOLFOX,No,No,No,No,12,poorly differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 60, bmi: 47.51, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 60-year-old white female with a high BMI of 47.51. She is receiving the FOLFOX treatment arm for her chemotherapy, with a planned 12 cycles. Her cancer histology is poorly differentiated. Despite her health challenges, she has a fully active performance status. The KRAS biomarker testing indicates that she has a wild-type status."
354,other,male,69,23.1,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,Yes,Yes,No,0,"race: other, sex: male, age: 69, bmi: 23.1, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type, adverse effect: diarrhea: Yes, adverse effect: infection: Yes","The patient is a 69-year-old male of a race categorized as ""other"" with a BMI of 23.1. He is receiving treatment in the FOLFOX + Cetuximab treatment arm and has completed 12 cycles of chemotherapy. The histology indicates well-differentiated cancer, and the patient's performance status is fully active. The KRAS biomarker shows wild-type status. The patient has experienced adverse effects of diarrhea and infection during the course of treatment."
355,white,female,76,27,FOLFOX,No,No,No,No,10,poorly differentiated,symptoms but ambulatory,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 76, bmi: 27.0, treatment arm: FOLFOX, chemotherapy cycles: 10, histology: poorly differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type","The patient is a 76-year-old white female with a BMI of 27.0. She is receiving the FOLFOX treatment regimen and has completed 10 cycles of chemotherapy. Her histology shows poorly differentiated cancer cells. Despite experiencing symptoms, she is still able to walk around (ambulatory). The KRAS biomarker analysis indicates that she has a wild-type KRAS status."
356,white,male,34,30.49,FOLFOX + Cetuximab,Yes,No,No,No,12,poorly differentiated,fully active,mutant,No,No,No,No,No,1,"race: white, sex: male, age: 34, bmi: 30.49, treatment arm: FOLFOX + Cetuximab, adherence: Yes, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 34-year-old white male with a BMI of 30.49. He is receiving treatment in the FOLFOX + Cetuximab treatment arm and has been adherent to the treatment. He has completed 12 chemotherapy cycles. His histology shows poorly differentiated cancer cells. Despite this, his performance status is fully active. The KRAS biomarker analysis indicates a mutant status."
357,white,male,50,22.86,FOLFIRI (KRAS mutant),No,No,No,No,12,well differentiated,fully active,mutant,No,No,No,No,No,0,"race: white, sex: male, age: 50, bmi: 22.86, treatment arm: FOLFIRI (KRAS mutant), chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant",The patient is a 50-year-old white male with a BMI of 22.86. He is undergoing treatment with the FOLFIRI regimen for KRAS mutant cancer. He has completed 12 cycles of chemotherapy. His cancer histology is well differentiated. The patient has a fully active performance status.
358,black,male,51,29.74,FOLFOX + Cetuximab,Yes,No,Yes,No,0,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: black, sex: male, age: 51, bmi: 29.74, treatment arm: FOLFOX + Cetuximab, adherence: Yes, bowel obstruction: Yes, chemotherapy cycles: 0, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 51-year-old Black male with a BMI of 29.74. He is receiving treatment in the FOLFOX + Cetuximab treatment arm and is adherent to the treatment. He has a bowel obstruction and has not yet undergone any chemotherapy cycles. His histology shows well-differentiated cells, and his performance status is fully active. The KRAS biomarker indicates that he has a wild-type status."
359,white,female,71,27.74,FOLFOX,No,No,No,No,5,poorly differentiated,fully active,wild-type,No,No,Yes,No,No,0,"race: white, sex: female, age: 71, bmi: 27.74, treatment arm: FOLFOX, chemotherapy cycles: 5, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type, adverse effect: diarrhea: Yes","The patient is a 71-year-old white female with a BMI of 27.74. She is receiving the FOLFOX treatment regimen and has completed 5 cycles of chemotherapy. Her histology shows poorly differentiated cancer cells. Despite this, her performance status is fully active. The KRAS biomarker testing revealed that she has a wild-type KRAS status. The patient is experiencing diarrhea as an adverse effect of the treatment."
360,white,female,62,30.97,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,fully active,wild-type,No,Yes,No,No,No,0,"race: white, sex: female, age: 62, bmi: 30.97, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type, adverse effect: hypersensitivity: Yes","The patient is a 62-year-old white female with a BMI of 30.97. She is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. Her cancer histology is well-differentiated, and she has a fully active performance status. The KRAS biomarker testing showed that she has a wild-type KRAS status. Additionally, she has experienced a hypersensitivity adverse effect during treatment."
361,white,female,60,35.67,FOLFIRI + Cetuximab,No,No,No,No,12,well differentiated,symptoms but ambulatory,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 60, bmi: 35.67, treatment arm: FOLFIRI + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type","The patient is a 60-year-old white female with a BMI of 35.67. She is receiving treatment with FOLFIRI + Cetuximab and has completed 12 cycles of chemotherapy. The histology shows well-differentiated cancer cells. Despite experiencing symptoms, the patient is still able to walk around (ambulatory). The KRAS biomarker indicates that the patient has a wild-type KRAS gene."
362,white,female,49,25.92,FOLFOX + Cetuximab,No,Yes,No,Yes,12,poorly differentiated,fully active,mutant,No,No,No,No,No,0,"race: white, sex: female, age: 49, bmi: 25.92, treatment arm: FOLFOX + Cetuximab, serious adverse effect: Yes, bowel perforation: Yes, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 49-year-old white female with a BMI of 25.92. She is receiving treatment with FOLFOX + Cetuximab and has experienced a serious adverse effect, specifically a bowel perforation. She has completed 12 cycles of chemotherapy. Her histology shows poorly differentiated cells. Despite these challenges, her performance status is fully active. Additionally, the KRAS biomarker testing revealed a mutant result."
363,white,female,51,21.94,FOLFIRI,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 51, bmi: 21.94, treatment arm: FOLFIRI, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type",The patient is a 51-year-old white female with a BMI of 21.94. She is receiving the FOLFIRI treatment regimen and has completed 12 cycles of chemotherapy. Her cancer histology is well-differentiated. She has a fully active performance status. The KRAS biomarker testing showed that she has a wild-type KRAS status.
364,white,female,71,34.86,FOLFOX + Cetuximab,No,Yes,No,No,12,well differentiated,fully active,mutant,No,No,No,No,No,0,"race: white, sex: female, age: 71, bmi: 34.86, treatment arm: FOLFOX + Cetuximab, serious adverse effect: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 71-year-old white female with a BMI of 34.86. She is receiving treatment with FOLFOX + Cetuximab and has experienced a serious adverse effect. She has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cells, and she has a fully active performance status. The KRAS biomarker indicates a mutant status."
365,black,male,41,23.34,FOLFOX,No,No,Yes,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: black, sex: male, age: 41, bmi: 23.34, treatment arm: FOLFOX, bowel obstruction: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 41-year-old Black male with a BMI of 23.34. He is receiving treatment with the FOLFOX regimen for his bowel obstruction. He has completed 12 cycles of chemotherapy. The histology of his cancer is well differentiated. Despite his condition, he has a fully active performance status. His KRAS biomarker status is wild-type."
366,white,female,57,27.06,FOLFOX,No,Yes,No,No,12,well differentiated,fully active,wild-type,No,No,No,Yes,No,0,"race: white, sex: female, age: 57, bmi: 27.06, treatment arm: FOLFOX, serious adverse effect: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type, adverse effect: infection: Yes","The patient is a 57-year-old white female with a BMI of 27.06. She is receiving treatment with FOLFOX chemotherapy regimen and has experienced a serious adverse effect. She has completed 12 cycles of chemotherapy. The histology of her cancer is well differentiated. Despite the serious adverse effect, her performance status is fully active. Her KRAS biomarker status is wild-type. Additionally, she has experienced an infection as an adverse effect during her treatment."
367,other,female,68,21.79,FOLFOX,No,No,No,No,0,well differentiated,symptoms but ambulatory,wild-type,No,No,No,No,No,0,"race: other, sex: female, age: 68, bmi: 21.79, treatment arm: FOLFOX, chemotherapy cycles: 0, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type","The patient is a 68-year-old female of a race classified as ""other"" with a BMI of 21.79. She is part of the FOLFOX treatment arm but has not undergone any chemotherapy cycles yet. Her histology shows well-differentiated characteristics. Despite experiencing symptoms, she is still able to walk around (ambulatory). Additionally, her KRAS biomarker indicates that it is wild-type."
368,white,male,40,27.52,FOLFIRI (KRAS mutant),No,No,No,No,12,poorly differentiated,fully active,mutant,Yes,No,No,No,No,0,"race: white, sex: male, age: 40, bmi: 27.52, treatment arm: FOLFIRI (KRAS mutant), chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: mutant, adverse effect: thrombosis: Yes","The patient is a 40-year-old white male with a BMI of 27.52. He is receiving the FOLFIRI treatment regimen for his KRAS mutant cancer. He has completed 12 cycles of chemotherapy. The histology of his cancer is poorly differentiated. Despite this, his performance status is fully active. The patient has a mutant KRAS biomarker. He has experienced an adverse effect of thrombosis."
369,white,male,66,56.4,FOLFOX + Cetuximab,No,Yes,No,No,12,poorly differentiated,fully active,mutant,No,No,Yes,Yes,No,0,"race: white, sex: male, age: 66, bmi: 56.4, treatment arm: FOLFOX + Cetuximab, serious adverse effect: Yes, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: mutant, adverse effect: diarrhea: Yes, adverse effect: infection: Yes","The patient is a 66-year-old white male with a high BMI of 56.4. He is receiving treatment with FOLFOX + Cetuximab and has experienced a serious adverse effect. He has undergone 12 cycles of chemotherapy and has a histology of poorly differentiated cancer. Despite this, his performance status is fully active. The patient's KRAS biomarker is mutant. He has also experienced adverse effects such as diarrhea and infection."
370,black,female,69,44.42,FOLFOX,No,Yes,No,No,9,well differentiated,fully active,mutant,No,No,No,No,No,0,"race: black, sex: female, age: 69, bmi: 44.42, treatment arm: FOLFOX, serious adverse effect: Yes, chemotherapy cycles: 9, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 69-year-old Black female with a BMI of 44.42. She is receiving the FOLFOX treatment regimen and has experienced a serious adverse effect. She has completed 9 cycles of chemotherapy. The histology shows that the cancer is well-differentiated. Despite the treatment, her performance status is fully active. The KRAS biomarker analysis indicates that she has a mutant KRAS status."
371,other,female,55,30.22,FOLFOX + Cetuximab,No,No,Yes,No,12,well differentiated,symptoms but ambulatory,mutant,No,No,Yes,No,No,0,"race: other, sex: female, age: 55, bmi: 30.22, treatment arm: FOLFOX + Cetuximab, bowel obstruction: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: mutant, adverse effect: diarrhea: Yes","This patient is a 55-year-old female of a race other than specified, with a BMI of 30.22. She is receiving treatment with FOLFOX + Cetuximab and has experienced a bowel obstruction. She has completed 12 cycles of chemotherapy and has well-differentiated histology. Despite experiencing symptoms, she is still ambulatory. The KRAS biomarker testing revealed a mutant status. Additionally, she has reported experiencing diarrhea as an adverse effect of her treatment."
372,white,female,51,44.64,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 51, bmi: 44.64, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 51-year-old white female with a BMI of 44.64. She is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. Her cancer histology is well-differentiated. Despite her cancer diagnosis, she has a fully active performance status. Additionally, her KRAS biomarker status is wild-type."
373,white,male,41,29.89,FOLFOX + Cetuximab,Yes,No,Yes,Yes,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 41, bmi: 29.89, treatment arm: FOLFOX + Cetuximab, adherence: Yes, bowel obstruction: Yes, bowel perforation: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 41-year-old white male with a BMI of 29.89. He is receiving treatment in the FOLFOX + Cetuximab treatment arm and has been adherent to the treatment. He has experienced both a bowel obstruction and a bowel perforation. The patient has completed 12 cycles of chemotherapy. His histology shows well-differentiated cells. Despite the bowel issues, his performance status is fully active. The KRAS biomarker indicates that he has a wild-type mutation."
374,white,female,51,28.18,FOLFIRI + Cetuximab,No,No,No,No,3,well differentiated,fully active,wild-type,Yes,No,No,No,No,1,"race: white, sex: female, age: 51, bmi: 28.18, treatment arm: FOLFIRI + Cetuximab, chemotherapy cycles: 3, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type, adverse effect: thrombosis: Yes","This patient is a 51-year-old white female with a BMI of 28.18. She is currently receiving treatment with FOLFIRI + Cetuximab and has completed 3 cycles of chemotherapy. Her cancer histology is well differentiated, and she has a fully active performance status. The KRAS biomarker testing showed that she has a wild-type KRAS status. Additionally, she has experienced an adverse effect of thrombosis."
375,white,male,37,23.24,FOLFOX,No,No,Yes,No,3,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 37, bmi: 23.24, treatment arm: FOLFOX, bowel obstruction: Yes, chemotherapy cycles: 3, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 37-year-old white male with a BMI of 23.24. He is receiving treatment with the FOLFOX regimen for his bowel obstruction. He has completed 3 cycles of chemotherapy. The histology shows that the cancer is well-differentiated. Despite the bowel obstruction, the patient's performance status is fully active. The KRAS biomarker analysis indicates that he has a wild-type KRAS status."
376,white,male,58,26.82,FOLFOX,No,No,No,No,12,well differentiated,fully active,mutant,No,No,No,No,No,0,"race: white, sex: male, age: 58, bmi: 26.82, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 58-year-old white male with a BMI of 26.82. He is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer cells. The patient has a fully active performance status. Additionally, the KRAS biomarker testing revealed a mutant status."
377,other,female,37,38.52,FOLFOX,No,No,No,No,12,well differentiated,fully active,interminate,No,No,No,No,No,0,"race: other, sex: female, age: 37, bmi: 38.52, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: interminate","The patient is a 37-year-old female of a race categorized as ""other"" with a BMI of 38.52. She is undergoing treatment with the FOLFOX chemotherapy regimen and has completed 12 cycles. The histology of her condition is well-differentiated. Despite her diagnosis, she maintains a fully active performance status. The KRAS biomarker status is indeterminate for this patient."
378,other,female,60,20.3,FOLFOX,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: other, sex: female, age: 60, bmi: 20.3, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 60-year-old female of a race categorized as ""other"" with a BMI of 20.3. She is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated characteristics. In terms of performance status, she is fully active. Additionally, her KRAS biomarker status is wild-type."
379,white,male,57,30.49,FOLFIRI,No,No,No,No,1,poorly differentiated,fully active,mutant,No,No,No,No,No,1,"race: white, sex: male, age: 57, bmi: 30.49, treatment arm: FOLFIRI, chemotherapy cycles: 1, histology: poorly differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 57-year-old white male with a BMI of 30.49. He is currently receiving treatment in the FOLFIRI chemotherapy arm and has completed one cycle of treatment. His histology shows poorly differentiated cancer cells. Despite this, his performance status is fully active. Additionally, the patient's KRAS biomarker indicates a mutant status."
380,white,male,56,32.46,FOLFOX,No,No,No,No,12,poorly differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 56, bmi: 32.46, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 56-year-old white male with a BMI of 32.46. He is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. His histology shows poorly differentiated cancer cells. Despite this, his performance status is fully active. The KRAS biomarker analysis indicates that he has a wild-type KRAS gene."
381,white,female,45,32.24,FOLFOX + Cetuximab,No,Yes,Yes,No,10,poorly differentiated,fully active,mutant,No,No,No,No,No,1,"race: white, sex: female, age: 45, bmi: 32.24, treatment arm: FOLFOX + Cetuximab, serious adverse effect: Yes, bowel obstruction: Yes, chemotherapy cycles: 10, histology: poorly differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 45-year-old white female with a BMI of 32.24. She is receiving treatment with FOLFOX + Cetuximab and has experienced a serious adverse effect, specifically a bowel obstruction. She has completed 10 cycles of chemotherapy. Her histology shows poorly differentiated cells. Despite these challenges, her performance status is fully active. Additionally, her KRAS biomarker is mutant."
382,white,male,38,36.16,FOLFOX + Cetuximab,Yes,No,No,No,9,well differentiated,symptoms but ambulatory,interminate,No,No,No,No,No,1,"race: white, sex: male, age: 38, bmi: 36.16, treatment arm: FOLFOX + Cetuximab, adherence: Yes, chemotherapy cycles: 9, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: interminate","The patient is a 38-year-old white male with a BMI of 36.16. He is receiving treatment in the FOLFOX + Cetuximab treatment arm and has been adherent to the treatment. He has completed 9 chemotherapy cycles. The histology shows well-differentiated cancer cells. Despite experiencing symptoms, the patient is still able to be ambulatory. The KRAS biomarker status is indeterminate for this patient."
383,white,male,64,21.21,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 64, bmi: 21.21, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type",The patient is a 64-year-old white male with a BMI of 21.21. He is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer cells. The patient has a fully active performance status and his KRAS biomarker is wild-type.
384,other,female,48,20.23,FOLFIRI + Cetuximab,No,No,No,Yes,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: other, sex: female, age: 48, bmi: 20.23, treatment arm: FOLFIRI + Cetuximab, bowel perforation: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","This patient is a 48-year-old female of a race categorized as ""other"" with a BMI of 20.23. She is receiving treatment with FOLFIRI + Cetuximab and has experienced a bowel perforation. She has completed 12 cycles of chemotherapy and her histology shows well-differentiated cells. Despite the bowel perforation, her performance status is fully active. Additionally, her KRAS biomarker status is wild-type."
385,white,female,50,25.35,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,fully active,mutant,No,No,No,No,No,0,"race: white, sex: female, age: 50, bmi: 25.35, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant",The patient is a 50-year-old white female with a BMI of 25.35. She is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. Her cancer histology is well differentiated. She has a fully active performance status. The KRAS biomarker analysis shows a mutant result.
386,white,female,41,29.71,FOLFOX,No,Yes,No,No,8,well differentiated,fully active,wild-type,Yes,No,Yes,No,No,0,"race: white, sex: female, age: 41, bmi: 29.71, treatment arm: FOLFOX, serious adverse effect: Yes, chemotherapy cycles: 8, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type, adverse effect: thrombosis: Yes, adverse effect: diarrhea: Yes","The patient is a 41-year-old white female with a BMI of 29.71 who is receiving the FOLFOX treatment regimen. She has experienced a serious adverse effect during the treatment. She has completed 8 cycles of chemotherapy. The histology shows that the cancer is well-differentiated. Despite the serious adverse effect, her performance status is fully active. The KRAS biomarker indicates that she has a wild-type mutation. Additionally, she has experienced adverse effects of thrombosis and diarrhea during the course of treatment."
387,black,male,61,34.61,FOLFOX,No,Yes,No,No,12,well differentiated,fully active,wild-type,Yes,No,No,No,No,0,"race: black, sex: male, age: 61, bmi: 34.61, treatment arm: FOLFOX, serious adverse effect: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type, adverse effect: thrombosis: Yes","The patient is a 61-year-old Black male with a BMI of 34.61. He is receiving the FOLFOX treatment regimen and has experienced a serious adverse effect. He has completed 12 cycles of chemotherapy. The histology shows that the cancer is well-differentiated. The patient has a fully active performance status. His KRAS biomarker is wild-type. Additionally, he has experienced thrombosis as an adverse effect."
388,white,female,66,29.04,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 66, bmi: 29.04, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 66-year-old white female with a BMI of 29.04. She is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. Her cancer histology is well-differentiated, and she has a fully active performance status. The KRAS biomarker analysis shows that she has a wild-type KRAS status."
389,white,male,70,26.01,FOLFOX,No,Yes,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 70, bmi: 26.01, treatment arm: FOLFOX, serious adverse effect: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 70-year-old white male with a BMI of 26.01. He is receiving the FOLFOX treatment arm and has experienced a serious adverse effect. He has completed 12 cycles of chemotherapy. The histology shows well-differentiated cancer cells. Despite this, his performance status is fully active. The KRAS biomarker indicates that he has a wild-type mutation."
390,white,female,38,22.8,FOLFIRI + Cetuximab,No,Yes,No,No,4,well differentiated,fully active,mutant,No,No,No,No,No,1,"race: white, sex: female, age: 38, bmi: 22.8, treatment arm: FOLFIRI + Cetuximab, serious adverse effect: Yes, chemotherapy cycles: 4, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 38-year-old white female with a BMI of 22.8. She is receiving treatment with FOLFIRI + Cetuximab and has experienced a serious adverse effect. She has completed 4 cycles of chemotherapy. Her histology shows well-differentiated cells, and her performance status is fully active. The KRAS biomarker indicates a mutant status."
391,white,female,63,26.24,FOLFIRI (KRAS mutant),No,No,Yes,No,3,well differentiated,fully active,mutant,No,No,Yes,No,No,0,"race: white, sex: female, age: 63, bmi: 26.24, treatment arm: FOLFIRI (KRAS mutant), bowel obstruction: Yes, chemotherapy cycles: 3, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant, adverse effect: diarrhea: Yes","This patient is a 63-year-old white female with a BMI of 26.24. She is receiving the FOLFIRI treatment regimen for her KRAS mutant cancer. She has experienced a bowel obstruction and has completed 3 cycles of chemotherapy. The histology of her cancer is well-differentiated. Despite her bowel obstruction, her performance status is fully active. The patient has a mutant KRAS biomarker and is experiencing diarrhea as an adverse effect of her treatment."
392,white,male,65,26.25,FOLFOX,No,Yes,Yes,No,1,well differentiated,symptoms but ambulatory,wild-type,No,No,No,No,Yes,0,"race: white, sex: male, age: 65, bmi: 26.25, treatment arm: FOLFOX, serious adverse effect: Yes, bowel obstruction: Yes, chemotherapy cycles: 1, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type, adverse effect: infarction: Yes","The patient is a 65-year-old white male with a BMI of 26.25 who is receiving the FOLFOX treatment regimen. He has experienced a serious adverse effect in the form of a bowel obstruction after completing one cycle of chemotherapy. The histology of his cancer is well-differentiated, and he has symptoms but is still able to be ambulatory. His KRAS biomarker status is wild-type. Additionally, he has also experienced an infarction as an adverse effect."
393,white,male,40,25.35,FOLFOX + Cetuximab,No,No,No,No,12,poorly differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 40, bmi: 25.35, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 40-year-old white male with a BMI of 25.35. He is receiving treatment in the FOLFOX + Cetuximab treatment arm and has completed 12 cycles of chemotherapy. His histology shows poorly differentiated cancer cells. Despite this, his performance status is fully active. The KRAS biomarker analysis indicates that he has a wild-type KRAS status."
394,white,male,59,28.46,FOLFOX + Cetuximab,No,No,Yes,No,5,well differentiated,symptoms but ambulatory,wild-type,No,No,No,No,No,1,"race: white, sex: male, age: 59, bmi: 28.46, treatment arm: FOLFOX + Cetuximab, bowel obstruction: Yes, chemotherapy cycles: 5, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type","The patient is a 59-year-old white male with a BMI of 28.46. He is currently receiving treatment in the FOLFOX + Cetuximab treatment arm. He is experiencing a bowel obstruction and has completed 5 cycles of chemotherapy. The histology shows that the cancer is well-differentiated. Despite experiencing symptoms, the patient is still able to be ambulatory. The KRAS biomarker indicates that the cancer is wild-type."
395,white,female,43,25.54,FOLFOX,No,Yes,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 43, bmi: 25.54, treatment arm: FOLFOX, serious adverse effect: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 43-year-old white female with a BMI of 25.54. She is receiving treatment with the FOLFOX regimen and has experienced a serious adverse effect. She has completed 12 cycles of chemotherapy. The histology of her cancer is well-differentiated. Despite the adverse effect, her performance status is fully active. The KRAS biomarker testing revealed that she has a wild-type KRAS status."
396,white,male,47,37.1,FOLFOX + Cetuximab,No,Yes,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 47, bmi: 37.1, treatment arm: FOLFOX + Cetuximab, serious adverse effect: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 47-year-old white male with a BMI of 37.1. He is receiving treatment with FOLFOX + Cetuximab and has experienced a serious adverse effect. He has completed 12 cycles of chemotherapy. His histology shows well-differentiated cells. Despite the adverse effect, his performance status is fully active. The KRAS biomarker indicates that he has a wild-type mutation."
397,white,male,66,30.17,FOLFOX,No,No,No,No,12,well differentiated,fully active,mutant,No,No,No,No,No,0,"race: white, sex: male, age: 66, bmi: 30.17, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant","This patient is a 66-year-old white male with a BMI of 30.17. He is undergoing treatment with the FOLFOX chemotherapy regimen and has completed 12 cycles. His cancer histology is well-differentiated, and he has a fully active performance status. The KRAS biomarker testing revealed a mutant status."
398,white,female,76,36.69,FOLFOX,No,No,No,No,12,well differentiated,symptoms but ambulatory,wild-type,Yes,No,No,No,No,1,"race: white, sex: female, age: 76, bmi: 36.69, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type, adverse effect: thrombosis: Yes","This patient is a 76-year-old white female with a BMI of 36.69 who is receiving the FOLFOX treatment regimen for her well-differentiated cancer. She has completed 12 cycles of chemotherapy and has a performance status of experiencing symptoms but still able to walk around. Her KRAS biomarker is wild-type. Additionally, she has experienced an adverse effect of thrombosis."
399,white,male,70,29.17,FOLFIRI (KRAS mutant),No,No,Yes,No,11,well differentiated,fully active,wild-type,No,No,No,No,No,1,"race: white, sex: male, age: 70, bmi: 29.17, treatment arm: FOLFIRI (KRAS mutant), bowel obstruction: Yes, chemotherapy cycles: 11, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 70-year-old white male with a BMI of 29.17. He is receiving the FOLFIRI treatment regimen for his KRAS mutant status. He has a bowel obstruction and has completed 11 cycles of chemotherapy. His histology shows well-differentiated cells. Despite his condition, he has a fully active performance status. His KRAS biomarker is wild-type."
400,white,female,67,25.89,FOLFOX,No,Yes,No,No,12,well differentiated,fully active,mutant,No,No,No,No,No,0,"race: white, sex: female, age: 67, bmi: 25.89, treatment arm: FOLFOX, serious adverse effect: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 67-year-old white female with a BMI of 25.89. She is undergoing treatment with the FOLFOX regimen and has experienced a serious adverse effect. She has completed 12 cycles of chemotherapy. The histology shows that the cancer is well-differentiated. Despite the treatment, the patient's performance status is fully active. The KRAS biomarker analysis indicates that the patient has a mutant KRAS status."
401,black,female,54,18.38,FOLFOX + Cetuximab,No,No,No,No,12,poorly differentiated,fully active,mutant,No,No,No,No,No,0,"race: black, sex: female, age: 54, bmi: 18.38, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 54-year-old Black female with a BMI of 18.38. She is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. Her histology shows poorly differentiated cancer. Despite this, her performance status is fully active. Additionally, the KRAS biomarker analysis indicates a mutant status."
402,white,male,47,32.4,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 47, bmi: 32.4, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 47-year-old white male with a BMI of 32.4. He is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. His cancer histology is well-differentiated, and he has a fully active performance status. The KRAS biomarker testing shows that he has a wild-type KRAS status."
403,white,female,50,17.14,FOLFOX + Cetuximab,No,No,No,No,11,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 50, bmi: 17.14, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 11, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 50-year-old white female with a low BMI of 17.14. She is receiving treatment with FOLFOX + Cetuximab and has completed 11 cycles of chemotherapy. Her cancer histology is well differentiated, and she has a fully active performance status. The KRAS biomarker testing showed that she has a wild-type KRAS status."
404,black,female,48,20.16,FOLFOX + Cetuximab,Yes,No,No,No,11,well differentiated,fully active,mutant,No,No,No,No,No,1,"race: black, sex: female, age: 48, bmi: 20.16, treatment arm: FOLFOX + Cetuximab, adherence: Yes, chemotherapy cycles: 11, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant",The patient is a 48-year-old Black female with a BMI of 20.16. She is receiving treatment in the FOLFOX + Cetuximab treatment arm and has been adherent to her chemotherapy. She has completed 11 cycles of chemotherapy. Her histology shows well-differentiated cancer cells. The patient has a fully active performance status. Her KRAS biomarker is mutant.
405,white,male,60,31.83,FOLFOX + Cetuximab,No,No,No,No,4,poorly differentiated,fully active,interminate,No,No,No,No,No,0,"race: white, sex: male, age: 60, bmi: 31.83, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 4, histology: poorly differentiated, performance status: fully active, KRAS biomarker: interminate","The patient is a 60-year-old white male with a BMI of 31.83. He is receiving treatment with FOLFOX + Cetuximab and has completed 4 cycles of chemotherapy. His cancer histology is poorly differentiated. Despite his cancer diagnosis, he has a fully active performance status. The KRAS biomarker status is indeterminate for this patient."
406,white,male,42,26.31,FOLFIRI + Cetuximab,No,Yes,No,No,8,well differentiated,fully active,wild-type,No,No,No,No,No,1,"race: white, sex: male, age: 42, bmi: 26.31, treatment arm: FOLFIRI + Cetuximab, serious adverse effect: Yes, chemotherapy cycles: 8, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 42-year-old white male with a BMI of 26.31. He is receiving treatment with FOLFIRI + Cetuximab and has experienced a serious adverse effect. He has completed 8 cycles of chemotherapy. The histology shows well-differentiated cells, and his performance status is fully active. The KRAS biomarker indicates that he has a wild-type status."
407,white,female,47,32.87,FOLFOX,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 47, bmi: 32.87, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type",The patient is a 47-year-old white female with a BMI of 32.87. She is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. The histology of her cancer is well-differentiated. She has a fully active performance status. Her KRAS biomarker status is wild-type.
408,white,male,74,30.64,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,Yes,No,No,1,"race: white, sex: male, age: 74, bmi: 30.64, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type, adverse effect: diarrhea: Yes",The patient is a 74-year-old white male with a BMI of 30.64 who is receiving treatment with FOLFOX + Cetuximab for well-differentiated histology. He has completed 12 cycles of chemotherapy and has a fully active performance status. His KRAS biomarker is wild-type. The patient is experiencing diarrhea as an adverse effect of the treatment.
409,white,female,51,28.04,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,fully active,wild-type,No,Yes,No,No,No,0,"race: white, sex: female, age: 51, bmi: 28.04, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type, adverse effect: hypersensitivity: Yes","The patient is a 51-year-old white female with a BMI of 28.04. She is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cells, and her performance status is fully active. The KRAS biomarker indicates that she is wild-type. She has experienced a hypersensitivity adverse effect."
410,white,female,59,22.9,FOLFOX + Cetuximab,No,No,No,No,1,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 59, bmi: 22.9, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 1, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 59-year-old white female with a BMI of 22.9. She is currently receiving treatment in the FOLFOX + Cetuximab treatment arm and has completed 1 cycle of chemotherapy. Her histology shows well-differentiated cells, and she has a fully active performance status. Additionally, her KRAS biomarker indicates that it is wild-type."
411,white,male,44,22.86,FOLFOX,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 44, bmi: 22.86, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type",The patient is a 44-year-old white male with a BMI of 22.86. He is receiving treatment with the FOLFOX chemotherapy regimen and has completed 12 cycles. The histology of his cancer is well-differentiated. He has a fully active performance status. His KRAS biomarker status is wild-type.
412,white,female,62,36.92,FOLFOX,No,Yes,Yes,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 62, bmi: 36.92, treatment arm: FOLFOX, serious adverse effect: Yes, bowel obstruction: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","This patient is a 62-year-old white female with a BMI of 36.92 who is receiving the FOLFOX treatment regimen. She has experienced a serious adverse effect and is currently dealing with a bowel obstruction. She has completed 12 cycles of chemotherapy. The histology of her condition is well-differentiated, and her performance status is fully active. Additionally, her KRAS biomarker status is wild-type."
413,white,male,60,24.69,FOLFOX,No,No,Yes,Yes,12,well differentiated,fully active,mutant,No,No,No,No,No,0,"race: white, sex: male, age: 60, bmi: 24.69, treatment arm: FOLFOX, bowel obstruction: Yes, bowel perforation: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 60-year-old white male with a BMI of 24.69. He is receiving the FOLFOX treatment regimen and has experienced both a bowel obstruction and perforation. He has completed 12 cycles of chemotherapy. The histology shows well-differentiated cells. Despite the bowel issues, his performance status is fully active. The KRAS biomarker indicates a mutant status."
414,white,male,61,23.12,FOLFOX,No,No,Yes,No,12,poorly differentiated,symptoms but ambulatory,mutant,No,No,No,No,No,0,"race: white, sex: male, age: 61, bmi: 23.12, treatment arm: FOLFOX, bowel obstruction: Yes, chemotherapy cycles: 12, histology: poorly differentiated, performance status: symptoms but ambulatory, KRAS biomarker: mutant","The patient is a 61-year-old white male with a BMI of 23.12. He is receiving the FOLFOX treatment regimen for his bowel obstruction. He has completed 12 cycles of chemotherapy. The histology of his cancer is poorly differentiated. Despite experiencing symptoms, he is still able to be ambulatory. The KRAS biomarker testing revealed a mutant status."
415,white,male,58,30.12,FOLFOX,No,No,Yes,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 58, bmi: 30.12, treatment arm: FOLFOX, bowel obstruction: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type",The patient is a 58-year-old white male with a BMI of 30.12. He is receiving the FOLFOX treatment regimen and has experienced a bowel obstruction. He has completed 12 cycles of chemotherapy. The histology shows well-differentiated cancer cells. The patient has a fully active performance status. The KRAS biomarker indicates that he has a wild-type mutation.
416,white,female,64,38.59,FOLFOX + Cetuximab,Yes,No,No,No,12,poorly differentiated,symptoms but ambulatory,wild-type,No,No,No,No,No,1,"race: white, sex: female, age: 64, bmi: 38.59, treatment arm: FOLFOX + Cetuximab, adherence: Yes, chemotherapy cycles: 12, histology: poorly differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type","The patient is a 64-year-old white female with a BMI of 38.59. She is receiving treatment with FOLFOX + Cetuximab and has been adherent to the treatment. She has completed 12 cycles of chemotherapy. The histology of her cancer is poorly differentiated. Despite experiencing symptoms, she is still able to be ambulatory. Her KRAS biomarker status is wild-type."
417,white,male,42,26.73,FOLFOX + Cetuximab,No,No,No,No,2,well differentiated,fully active,wild-type,No,No,No,No,Yes,0,"race: white, sex: male, age: 42, bmi: 26.73, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 2, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type, adverse effect: infarction: Yes","The patient is a 42-year-old white male with a BMI of 26.73. He is currently receiving treatment with FOLFOX + Cetuximab and has completed 2 cycles of chemotherapy. His histology shows well-differentiated cells, and he has a fully active performance status. The KRAS biomarker analysis indicates that he has a wild-type KRAS status. The patient has experienced an adverse effect in the form of an infarction."
418,white,male,73,32.8,FOLFIRI + Cetuximab,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,Yes,No,No,1,"race: white, sex: male, age: 73, bmi: 32.8, treatment arm: FOLFIRI + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type, adverse effect: diarrhea: Yes",The patient is a 73-year-old white male with a BMI of 32.8 who is undergoing treatment with FOLFIRI + Cetuximab for well-differentiated histology. He has completed 12 cycles of chemotherapy and has a fully active performance status. His KRAS biomarker is wild-type. The patient is experiencing diarrhea as an adverse effect of the treatment.
419,white,male,49,27.2,FOLFOX,No,No,No,No,12,poorly differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 49, bmi: 27.2, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 49-year-old white male with a BMI of 27.2. He is receiving the FOLFOX treatment arm and is scheduled for 12 cycles of chemotherapy. His histology shows poorly differentiated cancer cells. Despite this, his performance status is fully active. Additionally, his KRAS biomarker indicates that he has a wild-type gene."
420,white,male,73,22.75,FOLFOX,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 73, bmi: 22.75, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 73-year-old white male with a BMI of 22.75. He is receiving treatment with the FOLFOX chemotherapy regimen and has completed 12 cycles. The histology of his cancer is well differentiated. Despite his age, he has a fully active performance status. Additionally, his KRAS biomarker status is wild-type."
421,white,male,43,30.49,FOLFOX,No,No,Yes,No,12,well differentiated,fully active,interminate,No,No,No,No,No,0,"race: white, sex: male, age: 43, bmi: 30.49, treatment arm: FOLFOX, bowel obstruction: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: interminate","This patient is a 43-year-old white male with a BMI of 30.49 who is receiving the FOLFOX treatment regimen for their cancer. They have experienced a bowel obstruction and have completed 12 cycles of chemotherapy. The histology of their cancer is well differentiated. Despite the bowel obstruction, the patient's performance status is fully active. Their KRAS biomarker status is indeterminate."
422,white,male,55,25.45,FOLFOX,No,Yes,No,No,12,poorly differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 55, bmi: 25.45, treatment arm: FOLFOX, serious adverse effect: Yes, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 55-year-old white male with a BMI of 25.45. He is receiving the FOLFOX treatment regimen and has experienced a serious adverse effect. He has completed 12 cycles of chemotherapy. The histology of his cancer is poorly differentiated. Despite this, his performance status is fully active. His KRAS biomarker status is wild-type."
423,black,female,76,23.46,FOLFOX,Yes,No,Yes,No,12,well differentiated,fully active,wild-type,No,No,No,Yes,No,1,"race: black, sex: female, age: 76, bmi: 23.46, treatment arm: FOLFOX, adherence: Yes, bowel obstruction: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type, adverse effect: infection: Yes","The patient is a 76-year-old Black female with a BMI of 23.46. She is receiving treatment with FOLFOX and has been adherent to her chemotherapy regimen. She has experienced a bowel obstruction and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cancer, and her performance status is fully active. The KRAS biomarker indicates she has a wild-type mutation. Additionally, she has experienced an infection as an adverse effect of her treatment."
424,white,male,60,24.11,FOLFOX + Cetuximab,No,Yes,Yes,No,12,well differentiated,fully active,mutant,No,No,Yes,No,No,0,"race: white, sex: male, age: 60, bmi: 24.11, treatment arm: FOLFOX + Cetuximab, serious adverse effect: Yes, bowel obstruction: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant, adverse effect: diarrhea: Yes","The patient is a 60-year-old white male with a BMI of 24.11 who is receiving treatment with FOLFOX + Cetuximab. He has experienced a serious adverse effect in the form of a bowel obstruction. He has completed 12 cycles of chemotherapy and has well-differentiated histology. Despite the adverse effect, his performance status remains fully active. The KRAS biomarker testing revealed a mutant status. Additionally, he has experienced diarrhea as an adverse effect of the treatment."
425,black,male,58,20,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: black, sex: male, age: 58, bmi: 20.0, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type",The patient is a 58-year-old Black male with a BMI of 20.0. He is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer cells. The patient has a fully active performance status and his KRAS biomarker is wild-type.
426,black,female,46,38.79,FOLFOX,No,No,Yes,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: black, sex: female, age: 46, bmi: 38.79, treatment arm: FOLFOX, bowel obstruction: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 46-year-old Black female with a BMI of 38.79. She is receiving the FOLFOX treatment arm and has experienced a bowel obstruction. She has completed 12 cycles of chemotherapy. The histology shows that the cancer is well-differentiated. Despite the bowel obstruction, her performance status is fully active. The KRAS biomarker indicates that she has a wild-type mutation."
427,white,female,73,23.21,FOLFIRI,No,No,No,No,12,well differentiated,symptoms but ambulatory,wild-type,No,No,Yes,No,No,0,"race: white, sex: female, age: 73, bmi: 23.21, treatment arm: FOLFIRI, chemotherapy cycles: 12, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type, adverse effect: diarrhea: Yes","The patient is a 73-year-old white female with a BMI of 23.21. She is undergoing treatment with the FOLFIRI chemotherapy regimen and has completed 12 cycles. Her histology shows well-differentiated cancer cells. Despite experiencing symptoms, she is still able to be ambulatory. The KRAS biomarker testing revealed that she has a wild-type KRAS status. The patient is experiencing diarrhea as an adverse effect of the treatment."
428,white,female,44,34.62,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 44, bmi: 34.62, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type",The patient is a 44-year-old white female with a BMI of 34.62. She is receiving treatment with FOLFOX + Cetuximab and is scheduled for 12 cycles of chemotherapy. Her histology shows well-differentiated cancer cells. The patient has a fully active performance status and her KRAS biomarker is wild-type.
429,white,female,46,34.76,FOLFOX,No,No,No,No,12,poorly differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 46, bmi: 34.76, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 46-year-old white female with a BMI of 34.76. She is receiving the FOLFOX treatment arm and has completed 12 cycles of chemotherapy. Her histology shows poorly differentiated cancer cells. Despite this, her performance status is fully active. Additionally, her KRAS biomarker indicates that it is wild-type."
430,white,female,62,26.19,FOLFOX,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 62, bmi: 26.19, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 62-year-old white female with a BMI of 26.19. She is receiving treatment with the FOLFOX chemotherapy regimen and is scheduled for 12 cycles. Her histology shows well-differentiated cancer cells. Despite her diagnosis, she maintains a fully active performance status. Additionally, her KRAS biomarker indicates that she has a wild-type gene."
431,white,male,67,27.96,FOLFOX + Cetuximab,No,No,No,No,10,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 67, bmi: 27.96, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 10, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 67-year-old white male with a BMI of 27.96. He is receiving treatment in the FOLFOX + Cetuximab treatment arm and has completed 10 cycles of chemotherapy. His histology shows well-differentiated cancer cells. Despite his age, he has a fully active performance status. Additionally, his KRAS biomarker indicates that he has a wild-type gene."
432,black,female,57,20.83,FOLFOX,No,No,Yes,No,6,well differentiated,symptoms but ambulatory,wild-type,No,No,No,No,No,0,"race: black, sex: female, age: 57, bmi: 20.83, treatment arm: FOLFOX, bowel obstruction: Yes, chemotherapy cycles: 6, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type","The patient is a 57-year-old Black female with a BMI of 20.83. She is receiving the FOLFOX treatment arm for her well-differentiated histology. She has experienced a bowel obstruction and has completed 6 cycles of chemotherapy. Despite experiencing symptoms, she is still ambulatory. The KRAS biomarker shows that she has a wild-type status."
433,white,male,42,30.76,FOLFOX + Cetuximab,No,No,No,No,4,well differentiated,symptoms but ambulatory,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 42, bmi: 30.76, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 4, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type","The patient is a 42-year-old white male with a BMI of 30.76. He is receiving treatment with FOLFOX + Cetuximab and has completed 4 cycles of chemotherapy. His cancer histology is well differentiated. Despite experiencing symptoms, he is still able to walk around (ambulatory). The KRAS biomarker analysis shows that he has a wild-type KRAS gene."
434,white,male,71,24.9,FOLFOX,No,No,No,No,12,well differentiated,symptoms but ambulatory,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 71, bmi: 24.9, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type","The patient is a 71-year-old white male with a BMI of 24.9. He is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer cells. Despite experiencing symptoms, he is still able to be ambulatory. The KRAS biomarker analysis indicates that he has a wild-type KRAS status."
435,other,male,72,22.5,FOLFOX,No,No,No,No,12,poorly differentiated,fully active,wild-type,No,No,No,No,No,0,"race: other, sex: male, age: 72, bmi: 22.5, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 72-year-old male of a race categorized as ""other"" with a BMI of 22.5. He is undergoing treatment with the FOLFOX regimen and has completed 12 cycles of chemotherapy. The histology of his cancer is poorly differentiated. Despite his age, he has a fully active performance status. Additionally, his KRAS biomarker status is wild-type."
436,white,female,43,20.45,FOLFOX,No,No,Yes,No,12,poorly differentiated,fully active,wild-type,No,No,No,No,No,1,"race: white, sex: female, age: 43, bmi: 20.45, treatment arm: FOLFOX, bowel obstruction: Yes, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 43-year-old white female with a BMI of 20.45. She is receiving treatment with the FOLFOX regimen and has experienced a bowel obstruction. She has completed 12 cycles of chemotherapy. The histology of her cancer is poorly differentiated. Despite these challenges, her performance status is fully active. Additionally, her KRAS biomarker status is wild-type."
437,white,male,59,30.81,FOLFOX,Yes,Yes,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 59, bmi: 30.81, treatment arm: FOLFOX, adherence: Yes, serious adverse effect: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 59-year-old white male with a BMI of 30.81. He is receiving the FOLFOX treatment regimen and has been adherent to the treatment. He experienced a serious adverse effect during the course of his 12 chemotherapy cycles. His histology shows well-differentiated cells, and he has a fully active performance status. The KRAS biomarker analysis indicates that he has a wild-type KRAS status."
438,white,male,42,27.41,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 42, bmi: 27.41, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 42-year-old white male with a BMI of 27.41. He is receiving treatment in the FOLFOX + Cetuximab treatment arm and has completed 12 cycles of chemotherapy. The histology shows well-differentiated cancer cells. The patient's performance status is fully active, and the KRAS biomarker indicates that he has a wild-type mutation."
439,white,female,50,35.78,FOLFIRI (KRAS mutant),No,No,No,No,12,well differentiated,fully active,mutant,No,No,No,No,No,0,"race: white, sex: female, age: 50, bmi: 35.78, treatment arm: FOLFIRI (KRAS mutant), chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 50-year-old white female with a BMI of 35.78. She is receiving the FOLFIRI treatment regimen for her KRAS mutant status. She has completed 12 cycles of chemotherapy. Her cancer histology is well differentiated. Despite her diagnosis, she has a fully active performance status."
440,white,male,43,26.06,FOLFOX,No,No,No,No,11,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 43, bmi: 26.06, treatment arm: FOLFOX, chemotherapy cycles: 11, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type",The patient is a 43-year-old white male with a BMI of 26.06. He is receiving treatment in the FOLFOX chemotherapy arm and has completed 11 cycles of chemotherapy. His histology shows well-differentiated cancer cells. The patient has a fully active performance status and his KRAS biomarker is wild-type.
441,other,male,65,26.09,FOLFOX + Cetuximab,No,No,No,No,10,well differentiated,fully active,wild-type,No,No,Yes,No,No,1,"race: other, sex: male, age: 65, bmi: 26.09, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 10, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type, adverse effect: diarrhea: Yes","The patient is a 65-year-old male of a race other than specified, with a BMI of 26.09. He is undergoing treatment with FOLFOX + Cetuximab and has completed 10 cycles of chemotherapy. The histology shows well-differentiated cells, and his performance status is fully active. The KRAS biomarker indicates that he has a wild-type status. The patient is experiencing diarrhea as an adverse effect of the treatment."
442,white,male,71,31.88,FOLFIRI + Cetuximab,No,No,Yes,No,12,well differentiated,symptoms but ambulatory,wild-type,No,No,No,Yes,No,0,"race: white, sex: male, age: 71, bmi: 31.88, treatment arm: FOLFIRI + Cetuximab, bowel obstruction: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type, adverse effect: infection: Yes","The patient is a 71-year-old white male with a BMI of 31.88 who is undergoing treatment with FOLFIRI + Cetuximab for bowel obstruction. He has completed 12 cycles of chemotherapy and has well-differentiated histology. Despite experiencing symptoms, he is still able to be ambulatory. His KRAS biomarker is wild-type. Additionally, he has developed an infection as an adverse effect of the treatment."
443,white,female,66,29.1,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,fully active,mutant,No,No,No,No,No,0,"race: white, sex: female, age: 66, bmi: 29.1, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant",The patient is a 66-year-old white female with a BMI of 29.1. She is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. Her cancer histology is well differentiated. The patient has a fully active performance status. The KRAS biomarker testing revealed a mutant status.
444,white,female,58,33.98,FOLFOX + Cetuximab,No,No,No,No,10,well differentiated,fully active,interminate,No,No,No,No,No,0,"race: white, sex: female, age: 58, bmi: 33.98, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 10, histology: well differentiated, performance status: fully active, KRAS biomarker: interminate",The patient is a 58-year-old white female with a BMI of 33.98. She is receiving treatment in the FOLFOX + Cetuximab treatment arm and has completed 10 cycles of chemotherapy. Her histology shows well-differentiated cancer cells. The patient has a fully active performance status. The KRAS biomarker status is indeterminate for this patient.
445,white,female,76,27.02,FOLFOX + Cetuximab,No,Yes,No,No,5,well differentiated,symptoms but ambulatory,wild-type,No,No,Yes,No,No,0,"race: white, sex: female, age: 76, bmi: 27.02, treatment arm: FOLFOX + Cetuximab, serious adverse effect: Yes, chemotherapy cycles: 5, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type, adverse effect: diarrhea: Yes","This patient is a 76-year-old white female with a BMI of 27.02 who is receiving treatment with FOLFOX + Cetuximab. She has experienced a serious adverse effect during her 5 chemotherapy cycles. Her histology shows that the cancer is well-differentiated. Despite experiencing symptoms, she is still able to be ambulatory. The KRAS biomarker testing revealed that she has a wild-type KRAS status. Additionally, she has developed diarrhea as an adverse effect of her treatment."
446,white,female,47,26,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 47, bmi: 26.0, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type",The patient is a 47-year-old white female with a BMI of 26.0. She is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cancer cells. She has a fully active performance status. The KRAS biomarker testing revealed that she has a wild-type KRAS status.
447,white,female,73,32.52,FOLFOX,No,No,No,No,11,well differentiated,fully active,wild-type,No,No,Yes,Yes,No,0,"race: white, sex: female, age: 73, bmi: 32.52, treatment arm: FOLFOX, chemotherapy cycles: 11, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type, adverse effect: diarrhea: Yes, adverse effect: infection: Yes","The patient is a 73-year-old white female with a BMI of 32.52. She is receiving the FOLFOX treatment regimen and has completed 11 cycles of chemotherapy. Her cancer histology is well-differentiated, and she has a fully active performance status. The KRAS biomarker testing shows that she has a wild-type KRAS status. The patient has experienced adverse effects of diarrhea and infection during her treatment."
448,white,male,55,22.2,FOLFOX,No,No,No,No,4,poorly differentiated,fully active,mutant,No,No,No,No,No,0,"race: white, sex: male, age: 55, bmi: 22.2, treatment arm: FOLFOX, chemotherapy cycles: 4, histology: poorly differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 55-year-old white male with a BMI of 22.2. He is receiving the FOLFOX treatment regimen and has completed 4 cycles of chemotherapy. His cancer histology is poorly differentiated. Despite his diagnosis, he has a fully active performance status. The patient's KRAS biomarker status is mutant."
449,white,female,63,50.32,FOLFOX,No,No,No,No,12,well differentiated,symptoms but ambulatory,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 63, bmi: 50.32, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type","The patient is a 63-year-old white female with a BMI of 50.32. She is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. The histology shows well-differentiated cancer cells. Despite experiencing symptoms, the patient is still able to walk around. The KRAS biomarker analysis indicates that the patient has a wild-type KRAS status."
450,white,female,54,19.38,FOLFOX,No,No,No,No,12,well differentiated,symptoms but ambulatory,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 54, bmi: 19.38, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type","The patient is a 54-year-old white female with a BMI of 19.38. She is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cells. Despite experiencing symptoms, she is still able to be ambulatory. The KRAS biomarker analysis indicates that she has a wild-type KRAS status."
451,white,female,51,37.23,FOLFOX,No,No,No,No,10,well differentiated,fully active,mutant,No,No,No,No,No,0,"race: white, sex: female, age: 51, bmi: 37.23, treatment arm: FOLFOX, chemotherapy cycles: 10, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 51-year-old white female with a BMI of 37.23. She is undergoing treatment with the FOLFOX chemotherapy regimen and has completed 10 cycles. Her cancer histology is well differentiated. Despite her cancer diagnosis, she has a fully active performance status. The KRAS biomarker testing revealed a mutant status."
452,white,male,45,27.55,FOLFOX + Cetuximab,No,No,Yes,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 45, bmi: 27.55, treatment arm: FOLFOX + Cetuximab, bowel obstruction: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 45-year-old white male with a BMI of 27.55. He is receiving treatment with FOLFOX + Cetuximab for his well-differentiated histology. He has experienced a bowel obstruction and has completed 12 cycles of chemotherapy. Despite the bowel obstruction, his performance status is fully active. His KRAS biomarker status is wild-type."
453,white,female,53,27.54,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 53, bmi: 27.54, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 53-year-old white female with a BMI of 27.54. She is receiving treatment in the FOLFOX + Cetuximab treatment arm and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cells, and she has a fully active performance status. The KRAS biomarker analysis indicates that she has a wild-type KRAS status."
454,white,female,74,22.32,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,symptoms but ambulatory,mutant,No,No,Yes,No,No,0,"race: white, sex: female, age: 74, bmi: 22.32, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: mutant, adverse effect: diarrhea: Yes","This patient is a 74-year-old white female with a BMI of 22.32 who is undergoing treatment with FOLFOX + Cetuximab for her well-differentiated cancer. She has completed 12 cycles of chemotherapy and has a mutant KRAS biomarker. Despite experiencing symptoms, she is still able to walk around. She has reported experiencing diarrhea as an adverse effect of her treatment."
455,white,female,74,22.38,FOLFOX,Yes,Yes,No,No,4,poorly differentiated,fully active,wild-type,No,No,Yes,No,No,0,"race: white, sex: female, age: 74, bmi: 22.38, treatment arm: FOLFOX, adherence: Yes, serious adverse effect: Yes, chemotherapy cycles: 4, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type, adverse effect: diarrhea: Yes","The patient is a 74-year-old white female with a BMI of 22.38 who is receiving the FOLFOX treatment regimen. She has been adherent to her treatment. However, she has experienced a serious adverse effect, specifically diarrhea, during her 4 chemotherapy cycles. Her histology shows poorly differentiated cells, but her performance status is fully active. The KRAS biomarker indicates she has a wild-type status."
456,white,female,65,35.97,FOLFIRI,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 65, bmi: 35.97, treatment arm: FOLFIRI, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 65-year-old white female with a BMI of 35.97. She is undergoing treatment with the FOLFIRI chemotherapy regimen and has completed 12 cycles so far. Her cancer histology is well-differentiated, and she has a fully active performance status. Additionally, her KRAS biomarker status is wild-type."
457,white,male,49,23.26,FOLFOX + Cetuximab,No,No,No,No,8,poorly differentiated,fully active,wild-type,No,No,Yes,Yes,No,0,"race: white, sex: male, age: 49, bmi: 23.26, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 8, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type, adverse effect: diarrhea: Yes, adverse effect: infection: Yes","The patient is a 49-year-old white male with a BMI of 23.26. He is receiving treatment with FOLFOX + Cetuximab and has completed 8 cycles of chemotherapy. His cancer histology is poorly differentiated. Despite experiencing diarrhea and infection as adverse effects, his performance status is fully active. Additionally, his KRAS biomarker status is wild-type."
458,white,male,51,19.63,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,Yes,No,0,"race: white, sex: male, age: 51, bmi: 19.63, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type, adverse effect: infection: Yes","The patient is a 51-year-old white male with a BMI of 19.63. He is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer cells. Despite experiencing an infection, the patient's performance status remains fully active. Additionally, his KRAS biomarker indicates a wild-type status."
459,white,male,59,20.25,FOLFOX,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 59, bmi: 20.25, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 59-year-old white male with a BMI of 20.25. He is undergoing treatment with the FOLFOX chemotherapy regimen and has completed 12 cycles. His cancer histology is well-differentiated, and he has a fully active performance status. The KRAS biomarker analysis shows that he has a wild-type KRAS status."
460,white,male,42,27.35,FOLFOX,No,Yes,No,No,12,well differentiated,fully active,mutant,Yes,No,No,No,No,1,"race: white, sex: male, age: 42, bmi: 27.35, treatment arm: FOLFOX, serious adverse effect: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant, adverse effect: thrombosis: Yes","This patient is a 42-year-old white male with a BMI of 27.35. He is receiving the FOLFOX treatment regimen and has experienced a serious adverse effect. He has undergone 12 cycles of chemotherapy and has well-differentiated histology. Despite experiencing a serious adverse effect, his performance status is fully active. The KRAS biomarker testing revealed a mutant status. Additionally, he has developed thrombosis as an adverse effect."
461,white,male,69,24.72,FOLFOX,No,Yes,No,No,4,well differentiated,fully active,wild-type,No,No,Yes,No,No,0,"race: white, sex: male, age: 69, bmi: 24.72, treatment arm: FOLFOX, serious adverse effect: Yes, chemotherapy cycles: 4, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type, adverse effect: diarrhea: Yes","The patient is a 69-year-old white male with a BMI of 24.72 who is receiving the FOLFOX treatment regimen. He has experienced a serious adverse effect during his 4 chemotherapy cycles. The histology shows that the cancer is well-differentiated. Despite the adverse effects, the patient's performance status is fully active. The KRAS biomarker indicates that he has a wild-type mutation. Additionally, he has experienced diarrhea as an adverse effect of the treatment."
462,white,male,44,33.23,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 44, bmi: 33.23, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type",The patient is a 44-year-old white male with a BMI of 33.23. He is receiving treatment in the FOLFOX + Cetuximab treatment arm and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer cells. The patient has a fully active performance status and his KRAS biomarker is wild-type.
463,white,female,64,24.88,FOLFOX + Cetuximab,Yes,No,No,No,4,well differentiated,symptoms but ambulatory,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 64, bmi: 24.88, treatment arm: FOLFOX + Cetuximab, adherence: Yes, chemotherapy cycles: 4, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type","The patient is a 64-year-old white female with a BMI of 24.88. She is currently receiving treatment in the FOLFOX + Cetuximab treatment arm and has been adherent to her medication. She has completed 4 cycles of chemotherapy. The histology shows that the cancer is well-differentiated. Despite experiencing symptoms, the patient is still able to be ambulatory. The KRAS biomarker indicates that she has a wild-type status."
464,white,female,43,29.87,FOLFOX + Cetuximab,No,No,No,No,7,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 43, bmi: 29.87, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 7, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type",The patient is a 43-year-old white female with a BMI of 29.87. She is receiving treatment with FOLFOX + Cetuximab and has completed 7 cycles of chemotherapy. Her histology shows well-differentiated cancer cells. The patient has a fully active performance status. Her KRAS biomarker status is wild-type.
465,white,female,56,33.99,FOLFOX + Cetuximab,No,No,No,No,1,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 56, bmi: 33.99, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 1, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 56-year-old white female with a BMI of 33.99. She is receiving treatment in the FOLFOX + Cetuximab treatment arm and has completed one cycle of chemotherapy. Her histology shows well-differentiated cancer cells. The patient has a fully active performance status. Additionally, her KRAS biomarker indicates that it is wild-type."
466,white,male,66,26.93,FOLFOX + Cetuximab,Yes,No,No,No,12,well differentiated,fully active,wild-type,No,Yes,No,No,No,0,"race: white, sex: male, age: 66, bmi: 26.93, treatment arm: FOLFOX + Cetuximab, adherence: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type, adverse effect: hypersensitivity: Yes","The patient is a 66-year-old white male with a BMI of 26.93. He is receiving treatment in the FOLFOX + Cetuximab treatment arm and has been adherent to the treatment. He has completed 12 chemotherapy cycles. His histology shows well-differentiated cells, and his performance status is fully active. The KRAS biomarker indicates that he is wild-type. The patient has experienced a hypersensitivity adverse effect."
467,white,male,42,37.22,FOLFOX + Cetuximab,No,No,No,No,1,well differentiated,fully active,mutant,No,No,Yes,No,No,0,"race: white, sex: male, age: 42, bmi: 37.22, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 1, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant, adverse effect: diarrhea: Yes",The patient is a 42-year-old white male with a BMI of 37.22. He is currently receiving treatment with FOLFOX + Cetuximab and has completed one cycle of chemotherapy. His histology shows well-differentiated cancer cells. The patient has a fully active performance status. His KRAS biomarker is mutant. He is experiencing diarrhea as an adverse effect of the treatment.
468,white,male,64,23.15,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 64, bmi: 23.15, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type",The patient is a 64-year-old white male with a BMI of 23.15. He is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. His cancer histology is well differentiated. The patient has a fully active performance status and has a wild-type KRAS biomarker.
469,white,male,52,27.02,FOLFOX,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 52, bmi: 27.02, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 52-year-old white male with a BMI of 27.02. He is receiving the FOLFOX treatment regimen and is scheduled for 12 cycles of chemotherapy. His cancer histology is well differentiated, and he has a fully active performance status. The KRAS biomarker analysis shows that he has a wild-type KRAS status."
470,white,male,73,26.06,FOLFOX,Yes,Yes,Yes,No,12,poorly differentiated,fully active,mutant,No,No,No,No,No,1,"race: white, sex: male, age: 73, bmi: 26.06, treatment arm: FOLFOX, adherence: Yes, serious adverse effect: Yes, bowel obstruction: Yes, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 73-year-old white male with a BMI of 26.06. He is receiving the FOLFOX treatment regimen and has been adherent to the treatment. However, he has experienced a serious adverse effect in the form of a bowel obstruction. He has completed 12 cycles of chemotherapy. The histology of his condition is poorly differentiated. Despite the adverse effect, his performance status is fully active. The KRAS biomarker analysis has shown a mutant status."
471,white,female,51,29.06,FOLFOX + Cetuximab,No,No,No,No,11,well differentiated,fully active,mutant,No,No,No,No,No,0,"race: white, sex: female, age: 51, bmi: 29.06, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 11, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 51-year-old white female with a BMI of 29.06. She is receiving treatment with FOLFOX + Cetuximab and has completed 11 cycles of chemotherapy. Her histology shows well-differentiated cancer cells. Despite her cancer diagnosis, she has a fully active performance status. Additionally, her KRAS biomarker is mutant."
472,white,male,67,28.56,FOLFOX,Yes,No,No,Yes,12,poorly differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 67, bmi: 28.56, treatment arm: FOLFOX, adherence: Yes, bowel perforation: Yes, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 67-year-old white male with a BMI of 28.56. He is receiving the FOLFOX treatment regimen and has been adherent to the treatment. The patient experienced a bowel perforation during the course of treatment. He has completed 12 cycles of chemotherapy. The histology of his cancer is poorly differentiated. Despite these challenges, the patient has a fully active performance status. His KRAS biomarker status is wild-type."
473,white,male,57,24.97,FOLFOX,No,No,Yes,No,9,poorly differentiated,fully active,mutant,No,No,No,No,No,0,"race: white, sex: male, age: 57, bmi: 24.97, treatment arm: FOLFOX, bowel obstruction: Yes, chemotherapy cycles: 9, histology: poorly differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 57-year-old white male with a BMI of 24.97. He is receiving treatment with FOLFOX chemotherapy regimen and has experienced a bowel obstruction. He has completed 9 cycles of chemotherapy. The histology of his cancer is poorly differentiated. Despite these challenges, his performance status is fully active. Additionally, the KRAS biomarker testing revealed a mutant status."
474,white,female,69,26.56,FOLFIRI (KRAS mutant),No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 69, bmi: 26.56, treatment arm: FOLFIRI (KRAS mutant), chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 69-year-old white female with a BMI of 26.56. She is receiving the FOLFIRI treatment regimen for her KRAS mutant status. She has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cancer cells. Despite her cancer diagnosis, she has a fully active performance status. Her KRAS biomarker is wild-type."
475,black,male,60,30.16,FOLFOX + Cetuximab,No,No,No,No,1,poorly differentiated,fully active,wild-type,No,No,No,No,No,0,"race: black, sex: male, age: 60, bmi: 30.16, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 1, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 60-year-old black male with a BMI of 30.16. He is receiving treatment with FOLFOX + Cetuximab and has completed one cycle of chemotherapy. His cancer histology is poorly differentiated, and he has a fully active performance status. The KRAS biomarker analysis shows that he has a wild-type KRAS status."
476,white,male,58,31.94,FOLFOX,Yes,No,No,No,0,well differentiated,symptoms but ambulatory,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 58, bmi: 31.94, treatment arm: FOLFOX, adherence: Yes, chemotherapy cycles: 0, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type","The patient is a 58-year-old white male with a BMI of 31.94. He is enrolled in the FOLFOX treatment arm and is adherent to the treatment. He has not yet started any chemotherapy cycles. His histology shows well-differentiated cancer cells. Despite experiencing symptoms, he is still able to be ambulatory. The KRAS biomarker indicates that he has a wild-type status."
477,white,male,71,27.8,FOLFOX,No,No,No,No,1,poorly differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 71, bmi: 27.8, treatment arm: FOLFOX, chemotherapy cycles: 1, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 71-year-old white male with a BMI of 27.8. He is currently receiving treatment with the FOLFOX chemotherapy regimen and has completed one cycle so far. His cancer histology is poorly differentiated. Despite his age, he has a fully active performance status. Additionally, his KRAS biomarker status is wild-type."
478,white,female,59,29.5,FOLFOX,No,Yes,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 59, bmi: 29.5, treatment arm: FOLFOX, serious adverse effect: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 59-year-old white female with a BMI of 29.5. She is undergoing treatment with the FOLFOX regimen and has experienced a serious adverse effect. She has completed 12 cycles of chemotherapy. The histology shows that the cancer is well-differentiated. Despite the adverse effect, her performance status is fully active. The KRAS biomarker indicates that she has a wild-type mutation."
479,white,male,61,22.86,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,fully active,wild-type,No,Yes,No,No,No,0,"race: white, sex: male, age: 61, bmi: 22.86, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type, adverse effect: hypersensitivity: Yes","The patient is a 61-year-old white male with a BMI of 22.86. He is receiving treatment with FOLFOX + Cetuximab and has completed 12 chemotherapy cycles. His histology shows well-differentiated cancer, and he has a fully active performance status. The KRAS biomarker indicates that he is wild-type. The patient has experienced a hypersensitivity adverse effect."
480,white,male,54,27.47,FOLFOX + Cetuximab,Yes,Yes,No,No,12,poorly differentiated,fully active,mutant,Yes,No,No,No,No,1,"race: white, sex: male, age: 54, bmi: 27.47, treatment arm: FOLFOX + Cetuximab, adherence: Yes, serious adverse effect: Yes, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: mutant, adverse effect: thrombosis: Yes","The patient is a 54-year-old white male with a BMI of 27.47 who is receiving treatment with FOLFOX + Cetuximab. He has been adherent to the treatment regimen and has completed 12 cycles of chemotherapy. The histology of his cancer is poorly differentiated, and he has a fully active performance status. The patient has a mutant KRAS biomarker and has experienced a serious adverse effect in the form of thrombosis."
481,white,male,55,26.66,FOLFOX,No,No,Yes,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 55, bmi: 26.66, treatment arm: FOLFOX, bowel obstruction: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 55-year-old white male with a BMI of 26.66. He is receiving treatment with the FOLFOX regimen and has experienced a bowel obstruction. He has completed 12 cycles of chemotherapy. The histology of his cancer is well-differentiated. Despite the bowel obstruction, his performance status is fully active. The KRAS biomarker testing revealed that he has a wild-type KRAS status."
482,white,male,68,36.04,FOLFOX,No,No,No,Yes,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 68, bmi: 36.04, treatment arm: FOLFOX, bowel perforation: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 68-year-old white male with a BMI of 36.04. He is receiving treatment with the FOLFOX regimen and has experienced a bowel perforation. He has completed 12 cycles of chemotherapy. The histology shows well-differentiated cancer cells. Despite the bowel perforation, the patient's performance status is fully active. The KRAS biomarker analysis indicates a wild-type status."
483,white,female,70,31.8,FOLFOX,No,Yes,No,Yes,4,well differentiated,fully active,wild-type,No,No,Yes,No,No,1,"race: white, sex: female, age: 70, bmi: 31.8, treatment arm: FOLFOX, serious adverse effect: Yes, bowel perforation: Yes, chemotherapy cycles: 4, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type, adverse effect: diarrhea: Yes","The patient is a 70-year-old white female with a BMI of 31.8 who is receiving the FOLFOX treatment regimen. She has experienced a serious adverse effect in the form of a bowel perforation after completing 4 cycles of chemotherapy. The histology shows that the cancer is well-differentiated. Despite the adverse effect, her performance status remains fully active. The KRAS biomarker indicates that she has a wild-type mutation. Additionally, she is experiencing diarrhea as an adverse effect of the treatment."
484,white,female,57,24.01,FOLFOX,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 57, bmi: 24.01, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 57-year-old white female with a BMI of 24.01. She is receiving treatment with the FOLFOX chemotherapy regimen and is scheduled for 12 cycles. Her cancer histology is well-differentiated, and she has a fully active performance status. The KRAS biomarker testing revealed that she has a wild-type KRAS status."
485,white,female,64,23.44,FOLFIRI,No,Yes,No,No,12,poorly differentiated,fully active,interminate,No,No,No,No,No,0,"race: white, sex: female, age: 64, bmi: 23.44, treatment arm: FOLFIRI, serious adverse effect: Yes, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: interminate","The patient is a 64-year-old white female with a BMI of 23.44. She is receiving the FOLFIRI treatment regimen and has experienced a serious adverse effect. She has completed 12 cycles of chemotherapy. The histology of her cancer is poorly differentiated. Despite this, her performance status is fully active. The KRAS biomarker status is indeterminate."
486,white,male,41,23.91,FOLFOX,No,No,No,Yes,1,poorly differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 41, bmi: 23.91, treatment arm: FOLFOX, bowel perforation: Yes, chemotherapy cycles: 1, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 41-year-old white male with a BMI of 23.91. He is currently receiving treatment with the FOLFOX regimen. He has experienced a bowel perforation and has completed one cycle of chemotherapy. The histology of his cancer is poorly differentiated. Despite these challenges, his performance status is fully active. His KRAS biomarker status is wild-type."
487,white,female,43,28.79,FOLFOX,No,No,No,No,6,poorly differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 43, bmi: 28.79, treatment arm: FOLFOX, chemotherapy cycles: 6, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 43-year-old white female with a BMI of 28.79. She is receiving the FOLFOX treatment regimen and has completed 6 cycles of chemotherapy. Her histology shows poorly differentiated cancer cells. Despite this, her performance status is fully active. Additionally, her KRAS biomarker status is wild-type."
488,white,female,43,16.19,FOLFOX + Cetuximab,No,No,Yes,No,1,poorly differentiated,symptoms but ambulatory,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 43, bmi: 16.19, treatment arm: FOLFOX + Cetuximab, bowel obstruction: Yes, chemotherapy cycles: 1, histology: poorly differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type","The patient is a 43-year-old white female with a BMI of 16.19. She is currently receiving treatment with FOLFOX + Cetuximab for her cancer. She is experiencing a bowel obstruction and has completed one cycle of chemotherapy. The histology of her cancer is poorly differentiated. Despite experiencing symptoms, she is still able to be ambulatory. Her KRAS biomarker status is wild-type."
489,white,female,48,27.99,FOLFOX,No,No,No,Yes,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 48, bmi: 27.99, treatment arm: FOLFOX, bowel perforation: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type",The patient is a 48-year-old white female with a BMI of 27.99. She is receiving treatment with FOLFOX and has experienced a bowel perforation. She has completed 12 cycles of chemotherapy. The histology shows well-differentiated cells. The patient has a fully active performance status. The KRAS biomarker is wild-type.
490,white,male,58,24.87,FOLFOX + Cetuximab,No,No,No,No,12,poorly differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 58, bmi: 24.87, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 58-year-old white male with a BMI of 24.87. He is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. His cancer histology is poorly differentiated. Despite this, his performance status is fully active. Additionally, his KRAS biomarker status is wild-type."
491,white,female,50,27.14,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,fully active,mutant,No,No,No,No,No,0,"race: white, sex: female, age: 50, bmi: 27.14, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 50-year-old white female with a BMI of 27.14. She is receiving treatment in the FOLFOX + Cetuximab treatment arm and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cancer cells. The patient has a fully active performance status. Additionally, her KRAS biomarker is mutant."
492,white,male,65,38.13,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,fully active,mutant,No,No,No,No,No,0,"race: white, sex: male, age: 65, bmi: 38.13, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant",The patient is a 65-year-old white male with a BMI of 38.13. He is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. His cancer histology is well-differentiated. The patient has a fully active performance status. The KRAS biomarker indicates that he has a mutant form of the gene.
493,white,female,70,32.52,FOLFOX + Cetuximab,No,No,No,No,10,well differentiated,symptoms but ambulatory,mutant,No,No,No,Yes,No,1,"race: white, sex: female, age: 70, bmi: 32.52, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 10, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: mutant, adverse effect: infection: Yes","The patient is a 70-year-old white female with a BMI of 32.52 who is undergoing treatment with FOLFOX + Cetuximab for 10 chemotherapy cycles. Her histology shows well-differentiated cancer, and she has symptoms but is still able to walk around (ambulatory). The KRAS biomarker test revealed a mutant result. Additionally, the patient has experienced an infection as an adverse effect of treatment."
494,white,female,59,31.2,FOLFOX,Yes,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 59, bmi: 31.2, treatment arm: FOLFOX, adherence: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 59-year-old white female with a BMI of 31.2. She is receiving the FOLFOX treatment regimen and has been adherent to her chemotherapy cycles, completing a total of 12 cycles. The histology of her cancer is well-differentiated. She has a fully active performance status. Additionally, her KRAS biomarker status is wild-type."
495,white,female,46,40.82,FOLFOX + Cetuximab,No,No,No,No,10,well differentiated,symptoms but ambulatory,mutant,Yes,No,No,No,No,0,"race: white, sex: female, age: 46, bmi: 40.82, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 10, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: mutant, adverse effect: thrombosis: Yes","The patient is a 46-year-old white female with a BMI of 40.82. She is receiving treatment with FOLFOX + Cetuximab and has completed 10 cycles of chemotherapy. Her cancer histology is well-differentiated, and she has symptoms but is still able to be ambulatory. The KRAS biomarker testing showed a mutant result. Additionally, she has experienced an adverse effect of thrombosis."
496,other,female,48,21.04,FOLFOX,No,No,Yes,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: other, sex: female, age: 48, bmi: 21.04, treatment arm: FOLFOX, bowel obstruction: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 48-year-old female of a race categorized as ""other"" with a BMI of 21.04. She is receiving treatment with the FOLFOX regimen and has experienced a bowel obstruction. She has completed 12 cycles of chemotherapy. The histology of her cancer is well-differentiated. Despite the bowel obstruction, her performance status is fully active. The KRAS biomarker analysis indicates that she has a wild-type KRAS status."
497,white,male,42,27.12,FOLFOX,No,No,Yes,No,12,well differentiated,fully active,mutant,No,No,Yes,No,No,0,"race: white, sex: male, age: 42, bmi: 27.12, treatment arm: FOLFOX, bowel obstruction: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant, adverse effect: diarrhea: Yes","The patient is a 42-year-old white male with a BMI of 27.12 who is receiving treatment with FOLFOX for bowel obstruction. He has undergone 12 cycles of chemotherapy and has well-differentiated histology. Despite experiencing diarrhea as an adverse effect, his performance status is fully active. Additionally, the patient's KRAS biomarker is mutant."
498,white,female,65,31.22,FOLFIRI (KRAS mutant),No,No,No,No,6,well differentiated,fully active,mutant,No,Yes,No,No,No,1,"race: white, sex: female, age: 65, bmi: 31.22, treatment arm: FOLFIRI (KRAS mutant), chemotherapy cycles: 6, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant, adverse effect: hypersensitivity: Yes",The patient is a 65-year-old white female with a BMI of 31.22. She is receiving treatment with FOLFIRI for her well-differentiated cancer with a KRAS mutation. She has completed 6 cycles of chemotherapy and has a fully active performance status. The patient has experienced hypersensitivity as an adverse effect to the treatment.
499,white,female,52,20.08,FOLFIRI,No,No,Yes,No,12,well differentiated,symptoms but ambulatory,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 52, bmi: 20.08, treatment arm: FOLFIRI, bowel obstruction: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type","This patient is a 52-year-old white female with a BMI of 20.08. She is receiving treatment with the FOLFIRI chemotherapy regimen and has experienced a bowel obstruction. She has completed 12 cycles of chemotherapy and her cancer histology is well-differentiated. Despite experiencing symptoms, she is still able to be ambulatory. Additionally, her KRAS biomarker status is wild-type."
500,white,female,48,27.03,FOLFOX,No,No,No,No,12,well differentiated,fully active,mutant,No,No,No,No,No,0,"race: white, sex: female, age: 48, bmi: 27.03, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 48-year-old white female with a BMI of 27.03. She is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cancer cells. Despite her cancer diagnosis, she has a fully active performance status. The KRAS biomarker testing revealed a mutant status."
501,white,male,54,22.63,FOLFOX,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 54, bmi: 22.63, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type",The patient is a 54-year-old white male with a BMI of 22.63. He is undergoing treatment with the FOLFOX chemotherapy regimen and has completed 12 cycles. The histology of his cancer is well-differentiated. He has a fully active performance status. The KRAS biomarker testing revealed that he has a wild-type KRAS status.
502,black,female,45,15.58,FOLFOX + Cetuximab,Yes,No,Yes,No,12,poorly differentiated,symptoms but ambulatory,wild-type,No,No,No,No,No,0,"race: black, sex: female, age: 45, bmi: 15.58, treatment arm: FOLFOX + Cetuximab, adherence: Yes, bowel obstruction: Yes, chemotherapy cycles: 12, histology: poorly differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type","The patient is a 45-year-old Black female with a BMI of 15.58. She is receiving treatment with FOLFOX + Cetuximab and has been adherent to the treatment. She is currently experiencing a bowel obstruction and has completed 12 cycles of chemotherapy. The histology of her cancer is poorly differentiated. Despite experiencing symptoms, she is still able to be ambulatory. Her KRAS biomarker status is wild-type."
503,other,male,56,26.57,FOLFIRI (KRAS mutant),No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: other, sex: male, age: 56, bmi: 26.57, treatment arm: FOLFIRI (KRAS mutant), chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 56-year-old male of a race categorized as ""other"" with a BMI of 26.57. He is receiving treatment with the FOLFIRI regimen for KRAS mutant cancer. He has completed 12 cycles of chemotherapy. The histology of his cancer is well-differentiated. The patient has a fully active performance status, and his KRAS biomarker is wild-type."
504,white,female,36,34.81,FOLFOX + Cetuximab,No,No,No,No,7,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 36, bmi: 34.81, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 7, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type",The patient is a 36-year-old white female with a BMI of 34.81. She is receiving treatment with FOLFOX + Cetuximab and has completed 7 cycles of chemotherapy. Her histology shows well-differentiated cancer. She has a fully active performance status. The KRAS biomarker indicates that she has a wild-type mutation.
505,black,male,69,23.55,FOLFOX + Cetuximab,No,No,No,No,7,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: black, sex: male, age: 69, bmi: 23.55, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 7, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 69-year-old Black male with a BMI of 23.55. He is currently receiving treatment in the FOLFOX + Cetuximab treatment arm and has completed 7 cycles of chemotherapy. His histology shows well-differentiated cancer cells. Despite his age, he has a fully active performance status. Additionally, his KRAS biomarker indicates that he has a wild-type status."
506,white,male,41,26.71,FOLFOX,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 41, bmi: 26.71, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type",The patient is a 41-year-old white male with a BMI of 26.71. He is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer cells. The patient has a fully active performance status and his KRAS biomarker is wild-type.
507,white,female,52,23.5,FOLFOX + Cetuximab,No,Yes,No,No,12,poorly differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 52, bmi: 23.5, treatment arm: FOLFOX + Cetuximab, serious adverse effect: Yes, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 52-year-old white female with a BMI of 23.5. She is receiving treatment with FOLFOX + Cetuximab and has experienced a serious adverse effect. She has completed 12 cycles of chemotherapy. Her histology shows poorly differentiated cells. Despite this, her performance status is fully active. Additionally, her KRAS biomarker is wild-type."
508,white,male,37,26.04,FOLFOX,Yes,No,Yes,No,9,well differentiated,fully active,mutant,No,Yes,Yes,Yes,No,0,"race: white, sex: male, age: 37, bmi: 26.04, treatment arm: FOLFOX, adherence: Yes, bowel obstruction: Yes, chemotherapy cycles: 9, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant, adverse effect: hypersensitivity: Yes, adverse effect: diarrhea: Yes, adverse effect: infection: Yes","The patient is a 37-year-old white male with a BMI of 26.04 who is receiving the FOLFOX treatment regimen. He has been adherent to his treatment and has completed 9 cycles of chemotherapy. His cancer histology is well-differentiated, and he has a fully active performance status. The patient's KRAS biomarker is mutant. He has experienced adverse effects including hypersensitivity, diarrhea, and infection. Additionally, he has developed a bowel obstruction."
509,white,female,48,29.89,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 48, bmi: 29.89, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type",The patient is a 48-year-old white female with a BMI of 29.89. She is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cancer cells. The patient has a fully active performance status and her KRAS biomarker is wild-type.
510,black,female,62,24.05,FOLFIRI + Cetuximab,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: black, sex: female, age: 62, bmi: 24.05, treatment arm: FOLFIRI + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type",The patient is a 62-year-old Black female with a BMI of 24.05. She is receiving treatment with FOLFIRI + Cetuximab and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cancer cells. She has a fully active performance status. The KRAS biomarker indicates that she has a wild-type gene.
511,white,male,63,41.52,FOLFOX + Cetuximab,No,No,Yes,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 63, bmi: 41.52, treatment arm: FOLFOX + Cetuximab, bowel obstruction: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 63-year-old white male with a BMI of 41.52. He is receiving treatment with FOLFOX + Cetuximab for his well-differentiated histology. He has experienced a bowel obstruction and has completed 12 cycles of chemotherapy. Despite the bowel obstruction, his performance status is fully active. His KRAS biomarker status is wild-type."
512,white,male,70,21.84,FOLFOX + Cetuximab,No,No,No,No,10,well differentiated,fully active,wild-type,No,No,No,No,No,1,"race: white, sex: male, age: 70, bmi: 21.84, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 10, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 70-year-old white male with a BMI of 21.84. He is receiving treatment in the FOLFOX + Cetuximab treatment arm and has completed 10 cycles of chemotherapy. His histology shows well-differentiated cancer cells. Despite his age, he has a fully active performance status. Additionally, his KRAS biomarker indicates that he has a wild-type gene."
513,white,female,48,21.73,FOLFOX + Cetuximab,No,No,No,No,5,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 48, bmi: 21.73, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 5, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type",The patient is a 48-year-old white female with a BMI of 21.73. She is currently receiving treatment with FOLFOX + Cetuximab and has completed 5 cycles of chemotherapy. Her histology shows well-differentiated cancer cells. She has a fully active performance status. The KRAS biomarker testing revealed that she has a wild-type KRAS status.
514,other,male,52,36.23,FOLFOX,No,No,No,No,12,well differentiated,fully active,mutant,No,No,No,No,No,0,"race: other, sex: male, age: 52, bmi: 36.23, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 52-year-old male of a race categorized as ""other"" with a BMI of 36.23. He is undergoing treatment with the FOLFOX chemotherapy regimen and has completed 12 cycles. His cancer histology is well-differentiated, and he has a fully active performance status. Additionally, the KRAS biomarker testing revealed a mutant status."
515,white,male,56,32.32,FOLFOX + Cetuximab,Yes,No,No,No,1,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 56, bmi: 32.32, treatment arm: FOLFOX + Cetuximab, adherence: Yes, chemotherapy cycles: 1, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 56-year-old white male with a BMI of 32.32. He is currently receiving treatment in the FOLFOX + Cetuximab treatment arm and has been adherent to the treatment. He has completed one cycle of chemotherapy. His histology shows well-differentiated cells, and his performance status is fully active. The KRAS biomarker indicates that he has a wild-type mutation."
516,white,female,49,27.22,FOLFIRI,No,Yes,No,No,4,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 49, bmi: 27.22, treatment arm: FOLFIRI, serious adverse effect: Yes, chemotherapy cycles: 4, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 49-year-old white female with a BMI of 27.22. She is receiving the FOLFIRI treatment regimen and has experienced a serious adverse effect. She has completed 4 cycles of chemotherapy. Her histology shows well-differentiated cells, and her performance status is fully active. The KRAS biomarker analysis indicates that she has a wild-type KRAS status."
517,white,male,34,32.01,FOLFOX + Cetuximab,No,Yes,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 34, bmi: 32.01, treatment arm: FOLFOX + Cetuximab, serious adverse effect: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 34-year-old white male with a BMI of 32.01. He is receiving treatment in the FOLFOX + Cetuximab treatment arm and has experienced a serious adverse effect. He has completed 12 cycles of chemotherapy. His histology shows well-differentiated cells, and his performance status is fully active. The KRAS biomarker indicates that he has a wild-type status."
518,white,male,51,27,FOLFOX + Cetuximab,Yes,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 51, bmi: 27.0, treatment arm: FOLFOX + Cetuximab, adherence: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type",The patient is a 51-year-old white male with a BMI of 27.0. He is receiving treatment in the FOLFOX + Cetuximab treatment arm and has been adherent to the treatment. He has completed 12 cycles of chemotherapy. The histology of his cancer is well differentiated. The patient has a fully active performance status. His KRAS biomarker status is wild-type.
519,white,male,61,23.22,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 61, bmi: 23.22, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type",The patient is a 61-year-old white male with a BMI of 23.22. He is receiving treatment in the FOLFOX + Cetuximab treatment arm and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer cells. The patient has a fully active performance status and his KRAS biomarker is wild-type.
520,white,female,73,27.56,FOLFOX,No,Yes,Yes,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 73, bmi: 27.56, treatment arm: FOLFOX, serious adverse effect: Yes, bowel obstruction: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 73-year-old white female with a BMI of 27.56. She is receiving the FOLFOX treatment regimen and has experienced a serious adverse effect, specifically a bowel obstruction. She has completed 12 cycles of chemotherapy. The histology of her condition is well-differentiated. Despite the adverse effects, her performance status is fully active. Additionally, her KRAS biomarker status is wild-type."
521,white,female,54,25.31,FOLFOX,No,No,No,No,12,poorly differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 54, bmi: 25.31, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 54-year-old white female with a BMI of 25.31. She is undergoing treatment with the FOLFOX chemotherapy regimen and has completed 12 cycles. The histology of her cancer is poorly differentiated. Despite her cancer diagnosis, she has a fully active performance status. Her KRAS biomarker status is wild-type."
522,white,male,61,26.46,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 61, bmi: 26.46, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type",The patient is a 61-year-old white male with a BMI of 26.46. He is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer cells. The patient has a fully active performance status and his KRAS biomarker is wild-type.
523,white,male,43,30.52,FOLFOX + Cetuximab,No,Yes,No,No,2,well differentiated,fully active,wild-type,No,No,No,No,No,1,"race: white, sex: male, age: 43, bmi: 30.52, treatment arm: FOLFOX + Cetuximab, serious adverse effect: Yes, chemotherapy cycles: 2, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type",The patient is a 43-year-old white male with a BMI of 30.52. He is receiving treatment with FOLFOX + Cetuximab and has experienced a serious adverse effect. He has completed 2 cycles of chemotherapy. His histology shows well-differentiated cells. The patient has a fully active performance status. His KRAS biomarker is wild-type.
524,white,male,46,24.69,FOLFOX + Cetuximab,No,No,Yes,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 46, bmi: 24.69, treatment arm: FOLFOX + Cetuximab, bowel obstruction: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type",The patient is a 46-year-old white male with a BMI of 24.69. He is receiving treatment in the FOLFOX + Cetuximab treatment arm. He has experienced a bowel obstruction and has completed 12 cycles of chemotherapy. The histology shows well-differentiated cells. The patient has a fully active performance status. His KRAS biomarker is wild-type.
525,black,female,63,19.9,FOLFOX + Cetuximab,Yes,No,No,No,12,well differentiated,fully active,interminate,No,No,No,No,No,0,"race: black, sex: female, age: 63, bmi: 19.9, treatment arm: FOLFOX + Cetuximab, adherence: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: interminate","The patient is a 63-year-old Black female with a BMI of 19.9. She is currently receiving treatment in the FOLFOX + Cetuximab treatment arm and has been adherent to her treatment. She has completed 12 chemotherapy cycles. The histology of her condition is well-differentiated. Despite her age, she has a fully active performance status. The KRAS biomarker status is intermediate."
526,white,male,70,29.26,FOLFOX + Cetuximab,No,Yes,No,No,12,poorly differentiated,fully active,wild-type,No,No,Yes,No,No,0,"race: white, sex: male, age: 70, bmi: 29.26, treatment arm: FOLFOX + Cetuximab, serious adverse effect: Yes, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type, adverse effect: diarrhea: Yes","The patient is a 70-year-old white male with a BMI of 29.26 who is receiving treatment with FOLFOX + Cetuximab. He has experienced a serious adverse effect during his 12 chemotherapy cycles. His cancer histology is poorly differentiated, but he has a fully active performance status. His KRAS biomarker is wild-type. Additionally, he has experienced diarrhea as an adverse effect."
527,white,male,49,27.21,FOLFOX + Cetuximab,No,No,Yes,Yes,12,well differentiated,symptoms but ambulatory,mutant,No,No,No,No,No,0,"race: white, sex: male, age: 49, bmi: 27.21, treatment arm: FOLFOX + Cetuximab, bowel obstruction: Yes, bowel perforation: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: mutant","The patient is a 49-year-old white male with a BMI of 27.21. He is receiving treatment with FOLFOX + Cetuximab. He has experienced both a bowel obstruction and a bowel perforation. He has completed 12 cycles of chemotherapy. The histology of his condition is well differentiated. Despite experiencing symptoms, he is still able to be ambulatory. The KRAS biomarker shows that it is mutant."
528,white,male,40,35.88,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,symptoms but ambulatory,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 40, bmi: 35.88, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type","The patient is a 40-year-old white male with a BMI of 35.88. He is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. His cancer histology is well-differentiated. Despite experiencing symptoms, he is still able to be ambulatory. The KRAS biomarker testing showed that he has a wild-type KRAS status."
529,white,male,56,27.62,FOLFOX + Cetuximab,No,No,No,No,12,poorly differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 56, bmi: 27.62, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 56-year-old white male with a BMI of 27.62. He is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. His cancer histology is poorly differentiated. Despite his diagnosis, he has a fully active performance status. Additionally, his KRAS biomarker status is wild-type."
530,white,male,67,23.46,FOLFOX + Cetuximab,No,No,No,No,6,well differentiated,fully active,mutant,No,No,No,No,No,0,"race: white, sex: male, age: 67, bmi: 23.46, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 6, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant",The patient is a 67-year-old white male with a BMI of 23.46. He is receiving treatment in the FOLFOX + Cetuximab treatment arm and has completed 6 cycles of chemotherapy. His histology shows well-differentiated cells. The patient has a fully active performance status. The KRAS biomarker indicates a mutant status.
531,white,male,53,25.18,FOLFOX,No,Yes,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 53, bmi: 25.18, treatment arm: FOLFOX, serious adverse effect: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 53-year-old white male with a BMI of 25.18. He is receiving the FOLFOX treatment arm and has experienced a serious adverse effect. He has completed 12 cycles of chemotherapy. The histology shows that the cancer is well-differentiated. Despite the adverse effect, his performance status is fully active. The KRAS biomarker indicates that he has a wild-type mutation."
532,white,female,47,24.76,FOLFIRI,No,No,No,No,12,well differentiated,fully active,mutant,No,No,No,No,No,0,"race: white, sex: female, age: 47, bmi: 24.76, treatment arm: FOLFIRI, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 47-year-old white female with a BMI of 24.76. She is receiving the FOLFIRI treatment regimen and has completed 12 cycles of chemotherapy. Her cancer histology is well-differentiated, and she has a fully active performance status. The KRAS biomarker testing revealed a mutant status."
533,black,female,47,26.23,FOLFOX,No,No,No,No,12,poorly differentiated,fully active,mutant,No,No,No,No,No,1,"race: black, sex: female, age: 47, bmi: 26.23, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 47-year-old Black female with a BMI of 26.23. She is receiving the FOLFOX treatment arm and has completed 12 cycles of chemotherapy. The histology shows poorly differentiated cancer cells. Despite this, her performance status is fully active. Additionally, the KRAS biomarker testing revealed a mutant status."
534,other,male,58,33.36,FOLFOX,Yes,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: other, sex: male, age: 58, bmi: 33.36, treatment arm: FOLFOX, adherence: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 58-year-old male of a race categorized as ""other"" with a BMI of 33.36. He is undergoing treatment with the FOLFOX regimen and has been adherent to the treatment. He has completed 12 cycles of chemotherapy. The histology of his cancer is well-differentiated. The patient has a fully active performance status. His KRAS biomarker status is wild-type."
535,white,male,55,28.94,FOLFOX,Yes,No,Yes,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 55, bmi: 28.94, treatment arm: FOLFOX, adherence: Yes, bowel obstruction: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type",The patient is a 55-year-old white male with a BMI of 28.94. He is receiving the FOLFOX treatment regimen and has been adherent to the treatment. He has experienced a bowel obstruction. The patient has completed 12 cycles of chemotherapy and has well-differentiated histology. His performance status is fully active. The KRAS biomarker shows that he has a wild-type status.
536,white,male,34,22.81,FOLFOX,No,No,Yes,No,12,well differentiated,symptoms but ambulatory,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 34, bmi: 22.81, treatment arm: FOLFOX, bowel obstruction: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type","The patient is a 34-year-old white male with a BMI of 22.81. He is receiving treatment with the FOLFOX regimen for his well-differentiated histology. He has experienced a bowel obstruction and has completed 12 cycles of chemotherapy. Despite experiencing symptoms, he is still able to ambulate. His KRAS biomarker status is wild-type."
537,white,female,55,18.78,FOLFIRI,No,No,No,Yes,12,poorly differentiated,symptoms but ambulatory,wild-type,No,No,No,No,No,1,"race: white, sex: female, age: 55, bmi: 18.78, treatment arm: FOLFIRI, bowel perforation: Yes, chemotherapy cycles: 12, histology: poorly differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type","This patient is a 55-year-old white female with a BMI of 18.78. She is receiving treatment with the FOLFIRI regimen and has experienced a bowel perforation. She has completed 12 cycles of chemotherapy. The histology of her cancer is poorly differentiated. Despite experiencing symptoms, she is still able to be ambulatory. Her KRAS biomarker status is wild-type."
538,white,male,59,37.62,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,Yes,No,No,0,"race: white, sex: male, age: 59, bmi: 37.62, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type, adverse effect: diarrhea: Yes","The patient is a 59-year-old white male with a BMI of 37.62. He is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. His cancer histology is well-differentiated, and he has a fully active performance status. The KRAS biomarker is wild-type. The patient is experiencing diarrhea as an adverse effect of the treatment."
539,white,male,41,37.12,FOLFOX + Cetuximab,No,No,No,No,4,poorly differentiated,symptoms but ambulatory,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 41, bmi: 37.12, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 4, histology: poorly differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type","The patient is a 41-year-old white male with a BMI of 37.12. He is receiving treatment with FOLFOX + Cetuximab and has completed 4 cycles of chemotherapy. His histology shows poorly differentiated cancer cells. Despite experiencing symptoms, he is still able to be ambulatory. The KRAS biomarker analysis indicates that he has a wild-type KRAS status."
540,white,male,36,23.96,FOLFOX,Yes,No,No,No,1,well differentiated,symptoms but ambulatory,mutant,No,No,No,No,No,0,"race: white, sex: male, age: 36, bmi: 23.96, treatment arm: FOLFOX, adherence: Yes, chemotherapy cycles: 1, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: mutant","The patient is a 36-year-old white male with a BMI of 23.96. He is receiving treatment in the FOLFOX arm and has been adherent to the prescribed chemotherapy. He has completed one cycle of chemotherapy. The histology shows well-differentiated cancer cells. Despite experiencing symptoms, the patient is still ambulatory. The KRAS biomarker analysis indicates a mutant status."
541,white,female,66,37.39,FOLFOX + Cetuximab,No,No,Yes,No,10,well differentiated,fully active,wild-type,No,No,Yes,No,No,1,"race: white, sex: female, age: 66, bmi: 37.39, treatment arm: FOLFOX + Cetuximab, bowel obstruction: Yes, chemotherapy cycles: 10, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type, adverse effect: diarrhea: Yes","The patient is a 66-year-old white female with a BMI of 37.39. She is receiving treatment with FOLFOX + Cetuximab for her well-differentiated histology. She has experienced a bowel obstruction and has completed 10 cycles of chemotherapy. Despite the adverse effect of diarrhea, her performance status is fully active. Additionally, her KRAS biomarker is wild-type."
542,white,male,75,28.54,FOLFOX,No,No,Yes,No,12,poorly differentiated,symptoms but ambulatory,wild-type,No,No,No,No,No,1,"race: white, sex: male, age: 75, bmi: 28.54, treatment arm: FOLFOX, bowel obstruction: Yes, chemotherapy cycles: 12, histology: poorly differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type","The patient is a 75-year-old white male with a BMI of 28.54. He is receiving the FOLFOX treatment arm for his bowel obstruction. He has undergone 12 cycles of chemotherapy. The histology shows poorly differentiated cells. Despite experiencing symptoms, he is still able to walk around (ambulatory). The KRAS biomarker indicates that he has a wild-type gene."
543,white,male,67,29.7,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,Yes,No,No,0,"race: white, sex: male, age: 67, bmi: 29.7, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type, adverse effect: diarrhea: Yes","The patient is a 67-year-old white male with a BMI of 29.7. He is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer cells. Despite experiencing diarrhea as an adverse effect, the patient's performance status is fully active. Additionally, his KRAS biomarker is wild-type."
544,white,male,62,24.59,FOLFOX,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,1,"race: white, sex: male, age: 62, bmi: 24.59, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type",The patient is a 62-year-old white male with a BMI of 24.59. He is undergoing treatment with the FOLFOX chemotherapy regimen and has completed 12 cycles. His histology shows well-differentiated cancer cells. The patient has a fully active performance status and has a wild-type KRAS biomarker.
545,white,female,55,23.02,FOLFOX,Yes,No,No,No,12,poorly differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 55, bmi: 23.02, treatment arm: FOLFOX, adherence: Yes, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 55-year-old white female with a BMI of 23.02. She is receiving the FOLFOX treatment regimen and has been adherent to her chemotherapy cycles, completing a total of 12 cycles. The histology of her cancer is poorly differentiated. Despite her diagnosis, she has a fully active performance status. Additionally, her KRAS biomarker status is wild-type."
546,white,female,65,43.42,FOLFOX + Cetuximab,No,Yes,No,No,1,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 65, bmi: 43.42, treatment arm: FOLFOX + Cetuximab, serious adverse effect: Yes, chemotherapy cycles: 1, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 65-year-old white female with a BMI of 43.42. She is receiving treatment with FOLFOX + Cetuximab and has experienced a serious adverse effect after one cycle of chemotherapy. Her histology shows well-differentiated cells, and she has a fully active performance status. Additionally, her KRAS biomarker is wild-type."
547,white,male,62,29.36,FOLFOX,No,No,No,No,12,poorly differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 62, bmi: 29.36, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 62-year-old white male with a BMI of 29.36. He is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. His histology shows poorly differentiated cancer cells. Despite this, his performance status is fully active. Additionally, his KRAS biomarker indicates that it is wild-type."
548,white,male,67,25.58,FOLFOX,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 67, bmi: 25.58, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 67-year-old white male with a BMI of 25.58. He is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. His cancer histology is well-differentiated, and he has a fully active performance status. The KRAS biomarker testing shows that he has a wild-type KRAS status."
549,white,female,59,27.96,FOLFOX + Cetuximab,No,No,No,No,12,poorly differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 59, bmi: 27.96, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 59-year-old white female with a BMI of 27.96. She is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. Her histology shows poorly differentiated cancer cells. Despite this, her performance status is fully active. Additionally, her KRAS biomarker indicates that she has a wild-type gene."
550,white,male,70,32.88,FOLFOX,No,No,Yes,No,12,well differentiated,fully active,mutant,No,No,No,No,No,0,"race: white, sex: male, age: 70, bmi: 32.88, treatment arm: FOLFOX, bowel obstruction: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 70-year-old white male with a BMI of 32.88. He is receiving the FOLFOX treatment arm for his well-differentiated histology. He has experienced a bowel obstruction and has completed 12 cycles of chemotherapy. Despite these challenges, his performance status is fully active. Additionally, the patient has a mutant KRAS biomarker."
551,white,female,60,23.82,FOLFOX,Yes,No,No,No,12,well differentiated,fully active,mutant,No,No,No,No,No,0,"race: white, sex: female, age: 60, bmi: 23.82, treatment arm: FOLFOX, adherence: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant",The patient is a 60-year-old white female with a BMI of 23.82. She is receiving treatment in the FOLFOX arm and has been adherent to her chemotherapy. She has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cancer cells. The patient has a fully active performance status. The KRAS biomarker testing revealed a mutant status.
552,white,male,60,23.56,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,fully active,mutant,No,No,No,No,No,0,"race: white, sex: male, age: 60, bmi: 23.56, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant",The patient is a 60-year-old white male with a BMI of 23.56. He is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer cells. The patient has a fully active performance status. The KRAS biomarker testing revealed a mutant status.
553,white,male,68,19.05,FOLFIRI (KRAS mutant),No,No,Yes,No,12,well differentiated,symptoms but ambulatory,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 68, bmi: 19.05, treatment arm: FOLFIRI (KRAS mutant), bowel obstruction: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type","This patient is a 68-year-old white male with a BMI of 19.05. He is receiving the FOLFIRI treatment regimen for his KRAS mutant status. He has a bowel obstruction and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer. Despite experiencing symptoms, he is still able to be ambulatory. His KRAS biomarker is wild-type."
554,white,male,42,29,FOLFOX + Cetuximab,No,No,No,No,12,poorly differentiated,fully active,interminate,No,No,No,No,No,0,"race: white, sex: male, age: 42, bmi: 29.0, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: interminate","The patient is a 42-year-old white male with a BMI of 29.0. He is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. His histology shows poorly differentiated cancer cells. Despite this, his performance status is fully active. The KRAS biomarker status is indeterminate for this patient."
555,white,male,59,21.6,FOLFOX + Cetuximab,No,Yes,No,No,2,well differentiated,symptoms but ambulatory,interminate,No,No,No,No,No,1,"race: white, sex: male, age: 59, bmi: 21.6, treatment arm: FOLFOX + Cetuximab, serious adverse effect: Yes, chemotherapy cycles: 2, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: interminate","The patient is a 59-year-old white male with a BMI of 21.6. He is receiving treatment in the FOLFOX + Cetuximab treatment arm. He has experienced a serious adverse effect. He has completed 2 cycles of chemotherapy. The histology shows well-differentiated cells. Despite experiencing symptoms, he is still able to be ambulatory. The KRAS biomarker status is indeterminate for this patient."
556,white,male,44,29.68,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 44, bmi: 29.68, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type",The patient is a 44-year-old white male with a BMI of 29.68. He is receiving treatment in the FOLFOX + Cetuximab treatment arm and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer cells. The patient has a fully active performance status and his KRAS biomarker is wild-type.
557,other,female,66,40.94,FOLFOX,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: other, sex: female, age: 66, bmi: 40.94, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 66-year-old female of a race categorized as ""other"" with a BMI of 40.94. She is receiving the FOLFOX treatment arm and has completed 12 cycles of chemotherapy. The histology indicates well-differentiated cancer cells. The patient has a fully active performance status and her KRAS biomarker is wild-type."
558,white,male,38,30.47,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,fully active,mutant,No,Yes,No,No,No,0,"race: white, sex: male, age: 38, bmi: 30.47, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant, adverse effect: hypersensitivity: Yes",The patient is a 38-year-old white male with a BMI of 30.47. He is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer cells. The patient has a fully active performance status. His KRAS biomarker is mutant. He has experienced a hypersensitivity adverse effect.
559,white,male,42,27.84,FOLFOX,No,No,No,No,12,poorly differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 42, bmi: 27.84, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 42-year-old white male with a BMI of 27.84. He is receiving treatment with the FOLFOX chemotherapy regimen and is scheduled for 12 cycles. His cancer histology is poorly differentiated. Despite his diagnosis, he has a fully active performance status. Additionally, his KRAS biomarker status is wild-type."
560,white,male,74,26.24,FOLFOX,No,No,Yes,No,12,well differentiated,fully active,mutant,No,No,No,No,No,0,"race: white, sex: male, age: 74, bmi: 26.24, treatment arm: FOLFOX, bowel obstruction: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 74-year-old white male with a BMI of 26.24. He is receiving the FOLFOX treatment arm for his well-differentiated histology. He has experienced a bowel obstruction and has completed 12 cycles of chemotherapy. Despite these challenges, his performance status is fully active. Additionally, the patient has a mutant KRAS biomarker."
561,white,male,68,27.71,FOLFOX,No,No,No,No,12,poorly differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 68, bmi: 27.71, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 68-year-old white male with a BMI of 27.71. He is undergoing treatment with the FOLFOX chemotherapy regimen and has completed 12 cycles. His histology shows poorly differentiated cancer cells. Despite this, his performance status is fully active. The KRAS biomarker analysis indicates that he has a wild-type KRAS status."
562,white,female,50,33.19,FOLFOX,No,Yes,No,No,12,well differentiated,fully active,wild-type,No,Yes,No,No,No,0,"race: white, sex: female, age: 50, bmi: 33.19, treatment arm: FOLFOX, serious adverse effect: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type, adverse effect: hypersensitivity: Yes","The patient is a 50-year-old white female with a BMI of 33.19. She is receiving the FOLFOX treatment regimen and has experienced a serious adverse effect. She has completed 12 cycles of chemotherapy. The histology shows that the cancer is well-differentiated. The patient has a fully active performance status. Her KRAS biomarker is wild-type. Additionally, she has experienced a hypersensitivity adverse effect."
563,white,male,59,40.01,FOLFOX,Yes,No,No,No,12,poorly differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 59, bmi: 40.01, treatment arm: FOLFOX, adherence: Yes, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 59-year-old white male with a BMI of 40.01. He is receiving the FOLFOX treatment regimen and has been adherent to the treatment. He has completed 12 cycles of chemotherapy. The histology shows poorly differentiated cancer cells. Despite this, the patient has a fully active performance status. The KRAS biomarker indicates that he has a wild-type mutation."
564,white,male,70,31.74,FOLFOX + Cetuximab,No,No,Yes,No,12,well differentiated,fully active,mutant,No,No,No,No,No,0,"race: white, sex: male, age: 70, bmi: 31.74, treatment arm: FOLFOX + Cetuximab, bowel obstruction: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 70-year-old white male with a BMI of 31.74. He is receiving treatment in the FOLFOX + Cetuximab treatment arm. He has a bowel obstruction and has completed 12 cycles of chemotherapy. The histology shows that the cancer is well-differentiated. Despite the bowel obstruction, the patient has a fully active performance status. The KRAS biomarker indicates that the patient has a mutant status."
565,white,female,69,26.56,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 69, bmi: 26.56, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 69-year-old white female with a BMI of 26.56. She is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. Her cancer histology is well-differentiated, and she has a fully active performance status. The KRAS biomarker analysis shows that she has a wild-type KRAS status."
566,white,male,37,24.99,FOLFOX,No,No,Yes,No,12,well differentiated,fully active,wild-type,No,No,No,Yes,No,1,"race: white, sex: male, age: 37, bmi: 24.99, treatment arm: FOLFOX, bowel obstruction: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type, adverse effect: infection: Yes","The patient is a 37-year-old white male with a BMI of 24.99. He is receiving treatment with the FOLFOX regimen for his well-differentiated histology. He has experienced a bowel obstruction and has completed 12 cycles of chemotherapy. Despite this, his performance status is fully active. His KRAS biomarker is wild-type. Additionally, he has experienced an infection as an adverse effect during his treatment."
567,black,male,62,31.53,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: black, sex: male, age: 62, bmi: 31.53, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type",The patient is a 62-year-old Black male with a BMI of 31.53. He is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer cells. The patient has a fully active performance status. His KRAS biomarker is wild-type.
568,white,male,42,30.37,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,fully active,mutant,No,No,No,No,No,0,"race: white, sex: male, age: 42, bmi: 30.37, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant",The patient is a 42-year-old white male with a BMI of 30.37. He is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer cells. The patient has a fully active performance status. The KRAS biomarker analysis indicates a mutant status.
569,white,female,56,52.09,FOLFOX,No,Yes,No,No,12,poorly differentiated,fully active,mutant,No,No,No,No,No,0,"race: white, sex: female, age: 56, bmi: 52.09, treatment arm: FOLFOX, serious adverse effect: Yes, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 56-year-old white female with a BMI of 52.09. She is undergoing treatment with the FOLFOX regimen and has experienced a serious adverse effect. She has completed 12 cycles of chemotherapy. The histology of her cancer is poorly differentiated. Despite this, her performance status is fully active. Additionally, the KRAS biomarker testing revealed a mutant status."
570,other,male,64,22.32,FOLFOX,Yes,No,No,Yes,12,well differentiated,fully active,mutant,No,No,No,No,No,0,"race: other, sex: male, age: 64, bmi: 22.32, treatment arm: FOLFOX, adherence: Yes, bowel perforation: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 64-year-old male of a race categorized as ""other"" with a BMI of 22.32. He is receiving treatment in the FOLFOX arm and has been adherent to the treatment. The patient experienced a bowel perforation and has completed 12 cycles of chemotherapy. Histologically, the cancer is well-differentiated. Despite the bowel perforation, the patient's performance status is fully active. The KRAS biomarker analysis revealed a mutant status."
571,other,female,75,28.18,FOLFOX + Cetuximab,No,No,No,No,8,well differentiated,symptoms but ambulatory,mutant,No,No,No,No,No,1,"race: other, sex: female, age: 75, bmi: 28.18, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 8, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: mutant","The patient is a 75-year-old female of a race categorized as ""other"" with a BMI of 28.18. She is receiving treatment in the FOLFOX + Cetuximab treatment arm and has completed 8 cycles of chemotherapy. The histology indicates that the cancer is well-differentiated. Despite experiencing symptoms, the patient is still able to be ambulatory. The KRAS biomarker testing revealed a mutant status."
572,white,male,46,38.2,FOLFOX,No,No,No,No,12,well differentiated,fully active,mutant,No,No,No,No,No,0,"race: white, sex: male, age: 46, bmi: 38.2, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 46-year-old white male with a BMI of 38.2. He is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer cells. Despite his cancer diagnosis, he has a fully active performance status. The KRAS biomarker testing revealed a mutant status."
573,white,female,71,17.72,FOLFOX,No,Yes,No,No,5,well differentiated,symptoms but ambulatory,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 71, bmi: 17.72, treatment arm: FOLFOX, serious adverse effect: Yes, chemotherapy cycles: 5, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type","The patient is a 71-year-old white female with a BMI of 17.72. She is receiving the FOLFOX treatment regimen and has experienced a serious adverse effect. She has completed 5 cycles of chemotherapy. The histology shows that the cancer is well-differentiated. Despite experiencing symptoms, she is still able to be ambulatory. The KRAS biomarker indicates that she has a wild-type status."
574,white,male,55,32.65,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,fully active,mutant,No,No,No,No,No,0,"race: white, sex: male, age: 55, bmi: 32.65, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 55-year-old white male with a BMI of 32.65. He is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. His cancer histology is well-differentiated, and he has a fully active performance status. The KRAS biomarker testing revealed a mutant status."
575,white,female,36,26.06,FOLFOX + Cetuximab,Yes,No,No,Yes,3,well differentiated,symptoms but ambulatory,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 36, bmi: 26.06, treatment arm: FOLFOX + Cetuximab, adherence: Yes, bowel perforation: Yes, chemotherapy cycles: 3, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type","The patient is a 36-year-old white female with a BMI of 26.06. She is receiving treatment in the FOLFOX + Cetuximab treatment arm and has been adherent to her treatment. She experienced a bowel perforation and has completed 3 cycles of chemotherapy. The histology shows that the cancer is well-differentiated. Despite experiencing symptoms, she is still able to be ambulatory. Her KRAS biomarker is wild-type."
576,black,male,62,24.95,FOLFOX,No,No,No,No,12,well differentiated,fully active,mutant,No,No,No,No,No,0,"race: black, sex: male, age: 62, bmi: 24.95, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 62-year-old Black male with a BMI of 24.95. He is receiving the FOLFOX treatment arm and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer cells. Despite his cancer diagnosis, he has a fully active performance status. The patient's KRAS biomarker is mutant."
577,other,male,55,23.56,FOLFOX,No,No,No,No,7,poorly differentiated,fully active,mutant,No,Yes,No,No,No,0,"race: other, sex: male, age: 55, bmi: 23.56, treatment arm: FOLFOX, chemotherapy cycles: 7, histology: poorly differentiated, performance status: fully active, KRAS biomarker: mutant, adverse effect: hypersensitivity: Yes","The patient is a 55-year-old male of a race categorized as ""other"" with a BMI of 23.56. He is undergoing treatment with the FOLFOX chemotherapy regimen and has completed 7 cycles. The histology of his cancer is poorly differentiated. Despite this, his performance status is fully active. The KRAS biomarker testing revealed a mutant status. The patient has experienced a hypersensitivity adverse effect."
578,white,female,57,43.53,FOLFOX,No,Yes,No,No,12,poorly differentiated,fully active,mutant,No,No,Yes,Yes,No,0,"race: white, sex: female, age: 57, bmi: 43.53, treatment arm: FOLFOX, serious adverse effect: Yes, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: mutant, adverse effect: diarrhea: Yes, adverse effect: infection: Yes","The patient is a 57-year-old white female with a BMI of 43.53. She is receiving the FOLFOX treatment regimen and has experienced a serious adverse effect. She has completed 12 cycles of chemotherapy. The histology of her cancer is poorly differentiated. Despite this, her performance status is fully active. The KRAS biomarker testing revealed a mutant status. She has also experienced adverse effects of diarrhea and infection during her treatment."
579,white,male,63,37.98,FOLFOX,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 63, bmi: 37.98, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type",The patient is a 63-year-old white male with a BMI of 37.98. He is receiving the FOLFOX treatment arm and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer cells. The patient has a fully active performance status. His KRAS biomarker is wild-type.
580,white,female,44,20.58,FOLFOX,No,No,Yes,No,2,poorly differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 44, bmi: 20.58, treatment arm: FOLFOX, bowel obstruction: Yes, chemotherapy cycles: 2, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 44-year-old white female with a BMI of 20.58. She is currently receiving treatment in the FOLFOX treatment arm. She has experienced a bowel obstruction and has completed 2 cycles of chemotherapy. The histology of her cancer is poorly differentiated. Despite these challenges, her performance status is fully active. The KRAS biomarker analysis indicates that she has a wild-type KRAS status."
581,white,male,40,30.48,FOLFOX + Cetuximab,Yes,No,No,Yes,12,poorly differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 40, bmi: 30.48, treatment arm: FOLFOX + Cetuximab, adherence: Yes, bowel perforation: Yes, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 40-year-old white male with a BMI of 30.48. He is receiving treatment in the FOLFOX + Cetuximab treatment arm and has been adherent to the treatment. He experienced a bowel perforation and has completed 12 cycles of chemotherapy. The histology of his cancer is poorly differentiated. Despite these challenges, his performance status is fully active. His KRAS biomarker status is wild-type."
582,white,male,74,36.73,FOLFOX + Cetuximab,No,No,No,No,5,well differentiated,symptoms but ambulatory,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 74, bmi: 36.73, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 5, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type","The patient is a 74-year-old white male with a BMI of 36.73. He is receiving treatment with FOLFOX + Cetuximab and has completed 5 cycles of chemotherapy. His histology shows well-differentiated cancer cells. Despite experiencing symptoms, he is still able to walk around (ambulatory). His KRAS biomarker status is wild-type."
583,white,female,68,23.44,FOLFOX + Cetuximab,No,Yes,Yes,No,12,poorly differentiated,symptoms but ambulatory,mutant,No,No,No,No,No,0,"race: white, sex: female, age: 68, bmi: 23.44, treatment arm: FOLFOX + Cetuximab, serious adverse effect: Yes, bowel obstruction: Yes, chemotherapy cycles: 12, histology: poorly differentiated, performance status: symptoms but ambulatory, KRAS biomarker: mutant","This patient is a 68-year-old white female with a BMI of 23.44. She is receiving treatment with FOLFOX + Cetuximab for her cancer. Unfortunately, she has experienced a serious adverse effect in the form of a bowel obstruction. She has completed 12 cycles of chemotherapy. The histology of her cancer is poorly differentiated. Despite experiencing symptoms, she is still able to be ambulatory. Additionally, her KRAS biomarker is mutant."
584,other,female,41,30.3,FOLFOX + Cetuximab,No,No,No,No,12,poorly differentiated,symptoms but ambulatory,wild-type,No,No,No,No,No,0,"race: other, sex: female, age: 41, bmi: 30.3, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: poorly differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type","The patient is a 41-year-old female of a race other than specified, with a BMI of 30.3. She is receiving treatment in the FOLFOX + Cetuximab treatment arm and has completed 12 cycles of chemotherapy. The histology of her condition is poorly differentiated. Despite experiencing symptoms, she is still able to be ambulatory. Additionally, her KRAS biomarker status is wild-type."
585,other,male,49,24.13,FOLFOX + Cetuximab,No,No,No,No,12,poorly differentiated,symptoms but ambulatory,wild-type,No,No,No,No,No,0,"race: other, sex: male, age: 49, bmi: 24.13, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: poorly differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type","The patient is a 49-year-old male of a race categorized as ""other"" with a BMI of 24.13. He is receiving treatment in the FOLFOX + Cetuximab treatment arm and has completed 12 cycles of chemotherapy. The histology indicates poorly differentiated cancer. Despite experiencing symptoms, the patient is still able to be ambulatory. The KRAS biomarker shows that the patient has a wild-type status."
586,white,male,63,29.09,FOLFOX,No,No,No,No,10,well differentiated,symptoms but ambulatory,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 63, bmi: 29.09, treatment arm: FOLFOX, chemotherapy cycles: 10, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type","The patient is a 63-year-old white male with a BMI of 29.09. He is undergoing treatment with the FOLFOX chemotherapy regimen and has completed 10 cycles so far. His histology shows well-differentiated cancer cells. Despite experiencing symptoms, he is still able to be ambulatory. The KRAS biomarker analysis indicates that he has a wild-type KRAS status."
587,white,female,40,31.8,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 40, bmi: 31.8, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 40-year-old white female with a BMI of 31.8. She is receiving treatment in the FOLFOX + Cetuximab treatment arm and is scheduled for 12 chemotherapy cycles. Her histology shows well-differentiated cells, and she has a fully active performance status. The KRAS biomarker analysis indicates that she has a wild-type KRAS status."
588,white,male,61,29.4,FOLFOX,Yes,No,No,No,4,well differentiated,fully active,mutant,No,No,No,No,No,0,"race: white, sex: male, age: 61, bmi: 29.4, treatment arm: FOLFOX, adherence: Yes, chemotherapy cycles: 4, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant",The patient is a 61-year-old white male with a BMI of 29.4. He is receiving the FOLFOX treatment regimen and has been adherent to the treatment. He has completed 4 cycles of chemotherapy. His histology shows well-differentiated cancer cells. The patient has a fully active performance status. The KRAS biomarker analysis indicates a mutant status.
589,white,female,63,28.42,FOLFOX,No,No,No,No,12,well differentiated,fully active,mutant,No,No,No,No,No,0,"race: white, sex: female, age: 63, bmi: 28.42, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant",The patient is a 63-year-old white female with a BMI of 28.42. She is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. The histology shows well-differentiated cancer cells. The patient has a fully active performance status. The KRAS biomarker testing revealed a mutant status.
590,white,female,51,34.91,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 51, bmi: 34.91, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type",The patient is a 51-year-old white female with a BMI of 34.91. She is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cancer cells. The patient has a fully active performance status. Her KRAS biomarker is wild-type.
591,white,male,41,32.47,FOLFOX,No,No,No,No,2,poorly differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 41, bmi: 32.47, treatment arm: FOLFOX, chemotherapy cycles: 2, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 41-year-old white male with a BMI of 32.47. He is receiving treatment with the FOLFOX chemotherapy regimen and has completed 2 cycles so far. His histology shows poorly differentiated cancer cells. Despite this, his performance status is fully active. Additionally, his KRAS biomarker indicates that it is wild-type."
592,white,female,53,29.55,FOLFOX,No,No,No,No,12,poorly differentiated,fully active,mutant,No,No,No,No,No,0,"race: white, sex: female, age: 53, bmi: 29.55, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 53-year-old white female with a BMI of 29.55. She is receiving treatment with the FOLFOX chemotherapy regimen and has completed 12 cycles. The histology of her cancer is poorly differentiated. Despite this, her performance status is fully active. Additionally, the KRAS biomarker testing revealed a mutant status."
593,white,female,73,33.16,FOLFOX + Cetuximab,No,No,No,No,1,poorly differentiated,fully active,wild-type,No,No,Yes,No,No,0,"race: white, sex: female, age: 73, bmi: 33.16, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 1, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type, adverse effect: diarrhea: Yes","The patient is a 73-year-old white female with a BMI of 33.16. She is currently receiving treatment in the FOLFOX + Cetuximab treatment arm and has completed one cycle of chemotherapy. Her histology shows poorly differentiated cancer cells, and she has a fully active performance status. The KRAS biomarker analysis indicates that she has a wild-type KRAS status. The patient is experiencing diarrhea as an adverse effect of the treatment."
594,white,male,36,17.47,FOLFIRI,No,No,No,No,6,poorly differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 36, bmi: 17.47, treatment arm: FOLFIRI, chemotherapy cycles: 6, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 36-year-old white male with a BMI of 17.47. He is undergoing treatment with the FOLFIRI chemotherapy regimen and has completed 6 cycles so far. His histology shows poorly differentiated cancer cells. Despite this, his performance status is fully active. Additionally, his KRAS biomarker status is wild-type."
595,white,female,65,38.96,FOLFOX,No,No,No,No,8,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 65, bmi: 38.96, treatment arm: FOLFOX, chemotherapy cycles: 8, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 65-year-old white female with a BMI of 38.96. She is receiving the FOLFOX treatment regimen and has completed 8 cycles of chemotherapy. Her histology shows well-differentiated cells. Despite her age, she has a fully active performance status. Additionally, her KRAS biomarker indicates that she has a wild-type status."
596,white,female,45,27.55,FOLFOX + Cetuximab,No,No,Yes,No,12,well differentiated,symptoms but ambulatory,mutant,No,No,No,No,No,0,"race: white, sex: female, age: 45, bmi: 27.55, treatment arm: FOLFOX + Cetuximab, bowel obstruction: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: mutant","This patient is a 45-year-old white female with a BMI of 27.55. She is receiving treatment with FOLFOX + Cetuximab for her well-differentiated histology. She has experienced a bowel obstruction and has completed 12 cycles of chemotherapy. Despite experiencing symptoms, she is still able to be ambulatory. Additionally, her KRAS biomarker is mutant."
597,white,female,64,24.96,FOLFOX + Cetuximab,No,No,No,No,12,poorly differentiated,fully active,wild-type,No,No,No,No,No,1,"race: white, sex: female, age: 64, bmi: 24.96, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 64-year-old white female with a BMI of 24.96. She is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. Her cancer histology is poorly differentiated. Despite this, her performance status is fully active. Additionally, her KRAS biomarker status is wild-type."
598,white,male,76,31.84,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,symptoms but ambulatory,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 76, bmi: 31.84, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type","The patient is a 76-year-old white male with a BMI of 31.84. He is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer. Despite experiencing symptoms, he is still able to walk around (ambulatory). Additionally, his KRAS biomarker indicates that it is wild-type."
599,white,female,54,31.92,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,symptoms but ambulatory,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 54, bmi: 31.92, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type","The patient is a 54-year-old white female with a BMI of 31.92. She is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cancer. Despite experiencing symptoms, she is still able to be ambulatory. The KRAS biomarker indicates that she has a wild-type status."
600,other,male,66,25.37,FOLFOX,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: other, sex: male, age: 66, bmi: 25.37, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 66-year-old male of a race categorized as ""other"" with a BMI of 25.37. He is undergoing treatment with the FOLFOX chemotherapy regimen and has completed 12 cycles. The histology of his cancer is well-differentiated. Despite his age, he has a fully active performance status. Additionally, the KRAS biomarker testing indicates that he has a wild-type KRAS status."
601,white,male,53,31.66,FOLFOX,No,No,No,No,12,poorly differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 53, bmi: 31.66, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 53-year-old white male with a BMI of 31.66. He is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. His histology shows poorly differentiated cells. Despite this, his performance status is fully active. Additionally, the KRAS biomarker indicates that he has a wild-type status."
602,black,female,74,34.84,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: black, sex: female, age: 74, bmi: 34.84, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 74-year-old Black female with a BMI of 34.84. She is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cancer, and she has a fully active performance status. The KRAS biomarker analysis indicates that she has a wild-type KRAS status."
603,white,male,71,30.48,FOLFOX,No,No,Yes,Yes,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 71, bmi: 30.48, treatment arm: FOLFOX, bowel obstruction: Yes, bowel perforation: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 71-year-old white male with a BMI of 30.48. He is undergoing treatment with FOLFOX chemotherapy regimen and has experienced both bowel obstruction and perforation. He has completed 12 cycles of chemotherapy. The histology of his cancer is well-differentiated. Despite his bowel issues, his performance status is fully active. His KRAS biomarker status is wild-type."
604,white,female,67,23.74,FOLFOX,No,No,No,No,1,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 67, bmi: 23.74, treatment arm: FOLFOX, chemotherapy cycles: 1, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 67-year-old white female with a BMI of 23.74. She is currently receiving treatment with the FOLFOX chemotherapy regimen and has completed one cycle so far. Her histology shows well-differentiated cancer cells. Despite her age, she has a fully active performance status. Additionally, her KRAS biomarker indicates that she has a wild-type gene."
605,white,male,41,27.62,FOLFIRI + Cetuximab,No,Yes,No,No,12,poorly differentiated,fully active,wild-type,Yes,No,No,No,No,0,"race: white, sex: male, age: 41, bmi: 27.62, treatment arm: FOLFIRI + Cetuximab, serious adverse effect: Yes, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type, adverse effect: thrombosis: Yes","The patient is a 41-year-old white male with a BMI of 27.62. He is receiving treatment with FOLFIRI + Cetuximab and has experienced a serious adverse effect. He has completed 12 cycles of chemotherapy. His histology shows poorly differentiated cells, and he has a fully active performance status. His KRAS biomarker is wild-type. Additionally, he has experienced thrombosis as an adverse effect."
606,white,male,40,20.71,FOLFOX + Cetuximab,No,No,No,No,4,poorly differentiated,symptoms but ambulatory,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 40, bmi: 20.71, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 4, histology: poorly differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type","The patient is a 40-year-old white male with a BMI of 20.71. He is receiving treatment with FOLFOX + Cetuximab and has completed 4 cycles of chemotherapy. His histology shows poorly differentiated cancer cells. Despite experiencing symptoms, he is still able to ambulate. The KRAS biomarker analysis indicates that he has a wild-type KRAS status."
607,white,female,49,22.15,FOLFOX + Cetuximab,Yes,No,Yes,Yes,12,well differentiated,fully active,wild-type,No,No,Yes,No,No,0,"race: white, sex: female, age: 49, bmi: 22.15, treatment arm: FOLFOX + Cetuximab, adherence: Yes, bowel obstruction: Yes, bowel perforation: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type, adverse effect: diarrhea: Yes","The patient is a 49-year-old white female with a BMI of 22.15. She is receiving treatment in the FOLFOX + Cetuximab treatment arm and has been adherent to her treatment. She has experienced a bowel obstruction and perforation. She has completed 12 chemotherapy cycles and her histology shows well-differentiated cells. Despite the bowel issues, her performance status is fully active. Her KRAS biomarker is wild-type. She has experienced diarrhea as an adverse effect of the treatment."
608,white,male,63,29.21,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,fully active,mutant,No,No,No,No,No,0,"race: white, sex: male, age: 63, bmi: 29.21, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant",The patient is a 63-year-old white male with a BMI of 29.21. He is receiving treatment in the FOLFOX + Cetuximab treatment arm and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer cells. The patient has a fully active performance status. The KRAS biomarker analysis indicates a mutant status.
609,white,female,60,22.7,FOLFOX + Cetuximab,No,No,No,No,2,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 60, bmi: 22.7, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 2, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type",The patient is a 60-year-old white female with a BMI of 22.7. She is currently receiving treatment with FOLFOX + Cetuximab and has completed 2 cycles of chemotherapy. Her histology shows well-differentiated cancer cells. The patient has a fully active performance status and her KRAS biomarker is wild-type.
610,white,male,73,37.76,FOLFOX,No,No,No,No,12,well differentiated,symptoms but ambulatory,wild-type,No,No,Yes,Yes,No,1,"race: white, sex: male, age: 73, bmi: 37.76, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type, adverse effect: diarrhea: Yes, adverse effect: infection: Yes","The patient is a 73-year-old white male with a BMI of 37.76. He is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. His cancer histology is well-differentiated. Despite experiencing symptoms, he is still able to move around. His KRAS biomarker is wild-type. The patient has reported experiencing diarrhea and infection as adverse effects of the treatment."
611,white,female,53,29.52,FOLFOX + Cetuximab,Yes,No,No,No,12,poorly differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 53, bmi: 29.52, treatment arm: FOLFOX + Cetuximab, adherence: Yes, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 53-year-old white female with a BMI of 29.52. She is receiving treatment in the FOLFOX + Cetuximab treatment arm and has been adherent to her chemotherapy regimen for 12 cycles. Her histology shows poorly differentiated cells, and she has a fully active performance status. The KRAS biomarker indicates that she has a wild-type mutation."
612,white,female,63,25.49,FOLFOX,No,No,Yes,No,11,well differentiated,symptoms but ambulatory,mutant,No,No,No,No,No,0,"race: white, sex: female, age: 63, bmi: 25.49, treatment arm: FOLFOX, bowel obstruction: Yes, chemotherapy cycles: 11, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: mutant","The patient is a 63-year-old white female with a BMI of 25.49. She is receiving treatment with FOLFOX chemotherapy. She has a bowel obstruction and has completed 11 cycles of chemotherapy. The histology shows well-differentiated cancer cells. Despite experiencing symptoms, she is still able to be ambulatory. The KRAS biomarker indicates a mutant status."
613,white,male,72,30,FOLFOX,Yes,No,No,No,8,poorly differentiated,fully active,wild-type,No,No,Yes,No,No,0,"race: white, sex: male, age: 72, bmi: 30.0, treatment arm: FOLFOX, adherence: Yes, chemotherapy cycles: 8, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type, adverse effect: diarrhea: Yes","The patient is a 72-year-old white male with a BMI of 30.0 who is receiving the FOLFOX treatment regimen. He has completed 8 cycles of chemotherapy and has been adherent to the treatment. His cancer histology is poorly differentiated, and he has a fully active performance status. The KRAS biomarker testing showed that he has a wild-type KRAS status. The patient has experienced diarrhea as an adverse effect of the treatment."
614,white,female,68,21.52,FOLFOX,No,No,No,No,12,poorly differentiated,symptoms but ambulatory,mutant,No,No,No,No,No,0,"race: white, sex: female, age: 68, bmi: 21.52, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: poorly differentiated, performance status: symptoms but ambulatory, KRAS biomarker: mutant","The patient is a 68-year-old white female with a BMI of 21.52. She is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. Her histology shows poorly differentiated cancer cells. Despite experiencing symptoms, she is still able to walk around (ambulatory). The KRAS biomarker testing revealed a mutation in the KRAS gene."
615,white,male,57,24.91,FOLFOX,No,No,No,Yes,12,poorly differentiated,fully active,mutant,No,No,No,No,No,0,"race: white, sex: male, age: 57, bmi: 24.91, treatment arm: FOLFOX, bowel perforation: Yes, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 57-year-old white male with a BMI of 24.91. He is receiving treatment with the FOLFOX regimen and has experienced a bowel perforation. He has completed 12 cycles of chemotherapy. The histology of his cancer is poorly differentiated. Despite these challenges, his performance status is fully active. Additionally, the KRAS biomarker testing revealed a mutant status."
616,white,male,66,24.96,FOLFOX + Cetuximab,No,No,No,No,4,well differentiated,fully active,mutant,No,No,Yes,No,No,0,"race: white, sex: male, age: 66, bmi: 24.96, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 4, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant, adverse effect: diarrhea: Yes","The patient is a 66-year-old white male with a BMI of 24.96. He is receiving treatment with FOLFOX + Cetuximab and has completed 4 cycles of chemotherapy. His histology shows well-differentiated cancer cells. Despite experiencing diarrhea as an adverse effect, his performance status remains fully active. Additionally, the KRAS biomarker analysis indicates a mutant status."
617,white,male,58,32.43,FOLFOX + Cetuximab,No,No,No,No,12,poorly differentiated,fully active,wild-type,No,No,No,No,No,1,"race: white, sex: male, age: 58, bmi: 32.43, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 58-year-old white male with a BMI of 32.43. He is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. The histology of his cancer is poorly differentiated. Despite his cancer diagnosis, he has a fully active performance status. His KRAS biomarker status is wild-type."
618,white,female,76,24.71,FOLFOX,Yes,No,No,No,12,well differentiated,symptoms but ambulatory,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 76, bmi: 24.71, treatment arm: FOLFOX, adherence: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type","The patient is a 76-year-old white female with a BMI of 24.71. She is receiving the FOLFOX treatment regimen and has been adherent to the treatment. She has completed 12 cycles of chemotherapy. The histology shows that the cancer is well-differentiated. Despite experiencing symptoms, she is still able to be ambulatory. The KRAS biomarker analysis indicates that she has a wild-type KRAS status."
619,other,male,49,38.01,FOLFOX,No,No,No,No,12,poorly differentiated,symptoms but ambulatory,wild-type,No,No,No,No,No,0,"race: other, sex: male, age: 49, bmi: 38.01, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: poorly differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type","The patient is a 49-year-old male of a race categorized as ""other"" with a BMI of 38.01. He is undergoing treatment with the FOLFOX chemotherapy regimen and has completed 12 cycles. The histology of his cancer is poorly differentiated. Despite experiencing symptoms, the patient is still able to be ambulatory. His KRAS biomarker status is wild-type."
620,white,female,62,27.97,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 62, bmi: 27.97, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 62-year-old white female with a BMI of 27.97. She is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. Her cancer histology is well differentiated, and she has a fully active performance status. The KRAS biomarker indicates that she has a wild-type status."
621,white,male,45,32.57,FOLFOX,No,Yes,No,No,12,well differentiated,fully active,mutant,No,No,No,No,No,0,"race: white, sex: male, age: 45, bmi: 32.57, treatment arm: FOLFOX, serious adverse effect: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 45-year-old white male with a BMI of 32.57. He is undergoing treatment with the FOLFOX chemotherapy regimen and has experienced a serious adverse effect. He has completed 12 cycles of chemotherapy. The histology of his cancer is well differentiated. Despite the adverse effect, his performance status is fully active. Additionally, the KRAS biomarker testing revealed a mutant status."
622,white,female,60,20.19,FOLFOX,No,No,No,No,12,poorly differentiated,fully active,mutant,No,No,No,No,No,0,"race: white, sex: female, age: 60, bmi: 20.19, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 60-year-old white female with a BMI of 20.19. She is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. Her cancer histology is poorly differentiated. Despite her diagnosis, she has a fully active performance status. The KRAS biomarker testing revealed a mutant status."
623,white,male,47,38.72,FOLFOX + Cetuximab,No,No,Yes,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 47, bmi: 38.72, treatment arm: FOLFOX + Cetuximab, bowel obstruction: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 47-year-old white male with a BMI of 38.72. He is receiving treatment with FOLFOX + Cetuximab for his well-differentiated histology. He has a bowel obstruction and has completed 12 cycles of chemotherapy. Despite the bowel obstruction, his performance status is fully active. His KRAS biomarker is wild-type."
624,other,female,70,20.94,FOLFOX,Yes,Yes,No,Yes,12,poorly differentiated,symptoms but ambulatory,wild-type,No,No,No,No,No,0,"race: other, sex: female, age: 70, bmi: 20.94, treatment arm: FOLFOX, adherence: Yes, serious adverse effect: Yes, bowel perforation: Yes, chemotherapy cycles: 12, histology: poorly differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type","The patient is a 70-year-old female of a race other than specified, with a BMI of 20.94. She is undergoing treatment with the FOLFOX regimen and has been adherent to the treatment. Unfortunately, she has experienced a serious adverse effect in the form of a bowel perforation. She has completed 12 cycles of chemotherapy and her histology shows poorly differentiated cells. Despite experiencing symptoms, she is still able to be ambulatory. Her KRAS biomarker status is wild-type."
625,white,male,42,19.5,FOLFOX,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 42, bmi: 19.5, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type",The patient is a 42-year-old white male with a BMI of 19.5. He is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cells. The patient has a fully active performance status and his KRAS biomarker is wild-type.
626,white,female,46,39.33,FOLFOX,Yes,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,1,"race: white, sex: female, age: 46, bmi: 39.33, treatment arm: FOLFOX, adherence: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type",The patient is a 46-year-old white female with a BMI of 39.33. She is receiving treatment in the FOLFOX arm and has been adherent to the chemotherapy regimen for 12 cycles. Her histology shows well-differentiated cancer cells. The patient has a fully active performance status and her KRAS biomarker is wild-type.
627,white,male,60,37.49,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,Yes,No,No,0,"race: white, sex: male, age: 60, bmi: 37.49, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type, adverse effect: diarrhea: Yes","The patient is a 60-year-old white male with a BMI of 37.49. He is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. His cancer histology is well-differentiated, and he has a fully active performance status. The KRAS biomarker shows that he is wild-type. The patient is experiencing diarrhea as an adverse effect of the treatment."
628,white,female,49,26.11,FOLFOX + Cetuximab,No,No,Yes,No,4,well differentiated,symptoms but ambulatory,wild-type,No,No,Yes,No,No,1,"race: white, sex: female, age: 49, bmi: 26.11, treatment arm: FOLFOX + Cetuximab, bowel obstruction: Yes, chemotherapy cycles: 4, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type, adverse effect: diarrhea: Yes","This patient is a 49-year-old white female with a BMI of 26.11. She is currently receiving treatment with FOLFOX + Cetuximab for her well-differentiated histology. She has experienced a bowel obstruction and has completed 4 cycles of chemotherapy. Despite experiencing symptoms, she is still ambulatory. Her KRAS biomarker is wild-type. She has also reported experiencing diarrhea as an adverse effect of her treatment."
629,white,female,43,31.56,FOLFOX,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 43, bmi: 31.56, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type",The patient is a 43-year-old white female with a BMI of 31.56. She is receiving the FOLFOX treatment regimen and is scheduled for 12 cycles of chemotherapy. The histology of her cancer is well-differentiated. She has a fully active performance status. The KRAS biomarker analysis shows that she has a wild-type KRAS status.
630,white,female,69,23.7,FOLFOX,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 69, bmi: 23.7, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type",The patient is a 69-year-old white female with a BMI of 23.7. She is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cancer cells. The patient has a fully active performance status and her KRAS biomarker is wild-type.
631,black,male,72,27.41,FOLFIRI + Cetuximab,No,Yes,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: black, sex: male, age: 72, bmi: 27.41, treatment arm: FOLFIRI + Cetuximab, serious adverse effect: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 72-year-old Black male with a BMI of 27.41. He is receiving treatment with FOLFIRI + Cetuximab and has experienced a serious adverse effect. He has completed 12 cycles of chemotherapy. His histology shows well-differentiated cells, and his performance status is fully active. The KRAS biomarker indicates that he has a wild-type status."
632,white,male,44,27.72,FOLFOX + Cetuximab,No,No,Yes,No,12,well differentiated,symptoms but ambulatory,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 44, bmi: 27.72, treatment arm: FOLFOX + Cetuximab, bowel obstruction: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type","This patient is a 44-year-old white male with a BMI of 27.72. He is receiving treatment with FOLFOX + Cetuximab for his well-differentiated histology. He has experienced a bowel obstruction and has completed 12 cycles of chemotherapy. Despite experiencing symptoms, he is still able to be ambulatory. His KRAS biomarker is wild-type."
633,other,female,64,22.5,FOLFOX + Cetuximab,No,No,No,No,2,poorly differentiated,fully active,wild-type,No,No,No,No,No,0,"race: other, sex: female, age: 64, bmi: 22.5, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 2, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 64-year-old female of a race categorized as ""other"" with a BMI of 22.5. She is currently undergoing treatment with FOLFOX + Cetuximab and has completed 2 cycles of chemotherapy. The histology of her condition is poorly differentiated. Despite this, her performance status is fully active. Additionally, her KRAS biomarker status is wild-type."
634,white,male,61,23.67,FOLFOX,No,No,No,No,12,well differentiated,symptoms but ambulatory,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 61, bmi: 23.67, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type","The patient is a 61-year-old white male with a BMI of 23.67. He is undergoing treatment with the FOLFOX chemotherapy regimen and has completed 12 cycles. His histology shows well-differentiated cancer cells. Despite experiencing symptoms, he is still able to ambulate. The KRAS biomarker analysis indicates that he has a wild-type KRAS status."
635,white,male,68,23.04,FOLFOX + Cetuximab,No,Yes,No,No,12,poorly differentiated,symptoms but ambulatory,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 68, bmi: 23.04, treatment arm: FOLFOX + Cetuximab, serious adverse effect: Yes, chemotherapy cycles: 12, histology: poorly differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type","The patient is a 68-year-old white male with a BMI of 23.04. He is undergoing treatment with FOLFOX + Cetuximab and has experienced a serious adverse effect. He has completed 12 cycles of chemotherapy. The histology of his cancer is poorly differentiated. Despite experiencing symptoms, he is still able to be ambulatory. His KRAS biomarker status is wild-type."
636,white,female,44,23.75,FOLFOX + Cetuximab,No,No,No,No,7,well differentiated,symptoms but ambulatory,mutant,No,No,No,No,No,0,"race: white, sex: female, age: 44, bmi: 23.75, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 7, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: mutant","The patient is a 44-year-old white female with a BMI of 23.75. She is currently receiving treatment with FOLFOX + Cetuximab and has completed 7 cycles of chemotherapy. Her histology shows well-differentiated cancer cells. Despite experiencing symptoms, she is still able to be ambulatory. The KRAS biomarker analysis revealed a mutant status."
637,white,male,49,27.39,FOLFIRI (KRAS mutant),No,No,No,No,3,well differentiated,symptoms but ambulatory,mutant,No,No,No,No,No,0,"race: white, sex: male, age: 49, bmi: 27.39, treatment arm: FOLFIRI (KRAS mutant), chemotherapy cycles: 3, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: mutant","The patient is a 49-year-old white male with a BMI of 27.39. He is receiving the FOLFIRI treatment regimen for his KRAS mutant status. He has completed 3 cycles of chemotherapy. His histology shows well-differentiated cancer. Despite experiencing symptoms, he is still able to walk around (ambulatory)."
638,white,male,44,22.18,FOLFOX,No,No,No,No,12,well differentiated,symptoms but ambulatory,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 44, bmi: 22.18, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type","The patient is a 44-year-old white male with a BMI of 22.18. He is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer cells. Despite experiencing symptoms, he is still able to be ambulatory. The KRAS biomarker analysis indicates that he has a wild-type KRAS status."
639,white,female,66,27.31,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,fully active,interminate,No,No,No,No,No,0,"race: white, sex: female, age: 66, bmi: 27.31, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: interminate","The patient is a 66-year-old white female with a BMI of 27.31. She is receiving treatment in the FOLFOX + Cetuximab treatment arm and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cancer cells. Despite her age, she has a fully active performance status. The KRAS biomarker status is indeterminate for this patient."
640,white,male,58,37.54,FOLFOX + Cetuximab,No,Yes,No,No,12,poorly differentiated,fully active,wild-type,Yes,No,No,No,No,0,"race: white, sex: male, age: 58, bmi: 37.54, treatment arm: FOLFOX + Cetuximab, serious adverse effect: Yes, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type, adverse effect: thrombosis: Yes","The patient is a 58-year-old white male with a BMI of 37.54 who is receiving treatment with FOLFOX + Cetuximab. He has experienced a serious adverse effect during his treatment. He has completed 12 cycles of chemotherapy. His histology shows poorly differentiated cells. Despite this, his performance status is fully active. His KRAS biomarker is wild-type. Additionally, he has developed thrombosis as an adverse effect."
641,white,male,69,35.4,FOLFOX,No,No,No,No,12,well differentiated,fully active,mutant,No,No,No,Yes,No,1,"race: white, sex: male, age: 69, bmi: 35.4, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant, adverse effect: infection: Yes","The patient is a 69-year-old white male with a BMI of 35.4. He is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer cells. Despite his age, he has a fully active performance status. The KRAS biomarker testing revealed a mutant status. The patient has experienced an adverse effect in the form of an infection."
642,white,male,45,31.3,FOLFOX + Cetuximab,No,No,No,No,8,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 45, bmi: 31.3, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 8, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 45-year-old white male with a BMI of 31.3. He is receiving treatment with FOLFOX + Cetuximab and has completed 8 cycles of chemotherapy. His histology shows well-differentiated cancer cells. Despite his cancer diagnosis, he has a fully active performance status. Additionally, his KRAS biomarker is wild-type."
643,white,male,60,30.83,FOLFOX + Cetuximab,No,Yes,No,No,2,well differentiated,fully active,mutant,No,No,No,No,Yes,1,"race: white, sex: male, age: 60, bmi: 30.83, treatment arm: FOLFOX + Cetuximab, serious adverse effect: Yes, chemotherapy cycles: 2, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant, adverse effect: infarction: Yes","The patient is a 60-year-old white male with a BMI of 30.83. He is receiving treatment with FOLFOX + Cetuximab and has experienced a serious adverse effect. He has completed 2 cycles of chemotherapy. His histology shows well-differentiated cells, and his performance status is fully active. The patient's KRAS biomarker is mutant. Additionally, he has experienced an adverse effect in the form of an infarction."
644,white,female,35,20.08,FOLFOX,No,No,No,Yes,5,well differentiated,fully active,mutant,No,No,No,No,No,0,"race: white, sex: female, age: 35, bmi: 20.08, treatment arm: FOLFOX, bowel perforation: Yes, chemotherapy cycles: 5, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 35-year-old white female with a BMI of 20.08. She is in the FOLFOX treatment arm and has experienced a bowel perforation. She has completed 5 cycles of chemotherapy. The histology shows well-differentiated cancer cells. Despite the bowel perforation, her performance status is fully active. The KRAS biomarker testing revealed a mutant status."
645,white,male,72,35.81,FOLFOX,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 72, bmi: 35.81, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 72-year-old white male with a BMI of 35.81. He is undergoing treatment with the FOLFOX chemotherapy regimen and has completed 12 cycles. The histology of his cancer is well differentiated. Despite his age, he has a fully active performance status. His KRAS biomarker status is wild-type."
646,white,female,62,27.55,FOLFOX,No,No,No,Yes,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 62, bmi: 27.55, treatment arm: FOLFOX, bowel perforation: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 62-year-old white female with a BMI of 27.55. She is receiving treatment with the FOLFOX regimen and has experienced a bowel perforation. She has completed 12 cycles of chemotherapy. The histology of her cancer is well-differentiated. Despite the bowel perforation, her performance status is fully active. The KRAS biomarker testing revealed that she has a wild-type KRAS status."
647,black,female,48,26.45,FOLFOX,No,No,Yes,No,12,poorly differentiated,in bed less than 50% of the time,mutant,No,No,No,No,No,0,"race: black, sex: female, age: 48, bmi: 26.45, treatment arm: FOLFOX, bowel obstruction: Yes, chemotherapy cycles: 12, histology: poorly differentiated, performance status: in bed less than 50% of the time, KRAS biomarker: mutant","The patient is a 48-year-old Black female with a BMI of 26.45. She is receiving the FOLFOX treatment arm for her bowel obstruction. She has undergone 12 cycles of chemotherapy. The histology of her condition is poorly differentiated. Her performance status indicates that she is in bed less than 50% of the time. Additionally, she has a mutant KRAS biomarker."
648,white,male,62,28.68,FOLFOX + Cetuximab,No,No,No,No,6,well differentiated,fully active,interminate,No,No,No,No,No,0,"race: white, sex: male, age: 62, bmi: 28.68, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 6, histology: well differentiated, performance status: fully active, KRAS biomarker: interminate",The patient is a 62-year-old white male with a BMI of 28.68. He is receiving treatment in the FOLFOX + Cetuximab treatment arm and has completed 6 cycles of chemotherapy. His histology shows well-differentiated cells. The patient has a fully active performance status. The KRAS biomarker status is indeterminate.
649,white,male,73,25.76,FOLFOX + Cetuximab,No,Yes,No,No,12,well differentiated,symptoms but ambulatory,mutant,No,No,No,No,No,0,"race: white, sex: male, age: 73, bmi: 25.76, treatment arm: FOLFOX + Cetuximab, serious adverse effect: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: mutant","The patient is a 73-year-old white male with a BMI of 25.76. He is receiving treatment with FOLFOX + Cetuximab and has experienced a serious adverse effect. He has completed 12 cycles of chemotherapy. His histology shows well-differentiated cells. Despite experiencing symptoms, he is still able to be ambulatory. The patient's KRAS biomarker is mutant."
650,other,male,60,20.17,FOLFOX,No,No,Yes,No,7,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: other, sex: male, age: 60, bmi: 20.17, treatment arm: FOLFOX, bowel obstruction: Yes, chemotherapy cycles: 7, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 60-year-old male of a race categorized as ""other"" with a BMI of 20.17. He is currently undergoing treatment with the FOLFOX regimen and has experienced a bowel obstruction. He has completed 7 cycles of chemotherapy. The histology of his cancer is well-differentiated. Despite the bowel obstruction, his performance status is fully active. Additionally, the KRAS biomarker testing indicates that he has a wild-type KRAS status."
651,white,female,72,18.67,FOLFOX + Cetuximab,No,No,No,No,12,poorly differentiated,fully active,mutant,No,No,No,No,No,1,"race: white, sex: female, age: 72, bmi: 18.67, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 72-year-old white female with a BMI of 18.67. She is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. Her histology shows poorly differentiated cancer cells. Despite this, her performance status is fully active. Additionally, the KRAS biomarker test revealed a mutant result."
652,white,male,76,24.59,FOLFOX + Cetuximab,No,No,No,No,12,poorly differentiated,fully active,mutant,No,No,No,No,No,0,"race: white, sex: male, age: 76, bmi: 24.59, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 76-year-old white male with a BMI of 24.59. He is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. His cancer histology is poorly differentiated. Despite his age, he has a fully active performance status. The KRAS biomarker testing revealed a mutant status."
653,white,male,54,28.12,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 54, bmi: 28.12, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 54-year-old white male with a BMI of 28.12. He is receiving treatment in the FOLFOX + Cetuximab treatment arm and is scheduled for 12 chemotherapy cycles. His histology shows well-differentiated cells, and he has a fully active performance status. The KRAS biomarker analysis indicates that he has a wild-type KRAS status."
654,white,male,54,24.41,FOLFOX + Cetuximab,No,Yes,No,No,1,well differentiated,fully active,wild-type,No,No,No,No,No,1,"race: white, sex: male, age: 54, bmi: 24.41, treatment arm: FOLFOX + Cetuximab, serious adverse effect: Yes, chemotherapy cycles: 1, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 54-year-old white male with a BMI of 24.41. He is receiving treatment in the FOLFOX + Cetuximab treatment arm. He has experienced a serious adverse effect after one cycle of chemotherapy. The histology shows that the cancer is well-differentiated. Despite the adverse effect, the patient's performance status is fully active. The KRAS biomarker indicates that the cancer is wild-type."
655,black,male,75,32.52,FOLFOX + Cetuximab,No,No,No,No,12,poorly differentiated,fully active,mutant,No,No,Yes,No,No,0,"race: black, sex: male, age: 75, bmi: 32.52, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: mutant, adverse effect: diarrhea: Yes","The patient is a 75-year-old Black male with a BMI of 32.52 who is receiving treatment with FOLFOX + Cetuximab for 12 chemotherapy cycles. The histology of the cancer is poorly differentiated, and the patient's performance status is fully active. The KRAS biomarker is mutant. The patient is experiencing diarrhea as an adverse effect of the treatment."
656,white,female,61,43.41,FOLFOX,No,No,No,No,12,well differentiated,symptoms but ambulatory,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 61, bmi: 43.41, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type","The patient is a 61-year-old white female with a BMI of 43.41. She is undergoing treatment with FOLFOX chemotherapy regimen and has completed 12 cycles. The histology shows well-differentiated cancer cells. Despite experiencing symptoms, she is still able to be ambulatory. The KRAS biomarker indicates that she has a wild-type status."
657,black,male,45,19.91,FOLFOX,No,No,No,No,2,well differentiated,symptoms but ambulatory,wild-type,No,No,No,No,No,0,"race: black, sex: male, age: 45, bmi: 19.91, treatment arm: FOLFOX, chemotherapy cycles: 2, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type","The patient is a 45-year-old Black male with a BMI of 19.91. He is currently receiving the FOLFOX treatment arm and has completed 2 cycles of chemotherapy. His histology shows well-differentiated cancer cells. Despite experiencing symptoms, he is still able to walk around (ambulatory). The KRAS biomarker analysis indicates that he has a wild-type KRAS status."
658,white,female,52,32.79,FOLFOX,No,No,No,No,7,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 52, bmi: 32.79, treatment arm: FOLFOX, chemotherapy cycles: 7, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type",The patient is a 52-year-old white female with a BMI of 32.79. She is receiving the FOLFOX treatment regimen and has completed 7 cycles of chemotherapy. Her histology shows well-differentiated cancer cells. The patient has a fully active performance status and her KRAS biomarker is wild-type.
659,white,female,55,29.98,FOLFOX + Cetuximab,Yes,Yes,No,No,4,well differentiated,symptoms but ambulatory,mutant,No,No,No,No,No,0,"race: white, sex: female, age: 55, bmi: 29.98, treatment arm: FOLFOX + Cetuximab, adherence: Yes, serious adverse effect: Yes, chemotherapy cycles: 4, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: mutant","The patient is a 55-year-old white female with a BMI of 29.98. She is receiving treatment with FOLFOX + Cetuximab and has been adherent to the treatment. However, she experienced a serious adverse effect. She has completed 4 cycles of chemotherapy. Her histology shows well-differentiated cells. Despite experiencing symptoms, she is still able to be ambulatory. The KRAS biomarker analysis revealed a mutant status."
660,other,female,49,19.06,FOLFOX + Cetuximab,No,No,No,No,12,poorly differentiated,fully active,mutant,No,No,No,No,No,0,"race: other, sex: female, age: 49, bmi: 19.06, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 49-year-old female of a race categorized as ""other"" with a BMI of 19.06. She is receiving treatment in the FOLFOX + Cetuximab treatment arm and is scheduled for 12 chemotherapy cycles. The histology of her condition is poorly differentiated. Despite this, her performance status is fully active. Additionally, the KRAS biomarker analysis has shown that she has a mutant KRAS status."
661,white,female,60,26.13,FOLFOX,Yes,No,No,No,12,poorly differentiated,fully active,wild-type,No,Yes,No,No,No,0,"race: white, sex: female, age: 60, bmi: 26.13, treatment arm: FOLFOX, adherence: Yes, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type, adverse effect: hypersensitivity: Yes","The patient is a 60-year-old white female with a BMI of 26.13. She is receiving treatment with FOLFOX and has adhered to the treatment plan. She has completed 12 cycles of chemotherapy. The histology of her cancer is poorly differentiated. Despite this, her performance status is fully active. Her KRAS biomarker is wild-type. She has experienced a hypersensitivity adverse effect."
662,other,male,62,25.46,FOLFOX,No,No,No,No,10,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: other, sex: male, age: 62, bmi: 25.46, treatment arm: FOLFOX, chemotherapy cycles: 10, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 62-year-old male of a race categorized as ""other"" with a BMI of 25.46. He is receiving the FOLFOX treatment arm and has completed 10 cycles of chemotherapy. The histology shows well-differentiated characteristics. The patient has a fully active performance status. The KRAS biomarker analysis indicates a wild-type result."
663,white,female,45,36.21,FOLFOX,No,No,No,No,12,poorly differentiated,fully active,mutant,No,No,No,No,No,0,"race: white, sex: female, age: 45, bmi: 36.21, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 45-year-old white female with a BMI of 36.21. She is receiving the FOLFOX treatment arm and has completed 12 cycles of chemotherapy. Her histology shows poorly differentiated cancer cells. Despite this, her performance status is fully active. Additionally, the KRAS biomarker analysis indicates a mutant status."
664,other,male,39,32.49,FOLFOX,No,No,Yes,No,12,poorly differentiated,fully active,wild-type,No,No,No,No,No,1,"race: other, sex: male, age: 39, bmi: 32.49, treatment arm: FOLFOX, bowel obstruction: Yes, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 39-year-old male of a race categorized as ""other"" with a BMI of 32.49. He is receiving treatment with FOLFOX chemotherapy regimen and has experienced a bowel obstruction. He has completed 12 cycles of chemotherapy. The histology of his cancer is poorly differentiated. Despite these challenges, his performance status is fully active. The KRAS biomarker testing indicates that he has a wild-type KRAS status."
665,white,female,52,25.14,FOLFOX + Cetuximab,No,No,No,No,11,well differentiated,symptoms but ambulatory,wild-type,No,No,No,Yes,No,0,"race: white, sex: female, age: 52, bmi: 25.14, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 11, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type, adverse effect: infection: Yes","The patient is a 52-year-old white female with a BMI of 25.14 who is receiving treatment with FOLFOX + Cetuximab. She has completed 11 cycles of chemotherapy and has well-differentiated histology. Despite experiencing symptoms, she is still able to ambulate. Her KRAS biomarker is wild-type. The patient has developed an infection as an adverse effect of the treatment."
666,white,male,35,25.82,FOLFOX,No,No,No,No,12,well differentiated,symptoms but ambulatory,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 35, bmi: 25.82, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type","The patient is a 35-year-old white male with a BMI of 25.82. He is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. His cancer histology is well-differentiated. Despite experiencing symptoms, he is still able to be ambulatory. The KRAS biomarker testing revealed that he has a wild-type KRAS status."
667,white,female,73,20.93,FOLFOX + Cetuximab,No,Yes,No,No,5,well differentiated,symptoms but ambulatory,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 73, bmi: 20.93, treatment arm: FOLFOX + Cetuximab, serious adverse effect: Yes, chemotherapy cycles: 5, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type","The patient is a 73-year-old white female with a BMI of 20.93. She is receiving treatment with FOLFOX + Cetuximab and has experienced a serious adverse effect. She has completed 5 cycles of chemotherapy. The histology shows that the cancer is well-differentiated. Despite experiencing symptoms, she is still able to be ambulatory. Her KRAS biomarker status is wild-type."
668,white,male,56,21.56,FOLFOX + Cetuximab,No,No,Yes,No,11,well differentiated,fully active,wild-type,No,No,Yes,No,No,0,"race: white, sex: male, age: 56, bmi: 21.56, treatment arm: FOLFOX + Cetuximab, bowel obstruction: Yes, chemotherapy cycles: 11, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type, adverse effect: diarrhea: Yes","The patient is a 56-year-old white male with a BMI of 21.56. He is receiving treatment with FOLFOX + Cetuximab for his well-differentiated histology. He has experienced a bowel obstruction and has completed 11 cycles of chemotherapy. His performance status is fully active, and his KRAS biomarker is wild-type. He is also experiencing diarrhea as an adverse effect of his treatment."
669,white,female,37,25.4,FOLFOX,No,No,Yes,No,12,well differentiated,fully active,mutant,No,No,No,No,No,0,"race: white, sex: female, age: 37, bmi: 25.4, treatment arm: FOLFOX, bowel obstruction: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 37-year-old white female with a BMI of 25.4. She is receiving the FOLFOX treatment regimen and has experienced a bowel obstruction. She has completed 12 cycles of chemotherapy. The histology of her cancer is well differentiated. Despite the bowel obstruction, her performance status is fully active. The KRAS biomarker testing revealed a mutant status."
670,white,male,69,25.1,FOLFOX,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 69, bmi: 25.1, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 69-year-old white male with a BMI of 25.1. He is undergoing treatment with the FOLFOX chemotherapy regimen and has completed 12 cycles. His cancer histology is well-differentiated, and he has a fully active performance status. The KRAS biomarker analysis shows that he has a wild-type KRAS status."
671,white,male,38,27.65,FOLFOX,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 38, bmi: 27.65, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 38-year-old white male with a BMI of 27.65. He is receiving the FOLFOX treatment regimen and is scheduled for 12 cycles of chemotherapy. His cancer histology is well-differentiated, and he has a fully active performance status. The KRAS biomarker testing revealed that he has a wild-type KRAS status."
672,white,female,63,30.43,FOLFOX,No,Yes,No,No,6,poorly differentiated,fully active,wild-type,Yes,No,No,Yes,No,1,"race: white, sex: female, age: 63, bmi: 30.43, treatment arm: FOLFOX, serious adverse effect: Yes, chemotherapy cycles: 6, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type, adverse effect: thrombosis: Yes, adverse effect: infection: Yes","The patient is a 63-year-old white female with a BMI of 30.43. She is receiving the FOLFOX treatment regimen and has experienced serious adverse effects during her 6 chemotherapy cycles. Her cancer histology is poorly differentiated, and her performance status is fully active. The KRAS biomarker testing revealed a wild-type result. She has also experienced adverse effects in the form of thrombosis and infection."
673,white,female,74,29.44,FOLFOX + Cetuximab,No,No,No,No,0,poorly differentiated,fully active,interminate,No,No,No,No,No,0,"race: white, sex: female, age: 74, bmi: 29.44, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 0, histology: poorly differentiated, performance status: fully active, KRAS biomarker: interminate","This patient is a 74-year-old white female with a BMI of 29.44. She is enrolled in the treatment arm receiving FOLFOX + Cetuximab but has not started chemotherapy cycles yet. Her cancer histology is poorly differentiated, and her performance status is fully active. The KRAS biomarker status is indeterminate for this patient."
674,white,female,75,24.71,FOLFOX,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 75, bmi: 24.71, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 75-year-old white female with a BMI of 24.71. She is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cells, and she has a fully active performance status. The KRAS biomarker analysis indicates that she has a wild-type KRAS status."
675,black,female,35,47.06,FOLFOX + Cetuximab,No,No,Yes,No,12,well differentiated,fully active,wild-type,No,Yes,No,No,No,1,"race: black, sex: female, age: 35, bmi: 47.06, treatment arm: FOLFOX + Cetuximab, bowel obstruction: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type, adverse effect: hypersensitivity: Yes","The patient is a 35-year-old Black female with a BMI of 47.06. She is receiving treatment with FOLFOX + Cetuximab and has experienced a bowel obstruction. She has completed 12 cycles of chemotherapy. The histology shows that the cancer is well-differentiated. Despite having a fully active performance status, she has experienced hypersensitivity as an adverse effect. Her KRAS biomarker is wild-type."
676,white,female,46,23.43,FOLFOX,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,Yes,No,No,0,"race: white, sex: female, age: 46, bmi: 23.43, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type, adverse effect: diarrhea: Yes","The patient is a 46-year-old white female with a BMI of 23.43. She is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cancer cells, and her performance status is fully active. The KRAS biomarker testing revealed that she has a wild-type KRAS status. The patient is experiencing diarrhea as an adverse effect of the treatment."
677,white,male,47,38.43,FOLFOX + Cetuximab,No,Yes,No,No,12,well differentiated,fully active,mutant,No,No,No,No,No,0,"race: white, sex: male, age: 47, bmi: 38.43, treatment arm: FOLFOX + Cetuximab, serious adverse effect: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 47-year-old white male with a BMI of 38.43. He is receiving treatment with FOLFOX + Cetuximab and has experienced a serious adverse effect. He has completed 12 cycles of chemotherapy. His histology shows well-differentiated cells, and his performance status is fully active. The patient's KRAS biomarker is mutant."
678,black,female,63,27.14,FOLFOX + Cetuximab,No,No,No,No,10,poorly differentiated,symptoms but ambulatory,mutant,No,No,No,No,No,0,"race: black, sex: female, age: 63, bmi: 27.14, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 10, histology: poorly differentiated, performance status: symptoms but ambulatory, KRAS biomarker: mutant","The patient is a 63-year-old Black female with a BMI of 27.14. She is receiving treatment with FOLFOX + Cetuximab and has completed 10 cycles of chemotherapy. Her histology shows poorly differentiated cancer cells. Despite experiencing symptoms, she is still able to be ambulatory. The KRAS biomarker analysis indicates a mutant status."
679,white,male,50,29.57,FOLFIRI + Cetuximab,No,No,No,No,12,well differentiated,symptoms but ambulatory,mutant,No,No,No,No,No,0,"race: white, sex: male, age: 50, bmi: 29.57, treatment arm: FOLFIRI + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: mutant","The patient is a 50-year-old white male with a BMI of 29.57. He is receiving treatment in the FOLFIRI + Cetuximab treatment arm and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer cells. Despite experiencing symptoms, he is still able to walk around (ambulatory). The KRAS biomarker analysis indicates that he has a mutant KRAS status."
680,white,female,61,29.1,FOLFOX,No,No,No,No,11,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 61, bmi: 29.1, treatment arm: FOLFOX, chemotherapy cycles: 11, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 61-year-old white female with a BMI of 29.1. She is receiving the FOLFOX treatment regimen and has completed 11 cycles of chemotherapy. Her histology shows well-differentiated cancer cells. Despite her cancer diagnosis, she has a fully active performance status. Additionally, her KRAS biomarker indicates that she has a wild-type KRAS gene."
681,white,male,59,23.08,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,symptoms but ambulatory,mutant,No,No,No,No,No,0,"race: white, sex: male, age: 59, bmi: 23.08, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: mutant","The patient is a 59-year-old white male with a BMI of 23.08. He is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer. Despite experiencing symptoms, he is still able to walk around (ambulatory). The KRAS biomarker analysis indicates a mutant status."
682,white,female,56,26.44,FOLFOX + Cetuximab,No,No,No,No,12,poorly differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 56, bmi: 26.44, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 56-year-old white female with a BMI of 26.44. She is receiving treatment with FOLFOX + Cetuximab and is scheduled for 12 cycles of chemotherapy. The histology of her cancer is poorly differentiated. Despite her diagnosis, she has a fully active performance status. Additionally, her KRAS biomarker status is wild-type."
683,white,male,62,21.52,FOLFOX + Cetuximab,Yes,No,Yes,No,12,well differentiated,fully active,mutant,No,No,No,No,No,0,"race: white, sex: male, age: 62, bmi: 21.52, treatment arm: FOLFOX + Cetuximab, adherence: Yes, bowel obstruction: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 62-year-old white male with a BMI of 21.52. He is receiving treatment in the FOLFOX + Cetuximab treatment arm and has been adherent to the treatment. He has experienced a bowel obstruction and has completed 12 cycles of chemotherapy. The histology shows well-differentiated cells, and his performance status is fully active. The KRAS biomarker indicates a mutant status."
684,white,female,63,23.17,FOLFOX,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 63, bmi: 23.17, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type",The patient is a 63-year-old white female with a BMI of 23.17. She is undergoing treatment with the FOLFOX chemotherapy regimen and has completed 12 cycles. Her cancer histology is well-differentiated. She has a fully active performance status. The KRAS biomarker testing revealed that she has a wild-type KRAS status.
685,white,male,64,37.26,FOLFOX,No,No,No,No,11,well differentiated,symptoms but ambulatory,wild-type,No,No,No,No,No,1,"race: white, sex: male, age: 64, bmi: 37.26, treatment arm: FOLFOX, chemotherapy cycles: 11, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type","The patient is a 64-year-old white male with a BMI of 37.26. He is currently receiving the FOLFOX treatment regimen and has completed 11 cycles of chemotherapy. His histology shows well-differentiated cancer cells. Despite experiencing symptoms, he is still able to be ambulatory. The KRAS biomarker analysis indicates that he has a wild-type KRAS status."
686,white,female,46,20.89,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,fully active,interminate,No,No,No,No,No,1,"race: white, sex: female, age: 46, bmi: 20.89, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: interminate","The patient is a 46-year-old white female with a BMI of 20.89. She is receiving treatment in the FOLFOX + Cetuximab treatment arm and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cells, and she has a fully active performance status. The KRAS biomarker status is indeterminate."
687,white,female,42,42.22,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,symptoms but ambulatory,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 42, bmi: 42.22, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type","The patient is a 42-year-old white female with a BMI of 42.22. She is receiving treatment in the FOLFOX + Cetuximab treatment arm and is scheduled for 12 chemotherapy cycles. Her histology shows well-differentiated cells. Despite experiencing symptoms, she is still able to walk around (ambulatory). The KRAS biomarker analysis indicates that she has a wild-type KRAS status."
688,other,male,64,18.93,FOLFOX,No,No,Yes,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: other, sex: male, age: 64, bmi: 18.93, treatment arm: FOLFOX, bowel obstruction: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 64-year-old male of a race categorized as ""other"" with a BMI of 18.93. He is receiving treatment in the FOLFOX regimen and has experienced a bowel obstruction. He has completed 12 cycles of chemotherapy. The histology of his condition is well-differentiated. Despite the challenges, his performance status is fully active. Additionally, the KRAS biomarker shows that he has a wild-type status."
689,black,female,56,27.03,FOLFIRI,Yes,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: black, sex: female, age: 56, bmi: 27.03, treatment arm: FOLFIRI, adherence: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 56-year-old Black female with a BMI of 27.03. She is receiving the FOLFIRI treatment regimen and has been adherent to her chemotherapy cycles, completing 12 cycles so far. Her histology shows well-differentiated cancer cells. Despite undergoing treatment, she maintains a fully active performance status. Additionally, her KRAS biomarker indicates that she has a wild-type status."
690,white,male,54,33.46,FOLFOX,No,No,No,No,5,well differentiated,fully active,wild-type,No,Yes,No,No,No,0,"race: white, sex: male, age: 54, bmi: 33.46, treatment arm: FOLFOX, chemotherapy cycles: 5, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type, adverse effect: hypersensitivity: Yes","The patient is a 54-year-old white male with a BMI of 33.46. He is receiving the FOLFOX treatment regimen and has completed 5 cycles of chemotherapy. His histology shows well-differentiated cells, and he has a fully active performance status. The KRAS biomarker indicates that he is wild-type. The patient has experienced a hypersensitivity adverse effect."
691,black,male,66,34.31,FOLFOX,Yes,No,No,Yes,12,poorly differentiated,fully active,wild-type,No,No,No,No,No,0,"race: black, sex: male, age: 66, bmi: 34.31, treatment arm: FOLFOX, adherence: Yes, bowel perforation: Yes, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 66-year-old Black male with a BMI of 34.31. He is receiving the FOLFOX treatment regimen and has been adherent to the treatment. He experienced a bowel perforation and has completed 12 cycles of chemotherapy. The histology of his cancer is poorly differentiated. Despite these challenges, his performance status is fully active. His KRAS biomarker status is wild-type."
692,white,male,75,30.28,FOLFOX + Cetuximab,No,Yes,No,No,12,well differentiated,fully active,mutant,No,No,No,No,No,0,"race: white, sex: male, age: 75, bmi: 30.28, treatment arm: FOLFOX + Cetuximab, serious adverse effect: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 75-year-old white male with a BMI of 30.28. He is receiving treatment with FOLFOX + Cetuximab and has experienced a serious adverse effect. He has completed 12 cycles of chemotherapy. The histology shows that the cancer is well-differentiated. Despite his age, the patient has a fully active performance status. The KRAS biomarker indicates that he has a mutant status."
693,white,female,49,36.34,FOLFOX,Yes,No,No,No,12,poorly differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 49, bmi: 36.34, treatment arm: FOLFOX, adherence: Yes, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 49-year-old white female with a BMI of 36.34. She is receiving the FOLFOX treatment regimen and has been adherent to her chemotherapy. She has completed 12 cycles of chemotherapy. The histology of her cancer is poorly differentiated. Despite this, her performance status is fully active. Her KRAS biomarker status is wild-type."
694,white,female,59,33.08,FOLFOX,No,No,No,No,12,well differentiated,symptoms but ambulatory,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 59, bmi: 33.08, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type","The patient is a 59-year-old white female with a BMI of 33.08. She is receiving the FOLFOX treatment arm and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cells. Despite experiencing symptoms, she is still able to walk around (ambulatory). The KRAS biomarker analysis indicates that she has a wild-type KRAS gene."
695,white,male,62,32.65,FOLFOX + Cetuximab,No,No,No,No,0,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 62, bmi: 32.65, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 0, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 62-year-old white male with a BMI of 32.65. He is enrolled in the treatment arm receiving FOLFOX + Cetuximab but has not started chemotherapy cycles yet. His histology shows well-differentiated cancer, and he has a fully active performance status. The KRAS biomarker analysis indicates that he has a wild-type KRAS status."
696,white,female,48,27.49,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,fully active,mutant,No,No,No,No,No,0,"race: white, sex: female, age: 48, bmi: 27.49, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 48-year-old white female with a BMI of 27.49. She is receiving treatment in the FOLFOX + Cetuximab treatment arm and is scheduled for 12 chemotherapy cycles. Her histology shows well-differentiated cells, and she has a fully active performance status. The KRAS biomarker analysis indicates a mutant status."
697,white,male,45,42.84,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,symptoms but ambulatory,mutant,No,No,No,No,No,1,"race: white, sex: male, age: 45, bmi: 42.84, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: mutant","The patient is a 45-year-old white male with a BMI of 42.84. He is receiving treatment with FOLFOX + Cetuximab and is scheduled for 12 chemotherapy cycles. His cancer histology is well-differentiated. Despite experiencing symptoms, he is still able to walk around (ambulatory). The KRAS biomarker testing revealed a mutant status."
698,white,female,71,27.93,FOLFOX,No,No,No,No,12,poorly differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 71, bmi: 27.93, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 71-year-old white female with a BMI of 27.93. She is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. Her histology shows poorly differentiated cancer cells. Despite her age, she has a fully active performance status. The KRAS biomarker analysis indicates that she has a wild-type KRAS status."
699,black,male,52,54.85,FOLFOX + Cetuximab,No,No,No,No,0,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: black, sex: male, age: 52, bmi: 54.85, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 0, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 52-year-old Black male with a BMI of 54.85. He is enrolled in the treatment arm receiving FOLFOX + Cetuximab but has not started chemotherapy cycles yet. His histology shows well-differentiated cancer, and he has a fully active performance status. The KRAS biomarker indicates that he has a wild-type status."
700,white,female,51,30.22,FOLFOX + Cetuximab,Yes,No,Yes,No,1,well differentiated,fully active,mutant,No,No,No,No,No,0,"race: white, sex: female, age: 51, bmi: 30.22, treatment arm: FOLFOX + Cetuximab, adherence: Yes, bowel obstruction: Yes, chemotherapy cycles: 1, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 51-year-old white female with a BMI of 30.22. She is currently receiving treatment in the FOLFOX + Cetuximab treatment arm and is adherent to her treatment. She has experienced a bowel obstruction and has completed one cycle of chemotherapy. The histology shows well-differentiated cells, and her performance status is fully active. The KRAS biomarker indicates a mutant status."
701,white,female,59,50.78,FOLFOX,No,Yes,No,Yes,2,well differentiated,symptoms but ambulatory,wild-type,No,No,No,No,No,1,"race: white, sex: female, age: 59, bmi: 50.78, treatment arm: FOLFOX, serious adverse effect: Yes, bowel perforation: Yes, chemotherapy cycles: 2, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type","This patient is a 59-year-old white female with a BMI of 50.78. She is receiving the FOLFOX treatment regimen and has experienced a serious adverse effect in the form of a bowel perforation after completing 2 cycles of chemotherapy. Her cancer histology shows well-differentiated cells. Despite experiencing symptoms, she is still able to be ambulatory. The KRAS biomarker analysis indicates that she has a wild-type KRAS status."
702,white,male,64,28.31,FOLFOX,No,No,No,No,12,poorly differentiated,fully active,wild-type,No,No,No,No,No,1,"race: white, sex: male, age: 64, bmi: 28.31, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 64-year-old white male with a BMI of 28.31. He is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. His histology shows poorly differentiated cancer cells. Despite this, his performance status is fully active. The KRAS biomarker analysis indicates that he has a wild-type KRAS status."
703,white,male,72,29.9,FOLFOX + Cetuximab,No,No,No,No,12,poorly differentiated,fully active,mutant,No,No,No,No,No,0,"race: white, sex: male, age: 72, bmi: 29.9, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 72-year-old white male with a BMI of 29.9. He is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. His cancer histology is poorly differentiated. Despite his age, he has a fully active performance status. The KRAS biomarker testing revealed a mutant status."
704,white,male,67,30.76,FOLFOX + Cetuximab,No,Yes,No,No,12,well differentiated,fully active,mutant,No,No,No,No,No,0,"race: white, sex: male, age: 67, bmi: 30.76, treatment arm: FOLFOX + Cetuximab, serious adverse effect: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 67-year-old white male with a BMI of 30.76. He is receiving treatment with FOLFOX + Cetuximab and has experienced a serious adverse effect. He has completed 12 cycles of chemotherapy. The histology shows well-differentiated cells, and his performance status is fully active. The KRAS biomarker indicates a mutant status."
705,white,female,75,31.88,FOLFOX + Cetuximab,No,No,No,No,12,poorly differentiated,fully active,wild-type,No,No,Yes,No,No,0,"race: white, sex: female, age: 75, bmi: 31.88, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type, adverse effect: diarrhea: Yes","The patient is a 75-year-old white female with a BMI of 31.88. She is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. Her cancer histology is poorly differentiated, and she has a fully active performance status. The KRAS biomarker testing showed that she has a wild-type KRAS status. The patient is experiencing diarrhea as an adverse effect of the treatment."
706,white,male,51,25.63,FOLFOX,No,No,No,No,12,poorly differentiated,symptoms but ambulatory,interminate,No,No,No,No,No,0,"race: white, sex: male, age: 51, bmi: 25.63, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: poorly differentiated, performance status: symptoms but ambulatory, KRAS biomarker: interminate","The patient is a 51-year-old white male with a BMI of 25.63. He is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. His histology shows poorly differentiated cancer cells. Despite experiencing symptoms, he is still able to walk around (ambulatory). The KRAS biomarker status is indeterminate."
707,white,female,64,44.98,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,fully active,interminate,No,No,No,No,No,0,"race: white, sex: female, age: 64, bmi: 44.98, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: interminate","The patient is a 64-year-old white female with a BMI of 44.98. She is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cancer cells. Despite her cancer diagnosis, she has a fully active performance status. The KRAS biomarker status is indeterminate for this patient."
708,white,male,65,27.16,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 65, bmi: 27.16, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type",The patient is a 65-year-old white male with a BMI of 27.16. He is receiving treatment in the FOLFOX + Cetuximab treatment arm and is scheduled for 12 chemotherapy cycles. His histology shows well-differentiated cancer cells. The patient has a fully active performance status and his KRAS biomarker is wild-type.
709,black,female,36,25.47,FOLFOX,No,No,No,No,12,well differentiated,fully active,mutant,No,No,No,No,No,0,"race: black, sex: female, age: 36, bmi: 25.47, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant",The patient is a 36-year-old Black female with a BMI of 25.47. She is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. Her cancer histology is well differentiated. She has a fully active performance status. The KRAS biomarker testing revealed a mutant status.
710,white,female,41,26.9,FOLFOX,Yes,No,No,No,12,well differentiated,symptoms but ambulatory,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 41, bmi: 26.9, treatment arm: FOLFOX, adherence: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type","The patient is a 41-year-old white female with a BMI of 26.9. She is receiving treatment in the FOLFOX treatment arm and has been adherent to her chemotherapy regimen for 12 cycles. Her histology shows well-differentiated cancer cells. Despite experiencing symptoms, she is still able to be ambulatory. The KRAS biomarker analysis indicates that she has a wild-type KRAS status."
711,white,male,62,20.03,FOLFOX,No,No,No,No,12,well differentiated,symptoms but ambulatory,mutant,No,No,Yes,No,No,0,"race: white, sex: male, age: 62, bmi: 20.03, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: mutant, adverse effect: diarrhea: Yes","The patient is a 62-year-old white male with a BMI of 20.03. He is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer cells. Despite experiencing symptoms, he is still able to be ambulatory. The KRAS biomarker testing revealed a mutant status. The patient is experiencing diarrhea as an adverse effect of the treatment."
712,white,female,76,26.52,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,symptoms but ambulatory,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 76, bmi: 26.52, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type","The patient is a 76-year-old white female with a BMI of 26.52. She is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cancer. Despite experiencing symptoms, she is still able to be ambulatory. The KRAS biomarker analysis indicates that she has a wild-type KRAS status."
713,white,female,74,26.52,FOLFOX,No,Yes,No,No,12,well differentiated,symptoms but ambulatory,mutant,No,No,No,No,No,0,"race: white, sex: female, age: 74, bmi: 26.52, treatment arm: FOLFOX, serious adverse effect: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: mutant","The patient is a 74-year-old white female with a BMI of 26.52. She is receiving the FOLFOX treatment regimen and has experienced a serious adverse effect. She has completed 12 cycles of chemotherapy. The histology shows well-differentiated cancer cells. Despite experiencing symptoms, she is still able to be ambulatory. The KRAS biomarker indicates a mutant status."
714,white,male,59,27.47,FOLFOX + Cetuximab,Yes,Yes,No,No,12,poorly differentiated,fully active,mutant,No,No,No,No,No,0,"race: white, sex: male, age: 59, bmi: 27.47, treatment arm: FOLFOX + Cetuximab, adherence: Yes, serious adverse effect: Yes, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 59-year-old white male with a BMI of 27.47. He is receiving treatment with FOLFOX + Cetuximab and has been adherent to the treatment. However, he experienced a serious adverse effect. He has completed 12 cycles of chemotherapy. His histology shows poorly differentiated cells. Despite this, his performance status is fully active. Additionally, the KRAS biomarker analysis revealed a mutant status."
715,white,male,61,31.72,FOLFIRI,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,Yes,No,No,1,"race: white, sex: male, age: 61, bmi: 31.72, treatment arm: FOLFIRI, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type, adverse effect: diarrhea: Yes","The patient is a 61-year-old white male with a BMI of 31.72 who is undergoing treatment with the FOLFIRI chemotherapy regimen. He has completed 12 cycles of chemotherapy. His cancer histology is well-differentiated, and he has a fully active performance status. The KRAS biomarker testing showed that he has a wild-type KRAS status. The patient is experiencing diarrhea as an adverse effect of the treatment."
716,white,male,35,25.4,FOLFOX,No,No,Yes,No,0,poorly differentiated,symptoms but ambulatory,wild-type,No,No,No,No,No,1,"race: white, sex: male, age: 35, bmi: 25.4, treatment arm: FOLFOX, bowel obstruction: Yes, chemotherapy cycles: 0, histology: poorly differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type","The patient is a 35-year-old white male with a BMI of 25.4. He is enrolled in the FOLFOX treatment arm and has a bowel obstruction. He has not started any chemotherapy cycles yet. The histology shows poorly differentiated cancer cells. Despite experiencing symptoms, the patient is still able to be ambulatory. The KRAS biomarker indicates that he has a wild-type mutation."
717,white,female,63,23.93,FOLFOX,Yes,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 63, bmi: 23.93, treatment arm: FOLFOX, adherence: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 63-year-old white female with a BMI of 23.93. She is receiving the FOLFOX treatment regimen and has been adherent to her chemotherapy cycles, completing a total of 12 cycles. Her cancer histology is well-differentiated, and she has a fully active performance status. Additionally, her KRAS biomarker status is wild-type."
718,white,male,57,33.64,FOLFOX,No,No,No,No,12,well differentiated,fully active,mutant,No,No,No,No,No,0,"race: white, sex: male, age: 57, bmi: 33.64, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 57-year-old white male with a BMI of 33.64. He is receiving treatment with the FOLFOX chemotherapy regimen and is scheduled for 12 cycles. His cancer histology is well-differentiated, and he has a fully active performance status. The patient's KRAS biomarker status is mutant."
719,white,male,54,23.79,FOLFOX,No,No,No,No,12,well differentiated,symptoms but ambulatory,interminate,No,No,No,No,No,0,"race: white, sex: male, age: 54, bmi: 23.79, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: interminate","The patient is a 54-year-old white male with a BMI of 23.79. He is undergoing treatment with the FOLFOX chemotherapy regimen and has completed 12 cycles. His histology shows well-differentiated cancer cells. Despite experiencing symptoms, he is still able to walk around (ambulatory). The KRAS biomarker status is indeterminate."
720,white,female,70,19.48,FOLFOX,No,No,No,No,2,well differentiated,symptoms but ambulatory,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 70, bmi: 19.48, treatment arm: FOLFOX, chemotherapy cycles: 2, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type","The patient is a 70-year-old white female with a BMI of 19.48. She is currently undergoing treatment with the FOLFOX chemotherapy regimen and has completed 2 cycles so far. Her histology shows well-differentiated cancer cells. Despite experiencing symptoms, she is still able to move around independently. Additionally, her KRAS biomarker indicates that she has a wild-type gene."
721,other,female,70,25,FOLFOX + Cetuximab,No,No,No,No,12,poorly differentiated,fully active,wild-type,No,No,No,No,No,0,"race: other, sex: female, age: 70, bmi: 25.0, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 70-year-old female of a race categorized as ""other"" with a BMI of 25.0. She is undergoing treatment with the FOLFOX + Cetuximab regimen and has completed 12 cycles of chemotherapy. Her histology shows poorly differentiated cancer cells. Despite this, her performance status is fully active. Additionally, her KRAS biomarker status is wild-type."
722,white,male,50,30.99,FOLFOX,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 50, bmi: 30.99, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 50-year-old white male with a BMI of 30.99. He is receiving the FOLFOX treatment regimen and is scheduled for 12 cycles of chemotherapy. His cancer histology is well-differentiated, and he has a fully active performance status. The KRAS biomarker analysis shows that he has a wild-type KRAS status."
723,white,female,68,40.67,FOLFOX,No,No,No,Yes,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 68, bmi: 40.67, treatment arm: FOLFOX, bowel perforation: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 68-year-old white female with a BMI of 40.67. She is receiving the FOLFOX treatment regimen and has experienced a bowel perforation. She has completed 12 cycles of chemotherapy. The histology of her cancer is well differentiated. Despite the bowel perforation, her performance status is fully active. Her KRAS biomarker status is wild-type."
724,white,female,65,27.44,FOLFOX,No,No,No,No,11,well differentiated,fully active,mutant,No,No,No,No,No,0,"race: white, sex: female, age: 65, bmi: 27.44, treatment arm: FOLFOX, chemotherapy cycles: 11, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 65-year-old white female with a BMI of 27.44. She is currently receiving the FOLFOX treatment regimen and has completed 11 cycles of chemotherapy. Her cancer histology is well-differentiated, and she has a fully active performance status. Additionally, the patient's KRAS biomarker status is mutant."
725,white,male,62,24.6,FOLFOX + Cetuximab,Yes,Yes,No,No,3,well differentiated,symptoms but ambulatory,mutant,No,No,No,No,Yes,1,"race: white, sex: male, age: 62, bmi: 24.6, treatment arm: FOLFOX + Cetuximab, adherence: Yes, serious adverse effect: Yes, chemotherapy cycles: 3, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: mutant, adverse effect: infarction: Yes","The patient is a 62-year-old white male with a BMI of 24.6. He is receiving treatment with FOLFOX + Cetuximab and has been adherent to the treatment regimen. He has experienced a serious adverse effect, specifically an infarction, after completing 3 cycles of chemotherapy. His histology shows well-differentiated cells, and he has a mutant KRAS biomarker. Despite experiencing symptoms, he is still able to be ambulatory."
726,white,male,68,28.8,FOLFOX + Cetuximab,Yes,No,Yes,No,12,poorly differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 68, bmi: 28.8, treatment arm: FOLFOX + Cetuximab, adherence: Yes, bowel obstruction: Yes, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 68-year-old white male with a BMI of 28.8. He is receiving treatment with FOLFOX + Cetuximab and has been adherent to the treatment regimen. He has experienced a bowel obstruction. The patient has completed 12 cycles of chemotherapy. His histology shows poorly differentiated cancer cells. Despite these challenges, his performance status is fully active. The KRAS biomarker analysis indicates that he has a wild-type KRAS status."
727,white,female,50,34.79,FOLFOX,No,No,No,No,12,poorly differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 50, bmi: 34.79, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 50-year-old white female with a BMI of 34.79. She is receiving treatment with the FOLFOX chemotherapy regimen and is scheduled for 12 cycles. The histology of her cancer is poorly differentiated. Despite this, her performance status is fully active. Additionally, her KRAS biomarker status is wild-type."
728,white,male,58,39.84,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 58, bmi: 39.84, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 58-year-old white male with a BMI of 39.84. He is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. His cancer histology is well-differentiated, and he has a fully active performance status. The KRAS biomarker testing showed that he has a wild-type KRAS status."
729,white,female,45,32.38,FOLFOX + Cetuximab,No,No,No,No,5,poorly differentiated,symptoms but ambulatory,mutant,No,No,No,No,No,1,"race: white, sex: female, age: 45, bmi: 32.38, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 5, histology: poorly differentiated, performance status: symptoms but ambulatory, KRAS biomarker: mutant","The patient is a 45-year-old white female with a BMI of 32.38. She is receiving treatment with FOLFOX + Cetuximab and has completed 5 cycles of chemotherapy. The histology shows poorly differentiated cancer cells. Despite experiencing symptoms, she is still able to be ambulatory. The KRAS biomarker indicates a mutant status."
730,white,male,68,27.96,FOLFOX,No,No,No,No,12,well differentiated,fully active,interminate,No,No,No,No,No,0,"race: white, sex: male, age: 68, bmi: 27.96, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: interminate",The patient is a 68-year-old white male with a BMI of 27.96. He is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer cells. The patient has a fully active performance status. The KRAS biomarker status is indeterminate.
731,white,female,53,24.61,FOLFOX + Cetuximab,Yes,No,No,No,12,well differentiated,fully active,mutant,No,No,No,No,No,0,"race: white, sex: female, age: 53, bmi: 24.61, treatment arm: FOLFOX + Cetuximab, adherence: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant",The patient is a 53-year-old white female with a BMI of 24.61. She is receiving treatment with FOLFOX + Cetuximab and has been adherent to the treatment. She has completed 12 cycles of chemotherapy. The histology of her cancer is well-differentiated. Her performance status is fully active. The KRAS biomarker shows a mutation.
732,white,female,45,19.85,FOLFOX + Cetuximab,No,Yes,No,No,7,poorly differentiated,fully active,mutant,No,No,No,No,No,0,"race: white, sex: female, age: 45, bmi: 19.85, treatment arm: FOLFOX + Cetuximab, serious adverse effect: Yes, chemotherapy cycles: 7, histology: poorly differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 45-year-old white female with a BMI of 19.85. She is receiving treatment with FOLFOX + Cetuximab and has experienced a serious adverse effect. She has completed 7 cycles of chemotherapy. The histology of her cancer is poorly differentiated. Despite this, her performance status is fully active. Additionally, the KRAS biomarker testing revealed a mutant status."
733,white,male,51,26.73,FOLFOX,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 51, bmi: 26.73, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 51-year-old white male with a BMI of 26.73. He is receiving treatment with the FOLFOX chemotherapy regimen and is scheduled for 12 cycles. His cancer histology is well-differentiated, and he has a fully active performance status. The KRAS biomarker analysis shows that he has a wild-type KRAS status."
734,other,female,43,22.7,FOLFOX + Cetuximab,No,No,No,Yes,11,well differentiated,fully active,mutant,No,No,No,Yes,No,0,"race: other, sex: female, age: 43, bmi: 22.7, treatment arm: FOLFOX + Cetuximab, bowel perforation: Yes, chemotherapy cycles: 11, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant, adverse effect: infection: Yes","The patient is a 43-year-old female of a race other than specified, with a BMI of 22.7. She is receiving treatment with FOLFOX + Cetuximab and has experienced a bowel perforation. She has completed 11 cycles of chemotherapy and her histology shows well-differentiated cells. Despite the bowel perforation, her performance status is fully active. The KRAS biomarker testing revealed a mutant status. Additionally, she has experienced an infection as an adverse effect of treatment."
735,white,female,51,20.87,FOLFOX,Yes,No,No,Yes,6,well differentiated,fully active,mutant,No,No,No,No,No,0,"race: white, sex: female, age: 51, bmi: 20.87, treatment arm: FOLFOX, adherence: Yes, bowel perforation: Yes, chemotherapy cycles: 6, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 51-year-old white female with a BMI of 20.87. She is receiving treatment with the FOLFOX regimen and has been adherent to the treatment. She experienced a bowel perforation during the course of her treatment. She completed 6 cycles of chemotherapy. The histology of her cancer is well-differentiated. Despite the bowel perforation, her performance status is fully active. The KRAS biomarker testing revealed a mutant status."
736,white,female,57,24.33,FOLFOX,Yes,Yes,No,No,12,well differentiated,fully active,mutant,No,No,No,No,No,0,"race: white, sex: female, age: 57, bmi: 24.33, treatment arm: FOLFOX, adherence: Yes, serious adverse effect: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 57-year-old white female with a BMI of 24.33. She is receiving the FOLFOX treatment regimen and has been adherent to the treatment. Unfortunately, she has experienced a serious adverse effect. She has completed 12 cycles of chemotherapy. The histology shows that the cancer is well-differentiated. The patient has a fully active performance status. The KRAS biomarker indicates that she has a mutant form."
737,white,male,37,29.1,FOLFOX,Yes,No,No,No,12,poorly differentiated,symptoms but ambulatory,mutant,No,No,No,No,No,0,"race: white, sex: male, age: 37, bmi: 29.1, treatment arm: FOLFOX, adherence: Yes, chemotherapy cycles: 12, histology: poorly differentiated, performance status: symptoms but ambulatory, KRAS biomarker: mutant","The patient is a 37-year-old white male with a BMI of 29.1. He is receiving treatment with FOLFOX chemotherapy and has been adherent to the treatment. He has completed 12 cycles of chemotherapy. The histology of his cancer is poorly differentiated. Despite experiencing symptoms, he is still able to be ambulatory. The KRAS biomarker testing revealed a mutant status."
738,other,female,50,45.14,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,fully active,wild-type,No,Yes,No,No,No,0,"race: other, sex: female, age: 50, bmi: 45.14, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type, adverse effect: hypersensitivity: Yes","The patient is a 50-year-old female of a race other than specified, with a BMI of 45.14. She is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cells, and she has a fully active performance status. The KRAS biomarker indicates she is wild-type. The patient has experienced a hypersensitivity adverse effect."
739,white,female,57,29.19,FOLFOX + Cetuximab,No,No,No,No,8,well differentiated,symptoms but ambulatory,wild-type,No,No,Yes,No,No,0,"race: white, sex: female, age: 57, bmi: 29.19, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 8, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type, adverse effect: diarrhea: Yes","The patient is a 57-year-old white female with a BMI of 29.19. She is receiving treatment with FOLFOX + Cetuximab and has completed 8 cycles of chemotherapy. Her cancer histology is well-differentiated, and she has symptoms but is still able to be ambulatory. The KRAS biomarker testing showed that she has a wild-type result. She is experiencing diarrhea as an adverse effect of the treatment."
740,white,male,60,31.84,FOLFOX + Cetuximab,No,No,No,No,1,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 60, bmi: 31.84, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 1, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 60-year-old white male with a BMI of 31.84. He is receiving treatment with FOLFOX + Cetuximab and has completed one cycle of chemotherapy. His cancer histology is well-differentiated, and he has a fully active performance status. The KRAS biomarker analysis shows that he has a wild-type KRAS status."
741,white,female,61,21.01,FOLFOX,No,No,Yes,No,12,well differentiated,fully active,mutant,No,No,No,No,No,0,"race: white, sex: female, age: 61, bmi: 21.01, treatment arm: FOLFOX, bowel obstruction: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 61-year-old white female with a BMI of 21.01. She is receiving the FOLFOX treatment regimen for her well-differentiated histology. She has experienced a bowel obstruction and has completed 12 cycles of chemotherapy. Despite these challenges, her performance status is fully active. Additionally, the KRAS biomarker testing revealed a mutant status."
742,black,female,57,26.58,FOLFOX,No,No,No,No,12,well differentiated,fully active,mutant,No,No,No,No,No,0,"race: black, sex: female, age: 57, bmi: 26.58, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 57-year-old Black female with a BMI of 26.58. She is receiving the FOLFOX treatment arm and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cancer cells. Despite her cancer diagnosis, she has a fully active performance status. The KRAS biomarker testing revealed a mutant status."
743,white,male,74,29.45,FOLFIRI,No,No,No,No,3,well differentiated,fully active,mutant,No,No,No,No,No,1,"race: white, sex: male, age: 74, bmi: 29.45, treatment arm: FOLFIRI, chemotherapy cycles: 3, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 74-year-old white male with a BMI of 29.45. He is currently receiving the FOLFIRI treatment regimen and has completed 3 cycles of chemotherapy. His cancer histology is well differentiated, and he has a fully active performance status. The KRAS biomarker analysis shows that he has a mutant KRAS status."
744,white,male,63,21.6,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 63, bmi: 21.6, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 63-year-old white male with a BMI of 21.6. He is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. His cancer histology is well differentiated, and he has a fully active performance status. The KRAS biomarker analysis shows that he has a wild-type KRAS status."
745,black,female,70,31.3,FOLFOX + Cetuximab,No,No,No,No,9,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: black, sex: female, age: 70, bmi: 31.3, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 9, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 70-year-old Black female with a BMI of 31.3. She is receiving treatment with FOLFOX + Cetuximab and has completed 9 cycles of chemotherapy. Her histology shows well-differentiated cells, and she has a fully active performance status. The KRAS biomarker analysis indicates that she has a wild-type KRAS status."
746,white,female,70,23.63,FOLFIRI (KRAS mutant),No,Yes,No,No,12,poorly differentiated,fully active,wild-type,No,No,Yes,No,No,0,"race: white, sex: female, age: 70, bmi: 23.63, treatment arm: FOLFIRI (KRAS mutant), serious adverse effect: Yes, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type, adverse effect: diarrhea: Yes","The patient is a 70-year-old white female with a BMI of 23.63. She is receiving FOLFIRI treatment for her poorly differentiated cancer, and her KRAS biomarker is wild-type. Despite being fully active, she has experienced a serious adverse effect of diarrhea during her 12 chemotherapy cycles."
747,white,male,51,26.79,FOLFOX,No,No,Yes,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 51, bmi: 26.79, treatment arm: FOLFOX, bowel obstruction: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type",The patient is a 51-year-old white male with a BMI of 26.79. He is receiving treatment with the FOLFOX regimen and has experienced a bowel obstruction. He has completed 12 cycles of chemotherapy. The histology shows well-differentiated cancer cells. The patient has a fully active performance status. The KRAS biomarker indicates that he has a wild-type gene.
748,white,female,59,19.96,FOLFOX + Cetuximab,No,No,No,Yes,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 59, bmi: 19.96, treatment arm: FOLFOX + Cetuximab, bowel perforation: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 59-year-old white female with a BMI of 19.96. She is receiving treatment with FOLFOX + Cetuximab and has experienced a bowel perforation. She has completed 12 cycles of chemotherapy. The histology shows well-differentiated cancer cells. Despite the bowel perforation, her performance status is fully active. The KRAS biomarker indicates that she has a wild-type mutation."
749,white,male,56,29.64,FOLFOX,No,No,Yes,No,12,well differentiated,fully active,mutant,No,No,No,No,No,1,"race: white, sex: male, age: 56, bmi: 29.64, treatment arm: FOLFOX, bowel obstruction: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 56-year-old white male with a BMI of 29.64. He is receiving treatment with the FOLFOX regimen for his well-differentiated histology. He has experienced a bowel obstruction and has completed 12 cycles of chemotherapy. Despite these challenges, his performance status is fully active. Additionally, the patient's KRAS biomarker is mutant."
750,white,male,59,25.23,FOLFOX,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 59, bmi: 25.23, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type",The patient is a 59-year-old white male with a BMI of 25.23. He is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer cells. The patient has a fully active performance status and his KRAS biomarker is wild-type.
751,white,male,59,30.97,FOLFOX,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,1,"race: white, sex: male, age: 59, bmi: 30.97, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type",The patient is a 59-year-old white male with a BMI of 30.97. He is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer cells. The patient has a fully active performance status and has a wild-type KRAS biomarker.
752,black,male,55,32.83,FOLFOX,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: black, sex: male, age: 55, bmi: 32.83, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type",The patient is a 55-year-old Black male with a BMI of 32.83. He is receiving the FOLFOX treatment arm and has completed 12 cycles of chemotherapy. The histology shows well-differentiated cancer cells. The patient has a fully active performance status. The KRAS biomarker indicates that he has a wild-type mutation.
753,white,female,63,32.67,FOLFOX + Cetuximab,No,No,No,No,12,poorly differentiated,fully active,wild-type,No,No,No,No,No,1,"race: white, sex: female, age: 63, bmi: 32.67, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 63-year-old white female with a BMI of 32.67. She is receiving treatment with FOLFOX + Cetuximab and is scheduled for 12 chemotherapy cycles. Her cancer histology is poorly differentiated. Despite her diagnosis, she has a fully active performance status. Additionally, her KRAS biomarker status is wild-type."
754,white,female,65,21.51,FOLFIRI (KRAS mutant),No,No,Yes,No,7,poorly differentiated,symptoms but ambulatory,mutant,No,No,No,No,No,0,"race: white, sex: female, age: 65, bmi: 21.51, treatment arm: FOLFIRI (KRAS mutant), bowel obstruction: Yes, chemotherapy cycles: 7, histology: poorly differentiated, performance status: symptoms but ambulatory, KRAS biomarker: mutant","This patient is a 65-year-old white female with a BMI of 21.51. She is currently receiving treatment with the FOLFIRI regimen for her KRAS mutant status. She is experiencing a bowel obstruction and has completed 7 cycles of chemotherapy. Her histology shows poorly differentiated cells. Despite experiencing symptoms, she is still able to be ambulatory."
755,white,female,56,38.66,FOLFIRI,No,Yes,No,No,12,well differentiated,symptoms but ambulatory,wild-type,No,No,No,No,No,1,"race: white, sex: female, age: 56, bmi: 38.66, treatment arm: FOLFIRI, serious adverse effect: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type","The patient is a 56-year-old white female with a BMI of 38.66. She is receiving the FOLFIRI treatment regimen and has experienced a serious adverse effect. She has completed 12 cycles of chemotherapy. The histology shows that the cancer is well-differentiated. Despite experiencing symptoms, she is still able to be ambulatory. The KRAS biomarker indicates that she has a wild-type status."
756,white,male,40,26.1,FOLFOX + Cetuximab,No,No,No,No,12,poorly differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 40, bmi: 26.1, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 40-year-old white male with a BMI of 26.1. He is receiving treatment with FOLFOX + Cetuximab and is scheduled for 12 chemotherapy cycles. His cancer histology is poorly differentiated, and he has a fully active performance status. The KRAS biomarker analysis shows that he has a wild-type KRAS status."
757,white,male,62,22.68,FOLFOX,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 62, bmi: 22.68, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 62-year-old white male with a BMI of 22.68. He is receiving treatment with the FOLFOX chemotherapy regimen and is scheduled for 12 cycles. The histology of his cancer is well-differentiated. Despite his age, he has a fully active performance status. His KRAS biomarker status is wild-type."
758,white,male,40,22.49,FOLFIRI + Cetuximab,Yes,No,Yes,Yes,12,poorly differentiated,fully active,wild-type,No,No,No,No,No,1,"race: white, sex: male, age: 40, bmi: 22.49, treatment arm: FOLFIRI + Cetuximab, adherence: Yes, bowel obstruction: Yes, bowel perforation: Yes, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 40-year-old white male with a BMI of 22.49. He is receiving treatment with FOLFIRI + Cetuximab and has been adherent to the treatment. He has experienced both bowel obstruction and bowel perforation. The patient has completed 12 cycles of chemotherapy and has a histology of poorly differentiated cancer. Despite these challenges, his performance status is fully active. Additionally, his KRAS biomarker is wild-type."
759,white,female,41,33.11,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,fully active,mutant,No,No,Yes,No,No,1,"race: white, sex: female, age: 41, bmi: 33.11, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant, adverse effect: diarrhea: Yes","The patient is a 41-year-old white female with a BMI of 33.11. She is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cancer, and she has a fully active performance status. The KRAS biomarker indicates a mutant status. The patient is experiencing diarrhea as an adverse effect of the treatment."
760,white,male,54,24.66,FOLFOX + Cetuximab,Yes,No,Yes,No,12,poorly differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 54, bmi: 24.66, treatment arm: FOLFOX + Cetuximab, adherence: Yes, bowel obstruction: Yes, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 54-year-old white male with a BMI of 24.66. He is receiving treatment in the FOLFOX + Cetuximab treatment arm and has been adherent to the treatment. He has experienced a bowel obstruction and has completed 12 cycles of chemotherapy. The histology of his cancer is poorly differentiated. Despite the bowel obstruction, his performance status is fully active. His KRAS biomarker status is wild-type."
761,black,male,48,25.18,FOLFOX,Yes,Yes,Yes,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,1,"race: black, sex: male, age: 48, bmi: 25.18, treatment arm: FOLFOX, adherence: Yes, serious adverse effect: Yes, bowel obstruction: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 48-year-old Black male with a BMI of 25.18. He is receiving the FOLFOX treatment regimen and has been adherent to the treatment. He experienced a serious adverse effect in the form of a bowel obstruction. He has completed 12 cycles of chemotherapy. The histology of his cancer is well-differentiated. Despite the adverse effect, his performance status remains fully active. The KRAS biomarker analysis showed that he has a wild-type KRAS status."
762,black,female,65,25.22,FOLFOX,No,Yes,No,No,6,well differentiated,fully active,wild-type,No,No,No,No,No,1,"race: black, sex: female, age: 65, bmi: 25.22, treatment arm: FOLFOX, serious adverse effect: Yes, chemotherapy cycles: 6, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 65-year-old Black female with a BMI of 25.22. She is receiving the FOLFOX treatment arm and has experienced a serious adverse effect. She has completed 6 cycles of chemotherapy. The histology shows that the cancer is well-differentiated. Despite the treatment, her performance status is fully active. The KRAS biomarker indicates that she has a wild-type status."
763,white,female,62,29.64,FOLFOX,No,No,No,No,12,poorly differentiated,fully active,interminate,No,No,No,No,No,0,"race: white, sex: female, age: 62, bmi: 29.64, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: interminate","The patient is a 62-year-old white female with a BMI of 29.64. She is receiving the FOLFOX treatment arm and has completed 12 cycles of chemotherapy. Her histology shows poorly differentiated cells. Despite this, her performance status is fully active. The KRAS biomarker status is indeterminate."
764,white,female,49,45.14,FOLFOX,No,No,Yes,No,12,well differentiated,fully active,mutant,No,No,No,No,No,0,"race: white, sex: female, age: 49, bmi: 45.14, treatment arm: FOLFOX, bowel obstruction: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 49-year-old white female with a BMI of 45.14. She is receiving treatment with FOLFOX and has experienced a bowel obstruction. She has completed 12 cycles of chemotherapy. The histology shows well-differentiated cells. Despite the bowel obstruction, her performance status is fully active. The KRAS biomarker indicates a mutant status."
765,white,male,63,33.71,FOLFOX + Cetuximab,No,Yes,No,No,12,well differentiated,fully active,wild-type,Yes,No,No,No,No,0,"race: white, sex: male, age: 63, bmi: 33.71, treatment arm: FOLFOX + Cetuximab, serious adverse effect: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type, adverse effect: thrombosis: Yes","The patient is a 63-year-old white male with a BMI of 33.71 who is receiving treatment with FOLFOX + Cetuximab. He has experienced a serious adverse effect during the treatment. He has completed 12 cycles of chemotherapy. The histology shows that the cancer is well-differentiated. The patient has a fully active performance status. His KRAS biomarker is wild-type. Additionally, he has experienced thrombosis as an adverse effect."
766,white,male,39,35.73,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,fully active,interminate,No,No,No,No,No,0,"race: white, sex: male, age: 39, bmi: 35.73, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: interminate",The patient is a 39-year-old white male with a BMI of 35.73. He is receiving treatment with FOLFOX + Cetuximab and is scheduled for 12 chemotherapy cycles. His histology shows well-differentiated cancer cells. The patient has a fully active performance status. His KRAS biomarker status is indeterminate.
767,white,female,52,25.72,FOLFOX,No,Yes,No,No,5,poorly differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 52, bmi: 25.72, treatment arm: FOLFOX, serious adverse effect: Yes, chemotherapy cycles: 5, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 52-year-old white female with a BMI of 25.72. She is receiving the FOLFOX treatment regimen and has experienced a serious adverse effect. She has completed 5 cycles of chemotherapy. The histology of her condition is poorly differentiated. Despite this, her performance status is fully active. Her KRAS biomarker status is wild-type."
768,white,female,40,22.8,FOLFIRI (KRAS mutant),No,Yes,No,No,10,well differentiated,fully active,wild-type,No,No,Yes,No,No,0,"race: white, sex: female, age: 40, bmi: 22.8, treatment arm: FOLFIRI (KRAS mutant), serious adverse effect: Yes, chemotherapy cycles: 10, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type, adverse effect: diarrhea: Yes","The patient is a 40-year-old white female with a BMI of 22.8. She is receiving the FOLFIRI treatment regimen for her KRAS mutant status. Unfortunately, she has experienced a serious adverse effect during her treatment. She has completed 10 cycles of chemotherapy. Her histology shows well-differentiated cancer cells. Despite the adverse effects, her performance status is fully active. It is worth noting that her KRAS biomarker is wild-type. Additionally, she has experienced diarrhea as an adverse effect of the treatment."
769,white,male,63,37.75,FOLFOX,No,No,No,No,12,well differentiated,symptoms but ambulatory,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 63, bmi: 37.75, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type","The patient is a 63-year-old white male with a BMI of 37.75. He is undergoing treatment with the FOLFOX chemotherapy regimen and has completed 12 cycles. His cancer histology is well-differentiated. Despite experiencing symptoms, he is still able to be ambulatory. The KRAS biomarker analysis shows that he has a wild-type KRAS status."
770,other,female,51,23.67,FOLFOX,No,Yes,Yes,No,12,well differentiated,fully active,mutant,No,No,No,No,No,0,"race: other, sex: female, age: 51, bmi: 23.67, treatment arm: FOLFOX, serious adverse effect: Yes, bowel obstruction: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 51-year-old female of a race categorized as ""other"" with a BMI of 23.67. She is undergoing treatment with the FOLFOX regimen and has experienced a serious adverse effect in the form of a bowel obstruction. She has completed 12 cycles of chemotherapy and her histology shows well-differentiated cells. Despite the adverse effect, her performance status is fully active. Additionally, the KRAS biomarker analysis indicates a mutant status."
771,white,male,56,30.01,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,fully active,mutant,No,Yes,No,No,No,0,"race: white, sex: male, age: 56, bmi: 30.01, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant, adverse effect: hypersensitivity: Yes","The patient is a 56-year-old white male with a BMI of 30.01. He is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. His cancer histology is well-differentiated, and he has a fully active performance status. The KRAS biomarker testing showed a mutant result. The patient experienced a hypersensitivity adverse effect during treatment."
772,white,female,53,34.3,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,symptoms but ambulatory,wild-type,No,No,Yes,Yes,No,0,"race: white, sex: female, age: 53, bmi: 34.3, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type, adverse effect: diarrhea: Yes, adverse effect: infection: Yes","The patient is a 53-year-old white female with a BMI of 34.3. She is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. Her cancer histology is well-differentiated, and she has symptoms but is still ambulatory. Her KRAS biomarker is wild-type. She is experiencing adverse effects of diarrhea and infection."
773,white,male,60,27.44,FOLFOX + Cetuximab,No,No,No,No,12,poorly differentiated,fully active,wild-type,No,No,No,No,No,1,"race: white, sex: male, age: 60, bmi: 27.44, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 60-year-old white male with a BMI of 27.44. He is receiving treatment in the FOLFOX + Cetuximab treatment arm and is scheduled for 12 chemotherapy cycles. His histology shows poorly differentiated cancer cells. Despite this, his performance status is fully active. Additionally, his KRAS biomarker indicates that he has a wild-type gene."
774,white,female,45,21.21,FOLFIRI (KRAS mutant),No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 45, bmi: 21.21, treatment arm: FOLFIRI (KRAS mutant), chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 45-year-old white female with a BMI of 21.21. She is receiving the FOLFIRI treatment regimen for KRAS mutant status and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cells, and she has a fully active performance status. The KRAS biomarker for this patient is wild-type."
775,white,female,64,33.81,FOLFOX,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 64, bmi: 33.81, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 64-year-old white female with a BMI of 33.81. She is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. Her cancer histology is well-differentiated, and she has a fully active performance status. The KRAS biomarker testing showed that she has a wild-type KRAS status."
776,white,male,74,24.25,FOLFOX + Cetuximab,Yes,Yes,No,Yes,9,well differentiated,fully active,mutant,No,No,Yes,Yes,No,1,"race: white, sex: male, age: 74, bmi: 24.25, treatment arm: FOLFOX + Cetuximab, adherence: Yes, serious adverse effect: Yes, bowel perforation: Yes, chemotherapy cycles: 9, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant, adverse effect: diarrhea: Yes, adverse effect: infection: Yes","The patient is a 74-year-old white male with a BMI of 24.25. He is receiving treatment with FOLFOX + Cetuximab and has been adherent to the treatment. Unfortunately, he experienced a serious adverse effect in the form of a bowel perforation. He has completed 9 cycles of chemotherapy and has a well-differentiated histology. Despite the adverse effect, his performance status remains fully active. The patient's KRAS biomarker is mutant. In addition to the bowel perforation, he has also experienced adverse effects in the form of diarrhea and infection."
777,white,female,65,24.62,FOLFOX,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,1,"race: white, sex: female, age: 65, bmi: 24.62, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type",The patient is a 65-year-old white female with a BMI of 24.62. She is undergoing treatment with the FOLFOX chemotherapy regimen and has completed 12 cycles. Her cancer histology is well differentiated. She has a fully active performance status. The KRAS biomarker testing showed that she has a wild-type KRAS status.
778,white,male,47,32.04,FOLFOX + Cetuximab,No,No,No,No,12,poorly differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 47, bmi: 32.04, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 47-year-old white male with a BMI of 32.04. He is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. His cancer histology is poorly differentiated. Despite his cancer diagnosis, he has a fully active performance status. Additionally, his KRAS biomarker status is wild-type."
779,white,male,56,24.66,FOLFIRI,Yes,No,No,Yes,12,well differentiated,symptoms but ambulatory,mutant,No,No,No,No,No,1,"race: white, sex: male, age: 56, bmi: 24.66, treatment arm: FOLFIRI, adherence: Yes, bowel perforation: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: mutant","The patient is a 56-year-old white male with a BMI of 24.66. He is receiving treatment in the FOLFIRI treatment arm and has been adherent to the treatment. The patient has experienced a bowel perforation and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cells. Despite experiencing symptoms, the patient is still ambulatory. The patient's KRAS biomarker is mutant."
780,white,male,63,28.52,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 63, bmi: 28.52, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type",The patient is a 63-year-old white male with a BMI of 28.52. He is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. His cancer histology is well differentiated. The patient has a fully active performance status and has a wild-type KRAS biomarker.
781,white,male,57,27.06,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,symptoms but ambulatory,mutant,No,No,Yes,No,No,0,"race: white, sex: male, age: 57, bmi: 27.06, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: mutant, adverse effect: diarrhea: Yes","The patient is a 57-year-old white male with a BMI of 27.06. He is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. His cancer histology is well-differentiated, and he has symptoms but is still able to be ambulatory. The KRAS biomarker testing showed a mutant result. The patient is experiencing diarrhea as an adverse effect of the treatment."
782,white,male,55,29.24,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 55, bmi: 29.24, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type",The patient is a 55-year-old white male with a BMI of 29.24. He is receiving treatment in the FOLFOX + Cetuximab treatment arm and is scheduled for 12 chemotherapy cycles. His histology shows well-differentiated cancer cells. The patient has a fully active performance status and his KRAS biomarker is wild-type.
783,white,male,73,30.64,FOLFOX,No,No,No,No,12,poorly differentiated,fully active,wild-type,No,No,Yes,No,No,0,"race: white, sex: male, age: 73, bmi: 30.64, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type, adverse effect: diarrhea: Yes","The patient is a 73-year-old white male with a BMI of 30.64. He is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. His histology shows poorly differentiated cancer cells. Despite this, his performance status is fully active. The KRAS biomarker analysis indicates that he has a wild-type KRAS gene. The patient is experiencing diarrhea as an adverse effect of the treatment."
784,white,female,56,25.69,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,symptoms but ambulatory,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 56, bmi: 25.69, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type","The patient is a 56-year-old white female with a BMI of 25.69. She is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cancer cells. Despite experiencing symptoms, she is still able to walk around (ambulatory). The KRAS biomarker indicates that she has a wild-type status."
785,other,male,61,25.97,FOLFOX + Cetuximab,No,No,No,No,12,poorly differentiated,fully active,wild-type,No,No,No,No,No,0,"race: other, sex: male, age: 61, bmi: 25.97, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 61-year-old male of a race categorized as ""other"" with a BMI of 25.97. He is undergoing treatment with the FOLFOX + Cetuximab regimen and has completed 12 cycles of chemotherapy. His histology shows poorly differentiated cancer cells. Despite this, his performance status is fully active, indicating that he is able to carry out his daily activities without limitations. Additionally, the KRAS biomarker analysis indicates that he has a wild-type KRAS status."
786,white,male,75,30.24,FOLFOX,Yes,No,No,No,12,well differentiated,fully active,wild-type,No,Yes,No,No,No,0,"race: white, sex: male, age: 75, bmi: 30.24, treatment arm: FOLFOX, adherence: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type, adverse effect: hypersensitivity: Yes","The patient is a 75-year-old white male with a BMI of 30.24 who is receiving the FOLFOX treatment regimen. He has been adherent to the treatment and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer, and he has a fully active performance status. The KRAS biomarker indicates that he is wild-type. The patient has experienced a hypersensitivity adverse effect."
787,white,female,62,31.79,FOLFOX + Cetuximab,No,No,No,No,2,well differentiated,fully active,mutant,No,No,No,No,No,0,"race: white, sex: female, age: 62, bmi: 31.79, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 2, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 62-year-old white female with a BMI of 31.79. She is currently receiving treatment in the FOLFOX + Cetuximab treatment arm and has completed 2 cycles of chemotherapy. Her histology shows well-differentiated cancer cells. Despite her cancer diagnosis, she has a fully active performance status. Additionally, the KRAS biomarker testing revealed a mutant status."
788,white,male,42,22.46,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 42, bmi: 22.46, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type",The patient is a 42-year-old white male with a BMI of 22.46. He is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer cells. The patient has a fully active performance status and his KRAS biomarker is wild-type.
789,white,male,70,35.25,FOLFOX,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 70, bmi: 35.25, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 70-year-old white male with a BMI of 35.25. He is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer cells. Despite his age, he has a fully active performance status. Additionally, his KRAS biomarker indicates that he has the wild-type variant."
790,white,female,66,29.74,FOLFOX + Cetuximab,No,No,No,No,6,well differentiated,fully active,interminate,No,No,No,No,No,0,"race: white, sex: female, age: 66, bmi: 29.74, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 6, histology: well differentiated, performance status: fully active, KRAS biomarker: interminate",The patient is a 66-year-old white female with a BMI of 29.74. She is receiving treatment with FOLFOX + Cetuximab and has completed 6 cycles of chemotherapy. Her histology shows well-differentiated cancer. The patient has a fully active performance status. The KRAS biomarker status is indeterminate.
791,black,male,61,21.98,FOLFOX,No,Yes,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: black, sex: male, age: 61, bmi: 21.98, treatment arm: FOLFOX, serious adverse effect: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 61-year-old Black male with a BMI of 21.98. He is receiving the FOLFOX treatment arm for his well-differentiated histology. Unfortunately, he has experienced a serious adverse effect during his 12 chemotherapy cycles. Despite this, his performance status is fully active. His KRAS biomarker is wild-type."
792,white,male,68,26.96,FOLFOX,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,Yes,No,No,0,"race: white, sex: male, age: 68, bmi: 26.96, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type, adverse effect: diarrhea: Yes",The patient is a 68-year-old white male with a BMI of 26.96. He is receiving the FOLFOX treatment arm and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer cells. The patient has a fully active performance status and has a wild-type KRAS biomarker. He is experiencing diarrhea as an adverse effect.
793,black,male,72,19.14,FOLFOX,No,No,No,No,12,well differentiated,fully active,mutant,No,No,No,No,No,1,"race: black, sex: male, age: 72, bmi: 19.14, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 72-year-old Black male with a BMI of 19.14. He is receiving the FOLFOX treatment arm and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cells. Despite his age, he has a fully active performance status. Additionally, the KRAS biomarker analysis indicates a mutant status."
794,white,female,69,25.66,FOLFOX,No,No,No,No,12,well differentiated,fully active,mutant,No,No,No,No,No,0,"race: white, sex: female, age: 69, bmi: 25.66, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 69-year-old white female with a BMI of 25.66. She is undergoing treatment with the FOLFOX chemotherapy regimen and has completed 12 cycles. The histology of her cancer is well-differentiated. Despite her age, she has a fully active performance status. The KRAS biomarker analysis shows that she has a mutant KRAS status."
795,white,male,61,23.87,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 61, bmi: 23.87, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 61-year-old white male with a BMI of 23.87. He is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. His cancer histology is well differentiated, and he has a fully active performance status. The KRAS biomarker analysis shows that he has a wild-type KRAS status."
796,white,female,47,34.3,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,fully active,mutant,No,Yes,No,Yes,No,0,"race: white, sex: female, age: 47, bmi: 34.3, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant, adverse effect: hypersensitivity: Yes, adverse effect: infection: Yes","The patient is a 47-year-old white female with a BMI of 34.3. She is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. Her cancer histology is well-differentiated, and she has a fully active performance status. The KRAS biomarker testing revealed a mutant status. The patient has experienced adverse effects of hypersensitivity and infection during the course of treatment."
797,white,female,70,20.08,FOLFOX + Cetuximab,No,No,No,No,12,poorly differentiated,fully active,wild-type,No,No,No,No,No,1,"race: white, sex: female, age: 70, bmi: 20.08, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 70-year-old white female with a BMI of 20.08. She is receiving treatment in the FOLFOX + Cetuximab treatment arm and has completed 12 cycles of chemotherapy. Her histology shows poorly differentiated cancer cells. Despite this, her performance status is fully active. Additionally, her KRAS biomarker status is wild-type."
798,white,male,49,41.86,FOLFOX,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 49, bmi: 41.86, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 49-year-old white male with a BMI of 41.86. He is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. The histology shows well-differentiated cancer cells. The patient's performance status is fully active, indicating he is able to carry out normal daily activities without limitations. The KRAS biomarker analysis reveals that the patient has a wild-type KRAS gene."
799,white,female,56,30.34,FOLFOX + Cetuximab,No,Yes,No,No,9,well differentiated,fully active,mutant,Yes,No,No,No,No,0,"race: white, sex: female, age: 56, bmi: 30.34, treatment arm: FOLFOX + Cetuximab, serious adverse effect: Yes, chemotherapy cycles: 9, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant, adverse effect: thrombosis: Yes","The patient is a 56-year-old white female with a BMI of 30.34 who is receiving treatment with FOLFOX + Cetuximab. She has experienced a serious adverse effect during her 9 chemotherapy cycles. Her histology shows well-differentiated cells, and she has a fully active performance status. The patient's KRAS biomarker is mutant, and she has also experienced thrombosis as an adverse effect."
800,white,male,59,23.42,FOLFOX,No,No,No,No,10,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 59, bmi: 23.42, treatment arm: FOLFOX, chemotherapy cycles: 10, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type",The patient is a 59-year-old white male with a BMI of 23.42. He is receiving the FOLFOX treatment regimen and has completed 10 cycles of chemotherapy. The histology shows well-differentiated cancer cells. The patient has a fully active performance status. The KRAS biomarker analysis indicates that the patient has a wild-type KRAS status.
801,other,female,56,20.95,FOLFOX,No,No,Yes,No,1,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: other, sex: female, age: 56, bmi: 20.95, treatment arm: FOLFOX, bowel obstruction: Yes, chemotherapy cycles: 1, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 56-year-old female of a race other than specified, with a BMI of 20.95. She is currently undergoing treatment with the FOLFOX regimen for her bowel obstruction. She has completed one cycle of chemotherapy. The histology of her condition is well-differentiated. Despite the bowel obstruction, her performance status is fully active. The KRAS biomarker analysis indicates that she has a wild-type KRAS status."
802,white,female,46,28.3,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 46, bmi: 28.3, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type",The patient is a 46-year-old white female with a BMI of 28.3. She is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cancer cells. She has a fully active performance status. The KRAS biomarker indicates that she has a wild-type mutation.
803,white,male,63,27.29,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,Yes,No,No,0,"race: white, sex: male, age: 63, bmi: 27.29, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type, adverse effect: diarrhea: Yes","The patient is a 63-year-old white male with a BMI of 27.29. He is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer, and he has a fully active performance status. The KRAS biomarker is wild-type. The patient is experiencing diarrhea as an adverse effect of the treatment."
804,white,male,65,26.06,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,symptoms but ambulatory,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 65, bmi: 26.06, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type","The patient is a 65-year-old white male with a BMI of 26.06. He is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. His cancer histology is well differentiated. Despite experiencing symptoms, he is still able to walk around (ambulatory). The KRAS biomarker testing showed that he has a wild-type KRAS status."
805,white,female,39,23.86,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,fully active,mutant,No,No,No,No,No,0,"race: white, sex: female, age: 39, bmi: 23.86, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 39-year-old white female with a BMI of 23.86. She is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cancer, and she has a fully active performance status. The KRAS biomarker indicates that she has a mutant status."
806,white,male,63,32.41,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,fully active,wild-type,Yes,No,No,No,No,0,"race: white, sex: male, age: 63, bmi: 32.41, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type, adverse effect: thrombosis: Yes","The patient is a 63-year-old white male with a BMI of 32.41. He is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer, and he has a fully active performance status. The KRAS biomarker is wild-type. The patient has experienced an adverse effect of thrombosis."
807,black,male,76,30.22,FOLFOX,No,No,No,No,12,well differentiated,symptoms but ambulatory,mutant,No,No,No,No,No,0,"race: black, sex: male, age: 76, bmi: 30.22, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: mutant","The patient is a 76-year-old Black male with a BMI of 30.22. He is undergoing treatment with the FOLFOX chemotherapy regimen and has completed 12 cycles. His histology shows well-differentiated cancer cells. Despite experiencing symptoms, he is still able to ambulate. The KRAS biomarker testing revealed a mutant status."
808,white,female,43,20.49,FOLFOX + Cetuximab,No,No,Yes,No,12,well differentiated,fully active,mutant,No,No,No,No,No,0,"race: white, sex: female, age: 43, bmi: 20.49, treatment arm: FOLFOX + Cetuximab, bowel obstruction: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 43-year-old white female with a BMI of 20.49. She is receiving treatment in the FOLFOX + Cetuximab treatment arm. She has experienced a bowel obstruction and has completed 12 cycles of chemotherapy. The histology shows well-differentiated cells. Despite the bowel obstruction, the patient's performance status is fully active. The KRAS biomarker indicates a mutant status."
809,white,female,55,45.12,FOLFOX + Cetuximab,No,No,No,No,8,poorly differentiated,symptoms but ambulatory,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 55, bmi: 45.12, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 8, histology: poorly differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type","The patient is a 55-year-old white female with a BMI of 45.12. She is receiving treatment in the FOLFOX + Cetuximab treatment arm and has completed 8 cycles of chemotherapy. Her histology shows poorly differentiated cancer cells. Despite experiencing symptoms, she is still able to walk around (ambulatory). Her KRAS biomarker indicates that it is wild-type."
810,white,male,68,36.51,FOLFIRI,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 68, bmi: 36.51, treatment arm: FOLFIRI, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 68-year-old white male with a BMI of 36.51. He is undergoing treatment with the FOLFIRI chemotherapy regimen and has completed 12 cycles. His cancer histology is well-differentiated, and he has a fully active performance status. The KRAS biomarker testing revealed that he has a wild-type KRAS status."
811,white,female,62,25.07,FOLFOX,Yes,No,No,No,12,well differentiated,symptoms but ambulatory,mutant,No,No,Yes,No,No,0,"race: white, sex: female, age: 62, bmi: 25.07, treatment arm: FOLFOX, adherence: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: mutant, adverse effect: diarrhea: Yes","The patient is a 62-year-old white female with a BMI of 25.07. She is receiving the FOLFOX treatment regimen and has been adherent to her chemotherapy cycles, completing 12 cycles so far. Her histology shows well-differentiated cancer cells. Despite experiencing symptoms, she is still able to be ambulatory. The KRAS biomarker testing revealed a mutant status. The patient has reported experiencing diarrhea as an adverse effect of the treatment."
812,white,male,69,30,FOLFOX,No,No,No,No,12,well differentiated,fully active,interminate,No,No,No,No,No,0,"race: white, sex: male, age: 69, bmi: 30.0, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: interminate","The patient is a 69-year-old white male with a BMI of 30.0. He is receiving treatment with the FOLFOX chemotherapy regimen and has completed 12 cycles. His cancer histology is well-differentiated, and he has a fully active performance status. The KRAS biomarker status is indeterminate."
813,white,female,74,24.92,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 74, bmi: 24.92, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 74-year-old white female with a BMI of 24.92. She is receiving treatment with FOLFOX + Cetuximab and is scheduled for 12 chemotherapy cycles. Her histology shows well-differentiated cancer. Despite her age, she has a fully active performance status. Additionally, her KRAS biomarker is wild-type."
814,white,female,42,21.97,FOLFOX,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,Yes,No,No,0,"race: white, sex: female, age: 42, bmi: 21.97, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type, adverse effect: diarrhea: Yes","The patient is a 42-year-old white female with a BMI of 21.97. She is undergoing treatment with the FOLFOX chemotherapy regimen and has completed 12 cycles. Her histology shows well-differentiated cancer cells. Despite experiencing diarrhea as an adverse effect, her performance status remains fully active. Additionally, her KRAS biomarker status is wild-type."
815,white,male,56,36.62,FOLFIRI + Cetuximab,No,Yes,No,No,12,well differentiated,fully active,wild-type,Yes,No,No,No,No,0,"race: white, sex: male, age: 56, bmi: 36.62, treatment arm: FOLFIRI + Cetuximab, serious adverse effect: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type, adverse effect: thrombosis: Yes","The patient is a 56-year-old white male with a BMI of 36.62 who is receiving treatment with FOLFIRI + Cetuximab. He has experienced a serious adverse effect during his treatment. He has completed 12 cycles of chemotherapy. His histology shows well-differentiated cells, and his performance status is fully active. The KRAS biomarker indicates that he has a wild-type gene. Additionally, he has experienced an adverse effect of thrombosis."
816,white,male,67,26.35,FOLFOX,No,No,No,No,12,well differentiated,symptoms but ambulatory,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 67, bmi: 26.35, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type","The patient is a 67-year-old white male with a BMI of 26.35. He is receiving treatment with the FOLFOX chemotherapy regimen and has completed 12 cycles. The histology of his cancer is well-differentiated. Despite experiencing symptoms, he is still able to ambulate. His KRAS biomarker status is wild-type."
817,white,male,53,29.79,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,symptoms but ambulatory,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 53, bmi: 29.79, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type","The patient is a 53-year-old white male with a BMI of 29.79. He is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer. Despite experiencing symptoms, he is still able to be ambulatory. The KRAS biomarker indicates that he has a wild-type status."
818,white,female,73,39.69,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,Yes,No,No,0,"race: white, sex: female, age: 73, bmi: 39.69, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type, adverse effect: diarrhea: Yes","The patient is a 73-year-old white female with a BMI of 39.69. She is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cells, and she has a fully active performance status. The KRAS biomarker indicates that she is wild-type. The patient is experiencing diarrhea as an adverse effect of the treatment."
819,white,male,41,23.5,FOLFOX + Cetuximab,Yes,No,Yes,Yes,12,well differentiated,symptoms but ambulatory,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 41, bmi: 23.5, treatment arm: FOLFOX + Cetuximab, adherence: Yes, bowel obstruction: Yes, bowel perforation: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type","The patient is a 41-year-old white male with a BMI of 23.5. He is undergoing treatment with FOLFOX + Cetuximab and has been adherent to the treatment. He has experienced bowel obstruction and perforation. He has completed 12 cycles of chemotherapy. The histology shows well-differentiated cells. Despite experiencing symptoms, the patient is still able to be ambulatory. The KRAS biomarker indicates that he has a wild-type status."
820,white,female,67,24.58,FOLFOX + Cetuximab,No,No,No,No,11,poorly differentiated,fully active,wild-type,No,No,No,No,No,1,"race: white, sex: female, age: 67, bmi: 24.58, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 11, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 67-year-old white female with a BMI of 24.58. She is receiving treatment with FOLFOX + Cetuximab and has completed 11 cycles of chemotherapy. Her cancer histology is poorly differentiated. Despite her cancer diagnosis, she has a fully active performance status. Additionally, her KRAS biomarker status is wild-type."
821,white,male,43,27.25,FOLFOX,No,No,No,No,9,well differentiated,fully active,wild-type,No,No,Yes,No,No,0,"race: white, sex: male, age: 43, bmi: 27.25, treatment arm: FOLFOX, chemotherapy cycles: 9, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type, adverse effect: diarrhea: Yes",The patient is a 43-year-old white male with a BMI of 27.25 who is receiving the FOLFOX treatment regimen for his well-differentiated histology. He has completed 9 cycles of chemotherapy and has a fully active performance status. His KRAS biomarker is wild-type. The patient is experiencing diarrhea as an adverse effect of the treatment.
822,white,female,36,23.78,FOLFOX,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 36, bmi: 23.78, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 36-year-old white female with a BMI of 23.78. She is receiving the FOLFOX treatment arm and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cells, and she has a fully active performance status. The KRAS biomarker analysis indicates that she has a wild-type KRAS status."
823,white,male,49,27.02,FOLFOX + Cetuximab,No,Yes,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 49, bmi: 27.02, treatment arm: FOLFOX + Cetuximab, serious adverse effect: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 49-year-old white male with a BMI of 27.02. He is receiving treatment with FOLFOX + Cetuximab and has experienced a serious adverse effect. He has completed 12 cycles of chemotherapy. His histology shows well-differentiated cells, and his performance status is fully active. The KRAS biomarker indicates that he has a wild-type gene."
824,white,male,50,39.26,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 50, bmi: 39.26, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type",The patient is a 50-year-old white male with a BMI of 39.26. He is receiving treatment in the FOLFOX + Cetuximab treatment arm and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer cells. The patient has a fully active performance status and has a wild-type KRAS biomarker.
825,white,male,74,24.69,FOLFOX,No,No,No,No,2,well differentiated,fully active,mutant,No,No,No,No,No,1,"race: white, sex: male, age: 74, bmi: 24.69, treatment arm: FOLFOX, chemotherapy cycles: 2, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 74-year-old white male with a BMI of 24.69. He is currently receiving the FOLFOX treatment regimen and has completed 2 cycles of chemotherapy. His histology shows well-differentiated cancer cells. Despite his age, he has a fully active performance status. The KRAS biomarker analysis indicates that he has a mutant KRAS status."
826,white,male,60,28.78,FOLFOX,No,Yes,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 60, bmi: 28.78, treatment arm: FOLFOX, serious adverse effect: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 60-year-old white male with a BMI of 28.78. He is receiving treatment with FOLFOX chemotherapy regimen and has experienced a serious adverse effect. He has completed 12 cycles of chemotherapy. The histology shows well-differentiated cancer cells. Despite the adverse effect, the patient's performance status is fully active. The KRAS biomarker analysis indicates a wild-type status."
827,white,male,54,38.86,FOLFOX,No,No,No,No,12,well differentiated,symptoms but ambulatory,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 54, bmi: 38.86, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type","The patient is a 54-year-old white male with a BMI of 38.86. He is receiving treatment with the FOLFOX chemotherapy regimen and has completed 12 cycles. His histology shows well-differentiated cells. Despite experiencing symptoms, he is still able to walk around (ambulatory). The KRAS biomarker analysis indicates that he has a wild-type KRAS status."
828,white,male,63,25.44,FOLFOX + Cetuximab,No,No,No,No,12,poorly differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 63, bmi: 25.44, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 63-year-old white male with a BMI of 25.44. He is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. His cancer histology is poorly differentiated. Despite his cancer diagnosis, he has a fully active performance status. The KRAS biomarker testing revealed that he has a wild-type KRAS status."
829,white,male,74,25.23,FOLFOX,No,No,No,No,12,well differentiated,fully active,mutant,No,No,No,No,No,0,"race: white, sex: male, age: 74, bmi: 25.23, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 74-year-old white male with a BMI of 25.23. He is undergoing treatment with the FOLFOX chemotherapy regimen and has completed 12 cycles. His histology shows well-differentiated cancer cells. Despite his age, he has a fully active performance status. The KRAS biomarker analysis indicates that he has a mutant form of the gene."
830,other,female,59,20.78,FOLFOX + Cetuximab,No,Yes,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: other, sex: female, age: 59, bmi: 20.78, treatment arm: FOLFOX + Cetuximab, serious adverse effect: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 59-year-old female of a race other than Caucasian. She has a BMI of 20.78 and is receiving treatment with FOLFOX + Cetuximab. She has experienced a serious adverse effect during her treatment. She has completed 12 cycles of chemotherapy. Her histology shows that the cancer is well-differentiated. Despite her treatment, she maintains a fully active performance status. Her KRAS biomarker is wild-type."
831,white,male,72,25.79,FOLFOX,No,No,No,No,12,poorly differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 72, bmi: 25.79, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 72-year-old white male with a BMI of 25.79. He is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. His cancer histology is poorly differentiated. Despite his age, he has a fully active performance status. Additionally, his KRAS biomarker status is wild-type."
832,white,female,76,25.82,FOLFOX + Cetuximab,Yes,No,No,No,0,well differentiated,fully active,wild-type,No,No,No,No,No,1,"race: white, sex: female, age: 76, bmi: 25.82, treatment arm: FOLFOX + Cetuximab, adherence: Yes, chemotherapy cycles: 0, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 76-year-old white female with a BMI of 25.82. She is enrolled in the FOLFOX + Cetuximab treatment arm and has been adherent to her treatment. She has not started any chemotherapy cycles yet. Her histology shows well-differentiated cancer cells. Despite her age, she has a fully active performance status. The KRAS biomarker analysis indicates that she has a wild-type KRAS status."
833,black,female,69,28.03,FOLFIRI (KRAS mutant),No,No,No,No,12,well differentiated,symptoms but ambulatory,mutant,No,No,No,No,No,0,"race: black, sex: female, age: 69, bmi: 28.03, treatment arm: FOLFIRI (KRAS mutant), chemotherapy cycles: 12, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: mutant","The patient is a 69-year-old Black female with a BMI of 28.03. She is receiving the FOLFIRI chemotherapy regimen for 12 cycles as part of her treatment plan. Her cancer histology is well differentiated, and she has a KRAS mutation. Despite experiencing symptoms, she is still able to be ambulatory."
834,white,male,40,26.24,FOLFOX + Cetuximab,No,No,No,No,1,well differentiated,symptoms but ambulatory,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 40, bmi: 26.24, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 1, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type","The patient is a 40-year-old white male with a BMI of 26.24. He is currently receiving treatment in the FOLFOX + Cetuximab treatment arm and has completed one cycle of chemotherapy. His histology shows well-differentiated cancer cells. Despite experiencing symptoms, he is still able to walk around (ambulatory). Additionally, his KRAS biomarker indicates that it is wild-type."
835,white,male,54,35.42,FOLFOX,No,Yes,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 54, bmi: 35.42, treatment arm: FOLFOX, serious adverse effect: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 54-year-old white male with a BMI of 35.42. He is receiving the FOLFOX treatment regimen and has experienced a serious adverse effect. He has completed 12 cycles of chemotherapy. His histology shows well-differentiated cells, and his performance status is fully active. The KRAS biomarker indicates that he has a wild-type status."
836,white,male,44,34.85,FOLFOX + Cetuximab,No,No,No,No,12,poorly differentiated,fully active,mutant,No,No,No,No,No,0,"race: white, sex: male, age: 44, bmi: 34.85, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 44-year-old white male with a BMI of 34.85. He is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. His histology shows poorly differentiated cancer cells. Despite this, his performance status is fully active. Additionally, the patient's KRAS biomarker indicates a mutant status."
837,white,female,67,23.04,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 67, bmi: 23.04, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type",The patient is a 67-year-old white female with a BMI of 23.04. She is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cancer cells. The patient has a fully active performance status. Her KRAS biomarker is wild-type.
838,white,female,65,24.22,FOLFOX,No,No,Yes,No,0,poorly differentiated,fully active,interminate,No,No,No,No,No,0,"race: white, sex: female, age: 65, bmi: 24.22, treatment arm: FOLFOX, bowel obstruction: Yes, chemotherapy cycles: 0, histology: poorly differentiated, performance status: fully active, KRAS biomarker: interminate","The patient is a 65-year-old white female with a BMI of 24.22. She is enrolled in the FOLFOX treatment arm for her cancer. She is currently experiencing a bowel obstruction. She has not started any chemotherapy cycles yet. The histology of her cancer is poorly differentiated. Despite her condition, her performance status is fully active. The KRAS biomarker status is indeterminate."
839,white,female,50,18.99,FOLFOX + Cetuximab,No,No,No,No,2,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 50, bmi: 18.99, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 2, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 50-year-old Caucasian woman with a BMI of 18.99. She is currently receiving treatment in the FOLFOX + Cetuximab treatment arm and has completed 2 cycles of chemotherapy. Her histology shows well-differentiated cancer cells. Despite her cancer diagnosis, she has a fully active performance status. Additionally, her KRAS biomarker indicates that it is wild-type."
840,white,male,74,20.28,FOLFIRI,No,No,Yes,No,12,well differentiated,symptoms but ambulatory,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 74, bmi: 20.28, treatment arm: FOLFIRI, bowel obstruction: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type","The patient is a 74-year-old white male with a BMI of 20.28. He is undergoing treatment with the FOLFIRI regimen and has experienced a bowel obstruction. He has completed 12 cycles of chemotherapy. The histology shows well-differentiated cancer cells. Despite experiencing symptoms, the patient is still able to be ambulatory. The KRAS biomarker indicates that the patient has a wild-type KRAS gene."
841,white,male,65,30.56,FOLFOX,No,No,Yes,No,4,poorly differentiated,fully active,wild-type,No,No,No,No,No,1,"race: white, sex: male, age: 65, bmi: 30.56, treatment arm: FOLFOX, bowel obstruction: Yes, chemotherapy cycles: 4, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 65-year-old white male with a BMI of 30.56. He is receiving treatment in the FOLFOX treatment arm and has experienced a bowel obstruction. He has completed 4 cycles of chemotherapy. The histology of his cancer is poorly differentiated. Despite these challenges, his performance status is fully active. His KRAS biomarker status is wild-type."
842,white,female,51,37.04,FOLFOX,No,No,Yes,No,12,poorly differentiated,fully active,wild-type,Yes,No,No,No,No,0,"race: white, sex: female, age: 51, bmi: 37.04, treatment arm: FOLFOX, bowel obstruction: Yes, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type, adverse effect: thrombosis: Yes","This patient is a 51-year-old white female with a BMI of 37.04. She is receiving the FOLFOX treatment regimen for her cancer. She has experienced a bowel obstruction and has undergone 12 cycles of chemotherapy. The histology of her cancer is poorly differentiated. Despite her condition, her performance status is fully active. Her KRAS biomarker is wild-type. Additionally, she has experienced the adverse effect of thrombosis."
843,other,male,59,23.95,FOLFOX,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: other, sex: male, age: 59, bmi: 23.95, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 59-year-old male of a race categorized as ""other"" with a BMI of 23.95. He is undergoing treatment with the FOLFOX chemotherapy regimen and has completed 12 cycles. His cancer histology is well-differentiated, and he has a fully active performance status. Additionally, his KRAS biomarker status is wild-type."
844,black,female,67,31.47,FOLFIRI (KRAS mutant),No,No,Yes,No,12,well differentiated,symptoms but ambulatory,wild-type,No,No,No,No,No,0,"race: black, sex: female, age: 67, bmi: 31.47, treatment arm: FOLFIRI (KRAS mutant), bowel obstruction: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type","This patient is a 67-year-old Black female with a BMI of 31.47. She is receiving the FOLFIRI chemotherapy regimen for her KRAS mutant status. She has experienced a bowel obstruction and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cancer. Despite experiencing symptoms, she is still able to be ambulatory. Her KRAS biomarker status is wild-type."
845,white,male,65,35.34,FOLFOX + Cetuximab,No,No,No,No,11,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 65, bmi: 35.34, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 11, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 65-year-old white male with a BMI of 35.34. He is undergoing treatment with FOLFOX + Cetuximab and has completed 11 cycles of chemotherapy. His cancer histology is well differentiated, and he has a fully active performance status. The KRAS biomarker analysis shows that he has a wild-type KRAS status."
846,white,male,69,24.98,FOLFOX + Cetuximab,No,Yes,Yes,No,12,poorly differentiated,symptoms but ambulatory,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 69, bmi: 24.98, treatment arm: FOLFOX + Cetuximab, serious adverse effect: Yes, bowel obstruction: Yes, chemotherapy cycles: 12, histology: poorly differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type","The patient is a 69-year-old white male with a BMI of 24.98. He is receiving treatment with FOLFOX + Cetuximab. Unfortunately, he has experienced a serious adverse effect in the form of a bowel obstruction. He has completed 12 cycles of chemotherapy. The histology of his cancer is poorly differentiated. Despite experiencing symptoms, he is still able to be ambulatory. His KRAS biomarker status is wild-type."
847,white,female,38,27.4,FOLFOX,Yes,No,Yes,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,1,"race: white, sex: female, age: 38, bmi: 27.4, treatment arm: FOLFOX, adherence: Yes, bowel obstruction: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 38-year-old white female with a BMI of 27.4. She is receiving the FOLFOX treatment regimen and has been adherent to her treatment. She has experienced a bowel obstruction. The patient has completed 12 cycles of chemotherapy and her histology shows well-differentiated cells. Her performance status is fully active. Additionally, her KRAS biomarker is wild-type."
848,white,female,61,17.23,FOLFOX + Cetuximab,No,No,Yes,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,1,"race: white, sex: female, age: 61, bmi: 17.23, treatment arm: FOLFOX + Cetuximab, bowel obstruction: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 61-year-old white female with a BMI of 17.23. She is receiving treatment with FOLFOX + Cetuximab and has experienced a bowel obstruction. She has completed 12 cycles of chemotherapy. The histology indicates that the cancer is well-differentiated. Despite the bowel obstruction, her performance status is fully active. The KRAS biomarker shows that she has a wild-type mutation."
849,white,female,53,29.8,FOLFOX,No,No,No,No,4,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 53, bmi: 29.8, treatment arm: FOLFOX, chemotherapy cycles: 4, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type",The patient is a 53-year-old white female with a BMI of 29.8. She is receiving the FOLFOX treatment regimen and has completed 4 cycles of chemotherapy. The histology of her cancer is well differentiated. She has a fully active performance status. The KRAS biomarker testing indicates that she has a wild-type KRAS status.
850,white,female,58,28.55,FOLFOX,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 58, bmi: 28.55, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type",The patient is a 58-year-old white female with a BMI of 28.55. She is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cancer cells. The patient has a fully active performance status and her KRAS biomarker is wild-type.
851,white,male,73,29.31,FOLFOX,No,No,No,No,12,well differentiated,symptoms but ambulatory,mutant,No,No,No,No,No,0,"race: white, sex: male, age: 73, bmi: 29.31, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: mutant","The patient is a 73-year-old white male with a BMI of 29.31. He is undergoing treatment with the FOLFOX chemotherapy regimen and has completed 12 cycles. His histology shows well-differentiated cancer cells. Despite experiencing symptoms, he is still able to be ambulatory. The patient's KRAS biomarker indicates a mutant status."
852,white,female,45,21.94,FOLFOX,No,No,No,Yes,12,well differentiated,fully active,mutant,No,No,No,No,No,0,"race: white, sex: female, age: 45, bmi: 21.94, treatment arm: FOLFOX, bowel perforation: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 45-year-old white female with a BMI of 21.94. She is receiving the FOLFOX treatment regimen and has experienced a bowel perforation. She has completed 12 cycles of chemotherapy. The histology shows well-differentiated cancer cells. Despite the bowel perforation, her performance status is fully active. The KRAS biomarker analysis indicates a mutant status."
853,white,female,76,24.48,FOLFOX + Cetuximab,No,No,No,No,2,well differentiated,fully active,wild-type,No,Yes,No,No,No,0,"race: white, sex: female, age: 76, bmi: 24.48, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 2, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type, adverse effect: hypersensitivity: Yes","The patient is a 76-year-old white female with a BMI of 24.48. She is currently receiving treatment with FOLFOX + Cetuximab and has completed 2 cycles of chemotherapy. Her cancer histology is well-differentiated, and she has a fully active performance status. The KRAS biomarker testing showed that she has a wild-type KRAS status. She has experienced a hypersensitivity adverse effect during her treatment."
854,white,male,69,27.28,FOLFOX,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 69, bmi: 27.28, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 69-year-old white male with a BMI of 27.28. He is receiving the FOLFOX treatment arm for his cancer and has completed 12 cycles of chemotherapy. The histology of his cancer is well-differentiated. Despite his age, he has a fully active performance status. His KRAS biomarker status is wild-type."
855,black,female,63,30.41,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: black, sex: female, age: 63, bmi: 30.41, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 63-year-old Black female with a BMI of 30.41. She is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cells, and she has a fully active performance status. The KRAS biomarker indicates that she has a wild-type status."
856,black,male,66,31.35,FOLFOX,No,No,No,No,12,poorly differentiated,fully active,wild-type,No,No,No,No,No,0,"race: black, sex: male, age: 66, bmi: 31.35, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 66-year-old Black male with a BMI of 31.35. He is receiving the FOLFOX treatment arm and has completed 12 cycles of chemotherapy. His histology shows poorly differentiated cancer cells. Despite this, his performance status is fully active. Additionally, his KRAS biomarker is wild-type."
857,white,female,64,24.92,FOLFOX + Cetuximab,No,No,No,No,9,well differentiated,fully active,mutant,No,No,Yes,No,No,0,"race: white, sex: female, age: 64, bmi: 24.92, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 9, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant, adverse effect: diarrhea: Yes","The patient is a 64-year-old white female with a BMI of 24.92. She is receiving treatment with FOLFOX + Cetuximab and has completed 9 cycles of chemotherapy. Her histology shows well-differentiated cancer, and she has a fully active performance status. The KRAS biomarker indicates a mutant status. The patient is experiencing diarrhea as an adverse effect of the treatment."
858,white,female,69,19.81,FOLFOX + Cetuximab,Yes,No,No,No,12,poorly differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 69, bmi: 19.81, treatment arm: FOLFOX + Cetuximab, adherence: Yes, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 69-year-old white female with a BMI of 19.81. She is receiving treatment in the FOLFOX + Cetuximab treatment arm and has been adherent to her chemotherapy regimen, completing 12 cycles. Her histology shows poorly differentiated cancer cells. Despite this, her performance status is fully active, indicating that she is able to carry out her daily activities without limitations. Additionally, her KRAS biomarker status is wild-type."
859,white,male,69,31.38,FOLFOX,No,Yes,No,No,2,well differentiated,symptoms but ambulatory,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 69, bmi: 31.38, treatment arm: FOLFOX, serious adverse effect: Yes, chemotherapy cycles: 2, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type","The patient is a 69-year-old white male with a BMI of 31.38. He is currently receiving the FOLFOX treatment regimen and has experienced a serious adverse effect. He has completed 2 cycles of chemotherapy. The histology shows that the cancer is well-differentiated. Despite experiencing symptoms, the patient is still able to be ambulatory. The KRAS biomarker indicates that the cancer is wild-type."
860,white,male,57,24.24,FOLFIRI (KRAS mutant),No,No,No,No,12,poorly differentiated,fully active,wild-type,No,No,No,No,No,1,"race: white, sex: male, age: 57, bmi: 24.24, treatment arm: FOLFIRI (KRAS mutant), chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 57-year-old white male with a BMI of 24.24. He is receiving the FOLFIRI treatment regimen for his KRAS mutant status. He has completed 12 cycles of chemotherapy. His histology shows poorly differentiated cancer cells. Despite his condition, he has a fully active performance status. His KRAS biomarker is wild-type."
861,white,male,40,35.49,FOLFOX,No,No,No,No,3,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 40, bmi: 35.49, treatment arm: FOLFOX, chemotherapy cycles: 3, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 40-year-old white male with a BMI of 35.49. He is currently undergoing treatment with the FOLFOX chemotherapy regimen and has completed 3 cycles so far. His cancer histology is well-differentiated, and he has a fully active performance status. Additionally, his KRAS biomarker status is wild-type."
862,white,female,68,29.07,FOLFOX + Cetuximab,Yes,No,Yes,No,6,poorly differentiated,fully active,mutant,No,No,No,No,No,0,"race: white, sex: female, age: 68, bmi: 29.07, treatment arm: FOLFOX + Cetuximab, adherence: Yes, bowel obstruction: Yes, chemotherapy cycles: 6, histology: poorly differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 68-year-old white female with a BMI of 29.07. She is receiving treatment in the FOLFOX + Cetuximab treatment arm and has been adherent to her treatment. She is currently experiencing a bowel obstruction. The patient has completed 6 cycles of chemotherapy and her histology shows poorly differentiated cells. Despite the bowel obstruction, her performance status is fully active. Additionally, the KRAS biomarker analysis indicates a mutant status."
863,white,male,72,22.85,FOLFOX,Yes,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 72, bmi: 22.85, treatment arm: FOLFOX, adherence: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type",The patient is a 72-year-old white male with a BMI of 22.85. He is receiving the FOLFOX treatment regimen and has been adherent to the treatment. He has completed 12 cycles of chemotherapy. The histology shows well-differentiated cancer cells. The patient has a fully active performance status. His KRAS biomarker is wild-type.
864,white,male,54,26.3,FOLFOX + Cetuximab,No,No,No,No,1,well differentiated,fully active,mutant,No,No,No,No,Yes,0,"race: white, sex: male, age: 54, bmi: 26.3, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 1, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant, adverse effect: infarction: Yes","The patient is a 54-year-old white male with a BMI of 26.3. He is currently receiving treatment with FOLFOX + Cetuximab and has completed 1 cycle of chemotherapy. His cancer histology is well-differentiated, and he has a fully active performance status. The KRAS biomarker testing revealed a mutant status. The patient has experienced an adverse effect in the form of an infarction."
865,white,female,71,26.7,FOLFIRI,No,Yes,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 71, bmi: 26.7, treatment arm: FOLFIRI, serious adverse effect: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 71-year-old white female with a BMI of 26.7. She is undergoing treatment with the FOLFIRI regimen and has experienced a serious adverse effect. She has completed 12 cycles of chemotherapy. The histology of her cancer is well-differentiated. Despite her age, she has a fully active performance status. Her KRAS biomarker status is wild-type."
866,white,male,62,28.82,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 62, bmi: 28.82, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 62-year-old white male with a BMI of 28.82. He is receiving treatment in the FOLFOX + Cetuximab treatment arm and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer cells. Despite his age, he has a fully active performance status. Additionally, his KRAS biomarker is wild-type."
867,white,female,51,24.26,FOLFOX,No,Yes,No,No,12,well differentiated,fully active,mutant,No,No,No,No,No,0,"race: white, sex: female, age: 51, bmi: 24.26, treatment arm: FOLFOX, serious adverse effect: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 51-year-old white female with a BMI of 24.26. She is receiving the FOLFOX treatment regimen and has experienced a serious adverse effect. She has undergone 12 cycles of chemotherapy. The histology shows well-differentiated cancer cells. Despite the treatment, her performance status remains fully active. The KRAS biomarker analysis indicates a mutant status."
868,white,female,64,20.72,FOLFOX + Cetuximab,No,No,No,No,11,poorly differentiated,symptoms but ambulatory,wild-type,No,No,Yes,No,No,0,"race: white, sex: female, age: 64, bmi: 20.72, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 11, histology: poorly differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type, adverse effect: diarrhea: Yes","The patient is a 64-year-old white female with a BMI of 20.72. She is receiving treatment with FOLFOX + Cetuximab and has completed 11 cycles of chemotherapy. Her histology shows poorly differentiated cancer. Despite experiencing symptoms, she is still able to be ambulatory. The KRAS biomarker indicates that she has a wild-type status. The patient is experiencing diarrhea as an adverse effect of the treatment."
869,white,female,63,23.81,FOLFOX,Yes,No,No,No,12,poorly differentiated,fully active,mutant,No,No,No,No,No,0,"race: white, sex: female, age: 63, bmi: 23.81, treatment arm: FOLFOX, adherence: Yes, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 63-year-old white female with a BMI of 23.81. She is receiving the FOLFOX treatment regimen and has been adherent to her chemotherapy cycles, completing a total of 12 cycles. Her histology shows poorly differentiated cancer cells. Despite this, her performance status is fully active. Additionally, the KRAS biomarker testing revealed a mutant status."
870,white,female,55,20.12,FOLFIRI + Cetuximab,No,No,No,No,12,well differentiated,symptoms but ambulatory,mutant,No,No,Yes,No,No,0,"race: white, sex: female, age: 55, bmi: 20.12, treatment arm: FOLFIRI + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: mutant, adverse effect: diarrhea: Yes","This patient is a 55-year-old white female with a BMI of 20.12. She is receiving treatment with FOLFIRI + Cetuximab for her well-differentiated cancer. She has completed 12 cycles of chemotherapy. Despite experiencing symptoms, she is still able to be ambulatory. Her KRAS biomarker is mutant. She is also experiencing diarrhea as an adverse effect of her treatment."
871,other,female,62,33.13,FOLFOX + Cetuximab,No,No,No,No,2,well differentiated,fully active,mutant,No,No,No,No,No,0,"race: other, sex: female, age: 62, bmi: 33.13, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 2, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 62-year-old female of a race categorized as ""other"" with a BMI of 33.13. She is currently receiving treatment with FOLFOX + Cetuximab and has completed 2 cycles of chemotherapy. The histology of her condition is well-differentiated, and her performance status is fully active. Additionally, the KRAS biomarker analysis has shown a mutant status."
872,white,male,46,25.97,FOLFOX,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 46, bmi: 25.97, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 46-year-old white male with a BMI of 25.97. He is receiving treatment with the FOLFOX chemotherapy regimen and is scheduled for 12 cycles. His cancer histology is well-differentiated, and he has a fully active performance status. The KRAS biomarker testing revealed that he has a wild-type KRAS status."
873,black,female,58,24.77,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: black, sex: female, age: 58, bmi: 24.77, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type",The patient is a 58-year-old Black female with a BMI of 24.77. She is receiving treatment in the FOLFOX + Cetuximab treatment arm and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cancer cells. The patient has a fully active performance status and her KRAS biomarker is wild-type.
874,white,male,44,27,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,symptoms but ambulatory,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 44, bmi: 27.0, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type","The patient is a 44-year-old white male with a BMI of 27.0. He is receiving treatment in the FOLFOX + Cetuximab treatment arm and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cells. Despite experiencing symptoms, he is still able to be ambulatory. The KRAS biomarker indicates that he has a wild-type status."
875,white,male,42,27.96,FOLFOX + Cetuximab,No,Yes,No,No,12,well differentiated,fully active,mutant,No,No,Yes,Yes,No,0,"race: white, sex: male, age: 42, bmi: 27.96, treatment arm: FOLFOX + Cetuximab, serious adverse effect: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant, adverse effect: diarrhea: Yes, adverse effect: infection: Yes",The patient is a 42-year-old white male with a BMI of 27.96. He is receiving treatment with FOLFOX + Cetuximab and has experienced a serious adverse effect. He has completed 12 cycles of chemotherapy. The histology shows well-differentiated cells. The patient has a fully active performance status. The KRAS biomarker is mutant. He has experienced adverse effects of diarrhea and infection.
876,white,male,64,38.57,FOLFOX,No,Yes,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 64, bmi: 38.57, treatment arm: FOLFOX, serious adverse effect: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 64-year-old white male with a BMI of 38.57. He is receiving the FOLFOX treatment regimen and has experienced a serious adverse effect. He has completed 12 cycles of chemotherapy. His histology shows well-differentiated cells. Despite the adverse effect, his performance status is fully active. The KRAS biomarker analysis indicates that he has a wild-type KRAS status."
877,white,male,47,32.15,FOLFOX + Cetuximab,Yes,No,Yes,No,12,well differentiated,fully active,mutant,No,No,No,No,No,0,"race: white, sex: male, age: 47, bmi: 32.15, treatment arm: FOLFOX + Cetuximab, adherence: Yes, bowel obstruction: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant",The patient is a 47-year-old white male with a BMI of 32.15. He is receiving treatment in the FOLFOX + Cetuximab treatment arm and has been adherent to the treatment. He has experienced a bowel obstruction. The patient has completed 12 cycles of chemotherapy and has well-differentiated histology. His performance status is fully active. The KRAS biomarker indicates that he has a mutant status.
878,white,male,50,32.72,FOLFOX,No,No,No,No,12,well differentiated,fully active,mutant,No,No,No,No,No,1,"race: white, sex: male, age: 50, bmi: 32.72, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant",The patient is a 50-year-old white male with a BMI of 32.72. He is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer cells. The patient has a fully active performance status and has a mutant KRAS biomarker.
879,white,female,44,25.62,FOLFOX,No,No,No,No,12,well differentiated,symptoms but ambulatory,mutant,No,No,Yes,No,No,0,"race: white, sex: female, age: 44, bmi: 25.62, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: mutant, adverse effect: diarrhea: Yes","The patient is a 44-year-old white female with a BMI of 25.62 who is receiving the FOLFOX treatment regimen for her well-differentiated histology. She has completed 12 cycles of chemotherapy. Despite experiencing symptoms, she is still able to be ambulatory. The patient's KRAS biomarker is mutant. She is also experiencing diarrhea as an adverse effect of the treatment."
880,white,female,68,19.37,FOLFOX,No,No,Yes,No,12,well differentiated,fully active,mutant,No,No,No,No,No,0,"race: white, sex: female, age: 68, bmi: 19.37, treatment arm: FOLFOX, bowel obstruction: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 68-year-old white female with a BMI of 19.37. She is receiving treatment with the FOLFOX regimen for her cancer. She has experienced a bowel obstruction and has completed 12 cycles of chemotherapy. The histology of her cancer is well-differentiated. Despite her condition, she has a fully active performance status. The KRAS biomarker testing revealed a mutant status."
881,black,male,49,31.35,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,symptoms but ambulatory,wild-type,No,No,No,No,No,0,"race: black, sex: male, age: 49, bmi: 31.35, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type","This patient is a 49-year-old Black male with a BMI of 31.35. He is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer. Despite experiencing symptoms, he is still able to be ambulatory. His KRAS biomarker status is wild-type."
882,black,female,53,25.58,FOLFOX,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: black, sex: female, age: 53, bmi: 25.58, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 53-year-old Black female with a BMI of 25.58. She is receiving the FOLFOX treatment arm and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cells, and she has a fully active performance status. The KRAS biomarker indicates that she has a wild-type status."
883,white,male,42,24.69,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,fully active,mutant,No,No,No,No,No,0,"race: white, sex: male, age: 42, bmi: 24.69, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 42-year-old white male with a BMI of 24.69. He is receiving treatment in the FOLFOX + Cetuximab treatment arm and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cells, and he has a fully active performance status. The KRAS biomarker analysis indicates a mutant status."
884,white,female,62,29.77,FOLFOX + Cetuximab,No,No,No,No,2,well differentiated,fully active,mutant,No,No,No,No,No,0,"race: white, sex: female, age: 62, bmi: 29.77, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 2, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 62-year-old white female with a BMI of 29.77. She is currently receiving treatment in the FOLFOX + Cetuximab treatment arm and has completed 2 cycles of chemotherapy. Her histology shows well-differentiated cancer cells. Despite her cancer diagnosis, she has a fully active performance status. Additionally, her KRAS biomarker indicates a mutant status."
885,white,female,64,32.61,FOLFOX,Yes,No,No,No,12,poorly differentiated,symptoms but ambulatory,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 64, bmi: 32.61, treatment arm: FOLFOX, adherence: Yes, chemotherapy cycles: 12, histology: poorly differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type","The patient is a 64-year-old white female with a BMI of 32.61. She is receiving the FOLFOX treatment regimen and has been adherent to the treatment. She has completed 12 cycles of chemotherapy. The histology of her cancer is poorly differentiated. Despite experiencing symptoms, she is still ambulatory. Her KRAS biomarker status is wild-type."
886,white,male,49,30.47,FOLFOX,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 49, bmi: 30.47, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 49-year-old white male with a BMI of 30.47. He is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. His cancer histology is well-differentiated, and he has a fully active performance status. The KRAS biomarker analysis shows that he has a wild-type KRAS status."
887,white,male,46,31.52,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,fully active,mutant,No,No,Yes,No,No,0,"race: white, sex: male, age: 46, bmi: 31.52, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant, adverse effect: diarrhea: Yes","The patient is a 46-year-old white male with a BMI of 31.52. He is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer, and he has a fully active performance status. The KRAS biomarker indicates a mutant status. The patient is experiencing diarrhea as an adverse effect of the treatment."
888,white,female,54,22.37,FOLFOX,No,No,Yes,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 54, bmi: 22.37, treatment arm: FOLFOX, bowel obstruction: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 54-year-old white female with a BMI of 22.37. She is receiving treatment with the FOLFOX regimen and has experienced a bowel obstruction. She has completed 12 cycles of chemotherapy. The histology of her cancer is well-differentiated. Despite the bowel obstruction, her performance status is fully active. The KRAS biomarker testing revealed that she has a wild-type KRAS gene."
889,white,female,52,20.31,FOLFOX + Cetuximab,No,No,No,No,12,poorly differentiated,fully active,mutant,No,No,No,No,No,0,"race: white, sex: female, age: 52, bmi: 20.31, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 52-year-old white female with a BMI of 20.31. She is receiving treatment in the FOLFOX + Cetuximab treatment arm and is scheduled for 12 chemotherapy cycles. Her histology shows poorly differentiated cancer cells. Despite this, her performance status is fully active. Additionally, the KRAS biomarker testing revealed a mutant status."
890,white,female,66,29.82,FOLFOX,No,Yes,No,No,12,well differentiated,fully active,wild-type,Yes,No,No,No,No,0,"race: white, sex: female, age: 66, bmi: 29.82, treatment arm: FOLFOX, serious adverse effect: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type, adverse effect: thrombosis: Yes","The patient is a 66-year-old white female with a BMI of 29.82 who is receiving the FOLFOX treatment regimen. She has experienced a serious adverse effect during her 12 cycles of chemotherapy. The histology of her cancer is well-differentiated, and her performance status is fully active. The KRAS biomarker shows that she has a wild-type mutation. Additionally, she has developed thrombosis as an adverse effect."
891,white,male,75,37.18,FOLFOX,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 75, bmi: 37.18, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 75-year-old white male with a BMI of 37.18. He is receiving treatment with the FOLFOX chemotherapy regimen and has completed 12 cycles. His cancer histology is well differentiated. Despite his age, he has a fully active performance status. The KRAS biomarker testing indicates that he has a wild-type KRAS status."
892,white,female,63,29.84,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 63, bmi: 29.84, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 63-year-old white female with a BMI of 29.84. She is receiving treatment in the FOLFOX + Cetuximab treatment arm and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cells, and she has a fully active performance status. Additionally, her KRAS biomarker is wild-type."
893,other,female,50,32.8,FOLFOX,No,No,No,No,12,well differentiated,symptoms but ambulatory,wild-type,No,No,No,No,No,0,"race: other, sex: female, age: 50, bmi: 32.8, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type","The patient is a 50-year-old female of a race categorized as ""other"" with a BMI of 32.8. She is undergoing treatment with the FOLFOX chemotherapy regimen and has completed 12 cycles. The histology of her cancer is well-differentiated. Despite experiencing symptoms, she is still able to ambulate. Her KRAS biomarker status is wild-type."
894,white,male,71,30.91,FOLFOX + Cetuximab,No,No,Yes,No,6,well differentiated,in bed less than 50% of the time,mutant,No,No,No,No,No,0,"race: white, sex: male, age: 71, bmi: 30.91, treatment arm: FOLFOX + Cetuximab, bowel obstruction: Yes, chemotherapy cycles: 6, histology: well differentiated, performance status: in bed less than 50% of the time, KRAS biomarker: mutant","The patient is a 71-year-old white male with a BMI of 30.91. He is receiving treatment with FOLFOX + Cetuximab for his cancer. He has a bowel obstruction and has completed 6 cycles of chemotherapy. The histology of his cancer is well-differentiated. His performance status indicates that he is in bed less than 50% of the time. Additionally, the KRAS biomarker testing revealed that he has a mutant KRAS status."
895,white,female,51,31.48,FOLFOX,No,No,Yes,No,12,well differentiated,symptoms but ambulatory,mutant,No,No,No,No,No,0,"race: white, sex: female, age: 51, bmi: 31.48, treatment arm: FOLFOX, bowel obstruction: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: mutant","The patient is a 51-year-old white female with a BMI of 31.48. She is receiving treatment with the FOLFOX regimen and has a bowel obstruction. She has completed 12 cycles of chemotherapy. The histology shows well-differentiated cancer cells. Despite experiencing symptoms, she is still able to be ambulatory. The KRAS biomarker analysis indicates a mutant status."
896,white,female,41,27.23,FOLFOX,No,Yes,No,No,12,well differentiated,fully active,wild-type,Yes,No,No,No,No,0,"race: white, sex: female, age: 41, bmi: 27.23, treatment arm: FOLFOX, serious adverse effect: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type, adverse effect: thrombosis: Yes","The patient is a 41-year-old white female with a BMI of 27.23 who is receiving the FOLFOX treatment regimen. She experienced a serious adverse effect during treatment. She completed 12 cycles of chemotherapy and has well-differentiated histology. Her performance status is fully active. The KRAS biomarker analysis showed that she has a wild-type KRAS status. Additionally, she experienced an adverse effect of thrombosis during her treatment."
897,other,female,44,25.56,FOLFOX + Cetuximab,No,No,Yes,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: other, sex: female, age: 44, bmi: 25.56, treatment arm: FOLFOX + Cetuximab, bowel obstruction: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 44-year-old female of a race other than specified, with a BMI of 25.56. She is receiving treatment with FOLFOX + Cetuximab and has experienced a bowel obstruction. She has completed 12 cycles of chemotherapy. The histology indicates that the cancer is well-differentiated. Despite the bowel obstruction, her performance status is fully active. The KRAS biomarker shows that she has a wild-type status."
898,white,male,52,34.72,FOLFOX + Cetuximab,No,No,No,No,12,poorly differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 52, bmi: 34.72, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 52-year-old white male with a BMI of 34.72. He is receiving treatment in the FOLFOX + Cetuximab treatment arm and has completed 12 cycles of chemotherapy. His histology shows poorly differentiated cancer cells. Despite this, his performance status is fully active. The KRAS biomarker analysis indicates that he has a wild-type KRAS gene."
899,white,female,60,32.4,FOLFIRI,Yes,Yes,Yes,Yes,10,poorly differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 60, bmi: 32.4, treatment arm: FOLFIRI, adherence: Yes, serious adverse effect: Yes, bowel obstruction: Yes, bowel perforation: Yes, chemotherapy cycles: 10, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 60-year-old white female with a BMI of 32.4 who is undergoing treatment with the FOLFIRI regimen. She has been adherent to her treatment. Unfortunately, she has experienced serious adverse effects in the form of bowel obstruction and perforation. She has completed 10 cycles of chemotherapy and her histology shows poorly differentiated cancer. Despite these challenges, her performance status remains fully active. Additionally, her KRAS biomarker indicates that she has a wild-type mutation."
900,white,male,73,28.55,FOLFOX + Cetuximab,No,No,No,No,6,poorly differentiated,fully active,wild-type,No,No,Yes,No,No,0,"race: white, sex: male, age: 73, bmi: 28.55, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 6, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type, adverse effect: diarrhea: Yes",The patient is a 73-year-old white male with a BMI of 28.55 who is receiving treatment with FOLFOX + Cetuximab for his poorly differentiated histology. He has completed 6 cycles of chemotherapy and has a fully active performance status. His KRAS biomarker is wild-type. The patient is experiencing diarrhea as an adverse effect of the treatment.
901,white,male,40,27.9,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 40, bmi: 27.9, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 40-year-old white male with a BMI of 27.9. He is receiving treatment in the FOLFOX + Cetuximab treatment arm and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cells, and he has a fully active performance status. The KRAS biomarker analysis indicates that he has a wild-type KRAS status."
902,other,female,51,26.17,FOLFOX,No,No,Yes,No,12,poorly differentiated,fully active,wild-type,No,No,No,No,No,0,"race: other, sex: female, age: 51, bmi: 26.17, treatment arm: FOLFOX, bowel obstruction: Yes, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 51-year-old female of a race classified as ""other"" with a BMI of 26.17. She is receiving treatment with FOLFOX chemotherapy regimen and has experienced a bowel obstruction. She has completed 12 cycles of chemotherapy. The histology of her cancer is poorly differentiated. Despite these challenges, her performance status is fully active. Additionally, the KRAS biomarker testing indicates that she has a wild-type KRAS status."
903,other,female,58,19.84,FOLFOX,No,No,No,No,7,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: other, sex: female, age: 58, bmi: 19.84, treatment arm: FOLFOX, chemotherapy cycles: 7, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 58-year-old female of a race categorized as ""other"" with a BMI of 19.84. She is undergoing treatment with the FOLFOX chemotherapy regimen and has completed 7 cycles so far. The histology of her cancer is well-differentiated. Despite her cancer diagnosis, her performance status is fully active, indicating that she is able to carry out daily activities without limitations. Additionally, her KRAS biomarker status is wild-type."
904,white,female,68,24.25,FOLFOX + Cetuximab,No,No,Yes,No,3,well differentiated,in bed less than 50% of the time,wild-type,No,No,No,No,No,1,"race: white, sex: female, age: 68, bmi: 24.25, treatment arm: FOLFOX + Cetuximab, bowel obstruction: Yes, chemotherapy cycles: 3, histology: well differentiated, performance status: in bed less than 50% of the time, KRAS biomarker: wild-type","This patient is a 68-year-old white female with a BMI of 24.25. She is receiving treatment with FOLFOX + Cetuximab for her cancer. She has experienced a bowel obstruction and has completed 3 cycles of chemotherapy. The histology of her cancer is well differentiated. Her performance status indicates that she is in bed less than 50% of the time. Additionally, her KRAS biomarker status is wild-type."
905,white,male,43,25.6,FOLFIRI (KRAS mutant),No,No,No,No,12,well differentiated,fully active,mutant,No,No,No,No,No,0,"race: white, sex: male, age: 43, bmi: 25.6, treatment arm: FOLFIRI (KRAS mutant), chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 43-year-old white male with a BMI of 25.6. He is undergoing treatment with the FOLFIRI regimen for KRAS mutant cancer. He has completed 12 cycles of chemotherapy. The histology of his cancer is well differentiated. Despite his cancer diagnosis, he has a fully active performance status."
906,white,male,49,28.47,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,Yes,No,No,0,"race: white, sex: male, age: 49, bmi: 28.47, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type, adverse effect: diarrhea: Yes","The patient is a 49-year-old white male with a BMI of 28.47. He is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. His cancer histology is well-differentiated, and he has a fully active performance status. The KRAS biomarker testing showed that he has a wild-type KRAS status. The patient is experiencing diarrhea as an adverse effect of the treatment."
907,white,male,53,29.63,FOLFOX + Cetuximab,Yes,No,No,No,1,well differentiated,fully active,mutant,No,No,No,No,No,0,"race: white, sex: male, age: 53, bmi: 29.63, treatment arm: FOLFOX + Cetuximab, adherence: Yes, chemotherapy cycles: 1, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 53-year-old white male with a BMI of 29.63. He is currently receiving treatment in the FOLFOX + Cetuximab treatment arm and has been adherent to the treatment. He has completed one cycle of chemotherapy. The histology shows well-differentiated cells, and his performance status is fully active. The KRAS biomarker analysis indicates a mutant status."
908,white,female,61,22.37,FOLFOX,No,No,Yes,No,0,well differentiated,fully active,mutant,No,No,No,No,No,0,"race: white, sex: female, age: 61, bmi: 22.37, treatment arm: FOLFOX, bowel obstruction: Yes, chemotherapy cycles: 0, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 61-year-old white female with a BMI of 22.37. She is enrolled in the FOLFOX treatment arm for her cancer. She is currently experiencing a bowel obstruction. She has not yet started chemotherapy cycles. The histology of her cancer is well differentiated. Despite the bowel obstruction, her performance status is fully active. The KRAS biomarker testing revealed a mutant status."
909,white,female,41,31.12,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,fully active,mutant,No,No,Yes,No,No,0,"race: white, sex: female, age: 41, bmi: 31.12, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant, adverse effect: diarrhea: Yes","The patient is a 41-year-old white female with a BMI of 31.12. She is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cancer cells. Despite her fully active performance status, she carries a mutant KRAS biomarker. The patient is experiencing diarrhea as an adverse effect of the treatment."
910,white,female,49,20.57,FOLFOX,Yes,No,Yes,No,12,well differentiated,fully active,wild-type,No,No,Yes,No,No,0,"race: white, sex: female, age: 49, bmi: 20.57, treatment arm: FOLFOX, adherence: Yes, bowel obstruction: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type, adverse effect: diarrhea: Yes","The patient is a 49-year-old white female with a BMI of 20.57 who is receiving treatment with FOLFOX for well-differentiated histology. She has been adherent to her treatment and has completed 12 cycles of chemotherapy. Despite experiencing a bowel obstruction and diarrhea as adverse effects, her performance status remains fully active. Additionally, her KRAS biomarker status is wild-type."
911,white,male,63,24.41,FOLFIRI,No,No,Yes,No,12,poorly differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 63, bmi: 24.41, treatment arm: FOLFIRI, bowel obstruction: Yes, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 63-year-old white male with a BMI of 24.41. He is receiving treatment with the FOLFIRI regimen and has experienced a bowel obstruction. He has completed 12 cycles of chemotherapy. The histology of his cancer is poorly differentiated. Despite these challenges, his performance status is fully active. His KRAS biomarker status is wild-type."
912,black,male,59,30.5,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: black, sex: male, age: 59, bmi: 30.5, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 59-year-old black male with a BMI of 30.5. He is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. His cancer histology is well differentiated, and he has a fully active performance status. The KRAS biomarker indicates that he has a wild-type mutation."
913,white,male,66,31.7,FOLFOX,No,No,No,No,12,well differentiated,symptoms but ambulatory,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 66, bmi: 31.7, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type","The patient is a 66-year-old white male with a BMI of 31.7. He is receiving treatment with the FOLFOX chemotherapy regimen and has completed 12 cycles. His histology shows well-differentiated cancer cells. Despite experiencing symptoms, he is still able to ambulate. The KRAS biomarker analysis indicates that he has a wild-type KRAS status."
914,white,female,64,23.63,FOLFOX,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,Yes,No,No,0,"race: white, sex: female, age: 64, bmi: 23.63, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type, adverse effect: diarrhea: Yes","The patient is a 64-year-old white female with a BMI of 23.63. She is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cancer cells. Despite experiencing diarrhea as an adverse effect, her performance status remains fully active. Additionally, her KRAS biomarker status is wild-type."
915,other,male,55,27.36,FOLFOX + Cetuximab,No,No,Yes,No,12,poorly differentiated,symptoms but ambulatory,mutant,No,No,No,No,No,1,"race: other, sex: male, age: 55, bmi: 27.36, treatment arm: FOLFOX + Cetuximab, bowel obstruction: Yes, chemotherapy cycles: 12, histology: poorly differentiated, performance status: symptoms but ambulatory, KRAS biomarker: mutant","The patient is a 55-year-old male of a race categorized as ""other"" with a BMI of 27.36. He is currently receiving treatment in the FOLFOX + Cetuximab treatment arm. The patient has a bowel obstruction and has completed 12 cycles of chemotherapy. The histology of the cancer is poorly differentiated. Despite experiencing symptoms, the patient is still ambulatory. Additionally, the KRAS biomarker testing revealed a mutant status."
916,other,male,67,26.7,FOLFIRI + Cetuximab,No,Yes,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: other, sex: male, age: 67, bmi: 26.7, treatment arm: FOLFIRI + Cetuximab, serious adverse effect: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 67-year-old male of a race categorized as ""other"" with a BMI of 26.7. He is undergoing treatment with FOLFIRI + Cetuximab and has experienced a serious adverse effect. He has completed 12 cycles of chemotherapy. The histology of his condition is well-differentiated. Despite the adverse effect, his performance status is fully active. Additionally, the KRAS biomarker indicates that he has a wild-type status."
917,white,male,41,15.37,FOLFOX + Cetuximab,No,No,No,No,12,poorly differentiated,in bed less than 50% of the time,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 41, bmi: 15.37, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: poorly differentiated, performance status: in bed less than 50% of the time, KRAS biomarker: wild-type",The patient is a 41-year-old white male with a very low BMI of 15.37. He is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. His histology shows poorly differentiated cancer cells. The patient's performance status indicates that he is in bed less than 50% of the time. His KRAS biomarker status is wild-type.
918,white,female,43,30.89,FOLFOX,Yes,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 43, bmi: 30.89, treatment arm: FOLFOX, adherence: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type",The patient is a 43-year-old white female with a BMI of 30.89. She is receiving the FOLFOX treatment regimen and has been adherent to the treatment. She has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cancer cells. The patient has a fully active performance status. Her KRAS biomarker is wild-type.
919,other,male,74,23.6,FOLFOX,No,No,Yes,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: other, sex: male, age: 74, bmi: 23.6, treatment arm: FOLFOX, bowel obstruction: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 74-year-old male of a race categorized as ""other"" with a BMI of 23.6. He is receiving the FOLFOX treatment arm for his condition. The patient has a bowel obstruction and has completed 12 cycles of chemotherapy. His histology shows that the cancer cells are well-differentiated. Despite his age, the patient has a fully active performance status. Additionally, his KRAS biomarker indicates that it is wild-type."
920,white,female,55,26.35,FOLFOX,No,Yes,No,No,4,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 55, bmi: 26.35, treatment arm: FOLFOX, serious adverse effect: Yes, chemotherapy cycles: 4, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 55-year-old white female with a BMI of 26.35. She is receiving the FOLFOX treatment regimen and has experienced a serious adverse effect. She has completed 4 cycles of chemotherapy. The histology of her condition is well-differentiated. Despite the adverse effect, her performance status is fully active. Her KRAS biomarker status is wild-type."
921,white,female,71,25.14,FOLFOX + Cetuximab,No,No,No,Yes,1,well differentiated,in bed less than 50% of the time,wild-type,No,No,No,No,No,1,"race: white, sex: female, age: 71, bmi: 25.14, treatment arm: FOLFOX + Cetuximab, bowel perforation: Yes, chemotherapy cycles: 1, histology: well differentiated, performance status: in bed less than 50% of the time, KRAS biomarker: wild-type",The patient is a 71-year-old white female with a BMI of 25.14. She is receiving treatment in the FOLFOX + Cetuximab treatment arm. She has experienced a bowel perforation and has completed 1 cycle of chemotherapy. The histology shows well-differentiated cells. Her performance status indicates that she is in bed less than 50% of the time. The KRAS biomarker indicates that she has a wild-type status.
922,white,female,38,30.98,FOLFOX,Yes,Yes,No,No,12,well differentiated,fully active,wild-type,No,No,Yes,No,No,0,"race: white, sex: female, age: 38, bmi: 30.98, treatment arm: FOLFOX, adherence: Yes, serious adverse effect: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type, adverse effect: diarrhea: Yes","The patient is a 38-year-old white female with a BMI of 30.98 who is receiving the FOLFOX treatment regimen. She has been adherent to her treatment and has completed 12 cycles of chemotherapy. The histology of her cancer is well-differentiated, and her performance status is fully active. The KRAS biomarker testing revealed that she has a wild-type KRAS status. The patient has experienced a serious adverse effect in the form of diarrhea during her treatment."
923,white,female,48,24.89,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 48, bmi: 24.89, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type",The patient is a 48-year-old white female with a BMI of 24.89. She is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cells. She has a fully active performance status. The KRAS biomarker indicates that she has a wild-type mutation.
924,white,male,74,28.77,FOLFOX + Cetuximab,No,Yes,No,No,12,well differentiated,symptoms but ambulatory,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 74, bmi: 28.77, treatment arm: FOLFOX + Cetuximab, serious adverse effect: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type","The patient is a 74-year-old white male with a BMI of 28.77. He is receiving treatment with FOLFOX + Cetuximab and has experienced a serious adverse effect. He has completed 12 cycles of chemotherapy. His histology shows well-differentiated cells. Despite experiencing symptoms, he is still able to be ambulatory. The KRAS biomarker indicates that he has a wild-type status."
925,black,female,50,24.62,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,symptoms but ambulatory,wild-type,No,No,No,No,No,0,"race: black, sex: female, age: 50, bmi: 24.62, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type","The patient is a 50-year-old Black female with a BMI of 24.62. She is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cancer. Despite experiencing symptoms, she is still able to walk around (ambulatory). The KRAS biomarker analysis indicates that she has a wild-type KRAS gene."
926,white,female,75,31.88,FOLFOX,No,Yes,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 75, bmi: 31.88, treatment arm: FOLFOX, serious adverse effect: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 75-year-old white female with a BMI of 31.88. She is receiving the FOLFOX treatment arm and has experienced a serious adverse effect. She has completed 12 cycles of chemotherapy. The histology shows well-differentiated cancer cells. Despite her age, she has a fully active performance status. The KRAS biomarker indicates that she has a wild-type gene."
927,white,male,58,28.04,FOLFOX,Yes,No,Yes,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 58, bmi: 28.04, treatment arm: FOLFOX, adherence: Yes, bowel obstruction: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type",The patient is a 58-year-old white male with a BMI of 28.04. He is receiving the FOLFOX treatment regimen and has been adherent to the treatment. He has experienced a bowel obstruction. The patient has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer cells. He has a fully active performance status. The KRAS biomarker indicates that he has a wild-type mutation.
928,black,male,55,30.77,FOLFOX + Cetuximab,Yes,No,No,No,9,poorly differentiated,fully active,interminate,No,No,No,No,No,0,"race: black, sex: male, age: 55, bmi: 30.77, treatment arm: FOLFOX + Cetuximab, adherence: Yes, chemotherapy cycles: 9, histology: poorly differentiated, performance status: fully active, KRAS biomarker: interminate","The patient is a 55-year-old Black male with a BMI of 30.77. He is receiving treatment in the FOLFOX + Cetuximab treatment arm and has been adherent to the treatment. He has completed 9 chemotherapy cycles. The histology of his cancer is poorly differentiated. Despite this, his performance status is fully active. The KRAS biomarker status is indeterminate."
929,white,female,72,26.96,FOLFOX + Cetuximab,No,No,No,No,1,poorly differentiated,fully active,interminate,No,No,No,No,No,0,"race: white, sex: female, age: 72, bmi: 26.96, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 1, histology: poorly differentiated, performance status: fully active, KRAS biomarker: interminate","The patient is a 72-year-old white female with a BMI of 26.96. She is currently receiving treatment in the FOLFOX + Cetuximab treatment arm and has completed one cycle of chemotherapy. Her histology shows poorly differentiated cancer cells. Despite this, her performance status is fully active, indicating that she is able to carry out her daily activities without limitations. The KRAS biomarker status is indeterminate, suggesting that further testing may be needed to determine its significance in her treatment plan."
930,white,female,35,33.67,FOLFOX + Cetuximab,No,No,No,No,12,poorly differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 35, bmi: 33.67, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 35-year-old white female with a BMI of 33.67. She is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. Her histology shows poorly differentiated cancer cells. Despite this, her performance status is fully active. Additionally, the KRAS biomarker testing indicates that she has a wild-type KRAS gene."
931,white,female,44,33.32,FOLFOX,No,No,Yes,No,2,poorly differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 44, bmi: 33.32, treatment arm: FOLFOX, bowel obstruction: Yes, chemotherapy cycles: 2, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 44-year-old white female with a BMI of 33.32. She is receiving the FOLFOX treatment arm for her cancer. She has experienced a bowel obstruction and has completed 2 cycles of chemotherapy. The histology of her cancer is poorly differentiated. Despite these challenges, her performance status is fully active. Additionally, her KRAS biomarker shows that it is wild-type."
932,black,female,59,28.05,FOLFOX,Yes,No,No,No,12,well differentiated,fully active,mutant,No,No,No,No,No,0,"race: black, sex: female, age: 59, bmi: 28.05, treatment arm: FOLFOX, adherence: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 59-year-old Black female with a BMI of 28.05. She is receiving treatment in the FOLFOX chemotherapy arm and has been adherent to the treatment. She has completed 12 cycles of chemotherapy. The histology shows well-differentiated cells, and her performance status is fully active. The KRAS biomarker indicates a mutant status."
933,other,male,76,21.87,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,symptoms but ambulatory,wild-type,No,No,No,No,No,0,"race: other, sex: male, age: 76, bmi: 21.87, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type","The patient is a 76-year-old male of a race categorized as ""other"" with a BMI of 21.87. He is receiving treatment in the FOLFOX + Cetuximab treatment arm and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cells. Despite experiencing symptoms, he is still able to ambulate, indicating a reasonable performance status. Additionally, his KRAS biomarker status is wild-type."
934,white,female,64,32.18,FOLFOX + Cetuximab,No,No,No,Yes,12,well differentiated,fully active,mutant,No,No,No,No,No,0,"race: white, sex: female, age: 64, bmi: 32.18, treatment arm: FOLFOX + Cetuximab, bowel perforation: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 64-year-old white female with a BMI of 32.18. She is receiving treatment with FOLFOX + Cetuximab and has experienced a bowel perforation. She has completed 12 cycles of chemotherapy. The histology shows well-differentiated cells. Despite the bowel perforation, her performance status is fully active. The KRAS biomarker indicates a mutant status."
935,black,female,38,31.87,FOLFOX + Cetuximab,No,No,No,Yes,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: black, sex: female, age: 38, bmi: 31.87, treatment arm: FOLFOX + Cetuximab, bowel perforation: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 38-year-old Black female with a BMI of 31.87. She is receiving treatment with FOLFOX + Cetuximab and has experienced a bowel perforation. She has completed 12 cycles of chemotherapy. The histology shows that the cancer is well-differentiated. Despite the bowel perforation, her performance status is fully active. The KRAS biomarker indicates that she has a wild-type KRAS gene."
936,white,male,66,33.8,FOLFIRI + Cetuximab,No,No,No,No,12,well differentiated,fully active,mutant,No,No,No,No,No,0,"race: white, sex: male, age: 66, bmi: 33.8, treatment arm: FOLFIRI + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 66-year-old white male with a BMI of 33.8. He is undergoing treatment with FOLFIRI + Cetuximab and has completed 12 cycles of chemotherapy. His cancer histology is well-differentiated, and he has a fully active performance status. The KRAS biomarker testing revealed a mutant status."
937,white,male,73,25.5,FOLFOX + Cetuximab,No,Yes,No,No,2,well differentiated,fully active,mutant,No,No,No,No,No,1,"race: white, sex: male, age: 73, bmi: 25.5, treatment arm: FOLFOX + Cetuximab, serious adverse effect: Yes, chemotherapy cycles: 2, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 73-year-old white male with a BMI of 25.5. He is currently receiving treatment with FOLFOX + Cetuximab. Unfortunately, he has experienced a serious adverse effect. He has completed 2 cycles of chemotherapy. His histology shows well-differentiated cells. Despite these challenges, his performance status is fully active. Additionally, his KRAS biomarker is mutant."
938,other,male,46,23.21,FOLFIRI,No,No,No,No,12,well differentiated,fully active,mutant,No,No,No,No,No,0,"race: other, sex: male, age: 46, bmi: 23.21, treatment arm: FOLFIRI, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 46-year-old male of a race classified as ""other"" with a BMI of 23.21. He is undergoing treatment with the FOLFIRI chemotherapy regimen and has completed 12 cycles. The histology of his condition is well-differentiated. Despite his treatment, he maintains a fully active performance status. Additionally, the patient's KRAS biomarker status is mutant."
939,other,female,68,21.06,FOLFOX,No,Yes,Yes,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: other, sex: female, age: 68, bmi: 21.06, treatment arm: FOLFOX, serious adverse effect: Yes, bowel obstruction: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 68-year-old female of a race categorized as ""other"" with a BMI of 21.06. She is undergoing treatment with the FOLFOX regimen and has experienced a serious adverse effect, specifically a bowel obstruction. She has completed 12 cycles of chemotherapy. The histology of her cancer is well-differentiated. Despite the adverse effects, her performance status is fully active. Additionally, her KRAS biomarker status is wild-type."
940,white,male,70,30.06,FOLFOX + Cetuximab,No,Yes,No,No,2,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 70, bmi: 30.06, treatment arm: FOLFOX + Cetuximab, serious adverse effect: Yes, chemotherapy cycles: 2, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 70-year-old white male with a BMI of 30.06. He is receiving treatment with FOLFOX + Cetuximab and has experienced a serious adverse effect. He has completed 2 cycles of chemotherapy. His histology shows well-differentiated cells. Despite his age, he has a fully active performance status. The KRAS biomarker indicates that he has a wild-type gene."
941,white,female,60,32.44,FOLFOX,No,No,No,No,3,well differentiated,fully active,mutant,No,No,No,No,No,1,"race: white, sex: female, age: 60, bmi: 32.44, treatment arm: FOLFOX, chemotherapy cycles: 3, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant",The patient is a 60-year-old white female with a BMI of 32.44. She is receiving the FOLFOX treatment arm and has completed 3 cycles of chemotherapy. The histology shows well-differentiated cancer cells. The patient has a fully active performance status. The KRAS biomarker indicates a mutant status.
942,white,male,58,22.44,FOLFOX + Cetuximab,No,Yes,No,No,12,poorly differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 58, bmi: 22.44, treatment arm: FOLFOX + Cetuximab, serious adverse effect: Yes, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 58-year-old white male with a BMI of 22.44. He is receiving treatment with FOLFOX + Cetuximab and has experienced a serious adverse effect. He has completed 12 cycles of chemotherapy. The histology of his cancer is poorly differentiated. Despite these challenges, his performance status is fully active. His KRAS biomarker status is wild-type."
943,white,male,42,23.53,FOLFOX + Cetuximab,No,No,No,No,8,poorly differentiated,fully active,mutant,No,No,No,Yes,No,1,"race: white, sex: male, age: 42, bmi: 23.53, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 8, histology: poorly differentiated, performance status: fully active, KRAS biomarker: mutant, adverse effect: infection: Yes","The patient is a 42-year-old white male with a BMI of 23.53. He is receiving treatment with FOLFOX + Cetuximab and has completed 8 cycles of chemotherapy. His histology shows poorly differentiated cancer cells. Despite this, his performance status is fully active. The patient has a mutant KRAS biomarker. He has experienced an infection as an adverse effect during his treatment."
944,white,female,40,30.72,FOLFOX,No,Yes,No,No,11,well differentiated,fully active,interminate,No,No,No,No,No,0,"race: white, sex: female, age: 40, bmi: 30.72, treatment arm: FOLFOX, serious adverse effect: Yes, chemotherapy cycles: 11, histology: well differentiated, performance status: fully active, KRAS biomarker: interminate","The patient is a 40-year-old white female with a BMI of 30.72. She is receiving the FOLFOX treatment arm for her well-differentiated histology. She has experienced a serious adverse effect during her 11 chemotherapy cycles. Despite this, her performance status remains fully active. The KRAS biomarker status is indeterminate for this patient."
945,white,male,71,27.39,FOLFOX,No,No,No,No,12,well differentiated,fully active,mutant,No,No,No,No,No,0,"race: white, sex: male, age: 71, bmi: 27.39, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 71-year-old white male with a BMI of 27.39. He is receiving treatment with the FOLFOX chemotherapy regimen and has completed 12 cycles. His cancer histology is well differentiated. Despite his age, he has a fully active performance status. The KRAS biomarker testing revealed a mutant status."
946,white,female,55,44.89,FOLFOX + Cetuximab,Yes,No,No,No,12,well differentiated,fully active,wild-type,No,No,Yes,No,No,0,"race: white, sex: female, age: 55, bmi: 44.89, treatment arm: FOLFOX + Cetuximab, adherence: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type, adverse effect: diarrhea: Yes",The patient is a 55-year-old white female with a BMI of 44.89. She is receiving treatment with FOLFOX + Cetuximab and has been adherent to the treatment. She has completed 12 chemotherapy cycles. Her histology shows well-differentiated cancer cells. The patient has a fully active performance status. Her KRAS biomarker is wild-type. She is experiencing diarrhea as an adverse effect of the treatment.
947,white,female,59,33.72,FOLFOX,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 59, bmi: 33.72, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 59-year-old white female with a BMI of 33.72. She is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. Her cancer histology is well-differentiated, and she has a fully active performance status. The KRAS biomarker analysis shows that she has a wild-type KRAS status."
948,white,male,63,31.56,FOLFOX + Cetuximab,No,No,No,No,12,poorly differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 63, bmi: 31.56, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 63-year-old white male with a BMI of 31.56. He is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. His cancer histology is poorly differentiated. Despite his cancer diagnosis, he has a fully active performance status. The KRAS biomarker testing revealed that he has a wild-type KRAS status."
949,white,male,72,23.27,FOLFIRI + Cetuximab,No,No,No,No,12,poorly differentiated,symptoms but ambulatory,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 72, bmi: 23.27, treatment arm: FOLFIRI + Cetuximab, chemotherapy cycles: 12, histology: poorly differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type","The patient is a 72-year-old white male with a BMI of 23.27. He is currently undergoing treatment with FOLFIRI + Cetuximab and has completed 12 cycles of chemotherapy. His histology shows poorly differentiated cancer cells. Despite experiencing symptoms, he is still able to be ambulatory. The KRAS biomarker analysis indicates that he has a wild-type KRAS status."
950,white,female,71,25.13,FOLFOX,No,Yes,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 71, bmi: 25.13, treatment arm: FOLFOX, serious adverse effect: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 71-year-old white female with a BMI of 25.13. She is undergoing treatment with the FOLFOX chemotherapy regimen and has experienced a serious adverse effect. She has completed 12 cycles of chemotherapy. The histology shows that the cancer is well-differentiated. Despite undergoing treatment, the patient's performance status is fully active. The KRAS biomarker indicates that it is wild-type."
951,white,male,63,55,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 63, bmi: 55.0, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 63-year-old white male with a BMI of 55.0. He is receiving treatment in the FOLFOX + Cetuximab treatment arm and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer cells. Despite his high BMI, his performance status is fully active, indicating that he is able to carry out daily activities without limitations. Additionally, the KRAS biomarker analysis revealed that he has a wild-type KRAS status."
952,white,male,63,35.49,FOLFOX + Cetuximab,No,Yes,No,No,6,poorly differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 63, bmi: 35.49, treatment arm: FOLFOX + Cetuximab, serious adverse effect: Yes, chemotherapy cycles: 6, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 63-year-old white male with a BMI of 35.49. He is receiving treatment with FOLFOX + Cetuximab and has experienced a serious adverse effect. He has completed 6 cycles of chemotherapy. The histology of his cancer is poorly differentiated. Despite this, his performance status is fully active. His KRAS biomarker status is wild-type."
953,white,male,75,26.99,FOLFOX,No,No,No,No,12,well differentiated,fully active,mutant,No,No,No,No,No,1,"race: white, sex: male, age: 75, bmi: 26.99, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 75-year-old white male with a BMI of 26.99. He is undergoing treatment with the FOLFOX chemotherapy regimen and has completed 12 cycles. His cancer histology is well differentiated, and he has a fully active performance status. The patient's KRAS biomarker status is mutant."
954,white,female,60,28.36,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,fully active,mutant,No,No,Yes,No,No,0,"race: white, sex: female, age: 60, bmi: 28.36, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant, adverse effect: diarrhea: Yes","The patient is a 60-year-old white female with a BMI of 28.36. She is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cancer, and she has a fully active performance status. The KRAS biomarker indicates a mutant status. The patient is experiencing diarrhea as an adverse effect of the treatment."
955,white,female,60,35.03,FOLFOX,No,No,No,No,10,poorly differentiated,fully active,mutant,No,No,No,No,No,0,"race: white, sex: female, age: 60, bmi: 35.03, treatment arm: FOLFOX, chemotherapy cycles: 10, histology: poorly differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 60-year-old white female with a BMI of 35.03. She is receiving the FOLFOX treatment arm and has completed 10 cycles of chemotherapy. Her histology shows poorly differentiated cancer cells. Despite this, her performance status is fully active. Additionally, the KRAS biomarker analysis indicates a mutant status."
956,white,female,38,30.8,FOLFOX,Yes,No,No,Yes,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 38, bmi: 30.8, treatment arm: FOLFOX, adherence: Yes, bowel perforation: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 38-year-old white female with a BMI of 30.8. She is undergoing treatment with the FOLFOX regimen and has been adherent to her treatment. She experienced a bowel perforation and has completed 12 cycles of chemotherapy. The histology of her cancer is well-differentiated. Despite the bowel perforation, her performance status is fully active. Her KRAS biomarker status is wild-type."
957,other,male,75,25.27,FOLFOX,Yes,Yes,No,No,12,well differentiated,fully active,mutant,No,No,No,No,No,0,"race: other, sex: male, age: 75, bmi: 25.27, treatment arm: FOLFOX, adherence: Yes, serious adverse effect: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 75-year-old male of a race categorized as ""other"" with a BMI of 25.27. He is undergoing treatment with the FOLFOX regimen and has been adherent to the treatment. The patient experienced a serious adverse effect during the treatment. He completed 12 cycles of chemotherapy. The histology of his cancer is well-differentiated. Despite his age, the patient has a fully active performance status. The KRAS biomarker analysis revealed a mutant status."
958,white,male,46,33.76,FOLFIRI (KRAS mutant),No,No,No,Yes,12,poorly differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 46, bmi: 33.76, treatment arm: FOLFIRI (KRAS mutant), bowel perforation: Yes, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 46-year-old white male with a BMI of 33.76. He is receiving the FOLFIRI treatment arm for his KRAS mutant status. He has experienced a bowel perforation and has completed 12 cycles of chemotherapy. The histology shows poorly differentiated cells. Despite these challenges, his performance status is fully active. It is worth noting that his KRAS biomarker is wild-type."
959,white,female,67,31.61,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,fully active,wild-type,No,Yes,No,No,No,0,"race: white, sex: female, age: 67, bmi: 31.61, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type, adverse effect: hypersensitivity: Yes","The patient is a 67-year-old white female with a BMI of 31.61. She is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. Her cancer histology is well-differentiated, and she has a fully active performance status. The KRAS biomarker testing showed that she has a wild-type KRAS status. The patient experienced a hypersensitivity reaction as an adverse effect during treatment."
960,white,male,73,23.57,FOLFIRI (KRAS mutant),No,No,No,No,0,poorly differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 73, bmi: 23.57, treatment arm: FOLFIRI (KRAS mutant), chemotherapy cycles: 0, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 73-year-old white male with a BMI of 23.57. He is enrolled in the FOLFIRI treatment arm for his KRAS mutant status. He has not undergone any chemotherapy cycles yet. His histology shows poorly differentiated cancer cells. Despite this, his performance status is fully active. It is important to note that his KRAS biomarker is wild-type."
961,white,male,58,24.31,FOLFOX,No,No,Yes,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 58, bmi: 24.31, treatment arm: FOLFOX, bowel obstruction: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type",The patient is a 58-year-old white male with a BMI of 24.31. He is receiving the FOLFOX treatment regimen and has experienced a bowel obstruction. He has completed 12 cycles of chemotherapy. The histology shows well-differentiated cancer cells. The patient has a fully active performance status. The KRAS biomarker indicates that he has a wild-type mutation.
962,white,female,69,40.2,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,fully active,wild-type,Yes,No,No,No,No,0,"race: white, sex: female, age: 69, bmi: 40.2, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type, adverse effect: thrombosis: Yes","The patient is a 69-year-old white female with a BMI of 40.2. She is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. Her cancer histology is well-differentiated, and she has a fully active performance status. The KRAS biomarker testing showed that she has a wild-type KRAS status. She has experienced an adverse effect of thrombosis."
963,black,male,46,23.36,FOLFOX + Cetuximab,No,Yes,No,No,12,poorly differentiated,symptoms but ambulatory,wild-type,No,No,No,No,No,0,"race: black, sex: male, age: 46, bmi: 23.36, treatment arm: FOLFOX + Cetuximab, serious adverse effect: Yes, chemotherapy cycles: 12, histology: poorly differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type","The patient is a 46-year-old Black male with a BMI of 23.36. He is receiving treatment with FOLFOX + Cetuximab and has experienced a serious adverse effect. He has undergone 12 cycles of chemotherapy. The histology of his condition is poorly differentiated. Despite experiencing symptoms, he is still able to be ambulatory. His KRAS biomarker status is wild-type."
964,white,male,51,48.85,FOLFOX,Yes,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 51, bmi: 48.85, treatment arm: FOLFOX, adherence: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type",The patient is a 51-year-old white male with a BMI of 48.85. He is receiving the FOLFOX treatment regimen and has been adherent to the treatment. He has completed 12 cycles of chemotherapy. The histology shows well-differentiated cancer cells. The patient has a fully active performance status. The KRAS biomarker analysis indicates a wild-type result.
965,white,female,51,29.07,FOLFOX + Cetuximab,No,No,No,No,10,well differentiated,symptoms but ambulatory,wild-type,No,No,No,No,No,1,"race: white, sex: female, age: 51, bmi: 29.07, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 10, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type","The patient is a 51-year-old white female with a BMI of 29.07. She is receiving treatment with FOLFOX + Cetuximab and has completed 10 cycles of chemotherapy. Her cancer histology is well-differentiated. Despite experiencing symptoms, she is still able to be ambulatory. The KRAS biomarker testing revealed that she has a wild-type KRAS status."
966,white,male,41,26.71,FOLFIRI (KRAS mutant),No,No,No,No,12,well differentiated,symptoms but ambulatory,mutant,No,No,No,No,No,1,"race: white, sex: male, age: 41, bmi: 26.71, treatment arm: FOLFIRI (KRAS mutant), chemotherapy cycles: 12, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: mutant","The patient is a 41-year-old white male with a BMI of 26.71. He is receiving treatment with the FOLFIRI regimen for his KRAS mutant status. He has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer cells. Despite experiencing symptoms, he is still able to walk around (ambulatory)."
967,white,female,67,33.61,FOLFOX,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 67, bmi: 33.61, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 67-year-old white female with a BMI of 33.61. She is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. Her cancer histology is well differentiated. Despite her age, she has a fully active performance status. Additionally, her KRAS biomarker status is wild-type."
968,white,male,58,34.23,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,fully active,mutant,No,No,No,No,No,0,"race: white, sex: male, age: 58, bmi: 34.23, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 58-year-old white male with a BMI of 34.23. He is receiving treatment in the FOLFOX + Cetuximab treatment arm and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer cells. Despite his cancer diagnosis, he has a fully active performance status. The KRAS biomarker analysis indicates that he has a mutant KRAS status."
969,white,male,51,37.06,FOLFOX,No,No,No,No,12,well differentiated,fully active,mutant,No,No,No,No,No,1,"race: white, sex: male, age: 51, bmi: 37.06, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 51-year-old white male with a BMI of 37.06. He is receiving the FOLFOX treatment arm and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer cells. Despite his cancer diagnosis, he has a fully active performance status. The KRAS biomarker analysis revealed a mutant status."
970,white,male,40,33.1,FOLFOX,Yes,No,Yes,Yes,6,poorly differentiated,fully active,wild-type,No,No,Yes,No,No,0,"race: white, sex: male, age: 40, bmi: 33.1, treatment arm: FOLFOX, adherence: Yes, bowel obstruction: Yes, bowel perforation: Yes, chemotherapy cycles: 6, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type, adverse effect: diarrhea: Yes","The patient is a 40-year-old white male with a BMI of 33.1 who is undergoing treatment with FOLFOX chemotherapy. He has been adherent to his treatment regimen and has completed 6 cycles of chemotherapy. The patient has a history of bowel obstruction and perforation. His cancer histology is poorly differentiated, and he has a fully active performance status. The KRAS biomarker testing showed that he has a wild-type KRAS status. The patient is experiencing diarrhea as an adverse effect of the treatment."
971,white,male,63,21.24,FOLFOX,Yes,Yes,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 63, bmi: 21.24, treatment arm: FOLFOX, adherence: Yes, serious adverse effect: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type",The patient is a 63-year-old white male with a BMI of 21.24. He is receiving the FOLFOX treatment regimen and has been adherent to the treatment. He experienced a serious adverse effect during the treatment. The patient has completed 12 cycles of chemotherapy. His histology shows well-differentiated cells. He has a fully active performance status. The KRAS biomarker analysis indicates that he has a wild-type KRAS status.
972,white,female,67,18.76,FOLFOX,No,No,No,No,12,poorly differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 67, bmi: 18.76, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 67-year-old white female with a BMI of 18.76. She is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. Her histology shows poorly differentiated cancer cells. Despite this, her performance status is fully active. Additionally, her KRAS biomarker status is wild-type."
973,white,male,71,29.24,FOLFOX,No,No,Yes,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 71, bmi: 29.24, treatment arm: FOLFOX, bowel obstruction: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 71-year-old white male with a BMI of 29.24. He is receiving treatment with FOLFOX chemotherapy regimen and has experienced a bowel obstruction. He has completed 12 cycles of chemotherapy. The histology of his cancer is well-differentiated. Despite his condition, his performance status is fully active. The KRAS biomarker analysis shows that he has a wild-type KRAS status."
974,black,female,55,40.72,FOLFOX,Yes,No,No,No,12,poorly differentiated,symptoms but ambulatory,mutant,No,No,No,No,No,0,"race: black, sex: female, age: 55, bmi: 40.72, treatment arm: FOLFOX, adherence: Yes, chemotherapy cycles: 12, histology: poorly differentiated, performance status: symptoms but ambulatory, KRAS biomarker: mutant","The patient is a 55-year-old Black female with a BMI of 40.72. She is receiving the FOLFOX treatment regimen and has been adherent to her chemotherapy cycles, completing 12 cycles so far. Her histology shows poorly differentiated cancer cells. Despite experiencing symptoms, she is still able to be ambulatory. The KRAS biomarker testing revealed a mutant status."
975,white,male,69,26.85,FOLFOX,No,No,No,No,2,well differentiated,symptoms but ambulatory,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 69, bmi: 26.85, treatment arm: FOLFOX, chemotherapy cycles: 2, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type","The patient is a 69-year-old white male with a BMI of 26.85. He is currently receiving the FOLFOX treatment regimen and has completed 2 cycles of chemotherapy. His histology shows well-differentiated cancer cells. Despite experiencing symptoms, he is still able to ambulate. The KRAS biomarker analysis indicates that he has a wild-type KRAS status."
976,white,male,42,23.9,FOLFOX,No,No,No,No,12,well differentiated,fully active,mutant,No,No,No,No,No,1,"race: white, sex: male, age: 42, bmi: 23.9, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant",The patient is a 42-year-old white male with a BMI of 23.9. He is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. His cancer histology is well differentiated. The patient has a fully active performance status. The KRAS biomarker testing revealed a mutant status.
977,white,female,44,24.44,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 44, bmi: 24.44, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 44-year-old white female with a BMI of 24.44. She is receiving treatment in the FOLFOX + Cetuximab treatment arm and is scheduled for 12 chemotherapy cycles. Her histology shows well-differentiated cells, and she has a fully active performance status. Additionally, her KRAS biomarker indicates that she has the wild-type variant."
978,white,male,34,31.79,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 34, bmi: 31.79, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type",The patient is a 34-year-old white male with a BMI of 31.79. He is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer cells. The patient has a fully active performance status. His KRAS biomarker indicates that it is wild-type.
979,white,female,52,39.04,FOLFOX + Cetuximab,No,Yes,No,No,12,well differentiated,fully active,interminate,No,No,No,No,No,0,"race: white, sex: female, age: 52, bmi: 39.04, treatment arm: FOLFOX + Cetuximab, serious adverse effect: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: interminate","This patient is a 52-year-old white female with a BMI of 39.04. She is receiving treatment in the FOLFOX + Cetuximab treatment arm and has experienced a serious adverse effect. She has completed 12 chemotherapy cycles. The histology of her cancer is well-differentiated. Despite her cancer diagnosis, she has a fully active performance status. Her KRAS biomarker status is indeterminate."
980,white,female,56,24.08,FOLFOX,No,No,No,No,12,well differentiated,fully active,mutant,No,No,No,No,No,0,"race: white, sex: female, age: 56, bmi: 24.08, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant",The patient is a 56-year-old white female with a BMI of 24.08. She is receiving treatment with the FOLFOX chemotherapy regimen and has completed 12 cycles. Her histology shows well-differentiated cancer cells. She has a fully active performance status. The KRAS biomarker testing revealed a mutant status.
981,white,female,60,34.6,FOLFOX,Yes,No,No,No,12,poorly differentiated,fully active,wild-type,No,No,No,No,No,1,"race: white, sex: female, age: 60, bmi: 34.6, treatment arm: FOLFOX, adherence: Yes, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 60-year-old white female with a BMI of 34.6. She is receiving the FOLFOX treatment regimen and has been adherent to her chemotherapy cycles, completing a total of 12 cycles. Her histology shows poorly differentiated cancer cells. Despite this, her performance status is fully active. Additionally, her KRAS biomarker indicates that she has a wild-type status."
982,other,female,44,19.46,FOLFOX,No,No,No,No,12,poorly differentiated,fully active,mutant,No,No,No,No,No,0,"race: other, sex: female, age: 44, bmi: 19.46, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 44-year-old female of a race categorized as ""other"" with a BMI of 19.46. She is undergoing treatment with the FOLFOX chemotherapy regimen and has completed 12 cycles. The histology of her cancer is poorly differentiated. Despite this, her performance status is fully active. Additionally, the KRAS biomarker analysis has revealed a mutant status."
983,white,male,68,23.86,FOLFOX,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 68, bmi: 23.86, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 68-year-old white male with a BMI of 23.86. He is undergoing treatment with the FOLFOX chemotherapy regimen and has completed 12 cycles. His cancer histology is well differentiated, and he has a fully active performance status. The KRAS biomarker analysis shows that he has a wild-type KRAS status."
984,white,male,60,33.65,FOLFOX,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 60, bmi: 33.65, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type",The patient is a 60-year-old white male with a BMI of 33.65. He is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. His cancer histology is well differentiated. The patient has a fully active performance status and his KRAS biomarker is wild-type.
985,white,male,56,24.82,FOLFOX,No,No,No,No,12,well differentiated,fully active,interminate,No,No,No,No,No,0,"race: white, sex: male, age: 56, bmi: 24.82, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: interminate",The patient is a 56-year-old white male with a BMI of 24.82. He is receiving treatment in the FOLFOX chemotherapy arm and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer cells. The patient has a fully active performance status. The KRAS biomarker status is indeterminate.
986,white,female,71,34.24,FOLFOX + Cetuximab,No,No,No,No,0,poorly differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 71, bmi: 34.24, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 0, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 71-year-old white female with a BMI of 34.24. She is enrolled in the FOLFOX + Cetuximab treatment arm but has not started chemotherapy cycles yet. Her cancer histology is poorly differentiated. Despite this, her performance status is fully active. Additionally, her KRAS biomarker status is wild-type."
987,other,female,44,22.31,FOLFOX,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: other, sex: female, age: 44, bmi: 22.31, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 44-year-old female of a race categorized as ""other"" with a BMI of 22.31. She is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. The histology of her condition is well-differentiated, and she has a fully active performance status. Additionally, the KRAS biomarker analysis indicates that she has a wild-type KRAS status."
988,white,male,40,36.11,FOLFOX,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 40, bmi: 36.11, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 40-year-old white male with a BMI of 36.11. He is undergoing treatment with the FOLFOX chemotherapy regimen and is expected to complete 12 cycles. His cancer histology is well-differentiated, and he has a fully active performance status. Additionally, his KRAS biomarker status is wild-type."
989,other,male,49,22.03,FOLFOX,No,Yes,Yes,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: other, sex: male, age: 49, bmi: 22.03, treatment arm: FOLFOX, serious adverse effect: Yes, bowel obstruction: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 49-year-old male of a race categorized as ""other"" with a BMI of 22.03. He is undergoing treatment with the FOLFOX regimen and has experienced a serious adverse effect, specifically a bowel obstruction. He has completed 12 cycles of chemotherapy. The histology of his condition is well-differentiated, and his performance status is fully active. Additionally, his KRAS biomarker status is wild-type."
990,white,female,55,29.76,FOLFOX,No,No,No,No,10,poorly differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 55, bmi: 29.76, treatment arm: FOLFOX, chemotherapy cycles: 10, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 55-year-old white female with a BMI of 29.76. She is receiving the FOLFOX treatment regimen and has completed 10 cycles of chemotherapy. The histology of her cancer is poorly differentiated. Despite her diagnosis, she has a fully active performance status. Additionally, her KRAS biomarker status is wild-type."
991,other,female,52,20.82,FOLFOX + Cetuximab,No,Yes,No,No,12,well differentiated,symptoms but ambulatory,mutant,No,Yes,No,No,No,0,"race: other, sex: female, age: 52, bmi: 20.82, treatment arm: FOLFOX + Cetuximab, serious adverse effect: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: mutant, adverse effect: hypersensitivity: Yes","The patient is a 52-year-old female of a race other than specified, with a BMI of 20.82. She is receiving treatment with FOLFOX + Cetuximab and has experienced a serious adverse effect. She has undergone 12 cycles of chemotherapy. Histologically, her cancer is well-differentiated. Despite experiencing symptoms, she is still ambulatory. The KRAS biomarker testing revealed a mutant status. Additionally, she has also experienced a hypersensitivity adverse effect."
992,white,female,46,22.77,FOLFOX + Cetuximab,Yes,No,Yes,No,12,well differentiated,symptoms but ambulatory,mutant,No,No,Yes,No,No,0,"race: white, sex: female, age: 46, bmi: 22.77, treatment arm: FOLFOX + Cetuximab, adherence: Yes, bowel obstruction: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: mutant, adverse effect: diarrhea: Yes","The patient is a 46-year-old white female with a BMI of 22.77. She is receiving treatment in the FOLFOX + Cetuximab treatment arm and has been adherent to her treatment. She has experienced a bowel obstruction and has completed 12 cycles of chemotherapy. The histology shows that the cancer is well-differentiated. Despite experiencing symptoms, she is still ambulatory. The KRAS biomarker indicates that it is mutant. She has also experienced diarrhea as an adverse effect of the treatment."
993,white,female,57,22.55,FOLFOX + Cetuximab,No,No,No,No,12,poorly differentiated,fully active,interminate,No,No,No,No,No,0,"race: white, sex: female, age: 57, bmi: 22.55, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: interminate","The patient is a 57-year-old white female with a BMI of 22.55. She is receiving treatment in the FOLFOX + Cetuximab treatment arm and has completed 12 cycles of chemotherapy. Her histology shows poorly differentiated cancer cells. Despite this, her performance status is fully active. The KRAS biomarker status is indeterminate for this patient."
994,white,male,71,26.57,FOLFOX,No,No,No,No,12,well differentiated,symptoms but ambulatory,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 71, bmi: 26.57, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type","The patient is a 71-year-old white male with a BMI of 26.57. He is receiving treatment with the FOLFOX regimen and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer cells. Despite experiencing symptoms, he is still able to be ambulatory. The KRAS biomarker analysis indicates that he has a wild-type KRAS status."
995,white,male,44,30.67,FOLFOX + Cetuximab,No,No,No,No,12,poorly differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 44, bmi: 30.67, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 44-year-old white male with a BMI of 30.67. He is receiving treatment in the FOLFOX + Cetuximab treatment arm and is scheduled for 12 chemotherapy cycles. His histology shows poorly differentiated cancer cells. Despite this, his performance status is fully active. Additionally, the KRAS biomarker indicates that he has a wild-type status."
996,white,female,54,24.02,FOLFIRI (KRAS mutant),No,No,No,No,10,well differentiated,symptoms but ambulatory,mutant,No,No,No,No,No,0,"race: white, sex: female, age: 54, bmi: 24.02, treatment arm: FOLFIRI (KRAS mutant), chemotherapy cycles: 10, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: mutant","The patient is a 54-year-old white female with a BMI of 24.02. She is receiving treatment with the FOLFIRI regimen for her KRAS mutant status. She has completed 10 cycles of chemotherapy. Her histology shows well-differentiated cells. Despite experiencing symptoms, she is still able to be ambulatory."
997,white,female,64,50.44,FOLFOX + Cetuximab,No,No,No,No,12,poorly differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 64, bmi: 50.44, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 64-year-old white female with a BMI of 50.44. She is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. Her histology shows poorly differentiated cancer cells. Despite this, her performance status is fully active. Additionally, her KRAS biomarker indicates that it is wild-type."
998,white,female,61,26.06,FOLFOX,No,No,No,No,12,poorly differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 61, bmi: 26.06, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 61-year-old white female with a BMI of 26.06. She is receiving treatment with the FOLFOX chemotherapy regimen and has completed 12 cycles. The histology of her cancer is poorly differentiated. Despite this, her performance status is fully active. Additionally, her KRAS biomarker status is wild-type."
999,white,male,49,31.44,FOLFOX,No,No,No,No,12,well differentiated,symptoms but ambulatory,interminate,No,No,No,No,No,1,"race: white, sex: male, age: 49, bmi: 31.44, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: interminate","The patient is a 49-year-old white male with a BMI of 31.44. He is receiving treatment with the FOLFOX chemotherapy regimen and has completed 12 cycles. His cancer histology is well-differentiated. Despite experiencing symptoms, he is still able to walk around (ambulatory). The KRAS biomarker status is indeterminate for this patient."
1000,white,male,40,22.9,FOLFOX,No,No,Yes,No,12,poorly differentiated,fully active,mutant,No,No,No,No,No,0,"race: white, sex: male, age: 40, bmi: 22.9, treatment arm: FOLFOX, bowel obstruction: Yes, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 40-year-old white male with a BMI of 22.9. He is receiving treatment with the FOLFOX regimen and has experienced a bowel obstruction. He has completed 12 cycles of chemotherapy. The histology of his cancer is poorly differentiated. Despite these challenges, his performance status is fully active. Additionally, the KRAS biomarker testing revealed a mutant status."
1001,white,female,76,22.58,FOLFIRI + Cetuximab,No,No,No,No,3,well differentiated,symptoms but ambulatory,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 76, bmi: 22.58, treatment arm: FOLFIRI + Cetuximab, chemotherapy cycles: 3, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type","The patient is a 76-year-old white female with a BMI of 22.58. She is currently receiving treatment with FOLFIRI + Cetuximab and has completed 3 cycles of chemotherapy. Her histology shows well-differentiated cancer cells. Despite experiencing symptoms, she is still able to be ambulatory. The KRAS biomarker testing revealed that she has a wild-type KRAS status."
1002,white,female,68,27.85,FOLFOX,No,No,No,No,8,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 68, bmi: 27.85, treatment arm: FOLFOX, chemotherapy cycles: 8, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 68-year-old white female with a BMI of 27.85. She is receiving the FOLFOX treatment regimen and has completed 8 cycles of chemotherapy. Her cancer histology is well differentiated. Despite her age, she has a fully active performance status. Additionally, her KRAS biomarker status is wild-type."
1003,white,male,74,30.01,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,Yes,No,No,0,"race: white, sex: male, age: 74, bmi: 30.01, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type, adverse effect: diarrhea: Yes","The patient is a 74-year-old white male with a BMI of 30.01. He is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer, and he has a fully active performance status. The KRAS biomarker indicates that he is wild-type. The patient is experiencing diarrhea as an adverse effect of the treatment."
1004,white,male,58,24.13,FOLFIRI + Cetuximab,Yes,No,No,No,12,poorly differentiated,fully active,wild-type,No,No,Yes,No,No,0,"race: white, sex: male, age: 58, bmi: 24.13, treatment arm: FOLFIRI + Cetuximab, adherence: Yes, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type, adverse effect: diarrhea: Yes","The patient is a 58-year-old white male with a BMI of 24.13. He is receiving treatment with FOLFIRI + Cetuximab and has been adherent to the treatment for 12 chemotherapy cycles. His histology shows poorly differentiated cancer cells. Despite experiencing diarrhea as an adverse effect, his performance status is fully active. Additionally, his KRAS biomarker status is wild-type."
1005,white,male,39,37.09,FOLFIRI,Yes,No,No,No,9,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 39, bmi: 37.09, treatment arm: FOLFIRI, adherence: Yes, chemotherapy cycles: 9, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type",The patient is a 39-year-old white male with a BMI of 37.09. He is receiving treatment with the FOLFIRI regimen and has been adherent to the treatment. He has completed 9 cycles of chemotherapy. The histology shows well-differentiated cancer cells. The patient has a fully active performance status. The KRAS biomarker analysis indicates a wild-type status.
1006,white,male,58,19.41,FOLFIRI + Cetuximab,Yes,No,No,No,9,well differentiated,fully active,mutant,No,Yes,No,No,No,0,"race: white, sex: male, age: 58, bmi: 19.41, treatment arm: FOLFIRI + Cetuximab, adherence: Yes, chemotherapy cycles: 9, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant, adverse effect: hypersensitivity: Yes",The patient is a 58-year-old white male with a BMI of 19.41. He is receiving treatment with FOLFIRI + Cetuximab and has been adherent to the treatment. He has completed 9 cycles of chemotherapy. The histology shows well-differentiated cancer. The patient has a fully active performance status. His KRAS biomarker is mutant. He has experienced hypersensitivity as an adverse effect.
1007,white,male,45,22.59,FOLFOX,No,No,Yes,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 45, bmi: 22.59, treatment arm: FOLFOX, bowel obstruction: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 45-year-old white male with a BMI of 22.59. He is receiving treatment with the FOLFOX regimen for his bowel obstruction. He has completed 12 cycles of chemotherapy. The histology of his cancer is well differentiated. Despite his condition, he has a fully active performance status. The KRAS biomarker testing revealed that he has a wild-type KRAS gene."
1008,white,female,67,29.26,FOLFOX,No,No,No,No,12,well differentiated,fully active,wild-type,Yes,No,No,No,No,0,"race: white, sex: female, age: 67, bmi: 29.26, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type, adverse effect: thrombosis: Yes",The patient is a 67-year-old white female with a BMI of 29.26. She is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. The histology of her cancer is well-differentiated. She has a fully active performance status. The KRAS biomarker testing showed that she has a wild-type KRAS status. The patient has experienced an adverse effect of thrombosis.
1009,white,female,57,21.22,FOLFOX + Cetuximab,Yes,Yes,No,No,12,well differentiated,symptoms but ambulatory,mutant,No,No,No,No,No,0,"race: white, sex: female, age: 57, bmi: 21.22, treatment arm: FOLFOX + Cetuximab, adherence: Yes, serious adverse effect: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: mutant","The patient is a 57-year-old white female with a BMI of 21.22. She is receiving treatment in the FOLFOX + Cetuximab treatment arm and has been adherent to her treatment. She experienced a serious adverse effect during the treatment. The patient completed 12 cycles of chemotherapy and has well-differentiated histology. Despite experiencing symptoms, she is still ambulatory. The KRAS biomarker analysis showed a mutant result."
1010,white,female,55,20.88,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 55, bmi: 20.88, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type",The patient is a 55-year-old white female with a BMI of 20.88. She is undergoing treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cancer cells. The patient has a fully active performance status and her KRAS biomarker is wild-type.
1011,white,male,44,24.86,FOLFOX,No,No,No,No,9,well differentiated,symptoms but ambulatory,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 44, bmi: 24.86, treatment arm: FOLFOX, chemotherapy cycles: 9, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type","The patient is a 44-year-old white male with a BMI of 24.86. He is receiving the FOLFOX treatment regimen and has completed 9 cycles of chemotherapy. His histology shows well-differentiated cancer cells. Despite experiencing symptoms, he is still able to be ambulatory. The KRAS biomarker analysis indicates that he has a wild-type KRAS status."
1012,other,male,45,35.09,FOLFOX + Cetuximab,No,Yes,No,No,12,well differentiated,fully active,wild-type,No,Yes,No,No,No,0,"race: other, sex: male, age: 45, bmi: 35.09, treatment arm: FOLFOX + Cetuximab, serious adverse effect: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type, adverse effect: hypersensitivity: Yes","The patient is a 45-year-old male of a race categorized as ""other"" with a BMI of 35.09. He is undergoing treatment with FOLFOX + Cetuximab and has experienced a serious adverse effect. He has completed 12 cycles of chemotherapy. His histology shows well-differentiated cells, and his performance status is fully active. The KRAS biomarker indicates that he has a wild-type mutation. Additionally, he has experienced a hypersensitivity adverse effect."
1013,white,female,57,29.93,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,symptoms but ambulatory,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 57, bmi: 29.93, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type","The patient is a 57-year-old white female with a BMI of 29.93. She is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. Her cancer histology is well-differentiated. Despite experiencing symptoms, she is still able to walk around (ambulatory). The KRAS biomarker analysis shows that she has a wild-type KRAS status."
1014,white,female,63,26.18,FOLFOX,Yes,Yes,Yes,No,12,well differentiated,symptoms but ambulatory,mutant,No,No,No,No,No,0,"race: white, sex: female, age: 63, bmi: 26.18, treatment arm: FOLFOX, adherence: Yes, serious adverse effect: Yes, bowel obstruction: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: mutant","The patient is a 63-year-old white female with a BMI of 26.18. She is receiving the FOLFOX treatment regimen and has been adherent to her chemotherapy. Unfortunately, she has experienced a serious adverse effect in the form of a bowel obstruction. She has completed 12 cycles of chemotherapy and her histology shows well-differentiated cells. Despite experiencing symptoms, she is still able to be ambulatory. Additionally, her KRAS biomarker indicates a mutant status."
1015,white,male,46,33.96,FOLFOX,No,No,No,No,12,poorly differentiated,symptoms but ambulatory,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 46, bmi: 33.96, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: poorly differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type","The patient is a 46-year-old white male with a BMI of 33.96. He is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. His histology shows poorly differentiated cells. Despite experiencing symptoms, he is still able to walk around (ambulatory). The KRAS biomarker analysis indicates that he has a wild-type KRAS status."
1016,white,male,42,23.8,FOLFOX,No,No,Yes,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 42, bmi: 23.8, treatment arm: FOLFOX, bowel obstruction: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 42-year-old white male with a BMI of 23.8. He is receiving the FOLFOX treatment regimen and has experienced a bowel obstruction. He has completed 12 cycles of chemotherapy. The histology shows well-differentiated cancer cells. Despite the bowel obstruction, his performance status is fully active. The KRAS biomarker indicates that he has a wild-type mutation."
1017,white,female,44,39.12,FOLFOX + Cetuximab,No,Yes,No,No,8,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 44, bmi: 39.12, treatment arm: FOLFOX + Cetuximab, serious adverse effect: Yes, chemotherapy cycles: 8, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 44-year-old white female with a BMI of 39.12. She is receiving treatment with FOLFOX + Cetuximab and has experienced a serious adverse effect. She has completed 8 cycles of chemotherapy. Her histology shows well-differentiated cells. Despite the adverse effect, her performance status is fully active. Her KRAS biomarker is wild-type."
1018,white,female,46,41.32,FOLFIRI + Cetuximab,No,No,Yes,No,12,well differentiated,symptoms but ambulatory,mutant,No,No,No,No,No,0,"race: white, sex: female, age: 46, bmi: 41.32, treatment arm: FOLFIRI + Cetuximab, bowel obstruction: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: mutant","The patient is a 46-year-old white female with a BMI of 41.32. She is receiving treatment with FOLFIRI + Cetuximab for her well-differentiated histology. She has experienced a bowel obstruction and has completed 12 cycles of chemotherapy. Despite experiencing symptoms, she is still able to be ambulatory. Additionally, her KRAS biomarker status is mutant."
1019,white,female,35,21.65,FOLFIRI,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,Yes,No,No,1,"race: white, sex: female, age: 35, bmi: 21.65, treatment arm: FOLFIRI, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type, adverse effect: diarrhea: Yes","The patient is a 35-year-old white female with a BMI of 21.65. She is receiving the FOLFIRI treatment regimen and has completed 12 cycles of chemotherapy. Her cancer histology is well-differentiated, and she has a fully active performance status. The KRAS biomarker testing showed a wild-type result. The patient is experiencing diarrhea as an adverse effect of the treatment."
1020,white,female,64,25.79,FOLFOX + Cetuximab,No,No,No,No,1,well differentiated,fully active,mutant,No,No,No,No,No,0,"race: white, sex: female, age: 64, bmi: 25.79, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 1, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant",The patient is a 64-year-old white female with a BMI of 25.79. She is receiving treatment in the FOLFOX + Cetuximab treatment arm and has completed one cycle of chemotherapy. The histology shows well-differentiated cancer cells. The patient has a fully active performance status. The KRAS biomarker indicates a mutant status.
1021,white,male,38,27.93,FOLFOX + Cetuximab,Yes,No,No,No,12,well differentiated,fully active,wild-type,No,No,Yes,No,No,0,"race: white, sex: male, age: 38, bmi: 27.93, treatment arm: FOLFOX + Cetuximab, adherence: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type, adverse effect: diarrhea: Yes","The patient is a 38-year-old white male with a BMI of 27.93 who is receiving treatment with FOLFOX + Cetuximab. He has been adherent to his treatment and has completed 12 chemotherapy cycles. His histology shows well-differentiated cells, and he has a fully active performance status. The KRAS biomarker testing indicates that he has a wild-type KRAS gene. The patient has experienced diarrhea as an adverse effect of the treatment."
1022,other,female,40,20.02,FOLFOX + Cetuximab,No,No,Yes,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: other, sex: female, age: 40, bmi: 20.02, treatment arm: FOLFOX + Cetuximab, bowel obstruction: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 40-year-old female of a race categorized as ""other"" with a BMI of 20.02. She is undergoing treatment with FOLFOX + Cetuximab and has experienced a bowel obstruction. She is scheduled for 12 cycles of chemotherapy. The histology indicates that the cancer is well-differentiated. Despite the bowel obstruction, her performance status is fully active. The KRAS biomarker shows that she has a wild-type status."
1023,white,female,55,33.07,FOLFOX + Cetuximab,Yes,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 55, bmi: 33.07, treatment arm: FOLFOX + Cetuximab, adherence: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type",The patient is a 55-year-old white female with a BMI of 33.07. She is receiving treatment with FOLFOX + Cetuximab and has been adherent to the treatment. She has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cancer cells. The patient has a fully active performance status. Her KRAS biomarker is wild-type.
1024,white,female,54,33.87,FOLFOX,No,No,No,No,12,poorly differentiated,fully active,mutant,Yes,No,No,No,No,0,"race: white, sex: female, age: 54, bmi: 33.87, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: mutant, adverse effect: thrombosis: Yes","The patient is a 54-year-old white female with a BMI of 33.87. She is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. Her histology shows poorly differentiated cancer cells. Despite this, her performance status is fully active. The KRAS biomarker testing revealed a mutant status. The patient has experienced an adverse effect of thrombosis."
1025,white,female,59,25.07,FOLFOX,No,No,No,No,12,poorly differentiated,fully active,mutant,No,No,Yes,No,No,0,"race: white, sex: female, age: 59, bmi: 25.07, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: mutant, adverse effect: diarrhea: Yes","The patient is a 59-year-old white female with a BMI of 25.07 who is undergoing treatment with the FOLFOX chemotherapy regimen. She has completed 12 cycles of chemotherapy. The histology of her cancer is poorly differentiated. Despite this, her performance status is fully active. The KRAS biomarker testing revealed a mutant status. The patient is experiencing diarrhea as an adverse effect of the treatment."
1026,black,male,67,42.79,FOLFOX,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: black, sex: male, age: 67, bmi: 42.79, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 67-year-old Black male with a BMI of 42.79. He is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer cells. Despite his age and BMI, his performance status is fully active, indicating he is able to carry out daily activities without limitations. The KRAS biomarker analysis revealed that he has a wild-type KRAS gene."
1027,white,male,38,24.43,FOLFOX + Cetuximab,Yes,No,No,No,12,well differentiated,fully active,wild-type,No,No,Yes,No,No,0,"race: white, sex: male, age: 38, bmi: 24.43, treatment arm: FOLFOX + Cetuximab, adherence: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type, adverse effect: diarrhea: Yes",The patient is a 38-year-old white male with a BMI of 24.43. He is receiving treatment in the FOLFOX + Cetuximab treatment arm and has been adherent to the treatment. He has completed 12 chemotherapy cycles. The histology of his cancer is well-differentiated. His performance status is fully active. The KRAS biomarker testing showed that he has a wild-type KRAS status. He has experienced diarrhea as an adverse effect of the treatment.
1028,white,male,72,27.58,FOLFOX,No,No,Yes,No,12,well differentiated,symptoms but ambulatory,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 72, bmi: 27.58, treatment arm: FOLFOX, bowel obstruction: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type","The patient is a 72-year-old white male with a BMI of 27.58. He is receiving the FOLFOX treatment regimen for his cancer. He has experienced a bowel obstruction and has undergone 12 cycles of chemotherapy. The histology of his cancer is well-differentiated. Despite experiencing symptoms, he is still able to walk around (ambulatory). His KRAS biomarker status is wild-type."
1029,black,female,47,27.7,FOLFOX,No,No,No,Yes,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: black, sex: female, age: 47, bmi: 27.7, treatment arm: FOLFOX, bowel perforation: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","This patient is a 47-year-old Black female with a BMI of 27.7. She is receiving the FOLFOX treatment regimen and has experienced a bowel perforation. She has completed 12 cycles of chemotherapy. The histology of her cancer is well differentiated. Despite her condition, her performance status is fully active. The KRAS biomarker analysis shows that she has a wild-type KRAS status."
1030,other,female,46,28.71,FOLFOX + Cetuximab,No,No,No,No,12,poorly differentiated,fully active,wild-type,No,No,No,Yes,No,0,"race: other, sex: female, age: 46, bmi: 28.71, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type, adverse effect: infection: Yes","The patient is a 46-year-old female of a race other than specified, with a BMI of 28.71. She is receiving treatment in the FOLFOX + Cetuximab treatment arm and has completed 12 cycles of chemotherapy. The histology of her condition is poorly differentiated. Despite this, her performance status is fully active. The KRAS biomarker indicates that she is wild-type. The patient has experienced an infection as an adverse effect of her treatment."
1031,white,male,70,35.14,FOLFIRI + Cetuximab,Yes,No,Yes,No,2,well differentiated,fully active,wild-type,No,No,No,No,Yes,0,"race: white, sex: male, age: 70, bmi: 35.14, treatment arm: FOLFIRI + Cetuximab, adherence: Yes, bowel obstruction: Yes, chemotherapy cycles: 2, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type, adverse effect: infarction: Yes","The patient is a 70-year-old white male with a BMI of 35.14 who is currently receiving treatment with FOLFIRI + Cetuximab. He is adherent to his treatment regimen and has experienced a bowel obstruction. He has completed 2 cycles of chemotherapy and has well-differentiated histology. Despite the bowel obstruction, his performance status is fully active. His KRAS biomarker is wild-type. Additionally, he has experienced an infarction as an adverse effect."
1032,white,male,50,28.8,FOLFOX + Cetuximab,No,Yes,Yes,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 50, bmi: 28.8, treatment arm: FOLFOX + Cetuximab, serious adverse effect: Yes, bowel obstruction: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 50-year-old white male with a BMI of 28.8 who is receiving treatment with FOLFOX + Cetuximab. He has experienced a serious adverse effect and developed a bowel obstruction. He has completed 12 cycles of chemotherapy. The histology shows that the cancer is well-differentiated. Despite these challenges, the patient has a fully active performance status. The KRAS biomarker indicates that the cancer is wild-type."
1033,white,female,40,29.51,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,symptoms but ambulatory,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 40, bmi: 29.51, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type","The patient is a 40-year-old white female with a BMI of 29.51. She is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cancer. Despite experiencing symptoms, she is still able to be ambulatory. The KRAS biomarker analysis indicates that she has a wild-type KRAS status."
1034,white,male,74,27.25,FOLFOX + Cetuximab,No,No,No,No,9,poorly differentiated,fully active,wild-type,No,No,Yes,No,No,0,"race: white, sex: male, age: 74, bmi: 27.25, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 9, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type, adverse effect: diarrhea: Yes","The patient is a 74-year-old white male with a BMI of 27.25. He is receiving treatment with FOLFOX + Cetuximab and has completed 9 cycles of chemotherapy. His histology shows poorly differentiated cancer cells. Despite this, his performance status is fully active. The KRAS biomarker testing revealed that he has a wild-type KRAS status. The patient is experiencing diarrhea as an adverse effect of the treatment."
1035,white,female,61,25.9,FOLFOX,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 61, bmi: 25.9, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 61-year-old white female with a BMI of 25.9. She is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. Her cancer histology is well-differentiated, and she has a fully active performance status. The KRAS biomarker testing revealed that she has a wild-type KRAS status."
1036,white,female,66,16.75,FOLFOX + Cetuximab,Yes,Yes,Yes,No,1,well differentiated,fully active,wild-type,No,Yes,No,No,No,1,"race: white, sex: female, age: 66, bmi: 16.75, treatment arm: FOLFOX + Cetuximab, adherence: Yes, serious adverse effect: Yes, bowel obstruction: Yes, chemotherapy cycles: 1, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type, adverse effect: hypersensitivity: Yes","The patient is a 66-year-old white female with a BMI of 16.75. She is receiving treatment in the FOLFOX + Cetuximab treatment arm and has been adherent to her treatment. She experienced a serious adverse effect in the form of a bowel obstruction after completing one cycle of chemotherapy. The histology of her cancer is well-differentiated, and her performance status is fully active. Her KRAS biomarker is wild-type. Additionally, she developed a hypersensitivity adverse effect during treatment."
1037,white,male,46,27.55,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,Yes,No,0,"race: white, sex: male, age: 46, bmi: 27.55, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type, adverse effect: infection: Yes","The patient is a 46-year-old white male with a BMI of 27.55. He is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer, and he has a fully active performance status. The KRAS biomarker indicates that he is wild-type. The patient has experienced an infection as an adverse effect during treatment."
1038,white,female,73,18.06,FOLFOX,No,No,Yes,No,11,well differentiated,fully active,mutant,No,No,No,No,No,0,"race: white, sex: female, age: 73, bmi: 18.06, treatment arm: FOLFOX, bowel obstruction: Yes, chemotherapy cycles: 11, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 73-year-old white female with a BMI of 18.06. She is currently receiving treatment in the FOLFOX treatment arm. She has a bowel obstruction and has completed 11 cycles of chemotherapy. The histology shows that the cancer is well-differentiated. Despite the bowel obstruction, her performance status is fully active. The KRAS biomarker analysis indicates that she has a mutant KRAS status."
1039,white,male,72,27.18,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,Yes,No,No,0,"race: white, sex: male, age: 72, bmi: 27.18, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type, adverse effect: diarrhea: Yes","The patient is a 72-year-old white male with a BMI of 27.18. He is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. His cancer histology is well-differentiated, and he has a fully active performance status. The KRAS biomarker testing showed that he has a wild-type KRAS status. The patient is experiencing diarrhea as an adverse effect of the treatment."
1040,white,male,35,23.25,FOLFOX,No,No,No,No,12,poorly differentiated,fully active,wild-type,No,No,No,No,No,1,"race: white, sex: male, age: 35, bmi: 23.25, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 35-year-old white male with a BMI of 23.25. He is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. His histology shows poorly differentiated cancer cells. Despite this, his performance status is fully active. Additionally, his KRAS biomarker status is wild-type."
1041,other,female,52,21.83,FOLFOX,No,No,No,Yes,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: other, sex: female, age: 52, bmi: 21.83, treatment arm: FOLFOX, bowel perforation: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 52-year-old female of a race other than specified, with a BMI of 21.83. She is undergoing treatment with the FOLFOX regimen and has experienced a bowel perforation. She has completed 12 cycles of chemotherapy. The histology of her condition is well-differentiated. Despite the bowel perforation, her performance status is fully active. Additionally, her KRAS biomarker status is wild-type."
1042,white,male,71,25.38,FOLFOX + Cetuximab,Yes,No,No,No,6,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 71, bmi: 25.38, treatment arm: FOLFOX + Cetuximab, adherence: Yes, chemotherapy cycles: 6, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type",The patient is a 71-year-old white male with a BMI of 25.38. He is receiving treatment in the FOLFOX + Cetuximab treatment arm and has been adherent to the treatment. He has completed 6 cycles of chemotherapy. His histology shows well-differentiated cancer cells. The patient has a fully active performance status. His KRAS biomarker is wild-type.
1043,white,female,70,19.61,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,fully active,mutant,No,No,No,No,No,0,"race: white, sex: female, age: 70, bmi: 19.61, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 70-year-old white female with a BMI of 19.61. She is receiving treatment in the FOLFOX + Cetuximab treatment arm and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cells, and she has a fully active performance status. The KRAS biomarker analysis indicates a mutant status."
1044,white,male,68,40.23,FOLFIRI (KRAS mutant),No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,1,"race: white, sex: male, age: 68, bmi: 40.23, treatment arm: FOLFIRI (KRAS mutant), chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 68-year-old white male with a BMI of 40.23. He is receiving the FOLFIRI treatment regimen for his KRAS mutant status. He has completed 12 cycles of chemotherapy. His histology shows well-differentiated cells, and he has a fully active performance status. His KRAS biomarker is wild-type."
1045,white,female,56,23.31,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 56, bmi: 23.31, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 56-year-old white female with a BMI of 23.31. She is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cells, and she has a fully active performance status. The KRAS biomarker indicates that she has a wild-type status."
1046,white,female,43,30.41,FOLFOX,No,No,No,No,12,well differentiated,fully active,wild-type,No,Yes,No,No,No,0,"race: white, sex: female, age: 43, bmi: 30.41, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type, adverse effect: hypersensitivity: Yes","The patient is a 43-year-old white female with a BMI of 30.41. She is receiving the FOLFOX treatment arm and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cells, and her performance status is fully active. The KRAS biomarker indicates that she is wild-type. The patient has experienced a hypersensitivity adverse effect."
1047,white,female,46,38.32,FOLFIRI,No,No,No,No,12,well differentiated,symptoms but ambulatory,interminate,No,No,No,No,No,0,"race: white, sex: female, age: 46, bmi: 38.32, treatment arm: FOLFIRI, chemotherapy cycles: 12, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: interminate","The patient is a 46-year-old white female with a BMI of 38.32. She is receiving the FOLFIRI treatment arm and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cancer cells. Despite experiencing symptoms, she is still able to be ambulatory. The KRAS biomarker status is indeterminate for this patient."
1048,white,male,55,25.53,FOLFOX,No,No,No,No,12,poorly differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 55, bmi: 25.53, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 55-year-old white male with a BMI of 25.53. He is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. His histology shows poorly differentiated cancer cells. Despite this, his performance status is fully active. Additionally, his KRAS biomarker indicates that he has a wild-type gene."
1049,white,male,49,28.78,FOLFOX,No,Yes,No,No,4,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 49, bmi: 28.78, treatment arm: FOLFOX, serious adverse effect: Yes, chemotherapy cycles: 4, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","This patient is a 49-year-old white male with a BMI of 28.78. He is receiving the FOLFOX treatment regimen and has experienced a serious adverse effect. He has completed 4 cycles of chemotherapy. The histology of his cancer is well differentiated. Despite the adverse effect, his performance status is fully active. His KRAS biomarker status is wild-type."
1050,white,male,51,36.38,FOLFOX,No,No,No,No,12,well differentiated,symptoms but ambulatory,mutant,No,No,No,No,No,0,"race: white, sex: male, age: 51, bmi: 36.38, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: mutant","The patient is a 51-year-old white male with a BMI of 36.38. He is undergoing treatment with the FOLFOX chemotherapy regimen and has completed 12 cycles. His histology shows well-differentiated cancer cells. Despite experiencing symptoms, he is still able to walk around (ambulatory). The KRAS biomarker testing revealed a mutation."
1051,white,male,45,38.82,FOLFOX,Yes,No,No,No,12,poorly differentiated,fully active,mutant,No,Yes,No,No,No,0,"race: white, sex: male, age: 45, bmi: 38.82, treatment arm: FOLFOX, adherence: Yes, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: mutant, adverse effect: hypersensitivity: Yes",The patient is a 45-year-old white male with a BMI of 38.82. He is receiving the FOLFOX treatment regimen and has adhered to the treatment. He has completed 12 cycles of chemotherapy. His histology shows poorly differentiated cells. The patient has a fully active performance status. His KRAS biomarker is mutant. He has experienced hypersensitivity as an adverse effect.
1052,white,female,50,19.18,FOLFOX + Cetuximab,No,Yes,No,No,12,poorly differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 50, bmi: 19.18, treatment arm: FOLFOX + Cetuximab, serious adverse effect: Yes, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 50-year-old Caucasian woman with a BMI of 19.18. She is undergoing treatment with FOLFOX and Cetuximab. Unfortunately, she has experienced a serious adverse effect. She has completed 12 cycles of chemotherapy. The histology of her cancer is poorly differentiated. Despite her condition, her performance status is fully active. Her KRAS biomarker is wild-type."
1053,black,male,61,23.22,FOLFIRI (KRAS mutant),No,Yes,No,No,12,well differentiated,fully active,wild-type,No,No,Yes,No,No,0,"race: black, sex: male, age: 61, bmi: 23.22, treatment arm: FOLFIRI (KRAS mutant), serious adverse effect: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type, adverse effect: diarrhea: Yes","The patient is a 61-year-old Black male with a BMI of 23.22. He is receiving the FOLFIRI treatment regimen for his well-differentiated histology with a KRAS mutant status. He has experienced a serious adverse effect during the treatment, specifically diarrhea. Despite this, he has completed 12 cycles of chemotherapy and has a fully active performance status. His KRAS biomarker is wild-type."
1054,white,female,46,26,FOLFOX + Cetuximab,No,Yes,No,No,12,well differentiated,symptoms but ambulatory,wild-type,No,No,Yes,No,No,0,"race: white, sex: female, age: 46, bmi: 26.0, treatment arm: FOLFOX + Cetuximab, serious adverse effect: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type, adverse effect: diarrhea: Yes","The patient is a 46-year-old white female with a BMI of 26.0 who is undergoing treatment with FOLFOX + Cetuximab. She has experienced a serious adverse effect during her 12 chemotherapy cycles. Her histology shows well-differentiated cells, and she has symptoms but is still able to be ambulatory. The KRAS biomarker indicates that she has a wild-type gene. Additionally, she has experienced diarrhea as an adverse effect of her treatment."
1055,white,male,56,27.44,FOLFOX + Cetuximab,No,No,No,No,1,poorly differentiated,fully active,mutant,No,No,No,No,No,0,"race: white, sex: male, age: 56, bmi: 27.44, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 1, histology: poorly differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 56-year-old white male with a BMI of 27.44. He is currently receiving treatment in the FOLFOX + Cetuximab treatment arm and has completed one cycle of chemotherapy. His histology shows poorly differentiated cancer cells. Despite this, his performance status is fully active. Additionally, the KRAS biomarker testing revealed a mutant status."
1056,white,female,55,21.84,FOLFOX,No,No,No,No,12,well differentiated,symptoms but ambulatory,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 55, bmi: 21.84, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type","The patient is a 55-year-old white female with a BMI of 21.84. She is undergoing treatment with the FOLFOX chemotherapy regimen and has completed 12 cycles. The histology of her cancer is well-differentiated. Despite experiencing symptoms, she is still able to ambulate. The KRAS biomarker testing revealed that she has a wild-type KRAS status."
1057,white,female,55,32.18,FOLFOX + Cetuximab,No,No,No,No,2,well differentiated,fully active,mutant,No,No,No,No,No,0,"race: white, sex: female, age: 55, bmi: 32.18, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 2, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 55-year-old white female with a BMI of 32.18. She is currently receiving treatment in the FOLFOX + Cetuximab treatment arm and has completed 2 cycles of chemotherapy. Her histology shows well-differentiated cells, and she has a fully active performance status. Additionally, the KRAS biomarker analysis indicates a mutant status."
1058,white,male,75,35.41,FOLFIRI,No,No,No,No,2,well differentiated,symptoms but ambulatory,wild-type,No,No,No,No,No,1,"race: white, sex: male, age: 75, bmi: 35.41, treatment arm: FOLFIRI, chemotherapy cycles: 2, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type","The patient is a 75-year-old white male with a BMI of 35.41. He is currently undergoing treatment with the FOLFIRI chemotherapy regimen and has completed 2 cycles so far. His cancer histology is well-differentiated. Despite experiencing symptoms, he is still able to be ambulatory. The KRAS biomarker testing revealed that he has a wild-type KRAS status."
1059,white,male,75,30.36,FOLFOX,Yes,No,Yes,No,12,poorly differentiated,fully active,mutant,No,No,No,No,No,0,"race: white, sex: male, age: 75, bmi: 30.36, treatment arm: FOLFOX, adherence: Yes, bowel obstruction: Yes, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 75-year-old white male with a BMI of 30.36 who is receiving the FOLFOX treatment regimen for bowel obstruction. He has completed 12 cycles of chemotherapy and has a histology of poorly differentiated cancer. Despite his condition, he has fully active performance status. The KRAS biomarker testing revealed a mutant status. The patient has been adherent to the prescribed treatment plan."
1060,white,male,74,27.62,FOLFOX,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 74, bmi: 27.62, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 74-year-old white male with a BMI of 27.62. He is receiving treatment with the FOLFOX chemotherapy regimen and has completed 12 cycles. His cancer histology is well-differentiated, and he has a fully active performance status. The KRAS biomarker testing indicates that he has a wild-type KRAS status."
1061,white,male,75,23.06,FOLFOX,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,Yes,No,Yes,0,"race: white, sex: male, age: 75, bmi: 23.06, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type, adverse effect: diarrhea: Yes, adverse effect: infarction: Yes","The patient is a 75-year-old white male with a BMI of 23.06. He is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cells, and he has a fully active performance status. The KRAS biomarker is wild-type. The patient has experienced adverse effects of diarrhea and infarction."
1062,other,female,66,26.91,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: other, sex: female, age: 66, bmi: 26.91, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 66-year-old female of a race categorized as ""other"" with a BMI of 26.91. She is receiving treatment in the FOLFOX + Cetuximab treatment arm and is scheduled for 12 chemotherapy cycles. The histology of her condition is well-differentiated, and her performance status is fully active. Additionally, the KRAS biomarker indicates that she has a wild-type status."
1063,white,male,35,27.44,FOLFOX + Cetuximab,No,No,No,No,2,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 35, bmi: 27.44, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 2, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type",The patient is a 35-year-old white male with a BMI of 27.44. He is currently receiving treatment with FOLFOX + Cetuximab and has completed 2 cycles of chemotherapy. His cancer histology is well differentiated. The patient has a fully active performance status and his KRAS biomarker is wild-type.
1064,white,male,67,44.49,FOLFOX,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 67, bmi: 44.49, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type",The patient is a 67-year-old white male with a BMI of 44.49. He is receiving the FOLFOX treatment arm and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cells. The patient has a fully active performance status and his KRAS biomarker is wild-type.
1065,white,female,46,22.39,FOLFOX + Cetuximab,No,Yes,Yes,No,12,well differentiated,symptoms but ambulatory,mutant,No,No,No,No,No,1,"race: white, sex: female, age: 46, bmi: 22.39, treatment arm: FOLFOX + Cetuximab, serious adverse effect: Yes, bowel obstruction: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: mutant","The patient is a 46-year-old white female with a BMI of 22.39. She is receiving treatment with FOLFOX + Cetuximab. Unfortunately, she has experienced a serious adverse effect and is currently dealing with a bowel obstruction. She has completed 12 cycles of chemotherapy. The histology shows that the cancer is well-differentiated. Despite experiencing symptoms, she is still able to be ambulatory. The KRAS biomarker indicates that she has a mutant status."
1066,white,male,73,28.29,FOLFOX,No,Yes,No,No,5,well differentiated,symptoms but ambulatory,wild-type,Yes,No,Yes,Yes,No,0,"race: white, sex: male, age: 73, bmi: 28.29, treatment arm: FOLFOX, serious adverse effect: Yes, chemotherapy cycles: 5, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type, adverse effect: thrombosis: Yes, adverse effect: diarrhea: Yes, adverse effect: infection: Yes","The patient is a 73-year-old white male with a BMI of 28.29 who is undergoing treatment with the FOLFOX chemotherapy regimen. He has experienced serious adverse effects during the treatment, including thrombosis, diarrhea, and infection. Despite these challenges, the patient has completed 5 cycles of chemotherapy and has a well-differentiated histology. His performance status is such that he experiences symptoms but is still able to be ambulatory. Additionally, the patient's KRAS biomarker is wild-type."
1067,other,female,75,21.93,FOLFOX,No,No,No,No,12,well differentiated,fully active,mutant,No,No,No,No,No,0,"race: other, sex: female, age: 75, bmi: 21.93, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 75-year-old female of a race categorized as ""other"" with a BMI of 21.93. She is undergoing treatment with the FOLFOX chemotherapy regimen and has completed 12 cycles. The histology of her cancer is well-differentiated. Despite her age, she has a fully active performance status. Additionally, the KRAS biomarker analysis has identified a mutant status."
1068,white,male,53,20.22,FOLFOX + Cetuximab,No,No,No,No,3,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 53, bmi: 20.22, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 3, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 53-year-old white male with a BMI of 20.22. He is currently receiving treatment in the FOLFOX + Cetuximab treatment arm and has completed 3 cycles of chemotherapy. His histology shows well-differentiated cells, and he has a fully active performance status. Additionally, his KRAS biomarker is wild-type."
1069,white,female,64,38.86,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,symptoms but ambulatory,wild-type,No,No,Yes,No,No,0,"race: white, sex: female, age: 64, bmi: 38.86, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type, adverse effect: diarrhea: Yes","The patient is a 64-year-old white female with a BMI of 38.86. She is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cancer. Despite experiencing symptoms, she is still able to ambulate. Her KRAS biomarker is wild-type. She is experiencing diarrhea as an adverse effect of treatment."
1070,white,male,42,29.92,FOLFOX,Yes,No,Yes,No,12,poorly differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 42, bmi: 29.92, treatment arm: FOLFOX, adherence: Yes, bowel obstruction: Yes, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 42-year-old white male with a BMI of 29.92. He is receiving the FOLFOX treatment regimen and has been adherent to the treatment. The patient has experienced a bowel obstruction. He has completed 12 cycles of chemotherapy. The histology of his cancer is poorly differentiated. Despite these challenges, the patient has a fully active performance status. His KRAS biomarker is wild-type."
1071,white,female,47,45.14,FOLFOX + Cetuximab,No,No,No,No,3,poorly differentiated,fully active,wild-type,No,No,Yes,No,No,0,"race: white, sex: female, age: 47, bmi: 45.14, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 3, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type, adverse effect: diarrhea: Yes",The patient is a 47-year-old white female with a BMI of 45.14 who is currently receiving treatment with FOLFOX + Cetuximab for her poorly differentiated histology. She has completed 3 cycles of chemotherapy and has a fully active performance status. Her KRAS biomarker status is wild-type. The patient is experiencing diarrhea as an adverse effect of the treatment.
1072,white,female,40,41.42,FOLFOX,No,No,No,No,12,well differentiated,symptoms but ambulatory,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 40, bmi: 41.42, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type","The patient is a 40-year-old white female with a BMI of 41.42. She is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cancer cells. Despite experiencing symptoms, she is still able to walk around (ambulatory). The KRAS biomarker analysis indicates that she has a wild-type KRAS status."
1073,white,female,57,18.48,FOLFOX + Cetuximab,No,No,Yes,No,12,well differentiated,fully active,mutant,No,No,No,No,No,0,"race: white, sex: female, age: 57, bmi: 18.48, treatment arm: FOLFOX + Cetuximab, bowel obstruction: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 57-year-old white female with a BMI of 18.48. She is receiving treatment in the FOLFOX + Cetuximab treatment arm. She has a bowel obstruction and has completed 12 cycles of chemotherapy. The histology shows well-differentiated cancer cells. Despite the bowel obstruction, her performance status is fully active. The KRAS biomarker analysis indicates a mutant status."
1074,white,female,50,25.35,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,symptoms but ambulatory,mutant,No,No,No,No,No,0,"race: white, sex: female, age: 50, bmi: 25.35, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: mutant","The patient is a 50-year-old white female with a BMI of 25.35. She is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cancer cells. Despite experiencing symptoms, she is still able to be ambulatory. The KRAS biomarker analysis indicates a mutant status."
1075,white,female,61,33.31,FOLFOX,No,No,No,No,1,well differentiated,fully active,wild-type,No,No,Yes,No,No,0,"race: white, sex: female, age: 61, bmi: 33.31, treatment arm: FOLFOX, chemotherapy cycles: 1, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type, adverse effect: diarrhea: Yes","The patient is a 61-year-old white female with a BMI of 33.31. She is receiving the FOLFOX treatment regimen and has completed one cycle of chemotherapy. Her histology shows well-differentiated cells, and she has a fully active performance status. The KRAS biomarker is wild-type. The patient is experiencing diarrhea as an adverse effect."
1076,white,male,66,34.38,FOLFOX,No,No,No,No,12,well differentiated,fully active,mutant,No,No,No,No,No,0,"race: white, sex: male, age: 66, bmi: 34.38, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant",The patient is a 66-year-old white male with a BMI of 34.38. He is receiving treatment with the FOLFOX chemotherapy regimen and has completed 12 cycles. His cancer histology is well differentiated. The patient has a fully active performance status. The KRAS biomarker testing revealed a mutant status.
1077,white,female,68,23.59,FOLFOX,No,No,No,No,12,well differentiated,fully active,mutant,No,No,No,No,No,0,"race: white, sex: female, age: 68, bmi: 23.59, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 68-year-old white female with a BMI of 23.59. She is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cancer cells. Despite her age, she has a fully active performance status. Additionally, the KRAS biomarker testing revealed a mutant status."
1078,white,male,40,24.56,FOLFOX,No,Yes,No,No,12,well differentiated,fully active,wild-type,No,No,Yes,No,No,0,"race: white, sex: male, age: 40, bmi: 24.56, treatment arm: FOLFOX, serious adverse effect: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type, adverse effect: diarrhea: Yes","The patient is a 40-year-old white male with a BMI of 24.56 who is undergoing treatment with the FOLFOX chemotherapy regimen. He has experienced a serious adverse effect during the treatment. He has completed 12 cycles of chemotherapy and has well-differentiated histology. Despite the serious adverse effect, his performance status is fully active. The KRAS biomarker shows that he has a wild-type status. Additionally, he has experienced diarrhea as an adverse effect during his treatment."
1079,white,female,49,20.17,FOLFIRI (KRAS mutant),No,No,No,No,12,well differentiated,fully active,interminate,No,No,No,No,No,0,"race: white, sex: female, age: 49, bmi: 20.17, treatment arm: FOLFIRI (KRAS mutant), chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: interminate","This patient is a 49-year-old white female with a BMI of 20.17. She is receiving the FOLFIRI treatment regimen for her KRAS mutant status. She has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cancer. Despite her cancer diagnosis, she has a fully active performance status. The KRAS biomarker status is indeterminate for this patient."
1080,white,female,37,25.12,FOLFOX + Cetuximab,No,No,No,No,12,poorly differentiated,fully active,wild-type,No,No,No,No,No,1,"race: white, sex: female, age: 37, bmi: 25.12, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 37-year-old white female with a BMI of 25.12. She is receiving treatment with FOLFOX + Cetuximab and is scheduled for 12 chemotherapy cycles. Her cancer histology is poorly differentiated. Despite this, her performance status is fully active. Additionally, her KRAS biomarker status is wild-type."
1081,white,female,67,33.8,FOLFOX + Cetuximab,Yes,Yes,No,Yes,12,well differentiated,symptoms but ambulatory,mutant,Yes,No,No,No,No,1,"race: white, sex: female, age: 67, bmi: 33.8, treatment arm: FOLFOX + Cetuximab, adherence: Yes, serious adverse effect: Yes, bowel perforation: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: mutant, adverse effect: thrombosis: Yes","This patient is a 67-year-old white female with a BMI of 33.8 who is undergoing treatment with FOLFOX + Cetuximab for well-differentiated histology. She has completed 12 cycles of chemotherapy and has been adherent to her treatment. However, she experienced a serious adverse effect in the form of bowel perforation. Additionally, she has a mutant KRAS biomarker and has also developed thrombosis as an adverse effect. Despite experiencing symptoms, she is still ambulatory and has a performance status that allows her to carry out daily activities."
1082,white,female,46,37.52,FOLFOX + Cetuximab,No,No,No,No,4,well differentiated,fully active,wild-type,No,No,No,Yes,No,1,"race: white, sex: female, age: 46, bmi: 37.52, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 4, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type, adverse effect: infection: Yes","The patient is a 46-year-old white female with a BMI of 37.52. She is receiving treatment with FOLFOX + Cetuximab and has completed 4 cycles of chemotherapy. Her histology shows well-differentiated cancer, and she has a fully active performance status. The KRAS biomarker indicates that she is wild-type. The patient has experienced an adverse effect of infection."
1083,white,male,35,25.96,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,fully active,wild-type,No,Yes,No,No,No,0,"race: white, sex: male, age: 35, bmi: 25.96, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type, adverse effect: hypersensitivity: Yes","The patient is a 35-year-old white male with a BMI of 25.96. He is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cells, and he has a fully active performance status. The KRAS biomarker indicates that he is wild-type. The patient has experienced a hypersensitivity adverse effect."
1084,white,female,43,22.77,FOLFOX,No,No,Yes,No,12,well differentiated,symptoms but ambulatory,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 43, bmi: 22.77, treatment arm: FOLFOX, bowel obstruction: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type","The patient is a 43-year-old white female with a BMI of 22.77. She is receiving the FOLFOX treatment arm for her well-differentiated histology. She has a bowel obstruction and has completed 12 cycles of chemotherapy. Despite experiencing symptoms, she is still ambulatory. Her KRAS biomarker shows that she is wild-type."
1085,white,female,64,24.6,FOLFOX + Cetuximab,No,Yes,No,No,2,well differentiated,fully active,wild-type,No,No,Yes,No,No,0,"race: white, sex: female, age: 64, bmi: 24.6, treatment arm: FOLFOX + Cetuximab, serious adverse effect: Yes, chemotherapy cycles: 2, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type, adverse effect: diarrhea: Yes","This patient is a 64-year-old white female with a BMI of 24.6. She is receiving treatment with FOLFOX + Cetuximab and has experienced a serious adverse effect. She has completed 2 cycles of chemotherapy. Her histology shows well-differentiated cells, and her performance status is fully active. Her KRAS biomarker is wild-type. She has also experienced diarrhea as an adverse effect of the treatment."
1086,white,male,68,27.43,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,Yes,No,No,0,"race: white, sex: male, age: 68, bmi: 27.43, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type, adverse effect: diarrhea: Yes","The patient is a 68-year-old white male with a BMI of 27.43. He is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer, and he has a fully active performance status. The KRAS biomarker indicates that he is wild-type. The patient is experiencing diarrhea as an adverse effect of the treatment."
1087,white,female,53,26.61,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,Yes,No,No,0,"race: white, sex: female, age: 53, bmi: 26.61, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type, adverse effect: diarrhea: Yes","The patient is a 53-year-old white female with a BMI of 26.61. She is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cancer, and she has a fully active performance status. The KRAS biomarker indicates that she has a wild-type mutation. She is experiencing diarrhea as an adverse effect of the treatment."
1088,white,male,70,27.66,FOLFOX + Cetuximab,No,Yes,No,No,12,poorly differentiated,symptoms but ambulatory,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 70, bmi: 27.66, treatment arm: FOLFOX + Cetuximab, serious adverse effect: Yes, chemotherapy cycles: 12, histology: poorly differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type","The patient is a 70-year-old white male with a BMI of 27.66. He is receiving treatment with FOLFOX + Cetuximab and has experienced a serious adverse effect. He has undergone 12 cycles of chemotherapy. The histology of his cancer is poorly differentiated. Despite experiencing symptoms, he is still able to be ambulatory. His KRAS biomarker status is wild-type."
1089,white,female,52,28.04,FOLFOX + Cetuximab,No,Yes,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 52, bmi: 28.04, treatment arm: FOLFOX + Cetuximab, serious adverse effect: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 52-year-old white female with a BMI of 28.04. She is receiving treatment with FOLFOX + Cetuximab and has experienced a serious adverse effect. She has completed 12 cycles of chemotherapy. The histology shows that the cancer is well-differentiated. Despite the treatment, her performance status is fully active. Additionally, the KRAS biomarker indicates that it is wild-type."
1090,white,male,56,30.54,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 56, bmi: 30.54, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type",The patient is a 56-year-old white male with a BMI of 30.54. He is receiving treatment in the FOLFOX + Cetuximab treatment arm and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer cells. The patient has a fully active performance status and his KRAS biomarker is wild-type.
1091,black,male,46,31.94,FOLFOX,No,No,No,No,9,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: black, sex: male, age: 46, bmi: 31.94, treatment arm: FOLFOX, chemotherapy cycles: 9, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type",The patient is a 46-year-old Black male with a BMI of 31.94. He is receiving the FOLFOX treatment regimen and has completed 9 cycles of chemotherapy. His histology shows well-differentiated cells. The patient has a fully active performance status. His KRAS biomarker is wild-type.
1092,white,male,70,25.54,FOLFOX + Cetuximab,No,No,No,No,12,poorly differentiated,fully active,mutant,No,No,Yes,No,No,0,"race: white, sex: male, age: 70, bmi: 25.54, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: mutant, adverse effect: diarrhea: Yes","The patient is a 70-year-old white male with a BMI of 25.54. He is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. His histology shows poorly differentiated cancer cells. Despite this, his performance status is fully active. The KRAS biomarker analysis revealed a mutant status. The patient is experiencing diarrhea as an adverse effect of the treatment."
1093,white,male,67,31.47,FOLFOX + Cetuximab,Yes,No,No,No,12,poorly differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 67, bmi: 31.47, treatment arm: FOLFOX + Cetuximab, adherence: Yes, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 67-year-old white male with a BMI of 31.47. He is receiving treatment in the FOLFOX + Cetuximab treatment arm and has been adherent to the treatment. He has completed 12 chemotherapy cycles. His histology shows poorly differentiated cells. Despite this, his performance status is fully active. Additionally, his KRAS biomarker is wild-type."
1094,white,male,48,31.56,FOLFOX,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 48, bmi: 31.56, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 48-year-old white male with a BMI of 31.56. He is undergoing treatment with the FOLFOX chemotherapy regimen and has completed 12 cycles. His cancer histology is well-differentiated, and he has a fully active performance status. The KRAS biomarker testing showed that he has a wild-type KRAS status."
1095,white,male,68,31.44,FOLFOX,No,No,No,No,5,poorly differentiated,fully active,wild-type,No,No,No,No,No,1,"race: white, sex: male, age: 68, bmi: 31.44, treatment arm: FOLFOX, chemotherapy cycles: 5, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 68-year-old white male with a BMI of 31.44. He is receiving the FOLFOX treatment regimen and has completed 5 cycles of chemotherapy. His cancer histology is poorly differentiated. Despite his diagnosis, he has a fully active performance status. Additionally, his KRAS biomarker status is wild-type."
1096,white,female,73,34.69,FOLFOX + Cetuximab,No,Yes,No,No,10,well differentiated,symptoms but ambulatory,wild-type,No,Yes,Yes,No,No,0,"race: white, sex: female, age: 73, bmi: 34.69, treatment arm: FOLFOX + Cetuximab, serious adverse effect: Yes, chemotherapy cycles: 10, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type, adverse effect: hypersensitivity: Yes, adverse effect: diarrhea: Yes","The patient is a 73-year-old white female with a BMI of 34.69 who is receiving treatment with FOLFOX + Cetuximab. She has experienced a serious adverse effect during her 10 chemotherapy cycles. Her histology shows well-differentiated cells, and her performance status indicates that she has symptoms but is still able to be ambulatory. The patient's KRAS biomarker is wild-type. She has also experienced adverse effects such as hypersensitivity and diarrhea."
1097,white,male,46,23.56,FOLFOX,No,No,No,No,12,well differentiated,symptoms but ambulatory,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 46, bmi: 23.56, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type","The patient is a 46-year-old white male with a BMI of 23.56. He is receiving treatment with the FOLFOX chemotherapy regimen and has completed 12 cycles. The histology of his cancer is well-differentiated. Despite experiencing symptoms, he is still able to be ambulatory. His KRAS biomarker status is wild-type."
1098,white,male,54,42.01,FOLFOX,No,No,No,No,12,well differentiated,symptoms but ambulatory,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 54, bmi: 42.01, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type","The patient is a 54-year-old white male with a BMI of 42.01. He is receiving treatment with the FOLFOX chemotherapy regimen and has completed 12 cycles so far. His cancer histology is well-differentiated. Despite experiencing symptoms, he is still able to be ambulatory. The KRAS biomarker testing revealed that he has a wild-type KRAS status."
1099,white,male,66,18.3,FOLFOX,Yes,No,No,Yes,12,poorly differentiated,symptoms but ambulatory,mutant,No,No,No,No,No,0,"race: white, sex: male, age: 66, bmi: 18.3, treatment arm: FOLFOX, adherence: Yes, bowel perforation: Yes, chemotherapy cycles: 12, histology: poorly differentiated, performance status: symptoms but ambulatory, KRAS biomarker: mutant","The patient is a 66-year-old white male with a BMI of 18.3. He is receiving treatment in the FOLFOX arm and has been adherent to the treatment. The patient experienced a bowel perforation and has completed 12 cycles of chemotherapy. The histology shows poorly differentiated cancer cells. Despite experiencing symptoms, the patient is still ambulatory. The KRAS biomarker analysis revealed a mutant status."
1100,white,male,45,28.05,FOLFOX,No,No,No,No,12,poorly differentiated,symptoms but ambulatory,mutant,No,No,No,No,No,0,"race: white, sex: male, age: 45, bmi: 28.05, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: poorly differentiated, performance status: symptoms but ambulatory, KRAS biomarker: mutant","The patient is a 45-year-old white male with a BMI of 28.05. He is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. The histology of his cancer is poorly differentiated. Despite experiencing symptoms, he is still able to be ambulatory. The KRAS biomarker testing revealed a mutant status."
1101,white,female,41,21.04,FOLFOX + Cetuximab,No,No,Yes,No,12,well differentiated,fully active,mutant,No,No,No,No,No,0,"race: white, sex: female, age: 41, bmi: 21.04, treatment arm: FOLFOX + Cetuximab, bowel obstruction: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant",The patient is a 41-year-old white female with a BMI of 21.04. She is receiving treatment in the FOLFOX + Cetuximab treatment arm. She has experienced a bowel obstruction and has completed 12 cycles of chemotherapy. The histology shows well-differentiated cells. The patient has a fully active performance status. The KRAS biomarker indicates a mutant status.
1102,white,female,37,43.43,FOLFOX + Cetuximab,No,No,No,No,1,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 37, bmi: 43.43, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 1, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type",The patient is a 37-year-old white female with a BMI of 43.43. She is receiving treatment in the FOLFOX + Cetuximab treatment arm and has completed 1 cycle of chemotherapy. Her histology shows well-differentiated cancer cells. The patient has a fully active performance status and her KRAS biomarker is wild-type.
1103,white,male,54,36.54,FOLFOX,No,No,No,No,12,well differentiated,symptoms but ambulatory,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 54, bmi: 36.54, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type","The patient is a 54-year-old white male with a BMI of 36.54. He is undergoing treatment with the FOLFOX chemotherapy regimen and has completed 12 cycles. His histology shows well-differentiated cancer cells. Despite experiencing symptoms, he is still able to ambulate. The KRAS biomarker analysis indicates that he has a wild-type KRAS status."
1104,white,female,35,21.33,FOLFOX,No,No,No,No,12,poorly differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 35, bmi: 21.33, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type","This patient is a 35-year-old white female with a BMI of 21.33. She is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. Her histology shows poorly differentiated cancer cells. Despite this, her performance status is fully active. Additionally, her KRAS biomarker indicates that she has a wild-type mutation."
1105,black,male,51,30.32,FOLFOX,No,No,No,No,12,well differentiated,fully active,mutant,No,No,No,No,No,0,"race: black, sex: male, age: 51, bmi: 30.32, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant",The patient is a 51-year-old Black male with a BMI of 30.32. He is receiving the FOLFOX treatment arm and has completed 12 cycles of chemotherapy. The histology shows well-differentiated cancer cells. The patient has a fully active performance status. The KRAS biomarker indicates a mutant status.
1106,white,male,48,25.73,FOLFOX,No,No,No,No,12,well differentiated,fully active,mutant,No,No,No,No,No,0,"race: white, sex: male, age: 48, bmi: 25.73, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 48-year-old white male with a BMI of 25.73. He is receiving the FOLFOX treatment arm and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cells. The patient has a fully active performance status. Additionally, the KRAS biomarker testing revealed a mutant status."
1107,white,male,73,23.3,FOLFOX,No,No,Yes,No,12,well differentiated,fully active,interminate,No,No,No,No,No,0,"race: white, sex: male, age: 73, bmi: 23.3, treatment arm: FOLFOX, bowel obstruction: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: interminate","The patient is a 73-year-old white male with a BMI of 23.3. He is undergoing treatment with the FOLFOX regimen and has experienced a bowel obstruction. He has completed 12 cycles of chemotherapy. The histology of his cancer is well-differentiated. Despite the bowel obstruction, his performance status is fully active. The KRAS biomarker status is indeterminate."
1108,white,female,72,42.09,FOLFOX + Cetuximab,No,No,No,No,3,well differentiated,symptoms but ambulatory,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 72, bmi: 42.09, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 3, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type","The patient is a 72-year-old white female with a BMI of 42.09. She is receiving treatment with FOLFOX + Cetuximab and has completed 3 cycles of chemotherapy. Her histology shows well-differentiated cancer. Despite experiencing symptoms, she is still able to walk around (ambulatory). The KRAS biomarker indicates that she has a wild-type status."
1109,white,female,70,47.72,FOLFOX + Cetuximab,Yes,No,No,No,4,well differentiated,fully active,interminate,No,No,No,No,No,0,"race: white, sex: female, age: 70, bmi: 47.72, treatment arm: FOLFOX + Cetuximab, adherence: Yes, chemotherapy cycles: 4, histology: well differentiated, performance status: fully active, KRAS biomarker: interminate","The patient is a 70-year-old white female with a BMI of 47.72. She is receiving treatment in the FOLFOX + Cetuximab treatment arm and has been adherent to her medication. She has completed 4 chemotherapy cycles. The histology shows well-differentiated cells, and her performance status is fully active. The KRAS biomarker status is indeterminate."
1110,white,male,59,46.18,FOLFOX + Cetuximab,No,No,No,No,3,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 59, bmi: 46.18, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 3, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 59-year-old white male with a BMI of 46.18. He is currently receiving treatment in the FOLFOX + Cetuximab treatment arm and has completed 3 cycles of chemotherapy. His histology shows well-differentiated cells, and he has a fully active performance status. Additionally, his KRAS biomarker indicates that he has a wild-type mutation."
1111,white,male,59,26.9,FOLFOX,No,No,No,No,12,poorly differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 59, bmi: 26.9, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 59-year-old white male with a BMI of 26.9. He is undergoing treatment with the FOLFOX chemotherapy regimen and has completed 12 cycles. The histology of his cancer is poorly differentiated. Despite this, his performance status is fully active. Additionally, his KRAS biomarker is wild-type."
1112,white,male,47,28.59,FOLFIRI (KRAS mutant),No,No,No,No,12,well differentiated,fully active,mutant,No,No,No,No,No,0,"race: white, sex: male, age: 47, bmi: 28.59, treatment arm: FOLFIRI (KRAS mutant), chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant",The patient is a 47-year-old white male with a BMI of 28.59. He is receiving the FOLFIRI treatment regimen for his well-differentiated cancer with a KRAS mutation. He has completed 12 cycles of chemotherapy and has a fully active performance status.
1113,white,female,68,24.96,FOLFOX + Cetuximab,No,No,No,No,5,well differentiated,symptoms but ambulatory,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 68, bmi: 24.96, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 5, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type","The patient is a 68-year-old white female with a BMI of 24.96. She is currently receiving treatment with FOLFOX + Cetuximab and has completed 5 cycles of chemotherapy. Her cancer histology is well-differentiated. Despite experiencing symptoms, she is still able to walk around (ambulatory). The KRAS biomarker testing revealed that she has a wild-type KRAS status."
1114,white,female,52,23.36,FOLFOX,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 52, bmi: 23.36, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 52-year-old white female with a BMI of 23.36. She is receiving treatment with the FOLFOX chemotherapy regimen and has completed 12 cycles. Her cancer histology is well-differentiated, and her performance status is fully active. The KRAS biomarker analysis shows that she has a wild-type KRAS status."
1115,white,male,54,24.54,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,fully active,mutant,No,No,Yes,No,No,1,"race: white, sex: male, age: 54, bmi: 24.54, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant, adverse effect: diarrhea: Yes","The patient is a 54-year-old white male with a BMI of 24.54. He is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer, and he has a fully active performance status. The KRAS biomarker testing revealed a mutant status. The patient is experiencing diarrhea as an adverse effect of the treatment."
1116,white,male,62,28.93,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,fully active,mutant,No,No,No,No,No,0,"race: white, sex: male, age: 62, bmi: 28.93, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 62-year-old white male with a BMI of 28.93. He is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer cells. Despite his cancer diagnosis, he has a fully active performance status. The patient's KRAS biomarker status is mutant."
1117,white,female,75,32.72,FOLFOX + Cetuximab,No,No,Yes,No,12,well differentiated,symptoms but ambulatory,wild-type,No,No,Yes,No,No,0,"race: white, sex: female, age: 75, bmi: 32.72, treatment arm: FOLFOX + Cetuximab, bowel obstruction: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type, adverse effect: diarrhea: Yes","This patient is a 75-year-old white female with a BMI of 32.72 who is receiving treatment with FOLFOX + Cetuximab. She has a bowel obstruction and has completed 12 cycles of chemotherapy. The histology shows well-differentiated cancer, and her performance status indicates that she has symptoms but is still able to walk around. Her KRAS biomarker is wild-type. She is experiencing diarrhea as an adverse effect of the treatment."
1118,black,female,49,22.53,FOLFOX + Cetuximab,No,No,No,No,5,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: black, sex: female, age: 49, bmi: 22.53, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 5, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type",The patient is a 49-year-old Black female with a BMI of 22.53. She is receiving treatment with FOLFOX + Cetuximab and has completed 5 cycles of chemotherapy. Her histology shows well-differentiated cancer cells. The patient has a fully active performance status. Her KRAS biomarker indicates that it is wild-type.
1119,white,male,67,28.2,FOLFOX,No,No,Yes,No,0,well differentiated,symptoms but ambulatory,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 67, bmi: 28.2, treatment arm: FOLFOX, bowel obstruction: Yes, chemotherapy cycles: 0, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type","The patient is a 67-year-old white male with a BMI of 28.2. He is part of the FOLFOX treatment arm and has a bowel obstruction. He has not undergone any chemotherapy cycles yet. His histology shows well-differentiated cells. Despite experiencing symptoms, he is still able to be ambulatory. The KRAS biomarker indicates that he has a wild-type status."
1120,white,male,62,26.82,FOLFIRI,No,No,No,No,12,well differentiated,fully active,mutant,No,No,No,No,No,0,"race: white, sex: male, age: 62, bmi: 26.82, treatment arm: FOLFIRI, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant",The patient is a 62-year-old white male with a BMI of 26.82. He is receiving treatment with the FOLFIRI chemotherapy regimen and has completed 12 cycles. His cancer histology is well differentiated. The patient has a fully active performance status and has a mutant KRAS biomarker.
1121,white,female,55,17.79,FOLFOX,No,No,Yes,No,12,poorly differentiated,symptoms but ambulatory,wild-type,No,No,Yes,No,No,0,"race: white, sex: female, age: 55, bmi: 17.79, treatment arm: FOLFOX, bowel obstruction: Yes, chemotherapy cycles: 12, histology: poorly differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type, adverse effect: diarrhea: Yes","The patient is a 55-year-old white female with a BMI of 17.79 who is receiving the FOLFOX treatment regimen. She is experiencing a bowel obstruction and has undergone 12 cycles of chemotherapy. The histology of her cancer is poorly differentiated. Despite experiencing symptoms, she is still able to be ambulatory. Her KRAS biomarker is wild-type. Additionally, she is experiencing diarrhea as an adverse effect of the treatment."
1122,white,male,68,26.74,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 68, bmi: 26.74, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 68-year-old white male with a BMI of 26.74. He is receiving treatment in the FOLFOX + Cetuximab treatment arm and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer cells. Despite his age, he has a fully active performance status. Additionally, his KRAS biomarker indicates that he has a wild-type gene."
1123,other,female,66,19.59,FOLFOX,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: other, sex: female, age: 66, bmi: 19.59, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 66-year-old female of a race categorized as ""other"" with a BMI of 19.59. She is undergoing treatment with the FOLFOX chemotherapy regimen and has completed 12 cycles. The histology of her cancer is well-differentiated. Despite her age, she has a fully active performance status. Additionally, her KRAS biomarker status is wild-type."
1124,white,male,59,30.74,FOLFOX + Cetuximab,No,No,No,No,12,poorly differentiated,fully active,mutant,No,No,No,No,No,0,"race: white, sex: male, age: 59, bmi: 30.74, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 59-year-old white male with a BMI of 30.74. He is receiving treatment in the FOLFOX + Cetuximab treatment arm and has completed 12 cycles of chemotherapy. His histology shows poorly differentiated cancer cells. Despite this, his performance status is fully active. The KRAS biomarker analysis revealed a mutant status."
1125,white,male,60,33.14,FOLFOX,Yes,No,No,No,7,well differentiated,fully active,wild-type,No,No,No,No,No,1,"race: white, sex: male, age: 60, bmi: 33.14, treatment arm: FOLFOX, adherence: Yes, chemotherapy cycles: 7, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type",The patient is a 60-year-old white male with a BMI of 33.14. He is receiving treatment in the FOLFOX chemotherapy arm and has been adherent to the treatment. He has completed 7 cycles of chemotherapy. The histology shows well-differentiated cancer cells. The patient has a fully active performance status. The KRAS biomarker indicates that he has a wild-type KRAS gene.
1126,white,male,40,42.07,FOLFOX,Yes,No,Yes,No,12,well differentiated,fully active,mutant,No,No,No,No,No,0,"race: white, sex: male, age: 40, bmi: 42.07, treatment arm: FOLFOX, adherence: Yes, bowel obstruction: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant",The patient is a 40-year-old white male with a BMI of 42.07. He is receiving the FOLFOX treatment regimen and has been adherent to the treatment. He has experienced a bowel obstruction. The patient has completed 12 cycles of chemotherapy and has well-differentiated histology. His performance status is fully active. The KRAS biomarker analysis shows a mutant status.
1127,white,female,63,24.76,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,fully active,mutant,No,No,No,No,No,0,"race: white, sex: female, age: 63, bmi: 24.76, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant",The patient is a 63-year-old white female with a BMI of 24.76. She is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. Her cancer histology is well differentiated. She has a fully active performance status. The KRAS biomarker testing revealed a mutant status.
1128,white,male,46,28.53,FOLFOX,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 46, bmi: 28.53, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type",The patient is a 46-year-old white male with a BMI of 28.53. He is receiving the FOLFOX treatment arm and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer cells. The patient has a fully active performance status and his KRAS biomarker is wild-type.
1129,white,male,71,28.8,FOLFOX + Cetuximab,Yes,No,Yes,Yes,2,poorly differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 71, bmi: 28.8, treatment arm: FOLFOX + Cetuximab, adherence: Yes, bowel obstruction: Yes, bowel perforation: Yes, chemotherapy cycles: 2, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 71-year-old white male with a BMI of 28.8. He is currently undergoing treatment with FOLFOX + Cetuximab and is adherent to the treatment. He has experienced both bowel obstruction and bowel perforation. So far, he has completed 2 cycles of chemotherapy. His histology shows poorly differentiated cells. Despite these challenges, his performance status is fully active. The KRAS biomarker analysis indicates that he has a wild-type KRAS status."
1130,white,male,56,23.47,FOLFOX,No,No,No,No,12,well differentiated,symptoms but ambulatory,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 56, bmi: 23.47, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type","The patient is a 56-year-old white male with a BMI of 23.47. He is undergoing treatment with the FOLFOX chemotherapy regimen and has completed 12 cycles. The histology of his cancer is well differentiated. Despite experiencing symptoms, he is still able to ambulate. His KRAS biomarker status is wild-type."
1131,white,female,64,36.43,FOLFOX,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 64, bmi: 36.43, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 64-year-old white female with a BMI of 36.43. She is receiving the FOLFOX treatment arm and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cells, and she has a fully active performance status. The KRAS biomarker analysis indicates that she has a wild-type KRAS status."
1132,white,male,44,33.52,FOLFOX,No,No,No,No,5,well differentiated,fully active,mutant,No,Yes,No,No,No,0,"race: white, sex: male, age: 44, bmi: 33.52, treatment arm: FOLFOX, chemotherapy cycles: 5, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant, adverse effect: hypersensitivity: Yes","The patient is a 44-year-old white male with a BMI of 33.52. He is receiving the FOLFOX treatment regimen and has completed 5 cycles of chemotherapy. His histology shows well-differentiated cells, and he has a fully active performance status. The KRAS biomarker testing revealed a mutant status. The patient has experienced a hypersensitivity adverse effect."
1133,white,male,48,22.35,FOLFOX,Yes,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 48, bmi: 22.35, treatment arm: FOLFOX, adherence: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type",The patient is a 48-year-old white male with a BMI of 22.35. He is receiving treatment in the FOLFOX chemotherapy arm and has been adherent to the treatment. He has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer cells. The patient has a fully active performance status. His KRAS biomarker is wild-type.
1134,white,female,43,28.37,FOLFOX,No,No,No,No,12,poorly differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 43, bmi: 28.37, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 43-year-old white female with a BMI of 28.37. She is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. The histology of her cancer is poorly differentiated. Despite this, her performance status is fully active. Additionally, her KRAS biomarker status is wild-type."
1135,white,female,66,26.36,FOLFOX + Cetuximab,No,Yes,No,No,3,well differentiated,fully active,wild-type,No,No,Yes,No,No,0,"race: white, sex: female, age: 66, bmi: 26.36, treatment arm: FOLFOX + Cetuximab, serious adverse effect: Yes, chemotherapy cycles: 3, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type, adverse effect: diarrhea: Yes","The patient is a 66-year-old white female with a BMI of 26.36. She is receiving treatment with FOLFOX + Cetuximab and has experienced a serious adverse effect. She has completed 3 cycles of chemotherapy. Her histology shows well-differentiated cells, and her performance status is fully active. The KRAS biomarker indicates she has a wild-type gene. Additionally, she has experienced diarrhea as an adverse effect of the treatment."
1136,white,female,47,30.35,FOLFOX,No,Yes,No,No,4,poorly differentiated,fully active,mutant,No,No,No,No,No,1,"race: white, sex: female, age: 47, bmi: 30.35, treatment arm: FOLFOX, serious adverse effect: Yes, chemotherapy cycles: 4, histology: poorly differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 47-year-old white female with a BMI of 30.35. She is undergoing treatment with FOLFOX chemotherapy regimen and has experienced a serious adverse effect. She has completed 4 cycles of chemotherapy. The histology of her cancer is poorly differentiated. Despite this, her performance status is fully active. Additionally, the KRAS biomarker testing revealed a mutant status."
1137,white,female,43,33.63,FOLFIRI,No,No,No,Yes,12,poorly differentiated,fully active,wild-type,No,No,Yes,No,No,0,"race: white, sex: female, age: 43, bmi: 33.63, treatment arm: FOLFIRI, bowel perforation: Yes, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type, adverse effect: diarrhea: Yes","The patient is a 43-year-old white female with a BMI of 33.63. She is receiving the FOLFIRI treatment regimen and has experienced a bowel perforation. She has completed 12 cycles of chemotherapy. The histology of her cancer is poorly differentiated. Despite these challenges, her performance status is fully active. Her KRAS biomarker status is wild-type. She is experiencing diarrhea as an adverse effect of her treatment."
1138,white,male,63,29.92,FOLFIRI (KRAS mutant),No,No,No,No,12,well differentiated,fully active,mutant,No,No,No,No,No,0,"race: white, sex: male, age: 63, bmi: 29.92, treatment arm: FOLFIRI (KRAS mutant), chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 63-year-old white male with a BMI of 29.92. He is receiving treatment with the FOLFIRI regimen for his KRAS mutant status. He has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer cells. Despite his cancer diagnosis, he has a fully active performance status."
1139,white,female,44,21.02,FOLFOX,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 44, bmi: 21.02, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 44-year-old white female with a BMI of 21.02. She is receiving treatment with the FOLFOX chemotherapy regimen and is scheduled for 12 cycles. Her cancer histology is well differentiated, and she has a fully active performance status. The KRAS biomarker analysis shows that she has a wild-type KRAS status."
1140,white,female,62,23.96,FOLFOX,No,No,No,No,6,poorly differentiated,symptoms but ambulatory,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 62, bmi: 23.96, treatment arm: FOLFOX, chemotherapy cycles: 6, histology: poorly differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type","The patient is a 62-year-old white female with a BMI of 23.96. She is receiving the FOLFOX treatment regimen and has completed 6 cycles of chemotherapy. Her histology shows poorly differentiated cancer cells. Despite experiencing symptoms, she is still able to walk around (ambulatory). The KRAS biomarker analysis indicates that she has a wild-type KRAS gene."
1141,white,male,51,32.35,FOLFOX + Cetuximab,No,Yes,No,No,11,poorly differentiated,fully active,mutant,No,No,No,No,No,1,"race: white, sex: male, age: 51, bmi: 32.35, treatment arm: FOLFOX + Cetuximab, serious adverse effect: Yes, chemotherapy cycles: 11, histology: poorly differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 51-year-old white male with a BMI of 32.35. He is receiving treatment with FOLFOX + Cetuximab and has experienced a serious adverse effect. He has completed 11 cycles of chemotherapy. His histology shows poorly differentiated cells. Despite this, his performance status is fully active. The KRAS biomarker analysis indicates a mutant status."
1142,white,male,47,26.16,FOLFOX + Cetuximab,Yes,Yes,Yes,No,12,poorly differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 47, bmi: 26.16, treatment arm: FOLFOX + Cetuximab, adherence: Yes, serious adverse effect: Yes, bowel obstruction: Yes, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 47-year-old white male with a BMI of 26.16. He is receiving treatment in the FOLFOX + Cetuximab treatment arm and has been adherent to the treatment. He experienced a serious adverse effect in the form of a bowel obstruction. He has completed 12 cycles of chemotherapy. The histology of his cancer is poorly differentiated. Despite the adverse effect, his performance status is fully active. His KRAS biomarker status is wild-type."
1143,white,male,35,24.4,FOLFOX + Cetuximab,Yes,No,Yes,Yes,12,well differentiated,fully active,wild-type,No,Yes,No,No,No,0,"race: white, sex: male, age: 35, bmi: 24.4, treatment arm: FOLFOX + Cetuximab, adherence: Yes, bowel obstruction: Yes, bowel perforation: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type, adverse effect: hypersensitivity: Yes","The patient is a 35-year-old white male with a BMI of 24.4. He is receiving treatment with FOLFOX + Cetuximab and has been adherent to the treatment. He has experienced bowel obstruction and perforation. He has completed 12 cycles of chemotherapy. His histology shows well-differentiated cells. Despite the bowel issues, his performance status is fully active. His KRAS biomarker is wild-type. He has also experienced a hypersensitivity adverse effect."
1144,white,female,75,21.21,FOLFOX + Cetuximab,No,No,No,No,1,well differentiated,fully active,mutant,No,No,No,No,No,0,"race: white, sex: female, age: 75, bmi: 21.21, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 1, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 75-year-old white female with a BMI of 21.21. She is receiving treatment in the FOLFOX + Cetuximab treatment arm and has completed one cycle of chemotherapy. Her histology shows well-differentiated cancer cells. Despite her age, she has a fully active performance status. The KRAS biomarker analysis indicates that she has a mutant KRAS status."
1145,white,female,44,26.12,FOLFOX,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 44, bmi: 26.12, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 44-year-old white female with a BMI of 26.12. She is undergoing treatment with the FOLFOX chemotherapy regimen and is scheduled for 12 cycles. Her cancer histology is well-differentiated, and she has a fully active performance status. The KRAS biomarker analysis shows that she has a wild-type KRAS status."
1146,white,female,59,30.19,FOLFOX,No,No,No,No,2,poorly differentiated,symptoms but ambulatory,mutant,No,No,No,No,No,0,"race: white, sex: female, age: 59, bmi: 30.19, treatment arm: FOLFOX, chemotherapy cycles: 2, histology: poorly differentiated, performance status: symptoms but ambulatory, KRAS biomarker: mutant","The patient is a 59-year-old white female with a BMI of 30.19. She is currently receiving the FOLFOX treatment regimen and has completed 2 cycles of chemotherapy. Her histology shows poorly differentiated cancer cells. Despite experiencing symptoms, she is still able to walk around (ambulatory). The KRAS biomarker analysis indicates that she has a mutant KRAS status."
1147,white,male,63,27.17,FOLFOX + Cetuximab,No,No,No,No,2,poorly differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 63, bmi: 27.17, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 2, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 63-year-old white male with a BMI of 27.17. He is currently receiving treatment in the FOLFOX + Cetuximab treatment arm and has completed 2 cycles of chemotherapy. His histology shows poorly differentiated cancer cells. Despite his diagnosis, he has a fully active performance status. Additionally, his KRAS biomarker indicates that he has a wild-type gene."
1148,white,male,47,27.93,FOLFOX,No,No,No,No,12,well differentiated,symptoms but ambulatory,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 47, bmi: 27.93, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type","The patient is a 47-year-old white male with a BMI of 27.93. He is undergoing treatment with the FOLFOX chemotherapy regimen and has completed 12 cycles. His histology shows well-differentiated cancer cells. Despite experiencing symptoms, he is still able to ambulate. The KRAS biomarker analysis indicates that he has a wild-type KRAS status."
1149,white,female,58,22.92,FOLFOX + Cetuximab,No,Yes,No,No,5,well differentiated,fully active,wild-type,No,No,No,Yes,No,0,"race: white, sex: female, age: 58, bmi: 22.92, treatment arm: FOLFOX + Cetuximab, serious adverse effect: Yes, chemotherapy cycles: 5, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type, adverse effect: infection: Yes","The patient is a 58-year-old white female with a BMI of 22.92. She is receiving treatment with FOLFOX + Cetuximab and has experienced a serious adverse effect. She has completed 5 cycles of chemotherapy. Her histology shows well-differentiated cells, and her performance status is fully active. The KRAS biomarker indicates that she is wild-type. Additionally, she has developed an infection as an adverse effect of the treatment."
1150,white,female,38,21.19,FOLFOX,Yes,No,No,No,12,poorly differentiated,symptoms but ambulatory,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 38, bmi: 21.19, treatment arm: FOLFOX, adherence: Yes, chemotherapy cycles: 12, histology: poorly differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type","The patient is a 38-year-old white female with a BMI of 21.19. She is receiving treatment in the FOLFOX chemotherapy arm and has been adherent to her treatment. She has completed 12 cycles of chemotherapy. Her histology shows poorly differentiated cancer cells. Despite experiencing symptoms, she is still able to be ambulatory. The KRAS biomarker analysis indicates that she has a wild-type KRAS status."
1151,white,female,37,37.54,FOLFOX + Cetuximab,No,No,No,No,12,poorly differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 37, bmi: 37.54, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 37-year-old white female with a BMI of 37.54. She is receiving treatment in the FOLFOX + Cetuximab treatment arm and is scheduled for 12 chemotherapy cycles. Her histology shows poorly differentiated cancer cells. Despite her diagnosis, she has a fully active performance status. Additionally, her KRAS biomarker indicates that it is wild-type."
1152,white,male,42,30.47,FOLFOX,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 42, bmi: 30.47, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 42-year-old white male with a BMI of 30.47. He is undergoing treatment with the FOLFOX chemotherapy regimen and is scheduled for 12 cycles. His cancer histology is well-differentiated, and he has a fully active performance status. The KRAS biomarker analysis shows that he has a wild-type KRAS status."
1153,white,female,51,29.16,FOLFOX,No,No,Yes,No,12,well differentiated,symptoms but ambulatory,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 51, bmi: 29.16, treatment arm: FOLFOX, bowel obstruction: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type","The patient is a 51-year-old white female with a BMI of 29.16. She is receiving the FOLFOX treatment arm for her well-differentiated histology. She has experienced a bowel obstruction and has completed 12 cycles of chemotherapy. Despite experiencing symptoms, she is still ambulatory. The KRAS biomarker shows that she has a wild-type status."
1154,white,male,34,28.96,FOLFOX,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 34, bmi: 28.96, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type",The patient is a 34-year-old white male with a BMI of 28.96. He is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer cells. The patient has a fully active performance status and his KRAS biomarker is wild-type.
1155,white,male,38,28.2,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,Yes,0,"race: white, sex: male, age: 38, bmi: 28.2, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type, adverse effect: infarction: Yes","The patient is a 38-year-old white male with a BMI of 28.2. He is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. His cancer histology is well-differentiated, and he has a fully active performance status. The KRAS biomarker testing showed that he has a wild-type KRAS status. Unfortunately, he experienced an adverse effect in the form of an infarction."
1156,white,male,64,31.09,FOLFOX + Cetuximab,No,No,Yes,No,7,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 64, bmi: 31.09, treatment arm: FOLFOX + Cetuximab, bowel obstruction: Yes, chemotherapy cycles: 7, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","This patient is a 64-year-old white male with a BMI of 31.09. He is receiving treatment with FOLFOX + Cetuximab for his cancer. He has experienced a bowel obstruction and has completed 7 cycles of chemotherapy. The histology of his cancer is well differentiated. Despite his condition, his performance status is fully active. His KRAS biomarker status is wild-type."
1157,white,female,55,25.9,FOLFIRI + Cetuximab,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,Yes,No,No,0,"race: white, sex: female, age: 55, bmi: 25.9, treatment arm: FOLFIRI + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type, adverse effect: diarrhea: Yes","The patient is a 55-year-old white female with a BMI of 25.9 who is undergoing treatment with FOLFIRI + Cetuximab. She has completed 12 cycles of chemotherapy and has well-differentiated histology. Her performance status is fully active, and her KRAS biomarker is wild-type. She is experiencing diarrhea as an adverse effect of the treatment."
1158,white,male,73,37.86,FOLFOX,Yes,No,Yes,No,11,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 73, bmi: 37.86, treatment arm: FOLFOX, adherence: Yes, bowel obstruction: Yes, chemotherapy cycles: 11, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 73-year-old white male with a BMI of 37.86. He is receiving treatment in the FOLFOX treatment arm and has been adherent to the treatment. He is currently experiencing a bowel obstruction. The patient has completed 11 cycles of chemotherapy and has a histology of well-differentiated cancer. Despite the bowel obstruction, his performance status is fully active. Additionally, the KRAS biomarker indicates that he has a wild-type status."
1159,white,female,61,34.45,FOLFOX,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 61, bmi: 34.45, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type",The patient is a 61-year-old white female with a BMI of 34.45. She is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. The histology of her cancer is well-differentiated. She has a fully active performance status. Her KRAS biomarker status is wild-type.
1160,white,male,56,27.22,FOLFOX,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 56, bmi: 27.22, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 56-year-old white male with a BMI of 27.22. He is receiving the FOLFOX treatment arm and is scheduled for 12 cycles of chemotherapy. His histology shows well-differentiated cells, and he has a fully active performance status. The KRAS biomarker analysis indicates that he has a wild-type KRAS status."
1161,white,female,58,28.28,FOLFOX,No,No,No,No,1,well differentiated,symptoms but ambulatory,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 58, bmi: 28.28, treatment arm: FOLFOX, chemotherapy cycles: 1, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type","The patient is a 58-year-old white female with a BMI of 28.28. She is currently receiving the FOLFOX treatment regimen and has completed one cycle of chemotherapy. Her histology shows well-differentiated cancer cells. Despite experiencing symptoms, she is still able to be ambulatory. Additionally, her KRAS biomarker indicates that it is wild-type."
1162,white,male,67,31.42,FOLFOX,Yes,No,Yes,Yes,12,well differentiated,symptoms but ambulatory,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 67, bmi: 31.42, treatment arm: FOLFOX, adherence: Yes, bowel obstruction: Yes, bowel perforation: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type","The patient is a 67-year-old white male with a BMI of 31.42. He is receiving the FOLFOX treatment regimen and has been adherent to the treatment. He has experienced a bowel obstruction and perforation. The patient has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer cells. Despite experiencing symptoms, he is still able to be ambulatory. The KRAS biomarker analysis indicates that he has a wild-type KRAS status."
1163,white,female,54,27.96,FOLFOX + Cetuximab,No,No,No,No,12,poorly differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 54, bmi: 27.96, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 54-year-old white female with a BMI of 27.96. She is undergoing treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. The histology of her cancer is poorly differentiated. Despite this, her performance status is fully active. Additionally, her KRAS biomarker status is wild-type."
1164,white,female,67,36.11,FOLFOX,No,No,No,No,12,well differentiated,fully active,mutant,No,No,No,No,No,0,"race: white, sex: female, age: 67, bmi: 36.11, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 67-year-old white female with a BMI of 36.11. She is receiving the FOLFOX treatment arm and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cancer cells. Despite her age and BMI, her performance status is fully active. Additionally, she has a mutant KRAS biomarker."
1165,white,female,42,43.49,FOLFOX,No,No,No,No,5,well differentiated,fully active,mutant,No,No,No,No,No,0,"race: white, sex: female, age: 42, bmi: 43.49, treatment arm: FOLFOX, chemotherapy cycles: 5, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 42-year-old white female with a BMI of 43.49. She is receiving the FOLFOX treatment arm and has completed 5 cycles of chemotherapy. Her histology shows well-differentiated cancer cells. Despite her high BMI, her performance status is fully active. The KRAS biomarker analysis indicates a mutant status."
1166,white,male,70,27.62,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,symptoms but ambulatory,wild-type,No,No,No,Yes,No,0,"race: white, sex: male, age: 70, bmi: 27.62, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type, adverse effect: infection: Yes","The patient is a 70-year-old white male with a BMI of 27.62. He is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer. Despite experiencing symptoms, he is still able to be ambulatory. His KRAS biomarker is wild-type. The patient has developed an infection as an adverse effect of the treatment."
1167,white,male,75,31.14,FOLFOX,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 75, bmi: 31.14, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 75-year-old white male with a BMI of 31.14. He is undergoing treatment with the FOLFOX chemotherapy regimen and has completed 12 cycles. His cancer histology is well differentiated, and he has a fully active performance status. The KRAS biomarker testing revealed that he has a wild-type KRAS status."
1168,white,female,44,24.3,FOLFOX + Cetuximab,No,Yes,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 44, bmi: 24.3, treatment arm: FOLFOX + Cetuximab, serious adverse effect: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 44-year-old white female with a BMI of 24.3. She is receiving treatment with FOLFOX + Cetuximab and has experienced a serious adverse effect. She has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cells. Despite the adverse effect, her performance status is fully active. The KRAS biomarker analysis indicates that she has a wild-type KRAS gene."
1169,white,male,42,27.64,FOLFOX,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 42, bmi: 27.64, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 42-year-old white male with a BMI of 27.64. He is undergoing treatment with the FOLFOX chemotherapy regimen and is scheduled for 12 cycles. His cancer histology is well-differentiated, and he has a fully active performance status. The KRAS biomarker analysis indicates that he has a wild-type KRAS status."
1170,white,male,48,30.25,FOLFIRI (KRAS mutant),Yes,No,No,No,12,well differentiated,symptoms but ambulatory,wild-type,No,No,No,No,No,1,"race: white, sex: male, age: 48, bmi: 30.25, treatment arm: FOLFIRI (KRAS mutant), adherence: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type","The patient is a 48-year-old white male with a BMI of 30.25. He is receiving the FOLFIRI treatment regimen for his KRAS mutant status and has been adherent to the treatment. He has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer cells. Despite experiencing symptoms, he is still able to be ambulatory. His KRAS biomarker is wild-type."
1171,white,female,67,18.66,FOLFOX + Cetuximab,No,Yes,Yes,No,12,well differentiated,symptoms but ambulatory,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 67, bmi: 18.66, treatment arm: FOLFOX + Cetuximab, serious adverse effect: Yes, bowel obstruction: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type","This patient is a 67-year-old white female with a BMI of 18.66. She is receiving treatment with FOLFOX + Cetuximab and has experienced a serious adverse effect, specifically a bowel obstruction. She has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cells. Despite experiencing symptoms, she is still able to be ambulatory. Additionally, her KRAS biomarker indicates that it is wild-type."
1172,other,female,38,20.62,FOLFOX + Cetuximab,Yes,No,No,No,12,well differentiated,symptoms but ambulatory,wild-type,No,No,No,No,No,0,"race: other, sex: female, age: 38, bmi: 20.62, treatment arm: FOLFOX + Cetuximab, adherence: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type","The patient is a 38-year-old female of a race categorized as ""other"" with a BMI of 20.62. She is currently undergoing treatment in the FOLFOX + Cetuximab treatment arm and has been adherent to her treatment. She has completed 12 cycles of chemotherapy. The histology indicates that the cancer is well-differentiated. Despite experiencing symptoms, the patient is still ambulatory. Additionally, the KRAS biomarker shows that it is wild-type."
1173,white,male,51,28.1,FOLFOX,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 51, bmi: 28.1, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type",The patient is a 51-year-old white male with a BMI of 28.1. He is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. His cancer histology is well differentiated. The patient has a fully active performance status. His KRAS biomarker status is wild-type.
1174,other,male,67,26.67,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,fully active,mutant,No,No,No,No,No,0,"race: other, sex: male, age: 67, bmi: 26.67, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 67-year-old male of a race categorized as ""other"" with a BMI of 26.67. He is receiving treatment in the FOLFOX + Cetuximab treatment arm and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cells, and he has a fully active performance status. The KRAS biomarker analysis indicates a mutant status."
1175,white,male,47,24.81,FOLFOX,No,No,Yes,No,0,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 47, bmi: 24.81, treatment arm: FOLFOX, bowel obstruction: Yes, chemotherapy cycles: 0, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 47-year-old white male with a BMI of 24.81. He is in the FOLFOX treatment arm and has a bowel obstruction. He has not undergone any chemotherapy cycles yet. His histology shows well-differentiated cells, and his performance status is fully active. The KRAS biomarker indicates that he has a wild-type gene."
1176,white,female,49,19.18,FOLFIRI (KRAS mutant),No,No,No,No,12,well differentiated,symptoms but ambulatory,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 49, bmi: 19.18, treatment arm: FOLFIRI (KRAS mutant), chemotherapy cycles: 12, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type","The patient is a 49-year-old white female with a BMI of 19.18. She is receiving the FOLFIRI treatment regimen for her KRAS mutant status. She has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cancer cells. Despite experiencing symptoms, she is still able to be ambulatory. The KRAS biomarker indicates that she has a wild-type KRAS gene."
1177,white,male,54,31.4,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,Yes,No,0,"race: white, sex: male, age: 54, bmi: 31.4, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type, adverse effect: infection: Yes","The patient is a 54-year-old white male with a BMI of 31.4. He is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer, and he has a fully active performance status. The KRAS biomarker is wild-type. The patient has experienced an infection as an adverse effect of the treatment."
1178,black,female,63,18.91,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,symptoms but ambulatory,mutant,No,No,No,No,No,0,"race: black, sex: female, age: 63, bmi: 18.91, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: mutant","The patient is a 63-year-old Black female with a BMI of 18.91. She is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cancer. Despite experiencing symptoms, she is still able to walk around (ambulatory). The KRAS biomarker analysis revealed a mutant status."
1179,black,male,56,16.54,FOLFOX + Cetuximab,No,No,No,No,9,well differentiated,fully active,interminate,No,No,No,No,No,0,"race: black, sex: male, age: 56, bmi: 16.54, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 9, histology: well differentiated, performance status: fully active, KRAS biomarker: interminate","The patient is a 56-year-old Black male with a BMI of 16.54. He is receiving treatment in the FOLFOX + Cetuximab treatment arm and has completed 9 chemotherapy cycles. His histology shows well-differentiated cancer cells. Despite his cancer diagnosis, he has a fully active performance status. The KRAS biomarker status is indeterminate for this patient."
1180,white,female,53,30.98,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 53, bmi: 30.98, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type",The patient is a 53-year-old white female with a BMI of 30.98. She is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. Her cancer histology is well differentiated. She has a fully active performance status. The KRAS biomarker testing showed that she has a wild-type KRAS status.
1181,white,male,55,29.6,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 55, bmi: 29.6, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 55-year-old white male with a BMI of 29.6. He is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. His cancer histology is well differentiated, and he has a fully active performance status. The KRAS biomarker testing revealed that he has a wild-type KRAS status."
1182,other,male,71,26.04,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,symptoms but ambulatory,mutant,No,No,No,No,No,0,"race: other, sex: male, age: 71, bmi: 26.04, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: mutant","The patient is a 71-year-old male of a race categorized as ""other"" with a BMI of 26.04. He is receiving treatment in the FOLFOX + Cetuximab treatment arm and has completed 12 cycles of chemotherapy. His histology shows well-differentiated characteristics. Despite experiencing symptoms, he is still able to be ambulatory. Additionally, the patient's KRAS biomarker indicates a mutant status."
1183,white,male,50,26.22,FOLFOX,No,No,No,No,12,well differentiated,fully active,mutant,No,No,No,No,No,0,"race: white, sex: male, age: 50, bmi: 26.22, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 50-year-old white male with a BMI of 26.22. He is receiving the FOLFOX treatment arm for his cancer and has completed 12 cycles of chemotherapy. The histology of his cancer is well-differentiated. Despite his cancer treatment, he has a fully active performance status. The KRAS biomarker testing revealed a mutant status."
1184,other,female,60,27.44,FOLFOX + Cetuximab,No,Yes,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: other, sex: female, age: 60, bmi: 27.44, treatment arm: FOLFOX + Cetuximab, serious adverse effect: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 60-year-old female of a race other than Caucasian, with a BMI of 27.44. She is receiving treatment with FOLFOX + Cetuximab for her well-differentiated histology. Unfortunately, she has experienced a serious adverse effect during her 12 chemotherapy cycles. Despite this, her performance status is fully active. Additionally, her KRAS biomarker is wild-type."
1185,white,male,51,28.99,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 51, bmi: 28.99, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 51-year-old white male with a BMI of 28.99. He is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. His cancer histology is well-differentiated, and he has a fully active performance status. The KRAS biomarker analysis shows that he has a wild-type KRAS status."
1186,white,male,37,30.58,FOLFOX,No,No,No,Yes,6,poorly differentiated,fully active,wild-type,Yes,No,No,No,No,0,"race: white, sex: male, age: 37, bmi: 30.58, treatment arm: FOLFOX, bowel perforation: Yes, chemotherapy cycles: 6, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type, adverse effect: thrombosis: Yes","This patient is a 37-year-old white male with a BMI of 30.58. He is receiving the FOLFOX treatment regimen and has experienced a bowel perforation. He has completed 6 cycles of chemotherapy. The histology of his cancer is poorly differentiated. Despite these challenges, his performance status is fully active. His KRAS biomarker is wild-type. Additionally, he has experienced the adverse effect of thrombosis."
1187,other,female,72,31.87,FOLFOX,Yes,Yes,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: other, sex: female, age: 72, bmi: 31.87, treatment arm: FOLFOX, adherence: Yes, serious adverse effect: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 72-year-old female of a race other than Caucasian. She has a BMI of 31.87 and is undergoing treatment with the FOLFOX regimen for her well-differentiated histology. She has completed 12 cycles of chemotherapy and has been adherent to her treatment. However, she has experienced a serious adverse effect. Despite this, her performance status remains fully active. Additionally, her KRAS biomarker status is wild-type."
1188,white,female,73,24.56,FOLFOX + Cetuximab,Yes,No,No,No,11,well differentiated,symptoms but ambulatory,interminate,No,No,No,No,No,0,"race: white, sex: female, age: 73, bmi: 24.56, treatment arm: FOLFOX + Cetuximab, adherence: Yes, chemotherapy cycles: 11, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: interminate","The patient is a 73-year-old white female with a BMI of 24.56. She is currently receiving treatment in the FOLFOX + Cetuximab treatment arm and has been adherent to her treatment. She has completed 11 chemotherapy cycles. Her histology shows well-differentiated cancer cells. Despite experiencing symptoms, she is still able to be ambulatory. The KRAS biomarker status is indeterminate for this patient."
1189,white,male,42,28.74,FOLFIRI + Cetuximab,No,No,Yes,No,6,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 42, bmi: 28.74, treatment arm: FOLFIRI + Cetuximab, bowel obstruction: Yes, chemotherapy cycles: 6, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type",The patient is a 42-year-old white male with a BMI of 28.74. He is receiving treatment in the FOLFIRI + Cetuximab treatment arm. He has a bowel obstruction and has completed 6 cycles of chemotherapy. The histology shows well-differentiated cells. The patient has a fully active performance status. The KRAS biomarker indicates that he has a wild-type gene.
1190,white,female,34,23.23,FOLFOX,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 34, bmi: 23.23, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 34-year-old white female with a BMI of 23.23. She is undergoing treatment with the FOLFOX chemotherapy regimen and has completed 12 cycles. Her cancer histology is well-differentiated, and she has a fully active performance status. Additionally, her KRAS biomarker status is wild-type."
1191,white,female,54,37.11,FOLFOX + Cetuximab,No,No,No,No,1,well differentiated,fully active,wild-type,No,No,No,No,No,1,"race: white, sex: female, age: 54, bmi: 37.11, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 1, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type",The patient is a 54-year-old white female with a BMI of 37.11. She is receiving treatment with FOLFOX + Cetuximab and has completed one cycle of chemotherapy. Her cancer histology is well differentiated. She has a fully active performance status. The KRAS biomarker analysis shows that she has a wild-type KRAS status.
1192,white,female,40,27.37,FOLFOX,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 40, bmi: 27.37, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 40-year-old white female with a BMI of 27.37. She is receiving treatment with the FOLFOX chemotherapy regimen and is scheduled for 12 cycles. Her cancer histology is well differentiated. Despite her diagnosis, she has a fully active performance status. Additionally, her KRAS biomarker status is wild-type."
1193,white,male,48,30.53,FOLFOX + Cetuximab,No,No,No,No,12,poorly differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 48, bmi: 30.53, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 48-year-old white male with a BMI of 30.53. He is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. His cancer histology is poorly differentiated, and he has a fully active performance status. The KRAS biomarker analysis shows that he has a wild-type KRAS status."
1194,white,male,40,38.58,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,symptoms but ambulatory,mutant,Yes,No,No,No,No,0,"race: white, sex: male, age: 40, bmi: 38.58, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: mutant, adverse effect: thrombosis: Yes","The patient is a 40-year-old white male with a BMI of 38.58. He is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer cells. Despite experiencing symptoms, he is still able to be ambulatory. The KRAS biomarker analysis revealed a mutant status. Additionally, the patient has developed thrombosis as an adverse effect."
1195,white,male,61,23.99,FOLFOX,No,No,No,No,12,poorly differentiated,fully active,wild-type,No,No,No,No,No,1,"race: white, sex: male, age: 61, bmi: 23.99, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 61-year-old white male with a BMI of 23.99. He is receiving treatment with the FOLFOX chemotherapy regimen and has completed 12 cycles. His cancer histology is poorly differentiated. Despite this, his performance status is fully active. Additionally, his KRAS biomarker status is wild-type."
1196,other,female,41,26.8,FOLFOX,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: other, sex: female, age: 41, bmi: 26.8, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 41-year-old female of a race categorized as ""other"" with a BMI of 26.8. She is receiving the FOLFOX treatment arm and has completed 12 cycles of chemotherapy. The histology shows well-differentiated cells, and her performance status is fully active. Additionally, the KRAS biomarker indicates that she has a wild-type status."
1197,white,male,59,29.48,FOLFOX,No,No,No,No,12,poorly differentiated,fully active,mutant,No,No,No,No,No,0,"race: white, sex: male, age: 59, bmi: 29.48, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 59-year-old white male with a BMI of 29.48. He is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. His histology shows poorly differentiated cancer cells. Despite this, his performance status is fully active. The KRAS biomarker analysis indicates that he has a mutant KRAS status."
1198,white,female,65,31.15,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 65, bmi: 31.15, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 65-year-old white female with a BMI of 31.15. She is receiving treatment in the FOLFOX + Cetuximab treatment arm and is scheduled for 12 chemotherapy cycles. Her histology shows well-differentiated cancer cells. Despite her age, she has a fully active performance status. Additionally, her KRAS biomarker indicates that it is wild-type."
1199,white,male,44,29.03,FOLFOX,Yes,No,No,No,12,well differentiated,symptoms but ambulatory,interminate,No,No,No,No,No,0,"race: white, sex: male, age: 44, bmi: 29.03, treatment arm: FOLFOX, adherence: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: interminate","The patient is a 44-year-old white male with a BMI of 29.03. He is receiving treatment in the FOLFOX arm and has been adherent to the chemotherapy regimen for 12 cycles. His histology shows well-differentiated cancer cells. Despite experiencing symptoms, he is still able to be ambulatory. The KRAS biomarker status is indeterminate for this patient."
1200,white,female,39,31.72,FOLFOX,No,No,No,No,12,well differentiated,fully active,mutant,No,No,No,No,No,0,"race: white, sex: female, age: 39, bmi: 31.72, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 39-year-old white female with a BMI of 31.72. She is receiving treatment with the FOLFOX chemotherapy regimen and has completed 12 cycles. Her cancer histology is well differentiated, and she has a fully active performance status. The KRAS biomarker testing revealed a mutant status."
1201,white,male,65,26.59,FOLFIRI,No,No,No,Yes,12,well differentiated,symptoms but ambulatory,wild-type,No,No,No,No,No,1,"race: white, sex: male, age: 65, bmi: 26.59, treatment arm: FOLFIRI, bowel perforation: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type","The patient is a 65-year-old white male with a BMI of 26.59. He is undergoing treatment with the FOLFIRI regimen and has experienced a bowel perforation. He has completed 12 cycles of chemotherapy. The histology shows well-differentiated cancer cells. Despite experiencing symptoms, the patient is still able to be ambulatory. The KRAS biomarker indicates that the cancer cells are wild-type."
1202,white,male,63,34.54,FOLFOX,No,Yes,No,No,12,poorly differentiated,fully active,mutant,No,No,No,No,No,0,"race: white, sex: male, age: 63, bmi: 34.54, treatment arm: FOLFOX, serious adverse effect: Yes, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 63-year-old white male with a BMI of 34.54. He is receiving the FOLFOX treatment arm for his cancer. Unfortunately, he has experienced a serious adverse effect during his treatment. He has completed 12 cycles of chemotherapy. His cancer histology is poorly differentiated. Despite his condition, he has a fully active performance status. The KRAS biomarker testing revealed that he has a mutant KRAS status."
1203,white,male,47,24.59,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,Yes,No,0,"race: white, sex: male, age: 47, bmi: 24.59, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type, adverse effect: infection: Yes","The patient is a 47-year-old white male with a BMI of 24.59 who is undergoing treatment with FOLFOX + Cetuximab for his well-differentiated cancer. He has completed 12 cycles of chemotherapy and has a fully active performance status. The KRAS biomarker testing showed that he has a wild-type KRAS status. Unfortunately, he has experienced an infection as an adverse effect during his treatment."
1204,white,female,74,19.6,FOLFOX,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 74, bmi: 19.6, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type",The patient is a 74-year-old white female with a BMI of 19.6. She is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cells. She has a fully active performance status. The KRAS biomarker analysis indicates that she has a wild-type KRAS status.
1205,white,female,63,30.32,FOLFOX,No,No,No,No,12,well differentiated,fully active,mutant,No,No,No,No,No,0,"race: white, sex: female, age: 63, bmi: 30.32, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 63-year-old white female with a BMI of 30.32. She is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. Her cancer histology is well differentiated. Despite her age, she has a fully active performance status. The KRAS biomarker testing revealed a mutant status."
1206,white,female,46,33.95,FOLFOX + Cetuximab,No,No,No,No,12,poorly differentiated,symptoms but ambulatory,mutant,No,No,No,No,No,0,"race: white, sex: female, age: 46, bmi: 33.95, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: poorly differentiated, performance status: symptoms but ambulatory, KRAS biomarker: mutant","The patient is a 46-year-old white female with a BMI of 33.95. She is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. Her histology shows poorly differentiated cancer. Despite experiencing symptoms, she is still able to be ambulatory. The patient's KRAS biomarker indicates a mutant status."
1207,white,female,52,29.44,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,Yes,No,No,0,"race: white, sex: female, age: 52, bmi: 29.44, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type, adverse effect: diarrhea: Yes","The patient is a 52-year-old white female with a BMI of 29.44. She is receiving treatment with FOLFOX + Cetuximab and has completed 12 chemotherapy cycles. Her histology shows well-differentiated cancer, and she has a fully active performance status. The KRAS biomarker is wild-type. The patient is experiencing diarrhea as an adverse effect of the treatment."
1208,white,male,54,23.19,FOLFOX,No,No,No,No,12,poorly differentiated,symptoms but ambulatory,wild-type,No,No,No,No,No,1,"race: white, sex: male, age: 54, bmi: 23.19, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: poorly differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type","The patient is a 54-year-old white male with a BMI of 23.19. He is receiving the FOLFOX treatment arm and has completed 12 cycles of chemotherapy. His histology shows poorly differentiated cancer cells. Despite experiencing symptoms, he is still able to be ambulatory. The KRAS biomarker analysis indicates that he has a wild-type KRAS status."
1209,white,male,69,29.79,FOLFOX,No,Yes,Yes,No,12,well differentiated,symptoms but ambulatory,mutant,No,No,No,No,No,0,"race: white, sex: male, age: 69, bmi: 29.79, treatment arm: FOLFOX, serious adverse effect: Yes, bowel obstruction: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: mutant","The patient is a 69-year-old white male with a BMI of 29.79. He is undergoing treatment with the FOLFOX regimen and has experienced a serious adverse effect. He is currently dealing with a bowel obstruction. He has completed 12 cycles of chemotherapy. The histology shows well-differentiated cells. Despite experiencing symptoms, the patient is still able to be ambulatory. The KRAS biomarker analysis indicates a mutant status."
1210,white,male,48,35.63,FOLFOX + Cetuximab,No,No,No,No,11,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 48, bmi: 35.63, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 11, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 48-year-old white male with a BMI of 35.63. He is receiving treatment with FOLFOX + Cetuximab and has completed 11 cycles of chemotherapy. His cancer histology is well-differentiated, and he has a fully active performance status. The KRAS biomarker testing showed that he has a wild-type KRAS status."
1211,black,male,58,35.8,FOLFOX + Cetuximab,Yes,No,No,No,0,poorly differentiated,fully active,interminate,No,No,No,No,No,0,"race: black, sex: male, age: 58, bmi: 35.8, treatment arm: FOLFOX + Cetuximab, adherence: Yes, chemotherapy cycles: 0, histology: poorly differentiated, performance status: fully active, KRAS biomarker: interminate","This patient is a 58-year-old Black male with a BMI of 35.8. He is enrolled in the treatment arm receiving FOLFOX + Cetuximab. He has been adherent to the treatment plan. So far, he has not started any chemotherapy cycles. His histology shows poorly differentiated cells. Despite this, his performance status is fully active. The KRAS biomarker status is indeterminate."
1212,white,female,67,40.94,FOLFOX + Cetuximab,Yes,No,Yes,No,12,poorly differentiated,symptoms but ambulatory,wild-type,No,No,Yes,No,No,1,"race: white, sex: female, age: 67, bmi: 40.94, treatment arm: FOLFOX + Cetuximab, adherence: Yes, bowel obstruction: Yes, chemotherapy cycles: 12, histology: poorly differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type, adverse effect: diarrhea: Yes","The patient is a 67-year-old white female with a BMI of 40.94. She is receiving treatment with FOLFOX + Cetuximab and has been adherent to the treatment. She is currently experiencing a bowel obstruction and has completed 12 cycles of chemotherapy. The histology shows poorly differentiated cells, and her performance status is symptomatic but still ambulatory. The KRAS biomarker is wild-type. She is also experiencing diarrhea as an adverse effect of the treatment."
1213,white,male,43,30.37,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,symptoms but ambulatory,mutant,No,No,No,No,No,0,"race: white, sex: male, age: 43, bmi: 30.37, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: mutant","The patient is a 43-year-old white male with a BMI of 30.37. He is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer. Despite experiencing symptoms, he is still able to walk around (ambulatory). The KRAS biomarker analysis indicates a mutant status."
1214,other,female,49,25.06,FOLFOX + Cetuximab,No,No,No,No,7,well differentiated,fully active,mutant,No,No,No,No,No,0,"race: other, sex: female, age: 49, bmi: 25.06, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 7, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 49-year-old female of a race other than specified, with a BMI of 25.06. She is currently undergoing treatment in the FOLFOX + Cetuximab treatment arm and has completed 7 cycles of chemotherapy. The histology of her condition is well-differentiated. Despite her treatment, she has a fully active performance status. Additionally, the KRAS biomarker testing has revealed a mutant status."
1215,white,male,52,22.82,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 52, bmi: 22.82, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type",The patient is a 52-year-old white male with a BMI of 22.82. He is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. His cancer histology is well-differentiated. The patient has a fully active performance status and his KRAS biomarker is wild-type.
1216,white,female,58,22.61,FOLFOX,No,No,No,No,12,poorly differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 58, bmi: 22.61, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 58-year-old white female with a BMI of 22.61. She is undergoing treatment with the FOLFOX chemotherapy regimen and has completed 12 cycles. The histology of her cancer is poorly differentiated. Despite this, her performance status is fully active. Additionally, her KRAS biomarker status is wild-type."
1217,white,female,72,23.54,FOLFOX,No,No,No,No,2,poorly differentiated,fully active,wild-type,No,No,Yes,No,No,0,"race: white, sex: female, age: 72, bmi: 23.54, treatment arm: FOLFOX, chemotherapy cycles: 2, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type, adverse effect: diarrhea: Yes","The patient is a 72-year-old white female with a BMI of 23.54. She is currently undergoing treatment with the FOLFOX chemotherapy regimen and has completed 2 cycles so far. The histology of her cancer is poorly differentiated. Despite this, her performance status is fully active. The KRAS biomarker testing revealed that she has a wild-type KRAS status. She is experiencing diarrhea as an adverse effect of the treatment."
1218,white,female,54,23.22,FOLFOX,Yes,No,No,No,12,well differentiated,fully active,wild-type,No,No,Yes,No,No,0,"race: white, sex: female, age: 54, bmi: 23.22, treatment arm: FOLFOX, adherence: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type, adverse effect: diarrhea: Yes","The patient is a 54-year-old white female with a BMI of 23.22 who is undergoing treatment with the FOLFOX chemotherapy regimen. She has been adherent to her treatment, completing 12 cycles of chemotherapy. Her histology shows well-differentiated cancer cells, and she has a fully active performance status. The KRAS biomarker testing indicates that she has a wild-type KRAS status. The patient has experienced diarrhea as an adverse effect of the treatment."
1219,white,female,65,22.83,FOLFOX + Cetuximab,No,Yes,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 65, bmi: 22.83, treatment arm: FOLFOX + Cetuximab, serious adverse effect: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 65-year-old white female with a BMI of 22.83. She is undergoing treatment with FOLFOX + Cetuximab and has experienced a serious adverse effect. She has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cells. Despite her treatment, her performance status is fully active. Additionally, her KRAS biomarker indicates that she has a wild-type mutation."
1220,other,female,67,26.78,FOLFOX,No,No,No,No,4,well differentiated,symptoms but ambulatory,wild-type,No,No,No,No,No,0,"race: other, sex: female, age: 67, bmi: 26.78, treatment arm: FOLFOX, chemotherapy cycles: 4, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type","The patient is a 67-year-old female of a race classified as ""other"" with a BMI of 26.78. She is currently undergoing treatment with the FOLFOX chemotherapy regimen and has completed 4 cycles so far. The histology of her cancer is well-differentiated. Despite experiencing symptoms, she is still able to be ambulatory. Additionally, her KRAS biomarker status is wild-type."
1221,other,female,45,25.39,FOLFOX,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,Yes,No,No,0,"race: other, sex: female, age: 45, bmi: 25.39, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type, adverse effect: diarrhea: Yes","The patient is a 45-year-old female of a race categorized as ""other"" with a BMI of 25.39. She is undergoing treatment with the FOLFOX regimen and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cancer cells, and she has a fully active performance status. The KRAS biomarker analysis indicates that she has a wild-type KRAS status. The patient is experiencing diarrhea as an adverse effect."
1222,white,male,66,36.56,FOLFOX,No,Yes,No,No,12,poorly differentiated,symptoms but ambulatory,mutant,No,Yes,No,No,No,0,"race: white, sex: male, age: 66, bmi: 36.56, treatment arm: FOLFOX, serious adverse effect: Yes, chemotherapy cycles: 12, histology: poorly differentiated, performance status: symptoms but ambulatory, KRAS biomarker: mutant, adverse effect: hypersensitivity: Yes","The patient is a 66-year-old white male with a BMI of 36.56. He is receiving the FOLFOX treatment regimen and has experienced a serious adverse effect. He has completed 12 cycles of chemotherapy. The histology of his cancer is poorly differentiated. Despite experiencing symptoms, he is still able to be ambulatory. The KRAS biomarker testing revealed a mutant status. Additionally, he has developed hypersensitivity as an adverse effect."
1223,white,male,48,33.53,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 48, bmi: 33.53, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 48-year-old white male with a BMI of 33.53. He is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. His cancer histology is well-differentiated, and he has a fully active performance status. The KRAS biomarker analysis shows that he has a wild-type KRAS status."
1224,black,male,41,24.65,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,fully active,interminate,No,No,No,No,No,0,"race: black, sex: male, age: 41, bmi: 24.65, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: interminate",The patient is a 41-year-old Black male with a BMI of 24.65. He is receiving treatment with FOLFOX + Cetuximab and is scheduled for 12 chemotherapy cycles. His histology shows well-differentiated cells. The patient has a fully active performance status. The KRAS biomarker status is indeterminate.
1225,other,female,41,28.76,FOLFOX,No,No,No,No,12,well differentiated,fully active,mutant,No,No,No,No,No,0,"race: other, sex: female, age: 41, bmi: 28.76, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 41-year-old female of a race categorized as ""other"" with a BMI of 28.76. She is undergoing treatment with the FOLFOX chemotherapy regimen and has completed 12 cycles. The histology of her condition is well-differentiated, and her performance status is fully active. Additionally, the KRAS biomarker analysis has shown a mutant status."
1226,white,female,44,28.52,FOLFOX,Yes,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 44, bmi: 28.52, treatment arm: FOLFOX, adherence: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 44-year-old white female with a BMI of 28.52. She is receiving treatment in the FOLFOX arm and has been adherent to her chemotherapy regimen, completing 12 cycles. Her histology shows well-differentiated cells, and she has a fully active performance status. Additionally, her KRAS biomarker is wild-type."
1227,white,female,45,33.73,FOLFOX,No,No,No,No,12,well differentiated,fully active,mutant,No,No,No,No,No,0,"race: white, sex: female, age: 45, bmi: 33.73, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant",The patient is a 45-year-old white female with a BMI of 33.73. She is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. The histology shows well-differentiated cancer cells. The patient has a fully active performance status. The KRAS biomarker testing revealed a mutant status.
1228,white,male,44,29.25,FOLFOX,No,No,No,No,7,well differentiated,symptoms but ambulatory,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 44, bmi: 29.25, treatment arm: FOLFOX, chemotherapy cycles: 7, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type","The patient is a 44-year-old white male with a BMI of 29.25. He is currently receiving the FOLFOX treatment regimen and has completed 7 cycles of chemotherapy. The histology shows that the cancer is well-differentiated. Despite experiencing symptoms, the patient is still able to be ambulatory. The KRAS biomarker analysis indicates that the patient has a wild-type KRAS status."
1229,white,male,46,24.49,FOLFOX + Cetuximab,No,Yes,No,No,12,poorly differentiated,fully active,mutant,No,No,No,No,No,0,"race: white, sex: male, age: 46, bmi: 24.49, treatment arm: FOLFOX + Cetuximab, serious adverse effect: Yes, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 46-year-old white male with a BMI of 24.49. He is receiving treatment in the FOLFOX + Cetuximab treatment arm and has experienced a serious adverse effect. He has undergone 12 cycles of chemotherapy. His histology shows poorly differentiated cells. Despite this, his performance status is fully active. Additionally, the KRAS biomarker indicates a mutant status."
1230,white,female,61,28.53,FOLFOX + Cetuximab,No,Yes,Yes,No,12,well differentiated,symptoms but ambulatory,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 61, bmi: 28.53, treatment arm: FOLFOX + Cetuximab, serious adverse effect: Yes, bowel obstruction: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type","This patient is a 61-year-old white female with a BMI of 28.53. She is receiving treatment with FOLFOX + Cetuximab and has experienced a serious adverse effect, specifically a bowel obstruction. She has completed 12 cycles of chemotherapy. The histology of her cancer is well differentiated. Despite experiencing symptoms, she is still able to be ambulatory. Her KRAS biomarker status is wild-type."
1231,white,female,72,30.71,FOLFOX + Cetuximab,No,Yes,Yes,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 72, bmi: 30.71, treatment arm: FOLFOX + Cetuximab, serious adverse effect: Yes, bowel obstruction: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","This patient is a 72-year-old white female with a BMI of 30.71. She is receiving treatment with FOLFOX + Cetuximab for her well-differentiated histology. Unfortunately, she has experienced a serious adverse effect in the form of a bowel obstruction. Despite this, she has completed 12 cycles of chemotherapy and has a fully active performance status. Her KRAS biomarker status is wild-type."
1232,other,male,53,25.63,FOLFOX + Cetuximab,No,No,No,No,12,poorly differentiated,fully active,wild-type,No,No,No,No,No,0,"race: other, sex: male, age: 53, bmi: 25.63, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 53-year-old male of a race categorized as ""other"" with a BMI of 25.63. He is receiving treatment in the FOLFOX + Cetuximab treatment arm and is scheduled for 12 chemotherapy cycles. The histology of the cancer is poorly differentiated. Despite the cancer diagnosis, the patient has a fully active performance status. Additionally, the KRAS biomarker indicates that the patient has a wild-type KRAS gene."
1233,white,male,57,28.89,FOLFOX,No,No,Yes,No,12,well differentiated,fully active,mutant,No,No,No,No,No,0,"race: white, sex: male, age: 57, bmi: 28.89, treatment arm: FOLFOX, bowel obstruction: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 57-year-old white male with a BMI of 28.89. He is receiving the FOLFOX treatment regimen for his well-differentiated histology. He has experienced a bowel obstruction and has completed 12 cycles of chemotherapy. Despite these challenges, his performance status is fully active. Additionally, the patient's KRAS biomarker is mutant."
1234,white,male,50,30.34,FOLFOX + Cetuximab,No,No,Yes,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 50, bmi: 30.34, treatment arm: FOLFOX + Cetuximab, bowel obstruction: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type",The patient is a 50-year-old white male with a BMI of 30.34. He is undergoing treatment with FOLFOX + Cetuximab for bowel obstruction. He has completed 12 cycles of chemotherapy. The histology shows well-differentiated cells. The patient has a fully active performance status. His KRAS biomarker is wild-type.
1235,black,female,49,45.14,FOLFOX + Cetuximab,No,No,No,No,8,poorly differentiated,fully active,wild-type,No,No,Yes,Yes,No,0,"race: black, sex: female, age: 49, bmi: 45.14, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 8, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type, adverse effect: diarrhea: Yes, adverse effect: infection: Yes","The patient is a 49-year-old Black female with a BMI of 45.14. She is receiving treatment with FOLFOX + Cetuximab and has completed 8 cycles of chemotherapy. Her cancer histology is poorly differentiated, and she has a fully active performance status. The KRAS biomarker testing showed that she has a wild-type KRAS status. She has experienced adverse effects of diarrhea and infection during her treatment."
1236,other,male,75,17.86,FOLFOX,No,Yes,No,No,12,well differentiated,symptoms but ambulatory,wild-type,No,No,No,Yes,No,0,"race: other, sex: male, age: 75, bmi: 17.86, treatment arm: FOLFOX, serious adverse effect: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type, adverse effect: infection: Yes","The patient is a 75-year-old male of a race categorized as ""other"" with a BMI of 17.86. He is undergoing treatment with the FOLFOX regimen and has experienced a serious adverse effect. He has completed 12 cycles of chemotherapy and has well-differentiated histology. Despite experiencing symptoms, he is still able to be ambulatory. The KRAS biomarker shows that he has a wild-type status. Additionally, the patient has developed an infection as an adverse effect of the treatment."
1237,white,female,72,28.4,FOLFOX + Cetuximab,Yes,No,No,No,3,poorly differentiated,fully active,wild-type,No,No,Yes,No,No,0,"race: white, sex: female, age: 72, bmi: 28.4, treatment arm: FOLFOX + Cetuximab, adherence: Yes, chemotherapy cycles: 3, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type, adverse effect: diarrhea: Yes","The patient is a 72-year-old white female with a BMI of 28.4. She is currently receiving treatment with FOLFOX + Cetuximab and has been adherent to her medication. She has completed 3 cycles of chemotherapy. Histologically, she has poorly differentiated cancer. Despite this, her performance status is fully active. Her KRAS biomarker is wild-type. The patient has experienced diarrhea as an adverse effect of the treatment."
1238,white,female,61,35.74,FOLFIRI (KRAS mutant),No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 61, bmi: 35.74, treatment arm: FOLFIRI (KRAS mutant), chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 61-year-old white female with a BMI of 35.74. She is receiving treatment with the FOLFIRI regimen for KRAS mutant cancer. She has completed 12 cycles of chemotherapy. The histology of her cancer is well differentiated. Despite her cancer diagnosis, she has a fully active performance status. Notably, her KRAS biomarker is wild-type."
1239,white,male,66,26,FOLFOX,No,No,Yes,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 66, bmi: 26.0, treatment arm: FOLFOX, bowel obstruction: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 66-year-old white male with a BMI of 26.0. He is receiving the FOLFOX treatment regimen and has experienced a bowel obstruction. He has completed 12 cycles of chemotherapy. The histology shows well-differentiated cancer cells. Despite the bowel obstruction, the patient's performance status is fully active. The KRAS biomarker analysis indicates that the patient has a wild-type KRAS gene."
1240,white,female,47,22.32,FOLFOX,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 47, bmi: 22.32, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 47-year-old white female with a BMI of 22.32. She is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cells, and she has a fully active performance status. The KRAS biomarker analysis indicates that she has a wild-type KRAS status."
1241,white,female,64,40.74,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,symptoms but ambulatory,wild-type,No,Yes,No,No,No,0,"race: white, sex: female, age: 64, bmi: 40.74, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type, adverse effect: hypersensitivity: Yes","The patient is a 64-year-old white female with a BMI of 40.74. She is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. Her cancer histology is well-differentiated, and she has symptoms but is still able to be ambulatory. The KRAS biomarker testing showed that she has a wild-type KRAS status. She has experienced a hypersensitivity adverse effect during treatment."
1242,white,male,45,32.96,FOLFOX + Cetuximab,No,Yes,Yes,No,11,poorly differentiated,fully active,wild-type,No,No,No,No,No,1,"race: white, sex: male, age: 45, bmi: 32.96, treatment arm: FOLFOX + Cetuximab, serious adverse effect: Yes, bowel obstruction: Yes, chemotherapy cycles: 11, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type","This patient is a 45-year-old white male with a BMI of 32.96. He is receiving treatment with FOLFOX + Cetuximab for his cancer. Unfortunately, he has experienced a serious adverse effect, specifically a bowel obstruction. He has completed 11 cycles of chemotherapy. The histology of his cancer is poorly differentiated. Despite these challenges, his performance status is fully active. His KRAS biomarker status is wild-type."
1243,white,male,50,31.21,FOLFOX + Cetuximab,No,Yes,Yes,No,12,poorly differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 50, bmi: 31.21, treatment arm: FOLFOX + Cetuximab, serious adverse effect: Yes, bowel obstruction: Yes, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 50-year-old white male with a BMI of 31.21. He is receiving treatment with FOLFOX + Cetuximab. Unfortunately, he has experienced a serious adverse effect and is currently dealing with a bowel obstruction. He has completed 12 cycles of chemotherapy. The histology of his condition is poorly differentiated. Despite these challenges, his performance status is fully active. His KRAS biomarker status is wild-type."
1244,white,female,61,24.7,FOLFOX,No,No,No,No,10,poorly differentiated,fully active,mutant,No,No,No,No,No,0,"race: white, sex: female, age: 61, bmi: 24.7, treatment arm: FOLFOX, chemotherapy cycles: 10, histology: poorly differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 61-year-old white female with a BMI of 24.7. She is receiving the FOLFOX treatment regimen and has completed 10 cycles of chemotherapy. Her histology shows poorly differentiated cancer cells. Despite this, her performance status is fully active. Additionally, the KRAS biomarker testing revealed a mutant status."
1245,white,female,57,36.07,FOLFOX,No,No,Yes,No,12,poorly differentiated,symptoms but ambulatory,mutant,No,No,No,No,No,0,"race: white, sex: female, age: 57, bmi: 36.07, treatment arm: FOLFOX, bowel obstruction: Yes, chemotherapy cycles: 12, histology: poorly differentiated, performance status: symptoms but ambulatory, KRAS biomarker: mutant","The patient is a 57-year-old white female with a BMI of 36.07. She is receiving the FOLFOX treatment arm for her cancer. She has a bowel obstruction and has completed 12 cycles of chemotherapy. The histology of her cancer is poorly differentiated. Despite experiencing symptoms, she is still able to walk around (ambulatory). The KRAS biomarker test showed that she has a mutant KRAS status."
1246,white,female,70,40.44,FOLFOX + Cetuximab,No,No,No,No,12,poorly differentiated,fully active,mutant,No,No,Yes,No,No,0,"race: white, sex: female, age: 70, bmi: 40.44, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: mutant, adverse effect: diarrhea: Yes",This patient is a 70-year-old white female with a high BMI of 40.44. She is receiving treatment with FOLFOX + Cetuximab for her poorly differentiated cancer. She has completed 12 cycles of chemotherapy and has a fully active performance status. Her KRAS biomarker is mutant. She is experiencing diarrhea as an adverse effect of her treatment.
1247,white,female,43,21.93,FOLFOX,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 43, bmi: 21.93, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type",The patient is a 43-year-old white female with a BMI of 21.93. She is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. The histology shows well-differentiated cancer cells. The patient has a fully active performance status. The KRAS biomarker analysis indicates that she has a wild-type KRAS status.
1248,white,male,52,21.88,FOLFOX + Cetuximab,No,No,No,No,12,poorly differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 52, bmi: 21.88, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 52-year-old white male with a BMI of 21.88. He is receiving treatment in the FOLFOX + Cetuximab treatment arm and has completed 12 cycles of chemotherapy. His histology shows poorly differentiated cancer cells. Despite this, his performance status is fully active. Additionally, the KRAS biomarker analysis indicates that he has a wild-type KRAS status."
1249,white,male,74,19.84,FOLFOX + Cetuximab,No,No,Yes,No,12,poorly differentiated,fully active,mutant,No,No,Yes,No,No,1,"race: white, sex: male, age: 74, bmi: 19.84, treatment arm: FOLFOX + Cetuximab, bowel obstruction: Yes, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: mutant, adverse effect: diarrhea: Yes",The patient is a 74-year-old white male with a BMI of 19.84. He is receiving treatment with FOLFOX + Cetuximab for his poorly differentiated histology. He has experienced a bowel obstruction and is fully active in terms of performance status. The patient has a mutant KRAS biomarker and has undergone 12 cycles of chemotherapy. He is also experiencing diarrhea as an adverse effect of the treatment.
1250,white,female,73,26.29,FOLFOX,No,No,No,No,12,poorly differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 73, bmi: 26.29, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 73-year-old white female with a BMI of 26.29. She is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. The histology of her cancer is poorly differentiated. Despite her age, she has a fully active performance status. Additionally, her KRAS biomarker status is wild-type."
1251,white,female,45,36.42,FOLFOX,No,No,No,No,12,poorly differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 45, bmi: 36.42, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 45-year-old white female with a BMI of 36.42. She is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. Her histology shows poorly differentiated cancer cells. Despite this, her performance status is fully active. Additionally, her KRAS biomarker is wild-type."
1252,white,male,48,31.91,FOLFOX,Yes,Yes,Yes,No,4,well differentiated,symptoms but ambulatory,wild-type,No,No,No,No,No,1,"race: white, sex: male, age: 48, bmi: 31.91, treatment arm: FOLFOX, adherence: Yes, serious adverse effect: Yes, bowel obstruction: Yes, chemotherapy cycles: 4, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type","The patient is a 48-year-old white male with a BMI of 31.91. He is receiving treatment in the FOLFOX treatment arm and has been adherent to the treatment. He experienced a serious adverse effect in the form of a bowel obstruction after completing 4 cycles of chemotherapy. The histology of his cancer is well-differentiated. Despite experiencing symptoms, he is still ambulatory. His KRAS biomarker status is wild-type."
1253,white,male,59,44.71,FOLFOX,No,No,Yes,No,12,poorly differentiated,fully active,wild-type,No,Yes,No,No,No,0,"race: white, sex: male, age: 59, bmi: 44.71, treatment arm: FOLFOX, bowel obstruction: Yes, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type, adverse effect: hypersensitivity: Yes","The patient is a 59-year-old white male with a BMI of 44.71. He is receiving treatment with the FOLFOX regimen and has experienced a bowel obstruction. He has completed 12 cycles of chemotherapy. The histology of his cancer is poorly differentiated. Despite this, his performance status is fully active. His KRAS biomarker is wild-type. He has also experienced a hypersensitivity adverse effect."
1254,white,female,66,23.13,FOLFOX,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 66, bmi: 23.13, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type",The patient is a 66-year-old white female with a BMI of 23.13. She is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. The histology shows well-differentiated cancer cells. The patient has a fully active performance status. The KRAS biomarker indicates that she has a wild-type gene.
1255,white,female,63,25.66,FOLFOX,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 63, bmi: 25.66, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 63-year-old white female with a BMI of 25.66. She is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cancer cells. Despite her cancer diagnosis, she has a fully active performance status. Additionally, her KRAS biomarker indicates that it is wild-type."
1256,white,male,53,31.14,FOLFIRI + Cetuximab,Yes,Yes,No,No,1,well differentiated,fully active,mutant,No,No,No,No,Yes,1,"race: white, sex: male, age: 53, bmi: 31.14, treatment arm: FOLFIRI + Cetuximab, adherence: Yes, serious adverse effect: Yes, chemotherapy cycles: 1, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant, adverse effect: infarction: Yes","The patient is a 53-year-old white male with a BMI of 31.14 who is receiving treatment with FOLFIRI + Cetuximab. He has been adherent to the treatment regimen. After one cycle of chemotherapy, he experienced a serious adverse effect in the form of an infarction. The histology of his condition is well differentiated, and his performance status is fully active. Additionally, the KRAS biomarker testing revealed a mutant status."
1257,black,female,60,47.58,FOLFOX + Cetuximab,No,Yes,Yes,No,12,well differentiated,fully active,mutant,No,No,Yes,Yes,No,0,"race: black, sex: female, age: 60, bmi: 47.58, treatment arm: FOLFOX + Cetuximab, serious adverse effect: Yes, bowel obstruction: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant, adverse effect: diarrhea: Yes, adverse effect: infection: Yes","The patient is a 60-year-old Black female with a BMI of 47.58 who is undergoing treatment with FOLFOX + Cetuximab. She has experienced a serious adverse effect, specifically a bowel obstruction. She has completed 12 cycles of chemotherapy and has well-differentiated histology. Despite experiencing adverse effects such as diarrhea and infection, her performance status remains fully active. Additionally, her KRAS biomarker is mutant."
1258,other,female,73,19.26,FOLFOX,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: other, sex: female, age: 73, bmi: 19.26, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 73-year-old female of a race categorized as ""other"" with a BMI of 19.26. She is undergoing treatment with the FOLFOX chemotherapy regimen and has completed 12 cycles. The histology of her condition is well-differentiated. Despite her age, she has a fully active performance status. Additionally, her KRAS biomarker status is wild-type."
1259,white,male,64,34.65,FOLFOX,No,No,No,No,12,poorly differentiated,fully active,wild-type,No,No,Yes,No,No,0,"race: white, sex: male, age: 64, bmi: 34.65, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type, adverse effect: diarrhea: Yes","The patient is a 64-year-old white male with a BMI of 34.65. He is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. His histology shows poorly differentiated cancer cells. Despite this, his performance status is fully active. The KRAS biomarker testing indicates a wild-type result. The patient is experiencing diarrhea as an adverse effect of the treatment."
1260,white,female,34,24.02,FOLFOX,No,No,No,No,12,poorly differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 34, bmi: 24.02, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 34-year-old white female with a BMI of 24.02. She is undergoing treatment with the FOLFOX chemotherapy regimen and has completed 12 cycles. Her cancer histology is poorly differentiated. Despite this, her performance status is fully active. Additionally, her KRAS biomarker status is wild-type."
1261,white,male,66,28.51,FOLFIRI,No,No,No,No,12,well differentiated,fully active,mutant,No,No,Yes,No,No,0,"race: white, sex: male, age: 66, bmi: 28.51, treatment arm: FOLFIRI, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant, adverse effect: diarrhea: Yes","The patient is a 66-year-old white male with a BMI of 28.51. He is receiving treatment with FOLFIRI chemotherapy, and has completed 12 cycles so far. His histology shows well-differentiated cancer cells. Despite experiencing diarrhea as an adverse effect, his performance status is fully active. Additionally, the KRAS biomarker testing revealed a mutant status."
1262,white,female,41,43.1,FOLFOX,No,No,Yes,No,11,poorly differentiated,fully active,mutant,Yes,No,No,No,No,1,"race: white, sex: female, age: 41, bmi: 43.1, treatment arm: FOLFOX, bowel obstruction: Yes, chemotherapy cycles: 11, histology: poorly differentiated, performance status: fully active, KRAS biomarker: mutant, adverse effect: thrombosis: Yes","This patient is a 41-year-old white female with a BMI of 43.1 who is receiving the FOLFOX treatment regimen. She has experienced a bowel obstruction and has completed 11 cycles of chemotherapy. The histology of her cancer is poorly differentiated. Despite these challenges, her performance status is fully active. The KRAS biomarker testing revealed a mutant status. Additionally, she has experienced the adverse effect of thrombosis."
1263,white,male,62,25.24,FOLFOX,No,No,No,No,12,poorly differentiated,symptoms but ambulatory,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 62, bmi: 25.24, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: poorly differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type","The patient is a 62-year-old white male with a BMI of 25.24. He is undergoing treatment with the FOLFOX chemotherapy regimen and has completed 12 cycles. His cancer histology is poorly differentiated. Despite experiencing symptoms, he is still able to walk around (ambulatory). The KRAS biomarker testing revealed that he has a wild-type KRAS status."
1264,white,female,53,19.69,FOLFOX + Cetuximab,Yes,Yes,No,No,1,well differentiated,fully active,mutant,No,No,Yes,No,No,0,"race: white, sex: female, age: 53, bmi: 19.69, treatment arm: FOLFOX + Cetuximab, adherence: Yes, serious adverse effect: Yes, chemotherapy cycles: 1, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant, adverse effect: diarrhea: Yes","The patient is a 53-year-old white female with a BMI of 19.69 who is receiving treatment in the FOLFOX + Cetuximab treatment arm. She has been adherent to her treatment. However, she experienced a serious adverse effect after completing one cycle of chemotherapy, which was diarrhea. Her histology shows well-differentiated cells, and she has a fully active performance status. The KRAS biomarker analysis revealed a mutant status."
1265,white,male,49,28.41,FOLFOX,No,No,Yes,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 49, bmi: 28.41, treatment arm: FOLFOX, bowel obstruction: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 49-year-old white male with a BMI of 28.41. He is receiving treatment with the FOLFOX regimen and has experienced a bowel obstruction. He is scheduled to undergo 12 cycles of chemotherapy. The histology of his cancer is well-differentiated. Despite the bowel obstruction, his performance status is fully active. The KRAS biomarker analysis indicates that he has a wild-type KRAS status."
1266,black,male,54,25.98,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,symptoms but ambulatory,wild-type,No,Yes,No,No,No,0,"race: black, sex: male, age: 54, bmi: 25.98, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type, adverse effect: hypersensitivity: Yes","The patient is a 54-year-old Black male with a BMI of 25.98. He is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cells, and he has symptoms but is still ambulatory. The KRAS biomarker indicates that he is wild-type. The patient has experienced hypersensitivity as an adverse effect."
1267,white,male,56,34.02,FOLFOX,No,No,No,No,12,well differentiated,fully active,wild-type,No,Yes,No,No,No,0,"race: white, sex: male, age: 56, bmi: 34.02, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type, adverse effect: hypersensitivity: Yes","The patient is a 56-year-old white male with a BMI of 34.02. He is receiving the FOLFOX treatment arm and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cells, and he has a fully active performance status. The KRAS biomarker indicates he is wild-type. The patient has experienced a hypersensitivity adverse effect."
1268,white,male,52,36.64,FOLFOX,No,No,No,No,10,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 52, bmi: 36.64, treatment arm: FOLFOX, chemotherapy cycles: 10, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 52-year-old white male with a BMI of 36.64. He is receiving the FOLFOX treatment arm and has completed 10 cycles of chemotherapy. His histology shows well-differentiated cells, and his performance status is fully active. The KRAS biomarker indicates that he has a wild-type status."
1269,white,male,51,33.49,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 51, bmi: 33.49, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type",The patient is a 51-year-old white male with a BMI of 33.49. He is receiving treatment with FOLFOX + Cetuximab and is scheduled for 12 chemotherapy cycles. His cancer histology is well differentiated. The patient has a fully active performance status and has a wild-type KRAS biomarker.
1270,white,male,49,32.55,FOLFOX,Yes,No,No,No,12,well differentiated,symptoms but ambulatory,wild-type,No,No,No,Yes,No,0,"race: white, sex: male, age: 49, bmi: 32.55, treatment arm: FOLFOX, adherence: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type, adverse effect: infection: Yes","The patient is a 49-year-old white male with a BMI of 32.55 who is receiving the FOLFOX treatment regimen. He has been adherent to the treatment and has completed 12 chemotherapy cycles. His histology shows well-differentiated cancer cells. Despite experiencing symptoms, he is still able to be ambulatory. The KRAS biomarker testing revealed that he has a wild-type KRAS status. The patient has developed an infection as an adverse effect of the treatment."
1271,white,female,75,34.45,FOLFOX,No,No,No,No,4,poorly differentiated,symptoms but ambulatory,interminate,No,No,No,No,No,0,"race: white, sex: female, age: 75, bmi: 34.45, treatment arm: FOLFOX, chemotherapy cycles: 4, histology: poorly differentiated, performance status: symptoms but ambulatory, KRAS biomarker: interminate","The patient is a 75-year-old white female with a BMI of 34.45. She is currently receiving the FOLFOX treatment arm and has completed 4 cycles of chemotherapy. Her histology shows poorly differentiated cancer cells. Despite experiencing symptoms, she is still able to walk around (ambulatory). The KRAS biomarker status is indeterminate."
1272,white,male,46,26.35,FOLFOX,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 46, bmi: 26.35, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type",The patient is a 46-year-old white male with a BMI of 26.35. He is receiving treatment in the FOLFOX chemotherapy arm and is scheduled for 12 cycles. The histology indicates well-differentiated cancer. The patient has a fully active performance status. The KRAS biomarker status is wild-type.
1273,white,male,53,29.24,FOLFOX + Cetuximab,No,Yes,Yes,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 53, bmi: 29.24, treatment arm: FOLFOX + Cetuximab, serious adverse effect: Yes, bowel obstruction: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 53-year-old white male with a BMI of 29.24. He is undergoing treatment with FOLFOX + Cetuximab. Unfortunately, he has experienced a serious adverse effect and is currently dealing with a bowel obstruction. He has completed 12 cycles of chemotherapy. His histology shows that the cancer is well-differentiated. Despite these challenges, his performance status is fully active. Additionally, his KRAS biomarker indicates that it is wild-type."
1274,white,female,72,28.45,FOLFOX,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,Yes,No,No,0,"race: white, sex: female, age: 72, bmi: 28.45, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type, adverse effect: diarrhea: Yes",The patient is a 72-year-old white female with a BMI of 28.45 who is receiving the FOLFOX treatment regimen for her well-differentiated histology. She has completed 12 cycles of chemotherapy and has a fully active performance status. The KRAS biomarker testing showed that she has a wild-type KRAS status. The patient is experiencing diarrhea as an adverse effect of the treatment.
1275,white,male,37,21.32,FOLFOX,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 37, bmi: 21.32, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type",The patient is a 37-year-old white male with a BMI of 21.32. He is receiving treatment with the FOLFOX regimen and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer cells. The patient has a fully active performance status and his KRAS biomarker is wild-type.
1276,white,male,63,28.53,FOLFOX,No,No,Yes,Yes,12,well differentiated,fully active,mutant,Yes,No,No,No,No,1,"race: white, sex: male, age: 63, bmi: 28.53, treatment arm: FOLFOX, bowel obstruction: Yes, bowel perforation: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant, adverse effect: thrombosis: Yes","The patient is a 63-year-old white male with a BMI of 28.53. He is receiving treatment with FOLFOX chemotherapy regimen and has experienced both bowel obstruction and perforation. He has completed 12 cycles of chemotherapy. His cancer histology is well-differentiated, and he has a fully active performance status. The KRAS biomarker testing revealed a mutant status. Additionally, he has experienced an adverse effect of thrombosis."
1277,white,male,64,27.45,FOLFOX,No,No,No,No,12,well differentiated,symptoms but ambulatory,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 64, bmi: 27.45, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type","The patient is a 64-year-old white male with a BMI of 27.45. He is receiving treatment with the FOLFOX chemotherapy regimen and has completed 12 cycles. His cancer histology is well-differentiated. Despite experiencing symptoms, he is still able to be ambulatory. His KRAS biomarker status is wild-type."
1278,other,female,51,16.88,FOLFOX + Cetuximab,Yes,No,No,Yes,1,well differentiated,fully active,mutant,No,No,No,No,No,0,"race: other, sex: female, age: 51, bmi: 16.88, treatment arm: FOLFOX + Cetuximab, adherence: Yes, bowel perforation: Yes, chemotherapy cycles: 1, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 51-year-old female of a race categorized as ""other"" with a BMI of 16.88. She is currently receiving treatment in the FOLFOX + Cetuximab treatment arm and has been adherent to her treatment. She has experienced a bowel perforation and has completed one cycle of chemotherapy. The histology of her condition is well-differentiated, and her performance status is fully active. Additionally, the KRAS biomarker testing has revealed a mutant status."
1279,black,female,53,26.53,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,symptoms but ambulatory,mutant,No,No,No,No,No,0,"race: black, sex: female, age: 53, bmi: 26.53, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: mutant","The patient is a 53-year-old Black female with a BMI of 26.53. She is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. The histology shows well-differentiated cancer. Despite experiencing symptoms, the patient is still able to ambulate. The KRAS biomarker indicates a mutant status."
1280,white,male,74,21.26,FOLFOX + Cetuximab,No,No,No,No,2,well differentiated,symptoms but ambulatory,mutant,No,No,No,No,No,0,"race: white, sex: male, age: 74, bmi: 21.26, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 2, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: mutant","The patient is a 74-year-old white male with a BMI of 21.26. He is currently receiving treatment in the FOLFOX + Cetuximab treatment arm and has completed 2 cycles of chemotherapy. His histology shows well-differentiated cancer cells. Despite experiencing symptoms, he is still able to walk around (ambulatory). The KRAS biomarker analysis indicates that he has a mutant KRAS status."
1281,white,female,42,38.19,FOLFOX + Cetuximab,No,Yes,No,No,12,poorly differentiated,symptoms but ambulatory,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 42, bmi: 38.19, treatment arm: FOLFOX + Cetuximab, serious adverse effect: Yes, chemotherapy cycles: 12, histology: poorly differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type","The patient is a 42-year-old white female with a BMI of 38.19. She is receiving treatment with FOLFOX + Cetuximab and has experienced a serious adverse effect. She has undergone 12 cycles of chemotherapy. The histology of her condition is poorly differentiated. Despite experiencing symptoms, she is still ambulatory. Her KRAS biomarker status is wild-type."
1282,white,female,56,32.49,FOLFOX + Cetuximab,No,No,No,No,12,poorly differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 56, bmi: 32.49, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 56-year-old white female with a BMI of 32.49. She is receiving treatment with FOLFOX + Cetuximab and is scheduled for 12 chemotherapy cycles. Her cancer histology is poorly differentiated. Despite her diagnosis, her performance status is fully active. The KRAS biomarker testing revealed that she has a wild-type KRAS status."
1283,white,male,50,27.11,FOLFOX,No,No,No,No,12,well differentiated,symptoms but ambulatory,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 50, bmi: 27.11, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type","The patient is a 50-year-old white male with a BMI of 27.11. He is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. The histology shows well-differentiated cancer cells. Despite experiencing symptoms, the patient is still able to walk around (ambulatory). His KRAS biomarker indicates that he has a wild-type status."
1284,white,female,41,39.18,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 41, bmi: 39.18, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 41-year-old white female with a BMI of 39.18. She is receiving treatment in the FOLFOX + Cetuximab treatment arm and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cancer cells. Despite her cancer diagnosis, she has a fully active performance status. Additionally, her KRAS biomarker status is wild-type."
1285,white,female,71,26,FOLFIRI,No,No,No,No,12,poorly differentiated,fully active,wild-type,Yes,No,Yes,No,No,0,"race: white, sex: female, age: 71, bmi: 26.0, treatment arm: FOLFIRI, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type, adverse effect: thrombosis: Yes, adverse effect: diarrhea: Yes","The patient is a 71-year-old white female with a BMI of 26.0. She is receiving the FOLFIRI treatment regimen and has completed 12 cycles of chemotherapy. Her cancer histology is poorly differentiated, and she has a fully active performance status. The KRAS biomarker testing showed that she has a wild-type KRAS status. The patient has experienced adverse effects of thrombosis and diarrhea during her treatment."
1286,white,male,35,23.63,FOLFOX + Cetuximab,No,No,No,No,11,poorly differentiated,fully active,wild-type,No,No,No,No,No,1,"race: white, sex: male, age: 35, bmi: 23.63, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 11, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 35-year-old white male with a BMI of 23.63. He is receiving treatment in the FOLFOX + Cetuximab treatment arm and has completed 11 cycles of chemotherapy. His histology shows poorly differentiated cancer cells. Despite this, his performance status is fully active. Additionally, his KRAS biomarker status is wild-type."
1287,white,female,73,33.41,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,fully active,mutant,No,No,No,No,No,1,"race: white, sex: female, age: 73, bmi: 33.41, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 73-year-old white female with a BMI of 33.41. She is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cancer cells. Despite her age, she has a fully active performance status. The KRAS biomarker analysis indicates that she has a mutant KRAS status."
1288,white,male,66,26.81,FOLFOX,No,Yes,No,No,12,poorly differentiated,fully active,wild-type,No,No,No,Yes,No,1,"race: white, sex: male, age: 66, bmi: 26.81, treatment arm: FOLFOX, serious adverse effect: Yes, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type, adverse effect: infection: Yes","The patient is a 66-year-old white male with a BMI of 26.81. He is undergoing treatment with the FOLFOX chemotherapy regimen and has experienced a serious adverse effect. He has completed 12 cycles of chemotherapy and has been diagnosed with poorly differentiated histology. Despite this, his performance status is fully active. His KRAS biomarker status is wild-type. Additionally, he has developed an infection as an adverse effect of his treatment."
1289,other,male,40,26.82,FOLFOX + Cetuximab,Yes,No,Yes,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: other, sex: male, age: 40, bmi: 26.82, treatment arm: FOLFOX + Cetuximab, adherence: Yes, bowel obstruction: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 40-year-old male of a race categorized as ""other"" with a BMI of 26.82. He is undergoing treatment in the FOLFOX + Cetuximab treatment arm and has been adherent to the prescribed treatment. The patient has experienced a bowel obstruction and has completed 12 cycles of chemotherapy. Histologically, the cancer is well-differentiated. Despite the bowel obstruction, the patient's performance status is fully active. The KRAS biomarker analysis indicates that the patient has a wild-type KRAS status."
1290,white,female,73,34.84,FOLFOX,No,No,No,No,12,poorly differentiated,symptoms but ambulatory,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 73, bmi: 34.84, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: poorly differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type","The patient is a 73-year-old white female with a BMI of 34.84. She is receiving the FOLFOX treatment arm and has completed 12 cycles of chemotherapy. The histology shows poorly differentiated cancer cells. Despite experiencing symptoms, she is still able to walk around (ambulatory). The KRAS biomarker indicates that she has a wild-type status."
1291,white,male,54,28.1,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 54, bmi: 28.1, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type",The patient is a 54-year-old white male with a BMI of 28.1. He is receiving treatment in the FOLFOX + Cetuximab treatment arm and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer cells. The patient has a fully active performance status and his KRAS biomarker is wild-type.
1292,white,female,36,34.8,FOLFOX + Cetuximab,No,No,No,No,12,poorly differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 36, bmi: 34.8, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 36-year-old white female with a BMI of 34.8. She is receiving treatment in the FOLFOX + Cetuximab treatment arm and has completed 12 cycles of chemotherapy. Her histology shows poorly differentiated cancer cells. Despite this, her performance status is fully active. Additionally, her KRAS biomarker indicates that it is wild-type."
1293,white,female,72,23.99,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 72, bmi: 23.99, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 72-year-old white female with a BMI of 23.99. She is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. Her cancer histology is well-differentiated, and she has a fully active performance status. The KRAS biomarker testing showed that she has a wild-type KRAS status."
1294,white,male,68,22.64,FOLFOX + Cetuximab,Yes,No,Yes,No,10,poorly differentiated,symptoms but ambulatory,wild-type,No,No,Yes,No,No,1,"race: white, sex: male, age: 68, bmi: 22.64, treatment arm: FOLFOX + Cetuximab, adherence: Yes, bowel obstruction: Yes, chemotherapy cycles: 10, histology: poorly differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type, adverse effect: diarrhea: Yes","The patient is a 68-year-old white male with a BMI of 22.64. He is receiving treatment with FOLFOX + Cetuximab and has been adherent to the treatment regimen. He is currently experiencing a bowel obstruction and has completed 10 cycles of chemotherapy. The histology of his cancer is poorly differentiated. Despite experiencing symptoms, he is still ambulatory. His KRAS biomarker is wild-type. He is also experiencing diarrhea as an adverse effect of the treatment."
1295,white,male,48,21.18,FOLFOX + Cetuximab,No,No,No,No,9,poorly differentiated,symptoms but ambulatory,wild-type,No,No,No,No,No,1,"race: white, sex: male, age: 48, bmi: 21.18, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 9, histology: poorly differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type","The patient is a 48-year-old white male with a BMI of 21.18. He is currently receiving treatment with FOLFOX + Cetuximab and has completed 9 cycles of chemotherapy. His histology shows poorly differentiated cancer cells. Despite experiencing symptoms, he is still able to move around. His KRAS biomarker indicates that it is wild-type."
1296,white,female,52,41.34,FOLFIRI,No,No,No,No,12,well differentiated,symptoms but ambulatory,mutant,No,No,No,No,No,1,"race: white, sex: female, age: 52, bmi: 41.34, treatment arm: FOLFIRI, chemotherapy cycles: 12, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: mutant","The patient is a 52-year-old white female with a BMI of 41.34. She is undergoing treatment with the FOLFIRI chemotherapy regimen and has completed 12 cycles. Her cancer histology is well-differentiated. Despite experiencing symptoms, she is still able to be ambulatory. The patient's KRAS biomarker status is mutant."
1297,white,male,40,30.84,FOLFOX,No,No,No,No,12,poorly differentiated,symptoms but ambulatory,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 40, bmi: 30.84, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: poorly differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type","The patient is a 40-year-old white male with a BMI of 30.84. He is receiving the FOLFOX treatment arm and has completed 12 cycles of chemotherapy. His histology shows poorly differentiated cancer cells. Despite experiencing symptoms, he is still able to walk around (ambulatory). The KRAS biomarker analysis indicates that he has a wild-type KRAS gene."
1298,white,male,59,41.7,FOLFOX,No,Yes,No,No,12,well differentiated,fully active,wild-type,Yes,No,No,No,Yes,0,"race: white, sex: male, age: 59, bmi: 41.7, treatment arm: FOLFOX, serious adverse effect: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type, adverse effect: thrombosis: Yes, adverse effect: infarction: Yes","The patient is a 59-year-old white male with a BMI of 41.7. He is receiving the FOLFOX treatment regimen and has experienced serious adverse effects during the 12 chemotherapy cycles. The histology shows well-differentiated cells, and the patient has a fully active performance status. The KRAS biomarker is wild-type. Additionally, the patient has experienced adverse effects including thrombosis and infarction."
1299,white,male,63,18.93,FOLFOX + Cetuximab,Yes,No,No,No,12,poorly differentiated,symptoms but ambulatory,wild-type,No,Yes,Yes,No,No,0,"race: white, sex: male, age: 63, bmi: 18.93, treatment arm: FOLFOX + Cetuximab, adherence: Yes, chemotherapy cycles: 12, histology: poorly differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type, adverse effect: hypersensitivity: Yes, adverse effect: diarrhea: Yes","The patient is a 63-year-old white male with a BMI of 18.93. He is receiving treatment in the FOLFOX + Cetuximab treatment arm and has been adherent to the treatment. He has completed 12 chemotherapy cycles. The histology of his cancer is poorly differentiated. Despite experiencing symptoms, he is still ambulatory. His KRAS biomarker is wild-type. He has experienced adverse effects including hypersensitivity and diarrhea."
1300,white,female,64,32.72,FOLFOX,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 64, bmi: 32.72, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type",The patient is a 64-year-old white female with a BMI of 32.72. She is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. Her cancer histology is well differentiated. The patient has a fully active performance status and her KRAS biomarker is wild-type.
1301,black,male,66,26.95,FOLFOX,No,No,No,No,7,well differentiated,fully active,mutant,No,No,No,No,No,0,"race: black, sex: male, age: 66, bmi: 26.95, treatment arm: FOLFOX, chemotherapy cycles: 7, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 66-year-old Black male with a BMI of 26.95. He is undergoing treatment with the FOLFOX regimen and has completed 7 cycles of chemotherapy. His histology shows well-differentiated cancer cells. Despite his age, he has a fully active performance status. The KRAS biomarker analysis indicates a mutant status."
1302,white,male,65,23.77,FOLFIRI + Cetuximab,No,No,No,No,12,poorly differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 65, bmi: 23.77, treatment arm: FOLFIRI + Cetuximab, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 65-year-old white male with a BMI of 23.77. He is receiving treatment in the FOLFIRI + Cetuximab treatment arm and has completed 12 cycles of chemotherapy. His histology shows poorly differentiated cancer cells. Despite this, his performance status is fully active. Additionally, his KRAS biomarker is wild-type."
1303,white,male,52,25.8,FOLFOX,No,No,No,No,6,well differentiated,fully active,mutant,No,Yes,No,No,No,0,"race: white, sex: male, age: 52, bmi: 25.8, treatment arm: FOLFOX, chemotherapy cycles: 6, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant, adverse effect: hypersensitivity: Yes",The patient is a 52-year-old white male with a BMI of 25.8 who is receiving the FOLFOX treatment regimen for his well-differentiated cancer. He has completed 6 cycles of chemotherapy and has a fully active performance status. The KRAS biomarker testing revealed a mutant status. The patient has experienced hypersensitivity as an adverse effect during the treatment.
1304,white,male,74,35.38,FOLFOX,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 74, bmi: 35.38, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 74-year-old white male with a BMI of 35.38. He is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. His cancer histology is well-differentiated. Despite his age, he has a fully active performance status. Additionally, his KRAS biomarker status is wild-type."
1305,white,female,49,21.64,FOLFOX + Cetuximab,No,No,No,No,6,well differentiated,fully active,mutant,No,No,No,No,No,0,"race: white, sex: female, age: 49, bmi: 21.64, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 6, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 49-year-old white female with a BMI of 21.64. She is receiving treatment in the FOLFOX + Cetuximab treatment arm and has completed 6 cycles of chemotherapy. Her histology shows well-differentiated cancer cells. Despite her cancer diagnosis, she has a fully active performance status. Additionally, her KRAS biomarker is identified as mutant."
1306,white,male,54,35.37,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 54, bmi: 35.37, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type",The patient is a 54-year-old white male with a BMI of 35.37. He is receiving treatment in the FOLFOX + Cetuximab treatment arm and is scheduled for 12 chemotherapy cycles. His histology shows well-differentiated cells. The patient has a fully active performance status and has a wild-type KRAS biomarker.
1307,white,female,48,21.6,FOLFIRI,No,Yes,No,No,12,poorly differentiated,fully active,mutant,No,No,No,No,No,0,"race: white, sex: female, age: 48, bmi: 21.6, treatment arm: FOLFIRI, serious adverse effect: Yes, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 48-year-old white female with a BMI of 21.6. She is receiving the FOLFIRI treatment regimen and has experienced a serious adverse effect. She has completed 12 cycles of chemotherapy. The histology of her cancer is poorly differentiated. Despite this, her performance status is fully active. Additionally, the KRAS biomarker testing revealed a mutant status."
1308,other,female,38,22.1,FOLFOX,Yes,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: other, sex: female, age: 38, bmi: 22.1, treatment arm: FOLFOX, adherence: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 38-year-old female of a race categorized as ""other"" with a BMI of 22.1. She is receiving the FOLFOX treatment regimen and has been adherent to her chemotherapy. She has completed 12 cycles of chemotherapy. The histology of her cancer is well-differentiated. The patient has a fully active performance status. Her KRAS biomarker status is wild-type."
1309,white,female,49,35.63,FOLFOX + Cetuximab,No,No,No,No,6,well differentiated,symptoms but ambulatory,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 49, bmi: 35.63, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 6, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type","The patient is a 49-year-old white female with a BMI of 35.63. She is receiving treatment with FOLFOX + Cetuximab and has completed 6 cycles of chemotherapy. Her histology shows well-differentiated cancer. Despite experiencing symptoms, she is still able to be ambulatory. The KRAS biomarker indicates that she has a wild-type status."
1310,white,male,55,29.2,FOLFOX,No,No,No,No,12,poorly differentiated,fully active,mutant,No,No,Yes,No,No,0,"race: white, sex: male, age: 55, bmi: 29.2, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: mutant, adverse effect: diarrhea: Yes","The patient is a 55-year-old white male with a BMI of 29.2. He is undergoing treatment with FOLFOX chemotherapy regimen and has completed 12 cycles. His cancer histology is poorly differentiated, and he has a fully active performance status. The KRAS biomarker testing showed a mutant result. The patient is experiencing diarrhea as an adverse effect of the treatment."
1311,other,male,70,25.44,FOLFOX,No,Yes,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: other, sex: male, age: 70, bmi: 25.44, treatment arm: FOLFOX, serious adverse effect: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 70-year-old male of a race other than specified, with a BMI of 25.44. He is receiving the FOLFOX treatment regimen and has experienced a serious adverse effect. He has completed 12 cycles of chemotherapy. The histology shows well-differentiated cells. Despite the adverse effect, the patient's performance status is fully active. The KRAS biomarker indicates that the patient has a wild-type gene."
1312,white,male,52,29.69,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,symptoms but ambulatory,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 52, bmi: 29.69, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type","The patient is a 52-year-old white male with a BMI of 29.69. He is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer cells. Despite experiencing symptoms, he is still able to walk around (ambulatory). His KRAS biomarker status is wild-type."
1313,white,female,53,30.25,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,Yes,No,No,0,"race: white, sex: female, age: 53, bmi: 30.25, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type, adverse effect: diarrhea: Yes","The patient is a 53-year-old white female with a BMI of 30.25. She is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. Her cancer histology is well-differentiated, and she has a fully active performance status. The KRAS biomarker testing showed that she has a wild-type KRAS status. She is experiencing diarrhea as an adverse effect of the treatment."
1314,other,male,41,26.96,FOLFOX,No,No,No,No,12,poorly differentiated,fully active,wild-type,No,No,No,No,No,0,"race: other, sex: male, age: 41, bmi: 26.96, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 41-year-old male of a race categorized as ""other"" with a BMI of 26.96. He is undergoing treatment with the FOLFOX chemotherapy regimen and has completed 12 cycles. The histology of his cancer is poorly differentiated. Despite this, his performance status is fully active. Additionally, the KRAS biomarker analysis indicates that he has a wild-type KRAS status."
1315,white,female,45,30.11,FOLFOX,No,No,No,No,12,well differentiated,symptoms but ambulatory,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 45, bmi: 30.11, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type","The patient is a 45-year-old white female with a BMI of 30.11. She is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cancer cells. Despite experiencing symptoms, she is still able to be ambulatory. The KRAS biomarker analysis indicates that she has a wild-type KRAS status."
1316,white,female,62,29.9,FOLFOX,No,No,No,No,12,well differentiated,symptoms but ambulatory,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 62, bmi: 29.9, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type","The patient is a 62-year-old white female with a BMI of 29.9. She is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. Her cancer histology is well-differentiated. Despite experiencing symptoms, she is still able to walk around (ambulatory). The KRAS biomarker analysis shows that she has a wild-type KRAS status."
1317,white,male,69,31.77,FOLFOX,No,No,No,No,12,well differentiated,symptoms but ambulatory,wild-type,No,No,No,Yes,No,1,"race: white, sex: male, age: 69, bmi: 31.77, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type, adverse effect: infection: Yes","The patient is a 69-year-old white male with a BMI of 31.77. He is receiving the FOLFOX treatment arm and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer cells. Despite experiencing symptoms, he is still able to walk around (ambulatory). The KRAS biomarker test results indicate that he has a wild-type KRAS status. Additionally, the patient has developed an infection as an adverse effect of the treatment."
1318,white,male,64,27.82,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,fully active,wild-type,No,Yes,Yes,No,No,0,"race: white, sex: male, age: 64, bmi: 27.82, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type, adverse effect: hypersensitivity: Yes, adverse effect: diarrhea: Yes","The patient is a 64-year-old white male with a BMI of 27.82. He is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cells, and he has a fully active performance status. The KRAS biomarker is wild-type. The patient has experienced adverse effects of hypersensitivity and diarrhea during treatment."
1319,other,male,36,20.76,FOLFOX,No,No,No,No,12,poorly differentiated,fully active,mutant,No,No,No,Yes,No,0,"race: other, sex: male, age: 36, bmi: 20.76, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: mutant, adverse effect: infection: Yes","The patient is a 36-year-old male of a race categorized as ""other"" with a BMI of 20.76. He is undergoing treatment with the FOLFOX chemotherapy regimen and has completed 12 cycles. The histology of his cancer is poorly differentiated. Despite this, his performance status is fully active. The KRAS biomarker testing revealed a mutant status. The patient has experienced an adverse effect in the form of an infection."
1320,white,female,38,33.24,FOLFOX,No,No,No,No,1,well differentiated,symptoms but ambulatory,mutant,No,No,No,No,No,0,"race: white, sex: female, age: 38, bmi: 33.24, treatment arm: FOLFOX, chemotherapy cycles: 1, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: mutant","The patient is a 38-year-old white female with a BMI of 33.24. She is currently undergoing treatment with the FOLFOX chemotherapy regimen and has completed one cycle so far. Her cancer histology is well differentiated. Despite experiencing symptoms, she is still able to be ambulatory. The KRAS biomarker testing revealed a mutant status."
1321,white,female,52,48.7,FOLFOX,Yes,No,No,No,12,well differentiated,symptoms but ambulatory,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 52, bmi: 48.7, treatment arm: FOLFOX, adherence: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type","The patient is a 52-year-old white female with a BMI of 48.7. She is receiving treatment in the FOLFOX arm and has been adherent to her chemotherapy regimen for 12 cycles. Her histology shows well-differentiated cancer cells. Despite experiencing symptoms, she is still able to be ambulatory. The KRAS biomarker analysis indicates that she has a wild-type KRAS status."
1322,white,male,76,27.43,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,1,"race: white, sex: male, age: 76, bmi: 27.43, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 76-year-old white male with a BMI of 27.43. He is receiving treatment in the FOLFOX + Cetuximab treatment arm and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer cells. Despite his age, he has a fully active performance status. Additionally, his KRAS biomarker is wild-type."
1323,white,female,64,39.41,FOLFOX + Cetuximab,No,No,No,No,0,well differentiated,symptoms but ambulatory,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 64, bmi: 39.41, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 0, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type","The patient is a 64-year-old white female with a BMI of 39.41. She is enrolled in the FOLFOX + Cetuximab treatment arm but has not started chemotherapy cycles yet. Her histology shows well-differentiated cancer. Despite experiencing symptoms, she is still able to be ambulatory. The KRAS biomarker indicates that she has a wild-type status."
1324,white,male,56,34.6,FOLFOX + Cetuximab,No,No,No,No,12,poorly differentiated,fully active,mutant,No,No,No,No,No,0,"race: white, sex: male, age: 56, bmi: 34.6, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 56-year-old white male with a BMI of 34.6. He is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. His cancer histology is poorly differentiated. Despite his cancer diagnosis, he has a fully active performance status. The patient's KRAS biomarker status is mutant."
1325,white,female,57,31,FOLFOX,No,Yes,No,No,12,well differentiated,fully active,mutant,No,No,No,No,No,0,"race: white, sex: female, age: 57, bmi: 31.0, treatment arm: FOLFOX, serious adverse effect: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 57-year-old white female with a BMI of 31.0. She is undergoing treatment with the FOLFOX regimen and has experienced a serious adverse effect. She has completed 12 cycles of chemotherapy. The histology of her cancer is well-differentiated. Despite the adverse effect, her performance status is fully active. The KRAS biomarker testing revealed a mutant status."
1326,other,female,42,26.84,FOLFOX + Cetuximab,Yes,No,Yes,No,12,well differentiated,symptoms but ambulatory,wild-type,No,No,No,No,No,0,"race: other, sex: female, age: 42, bmi: 26.84, treatment arm: FOLFOX + Cetuximab, adherence: Yes, bowel obstruction: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type","The patient is a 42-year-old female of a race categorized as ""other"" with a BMI of 26.84. She is receiving treatment in the FOLFOX + Cetuximab treatment arm and has been adherent to her treatment plan. The patient has experienced a bowel obstruction and has completed 12 cycles of chemotherapy. Histologically, her cancer is classified as well-differentiated. Despite experiencing symptoms, the patient is still able to be ambulatory. Additionally, her KRAS biomarker status is wild-type."
1327,white,female,65,28.05,FOLFOX,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 65, bmi: 28.05, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type",The patient is a 65-year-old white female with a BMI of 28.05. She is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. The histology shows well-differentiated cancer cells. The patient has a fully active performance status and her KRAS biomarker is wild-type.
1328,white,female,64,25.3,FOLFOX,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 64, bmi: 25.3, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type",The patient is a 64-year-old white female with a BMI of 25.3. She is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cancer cells. She has a fully active performance status and her KRAS biomarker is wild-type.
1329,other,female,63,32.55,FOLFOX,No,Yes,No,No,12,well differentiated,fully active,mutant,No,No,Yes,No,No,0,"race: other, sex: female, age: 63, bmi: 32.55, treatment arm: FOLFOX, serious adverse effect: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant, adverse effect: diarrhea: Yes","The patient is a 63-year-old female of a race other than specified, with a BMI of 32.55. She is undergoing treatment with the FOLFOX regimen and has experienced a serious adverse effect. She has completed 12 cycles of chemotherapy. The histology of her condition is well-differentiated, and her performance status is fully active. The KRAS biomarker is mutant in this patient. Additionally, she has experienced diarrhea as an adverse effect of the treatment."
1330,other,male,40,22.75,FOLFOX,No,No,No,No,12,well differentiated,symptoms but ambulatory,wild-type,No,No,No,No,No,0,"race: other, sex: male, age: 40, bmi: 22.75, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type","The patient is a 40-year-old male of a race categorized as ""other"" with a BMI of 22.75. He is undergoing treatment with the FOLFOX chemotherapy regimen and is scheduled for 12 cycles. The histology of his condition is well-differentiated. Despite experiencing symptoms, the patient is still able to be ambulatory. Additionally, his KRAS biomarker status is wild-type."
1331,white,male,45,28.37,FOLFOX + Cetuximab,No,Yes,Yes,No,12,poorly differentiated,symptoms but ambulatory,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 45, bmi: 28.37, treatment arm: FOLFOX + Cetuximab, serious adverse effect: Yes, bowel obstruction: Yes, chemotherapy cycles: 12, histology: poorly differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type","The patient is a 45-year-old white male with a BMI of 28.37. He is receiving treatment with FOLFOX + Cetuximab. He has experienced a serious adverse effect and is currently dealing with a bowel obstruction. He has completed 12 cycles of chemotherapy. The histology of his condition is poorly differentiated. Despite experiencing symptoms, he is still able to be ambulatory. His KRAS biomarker status is wild-type."
1332,white,male,34,28.4,FOLFOX + Cetuximab,No,Yes,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 34, bmi: 28.4, treatment arm: FOLFOX + Cetuximab, serious adverse effect: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 34-year-old white male with a BMI of 28.4. He is receiving treatment with FOLFOX + Cetuximab and has experienced a serious adverse effect. He has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer cells. Despite the treatment, he maintains a fully active performance status. His KRAS biomarker status is wild-type."
1333,white,male,52,19.72,FOLFOX,Yes,No,No,No,12,well differentiated,symptoms but ambulatory,mutant,No,No,No,No,No,0,"race: white, sex: male, age: 52, bmi: 19.72, treatment arm: FOLFOX, adherence: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: mutant","The patient is a 52-year-old white male with a BMI of 19.72. He is receiving treatment with the FOLFOX regimen and has been adherent to the chemotherapy. He has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer cells. Despite experiencing symptoms, he is still able to be ambulatory. The KRAS biomarker analysis revealed a mutant status."
1334,white,male,74,27.28,FOLFOX + Cetuximab,No,No,No,No,3,well differentiated,fully active,wild-type,No,No,No,No,No,1,"race: white, sex: male, age: 74, bmi: 27.28, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 3, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 74-year-old white male with a BMI of 27.28. He is receiving treatment in the FOLFOX + Cetuximab treatment arm and has completed 3 cycles of chemotherapy. His histology shows well-differentiated cancer cells. Despite his age, he has a fully active performance status. Additionally, his KRAS biomarker is wild-type."
1335,white,female,62,32.87,FOLFOX + Cetuximab,No,No,No,No,11,well differentiated,fully active,mutant,No,No,No,No,No,0,"race: white, sex: female, age: 62, bmi: 32.87, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 11, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 62-year-old white female with a BMI of 32.87. She is currently receiving treatment with FOLFOX + Cetuximab and has completed 11 cycles of chemotherapy. Her cancer histology is well differentiated. Despite her age, she has a fully active performance status. The KRAS biomarker testing revealed a mutant status."
1336,white,male,65,35.03,FOLFOX,No,No,No,No,12,well differentiated,symptoms but ambulatory,wild-type,Yes,No,Yes,No,No,0,"race: white, sex: male, age: 65, bmi: 35.03, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type, adverse effect: thrombosis: Yes, adverse effect: diarrhea: Yes","The patient is a 65-year-old white male with a BMI of 35.03. He is undergoing treatment with the FOLFOX chemotherapy regimen and has completed 12 cycles. His cancer histology is well-differentiated, and he has symptoms but is still able to be ambulatory. The KRAS biomarker testing showed that he has a wild-type KRAS status. The patient has experienced adverse effects of thrombosis and diarrhea during his treatment."
1337,white,male,58,30.98,FOLFIRI,Yes,Yes,Yes,No,12,well differentiated,symptoms but ambulatory,wild-type,Yes,No,Yes,No,No,1,"race: white, sex: male, age: 58, bmi: 30.98, treatment arm: FOLFIRI, adherence: Yes, serious adverse effect: Yes, bowel obstruction: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type, adverse effect: thrombosis: Yes, adverse effect: diarrhea: Yes","The patient is a 58-year-old white male with a BMI of 30.98 who is undergoing treatment with the FOLFIRI regimen. He has been adherent to the treatment and has completed 12 cycles of chemotherapy. The patient has experienced a serious adverse effect in the form of bowel obstruction and has also reported experiencing thrombosis and diarrhea as additional adverse effects. His histology shows well-differentiated cancer, and his KRAS biomarker is wild-type. Despite experiencing symptoms, the patient is still ambulatory and able to move around."
1338,white,male,67,32.48,FOLFOX,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 67, bmi: 32.48, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type",The patient is a 67-year-old white male with a BMI of 32.48. He is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. His cancer histology is well differentiated. The patient has a fully active performance status and his KRAS biomarker is wild-type.
1339,white,male,69,33.08,FOLFOX + Cetuximab,No,No,No,No,6,well differentiated,fully active,wild-type,No,No,No,No,No,1,"race: white, sex: male, age: 69, bmi: 33.08, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 6, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 69-year-old white male with a BMI of 33.08. He is receiving treatment with FOLFOX + Cetuximab and has completed 6 cycles of chemotherapy. His cancer histology is well-differentiated, and he has a fully active performance status. The KRAS biomarker analysis shows that he has a wild-type KRAS status."
1340,white,male,44,21.92,FOLFOX,No,No,No,No,5,poorly differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 44, bmi: 21.92, treatment arm: FOLFOX, chemotherapy cycles: 5, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 44-year-old white male with a BMI of 21.92. He is receiving the FOLFOX treatment arm and has completed 5 cycles of chemotherapy. His histology shows poorly differentiated cells. Despite this, his performance status is fully active. Additionally, the KRAS biomarker indicates that he has a wild-type status."
1341,white,female,40,33.31,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,symptoms but ambulatory,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 40, bmi: 33.31, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type","The patient is a 40-year-old white female with a BMI of 33.31. She is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cancer cells. Despite experiencing symptoms, she is still able to walk around (ambulatory). The KRAS biomarker analysis indicates that she has a wild-type KRAS gene."
1342,white,female,53,32.12,FOLFOX + Cetuximab,No,No,No,No,5,well differentiated,fully active,mutant,No,No,Yes,No,No,0,"race: white, sex: female, age: 53, bmi: 32.12, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 5, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant, adverse effect: diarrhea: Yes","The patient is a 53-year-old white female with a BMI of 32.12. She is receiving treatment with FOLFOX + Cetuximab and has completed 5 cycles of chemotherapy. Her cancer histology is well-differentiated, and she has a fully active performance status. The KRAS biomarker testing showed a mutant result. The patient is experiencing diarrhea as an adverse effect of the treatment."
1343,white,female,34,24.52,FOLFOX,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 34, bmi: 24.52, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type",The patient is a 34-year-old white female with a BMI of 24.52. She is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cancer cells. She has a fully active performance status. The KRAS biomarker analysis indicates that she has a wild-type KRAS gene.
1344,white,male,41,29.38,FOLFOX,No,No,No,No,12,well differentiated,symptoms but ambulatory,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 41, bmi: 29.38, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type","The patient is a 41-year-old white male with a BMI of 29.38. He is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer cells. Despite experiencing symptoms, he is still able to be ambulatory. The KRAS biomarker analysis indicates that he has a wild-type KRAS status."
1345,white,male,64,32.55,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 64, bmi: 32.55, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 64-year-old white male with a BMI of 32.55. He is receiving treatment in the FOLFOX + Cetuximab treatment arm and is scheduled for 12 chemotherapy cycles. His histology shows well-differentiated cancer cells. Despite his age, he has a fully active performance status. Additionally, his KRAS biomarker indicates that he has a wild-type status."
1346,white,male,66,38.68,FOLFIRI (KRAS mutant),No,No,Yes,No,12,well differentiated,fully active,mutant,No,No,Yes,No,No,0,"race: white, sex: male, age: 66, bmi: 38.68, treatment arm: FOLFIRI (KRAS mutant), bowel obstruction: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant, adverse effect: diarrhea: Yes","The patient is a 66-year-old white male with a BMI of 38.68 who is receiving the FOLFIRI treatment regimen for KRAS mutant colorectal cancer. He has a history of bowel obstruction and has completed 12 cycles of chemotherapy. The histology of his cancer is well differentiated. Despite experiencing diarrhea as an adverse effect of treatment, his performance status remains fully active."
1347,white,female,55,27.82,FOLFOX + Cetuximab,No,No,No,No,11,poorly differentiated,fully active,mutant,No,No,No,No,No,0,"race: white, sex: female, age: 55, bmi: 27.82, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 11, histology: poorly differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 55-year-old white female with a BMI of 27.82. She is receiving treatment in the FOLFOX + Cetuximab treatment arm and has completed 11 cycles of chemotherapy. Her histology shows poorly differentiated cancer cells. Despite this, her performance status is fully active. The KRAS biomarker analysis indicates a mutant status."
1348,white,female,53,27.7,FOLFOX,No,No,Yes,No,2,poorly differentiated,fully active,wild-type,No,No,Yes,No,No,0,"race: white, sex: female, age: 53, bmi: 27.7, treatment arm: FOLFOX, bowel obstruction: Yes, chemotherapy cycles: 2, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type, adverse effect: diarrhea: Yes","The patient is a 53-year-old white female with a BMI of 27.7. She is currently receiving treatment with FOLFOX for her poorly differentiated histology. She has experienced a bowel obstruction and has completed 2 cycles of chemotherapy. Despite the adverse effect of diarrhea, her performance status is fully active. Additionally, her KRAS biomarker status is wild-type."
1349,white,female,55,24.11,FOLFOX,No,No,No,No,12,well differentiated,symptoms but ambulatory,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 55, bmi: 24.11, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type","The patient is a 55-year-old white female with a BMI of 24.11. She is receiving the FOLFOX treatment arm and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cells. Despite experiencing symptoms, she is still able to walk around (ambulatory). The KRAS biomarker analysis indicates that she has a wild-type KRAS status."
1350,white,female,51,27.35,FOLFOX,Yes,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 51, bmi: 27.35, treatment arm: FOLFOX, adherence: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 51-year-old white female with a BMI of 27.35. She is receiving treatment with the FOLFOX regimen and has been adherent to her chemotherapy cycles, completing a total of 12 cycles. Her cancer histology is well-differentiated, and she has a fully active performance status. Additionally, her KRAS biomarker status is wild-type."
1351,white,male,57,29.15,FOLFOX,No,No,No,No,12,well differentiated,fully active,mutant,No,No,No,No,No,0,"race: white, sex: male, age: 57, bmi: 29.15, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant",The patient is a 57-year-old white male with a BMI of 29.15. He is undergoing treatment with the FOLFOX chemotherapy regimen and has completed 12 cycles. His cancer histology is well differentiated. The patient has a fully active performance status. The KRAS biomarker testing revealed a mutant status.
1352,white,male,56,32.15,FOLFOX + Cetuximab,No,Yes,No,No,12,well differentiated,fully active,wild-type,No,No,Yes,No,No,0,"race: white, sex: male, age: 56, bmi: 32.15, treatment arm: FOLFOX + Cetuximab, serious adverse effect: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type, adverse effect: diarrhea: Yes","The patient is a 56-year-old white male with a BMI of 32.15. He is receiving treatment with FOLFOX + Cetuximab and has experienced a serious adverse effect. He has completed 12 cycles of chemotherapy. His histology shows well-differentiated cells, and his performance status is fully active. The KRAS biomarker is wild-type. Additionally, he has experienced diarrhea as an adverse effect."
1353,white,male,52,28.09,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,fully active,mutant,No,No,No,No,No,0,"race: white, sex: male, age: 52, bmi: 28.09, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant",The patient is a 52-year-old white male with a BMI of 28.09. He is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. His cancer histology is well differentiated. The patient has a fully active performance status. The KRAS biomarker testing showed a mutant result.
1354,white,female,64,28.29,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 64, bmi: 28.29, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 64-year-old white female with a BMI of 28.29. She is receiving treatment in the FOLFOX + Cetuximab treatment arm and has completed 12 cycles of chemotherapy. Her cancer histology is well-differentiated, and she has a fully active performance status. The KRAS biomarker testing showed that she has a wild-type KRAS status."
1355,black,female,54,26.36,FOLFOX,No,Yes,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: black, sex: female, age: 54, bmi: 26.36, treatment arm: FOLFOX, serious adverse effect: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 54-year-old Black female with a BMI of 26.36. She is receiving the FOLFOX treatment arm for her well-differentiated histology. She has experienced a serious adverse effect during her 12 chemotherapy cycles. Despite this, her performance status is fully active. Additionally, her KRAS biomarker is wild-type."
1356,white,male,64,34.63,FOLFOX + Cetuximab,No,No,No,No,5,well differentiated,fully active,mutant,No,No,No,No,No,0,"race: white, sex: male, age: 64, bmi: 34.63, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 5, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 64-year-old white male with a BMI of 34.63. He is currently receiving treatment with FOLFOX + Cetuximab and has completed 5 cycles of chemotherapy. His cancer histology is well-differentiated, and he has a fully active performance status. The KRAS biomarker testing revealed a mutant status."
1357,white,female,53,23.69,FOLFOX + Cetuximab,No,Yes,No,No,12,well differentiated,symptoms but ambulatory,wild-type,No,No,Yes,No,No,0,"race: white, sex: female, age: 53, bmi: 23.69, treatment arm: FOLFOX + Cetuximab, serious adverse effect: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type, adverse effect: diarrhea: Yes","The patient is a 53-year-old white female with a BMI of 23.69. She is receiving treatment with FOLFOX + Cetuximab and has experienced a serious adverse effect. She has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cells. Despite experiencing symptoms, she is still able to be ambulatory. Her KRAS biomarker is wild-type. Additionally, she has experienced diarrhea as an adverse effect of the treatment."
1358,white,male,36,28.97,FOLFOX,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 36, bmi: 28.97, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 36-year-old white male with a BMI of 28.97. He is undergoing treatment with the FOLFOX chemotherapy regimen and is scheduled for 12 cycles. His cancer histology is well-differentiated, and he has a fully active performance status. The KRAS biomarker testing revealed that he has a wild-type KRAS status."
1359,white,male,53,34.1,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 53, bmi: 34.1, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type",The patient is a 53-year-old white male with a BMI of 34.1. He is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. His cancer histology is well differentiated. The patient has a fully active performance status and his KRAS biomarker is wild-type.
1360,white,male,66,22.38,FOLFOX,Yes,No,No,No,7,poorly differentiated,symptoms but ambulatory,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 66, bmi: 22.38, treatment arm: FOLFOX, adherence: Yes, chemotherapy cycles: 7, histology: poorly differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type","The patient is a 66-year-old white male with a BMI of 22.38. He is undergoing treatment with the FOLFOX regimen and has been adherent to the treatment. He has completed 7 cycles of chemotherapy. The histology of his cancer is poorly differentiated. Despite experiencing symptoms, he is still able to be ambulatory. The KRAS biomarker shows that he has a wild-type status."
1361,white,male,38,24.34,FOLFOX + Cetuximab,Yes,No,Yes,No,12,poorly differentiated,fully active,wild-type,No,Yes,No,No,No,0,"race: white, sex: male, age: 38, bmi: 24.34, treatment arm: FOLFOX + Cetuximab, adherence: Yes, bowel obstruction: Yes, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type, adverse effect: hypersensitivity: Yes","The patient is a 38-year-old white male with a BMI of 24.34. He is receiving treatment in the FOLFOX + Cetuximab treatment arm and has been adherent to the treatment. He has experienced a bowel obstruction and has completed 12 cycles of chemotherapy. The histology shows poorly differentiated cells. Despite the bowel obstruction, the patient's performance status is fully active. His KRAS biomarker is wild-type. He has experienced a hypersensitivity adverse effect."
1362,white,female,67,18.47,FOLFOX + Cetuximab,No,No,No,No,12,poorly differentiated,fully active,interminate,No,No,No,No,No,0,"race: white, sex: female, age: 67, bmi: 18.47, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: interminate","The patient is a 67-year-old white female with a BMI of 18.47. She is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. Her histology shows poorly differentiated cancer cells. Despite this, her performance status is fully active. The KRAS biomarker status is indeterminate for this patient."
1363,white,female,75,32.53,FOLFIRI (KRAS mutant),No,No,No,No,10,poorly differentiated,fully active,wild-type,No,No,Yes,No,No,0,"race: white, sex: female, age: 75, bmi: 32.53, treatment arm: FOLFIRI (KRAS mutant), chemotherapy cycles: 10, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type, adverse effect: diarrhea: Yes","The patient is a 75-year-old white female with a BMI of 32.53. She is receiving FOLFIRI chemotherapy for 10 cycles. Her cancer histology is poorly differentiated, and she has a fully active performance status. The KRAS biomarker is wild-type. The patient is experiencing diarrhea as an adverse effect of the treatment."
1364,white,male,43,28.38,FOLFOX + Cetuximab,No,No,Yes,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,1,"race: white, sex: male, age: 43, bmi: 28.38, treatment arm: FOLFOX + Cetuximab, bowel obstruction: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","This patient is a 43-year-old white male with a BMI of 28.38. He is receiving treatment with FOLFOX + Cetuximab for his cancer. He has experienced a bowel obstruction and has completed 12 cycles of chemotherapy. The histology of his cancer is well-differentiated. Despite his condition, he has a fully active performance status. His KRAS biomarker status is wild-type."
1365,black,male,42,38.58,FOLFIRI,No,Yes,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: black, sex: male, age: 42, bmi: 38.58, treatment arm: FOLFIRI, serious adverse effect: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 42-year-old Black male with a BMI of 38.58. He is receiving the FOLFIRI treatment arm and has experienced a serious adverse effect. He has completed 12 cycles of chemotherapy. His histology shows well-differentiated cells, and he has a fully active performance status. The KRAS biomarker indicates that he has a wild-type gene."
1366,white,male,36,23.14,FOLFOX,No,No,Yes,No,12,well differentiated,fully active,mutant,No,No,No,No,No,0,"race: white, sex: male, age: 36, bmi: 23.14, treatment arm: FOLFOX, bowel obstruction: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant",The patient is a 36-year-old white male with a BMI of 23.14. He is receiving treatment in the FOLFOX treatment arm and has experienced a bowel obstruction. He has completed 12 cycles of chemotherapy. The histology shows that the cancer is well-differentiated. The patient has a fully active performance status. The KRAS biomarker indicates that the patient has a mutant form of the gene.
1367,white,female,47,20.51,FOLFOX,No,No,No,No,12,well differentiated,fully active,mutant,No,No,No,No,No,0,"race: white, sex: female, age: 47, bmi: 20.51, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant",The patient is a 47-year-old white female with a BMI of 20.51. She is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cancer cells. The patient has a fully active performance status and carries a mutant KRAS biomarker.
1368,white,female,40,42.6,FOLFIRI (KRAS mutant),No,Yes,No,No,12,poorly differentiated,fully active,mutant,No,No,No,No,No,0,"race: white, sex: female, age: 40, bmi: 42.6, treatment arm: FOLFIRI (KRAS mutant), serious adverse effect: Yes, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 40-year-old white female with a BMI of 42.6. She is receiving the FOLFIRI treatment regimen for her KRAS mutant status. She has experienced a serious adverse effect during her treatment. The patient has undergone 12 cycles of chemotherapy. Her histology shows poorly differentiated cells. Despite these challenges, her performance status is fully active."
1369,white,female,46,44.45,FOLFOX + Cetuximab,Yes,No,Yes,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 46, bmi: 44.45, treatment arm: FOLFOX + Cetuximab, adherence: Yes, bowel obstruction: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 46-year-old white female with a BMI of 44.45. She is receiving treatment with FOLFOX + Cetuximab and has been adherent to the treatment. She has experienced a bowel obstruction. The patient has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cancer cells. Despite the bowel obstruction, her performance status is fully active. The KRAS biomarker analysis indicates that she has a wild-type KRAS gene."
1370,white,female,34,23.03,FOLFOX,No,Yes,No,No,12,well differentiated,fully active,mutant,No,No,No,No,No,0,"race: white, sex: female, age: 34, bmi: 23.03, treatment arm: FOLFOX, serious adverse effect: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 34-year-old white female with a BMI of 23.03. She is receiving the FOLFOX treatment regimen and has experienced a serious adverse effect. She has completed 12 cycles of chemotherapy. The histology shows that the cancer is well-differentiated. Despite the treatment, her performance status is fully active. The KRAS biomarker analysis indicates that she has a mutant KRAS status."
1371,white,male,70,33.65,FOLFOX + Cetuximab,Yes,Yes,No,No,6,poorly differentiated,fully active,wild-type,No,No,No,No,No,1,"race: white, sex: male, age: 70, bmi: 33.65, treatment arm: FOLFOX + Cetuximab, adherence: Yes, serious adverse effect: Yes, chemotherapy cycles: 6, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 70-year-old white male with a BMI of 33.65. He is receiving treatment with FOLFOX + Cetuximab and has been adherent to the treatment. However, he experienced a serious adverse effect during the course of his 6 chemotherapy cycles. His histology shows poorly differentiated cells, but his performance status is fully active. The KRAS biomarker indicates that he has a wild-type status."
1372,white,male,70,28.76,FOLFOX + Cetuximab,No,No,No,No,12,poorly differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 70, bmi: 28.76, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 70-year-old white male with a BMI of 28.76. He is receiving treatment in the FOLFOX + Cetuximab treatment arm and has completed 12 cycles of chemotherapy. His histology shows poorly differentiated cancer cells. Despite his age, he has a fully active performance status. The KRAS biomarker analysis indicates that he has a wild-type KRAS gene."
1373,other,female,46,18.18,FOLFOX + Cetuximab,Yes,No,No,No,6,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: other, sex: female, age: 46, bmi: 18.18, treatment arm: FOLFOX + Cetuximab, adherence: Yes, chemotherapy cycles: 6, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 46-year-old female of a race other than specified, with a BMI of 18.18. She is receiving treatment in the FOLFOX + Cetuximab treatment arm and has been adherent to her treatment. She has completed 6 cycles of chemotherapy. Histologically, her cancer is well-differentiated. The patient has a fully active performance status. Her KRAS biomarker status is wild-type."
1374,white,female,52,23.39,FOLFOX,No,No,Yes,No,12,well differentiated,fully active,interminate,No,No,No,No,No,0,"race: white, sex: female, age: 52, bmi: 23.39, treatment arm: FOLFOX, bowel obstruction: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: interminate","The patient is a 52-year-old white female with a BMI of 23.39. She is receiving the FOLFOX treatment regimen and has experienced a bowel obstruction. She has completed 12 cycles of chemotherapy. The histology of her cancer is well-differentiated. Despite the bowel obstruction, her performance status is fully active. The KRAS biomarker status is indeterminate."
1375,white,female,55,40.01,FOLFIRI (KRAS mutant),No,No,No,No,12,well differentiated,fully active,wild-type,No,No,Yes,No,No,1,"race: white, sex: female, age: 55, bmi: 40.01, treatment arm: FOLFIRI (KRAS mutant), chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type, adverse effect: diarrhea: Yes","The patient is a 55-year-old white female with a BMI of 40.01. She is receiving the FOLFIRI treatment regimen for her well-differentiated cancer with a KRAS wild-type biomarker. Despite experiencing diarrhea as an adverse effect, her performance status remains fully active. She has completed 12 cycles of chemotherapy."
1376,white,female,52,31.78,FOLFOX,No,No,Yes,No,12,poorly differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 52, bmi: 31.78, treatment arm: FOLFOX, bowel obstruction: Yes, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 52-year-old white female with a BMI of 31.78. She is receiving treatment with the FOLFOX regimen for her cancer. She has experienced a bowel obstruction and has completed 12 cycles of chemotherapy. The histology of her cancer is poorly differentiated. Despite these challenges, her performance status is fully active. Additionally, her KRAS biomarker status is wild-type."
1377,white,male,35,24.02,FOLFOX,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 35, bmi: 24.02, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 35-year-old white male with a BMI of 24.02. He is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cells, and he has a fully active performance status. The KRAS biomarker analysis indicates that he has a wild-type KRAS status."
1378,black,male,53,27.62,FOLFOX,Yes,Yes,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: black, sex: male, age: 53, bmi: 27.62, treatment arm: FOLFOX, adherence: Yes, serious adverse effect: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type",The patient is a 53-year-old Black male with a BMI of 27.62. He is receiving the FOLFOX treatment regimen and has been adherent to the treatment. He experienced a serious adverse effect during the treatment. The patient completed 12 cycles of chemotherapy. His histology shows well-differentiated cells. He has a fully active performance status. The KRAS biomarker analysis revealed a wild-type result.
1379,black,male,36,17.15,FOLFIRI (KRAS mutant),No,No,No,No,12,poorly differentiated,fully active,wild-type,No,No,No,No,No,1,"race: black, sex: male, age: 36, bmi: 17.15, treatment arm: FOLFIRI (KRAS mutant), chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 36-year-old Black male with a BMI of 17.15. He is receiving treatment in the FOLFIRI chemotherapy arm for KRAS mutant status. He has completed 12 cycles of chemotherapy. The histology of his cancer is poorly differentiated. Despite this, his performance status is fully active. His KRAS biomarker status is wild-type."
1380,white,female,55,19.14,FOLFOX + Cetuximab,Yes,No,No,No,5,poorly differentiated,fully active,wild-type,No,No,Yes,No,No,0,"race: white, sex: female, age: 55, bmi: 19.14, treatment arm: FOLFOX + Cetuximab, adherence: Yes, chemotherapy cycles: 5, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type, adverse effect: diarrhea: Yes","The patient is a 55-year-old white female with a BMI of 19.14. She is receiving treatment with FOLFOX + Cetuximab and has been adherent to the treatment. She has completed 5 cycles of chemotherapy. The histology of her cancer is poorly differentiated. Despite this, her performance status is fully active. Her KRAS biomarker is wild-type. She is experiencing diarrhea as an adverse effect of the treatment."
1381,black,female,55,31.88,FOLFOX,No,Yes,No,No,12,well differentiated,fully active,mutant,No,No,No,No,No,0,"race: black, sex: female, age: 55, bmi: 31.88, treatment arm: FOLFOX, serious adverse effect: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant",The patient is a 55-year-old Black female with a BMI of 31.88. She is receiving the FOLFOX treatment regimen and has experienced a serious adverse effect. She has completed 12 cycles of chemotherapy. The histology shows that the cancer is well-differentiated. The patient has a fully active performance status. The KRAS biomarker indicates that it is mutant.
1382,white,male,50,29.38,FOLFOX,No,No,No,No,12,poorly differentiated,fully active,mutant,No,No,No,No,No,0,"race: white, sex: male, age: 50, bmi: 29.38, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 50-year-old white male with a BMI of 29.38. He is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. His histology shows poorly differentiated cancer cells. Despite this, his performance status is fully active. Additionally, the patient has a mutant KRAS biomarker."
1383,other,male,39,26.56,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: other, sex: male, age: 39, bmi: 26.56, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 39-year-old male of a race categorized as ""other"" with a BMI of 26.56. He is receiving treatment in the FOLFOX + Cetuximab treatment arm and has completed 12 cycles of chemotherapy. The histology of his condition is well-differentiated. He has a fully active performance status and his KRAS biomarker status is wild-type."
1384,white,female,57,24.6,FOLFOX + Cetuximab,Yes,No,Yes,Yes,12,poorly differentiated,fully active,mutant,No,No,No,No,No,0,"race: white, sex: female, age: 57, bmi: 24.6, treatment arm: FOLFOX + Cetuximab, adherence: Yes, bowel obstruction: Yes, bowel perforation: Yes, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 57-year-old white female with a BMI of 24.6. She is receiving treatment with FOLFOX + Cetuximab and has been adherent to her treatment. She has experienced both a bowel obstruction and a bowel perforation. She has completed 12 cycles of chemotherapy. The histology of her cancer is poorly differentiated. Despite her bowel issues, her performance status is fully active. Additionally, her KRAS biomarker is mutant."
1385,white,male,57,25.9,FOLFOX,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 57, bmi: 25.9, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type",The patient is a 57-year-old white male with a BMI of 25.9. He is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer cells. The patient has a fully active performance status and his KRAS biomarker is wild-type.
1386,black,female,73,27.36,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,symptoms but ambulatory,wild-type,No,No,No,No,No,0,"race: black, sex: female, age: 73, bmi: 27.36, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type","The patient is a 73-year-old Black female with a BMI of 27.36. She is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cancer. Despite experiencing symptoms, she is still able to ambulate. The KRAS biomarker analysis indicates that she has a wild-type KRAS status."
1387,white,male,75,26.47,FOLFOX + Cetuximab,No,No,No,No,8,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 75, bmi: 26.47, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 8, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 75-year-old white male with a BMI of 26.47. He is receiving treatment with FOLFOX + Cetuximab and has completed 8 cycles of chemotherapy. His histology shows well-differentiated cancer cells. Despite his age, he has a fully active performance status. Additionally, his KRAS biomarker is wild-type."
1388,other,male,63,34.94,FOLFOX + Cetuximab,No,No,No,No,7,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: other, sex: male, age: 63, bmi: 34.94, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 7, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 63-year-old male of a race other than specified, with a BMI of 34.94. He is currently receiving treatment in the FOLFOX + Cetuximab treatment arm and has completed 7 cycles of chemotherapy. His histology shows well-differentiated cells, and he has a fully active performance status. Additionally, the KRAS biomarker analysis indicates that he has a wild-type KRAS status."
1389,black,female,59,26.44,FOLFOX,No,Yes,No,No,12,well differentiated,fully active,mutant,No,No,No,No,No,0,"race: black, sex: female, age: 59, bmi: 26.44, treatment arm: FOLFOX, serious adverse effect: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 59-year-old Black female with a BMI of 26.44. She is undergoing treatment with FOLFOX chemotherapy regimen and has experienced a serious adverse effect. She has completed 12 cycles of chemotherapy. The histology shows well-differentiated cancer cells. Despite the treatment, her performance status is fully active. The KRAS biomarker analysis indicates a mutant status."
1390,white,female,47,30.01,FOLFOX + Cetuximab,No,Yes,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 47, bmi: 30.01, treatment arm: FOLFOX + Cetuximab, serious adverse effect: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 47-year-old white female with a BMI of 30.01. She is receiving treatment with FOLFOX + Cetuximab and has experienced a serious adverse effect. She has completed 12 cycles of chemotherapy. The histology of her condition is well-differentiated. Despite the adverse effect, her performance status is fully active. Her KRAS biomarker status is wild-type."
1391,white,male,73,28.79,FOLFOX,No,No,Yes,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 73, bmi: 28.79, treatment arm: FOLFOX, bowel obstruction: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 73-year-old white male with a BMI of 28.79. He is receiving treatment with FOLFOX chemotherapy regimen and has experienced a bowel obstruction. He has completed 12 cycles of chemotherapy. The histology of his cancer is well differentiated. Despite his condition, he has a fully active performance status. The KRAS biomarker analysis shows that he has a wild-type KRAS status."
1392,other,male,55,24.57,FOLFOX + Cetuximab,Yes,No,No,No,12,poorly differentiated,symptoms but ambulatory,wild-type,No,No,No,No,No,0,"race: other, sex: male, age: 55, bmi: 24.57, treatment arm: FOLFOX + Cetuximab, adherence: Yes, chemotherapy cycles: 12, histology: poorly differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type","The patient is a 55-year-old male of a race categorized as ""other"" with a BMI of 24.57. He is currently receiving treatment in the FOLFOX + Cetuximab treatment arm and has been adherent to the prescribed regimen. He has completed 12 cycles of chemotherapy. The histology of his cancer is poorly differentiated. Despite experiencing symptoms, he is still able to be ambulatory. His KRAS biomarker status is wild-type."
1393,black,male,58,25.24,FOLFIRI,Yes,No,No,No,12,well differentiated,symptoms but ambulatory,mutant,No,No,No,No,No,0,"race: black, sex: male, age: 58, bmi: 25.24, treatment arm: FOLFIRI, adherence: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: mutant","The patient is a 58-year-old Black male with a BMI of 25.24. He is receiving the FOLFIRI treatment regimen and has been adherent to the treatment. He has completed 12 cycles of chemotherapy. The histology shows well-differentiated cancer cells. Despite experiencing symptoms, the patient is still able to be ambulatory. The KRAS biomarker analysis indicates a mutant status."
1394,other,female,46,29.46,FOLFOX,No,No,No,No,12,well differentiated,symptoms but ambulatory,wild-type,No,No,No,No,No,0,"race: other, sex: female, age: 46, bmi: 29.46, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type","The patient is a 46-year-old female of a race categorized as ""other"" with a BMI of 29.46. She is undergoing treatment with the FOLFOX chemotherapy regimen and has completed 12 cycles. Her histology shows well-differentiated characteristics. Despite experiencing symptoms, she is still able to be ambulatory. The KRAS biomarker analysis indicates that she has a wild-type KRAS status."
1395,white,female,70,29.68,FOLFOX + Cetuximab,No,No,No,No,12,poorly differentiated,fully active,wild-type,No,No,Yes,No,No,0,"race: white, sex: female, age: 70, bmi: 29.68, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type, adverse effect: diarrhea: Yes","The patient is a 70-year-old white female with a BMI of 29.68. She is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. Her histology shows poorly differentiated cancer cells. Despite this, her performance status is fully active. The KRAS biomarker indicates that she has a wild-type gene. She is experiencing diarrhea as an adverse effect of the treatment."
1396,black,male,35,31.18,FOLFOX,No,No,Yes,No,12,well differentiated,fully active,mutant,No,No,No,No,No,0,"race: black, sex: male, age: 35, bmi: 31.18, treatment arm: FOLFOX, bowel obstruction: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 35-year-old Black male with a BMI of 31.18. He is receiving treatment with the FOLFOX regimen and has experienced a bowel obstruction. He has completed 12 cycles of chemotherapy. The histology of his cancer is well-differentiated. Despite the bowel obstruction, his performance status is fully active. The KRAS biomarker testing revealed a mutant status."
1397,white,male,52,18.83,FOLFOX,Yes,No,No,No,12,poorly differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 52, bmi: 18.83, treatment arm: FOLFOX, adherence: Yes, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 52-year-old white male with a BMI of 18.83. He is receiving treatment in the FOLFOX arm and has been adherent to his chemotherapy regimen for 12 cycles. His histology shows poorly differentiated cancer cells. Despite this, his performance status is fully active. The KRAS biomarker analysis indicates that he has a wild-type KRAS gene."
1398,white,male,57,27.95,FOLFOX,Yes,No,No,No,3,well differentiated,symptoms but ambulatory,mutant,No,No,No,No,No,0,"race: white, sex: male, age: 57, bmi: 27.95, treatment arm: FOLFOX, adherence: Yes, chemotherapy cycles: 3, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: mutant","The patient is a 57-year-old white male with a BMI of 27.95. He is receiving treatment in the FOLFOX arm and has been adherent to the chemotherapy regimen for 3 cycles. His histology shows well-differentiated cancer. Despite experiencing symptoms, he is still able to be ambulatory. The KRAS biomarker analysis indicates a mutant status."
1399,white,male,56,25.17,FOLFOX + Cetuximab,No,Yes,No,No,12,well differentiated,symptoms but ambulatory,wild-type,No,No,Yes,Yes,No,0,"race: white, sex: male, age: 56, bmi: 25.17, treatment arm: FOLFOX + Cetuximab, serious adverse effect: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type, adverse effect: diarrhea: Yes, adverse effect: infection: Yes","The patient is a 56-year-old white male with a BMI of 25.17. He is receiving treatment with FOLFOX + Cetuximab for his well-differentiated cancer. He has experienced serious adverse effects, including diarrhea and infection, during the 12 cycles of chemotherapy. Despite experiencing symptoms, he is still able to be ambulatory. His KRAS biomarker status is wild-type."
1400,black,male,39,30.99,FOLFOX,No,No,No,Yes,3,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: black, sex: male, age: 39, bmi: 30.99, treatment arm: FOLFOX, bowel perforation: Yes, chemotherapy cycles: 3, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 39-year-old Black male with a BMI of 30.99. He is receiving the FOLFOX treatment arm for his colorectal cancer. He has experienced a bowel perforation and has completed 3 cycles of chemotherapy. The histology of his cancer is well-differentiated. Despite his condition, he has a fully active performance status. His KRAS biomarker status is wild-type."
1401,white,male,45,32.03,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,Yes,No,No,0,"race: white, sex: male, age: 45, bmi: 32.03, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type, adverse effect: diarrhea: Yes","The patient is a 45-year-old white male with a BMI of 32.03 who is receiving treatment with FOLFOX + Cetuximab for 12 chemotherapy cycles. His histology shows well-differentiated cancer, and he has a fully active performance status. The KRAS biomarker is wild-type. The patient is experiencing diarrhea as an adverse effect of the treatment."
1402,black,male,75,24.88,FOLFOX,No,No,No,No,12,well differentiated,fully active,interminate,No,No,No,No,No,0,"race: black, sex: male, age: 75, bmi: 24.88, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: interminate","The patient is a 75-year-old Black male with a BMI of 24.88. He is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. The histology of his cancer is well-differentiated. Despite his age, he has a fully active performance status. The KRAS biomarker status is indeterminate."
1403,other,male,55,18.21,FOLFOX + Cetuximab,Yes,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: other, sex: male, age: 55, bmi: 18.21, treatment arm: FOLFOX + Cetuximab, adherence: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 55-year-old male of a race categorized as ""other"" with a BMI of 18.21. He is undergoing treatment with FOLFOX + Cetuximab and has been adherent to the treatment. He has completed 12 cycles of chemotherapy. The histology shows well-differentiated cells, and his performance status is fully active. The KRAS biomarker indicates that he has a wild-type KRAS status."
1404,other,female,67,26.21,FOLFOX,No,No,No,No,7,poorly differentiated,fully active,wild-type,No,No,No,No,No,0,"race: other, sex: female, age: 67, bmi: 26.21, treatment arm: FOLFOX, chemotherapy cycles: 7, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 67-year-old female of a race categorized as ""other."" She has a BMI of 26.21 and is currently receiving the FOLFOX treatment regimen. She has completed 7 cycles of chemotherapy. The histology of her cancer is poorly differentiated. Despite her cancer diagnosis, her performance status is fully active. Her KRAS biomarker status is wild-type."
1405,white,female,57,33.91,FOLFOX,No,Yes,No,No,12,poorly differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 57, bmi: 33.91, treatment arm: FOLFOX, serious adverse effect: Yes, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 57-year-old white female with a BMI of 33.91. She is receiving the FOLFOX treatment arm and has experienced a serious adverse effect. She has completed 12 cycles of chemotherapy. The histology shows poorly differentiated cancer cells. Despite this, her performance status is fully active. The KRAS biomarker indicates that she has a wild-type status."
1406,white,male,44,26.07,FOLFOX + Cetuximab,No,No,No,No,6,well differentiated,fully active,wild-type,No,Yes,No,No,No,0,"race: white, sex: male, age: 44, bmi: 26.07, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 6, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type, adverse effect: hypersensitivity: Yes","The patient is a 44-year-old white male with a BMI of 26.07. He is receiving treatment with FOLFOX + Cetuximab and has completed 6 cycles of chemotherapy. His histology shows well-differentiated cells, and he has a fully active performance status. The KRAS biomarker indicates he is wild-type. The patient has experienced a hypersensitivity adverse effect."
1407,other,female,42,21.84,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: other, sex: female, age: 42, bmi: 21.84, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 42-year-old female of a race categorized as ""other"" with a BMI of 21.84. She is receiving treatment in the FOLFOX + Cetuximab treatment arm and has completed 12 cycles of chemotherapy. The histology of her condition is well-differentiated, and her performance status is fully active. Additionally, her KRAS biomarker status is wild-type."
1408,white,male,42,25.16,FOLFOX,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 42, bmi: 25.16, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 42-year-old white male with a BMI of 25.16. He is receiving treatment with the FOLFOX chemotherapy regimen and is scheduled for 12 cycles. His cancer histology is well-differentiated, and he has a fully active performance status. The KRAS biomarker analysis indicates that he has a wild-type KRAS status."
1409,white,male,58,26.3,FOLFOX + Cetuximab,No,No,No,No,8,well differentiated,fully active,wild-type,No,No,Yes,No,No,0,"race: white, sex: male, age: 58, bmi: 26.3, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 8, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type, adverse effect: diarrhea: Yes","The patient is a 58-year-old white male with a BMI of 26.3. He is receiving treatment with FOLFOX + Cetuximab and has completed 8 cycles of chemotherapy. His histology shows well-differentiated cancer, and he has a fully active performance status. The KRAS biomarker indicates that he is wild-type. The patient is experiencing diarrhea as an adverse effect of the treatment."
1410,white,female,59,25.32,FOLFOX,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 59, bmi: 25.32, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type",The patient is a 59-year-old white female with a BMI of 25.32. She is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. The histology shows well-differentiated cancer cells. The patient has a fully active performance status. The KRAS biomarker analysis indicates that the patient has a wild-type KRAS status.
1411,white,male,53,23.89,FOLFOX,No,No,No,No,12,well differentiated,fully active,mutant,No,No,No,No,No,0,"race: white, sex: male, age: 53, bmi: 23.89, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant",The patient is a 53-year-old white male with a BMI of 23.89. He is undergoing treatment with the FOLFOX chemotherapy regimen and has completed 12 cycles. His histology shows well-differentiated cancer cells. The patient has a fully active performance status. The KRAS biomarker analysis revealed a mutant status.
1412,white,male,49,22.79,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,fully active,mutant,No,No,No,No,No,0,"race: white, sex: male, age: 49, bmi: 22.79, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant",The patient is a 49-year-old white male with a BMI of 22.79. He is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. His cancer histology is well differentiated. He has a fully active performance status. The KRAS biomarker testing showed a mutant result.
1413,white,male,45,30.16,FOLFOX,No,No,No,No,12,poorly differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 45, bmi: 30.16, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 45-year-old white male with a BMI of 30.16. He is receiving the FOLFOX treatment regimen and is scheduled for 12 cycles of chemotherapy. His cancer histology is poorly differentiated. Despite his diagnosis, he has a fully active performance status. Additionally, his KRAS biomarker status is wild-type."
1414,white,male,75,29.6,FOLFOX + Cetuximab,No,Yes,No,No,1,well differentiated,symptoms but ambulatory,mutant,No,No,Yes,No,No,1,"race: white, sex: male, age: 75, bmi: 29.6, treatment arm: FOLFOX + Cetuximab, serious adverse effect: Yes, chemotherapy cycles: 1, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: mutant, adverse effect: diarrhea: Yes","The patient is a 75-year-old white male with a BMI of 29.6. He is receiving treatment with FOLFOX + Cetuximab and has experienced a serious adverse effect after one cycle of chemotherapy. His histology shows well-differentiated cancer, and he has symptoms but is still able to be ambulatory. The KRAS biomarker indicates a mutation. Additionally, he is experiencing diarrhea as an adverse effect of the treatment."
1415,white,male,69,25.57,FOLFOX + Cetuximab,No,Yes,No,No,6,well differentiated,fully active,mutant,Yes,No,No,No,No,0,"race: white, sex: male, age: 69, bmi: 25.57, treatment arm: FOLFOX + Cetuximab, serious adverse effect: Yes, chemotherapy cycles: 6, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant, adverse effect: thrombosis: Yes","The patient is a 69-year-old white male with a BMI of 25.57. He is receiving treatment with FOLFOX + Cetuximab and has experienced a serious adverse effect. He has completed 6 cycles of chemotherapy. His histology shows well-differentiated cancer, and he has a fully active performance status. The KRAS biomarker is mutant in this patient. Additionally, he has experienced thrombosis as an adverse effect."
1416,other,female,37,21.38,FOLFOX,No,No,Yes,Yes,12,well differentiated,fully active,mutant,No,No,No,No,No,1,"race: other, sex: female, age: 37, bmi: 21.38, treatment arm: FOLFOX, bowel obstruction: Yes, bowel perforation: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 37-year-old female of a race categorized as ""other"" with a BMI of 21.38. She is undergoing treatment with the FOLFOX regimen and has experienced both a bowel obstruction and perforation. She is expected to complete a total of 12 cycles of chemotherapy. The histology of her condition is well-differentiated. Despite the challenges with her bowel, her performance status is noted as fully active. Additionally, the KRAS biomarker analysis has revealed a mutation in this patient."
1417,white,female,49,25.27,FOLFOX + Cetuximab,No,No,No,No,6,well differentiated,fully active,mutant,No,No,Yes,No,No,0,"race: white, sex: female, age: 49, bmi: 25.27, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 6, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant, adverse effect: diarrhea: Yes","The patient is a 49-year-old white female with a BMI of 25.27. She is receiving treatment in the FOLFOX + Cetuximab treatment arm and has completed 6 chemotherapy cycles. Her histology shows well-differentiated cancer, and she has a fully active performance status. The KRAS biomarker testing revealed a mutant status. The patient is experiencing diarrhea as an adverse effect of the treatment."
1418,white,female,50,26.33,FOLFIRI + Cetuximab,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 50, bmi: 26.33, treatment arm: FOLFIRI + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 50-year-old white female with a BMI of 26.33. She is receiving treatment with FOLFIRI + Cetuximab and has completed 12 cycles of chemotherapy. Her cancer histology is well-differentiated, and she has a fully active performance status. Additionally, her KRAS biomarker status is wild-type."
1419,white,female,45,43.97,FOLFOX,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 45, bmi: 43.97, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type",The patient is a 45-year-old white female with a BMI of 43.97. She is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. The histology shows well-differentiated cancer cells. The patient has a fully active performance status. The KRAS biomarker analysis indicates that she has the wild-type KRAS gene.
1420,white,male,69,27.95,FOLFOX,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,Yes,No,No,0,"race: white, sex: male, age: 69, bmi: 27.95, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type, adverse effect: diarrhea: Yes",The patient is a 69-year-old white male with a BMI of 27.95 who is receiving the FOLFOX treatment regimen for his well-differentiated histology. He has completed 12 cycles of chemotherapy and has a fully active performance status. His KRAS biomarker is wild-type. The patient is experiencing diarrhea as an adverse effect of the treatment.
1421,other,female,54,24.95,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: other, sex: female, age: 54, bmi: 24.95, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 54-year-old female of a race categorized as ""other"" with a BMI of 24.95. She is receiving treatment in the FOLFOX + Cetuximab treatment arm and has completed 12 cycles of chemotherapy. The histology of her condition is well-differentiated, and her performance status is fully active. Additionally, her KRAS biomarker status is wild-type."
1422,white,male,76,19.25,FOLFOX,Yes,Yes,No,No,12,well differentiated,symptoms but ambulatory,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 76, bmi: 19.25, treatment arm: FOLFOX, adherence: Yes, serious adverse effect: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type","The patient is a 76-year-old white male with a BMI of 19.25. He is receiving the FOLFOX treatment regimen and has been adherent to the treatment. However, he experienced a serious adverse effect during the course of his 12 chemotherapy cycles. The histology shows that the cancer is well-differentiated. Despite experiencing symptoms, the patient is still ambulatory. The KRAS biomarker analysis indicates that the patient has a wild-type KRAS status."
1423,white,female,54,44.96,FOLFOX + Cetuximab,No,No,Yes,Yes,12,well differentiated,fully active,mutant,No,No,No,No,No,0,"race: white, sex: female, age: 54, bmi: 44.96, treatment arm: FOLFOX + Cetuximab, bowel obstruction: Yes, bowel perforation: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant","This patient is a 54-year-old white female with a BMI of 44.96. She is receiving treatment with FOLFOX + Cetuximab for her cancer. She has experienced both a bowel obstruction and a bowel perforation. She has completed 12 cycles of chemotherapy. The histology of her cancer is well differentiated. Despite her medical challenges, her performance status is fully active. Additionally, her KRAS biomarker is mutant."
1424,white,female,57,21.92,FOLFOX,Yes,No,No,Yes,12,poorly differentiated,symptoms but ambulatory,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 57, bmi: 21.92, treatment arm: FOLFOX, adherence: Yes, bowel perforation: Yes, chemotherapy cycles: 12, histology: poorly differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type","The patient is a 57-year-old white female with a BMI of 21.92. She is receiving the FOLFOX treatment regimen and has been adherent to her chemotherapy. She experienced a bowel perforation and has completed 12 cycles of chemotherapy. The histology of her cancer is poorly differentiated. Despite experiencing symptoms, she is still able to be ambulatory. Her KRAS biomarker status is wild-type."
1425,black,male,74,26.85,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,symptoms but ambulatory,wild-type,No,No,No,No,No,0,"race: black, sex: male, age: 74, bmi: 26.85, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type","The patient is a 74-year-old Black male with a BMI of 26.85. He is receiving treatment in the FOLFOX + Cetuximab treatment arm and has completed 12 cycles of chemotherapy. The histology shows well-differentiated cancer cells. Despite experiencing symptoms, the patient is still able to walk around (ambulatory). His KRAS biomarker status is wild-type."
1426,white,male,70,27.5,FOLFOX,No,No,Yes,No,12,poorly differentiated,symptoms but ambulatory,wild-type,No,No,No,No,No,1,"race: white, sex: male, age: 70, bmi: 27.5, treatment arm: FOLFOX, bowel obstruction: Yes, chemotherapy cycles: 12, histology: poorly differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type","This patient is a 70-year-old white male with a BMI of 27.5. He is receiving the FOLFOX treatment regimen and has a bowel obstruction. He has completed 12 cycles of chemotherapy. The histology of his cancer is poorly differentiated. Despite experiencing symptoms, he is still able to be ambulatory. His KRAS biomarker status is wild-type."
1427,other,female,60,22.95,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,fully active,mutant,No,No,No,No,No,0,"race: other, sex: female, age: 60, bmi: 22.95, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 60-year-old female of a race categorized as ""other"" with a BMI of 22.95. She is undergoing treatment with the FOLFOX + Cetuximab regimen and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cancer cells. Despite her age, she has a fully active performance status. Additionally, her KRAS biomarker indicates a mutant status."
1428,white,male,57,23.76,FOLFOX + Cetuximab,No,Yes,No,No,12,well differentiated,fully active,mutant,Yes,No,No,No,No,0,"race: white, sex: male, age: 57, bmi: 23.76, treatment arm: FOLFOX + Cetuximab, serious adverse effect: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant, adverse effect: thrombosis: Yes","The patient is a 57-year-old white male with a BMI of 23.76. He is receiving treatment with FOLFOX + Cetuximab and has experienced a serious adverse effect. He has completed 12 cycles of chemotherapy. His histology shows well-differentiated cells, and he has a fully active performance status. The KRAS biomarker is mutant in this patient. Additionally, he has experienced thrombosis as an adverse effect."
1429,black,male,61,25.1,FOLFOX,No,No,No,No,6,well differentiated,fully active,mutant,No,No,No,No,No,0,"race: black, sex: male, age: 61, bmi: 25.1, treatment arm: FOLFOX, chemotherapy cycles: 6, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant",The patient is a 61-year-old Black male with a BMI of 25.1. He is receiving the FOLFOX treatment regimen and has completed 6 cycles of chemotherapy. The histology shows well-differentiated cancer cells. The patient's performance status is fully active. The KRAS biomarker analysis indicates a mutant status.
1430,white,female,64,25.37,FOLFOX,No,No,Yes,No,12,poorly differentiated,symptoms but ambulatory,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 64, bmi: 25.37, treatment arm: FOLFOX, bowel obstruction: Yes, chemotherapy cycles: 12, histology: poorly differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type","The patient is a 64-year-old white female with a BMI of 25.37. She is receiving the FOLFOX treatment regimen and has experienced a bowel obstruction. She has completed 12 cycles of chemotherapy. The histology of her cancer is poorly differentiated. Despite experiencing symptoms, she is still able to be ambulatory. Her KRAS biomarker status is wild-type."
1431,white,male,71,26.37,FOLFOX + Cetuximab,No,No,Yes,No,4,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 71, bmi: 26.37, treatment arm: FOLFOX + Cetuximab, bowel obstruction: Yes, chemotherapy cycles: 4, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 71-year-old white male with a BMI of 26.37. He is receiving treatment with FOLFOX + Cetuximab for his bowel obstruction. He has completed 4 cycles of chemotherapy. His histology shows well-differentiated cancer cells. Despite his condition, he has a fully active performance status. The KRAS biomarker indicates that he has a wild-type gene."
1432,white,female,61,35.08,FOLFOX,No,No,No,No,12,well differentiated,fully active,mutant,No,No,No,No,No,0,"race: white, sex: female, age: 61, bmi: 35.08, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 61-year-old white female with a BMI of 35.08. She is receiving the FOLFOX treatment arm and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cells, and she has a fully active performance status. The KRAS biomarker indicates that she has a mutant status."
1433,white,male,55,27.55,FOLFOX + Cetuximab,No,No,No,No,12,poorly differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 55, bmi: 27.55, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 55-year-old white male with a BMI of 27.55. He is receiving treatment in the FOLFOX + Cetuximab treatment arm and is scheduled for 12 chemotherapy cycles. His histology shows poorly differentiated cancer cells. Despite this, his performance status is fully active. Additionally, his KRAS biomarker status is wild-type."
1434,white,male,54,30.65,FOLFOX + Cetuximab,No,No,Yes,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 54, bmi: 30.65, treatment arm: FOLFOX + Cetuximab, bowel obstruction: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 54-year-old white male with a BMI of 30.65. He is receiving treatment with FOLFOX + Cetuximab for his well-differentiated histology. He has experienced a bowel obstruction and has completed 12 cycles of chemotherapy. Despite the bowel obstruction, his performance status is fully active. Additionally, his KRAS biomarker is wild-type."
1435,white,male,54,23.92,FOLFOX + Cetuximab,No,No,Yes,No,12,well differentiated,fully active,mutant,No,No,No,No,No,0,"race: white, sex: male, age: 54, bmi: 23.92, treatment arm: FOLFOX + Cetuximab, bowel obstruction: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant","This patient is a 54-year-old white male with a BMI of 23.92. He is receiving treatment with FOLFOX + Cetuximab for his cancer. He has experienced a bowel obstruction and has completed 12 cycles of chemotherapy. The histology of his cancer is well differentiated. Despite the challenges, his performance status is fully active. Additionally, the KRAS biomarker testing revealed a mutant status."
1436,white,male,76,25.49,FOLFIRI + Cetuximab,No,No,No,No,12,poorly differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 76, bmi: 25.49, treatment arm: FOLFIRI + Cetuximab, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 76-year-old white male with a BMI of 25.49. He is receiving treatment with FOLFIRI + Cetuximab and has completed 12 cycles of chemotherapy. His histology shows poorly differentiated cancer cells. Despite his age, he has a fully active performance status. Additionally, his KRAS biomarker is wild-type."
1437,white,male,60,20.9,FOLFIRI + Cetuximab,No,No,No,No,12,well differentiated,fully active,mutant,No,No,No,No,No,0,"race: white, sex: male, age: 60, bmi: 20.9, treatment arm: FOLFIRI + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 60-year-old white male with a BMI of 20.9. He is receiving treatment in the FOLFIRI + Cetuximab treatment arm and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer cells. Despite his cancer diagnosis, he has a fully active performance status. The patient's KRAS biomarker indicates a mutant status."
1438,white,male,42,22.44,FOLFOX,Yes,No,Yes,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 42, bmi: 22.44, treatment arm: FOLFOX, adherence: Yes, bowel obstruction: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 42-year-old white male with a BMI of 22.44. He is receiving treatment in the FOLFOX arm and has been adherent to the treatment. He has experienced a bowel obstruction. The patient has completed 12 cycles of chemotherapy and has well-differentiated histology. His performance status is fully active, and his KRAS biomarker is wild-type."
1439,white,male,40,23.89,FOLFOX,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 40, bmi: 23.89, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type",The patient is a 40-year-old white male with a BMI of 23.89. He is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. His cancer histology is well differentiated. The patient has a fully active performance status and his KRAS biomarker is wild-type.
1440,white,male,66,26.7,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,symptoms but ambulatory,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 66, bmi: 26.7, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type","The patient is a 66-year-old white male with a BMI of 26.7. He is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer cells. Despite experiencing symptoms, he is still able to walk around (ambulatory). The KRAS biomarker analysis indicates that he has a wild-type KRAS gene."
1441,white,female,64,22.4,FOLFOX,No,No,No,No,12,poorly differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 64, bmi: 22.4, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 64-year-old white female with a BMI of 22.4. She is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. Her histology shows poorly differentiated cancer cells. Despite this, her performance status is fully active. The KRAS biomarker analysis indicates that she has a wild-type KRAS status."
1442,other,female,54,22.35,FOLFOX + Cetuximab,No,Yes,Yes,No,11,poorly differentiated,fully active,wild-type,No,No,No,No,No,1,"race: other, sex: female, age: 54, bmi: 22.35, treatment arm: FOLFOX + Cetuximab, serious adverse effect: Yes, bowel obstruction: Yes, chemotherapy cycles: 11, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 54-year-old female of a race other than Caucasian, with a BMI of 22.35. She is receiving treatment with FOLFOX + Cetuximab. She has experienced a serious adverse effect and is currently dealing with a bowel obstruction. She has completed 11 cycles of chemotherapy. The histology of her cancer is poorly differentiated. Despite these challenges, her performance status is fully active. Her KRAS biomarker status is wild-type."
1443,white,male,38,23.11,FOLFOX,No,Yes,Yes,No,9,well differentiated,fully active,wild-type,No,No,Yes,No,No,0,"race: white, sex: male, age: 38, bmi: 23.11, treatment arm: FOLFOX, serious adverse effect: Yes, bowel obstruction: Yes, chemotherapy cycles: 9, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type, adverse effect: diarrhea: Yes","The patient is a 38-year-old white male with a BMI of 23.11 who is receiving the FOLFOX treatment regimen. He has experienced a serious adverse effect, specifically a bowel obstruction. He has completed 9 cycles of chemotherapy and has well-differentiated histology. Despite the adverse effects, he maintains a fully active performance status. His KRAS biomarker status is wild-type. Additionally, he has experienced diarrhea as an adverse effect."
1444,black,female,57,25.16,FOLFOX,No,No,No,No,3,poorly differentiated,symptoms but ambulatory,wild-type,No,No,No,No,No,0,"race: black, sex: female, age: 57, bmi: 25.16, treatment arm: FOLFOX, chemotherapy cycles: 3, histology: poorly differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type","The patient is a 57-year-old Black female with a BMI of 25.16. She is currently receiving the FOLFOX treatment regimen and has completed 3 cycles of chemotherapy. The histology of her cancer is poorly differentiated. Despite experiencing symptoms, she is still able to move around independently (ambulatory). The KRAS biomarker testing revealed that she has a wild-type KRAS status."
1445,white,male,34,30.45,FOLFOX,No,No,No,Yes,12,poorly differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 34, bmi: 30.45, treatment arm: FOLFOX, bowel perforation: Yes, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 34-year-old white male with a BMI of 30.45. He is receiving treatment with FOLFOX and has experienced a bowel perforation. He has completed 12 cycles of chemotherapy. The histology of his cancer is poorly differentiated. Despite these challenges, his performance status is fully active. His KRAS biomarker status is wild-type."
1446,white,female,70,32.9,FOLFIRI + Cetuximab,No,No,Yes,No,2,well differentiated,symptoms but ambulatory,wild-type,No,No,Yes,No,No,0,"race: white, sex: female, age: 70, bmi: 32.9, treatment arm: FOLFIRI + Cetuximab, bowel obstruction: Yes, chemotherapy cycles: 2, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type, adverse effect: diarrhea: Yes","The patient is a 70-year-old white female with a BMI of 32.9 who is receiving treatment with FOLFIRI + Cetuximab. She is experiencing a bowel obstruction and has completed 2 cycles of chemotherapy. Her histology shows well-differentiated cells, and she has symptoms but is still able to be ambulatory. The KRAS biomarker indicates that she is wild-type. Additionally, she is experiencing diarrhea as an adverse effect of the treatment."
1447,white,female,71,28.76,FOLFOX,No,Yes,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 71, bmi: 28.76, treatment arm: FOLFOX, serious adverse effect: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 71-year-old white female with a BMI of 28.76. She is receiving the FOLFOX treatment arm for her well-differentiated histology. She has experienced a serious adverse effect during her 12 chemotherapy cycles. Despite this, her performance status is fully active. Additionally, her KRAS biomarker is wild-type."
1448,white,female,42,34.18,FOLFOX + Cetuximab,No,Yes,No,No,10,well differentiated,fully active,wild-type,Yes,No,Yes,No,No,0,"race: white, sex: female, age: 42, bmi: 34.18, treatment arm: FOLFOX + Cetuximab, serious adverse effect: Yes, chemotherapy cycles: 10, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type, adverse effect: thrombosis: Yes, adverse effect: diarrhea: Yes","The patient is a 42-year-old white female with a BMI of 34.18. She is receiving treatment with FOLFOX + Cetuximab and has experienced a serious adverse effect. She has completed 10 cycles of chemotherapy. Her histology shows well-differentiated cells, and her performance status is fully active. The KRAS biomarker is wild-type. She has experienced adverse effects including thrombosis and diarrhea."
1449,white,female,56,22.65,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 56, bmi: 22.65, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 56-year-old white female with a BMI of 22.65. She is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. Her cancer histology is well-differentiated, and she has a fully active performance status. The KRAS biomarker testing revealed that she has a wild-type KRAS status."
1450,white,female,46,37.48,FOLFOX,No,No,No,No,12,well differentiated,fully active,mutant,No,No,No,No,No,0,"race: white, sex: female, age: 46, bmi: 37.48, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 46-year-old white female with a BMI of 37.48. She is undergoing treatment with the FOLFOX chemotherapy regimen and has completed 12 cycles. Her histology shows well-differentiated cancer cells. Despite her cancer diagnosis, she has a fully active performance status. The KRAS biomarker testing revealed a mutant status."
1451,white,male,60,26.79,FOLFOX + Cetuximab,Yes,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 60, bmi: 26.79, treatment arm: FOLFOX + Cetuximab, adherence: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type",The patient is a 60-year-old white male with a BMI of 26.79. He is receiving treatment in the FOLFOX + Cetuximab treatment arm and has been adherent to the treatment. He has completed 12 cycles of chemotherapy. The histology shows well-differentiated cancer cells. The patient has a fully active performance status. The KRAS biomarker indicates that he has a wild-type KRAS gene.
1452,white,female,57,29.45,FOLFOX,No,No,No,No,8,poorly differentiated,fully active,interminate,No,No,No,No,No,1,"race: white, sex: female, age: 57, bmi: 29.45, treatment arm: FOLFOX, chemotherapy cycles: 8, histology: poorly differentiated, performance status: fully active, KRAS biomarker: interminate","The patient is a 57-year-old white female with a BMI of 29.45. She is receiving the FOLFOX treatment regimen and has completed 8 cycles of chemotherapy. Her histology shows poorly differentiated cancer cells. Despite this, her performance status is fully active. The KRAS biomarker status is indeterminate for this patient."
1453,other,male,63,26.4,FOLFOX,No,No,No,No,12,poorly differentiated,fully active,wild-type,No,No,No,No,No,0,"race: other, sex: male, age: 63, bmi: 26.4, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 63-year-old male of a race categorized as ""other"" with a BMI of 26.4. He is undergoing treatment with the FOLFOX regimen and has completed 12 cycles of chemotherapy. The histology of his cancer is poorly differentiated. Despite his cancer diagnosis, he has a fully active performance status. The KRAS biomarker testing revealed that he has a wild-type KRAS status."
1454,white,male,63,21.25,FOLFOX,No,No,No,No,10,poorly differentiated,fully active,wild-type,No,Yes,No,No,No,0,"race: white, sex: male, age: 63, bmi: 21.25, treatment arm: FOLFOX, chemotherapy cycles: 10, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type, adverse effect: hypersensitivity: Yes","The patient is a 63-year-old white male with a BMI of 21.25. He is receiving the FOLFOX treatment arm and has completed 10 cycles of chemotherapy. His histology shows poorly differentiated cancer cells. Despite this, his performance status is fully active. The KRAS biomarker analysis indicates that he has a wild-type KRAS gene. The patient has experienced a hypersensitivity adverse effect."
1455,white,female,73,36.36,FOLFOX + Cetuximab,No,Yes,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 73, bmi: 36.36, treatment arm: FOLFOX + Cetuximab, serious adverse effect: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 73-year-old white female with a BMI of 36.36. She is receiving treatment with FOLFOX + Cetuximab and has experienced a serious adverse effect. She has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cells, and her performance status is fully active. The KRAS biomarker indicates that she has a wild-type status."
1456,white,male,54,33.3,FOLFIRI,No,No,No,No,8,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 54, bmi: 33.3, treatment arm: FOLFIRI, chemotherapy cycles: 8, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 54-year-old white male with a BMI of 33.3. He is receiving treatment with the FOLFIRI chemotherapy regimen and has completed 8 cycles so far. His cancer histology is well-differentiated, and he has a fully active performance status. The KRAS biomarker testing showed that he has a wild-type KRAS status."
1457,white,male,46,30.04,FOLFOX + Cetuximab,No,No,Yes,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 46, bmi: 30.04, treatment arm: FOLFOX + Cetuximab, bowel obstruction: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 46-year-old white male with a BMI of 30.04. He is receiving treatment with FOLFOX + Cetuximab and has experienced a bowel obstruction. He is scheduled for 12 cycles of chemotherapy. The histology indicates well-differentiated cancer, and his performance status is fully active. The KRAS biomarker shows that he has a wild-type status."
1458,white,male,41,30.56,FOLFIRI,No,No,Yes,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 41, bmi: 30.56, treatment arm: FOLFIRI, bowel obstruction: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type",The patient is a 41-year-old white male with a BMI of 30.56. He is receiving the FOLFIRI treatment regimen and has experienced a bowel obstruction. He has completed 12 cycles of chemotherapy. The histology shows well-differentiated cancer cells. The patient has a fully active performance status. His KRAS biomarker is wild-type.
1459,white,female,42,26.49,FOLFOX + Cetuximab,No,No,No,No,5,poorly differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 42, bmi: 26.49, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 5, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 42-year-old white female with a BMI of 26.49. She is currently receiving treatment in the FOLFOX + Cetuximab treatment arm and has completed 5 cycles of chemotherapy. Her histology shows poorly differentiated cancer cells. Despite this, her performance status is fully active. Additionally, her KRAS biomarker status is wild-type."
1460,white,female,65,29.02,FOLFOX,No,No,Yes,No,12,poorly differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 65, bmi: 29.02, treatment arm: FOLFOX, bowel obstruction: Yes, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 65-year-old white female with a BMI of 29.02. She is receiving the FOLFOX treatment regimen and has experienced a bowel obstruction. She has completed 12 cycles of chemotherapy. The histology of her cancer is poorly differentiated. Despite these challenges, her performance status is fully active. The KRAS biomarker testing indicates that she has a wild-type KRAS status."
1461,white,female,68,21.49,FOLFOX,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,Yes,No,No,0,"race: white, sex: female, age: 68, bmi: 21.49, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type, adverse effect: diarrhea: Yes","The patient is a 68-year-old white female with a BMI of 21.49. She is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cancer cells. Despite experiencing diarrhea as an adverse effect, her performance status is fully active. Additionally, her KRAS biomarker status is wild-type."
1462,white,male,69,24.43,FOLFOX,No,No,No,No,12,well differentiated,symptoms but ambulatory,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 69, bmi: 24.43, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type","The patient is a 69-year-old white male with a BMI of 24.43. He is receiving the FOLFOX treatment arm and has completed 12 cycles of chemotherapy. The histology shows well-differentiated cancer cells. Despite experiencing symptoms, the patient is still able to be ambulatory. The KRAS biomarker indicates that the cancer is wild-type."
1463,white,male,55,27.17,FOLFOX + Cetuximab,No,Yes,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 55, bmi: 27.17, treatment arm: FOLFOX + Cetuximab, serious adverse effect: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 55-year-old white male with a BMI of 27.17. He is receiving treatment with FOLFOX + Cetuximab and has experienced a serious adverse effect. He has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer cells. Despite the adverse effect, his performance status is fully active. His KRAS biomarker is wild-type."
1464,white,male,67,32.42,FOLFOX,Yes,No,No,No,12,well differentiated,symptoms but ambulatory,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 67, bmi: 32.42, treatment arm: FOLFOX, adherence: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type","The patient is a 67-year-old white male with a BMI of 32.42. He is receiving the FOLFOX treatment regimen and has been adherent to the treatment. He has completed 12 cycles of chemotherapy. The histology shows well-differentiated cancer cells. Despite experiencing symptoms, the patient is still able to walk around (ambulatory). The KRAS biomarker analysis indicates that the patient has a wild-type KRAS status."
1465,white,male,66,21.81,FOLFOX,No,No,No,No,12,poorly differentiated,symptoms but ambulatory,wild-type,No,No,Yes,No,No,0,"race: white, sex: male, age: 66, bmi: 21.81, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: poorly differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type, adverse effect: diarrhea: Yes","The patient is a 66-year-old white male with a BMI of 21.81 who is receiving the FOLFOX treatment regimen. He has undergone 12 cycles of chemotherapy. His cancer histology is poorly differentiated. Despite experiencing symptoms, he is still able to be ambulatory. The KRAS biomarker testing revealed that he has a wild-type KRAS status. The patient is experiencing diarrhea as an adverse effect of the treatment."
1466,white,male,47,26.05,FOLFOX,No,No,No,No,12,poorly differentiated,symptoms but ambulatory,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 47, bmi: 26.05, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: poorly differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type","The patient is a 47-year-old white male with a BMI of 26.05. He is receiving treatment with the FOLFOX chemotherapy regimen and has completed 12 cycles. His cancer histology is poorly differentiated. Despite experiencing symptoms, he is still able to walk around (ambulatory). The KRAS biomarker testing showed that he has a wild-type KRAS status."
1467,white,female,71,31.07,FOLFOX + Cetuximab,No,No,No,No,2,poorly differentiated,fully active,wild-type,Yes,No,Yes,No,No,1,"race: white, sex: female, age: 71, bmi: 31.07, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 2, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type, adverse effect: thrombosis: Yes, adverse effect: diarrhea: Yes","The patient is a 71-year-old white female with a BMI of 31.07. She is currently receiving treatment with FOLFOX + Cetuximab and has completed 2 cycles of chemotherapy. Her cancer histology is poorly differentiated, and she has a fully active performance status. The KRAS biomarker testing showed that she has a wild-type KRAS status. The patient has experienced adverse effects of thrombosis and diarrhea."
1468,other,male,66,18.92,FOLFOX,No,No,Yes,No,12,well differentiated,symptoms but ambulatory,mutant,No,No,No,No,No,0,"race: other, sex: male, age: 66, bmi: 18.92, treatment arm: FOLFOX, bowel obstruction: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: mutant","The patient is a 66-year-old male of a race categorized as ""other"" with a BMI of 18.92. He is undergoing treatment with the FOLFOX regimen and has experienced a bowel obstruction. He has completed 12 cycles of chemotherapy. The histology of his cancer is well-differentiated. Despite experiencing symptoms, he is still able to be ambulatory. The KRAS biomarker testing revealed a mutant status."
1469,white,male,44,22.83,FOLFOX,No,No,No,No,4,well differentiated,fully active,mutant,No,No,No,No,No,0,"race: white, sex: male, age: 44, bmi: 22.83, treatment arm: FOLFOX, chemotherapy cycles: 4, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 44-year-old white male with a BMI of 22.83. He is receiving the FOLFOX treatment regimen and has completed 4 cycles of chemotherapy. His histology shows well-differentiated cancer cells. The patient has a fully active performance status. Additionally, the KRAS biomarker testing indicates a mutant status."
1470,white,male,76,28.94,FOLFOX,No,No,No,No,12,well differentiated,fully active,interminate,No,No,No,No,No,0,"race: white, sex: male, age: 76, bmi: 28.94, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: interminate","The patient is a 76-year-old white male with a BMI of 28.94. He is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer cells. Despite his age, he has a fully active performance status. The KRAS biomarker status is indeterminate for this patient."
1471,white,male,62,27.84,FOLFOX,No,No,No,No,12,poorly differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 62, bmi: 27.84, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 62-year-old white male with a BMI of 27.84. He is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. His histology shows poorly differentiated cancer cells. Despite this, his performance status is fully active. Additionally, his KRAS biomarker indicates that he has a wild-type status."
1472,white,male,38,34.43,FOLFOX,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 38, bmi: 34.43, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type",The patient is a 38-year-old white male with a BMI of 34.43. He is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. The histology shows well-differentiated cancer cells. The patient has a fully active performance status. His KRAS biomarker status is wild-type.
1473,white,male,67,34.19,FOLFOX + Cetuximab,No,No,No,No,2,poorly differentiated,fully active,mutant,No,No,No,No,No,0,"race: white, sex: male, age: 67, bmi: 34.19, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 2, histology: poorly differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 67-year-old white male with a BMI of 34.19. He is currently receiving treatment with FOLFOX + Cetuximab and has completed 2 cycles of chemotherapy. His histology shows poorly differentiated cancer cells. Despite his cancer diagnosis, the patient has a fully active performance status. Additionally, the KRAS biomarker testing revealed a mutant status."
1474,white,male,67,30.27,FOLFOX,No,No,No,No,1,well differentiated,fully active,interminate,No,No,No,No,No,0,"race: white, sex: male, age: 67, bmi: 30.27, treatment arm: FOLFOX, chemotherapy cycles: 1, histology: well differentiated, performance status: fully active, KRAS biomarker: interminate","The patient is a 67-year-old white male with a BMI of 30.27. He is currently undergoing treatment with the FOLFOX regimen and has completed one cycle of chemotherapy. His histology shows well-differentiated cancer cells. The patient's performance status is fully active, indicating that he is able to carry out his daily activities without limitations. The KRAS biomarker status is indeterminate, meaning further testing may be needed to determine its significance in his treatment plan."
1475,white,female,76,24.06,FOLFOX,Yes,Yes,Yes,Yes,12,well differentiated,symptoms but ambulatory,wild-type,Yes,No,No,No,No,0,"race: white, sex: female, age: 76, bmi: 24.06, treatment arm: FOLFOX, adherence: Yes, serious adverse effect: Yes, bowel obstruction: Yes, bowel perforation: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type, adverse effect: thrombosis: Yes","The patient is a 76-year-old white female with a BMI of 24.06 who is receiving the FOLFOX treatment regimen. She has been adherent to her treatment. Unfortunately, she has experienced serious adverse effects, including bowel obstruction and perforation. Despite these challenges, she has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cells, and her performance status indicates that she has symptoms but is still able to be ambulatory. Additionally, her KRAS biomarker is wild-type. She has also experienced the adverse effect of thrombosis."
1476,white,female,42,21.56,FOLFOX,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 42, bmi: 21.56, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type",The patient is a 42-year-old white female with a BMI of 21.56. She is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cancer cells. She has a fully active performance status and her KRAS biomarker is wild-type.
1477,white,male,36,24.36,FOLFOX,No,No,No,No,12,poorly differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 36, bmi: 24.36, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 36-year-old white male with a BMI of 24.36. He is receiving treatment with the FOLFOX chemotherapy regimen and is scheduled for 12 cycles. His histology shows poorly differentiated cancer cells. Despite this, his performance status is fully active. Additionally, his KRAS biomarker status is wild-type."
1478,white,male,39,36.08,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,fully active,mutant,No,No,No,No,No,0,"race: white, sex: male, age: 39, bmi: 36.08, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 39-year-old white male with a BMI of 36.08. He is receiving treatment in the FOLFOX + Cetuximab treatment arm and is scheduled for 12 chemotherapy cycles. His cancer histology is well-differentiated, and he has a fully active performance status. The KRAS biomarker testing revealed a mutant status."
1479,white,male,68,32.81,FOLFOX,No,No,Yes,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 68, bmi: 32.81, treatment arm: FOLFOX, bowel obstruction: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 68-year-old white male with a BMI of 32.81. He is receiving treatment with the FOLFOX regimen for his cancer. He has experienced a bowel obstruction and has completed 12 cycles of chemotherapy. The histology of his cancer is well-differentiated. Despite his condition, his performance status is fully active. The KRAS biomarker testing revealed that he has a wild-type KRAS status."
1480,white,male,54,26.4,FOLFOX + Cetuximab,Yes,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,Yes,No,0,"race: white, sex: male, age: 54, bmi: 26.4, treatment arm: FOLFOX + Cetuximab, adherence: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type, adverse effect: infection: Yes","The patient is a 54-year-old white male with a BMI of 26.4. He is receiving treatment with FOLFOX + Cetuximab and has been adherent to the treatment. He has completed 12 cycles of chemotherapy. The histology shows well-differentiated cells, and his performance status is fully active. The KRAS biomarker is wild-type. The patient has experienced an infection as an adverse effect."
1481,white,male,36,30.43,FOLFOX + Cetuximab,No,No,Yes,No,12,well differentiated,symptoms but ambulatory,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 36, bmi: 30.43, treatment arm: FOLFOX + Cetuximab, bowel obstruction: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type","This patient is a 36-year-old white male with a BMI of 30.43. He is receiving treatment with FOLFOX + Cetuximab for his well-differentiated histology. He has experienced a bowel obstruction and has completed 12 cycles of chemotherapy. Despite experiencing symptoms, he is still able to be ambulatory. His KRAS biomarker status is wild-type."
1482,white,male,53,37.06,FOLFOX,No,No,No,No,7,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 53, bmi: 37.06, treatment arm: FOLFOX, chemotherapy cycles: 7, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type",The patient is a 53-year-old white male with a BMI of 37.06. He is receiving treatment in the FOLFOX chemotherapy arm and has completed 7 cycles of chemotherapy. His histology shows well-differentiated cells. The patient has a fully active performance status and his KRAS biomarker is wild-type.
1483,white,female,61,29.72,FOLFOX + Cetuximab,No,No,Yes,Yes,12,well differentiated,symptoms but ambulatory,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 61, bmi: 29.72, treatment arm: FOLFOX + Cetuximab, bowel obstruction: Yes, bowel perforation: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type","This patient is a 61-year-old white female with a BMI of 29.72. She is receiving treatment with FOLFOX + Cetuximab for her cancer. She has experienced both bowel obstruction and perforation. She has completed 12 cycles of chemotherapy. The histology of her cancer is well differentiated. Despite experiencing symptoms, she is still able to be ambulatory. Her KRAS biomarker status is wild-type."
1484,white,male,44,27.62,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,symptoms but ambulatory,mutant,No,No,No,No,No,0,"race: white, sex: male, age: 44, bmi: 27.62, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: mutant","The patient is a 44-year-old white male with a BMI of 27.62. He is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer cells. Despite experiencing symptoms, he is still able to walk around (ambulatory). The KRAS biomarker analysis indicates a mutant status."
1485,white,female,41,31.9,FOLFOX + Cetuximab,No,No,No,No,12,poorly differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 41, bmi: 31.9, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 41-year-old white female with a BMI of 31.9. She is receiving treatment in the FOLFOX + Cetuximab treatment arm and is scheduled for 12 chemotherapy cycles. The histology of her condition is poorly differentiated. Despite this, her performance status is fully active. Additionally, her KRAS biomarker status is wild-type."
1486,white,female,47,34.93,FOLFOX,No,No,Yes,No,12,well differentiated,symptoms but ambulatory,mutant,No,No,No,No,No,0,"race: white, sex: female, age: 47, bmi: 34.93, treatment arm: FOLFOX, bowel obstruction: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: mutant","The patient is a 47-year-old white female with a BMI of 34.93. She is receiving treatment with FOLFOX chemotherapy regimen and has experienced a bowel obstruction. She has completed 12 cycles of chemotherapy. The histology of her cancer is well differentiated. Despite experiencing symptoms, she is still able to be ambulatory. The KRAS biomarker testing revealed a mutant status."
1487,other,male,58,26.4,FOLFOX + Cetuximab,No,No,No,Yes,12,well differentiated,symptoms but ambulatory,mutant,No,No,No,No,No,0,"race: other, sex: male, age: 58, bmi: 26.4, treatment arm: FOLFOX + Cetuximab, bowel perforation: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: mutant","The patient is a 58-year-old male of a race categorized as ""other"" with a BMI of 26.4. He is undergoing treatment with FOLFOX + Cetuximab and has experienced a bowel perforation. He has completed 12 cycles of chemotherapy. The histology shows that the cancer is well-differentiated. Despite experiencing symptoms, the patient is still able to be ambulatory. The KRAS biomarker indicates that it is mutant."
1488,white,male,65,26.04,FOLFOX,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 65, bmi: 26.04, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 65-year-old white male with a BMI of 26.04. He is undergoing treatment with the FOLFOX chemotherapy regimen and has completed 12 cycles. His cancer histology is well-differentiated, and he has a fully active performance status. The KRAS biomarker testing showed that he has a wild-type KRAS status."
1489,white,male,46,44.79,FOLFOX,No,No,Yes,No,12,poorly differentiated,fully active,mutant,No,No,No,No,No,0,"race: white, sex: male, age: 46, bmi: 44.79, treatment arm: FOLFOX, bowel obstruction: Yes, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 46-year-old white male with a BMI of 44.79. He is receiving the FOLFOX treatment regimen for his poorly differentiated histology. He has experienced a bowel obstruction and has completed 12 cycles of chemotherapy. Despite these challenges, his performance status is fully active. Additionally, the patient's KRAS biomarker status is mutant."
1490,other,female,41,25.96,FOLFIRI + Cetuximab,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: other, sex: female, age: 41, bmi: 25.96, treatment arm: FOLFIRI + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 41-year-old female of a race categorized as ""other"" with a BMI of 25.96. She is receiving treatment in the FOLFIRI + Cetuximab treatment arm and has completed 12 cycles of chemotherapy. The histology of her cancer is well-differentiated. She has a fully active performance status and her KRAS biomarker is wild-type."
1491,white,male,42,38.41,FOLFOX,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 42, bmi: 38.41, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type",The patient is a 42-year-old white male with a BMI of 38.41. He is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer cells. The patient has a fully active performance status and his KRAS biomarker is wild-type.
1492,other,female,69,21.3,FOLFOX,Yes,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: other, sex: female, age: 69, bmi: 21.3, treatment arm: FOLFOX, adherence: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 69-year-old female of a race categorized as ""other"" with a BMI of 21.3. She is currently receiving treatment in the FOLFOX chemotherapy arm and has been adherent to the treatment. She has completed 12 cycles of chemotherapy. The histology of her cancer is well-differentiated. The patient has a performance status of fully active, indicating she is able to carry out normal daily activities without limitations. Additionally, her KRAS biomarker status is wild-type."
1493,white,female,44,31.06,FOLFOX + Cetuximab,No,No,Yes,No,12,well differentiated,symptoms but ambulatory,wild-type,No,No,No,No,No,1,"race: white, sex: female, age: 44, bmi: 31.06, treatment arm: FOLFOX + Cetuximab, bowel obstruction: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type","The patient is a 44-year-old white female with a BMI of 31.06. She is receiving treatment with FOLFOX + Cetuximab for her well-differentiated histology. She has experienced a bowel obstruction and has completed 12 cycles of chemotherapy. Despite experiencing symptoms, she is still able to be ambulatory. Her KRAS biomarker status is wild-type."
1494,other,female,64,19.95,FOLFIRI,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,1,"race: other, sex: female, age: 64, bmi: 19.95, treatment arm: FOLFIRI, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 64-year-old female of a race categorized as ""other"" with a BMI of 19.95. She is undergoing treatment with the FOLFIRI chemotherapy regimen and has completed 12 cycles. Her histology shows well-differentiated characteristics. Despite her age, she has a fully active performance status. Additionally, her KRAS biomarker status is wild-type."
1495,white,male,54,33.66,FOLFOX,Yes,No,No,No,12,poorly differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 54, bmi: 33.66, treatment arm: FOLFOX, adherence: Yes, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 54-year-old white male with a BMI of 33.66. He is receiving the FOLFOX treatment regimen and has been adherent to the treatment. He has completed 12 cycles of chemotherapy. The histology shows poorly differentiated cancer cells. Despite this, the patient has a fully active performance status. The KRAS biomarker indicates that he has a wild-type KRAS gene."
1496,white,female,58,30.77,FOLFOX + Cetuximab,No,No,No,No,7,well differentiated,symptoms but ambulatory,mutant,No,No,No,No,No,0,"race: white, sex: female, age: 58, bmi: 30.77, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 7, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: mutant","The patient is a 58-year-old white female with a BMI of 30.77. She is currently undergoing treatment with FOLFOX + Cetuximab and has completed 7 cycles of chemotherapy. The histology shows well-differentiated cancer cells. Despite experiencing symptoms, the patient is still able to walk around (ambulatory). The KRAS biomarker analysis revealed a mutant status."
1497,white,male,73,26.49,FOLFOX,No,No,Yes,No,3,well differentiated,symptoms but ambulatory,mutant,No,No,Yes,No,No,0,"race: white, sex: male, age: 73, bmi: 26.49, treatment arm: FOLFOX, bowel obstruction: Yes, chemotherapy cycles: 3, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: mutant, adverse effect: diarrhea: Yes","The patient is a 73-year-old white male with a BMI of 26.49. He is receiving the FOLFOX treatment regimen and has experienced a bowel obstruction. He has completed 3 cycles of chemotherapy. The histology shows well-differentiated cancer cells. Despite experiencing symptoms, the patient is still able to walk around. The KRAS biomarker indicates a mutant status. The patient is also experiencing diarrhea as an adverse effect of the treatment."
1498,other,female,43,20.4,FOLFOX,No,No,Yes,No,12,poorly differentiated,symptoms but ambulatory,mutant,No,No,No,No,No,0,"race: other, sex: female, age: 43, bmi: 20.4, treatment arm: FOLFOX, bowel obstruction: Yes, chemotherapy cycles: 12, histology: poorly differentiated, performance status: symptoms but ambulatory, KRAS biomarker: mutant","The patient is a 43-year-old female of a race classified as ""other"" with a BMI of 20.4. She is receiving treatment with the FOLFOX regimen and has experienced a bowel obstruction. She has completed 12 cycles of chemotherapy. The histology of her cancer is poorly differentiated. Despite experiencing symptoms, she is still able to be ambulatory. The KRAS biomarker testing revealed a mutation."
1499,white,female,73,32.3,FOLFOX,No,No,No,No,12,well differentiated,symptoms but ambulatory,wild-type,No,No,Yes,No,No,0,"race: white, sex: female, age: 73, bmi: 32.3, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type, adverse effect: diarrhea: Yes","The patient is a 73-year-old white female with a BMI of 32.3 who is receiving the FOLFOX treatment regimen for her well-differentiated cancer. She has completed 12 cycles of chemotherapy. Despite experiencing symptoms, she is still able to move around (ambulatory). The KRAS biomarker testing showed that she has a wild-type KRAS status. She is currently experiencing diarrhea as an adverse effect of the treatment."
1500,black,female,46,27.3,FOLFOX,No,No,No,No,12,well differentiated,symptoms but ambulatory,wild-type,No,No,No,No,No,0,"race: black, sex: female, age: 46, bmi: 27.3, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type","The patient is a 46-year-old Black female with a BMI of 27.3. She is undergoing treatment with the FOLFOX chemotherapy regimen and has completed 12 cycles. Her cancer histology is well-differentiated. Despite experiencing symptoms, she is still able to ambulate. The KRAS biomarker testing revealed that she has a wild-type KRAS status."
1501,white,male,65,28.27,FOLFOX,Yes,Yes,No,No,12,well differentiated,fully active,mutant,No,No,No,No,Yes,0,"race: white, sex: male, age: 65, bmi: 28.27, treatment arm: FOLFOX, adherence: Yes, serious adverse effect: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant, adverse effect: infarction: Yes","The patient is a 65-year-old white male with a BMI of 28.27 who is receiving the FOLFOX treatment regimen. He has been adherent to his treatment and has completed 12 cycles of chemotherapy. The histology of his cancer is well-differentiated, and his performance status is fully active. The patient has a mutant KRAS biomarker and has experienced a serious adverse effect in the form of an infarction."
1502,white,female,56,22.85,FOLFOX,No,No,No,No,1,poorly differentiated,fully active,wild-type,No,No,Yes,No,No,0,"race: white, sex: female, age: 56, bmi: 22.85, treatment arm: FOLFOX, chemotherapy cycles: 1, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type, adverse effect: diarrhea: Yes","The patient is a 56-year-old white female with a BMI of 22.85 who is currently receiving treatment with FOLFOX chemotherapy. She has completed one cycle of chemotherapy and has been diagnosed with poorly differentiated histology. Despite experiencing diarrhea as an adverse effect, her performance status remains fully active. Additionally, her KRAS biomarker status is wild-type."
1503,white,male,44,28.93,FOLFOX + Cetuximab,Yes,No,No,Yes,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 44, bmi: 28.93, treatment arm: FOLFOX + Cetuximab, adherence: Yes, bowel perforation: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 44-year-old white male with a BMI of 28.93. He is receiving treatment with FOLFOX + Cetuximab and has been adherent to the treatment. He experienced a bowel perforation during the course of treatment. He completed 12 cycles of chemotherapy. The histology of his cancer is well differentiated. Despite the bowel perforation, his performance status is fully active. His KRAS biomarker status is wild-type."
1504,white,male,60,29.34,FOLFOX + Cetuximab,Yes,Yes,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 60, bmi: 29.34, treatment arm: FOLFOX + Cetuximab, adherence: Yes, serious adverse effect: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 60-year-old white male with a BMI of 29.34. He is receiving treatment in the FOLFOX + Cetuximab treatment arm and has been adherent to the treatment. He experienced a serious adverse effect during the treatment. The patient completed 12 chemotherapy cycles and has well-differentiated histology. His performance status is fully active, and his KRAS biomarker is wild-type."
1505,black,female,68,21.59,FOLFOX,No,No,No,No,12,well differentiated,fully active,mutant,No,No,No,No,No,0,"race: black, sex: female, age: 68, bmi: 21.59, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 68-year-old Black female with a BMI of 21.59. She is receiving the FOLFOX treatment arm and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cancer cells. Despite her age, she has a fully active performance status. The KRAS biomarker analysis indicates that she has a mutant KRAS status."
1506,white,female,63,24.34,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 63, bmi: 24.34, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 63-year-old white female with a BMI of 24.34. She is receiving treatment in the FOLFOX + Cetuximab treatment arm and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cells, and she has a fully active performance status. Additionally, her KRAS biomarker indicates that it is wild-type."
1507,white,male,48,47.18,FOLFOX + Cetuximab,Yes,Yes,No,No,5,well differentiated,symptoms but ambulatory,wild-type,Yes,Yes,No,No,No,0,"race: white, sex: male, age: 48, bmi: 47.18, treatment arm: FOLFOX + Cetuximab, adherence: Yes, serious adverse effect: Yes, chemotherapy cycles: 5, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type, adverse effect: thrombosis: Yes, adverse effect: hypersensitivity: Yes","The patient is a 48-year-old white male with a BMI of 47.18. He is receiving treatment with FOLFOX + Cetuximab and has been adherent to the treatment. He has experienced serious adverse effects, including thrombosis and hypersensitivity reactions. The patient has completed 5 cycles of chemotherapy. His histology shows well-differentiated cells, and his KRAS biomarker is wild-type. Despite experiencing symptoms, the patient is still ambulatory."
1508,white,female,65,24.34,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 65, bmi: 24.34, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 65-year-old white female with a BMI of 24.34. She is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cancer cells. Despite her age, she has a fully active performance status. Additionally, her KRAS biomarker indicates that she has a wild-type gene."
1509,white,male,73,38.62,FOLFOX + Cetuximab,Yes,No,No,No,12,well differentiated,symptoms but ambulatory,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 73, bmi: 38.62, treatment arm: FOLFOX + Cetuximab, adherence: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type","The patient is a 73-year-old white male with a BMI of 38.62. He is receiving treatment in the FOLFOX + Cetuximab treatment arm and has been adherent to the treatment. He has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer cells. Despite experiencing symptoms, he is still able to be ambulatory. The KRAS biomarker analysis indicates that he has a wild-type KRAS status."
1510,white,male,52,27.47,FOLFOX,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,Yes,No,No,0,"race: white, sex: male, age: 52, bmi: 27.47, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type, adverse effect: diarrhea: Yes",The patient is a 52-year-old white male with a BMI of 27.47 who is receiving the FOLFOX treatment regimen for his well-differentiated cancer. He has completed 12 cycles of chemotherapy and has a fully active performance status. His KRAS biomarker status is wild-type. The patient is experiencing diarrhea as an adverse effect of the treatment.
1511,white,male,61,26.14,FOLFOX + Cetuximab,Yes,No,Yes,No,12,poorly differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 61, bmi: 26.14, treatment arm: FOLFOX + Cetuximab, adherence: Yes, bowel obstruction: Yes, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 61-year-old white male with a BMI of 26.14. He is currently receiving treatment in the FOLFOX + Cetuximab treatment arm and has been adherent to the treatment. He has experienced a bowel obstruction. The patient has completed 12 cycles of chemotherapy. His histology shows poorly differentiated cells. Despite the bowel obstruction, his performance status is fully active. The KRAS biomarker indicates that he has a wild-type status."
1512,white,female,39,29.94,FOLFOX,No,No,No,No,12,well differentiated,fully active,interminate,No,No,No,No,No,0,"race: white, sex: female, age: 39, bmi: 29.94, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: interminate","The patient is a 39-year-old white female with a BMI of 29.94. She is receiving the FOLFOX treatment arm and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cells, and her performance status is fully active. The KRAS biomarker status is indeterminate."
1513,white,male,55,25.97,FOLFOX,No,No,No,No,12,poorly differentiated,fully active,wild-type,No,No,No,No,No,1,"race: white, sex: male, age: 55, bmi: 25.97, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 55-year-old white male with a BMI of 25.97. He is undergoing treatment with the FOLFOX chemotherapy regimen and has completed 12 cycles. The histology of his cancer is poorly differentiated. Despite his cancer diagnosis, he has a fully active performance status. His KRAS biomarker status is wild-type."
1514,black,male,67,34.08,FOLFOX + Cetuximab,No,No,No,No,1,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: black, sex: male, age: 67, bmi: 34.08, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 1, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 67-year-old Black male with a BMI of 34.08. He is currently receiving treatment in the FOLFOX + Cetuximab treatment arm and has completed one cycle of chemotherapy. His histology shows well-differentiated cancer cells. Despite his age, he has a fully active performance status. Additionally, his KRAS biomarker status is wild-type."
1515,white,female,53,33.87,FOLFOX,Yes,No,No,Yes,12,well differentiated,symptoms but ambulatory,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 53, bmi: 33.87, treatment arm: FOLFOX, adherence: Yes, bowel perforation: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type","The patient is a 53-year-old white female with a BMI of 33.87. She is receiving the FOLFOX treatment regimen and has been adherent to her chemotherapy. She experienced a bowel perforation and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cancer. Despite experiencing symptoms, she is still able to be ambulatory. The KRAS biomarker analysis revealed that she has a wild-type KRAS status."
1516,white,female,41,31.7,FOLFOX + Cetuximab,No,No,No,No,8,well differentiated,fully active,mutant,No,No,No,No,No,0,"race: white, sex: female, age: 41, bmi: 31.7, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 8, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant",The patient is a 41-year-old white female with a BMI of 31.7. She is receiving treatment with FOLFOX + Cetuximab and has completed 8 cycles of chemotherapy. Her cancer histology is well-differentiated. She has a fully active performance status. The KRAS biomarker shows a mutation.
1517,white,female,49,20.61,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,symptoms but ambulatory,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 49, bmi: 20.61, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type","The patient is a 49-year-old white female with a BMI of 20.61. She is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cells. Despite experiencing symptoms, she is still able to walk around (ambulatory). The KRAS biomarker analysis indicates that she has a wild-type KRAS status."
1518,white,male,40,27.05,FOLFOX,No,Yes,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 40, bmi: 27.05, treatment arm: FOLFOX, serious adverse effect: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type",The patient is a 40-year-old white male with a BMI of 27.05. He is receiving the FOLFOX treatment arm and has experienced a serious adverse effect. He has completed 12 cycles of chemotherapy. The histology shows that the cancer is well-differentiated. The patient has a fully active performance status. His KRAS biomarker is wild-type.
1519,white,female,46,28.03,FOLFIRI + Cetuximab,No,No,No,No,1,poorly differentiated,symptoms but ambulatory,mutant,No,No,No,No,No,1,"race: white, sex: female, age: 46, bmi: 28.03, treatment arm: FOLFIRI + Cetuximab, chemotherapy cycles: 1, histology: poorly differentiated, performance status: symptoms but ambulatory, KRAS biomarker: mutant","The patient is a 46-year-old white female with a BMI of 28.03. She is currently receiving treatment in the FOLFIRI + Cetuximab treatment arm and has completed one cycle of chemotherapy. Her histology shows poorly differentiated cancer cells. Despite experiencing symptoms, she is still able to be ambulatory. Additionally, the patient's KRAS biomarker status indicates that it is mutant."
1520,white,female,44,39.93,FOLFOX,No,No,Yes,No,12,well differentiated,fully active,mutant,No,No,No,No,No,0,"race: white, sex: female, age: 44, bmi: 39.93, treatment arm: FOLFOX, bowel obstruction: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 44-year-old white female with a BMI of 39.93. She is receiving the FOLFOX treatment regimen and has experienced a bowel obstruction. She has completed 12 cycles of chemotherapy. The histology shows well-differentiated cancer cells. Despite the bowel obstruction, her performance status is fully active. The KRAS biomarker analysis indicates a mutant status."
1521,white,female,51,26.8,FOLFOX,No,No,No,No,12,poorly differentiated,fully active,mutant,No,No,Yes,No,No,0,"race: white, sex: female, age: 51, bmi: 26.8, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: mutant, adverse effect: diarrhea: Yes","The patient is a 51-year-old white female with a BMI of 26.8. She is receiving the FOLFOX treatment arm and has completed 12 cycles of chemotherapy. The histology shows poorly differentiated cancer cells. Despite this, her performance status is fully active. The KRAS biomarker indicates a mutant status. The patient is experiencing diarrhea as an adverse effect."
1522,white,female,48,37.87,FOLFOX + Cetuximab,No,No,Yes,No,4,well differentiated,fully active,interminate,No,No,No,No,No,0,"race: white, sex: female, age: 48, bmi: 37.87, treatment arm: FOLFOX + Cetuximab, bowel obstruction: Yes, chemotherapy cycles: 4, histology: well differentiated, performance status: fully active, KRAS biomarker: interminate","The patient is a 48-year-old white female with a BMI of 37.87. She is receiving treatment with FOLFOX + Cetuximab for her well-differentiated histology. She has experienced a bowel obstruction and has completed 4 cycles of chemotherapy. Her performance status is fully active, and her KRAS biomarker status is indeterminate."
1523,white,male,43,26.91,FOLFIRI,Yes,No,No,No,1,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 43, bmi: 26.91, treatment arm: FOLFIRI, adherence: Yes, chemotherapy cycles: 1, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type",The patient is a 43-year-old white male with a BMI of 26.91. He is currently receiving treatment in the FOLFIRI treatment arm and has been adherent to the treatment. He has completed one cycle of chemotherapy. The histology of his cancer is well-differentiated. The patient has a fully active performance status. His KRAS biomarker status is wild-type.
1524,white,male,60,32.7,FOLFOX,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 60, bmi: 32.7, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 60-year-old white male with a BMI of 32.7. He is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. His cancer histology is well-differentiated, and he has a fully active performance status. The KRAS biomarker analysis shows that he has a wild-type KRAS status."
1525,white,female,42,21.23,FOLFOX + Cetuximab,No,No,No,No,11,well differentiated,fully active,mutant,No,No,No,No,No,0,"race: white, sex: female, age: 42, bmi: 21.23, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 11, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 42-year-old white female with a BMI of 21.23. She is receiving treatment in the FOLFOX + Cetuximab treatment arm and has completed 11 cycles of chemotherapy. Her histology shows well-differentiated cells, and she has a fully active performance status. The KRAS biomarker analysis indicates a mutant status."
1526,white,male,76,30.44,FOLFOX + Cetuximab,Yes,No,No,No,10,well differentiated,fully active,mutant,No,No,No,No,No,0,"race: white, sex: male, age: 76, bmi: 30.44, treatment arm: FOLFOX + Cetuximab, adherence: Yes, chemotherapy cycles: 10, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant",The patient is a 76-year-old white male with a BMI of 30.44. He is receiving treatment with FOLFOX + Cetuximab and has been adherent to the treatment. He has completed 10 cycles of chemotherapy. His histology shows well-differentiated cells. The patient has a fully active performance status. The KRAS biomarker indicates a mutant status.
1527,white,male,44,29.15,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,fully active,mutant,No,No,No,No,No,0,"race: white, sex: male, age: 44, bmi: 29.15, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 44-year-old white male with a BMI of 29.15. He is receiving treatment in the FOLFOX + Cetuximab treatment arm and is scheduled for 12 chemotherapy cycles. His histology shows well-differentiated cells, and he has a fully active performance status. The KRAS biomarker analysis indicates a mutant status."
1528,white,male,70,24.7,FOLFIRI (KRAS mutant),No,No,No,No,3,well differentiated,symptoms but ambulatory,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 70, bmi: 24.7, treatment arm: FOLFIRI (KRAS mutant), chemotherapy cycles: 3, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type","The patient is a 70-year-old white male with a BMI of 24.7. He is receiving the FOLFIRI treatment regimen for his KRAS mutant status. He has completed 3 cycles of chemotherapy. His histology shows well-differentiated cancer. Despite experiencing symptoms, he is still able to be ambulatory. His KRAS biomarker indicates that he has a wild-type KRAS gene."
1529,white,male,68,31.77,FOLFOX,No,No,No,No,12,poorly differentiated,fully active,mutant,No,No,No,No,No,0,"race: white, sex: male, age: 68, bmi: 31.77, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 68-year-old white male with a BMI of 31.77. He is undergoing treatment with the FOLFOX chemotherapy regimen and has completed 12 cycles. His cancer histology is poorly differentiated. Despite his cancer diagnosis, he has a fully active performance status. The KRAS biomarker testing revealed a mutant status."
1530,white,female,56,37.47,FOLFOX + Cetuximab,No,No,No,No,12,poorly differentiated,fully active,mutant,No,No,No,No,No,1,"race: white, sex: female, age: 56, bmi: 37.47, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 56-year-old white female with a BMI of 37.47. She is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. Her cancer histology is poorly differentiated. Despite this, her performance status is fully active. Additionally, she has a mutant KRAS biomarker."
1531,white,male,36,34.95,FOLFOX,No,No,Yes,No,12,poorly differentiated,fully active,wild-type,No,No,No,No,No,1,"race: white, sex: male, age: 36, bmi: 34.95, treatment arm: FOLFOX, bowel obstruction: Yes, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 36-year-old white male with a BMI of 34.95. He is receiving the FOLFOX treatment arm for his bowel obstruction. He has completed 12 cycles of chemotherapy. The histology shows poorly differentiated cells. Despite the bowel obstruction, his performance status is fully active. His KRAS biomarker is wild-type."
1532,white,female,71,26.37,FOLFOX + Cetuximab,No,No,No,No,11,poorly differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 71, bmi: 26.37, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 11, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 71-year-old white female with a BMI of 26.37. She is receiving treatment with FOLFOX + Cetuximab and has completed 11 cycles of chemotherapy. Her cancer histology is poorly differentiated. Despite her age, she has a fully active performance status. Additionally, her KRAS biomarker status is wild-type."
1533,white,male,55,30.18,FOLFOX,Yes,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 55, bmi: 30.18, treatment arm: FOLFOX, adherence: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type",The patient is a 55-year-old white male with a BMI of 30.18. He is receiving treatment with the FOLFOX regimen and has been adherent to the treatment. He has completed 12 cycles of chemotherapy. The histology of his cancer is well-differentiated. The patient has a fully active performance status. His KRAS biomarker status is wild-type.
1534,white,female,75,31.13,FOLFOX,No,No,No,No,1,well differentiated,fully active,wild-type,No,No,Yes,No,No,0,"race: white, sex: female, age: 75, bmi: 31.13, treatment arm: FOLFOX, chemotherapy cycles: 1, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type, adverse effect: diarrhea: Yes","The patient is a 75-year-old white female with a BMI of 31.13. She is currently receiving treatment with FOLFOX chemotherapy regimen and has completed 1 cycle so far. Her histology shows well-differentiated cells, and she has a fully active performance status. The KRAS biomarker testing indicates that she has a wild-type KRAS status. The patient is experiencing diarrhea as an adverse effect of the treatment."
1535,white,male,40,32.49,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 40, bmi: 32.49, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type",The patient is a 40-year-old white male with a BMI of 32.49. He is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer cells. The patient has a fully active performance status and his KRAS biomarker is wild-type.
1536,white,male,57,28.54,FOLFOX + Cetuximab,No,No,No,No,3,poorly differentiated,fully active,wild-type,No,No,Yes,No,Yes,0,"race: white, sex: male, age: 57, bmi: 28.54, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 3, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type, adverse effect: diarrhea: Yes, adverse effect: infarction: Yes","The patient is a 57-year-old white male with a BMI of 28.54. He is currently receiving treatment with FOLFOX + Cetuximab and has completed 3 cycles of chemotherapy. His cancer histology is poorly differentiated, and he has a fully active performance status. The KRAS biomarker testing showed that he has a wild-type KRAS status. The patient has experienced adverse effects of diarrhea and infarction."
1537,white,female,69,22.02,FOLFOX,No,No,No,No,6,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 69, bmi: 22.02, treatment arm: FOLFOX, chemotherapy cycles: 6, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 69-year-old white female with a BMI of 22.02. She is undergoing treatment with the FOLFOX chemotherapy regimen and has completed 6 cycles. Her histology shows well-differentiated cancer cells. Despite her age, she has a fully active performance status. Additionally, her KRAS biomarker status is wild-type."
1538,black,female,40,34.77,FOLFOX,No,No,No,No,12,well differentiated,fully active,interminate,No,No,No,No,No,0,"race: black, sex: female, age: 40, bmi: 34.77, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: interminate",The patient is a 40-year-old Black female with a BMI of 34.77. She is receiving the FOLFOX treatment arm and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cancer cells. The patient has a fully active performance status. The KRAS biomarker status is indeterminate.
1539,other,female,74,21.91,FOLFOX,No,No,No,No,12,well differentiated,symptoms but ambulatory,mutant,No,No,No,No,No,0,"race: other, sex: female, age: 74, bmi: 21.91, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: mutant","The patient is a 74-year-old female of a race categorized as ""other"" with a BMI of 21.91. She is undergoing treatment with the FOLFOX chemotherapy regimen and has completed 12 cycles. The histology of her condition is well-differentiated. Despite experiencing symptoms, she is still able to be ambulatory. Additionally, the KRAS biomarker testing revealed a mutant status."
1540,white,male,54,31.15,FOLFOX,Yes,No,No,No,12,poorly differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 54, bmi: 31.15, treatment arm: FOLFOX, adherence: Yes, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type",The patient is a 54-year-old white male with a BMI of 31.15. He is receiving the FOLFOX treatment regimen and has been adherent to the treatment. He has completed 12 cycles of chemotherapy. The histology shows poorly differentiated cancer cells. The patient has a fully active performance status. His KRAS biomarker is wild-type.
1541,other,male,43,21.82,FOLFOX,No,No,No,No,12,well differentiated,fully active,mutant,No,No,No,No,No,0,"race: other, sex: male, age: 43, bmi: 21.82, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 43-year-old male of a race categorized as ""other"" with a BMI of 21.82. He is receiving the FOLFOX treatment arm and has completed 12 cycles of chemotherapy. The histology of his condition is well-differentiated. Despite his treatment, he maintains a fully active performance status. Additionally, the patient's KRAS biomarker is identified as mutant."
1542,white,female,54,40.83,FOLFOX + Cetuximab,No,No,No,No,0,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 54, bmi: 40.83, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 0, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 54-year-old white female with a BMI of 40.83. She is enrolled in the FOLFOX + Cetuximab treatment arm but has not yet started chemotherapy cycles. Her histology shows well-differentiated cancer, and she has a fully active performance status. The KRAS biomarker indicates that she has a wild-type status."
1543,white,female,66,20.32,FOLFIRI (KRAS mutant),No,Yes,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,1,"race: white, sex: female, age: 66, bmi: 20.32, treatment arm: FOLFIRI (KRAS mutant), serious adverse effect: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 66-year-old white female with a BMI of 20.32. She is receiving the FOLFIRI treatment regimen for her KRAS mutant status. She has experienced a serious adverse effect. She has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cells. Despite her treatment, she has a fully active performance status. Her KRAS biomarker is wild-type."
1544,black,male,61,28.21,FOLFOX,No,No,No,No,12,well differentiated,fully active,wild-type,Yes,No,No,Yes,No,0,"race: black, sex: male, age: 61, bmi: 28.21, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type, adverse effect: thrombosis: Yes, adverse effect: infection: Yes","The patient is a 61-year-old Black male with a BMI of 28.21. He is receiving the FOLFOX treatment arm and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cells, and he has a fully active performance status. The KRAS biomarker is wild-type. The patient has experienced adverse effects of thrombosis and infection."
1545,white,female,44,30.02,FOLFIRI,No,No,No,No,12,poorly differentiated,fully active,wild-type,No,No,No,No,No,1,"race: white, sex: female, age: 44, bmi: 30.02, treatment arm: FOLFIRI, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 44-year-old white female with a BMI of 30.02. She is receiving the FOLFIRI treatment arm and has completed 12 cycles of chemotherapy. Her histology shows poorly differentiated cancer cells. Despite this, her performance status is fully active. Additionally, her KRAS biomarker indicates that it is wild-type."
1546,white,female,37,23.74,FOLFIRI,No,No,No,No,12,well differentiated,symptoms but ambulatory,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 37, bmi: 23.74, treatment arm: FOLFIRI, chemotherapy cycles: 12, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type","The patient is a 37-year-old white female with a BMI of 23.74. She is receiving the FOLFIRI treatment arm and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cancer cells. Despite experiencing symptoms, she is still able to be ambulatory. The KRAS biomarker analysis indicates that she has a wild-type KRAS status."
1547,white,male,44,40.56,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 44, bmi: 40.56, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 44-year-old white male with a BMI of 40.56. He is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cells, and he has a fully active performance status. The KRAS biomarker analysis indicates that he has a wild-type KRAS status."
1548,white,male,63,24.91,FOLFOX,No,No,Yes,No,3,poorly differentiated,fully active,wild-type,No,No,No,No,No,1,"race: white, sex: male, age: 63, bmi: 24.91, treatment arm: FOLFOX, bowel obstruction: Yes, chemotherapy cycles: 3, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 63-year-old white male with a BMI of 24.91. He is receiving the FOLFOX treatment regimen and has experienced a bowel obstruction. He has completed 3 cycles of chemotherapy. The histology of his cancer is poorly differentiated. Despite these challenges, his performance status is fully active. His KRAS biomarker status is wild-type."
1549,white,female,48,36.91,FOLFOX + Cetuximab,No,Yes,Yes,No,12,well differentiated,fully active,mutant,Yes,No,No,No,No,0,"race: white, sex: female, age: 48, bmi: 36.91, treatment arm: FOLFOX + Cetuximab, serious adverse effect: Yes, bowel obstruction: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant, adverse effect: thrombosis: Yes","The patient is a 48-year-old white female with a BMI of 36.91. She is receiving treatment with FOLFOX + Cetuximab and has experienced a serious adverse effect, specifically a bowel obstruction. She has completed 12 cycles of chemotherapy and her histology shows well-differentiated cells. Despite the adverse effects, her performance status is fully active. Additionally, the KRAS biomarker testing revealed a mutant status, and she has also experienced thrombosis as an adverse effect."
1550,white,male,49,40.17,FOLFOX,Yes,No,No,No,12,poorly differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 49, bmi: 40.17, treatment arm: FOLFOX, adherence: Yes, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 49-year-old white male with a BMI of 40.17. He is receiving treatment with the FOLFOX regimen and has been adherent to the chemotherapy. He has completed 12 cycles of chemotherapy. The histology of his cancer is poorly differentiated. Despite his cancer diagnosis, he is fully active in terms of performance status. The KRAS biomarker testing revealed that he has a wild-type KRAS status."
1551,other,male,67,27.56,FOLFOX + Cetuximab,No,No,Yes,No,1,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: other, sex: male, age: 67, bmi: 27.56, treatment arm: FOLFOX + Cetuximab, bowel obstruction: Yes, chemotherapy cycles: 1, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 67-year-old male of a race categorized as ""other"" with a BMI of 27.56. He is currently receiving treatment in the FOLFOX + Cetuximab treatment arm. The patient has experienced a bowel obstruction and has completed one cycle of chemotherapy. Histologically, the cancer is classified as well-differentiated. Despite the bowel obstruction, the patient's performance status is fully active. Additionally, the KRAS biomarker indicates that the cancer is wild-type."
1552,white,female,58,21.11,FOLFOX + Cetuximab,Yes,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 58, bmi: 21.11, treatment arm: FOLFOX + Cetuximab, adherence: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type",The patient is a 58-year-old white female with a BMI of 21.11. She is receiving treatment in the FOLFOX + Cetuximab treatment arm and has been adherent to the treatment. She has completed 12 cycles of chemotherapy. The histology shows well-differentiated cancer cells. The patient has a fully active performance status. The KRAS biomarker indicates that she has a wild-type mutation.
1553,other,female,70,24.58,FOLFOX + Cetuximab,No,Yes,No,No,9,well differentiated,symptoms but ambulatory,interminate,No,No,No,No,No,0,"race: other, sex: female, age: 70, bmi: 24.58, treatment arm: FOLFOX + Cetuximab, serious adverse effect: Yes, chemotherapy cycles: 9, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: interminate","The patient is a 70-year-old female of a race other than Caucasian. She has a BMI of 24.58 and is receiving treatment with FOLFOX + Cetuximab. She has experienced a serious adverse effect from the treatment. So far, she has completed 9 cycles of chemotherapy. The histology of her cancer is well-differentiated. Despite experiencing symptoms, she is still able to be ambulatory. Her KRAS biomarker status is indeterminate."
1554,white,male,61,26.94,FOLFOX + Cetuximab,No,No,No,No,12,poorly differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 61, bmi: 26.94, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 61-year-old white male with a BMI of 26.94. He is receiving treatment with FOLFOX + Cetuximab and is scheduled for 12 chemotherapy cycles. His cancer histology is poorly differentiated. Despite his diagnosis, he has a fully active performance status. Additionally, his KRAS biomarker status is wild-type."
1555,white,male,69,27.26,FOLFIRI + Cetuximab,No,No,No,No,12,well differentiated,fully active,mutant,No,No,No,No,No,0,"race: white, sex: male, age: 69, bmi: 27.26, treatment arm: FOLFIRI + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 69-year-old white male with a BMI of 27.26. He is receiving treatment with FOLFIRI + Cetuximab and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer cells. Despite his age, he has a fully active performance status. The KRAS biomarker analysis indicates a mutant status."
1556,black,male,50,35.42,FOLFOX + Cetuximab,No,No,Yes,No,11,well differentiated,fully active,mutant,No,No,No,No,No,0,"race: black, sex: male, age: 50, bmi: 35.42, treatment arm: FOLFOX + Cetuximab, bowel obstruction: Yes, chemotherapy cycles: 11, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 50-year-old Black male with a BMI of 35.42. He is undergoing treatment with FOLFOX + Cetuximab for his colorectal cancer. He has experienced a bowel obstruction and has completed 11 cycles of chemotherapy. The histology of his cancer is well-differentiated. Despite his condition, he has a fully active performance status. The KRAS biomarker testing revealed a mutant status."
1557,white,female,72,24.24,FOLFOX + Cetuximab,No,Yes,No,No,12,well differentiated,fully active,wild-type,No,Yes,Yes,No,No,0,"race: white, sex: female, age: 72, bmi: 24.24, treatment arm: FOLFOX + Cetuximab, serious adverse effect: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type, adverse effect: hypersensitivity: Yes, adverse effect: diarrhea: Yes","The patient is a 72-year-old white female with a BMI of 24.24. She is receiving treatment with FOLFOX + Cetuximab and has experienced a serious adverse effect. She has completed 12 cycles of chemotherapy. The histology of her cancer is well-differentiated, and her performance status is fully active. Her KRAS biomarker is wild-type. She has also experienced adverse effects including hypersensitivity and diarrhea."
1558,white,female,49,35.42,FOLFOX,No,No,No,No,12,well differentiated,symptoms but ambulatory,mutant,No,No,Yes,No,No,0,"race: white, sex: female, age: 49, bmi: 35.42, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: mutant, adverse effect: diarrhea: Yes","The patient is a 49-year-old white female with a BMI of 35.42 who is undergoing treatment with the FOLFOX chemotherapy regimen. She has completed 12 cycles of chemotherapy. The histology of her cancer is well-differentiated. Despite experiencing symptoms, she is still able to be ambulatory. The KRAS biomarker testing revealed a mutation. Additionally, she is experiencing diarrhea as an adverse effect of the treatment."
1559,other,male,56,21.45,FOLFOX,No,No,No,No,12,poorly differentiated,fully active,wild-type,No,No,No,No,No,0,"race: other, sex: male, age: 56, bmi: 21.45, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 56-year-old male of a race categorized as ""other"" with a BMI of 21.45. He is receiving treatment in the FOLFOX chemotherapy arm and is scheduled for a total of 12 cycles. The histology of his condition is poorly differentiated. Despite this, his performance status is fully active. Additionally, the KRAS biomarker analysis indicates that he has a wild-type KRAS status."
1560,white,female,72,27.18,FOLFOX + Cetuximab,Yes,No,Yes,No,12,poorly differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 72, bmi: 27.18, treatment arm: FOLFOX + Cetuximab, adherence: Yes, bowel obstruction: Yes, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 72-year-old white female with a BMI of 27.18. She is receiving treatment with FOLFOX + Cetuximab and has been adherent to the treatment. She has experienced a bowel obstruction. The patient has completed 12 cycles of chemotherapy. Her histology shows poorly differentiated cancer cells. Despite these challenges, her performance status is fully active. Additionally, her KRAS biomarker indicates that she has a wild-type status."
1561,white,female,76,40.87,FOLFOX,No,No,No,No,5,well differentiated,fully active,mutant,No,No,No,No,No,0,"race: white, sex: female, age: 76, bmi: 40.87, treatment arm: FOLFOX, chemotherapy cycles: 5, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 76-year-old white female with a BMI of 40.87. She is receiving the FOLFOX treatment arm and has completed 5 cycles of chemotherapy. Her histology shows well-differentiated cancer cells. Despite her age, she has a fully active performance status. The KRAS biomarker analysis indicates a mutant status."
1562,white,male,69,23.73,FOLFOX,No,No,Yes,No,3,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 69, bmi: 23.73, treatment arm: FOLFOX, bowel obstruction: Yes, chemotherapy cycles: 3, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 69-year-old white male with a BMI of 23.73. He is currently receiving treatment with the FOLFOX regimen for his well-differentiated histology. He has experienced a bowel obstruction and has completed 3 cycles of chemotherapy. Despite the bowel obstruction, his performance status is fully active. The KRAS biomarker testing revealed that he has a wild-type KRAS status."
1563,white,female,68,31.81,FOLFOX,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 68, bmi: 31.81, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 68-year-old white female with a BMI of 31.81. She is undergoing treatment with the FOLFOX chemotherapy regimen and has completed 12 cycles. Her cancer histology is well-differentiated, and she has a fully active performance status. The KRAS biomarker analysis shows that she has a wild-type KRAS status."
1564,white,male,55,22.44,FOLFOX,No,No,Yes,No,3,poorly differentiated,symptoms but ambulatory,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 55, bmi: 22.44, treatment arm: FOLFOX, bowel obstruction: Yes, chemotherapy cycles: 3, histology: poorly differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type","The patient is a 55-year-old white male with a BMI of 22.44. He is currently receiving FOLFOX treatment for bowel obstruction and has completed 3 cycles of chemotherapy. The histology shows poorly differentiated cancer cells. Despite experiencing symptoms, the patient is still able to ambulate. The KRAS biomarker indicates that the cancer is wild-type."
1565,white,male,34,37.39,FOLFOX,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 34, bmi: 37.39, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 34-year-old white male with a BMI of 37.39. He is receiving treatment with the FOLFOX chemotherapy regimen and is scheduled for 12 cycles. His cancer histology is well-differentiated, and he has a fully active performance status. The KRAS biomarker analysis shows that he has a wild-type KRAS status."
1566,white,male,44,28.96,FOLFOX + Cetuximab,No,No,Yes,No,12,well differentiated,fully active,mutant,No,Yes,No,No,No,0,"race: white, sex: male, age: 44, bmi: 28.96, treatment arm: FOLFOX + Cetuximab, bowel obstruction: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant, adverse effect: hypersensitivity: Yes","The patient is a 44-year-old white male with a BMI of 28.96 who is receiving treatment with FOLFOX + Cetuximab. He has a bowel obstruction and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cells, and he has a fully active performance status. The KRAS biomarker indicates a mutant status. The patient has experienced a hypersensitivity adverse effect."
1567,white,male,65,28.87,FOLFOX + Cetuximab,No,No,No,No,12,poorly differentiated,symptoms but ambulatory,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 65, bmi: 28.87, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: poorly differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type","The patient is a 65-year-old white male with a BMI of 28.87. He is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. His cancer histology is poorly differentiated. Despite experiencing symptoms, he is still able to be ambulatory. The KRAS biomarker testing revealed that he has a wild-type KRAS status."
1568,white,female,39,23.09,FOLFOX,No,No,Yes,No,12,poorly differentiated,fully active,wild-type,No,No,No,No,No,1,"race: white, sex: female, age: 39, bmi: 23.09, treatment arm: FOLFOX, bowel obstruction: Yes, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 39-year-old white female with a BMI of 23.09. She is receiving treatment with the FOLFOX regimen and has experienced a bowel obstruction. She has completed 12 cycles of chemotherapy. The histology of her cancer is poorly differentiated. Despite these challenges, her performance status is fully active. The KRAS biomarker testing indicates that she has a wild-type KRAS gene."
1569,white,male,51,26.79,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,fully active,mutant,No,No,No,No,No,0,"race: white, sex: male, age: 51, bmi: 26.79, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 51-year-old white male with a BMI of 26.79. He is receiving treatment in the FOLFOX + Cetuximab treatment arm and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer cells. Despite his cancer diagnosis, he has a fully active performance status. Additionally, the KRAS biomarker testing revealed a mutant status."
1570,white,male,48,27.28,FOLFOX + Cetuximab,No,No,No,No,12,poorly differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 48, bmi: 27.28, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 48-year-old white male with a BMI of 27.28. He is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. His histology shows poorly differentiated cancer cells. Despite this, his performance status is fully active. Additionally, his KRAS biomarker status is wild-type."
1571,black,male,69,30.25,FOLFOX,Yes,No,No,No,2,poorly differentiated,fully active,wild-type,No,No,No,No,No,0,"race: black, sex: male, age: 69, bmi: 30.25, treatment arm: FOLFOX, adherence: Yes, chemotherapy cycles: 2, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 69-year-old Black male with a BMI of 30.25. He is receiving the FOLFOX treatment regimen and has been adherent to the treatment. He has completed 2 cycles of chemotherapy. Histologically, the cancer is poorly differentiated. The patient has a fully active performance status. His KRAS biomarker status is wild-type."
1572,white,female,46,25.21,FOLFOX + Cetuximab,No,No,No,No,12,poorly differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 46, bmi: 25.21, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 46-year-old white female with a BMI of 25.21. She is receiving treatment with FOLFOX + Cetuximab and is scheduled for 12 chemotherapy cycles. The histology of her cancer is poorly differentiated. Despite her diagnosis, she has a fully active performance status. Additionally, her KRAS biomarker status is wild-type."
1573,white,male,41,27.02,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 41, bmi: 27.02, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 41-year-old white male with a BMI of 27.02. He is receiving treatment in the FOLFOX + Cetuximab treatment arm and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cells, and he has a fully active performance status. The KRAS biomarker indicates that he has a wild-type status."
1574,white,male,73,25.2,FOLFIRI,No,No,No,No,12,well differentiated,fully active,mutant,No,No,No,No,No,0,"race: white, sex: male, age: 73, bmi: 25.2, treatment arm: FOLFIRI, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant",The patient is a 73-year-old white male with a BMI of 25.2. He is receiving treatment with the FOLFIRI regimen and has completed 12 cycles of chemotherapy. The histology shows well-differentiated cancer cells. The patient has a fully active performance status. The KRAS biomarker analysis revealed a mutant status.
1575,white,male,54,32.54,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,fully active,mutant,No,No,No,No,No,0,"race: white, sex: male, age: 54, bmi: 32.54, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant",The patient is a 54-year-old white male with a BMI of 32.54. He is receiving treatment with FOLFOX + Cetuximab and is scheduled for 12 cycles of chemotherapy. The histology shows well-differentiated cancer cells. The patient has a fully active performance status. The KRAS biomarker indicates a mutant status.
1576,white,male,57,25.18,FOLFOX + Cetuximab,Yes,No,No,No,12,well differentiated,fully active,wild-type,Yes,No,No,No,No,0,"race: white, sex: male, age: 57, bmi: 25.18, treatment arm: FOLFOX + Cetuximab, adherence: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type, adverse effect: thrombosis: Yes","The patient is a 57-year-old white male with a BMI of 25.18. He is receiving treatment with FOLFOX + Cetuximab and has been adherent to the treatment. He has completed 12 cycles of chemotherapy. His histology shows well-differentiated cells, and he has a fully active performance status. The KRAS biomarker indicates that he is wild-type. Unfortunately, he has experienced a thrombosis as an adverse effect."
1577,white,male,61,28.73,FOLFOX,No,No,Yes,No,6,well differentiated,fully active,mutant,No,No,No,No,No,1,"race: white, sex: male, age: 61, bmi: 28.73, treatment arm: FOLFOX, bowel obstruction: Yes, chemotherapy cycles: 6, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 61-year-old white male with a BMI of 28.73. He is receiving the FOLFOX treatment regimen for his well-differentiated histology. He has experienced a bowel obstruction and has completed 6 cycles of chemotherapy. Despite this, his performance status is fully active. The patient's KRAS biomarker status is mutant."
1578,white,female,51,19.65,FOLFOX + Cetuximab,No,No,No,No,12,poorly differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 51, bmi: 19.65, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 51-year-old white female with a BMI of 19.65. She is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. The histology of her cancer is poorly differentiated. Despite her diagnosis, she has a fully active performance status. Her KRAS biomarker status is wild-type."
1579,white,male,70,31.97,FOLFOX + Cetuximab,No,No,No,No,3,poorly differentiated,fully active,wild-type,No,No,No,Yes,No,1,"race: white, sex: male, age: 70, bmi: 31.97, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 3, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type, adverse effect: infection: Yes","The patient is a 70-year-old white male with a BMI of 31.97. He is receiving treatment with FOLFOX + Cetuximab and has completed 3 cycles of chemotherapy. His cancer histology is poorly differentiated, and he has a fully active performance status. The KRAS biomarker shows that he is wild-type. The patient has experienced an infection as an adverse effect of the treatment."
1580,white,male,52,25.88,FOLFOX,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 52, bmi: 25.88, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 52-year-old white male with a BMI of 25.88. He is receiving the FOLFOX treatment arm and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cells, and he has a fully active performance status. The KRAS biomarker analysis indicates that he has a wild-type KRAS status."
1581,white,male,66,29.67,FOLFOX + Cetuximab,No,No,No,No,12,poorly differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 66, bmi: 29.67, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 66-year-old white male with a BMI of 29.67. He is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. His cancer histology is poorly differentiated. Despite his age, he has a fully active performance status. The KRAS biomarker testing revealed that he has a wild-type KRAS status."
1582,white,male,43,38.42,FOLFOX,No,No,No,No,10,poorly differentiated,fully active,mutant,No,No,No,No,No,1,"race: white, sex: male, age: 43, bmi: 38.42, treatment arm: FOLFOX, chemotherapy cycles: 10, histology: poorly differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 43-year-old white male with a BMI of 38.42. He is receiving treatment with the FOLFOX chemotherapy regimen and has completed 10 cycles so far. The histology of his cancer is poorly differentiated. Despite this, his performance status is fully active. Additionally, the KRAS biomarker testing revealed a mutant status."
1583,white,male,44,25.6,FOLFOX,No,No,No,No,2,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 44, bmi: 25.6, treatment arm: FOLFOX, chemotherapy cycles: 2, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 44-year-old white male with a BMI of 25.6. He is currently receiving the FOLFOX treatment regimen and has completed 2 cycles of chemotherapy. His histology shows well-differentiated cancer cells. Despite his cancer diagnosis, he has a fully active performance status. Additionally, his KRAS biomarker indicates that he has a wild-type gene."
1584,white,female,55,20.46,FOLFOX,No,No,Yes,No,2,poorly differentiated,fully active,mutant,No,No,No,No,No,0,"race: white, sex: female, age: 55, bmi: 20.46, treatment arm: FOLFOX, bowel obstruction: Yes, chemotherapy cycles: 2, histology: poorly differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 55-year-old white female with a BMI of 20.46. She is receiving the FOLFOX treatment regimen and has experienced a bowel obstruction. She has completed 2 cycles of chemotherapy. The histology of her cancer is poorly differentiated. Despite these challenges, her performance status is fully active. Additionally, the KRAS biomarker testing revealed a mutant status."
1585,white,male,49,24.69,FOLFIRI (KRAS mutant),No,No,No,No,12,well differentiated,fully active,mutant,No,No,No,No,No,0,"race: white, sex: male, age: 49, bmi: 24.69, treatment arm: FOLFIRI (KRAS mutant), chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 49-year-old white male with a BMI of 24.69. He is receiving treatment with the FOLFIRI regimen for his KRAS mutant status. He has completed 12 cycles of chemotherapy. His histology shows well-differentiated cells. Despite his cancer treatment, he maintains a fully active performance status."
1586,white,female,42,29.33,FOLFOX,No,No,No,No,12,well differentiated,symptoms but ambulatory,mutant,No,No,No,No,No,0,"race: white, sex: female, age: 42, bmi: 29.33, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: mutant","The patient is a 42-year-old white female with a BMI of 29.33. She is undergoing treatment with the FOLFOX chemotherapy regimen and has completed 12 cycles. Her histology shows well-differentiated cancer cells. Despite experiencing symptoms, she is still able to be ambulatory. The KRAS biomarker analysis indicates a mutant status."
1587,white,female,68,24.84,FOLFIRI + Cetuximab,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 68, bmi: 24.84, treatment arm: FOLFIRI + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 68-year-old white female with a BMI of 24.84. She is undergoing treatment with the FOLFIRI + Cetuximab regimen and has completed 12 cycles of chemotherapy. Her cancer histology is well differentiated, and she has a fully active performance status. Additionally, her KRAS biomarker status is wild-type."
1588,white,male,55,24.04,FOLFOX,No,No,No,No,0,well differentiated,fully active,mutant,No,No,No,No,No,0,"race: white, sex: male, age: 55, bmi: 24.04, treatment arm: FOLFOX, chemotherapy cycles: 0, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 55-year-old white male with a BMI of 24.04. He is in the FOLFOX treatment arm and has not yet started chemotherapy cycles. His histology shows well-differentiated cells, and he has a fully active performance status. The KRAS biomarker indicates a mutant status."
1589,white,male,54,30.15,FOLFOX + Cetuximab,No,Yes,No,No,12,well differentiated,fully active,wild-type,Yes,No,No,No,No,0,"race: white, sex: male, age: 54, bmi: 30.15, treatment arm: FOLFOX + Cetuximab, serious adverse effect: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type, adverse effect: thrombosis: Yes","The patient is a 54-year-old white male with a BMI of 30.15. He is receiving treatment with FOLFOX + Cetuximab for his well-differentiated histology cancer. Despite being fully active, he experienced a serious adverse effect in the form of thrombosis during his 12 cycles of chemotherapy. His KRAS biomarker status is wild-type."
1590,white,male,52,29.86,FOLFOX,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 52, bmi: 29.86, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type",The patient is a 52-year-old white male with a BMI of 29.86. He is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. The histology shows well-differentiated cancer cells. The patient has a fully active performance status. The KRAS biomarker analysis indicates that the patient has a wild-type KRAS gene.
1591,white,female,34,28.14,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,fully active,wild-type,No,Yes,No,No,No,0,"race: white, sex: female, age: 34, bmi: 28.14, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type, adverse effect: hypersensitivity: Yes","The patient is a 34-year-old white female with a BMI of 28.14. She is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cancer, and she has a fully active performance status. The KRAS biomarker indicates she is wild-type. She has experienced a hypersensitivity adverse effect."
1592,white,male,38,25.09,FOLFOX + Cetuximab,No,No,No,No,7,well differentiated,symptoms but ambulatory,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 38, bmi: 25.09, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 7, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type","The patient is a 38-year-old white male with a BMI of 25.09. He is receiving treatment in the FOLFOX + Cetuximab treatment arm and has completed 7 cycles of chemotherapy. His histology shows well-differentiated cancer. Despite experiencing symptoms, he is still able to be ambulatory. The KRAS biomarker analysis indicates that he has a wild-type KRAS status."
1593,white,female,66,37,FOLFIRI,Yes,No,No,No,12,poorly differentiated,symptoms but ambulatory,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 66, bmi: 37.0, treatment arm: FOLFIRI, adherence: Yes, chemotherapy cycles: 12, histology: poorly differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type","The patient is a 66-year-old white female with a BMI of 37.0. She is receiving treatment with the FOLFIRI regimen and has been adherent to the treatment. She has completed 12 cycles of chemotherapy. The histology of her cancer is poorly differentiated. Despite experiencing symptoms, she is still able to be ambulatory. Her KRAS biomarker status is wild-type."
1594,black,male,36,39.02,FOLFOX + Cetuximab,No,Yes,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: black, sex: male, age: 36, bmi: 39.02, treatment arm: FOLFOX + Cetuximab, serious adverse effect: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 36-year-old Black male with a BMI of 39.02. He is receiving treatment with FOLFOX + Cetuximab and has experienced a serious adverse effect. He has completed 12 cycles of chemotherapy. His histology shows well-differentiated cells, and his performance status is fully active. The KRAS biomarker indicates that he has a wild-type status."
1595,white,female,48,22.32,FOLFOX,No,No,No,No,11,poorly differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 48, bmi: 22.32, treatment arm: FOLFOX, chemotherapy cycles: 11, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 48-year-old white female with a BMI of 22.32. She is undergoing treatment with FOLFOX chemotherapy and has completed 11 cycles so far. The histology of her cancer is poorly differentiated. Despite her diagnosis, she maintains a fully active performance status. Additionally, her KRAS biomarker status is wild-type."
1596,white,female,53,20.65,FOLFOX + Cetuximab,No,No,Yes,No,12,well differentiated,symptoms but ambulatory,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 53, bmi: 20.65, treatment arm: FOLFOX + Cetuximab, bowel obstruction: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type","This patient is a 53-year-old white female with a BMI of 20.65. She is receiving treatment with FOLFOX + Cetuximab for her well-differentiated histology. She has experienced a bowel obstruction and has completed 12 cycles of chemotherapy. Despite experiencing symptoms, she is still able to be ambulatory. Her KRAS biomarker status is wild-type."
1597,white,female,75,26.33,FOLFOX,No,No,No,No,9,well differentiated,fully active,mutant,No,No,Yes,No,No,1,"race: white, sex: female, age: 75, bmi: 26.33, treatment arm: FOLFOX, chemotherapy cycles: 9, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant, adverse effect: diarrhea: Yes","The patient is a 75-year-old white female with a BMI of 26.33. She is receiving the FOLFOX treatment regimen and has completed 9 cycles of chemotherapy. Her histology shows well-differentiated cancer cells. Despite her age, she has a fully active performance status. The KRAS biomarker testing revealed a mutant status. The patient is experiencing diarrhea as an adverse effect of the treatment."
1598,white,male,56,27.9,FOLFOX + Cetuximab,No,No,No,No,5,well differentiated,fully active,mutant,No,No,Yes,No,No,0,"race: white, sex: male, age: 56, bmi: 27.9, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 5, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant, adverse effect: diarrhea: Yes","The patient is a 56-year-old white male with a BMI of 27.9. He is receiving treatment with FOLFOX + Cetuximab and has completed 5 cycles of chemotherapy. His histology shows well-differentiated cancer, and he has a fully active performance status. The KRAS biomarker testing revealed a mutant status. The patient is experiencing diarrhea as an adverse effect of the treatment."
1599,white,female,69,39.37,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 69, bmi: 39.37, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 69-year-old white female with a BMI of 39.37. She is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. Her cancer histology is well-differentiated, and she has a fully active performance status. The KRAS biomarker testing showed that she has a wild-type KRAS status."
1600,white,male,48,18.71,FOLFOX,No,No,No,No,12,well differentiated,fully active,mutant,No,No,No,No,No,0,"race: white, sex: male, age: 48, bmi: 18.71, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 48-year-old white male with a BMI of 18.71. He is receiving treatment in the FOLFOX chemotherapy arm and has completed 12 cycles of chemotherapy. The histology of his cancer is well differentiated. Despite his cancer diagnosis, he has a fully active performance status. The patient's KRAS biomarker is mutant."
1601,white,female,45,26.73,FOLFIRI + Cetuximab,No,No,Yes,No,0,well differentiated,symptoms but ambulatory,mutant,No,No,No,No,No,1,"race: white, sex: female, age: 45, bmi: 26.73, treatment arm: FOLFIRI + Cetuximab, bowel obstruction: Yes, chemotherapy cycles: 0, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: mutant","The patient is a 45-year-old white female with a BMI of 26.73. She is enrolled in the treatment arm receiving FOLFIRI + Cetuximab. She has a bowel obstruction and has not started any chemotherapy cycles yet. The histology shows well-differentiated cells. Despite experiencing symptoms, she is still able to be ambulatory. The KRAS biomarker indicates a mutant status."
1602,white,female,75,23.2,FOLFOX + Cetuximab,Yes,No,No,No,1,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 75, bmi: 23.2, treatment arm: FOLFOX + Cetuximab, adherence: Yes, chemotherapy cycles: 1, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 75-year-old white female with a BMI of 23.2. She is currently receiving treatment in the FOLFOX + Cetuximab treatment arm and has been adherent to her medication. She has completed one cycle of chemotherapy. Her histology shows well-differentiated cells, and her performance status is fully active. Additionally, her KRAS biomarker indicates that she has a wild-type mutation."
1603,white,male,58,25.21,FOLFOX,Yes,No,No,No,6,poorly differentiated,fully active,mutant,No,No,No,No,No,0,"race: white, sex: male, age: 58, bmi: 25.21, treatment arm: FOLFOX, adherence: Yes, chemotherapy cycles: 6, histology: poorly differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 58-year-old white male with a BMI of 25.21. He is receiving the FOLFOX treatment regimen and has been adherent to the treatment. He has completed 6 cycles of chemotherapy. His histology shows poorly differentiated cancer cells. Despite this, his performance status is fully active. Additionally, the KRAS biomarker testing revealed a mutant status."
1604,white,female,70,24.8,FOLFOX + Cetuximab,No,No,No,No,1,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 70, bmi: 24.8, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 1, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 70-year-old white female with a BMI of 24.8. She is currently receiving treatment with FOLFOX + Cetuximab and has completed one cycle of chemotherapy. Her cancer histology is well-differentiated, and she has a fully active performance status. Additionally, her KRAS biomarker status is wild-type."
1605,black,female,53,34.44,FOLFOX,No,No,No,No,5,well differentiated,symptoms but ambulatory,mutant,No,No,No,No,No,0,"race: black, sex: female, age: 53, bmi: 34.44, treatment arm: FOLFOX, chemotherapy cycles: 5, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: mutant","The patient is a 53-year-old Black female with a BMI of 34.44. She is receiving the FOLFOX treatment regimen and has completed 5 cycles of chemotherapy. The histology shows well-differentiated cancer cells. Despite experiencing symptoms, the patient is still ambulatory. The KRAS biomarker indicates a mutant status."
1606,white,female,63,29.91,FOLFOX + Cetuximab,No,Yes,Yes,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 63, bmi: 29.91, treatment arm: FOLFOX + Cetuximab, serious adverse effect: Yes, bowel obstruction: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 63-year-old white female with a BMI of 29.91. She is receiving treatment with FOLFOX + Cetuximab and has experienced a serious adverse effect, specifically a bowel obstruction. She has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cells, and her performance status is fully active. The KRAS biomarker indicates that she has a wild-type status."
1607,white,female,66,24.1,FOLFOX + Cetuximab,No,No,No,No,12,poorly differentiated,fully active,mutant,No,No,No,No,No,0,"race: white, sex: female, age: 66, bmi: 24.1, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 66-year-old white female with a BMI of 24.1. She is receiving treatment in the FOLFOX + Cetuximab treatment arm and has completed 12 cycles of chemotherapy. The histology of her cancer is poorly differentiated. Despite this, her performance status is fully active. Additionally, the KRAS biomarker testing revealed a mutant status."
1608,white,male,76,29.62,FOLFOX,No,Yes,No,No,10,poorly differentiated,fully active,mutant,No,No,No,No,No,0,"race: white, sex: male, age: 76, bmi: 29.62, treatment arm: FOLFOX, serious adverse effect: Yes, chemotherapy cycles: 10, histology: poorly differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 76-year-old white male with a BMI of 29.62. He is receiving the FOLFOX treatment regimen and has experienced a serious adverse effect. He has completed 10 cycles of chemotherapy. The histology of his cancer is poorly differentiated. Despite his age, he has a fully active performance status. The KRAS biomarker testing revealed a mutant status."
1609,white,male,58,29.54,FOLFOX,Yes,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 58, bmi: 29.54, treatment arm: FOLFOX, adherence: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type",The patient is a 58-year-old white male with a BMI of 29.54. He is receiving treatment with the FOLFOX regimen and has been adherent to the treatment. He has completed 12 cycles of chemotherapy. The histology shows well-differentiated cancer cells. The patient has a fully active performance status. The KRAS biomarker analysis indicates that the patient has a wild-type KRAS status.
1610,white,female,43,23.98,FOLFIRI + Cetuximab,No,No,No,No,5,well differentiated,fully active,mutant,No,No,No,No,No,0,"race: white, sex: female, age: 43, bmi: 23.98, treatment arm: FOLFIRI + Cetuximab, chemotherapy cycles: 5, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 43-year-old white female with a BMI of 23.98. She is currently undergoing treatment with FOLFIRI + Cetuximab and has completed 5 cycles of chemotherapy. Her histology shows well-differentiated cancer cells. Despite her cancer diagnosis, she has a fully active performance status. The patient's KRAS biomarker is mutant."
1611,white,male,38,22.46,FOLFOX + Cetuximab,No,No,No,No,0,well differentiated,symptoms but ambulatory,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 38, bmi: 22.46, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 0, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type","The patient is a 38-year-old white male with a BMI of 22.46. He is enrolled in the FOLFOX + Cetuximab treatment arm and has not started any chemotherapy cycles yet. His histology shows well-differentiated cancer. Despite experiencing symptoms, he is still able to be ambulatory. The KRAS biomarker indicates that he has a wild-type status."
1612,white,female,59,34.13,FOLFOX,No,Yes,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 59, bmi: 34.13, treatment arm: FOLFOX, serious adverse effect: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 59-year-old white female with a BMI of 34.13. She is receiving the FOLFOX treatment regimen and has experienced a serious adverse effect. She has completed 12 cycles of chemotherapy. The histology shows well-differentiated cancer cells. Despite the adverse effect, her performance status is fully active. The KRAS biomarker indicates that she has a wild-type KRAS gene."
1613,black,male,58,23.22,FOLFOX,No,No,No,No,12,well differentiated,symptoms but ambulatory,wild-type,No,No,No,No,No,0,"race: black, sex: male, age: 58, bmi: 23.22, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type","The patient is a 58-year-old Black male with a BMI of 23.22. He is undergoing treatment with the FOLFOX chemotherapy regimen and has completed 12 cycles. His histology shows well-differentiated cancer cells. Despite experiencing symptoms, he is still able to ambulate. The KRAS biomarker analysis indicates that he has a wild-type KRAS status."
1614,white,male,71,21.8,FOLFOX + Cetuximab,No,No,Yes,No,6,poorly differentiated,symptoms but ambulatory,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 71, bmi: 21.8, treatment arm: FOLFOX + Cetuximab, bowel obstruction: Yes, chemotherapy cycles: 6, histology: poorly differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type","The patient is a 71-year-old white male with a BMI of 21.8. He is receiving treatment with FOLFOX + Cetuximab for his cancer. He has experienced a bowel obstruction and has completed 6 cycles of chemotherapy. The histology of his cancer is poorly differentiated. Despite experiencing symptoms, he is still able to be ambulatory. His KRAS biomarker status is wild-type."
1615,white,female,53,27.73,FOLFOX + Cetuximab,No,Yes,No,No,12,poorly differentiated,fully active,mutant,Yes,No,No,No,No,0,"race: white, sex: female, age: 53, bmi: 27.73, treatment arm: FOLFOX + Cetuximab, serious adverse effect: Yes, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: mutant, adverse effect: thrombosis: Yes","The patient is a 53-year-old white female with a BMI of 27.73. She is receiving treatment with FOLFOX + Cetuximab and has experienced a serious adverse effect. She has completed 12 cycles of chemotherapy. The histology of her cancer is poorly differentiated. Despite this, her performance status is fully active. Her KRAS biomarker is mutant. Additionally, she has experienced thrombosis as an adverse effect."
1616,white,female,41,28.39,FOLFOX,Yes,No,Yes,Yes,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 41, bmi: 28.39, treatment arm: FOLFOX, adherence: Yes, bowel obstruction: Yes, bowel perforation: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 41-year-old white female with a BMI of 28.39. She is receiving treatment with FOLFOX and has been adherent to the treatment. She has experienced both bowel obstruction and bowel perforation. The patient has completed 12 cycles of chemotherapy. Histologically, the cancer is well-differentiated. Despite the bowel issues, her performance status is fully active. The KRAS biomarker shows that she has a wild-type status."
1617,other,female,42,23.21,FOLFOX + Cetuximab,No,No,No,Yes,12,poorly differentiated,fully active,wild-type,No,No,No,No,No,0,"race: other, sex: female, age: 42, bmi: 23.21, treatment arm: FOLFOX + Cetuximab, bowel perforation: Yes, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 42-year-old female of a race categorized as ""other"" with a BMI of 23.21. She is receiving treatment in the FOLFOX + Cetuximab treatment arm. The patient has experienced a bowel perforation and has completed 12 cycles of chemotherapy. The histology of the cancer is poorly differentiated. Despite these challenges, the patient has a fully active performance status. Additionally, the KRAS biomarker is wild-type in this case."
1618,white,male,54,33.34,FOLFOX,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 54, bmi: 33.34, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 54-year-old white male with a BMI of 33.34. He is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cells, and he has a fully active performance status. The KRAS biomarker analysis indicates that he has a wild-type KRAS status."
1619,white,male,74,23.03,FOLFOX + Cetuximab,No,No,No,No,3,well differentiated,symptoms but ambulatory,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 74, bmi: 23.03, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 3, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type","The patient is a 74-year-old white male with a BMI of 23.03. He is currently receiving treatment with FOLFOX + Cetuximab and has completed 3 cycles of chemotherapy. His histology shows well-differentiated cancer cells. Despite experiencing symptoms, he is still able to walk around (ambulatory). His KRAS biomarker status is wild-type."
1620,white,female,49,37.82,FOLFOX,No,Yes,No,No,12,poorly differentiated,fully active,wild-type,Yes,No,No,No,No,0,"race: white, sex: female, age: 49, bmi: 37.82, treatment arm: FOLFOX, serious adverse effect: Yes, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type, adverse effect: thrombosis: Yes","This patient is a 49-year-old white female with a BMI of 37.82. She is receiving treatment with FOLFOX chemotherapy regimen and has experienced a serious adverse effect. She has completed 12 cycles of chemotherapy. The histology of her cancer is poorly differentiated. Despite this, her performance status is fully active. Her KRAS biomarker is wild-type. Additionally, she has experienced an adverse effect of thrombosis."
1621,white,female,70,23.1,FOLFOX + Cetuximab,No,No,Yes,No,2,poorly differentiated,symptoms but ambulatory,wild-type,No,No,Yes,Yes,No,1,"race: white, sex: female, age: 70, bmi: 23.1, treatment arm: FOLFOX + Cetuximab, bowel obstruction: Yes, chemotherapy cycles: 2, histology: poorly differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type, adverse effect: diarrhea: Yes, adverse effect: infection: Yes","The patient is a 70-year-old white female with a BMI of 23.1. She is currently receiving treatment with FOLFOX + Cetuximab for her poorly differentiated histology. She has experienced a bowel obstruction and has completed 2 cycles of chemotherapy. Despite experiencing symptoms, she is still able to be ambulatory. Her KRAS biomarker is wild-type. She has also reported experiencing diarrhea and infection as adverse effects of her treatment."
1622,white,female,65,22.76,FOLFIRI,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 65, bmi: 22.76, treatment arm: FOLFIRI, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 65-year-old white female with a BMI of 22.76. She is receiving the FOLFIRI treatment regimen and has completed 12 cycles of chemotherapy. Her cancer histology is well-differentiated, and she has a fully active performance status. The KRAS biomarker testing showed that she has a wild-type KRAS status."
1623,white,female,53,23.53,FOLFOX,No,Yes,No,No,12,well differentiated,fully active,mutant,No,No,No,No,No,0,"race: white, sex: female, age: 53, bmi: 23.53, treatment arm: FOLFOX, serious adverse effect: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 53-year-old white female with a BMI of 23.53. She is receiving the FOLFOX treatment regimen and has experienced a serious adverse effect. She has completed 12 cycles of chemotherapy. The histology shows that the cancer is well-differentiated. Despite the adverse effect, her performance status is fully active. The KRAS biomarker analysis indicates that she has a mutant form of the KRAS gene."
1624,white,male,54,26.21,FOLFIRI (KRAS mutant),No,Yes,No,No,12,well differentiated,symptoms but ambulatory,mutant,Yes,No,No,No,No,0,"race: white, sex: male, age: 54, bmi: 26.21, treatment arm: FOLFIRI (KRAS mutant), serious adverse effect: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: mutant, adverse effect: thrombosis: Yes","The patient is a 54-year-old white male with a BMI of 26.21. He is receiving FOLFIRI treatment for his well-differentiated histology with a KRAS mutant biomarker. He has experienced a serious adverse effect in the form of thrombosis after completing 12 cycles of chemotherapy. Despite experiencing symptoms, he is still able to be ambulatory."
1625,white,female,57,24.62,FOLFIRI (KRAS mutant),No,No,No,No,3,poorly differentiated,symptoms but ambulatory,wild-type,No,No,No,No,No,1,"race: white, sex: female, age: 57, bmi: 24.62, treatment arm: FOLFIRI (KRAS mutant), chemotherapy cycles: 3, histology: poorly differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type","The patient is a 57-year-old white female with a BMI of 24.62. She is currently receiving FOLFIRI chemotherapy treatment for KRAS mutant cancer. She has completed 3 cycles of chemotherapy. The histology of her cancer is poorly differentiated. Despite experiencing symptoms, she is still able to be ambulatory. Her KRAS biomarker is wild-type."
1626,white,male,57,26.03,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,symptoms but ambulatory,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 57, bmi: 26.03, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type","The patient is a 57-year-old white male with a BMI of 26.03. He is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer. Despite experiencing symptoms, he is still able to walk around (ambulatory). His KRAS biomarker indicates that he has a wild-type mutation."
1627,other,male,57,24.42,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,symptoms but ambulatory,mutant,No,No,No,No,No,0,"race: other, sex: male, age: 57, bmi: 24.42, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: mutant","The patient is a 57-year-old male of a race other than specified, with a BMI of 24.42. He is undergoing treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. The histology indicates well-differentiated cancer. Despite experiencing symptoms, the patient is still able to ambulate. The KRAS biomarker shows a mutation in this patient."
1628,black,male,45,27.13,FOLFOX + Cetuximab,No,No,No,No,5,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: black, sex: male, age: 45, bmi: 27.13, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 5, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type",The patient is a 45-year-old Black male with a BMI of 27.13. He is receiving treatment in the FOLFOX + Cetuximab treatment arm and has completed 5 cycles of chemotherapy. The histology shows well-differentiated cancer cells. The patient has a fully active performance status. The KRAS biomarker indicates that the patient has a wild-type KRAS gene.
1629,white,male,51,34.19,FOLFOX + Cetuximab,No,No,No,No,0,poorly differentiated,symptoms but ambulatory,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 51, bmi: 34.19, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 0, histology: poorly differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type","The patient is a 51-year-old white male with a BMI of 34.19. He is enrolled in the FOLFOX + Cetuximab treatment arm but has not started chemotherapy cycles yet. His histology shows poorly differentiated cancer cells. Despite experiencing symptoms, he is still able to be ambulatory. The KRAS biomarker analysis indicates that he has a wild-type KRAS status."
1630,white,female,64,31.99,FOLFOX + Cetuximab,No,No,No,No,1,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 64, bmi: 31.99, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 1, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 64-year-old white female with a BMI of 31.99. She is receiving treatment in the FOLFOX + Cetuximab treatment arm and has completed one cycle of chemotherapy. Her histology shows well-differentiated cancer cells. Despite her age, she has a fully active performance status. Additionally, her KRAS biomarker status is wild-type."
1631,white,female,39,17.92,FOLFIRI (KRAS mutant),No,No,No,No,9,poorly differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 39, bmi: 17.92, treatment arm: FOLFIRI (KRAS mutant), chemotherapy cycles: 9, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 39-year-old white female with a BMI of 17.92. She is receiving treatment in the FOLFIRI chemotherapy arm for KRAS mutant status. She has completed 9 cycles of chemotherapy. The histology of her cancer is poorly differentiated. Despite this, her performance status is fully active. The KRAS biomarker for this patient is wild-type."
1632,white,male,75,22.8,FOLFIRI,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 75, bmi: 22.8, treatment arm: FOLFIRI, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 75-year-old white male with a BMI of 22.8. He is receiving the FOLFIRI treatment regimen and has completed 12 cycles of chemotherapy. His cancer histology is well-differentiated, and he has a fully active performance status. The KRAS biomarker testing revealed that he has a wild-type KRAS status."
1633,white,female,48,30.04,FOLFOX + Cetuximab,No,Yes,No,No,5,well differentiated,fully active,wild-type,No,Yes,Yes,No,No,0,"race: white, sex: female, age: 48, bmi: 30.04, treatment arm: FOLFOX + Cetuximab, serious adverse effect: Yes, chemotherapy cycles: 5, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type, adverse effect: hypersensitivity: Yes, adverse effect: diarrhea: Yes","The patient is a 48-year-old white female with a BMI of 30.04. She is receiving treatment with FOLFOX + Cetuximab and has experienced a serious adverse effect. She has completed 5 cycles of chemotherapy. The histology shows well-differentiated cells, and her performance status is fully active. The KRAS biomarker is wild-type. She has experienced adverse effects of hypersensitivity and diarrhea during her treatment."
1634,white,female,47,35.18,FOLFOX,No,No,No,No,12,well differentiated,fully active,mutant,No,No,No,No,No,0,"race: white, sex: female, age: 47, bmi: 35.18, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant",The patient is a 47-year-old white female with a BMI of 35.18. She is receiving the FOLFOX treatment arm for her well-differentiated histology. She is fully active with a mutant KRAS biomarker. She is scheduled to undergo 12 cycles of chemotherapy.
1635,white,female,48,19.72,FOLFOX,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 48, bmi: 19.72, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 48-year-old white female with a BMI of 19.72. She is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. Her cancer histology is well-differentiated, and she has a fully active performance status. The KRAS biomarker analysis shows that she has a wild-type KRAS status."
1636,white,male,46,26.29,FOLFOX + Cetuximab,No,No,No,No,1,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 46, bmi: 26.29, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 1, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type",The patient is a 46-year-old white male with a BMI of 26.29. He is currently receiving treatment in the FOLFOX + Cetuximab treatment arm and has completed 1 cycle of chemotherapy. His histology shows well-differentiated cancer cells. The patient has a fully active performance status and his KRAS biomarker is wild-type.
1637,white,female,58,43.49,FOLFOX + Cetuximab,No,No,No,No,12,poorly differentiated,symptoms but ambulatory,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 58, bmi: 43.49, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: poorly differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type","The patient is a 58-year-old white female with a BMI of 43.49. She is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. Her histology shows poorly differentiated cancer cells. Despite experiencing symptoms, she is still able to be ambulatory. The KRAS biomarker analysis indicates that she has a wild-type KRAS status."
1638,white,female,35,28.54,FOLFOX + Cetuximab,Yes,No,No,No,2,poorly differentiated,symptoms but ambulatory,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 35, bmi: 28.54, treatment arm: FOLFOX + Cetuximab, adherence: Yes, chemotherapy cycles: 2, histology: poorly differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type","The patient is a 35-year-old white female with a BMI of 28.54. She is currently receiving treatment in the FOLFOX + Cetuximab treatment arm and has been adherent to her treatment. She has completed 2 cycles of chemotherapy. The histology of her cancer is poorly differentiated. Despite experiencing symptoms, she is still able to be ambulatory. Her KRAS biomarker status is wild-type."
1639,white,female,40,29.4,FOLFOX + Cetuximab,No,No,No,No,8,well differentiated,fully active,mutant,No,No,No,No,No,0,"race: white, sex: female, age: 40, bmi: 29.4, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 8, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 40-year-old white female with a BMI of 29.4. She is receiving treatment in the FOLFOX + Cetuximab treatment arm and has completed 8 cycles of chemotherapy. Her histology shows well-differentiated cancer cells. Despite her cancer diagnosis, she has a fully active performance status. The KRAS biomarker analysis indicates that she has a mutant KRAS status."
1640,other,male,41,24.38,FOLFOX,Yes,No,Yes,Yes,12,well differentiated,fully active,mutant,No,No,No,No,No,0,"race: other, sex: male, age: 41, bmi: 24.38, treatment arm: FOLFOX, adherence: Yes, bowel obstruction: Yes, bowel perforation: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 41-year-old male of a race categorized as ""other"" with a BMI of 24.38. He is undergoing treatment with the FOLFOX regimen and has been adherent to the treatment. The patient has experienced both a bowel obstruction and a bowel perforation. He has completed 12 cycles of chemotherapy. The histology shows that the cancer is well-differentiated. Despite the bowel issues, the patient's performance status is fully active. The KRAS biomarker analysis indicates that the patient has a mutant KRAS status."
1641,white,male,66,30.94,FOLFOX,No,No,No,No,12,poorly differentiated,fully active,wild-type,No,No,Yes,No,No,0,"race: white, sex: male, age: 66, bmi: 30.94, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type, adverse effect: diarrhea: Yes","The patient is a 66-year-old white male with a BMI of 30.94. He is undergoing treatment with the FOLFOX chemotherapy regimen and has completed 12 cycles. His cancer histology is poorly differentiated, and he has a fully active performance status. The KRAS biomarker testing showed that he has a wild-type KRAS status. The patient is experiencing diarrhea as an adverse effect of the treatment."
1642,white,female,55,30.83,FOLFOX + Cetuximab,No,No,No,No,4,well differentiated,fully active,mutant,No,No,No,No,No,0,"race: white, sex: female, age: 55, bmi: 30.83, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 4, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant",The patient is a 55-year-old white female with a BMI of 30.83. She is receiving treatment with FOLFOX + Cetuximab and has completed 4 cycles of chemotherapy. Her cancer histology is well differentiated. The patient has a fully active performance status. The KRAS biomarker testing showed a mutant result.
1643,white,male,57,32.53,FOLFOX + Cetuximab,No,No,No,No,12,poorly differentiated,fully active,mutant,No,No,No,No,No,0,"race: white, sex: male, age: 57, bmi: 32.53, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 57-year-old white male with a BMI of 32.53. He is receiving treatment with FOLFOX + Cetuximab and is scheduled for 12 chemotherapy cycles. The histology of his cancer is poorly differentiated. Despite his cancer diagnosis, he has a fully active performance status. Additionally, the KRAS biomarker testing revealed a mutant status."
1644,white,female,68,17.54,FOLFOX,No,No,Yes,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 68, bmi: 17.54, treatment arm: FOLFOX, bowel obstruction: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 68-year-old white female with a BMI of 17.54. She is receiving the FOLFOX treatment regimen for her well-differentiated histology. She has experienced a bowel obstruction and has completed 12 cycles of chemotherapy. Despite the bowel obstruction, her performance status is fully active. The KRAS biomarker testing revealed that she has a wild-type KRAS status."
1645,white,female,59,25.96,FOLFOX + Cetuximab,No,No,No,No,12,poorly differentiated,fully active,wild-type,No,No,Yes,No,No,0,"race: white, sex: female, age: 59, bmi: 25.96, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type, adverse effect: diarrhea: Yes","The patient is a 59-year-old white female with a BMI of 25.96. She is receiving treatment with FOLFOX + Cetuximab and has completed 12 chemotherapy cycles. Her cancer histology is poorly differentiated. Despite experiencing diarrhea as an adverse effect, her performance status is fully active. Additionally, her KRAS biomarker status is wild-type."
1646,white,male,65,32.15,FOLFOX + Cetuximab,Yes,Yes,No,No,12,well differentiated,symptoms but ambulatory,mutant,No,No,No,No,No,0,"race: white, sex: male, age: 65, bmi: 32.15, treatment arm: FOLFOX + Cetuximab, adherence: Yes, serious adverse effect: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: mutant","The patient is a 65-year-old white male with a BMI of 32.15. He is receiving treatment with FOLFOX + Cetuximab and has been adherent to the treatment. However, he experienced a serious adverse effect during the treatment. He has completed 12 cycles of chemotherapy. The histology shows well-differentiated cells. Despite experiencing symptoms, the patient is still ambulatory. The KRAS biomarker indicates a mutant status."
1647,white,male,63,23.2,FOLFOX,No,No,No,No,12,poorly differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 63, bmi: 23.2, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 63-year-old white male with a BMI of 23.2. He is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. His histology shows poorly differentiated cells. Despite this, his performance status is fully active. Additionally, his KRAS biomarker is wild-type."
1648,white,female,57,30.12,FOLFOX + Cetuximab,Yes,No,No,Yes,3,well differentiated,symptoms but ambulatory,interminate,No,No,No,No,No,0,"race: white, sex: female, age: 57, bmi: 30.12, treatment arm: FOLFOX + Cetuximab, adherence: Yes, bowel perforation: Yes, chemotherapy cycles: 3, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: interminate","The patient is a 57-year-old white female with a BMI of 30.12. She is currently receiving treatment in the FOLFOX + Cetuximab treatment arm and has been adherent to her treatment. She experienced a bowel perforation and has completed 3 cycles of chemotherapy. The histology shows that the cancer is well-differentiated. Despite experiencing symptoms, the patient is still ambulatory. The KRAS biomarker status is indeterminate for this patient."
1649,white,male,34,31.12,FOLFIRI,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 34, bmi: 31.12, treatment arm: FOLFIRI, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 34-year-old white male with a BMI of 31.12. He is receiving treatment with the FOLFIRI chemotherapy regimen and has completed 12 cycles. His cancer histology is well-differentiated, and he has a fully active performance status. The KRAS biomarker analysis shows that he has a wild-type KRAS status."
1650,white,female,43,26.01,FOLFOX,No,No,No,No,5,well differentiated,fully active,wild-type,Yes,No,No,No,No,0,"race: white, sex: female, age: 43, bmi: 26.01, treatment arm: FOLFOX, chemotherapy cycles: 5, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type, adverse effect: thrombosis: Yes","The patient is a 43-year-old white female with a BMI of 26.01. She is receiving the FOLFOX treatment regimen and has completed 5 cycles of chemotherapy. Her histology shows well-differentiated cells, and she has a fully active performance status. The KRAS biomarker indicates that she has a wild-type gene. The patient has experienced an adverse effect of thrombosis."
1651,white,female,46,49.83,FOLFOX + Cetuximab,No,Yes,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 46, bmi: 49.83, treatment arm: FOLFOX + Cetuximab, serious adverse effect: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 46-year-old white female with a BMI of 49.83. She is receiving treatment with FOLFOX + Cetuximab and has experienced a serious adverse effect. She has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cells. Despite the adverse effect, her performance status is fully active. Additionally, her KRAS biomarker is wild-type."
1652,white,male,44,32.4,FOLFOX,No,No,No,No,12,poorly differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 44, bmi: 32.4, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 44-year-old white male with a BMI of 32.4. He is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. His histology shows poorly differentiated cancer cells. Despite this, his performance status is fully active. Additionally, his KRAS biomarker indicates that it is wild-type."
1653,white,female,40,40.09,FOLFOX,No,No,Yes,No,12,poorly differentiated,fully active,wild-type,No,No,No,No,No,1,"race: white, sex: female, age: 40, bmi: 40.09, treatment arm: FOLFOX, bowel obstruction: Yes, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 40-year-old white female with a BMI of 40.09. She is receiving the FOLFOX treatment regimen for her cancer. She has a bowel obstruction and has completed 12 cycles of chemotherapy. The histology of her cancer is poorly differentiated. Despite her condition, her performance status is fully active. The KRAS biomarker analysis shows that she has a wild-type KRAS status."
1654,white,male,60,27.18,FOLFOX,No,No,No,Yes,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 60, bmi: 27.18, treatment arm: FOLFOX, bowel perforation: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 60-year-old white male with a BMI of 27.18. He is receiving the FOLFOX treatment regimen and has experienced a bowel perforation. He has completed 12 cycles of chemotherapy. The histology shows that the cancer is well-differentiated. Despite the bowel perforation, the patient's performance status is fully active. The KRAS biomarker analysis indicates that the patient has a wild-type KRAS status."
1655,white,female,45,18.79,FOLFOX,No,No,Yes,No,7,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 45, bmi: 18.79, treatment arm: FOLFOX, bowel obstruction: Yes, chemotherapy cycles: 7, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 45-year-old white female with a BMI of 18.79. She is currently receiving the FOLFOX treatment regimen for her cancer. She is experiencing a bowel obstruction and has completed 7 cycles of chemotherapy. The histology of her cancer is well-differentiated. Despite her condition, she has a fully active performance status. Additionally, her KRAS biomarker status is wild-type."
1656,white,male,61,25.04,FOLFOX + Cetuximab,No,No,No,No,6,poorly differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 61, bmi: 25.04, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 6, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 61-year-old white male with a BMI of 25.04. He is receiving treatment with FOLFOX + Cetuximab and has completed 6 cycles of chemotherapy. His histology shows poorly differentiated cancer cells. Despite this, his performance status is fully active. The KRAS biomarker analysis indicates that he has a wild-type KRAS gene."
1657,white,female,43,21.76,FOLFOX,Yes,No,Yes,No,12,poorly differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 43, bmi: 21.76, treatment arm: FOLFOX, adherence: Yes, bowel obstruction: Yes, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 43-year-old white female with a BMI of 21.76. She is receiving treatment in the FOLFOX regimen and has been adherent to the treatment. She has experienced a bowel obstruction. The patient has completed 12 cycles of chemotherapy. The histology of the cancer is poorly differentiated. Despite these challenges, her performance status is fully active. The KRAS biomarker shows that it is wild-type."
1658,white,male,57,30.65,FOLFIRI,No,No,No,No,12,poorly differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 57, bmi: 30.65, treatment arm: FOLFIRI, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 57-year-old white male with a BMI of 30.65. He is receiving the FOLFIRI treatment regimen and has completed 12 cycles of chemotherapy. His cancer histology is poorly differentiated. Despite his diagnosis, he has a fully active performance status. The KRAS biomarker analysis shows that he has a wild-type KRAS status."
1659,white,male,71,23.34,FOLFIRI (KRAS mutant),No,Yes,No,No,12,well differentiated,symptoms but ambulatory,mutant,No,No,No,Yes,No,1,"race: white, sex: male, age: 71, bmi: 23.34, treatment arm: FOLFIRI (KRAS mutant), serious adverse effect: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: mutant, adverse effect: infection: Yes","The patient is a 71-year-old white male with a BMI of 23.34. He is undergoing treatment with the FOLFIRI regimen for his well-differentiated histology and mutant KRAS biomarker. He has experienced a serious adverse effect during the treatment, specifically an infection. Despite experiencing symptoms, he is still able to be ambulatory. He has completed 12 cycles of chemotherapy."
1660,white,female,45,26.49,FOLFOX + Cetuximab,Yes,Yes,No,No,12,well differentiated,fully active,mutant,No,No,No,No,No,0,"race: white, sex: female, age: 45, bmi: 26.49, treatment arm: FOLFOX + Cetuximab, adherence: Yes, serious adverse effect: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 45-year-old white female with a BMI of 26.49. She is receiving treatment with FOLFOX + Cetuximab and has been adherent to the treatment. She experienced a serious adverse effect during the treatment. She completed 12 cycles of chemotherapy. The histology of her cancer is well-differentiated. Despite the treatment, her performance status is fully active. The KRAS biomarker analysis showed a mutant status."
1661,white,male,70,28.49,FOLFOX,Yes,No,No,No,12,poorly differentiated,fully active,mutant,No,No,No,No,No,0,"race: white, sex: male, age: 70, bmi: 28.49, treatment arm: FOLFOX, adherence: Yes, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 70-year-old white male with a BMI of 28.49. He is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy with good adherence. His cancer histology is poorly differentiated, and he has a fully active performance status. The KRAS biomarker testing revealed a mutant status."
1662,white,female,66,27.89,FOLFOX,No,No,Yes,No,12,well differentiated,fully active,interminate,No,No,No,No,No,0,"race: white, sex: female, age: 66, bmi: 27.89, treatment arm: FOLFOX, bowel obstruction: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: interminate","The patient is a 66-year-old white female with a BMI of 27.89. She is receiving the FOLFOX treatment arm for her cancer. She has a bowel obstruction and has completed 12 cycles of chemotherapy. The histology of her cancer is well-differentiated. Despite the bowel obstruction, her performance status is fully active. The KRAS biomarker status is indeterminate."
1663,white,male,68,22.79,FOLFOX + Cetuximab,No,Yes,Yes,No,12,well differentiated,symptoms but ambulatory,wild-type,No,No,No,Yes,No,0,"race: white, sex: male, age: 68, bmi: 22.79, treatment arm: FOLFOX + Cetuximab, serious adverse effect: Yes, bowel obstruction: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type, adverse effect: infection: Yes","The patient is a 68-year-old white male with a BMI of 22.79. He is receiving treatment with FOLFOX + Cetuximab and has experienced a serious adverse effect, specifically a bowel obstruction. He has completed 12 cycles of chemotherapy. The histology shows well-differentiated cells, and his performance status indicates that he has symptoms but is still ambulatory. The KRAS biomarker is wild-type. Additionally, he has developed an infection as an adverse effect."
1664,white,female,46,25.16,FOLFOX + Cetuximab,No,No,No,No,5,well differentiated,fully active,mutant,No,No,No,No,No,0,"race: white, sex: female, age: 46, bmi: 25.16, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 5, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 46-year-old white female with a BMI of 25.16. She is receiving treatment in the FOLFOX + Cetuximab treatment arm and has completed 5 cycles of chemotherapy. Her histology shows well-differentiated cancer cells. Despite her cancer diagnosis, her performance status is fully active. The KRAS biomarker testing revealed a mutant status."
1665,white,female,62,20.89,FOLFOX + Cetuximab,No,Yes,No,No,2,well differentiated,fully active,mutant,No,No,Yes,No,No,1,"race: white, sex: female, age: 62, bmi: 20.89, treatment arm: FOLFOX + Cetuximab, serious adverse effect: Yes, chemotherapy cycles: 2, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant, adverse effect: diarrhea: Yes","The patient is a 62-year-old white female with a BMI of 20.89. She is receiving treatment in the FOLFOX + Cetuximab treatment arm. She has experienced a serious adverse effect during her treatment. So far, she has completed 2 cycles of chemotherapy. Her histology shows well-differentiated cells. Despite the serious adverse effect, her performance status is fully active. The KRAS biomarker analysis indicates a mutant status. Additionally, she has experienced diarrhea as an adverse effect."
1666,white,female,58,36.06,FOLFOX + Cetuximab,No,No,No,No,6,well differentiated,fully active,wild-type,No,No,Yes,No,No,0,"race: white, sex: female, age: 58, bmi: 36.06, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 6, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type, adverse effect: diarrhea: Yes",The patient is a 58-year-old white female with a BMI of 36.06 who is undergoing treatment with FOLFOX + Cetuximab for her well-differentiated histology. She has completed 6 cycles of chemotherapy and has a fully active performance status. Her KRAS biomarker is wild-type. She is experiencing diarrhea as an adverse effect of her treatment.
1667,white,male,67,23.86,FOLFOX + Cetuximab,No,No,No,No,2,poorly differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 67, bmi: 23.86, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 2, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 67-year-old white male with a BMI of 23.86. He is receiving treatment in the FOLFOX + Cetuximab treatment arm and has completed 2 cycles of chemotherapy. His histology shows poorly differentiated cancer cells. Despite this, his performance status is fully active. Additionally, his KRAS biomarker indicates that it is wild-type."
1668,white,female,72,28.02,FOLFIRI + Cetuximab,No,No,No,No,3,well differentiated,symptoms but ambulatory,wild-type,No,No,Yes,No,No,0,"race: white, sex: female, age: 72, bmi: 28.02, treatment arm: FOLFIRI + Cetuximab, chemotherapy cycles: 3, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type, adverse effect: diarrhea: Yes","The patient is a 72-year-old white female with a BMI of 28.02 who is currently undergoing treatment with FOLFIRI + Cetuximab. She has completed 3 cycles of chemotherapy. Her histology shows well-differentiated cancer, and she has symptoms but is still able to be ambulatory. Her KRAS biomarker is wild-type. She is experiencing diarrhea as an adverse effect of the treatment."
1669,white,male,66,33.43,FOLFOX,No,No,No,No,12,well differentiated,fully active,mutant,No,No,No,No,No,0,"race: white, sex: male, age: 66, bmi: 33.43, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant",The patient is a 66-year-old white male with a BMI of 33.43. He is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. The histology shows well-differentiated cells. The patient has a fully active performance status. The KRAS biomarker analysis indicates a mutant status.
1670,white,female,68,30.12,FOLFOX,No,No,No,No,12,well differentiated,fully active,mutant,No,No,No,No,No,0,"race: white, sex: female, age: 68, bmi: 30.12, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 68-year-old white female with a BMI of 30.12. She is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. The histology of her cancer is well differentiated. Despite her age, she has a fully active performance status. The KRAS biomarker testing revealed a mutant status."
1671,white,male,60,26.78,FOLFOX,No,Yes,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 60, bmi: 26.78, treatment arm: FOLFOX, serious adverse effect: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","This patient is a 60-year-old white male with a BMI of 26.78. He is undergoing treatment with the FOLFOX regimen and has experienced a serious adverse effect. He has completed 12 cycles of chemotherapy. The histology of his cancer is well differentiated. Despite his treatment, he maintains a fully active performance status. His KRAS biomarker status is wild-type."
1672,white,male,55,41.95,FOLFIRI + Cetuximab,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 55, bmi: 41.95, treatment arm: FOLFIRI + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 55-year-old white male with a BMI of 41.95. He is receiving treatment with FOLFIRI + Cetuximab and has completed 12 cycles of chemotherapy. His cancer histology is well-differentiated, and he has a fully active performance status. The KRAS biomarker testing shows that he has a wild-type KRAS status."
1673,white,male,64,23.56,FOLFOX,No,No,Yes,Yes,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 64, bmi: 23.56, treatment arm: FOLFOX, bowel obstruction: Yes, bowel perforation: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","This patient is a 64-year-old white male with a BMI of 23.56. He is receiving treatment with the FOLFOX regimen and has experienced both a bowel obstruction and perforation. He has completed 12 cycles of chemotherapy. The histology of his cancer is well differentiated. Despite the bowel complications, his performance status is fully active. His KRAS biomarker status is wild-type."
1674,white,female,69,25.47,FOLFOX + Cetuximab,No,Yes,No,No,12,well differentiated,fully active,mutant,No,No,No,No,No,0,"race: white, sex: female, age: 69, bmi: 25.47, treatment arm: FOLFOX + Cetuximab, serious adverse effect: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 69-year-old white female with a BMI of 25.47. She is receiving treatment with FOLFOX + Cetuximab and has experienced a serious adverse effect. She has undergone 12 cycles of chemotherapy. The histology shows that the cancer is well-differentiated. Despite the treatment, her performance status is fully active. The KRAS biomarker indicates that it is mutant."
1675,white,male,61,30.03,FOLFOX + Cetuximab,Yes,No,No,Yes,12,well differentiated,symptoms but ambulatory,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 61, bmi: 30.03, treatment arm: FOLFOX + Cetuximab, adherence: Yes, bowel perforation: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type","The patient is a 61-year-old white male with a BMI of 30.03. He is receiving treatment in the FOLFOX + Cetuximab treatment arm and has been adherent to the treatment. He experienced a bowel perforation and has completed 12 cycles of chemotherapy. The histology shows well-differentiated cells. Despite experiencing symptoms, the patient is still ambulatory. His KRAS biomarker is wild-type."
1676,white,female,47,30.98,FOLFOX,No,No,No,No,12,well differentiated,fully active,mutant,No,No,No,No,No,0,"race: white, sex: female, age: 47, bmi: 30.98, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 47-year-old white female with a BMI of 30.98. She is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cancer cells. Despite her cancer diagnosis, she has a fully active performance status. The patient's KRAS biomarker is mutant."
1677,white,male,64,24.1,FOLFIRI,No,No,No,No,10,well differentiated,fully active,wild-type,No,No,No,No,No,1,"race: white, sex: male, age: 64, bmi: 24.1, treatment arm: FOLFIRI, chemotherapy cycles: 10, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 64-year-old white male with a BMI of 24.1. He is receiving treatment with the FOLFIRI chemotherapy regimen and has completed 10 cycles of chemotherapy. His cancer histology is well-differentiated, and he has a fully active performance status. The KRAS biomarker testing showed that he has a wild-type KRAS status."
1678,black,female,51,21.02,FOLFOX,No,No,No,No,12,well differentiated,symptoms but ambulatory,mutant,No,No,No,No,No,0,"race: black, sex: female, age: 51, bmi: 21.02, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: mutant","The patient is a 51-year-old Black female with a BMI of 21.02. She is undergoing treatment with the FOLFOX chemotherapy regimen and has completed 12 cycles. Her histology shows well-differentiated cancer cells. Despite experiencing symptoms, she is still able to walk around (ambulatory). The KRAS biomarker testing revealed a mutant status."
1679,white,female,48,32.66,FOLFOX,Yes,No,Yes,No,6,well differentiated,fully active,wild-type,No,No,No,No,No,1,"race: white, sex: female, age: 48, bmi: 32.66, treatment arm: FOLFOX, adherence: Yes, bowel obstruction: Yes, chemotherapy cycles: 6, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type",The patient is a 48-year-old white female with a BMI of 32.66. She is receiving treatment with FOLFOX and has been adherent to the treatment. She has experienced a bowel obstruction. The patient has completed 6 cycles of chemotherapy. The histology shows well-differentiated cancer cells. Her performance status is fully active. The KRAS biomarker indicates that she has a wild-type KRAS gene.
1680,white,male,50,25.08,FOLFIRI + Cetuximab,No,No,No,No,10,well differentiated,fully active,wild-type,No,No,No,No,No,1,"race: white, sex: male, age: 50, bmi: 25.08, treatment arm: FOLFIRI + Cetuximab, chemotherapy cycles: 10, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 50-year-old white male with a BMI of 25.08. He is receiving treatment with FOLFIRI + Cetuximab and has completed 10 cycles of chemotherapy. His cancer histology is well-differentiated, and he has a fully active performance status. The KRAS biomarker testing showed that he has a wild-type KRAS status."
1681,white,female,59,21.29,FOLFOX + Cetuximab,No,No,Yes,No,12,well differentiated,symptoms but ambulatory,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 59, bmi: 21.29, treatment arm: FOLFOX + Cetuximab, bowel obstruction: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type","This patient is a 59-year-old white female with a BMI of 21.29. She is receiving treatment with FOLFOX + Cetuximab for her cancer. She has experienced a bowel obstruction and has completed 12 cycles of chemotherapy. The histology of her cancer is well differentiated. Despite experiencing symptoms, she is still able to be ambulatory. Additionally, her KRAS biomarker is wild-type."
1682,white,male,42,31.62,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,fully active,mutant,No,No,No,No,No,0,"race: white, sex: male, age: 42, bmi: 31.62, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant",The patient is a 42-year-old white male with a BMI of 31.62. He is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cells. The patient has a fully active performance status. The KRAS biomarker indicates a mutant status.
1683,white,male,45,30.42,FOLFOX,Yes,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 45, bmi: 30.42, treatment arm: FOLFOX, adherence: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type",The patient is a 45-year-old white male with a BMI of 30.42. He is enrolled in the FOLFOX treatment arm and has been adherent to the treatment. He has completed 12 cycles of chemotherapy. His histology shows well-differentiated cells. The patient has a fully active performance status. His KRAS biomarker is wild-type.
1684,white,male,46,27.32,FOLFOX + Cetuximab,No,No,No,No,4,well differentiated,fully active,mutant,No,No,No,No,No,0,"race: white, sex: male, age: 46, bmi: 27.32, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 4, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant",The patient is a 46-year-old white male with a BMI of 27.32. He is receiving treatment with FOLFOX + Cetuximab and has completed 4 cycles of chemotherapy. His cancer histology is well-differentiated. The patient has a fully active performance status. The KRAS biomarker testing revealed a mutant status.
1685,black,male,40,21.61,FOLFOX + Cetuximab,No,No,Yes,No,10,well differentiated,fully active,mutant,Yes,No,No,No,No,0,"race: black, sex: male, age: 40, bmi: 21.61, treatment arm: FOLFOX + Cetuximab, bowel obstruction: Yes, chemotherapy cycles: 10, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant, adverse effect: thrombosis: Yes","The patient is a 40-year-old Black male with a BMI of 21.61. He is receiving treatment with FOLFOX + Cetuximab for his well-differentiated histology. He has experienced a bowel obstruction and has completed 10 cycles of chemotherapy. Despite this, his performance status is fully active. The patient has a mutant KRAS biomarker and has also experienced thrombosis as an adverse effect."
1686,white,male,56,25.91,FOLFOX + Cetuximab,No,No,No,No,8,well differentiated,fully active,mutant,No,Yes,No,No,No,0,"race: white, sex: male, age: 56, bmi: 25.91, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 8, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant, adverse effect: hypersensitivity: Yes",The patient is a 56-year-old white male with a BMI of 25.91 who is receiving treatment with FOLFOX + Cetuximab for his well-differentiated cancer. He has completed 8 cycles of chemotherapy and has a fully active performance status. The patient's KRAS biomarker is mutant. He has experienced a hypersensitivity reaction as an adverse effect.
1687,white,female,40,25.62,FOLFOX + Cetuximab,No,Yes,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 40, bmi: 25.62, treatment arm: FOLFOX + Cetuximab, serious adverse effect: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 40-year-old white female with a BMI of 25.62. She is receiving treatment with FOLFOX + Cetuximab and has experienced a serious adverse effect. She has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cells, and her performance status is fully active. The KRAS biomarker indicates that she has a wild-type gene."
1688,white,female,60,22.5,FOLFOX + Cetuximab,No,Yes,No,No,3,well differentiated,symptoms but ambulatory,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 60, bmi: 22.5, treatment arm: FOLFOX + Cetuximab, serious adverse effect: Yes, chemotherapy cycles: 3, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type","The patient is a 60-year-old white female with a BMI of 22.5. She is receiving treatment with FOLFOX + Cetuximab and has experienced a serious adverse effect. She has completed 3 cycles of chemotherapy. Her histology shows well-differentiated cells. Despite experiencing symptoms, she is still able to be ambulatory. Her KRAS biomarker indicates that it is wild-type."
1689,white,male,56,26.83,FOLFOX,No,Yes,No,No,1,well differentiated,fully active,interminate,No,No,No,No,No,0,"race: white, sex: male, age: 56, bmi: 26.83, treatment arm: FOLFOX, serious adverse effect: Yes, chemotherapy cycles: 1, histology: well differentiated, performance status: fully active, KRAS biomarker: interminate","The patient is a 56-year-old white male with a BMI of 26.83 who is receiving the FOLFOX treatment regimen. He has experienced a serious adverse effect after completing one cycle of chemotherapy. The histology shows that the cancer is well-differentiated. Despite the adverse effect, the patient's performance status is fully active. The KRAS biomarker status is indeterminate."
1690,white,female,70,18.07,FOLFOX,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 70, bmi: 18.07, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type",The patient is a 70-year-old white female with a BMI of 18.07. She is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. The histology shows well-differentiated cancer cells. The patient has a fully active performance status. The KRAS biomarker indicates that she has a wild-type mutation.
1691,white,male,38,29.76,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,1,"race: white, sex: male, age: 38, bmi: 29.76, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type",The patient is a 38-year-old white male with a BMI of 29.76. He is receiving treatment in the FOLFOX + Cetuximab treatment arm and is scheduled for 12 chemotherapy cycles. The histology indicates well-differentiated cancer. The patient has a fully active performance status and the KRAS biomarker is wild-type.
1692,white,female,66,25.51,FOLFIRI,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 66, bmi: 25.51, treatment arm: FOLFIRI, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 66-year-old white female with a BMI of 25.51. She is receiving the FOLFIRI treatment regimen and has completed 12 cycles of chemotherapy. Her cancer histology is well-differentiated, and she has a fully active performance status. Additionally, her KRAS biomarker status is wild-type."
1693,black,female,52,25.97,FOLFOX + Cetuximab,Yes,No,No,No,5,well differentiated,fully active,mutant,No,Yes,No,No,No,0,"race: black, sex: female, age: 52, bmi: 25.97, treatment arm: FOLFOX + Cetuximab, adherence: Yes, chemotherapy cycles: 5, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant, adverse effect: hypersensitivity: Yes","The patient is a 52-year-old Black female with a BMI of 25.97. She is receiving treatment in the FOLFOX + Cetuximab treatment arm and has been adherent to her chemotherapy regimen, completing 5 cycles. Her histology shows well-differentiated cancer, and she has a fully active performance status. The KRAS biomarker testing revealed a mutant status. The patient experienced a hypersensitivity adverse effect during treatment."
1694,white,female,37,26.99,FOLFOX,No,No,No,No,12,well differentiated,fully active,mutant,No,No,No,No,No,0,"race: white, sex: female, age: 37, bmi: 26.99, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant",The patient is a 37-year-old white female with a BMI of 26.99. She is receiving the FOLFOX treatment arm and has completed 12 cycles of chemotherapy. The histology shows well-differentiated cancer cells. The patient has a fully active performance status. The KRAS biomarker indicates a mutant status.
1695,white,female,76,24.44,FOLFIRI,No,No,No,No,12,well differentiated,symptoms but ambulatory,mutant,No,No,No,No,No,1,"race: white, sex: female, age: 76, bmi: 24.44, treatment arm: FOLFIRI, chemotherapy cycles: 12, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: mutant","The patient is a 76-year-old white female with a BMI of 24.44. She is undergoing treatment with the FOLFIRI chemotherapy regimen and has completed 12 cycles. Her histology shows well-differentiated cancer cells. Despite experiencing symptoms, she is still able to ambulate. The KRAS biomarker analysis indicates a mutant status."
1696,white,male,63,31.35,FOLFOX,Yes,No,No,No,12,poorly differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 63, bmi: 31.35, treatment arm: FOLFOX, adherence: Yes, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 63-year-old white male with a BMI of 31.35. He is receiving the FOLFOX treatment regimen and has been adherent to the treatment. He has completed 12 cycles of chemotherapy. His histology shows poorly differentiated cancer cells. Despite this, his performance status is fully active. The KRAS biomarker analysis indicates that he has a wild-type KRAS status."
1697,other,female,58,36.89,FOLFOX + Cetuximab,No,Yes,No,No,1,well differentiated,fully active,wild-type,Yes,No,No,No,Yes,0,"race: other, sex: female, age: 58, bmi: 36.89, treatment arm: FOLFOX + Cetuximab, serious adverse effect: Yes, chemotherapy cycles: 1, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type, adverse effect: thrombosis: Yes, adverse effect: infarction: Yes","The patient is a 58-year-old female of a race other than specified, with a BMI of 36.89. She is receiving treatment in the FOLFOX + Cetuximab treatment arm and has experienced serious adverse effects after one chemotherapy cycle. The histology shows that the cancer is well-differentiated. Despite the serious adverse effects, the patient's performance status is fully active. The KRAS biomarker indicates that the cancer is wild-type. Additionally, the patient has experienced adverse effects of thrombosis and infarction."
1698,white,male,74,47.85,FOLFOX + Cetuximab,No,Yes,No,No,2,poorly differentiated,fully active,wild-type,No,No,No,No,No,1,"race: white, sex: male, age: 74, bmi: 47.85, treatment arm: FOLFOX + Cetuximab, serious adverse effect: Yes, chemotherapy cycles: 2, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 74-year-old white male with a BMI of 47.85. He is receiving treatment with FOLFOX + Cetuximab and has experienced a serious adverse effect. He has completed 2 cycles of chemotherapy. His histology shows poorly differentiated cells. Despite this, his performance status is fully active. The KRAS biomarker indicates that he has a wild-type status."
1699,white,female,67,37.01,FOLFOX + Cetuximab,No,No,No,No,0,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 67, bmi: 37.01, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 0, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 67-year-old white female with a BMI of 37.01. She is enrolled in the treatment arm receiving FOLFOX + Cetuximab but has not started chemotherapy cycles yet. Her cancer histology is well-differentiated, and she has a fully active performance status. The KRAS biomarker indicates that she has a wild-type mutation."
1700,white,female,37,22.22,FOLFOX,No,No,No,Yes,5,poorly differentiated,fully active,wild-type,No,No,No,Yes,No,0,"race: white, sex: female, age: 37, bmi: 22.22, treatment arm: FOLFOX, bowel perforation: Yes, chemotherapy cycles: 5, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type, adverse effect: infection: Yes","The patient is a 37-year-old white female with a BMI of 22.22 who is receiving the FOLFOX treatment regimen. She has experienced a bowel perforation and has completed 5 cycles of chemotherapy. The histology of her cancer is poorly differentiated. Despite these challenges, her performance status is fully active. Her KRAS biomarker status is wild-type. Additionally, she has developed an infection as an adverse effect of her treatment."
1701,white,female,54,26.04,FOLFOX,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 54, bmi: 26.04, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type",The patient is a 54-year-old white female with a BMI of 26.04. She is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. The histology shows well-differentiated cancer cells. The patient has a fully active performance status. The KRAS biomarker analysis indicates that she has a wild-type KRAS status.
1702,white,female,75,28.68,FOLFOX,No,No,Yes,No,10,well differentiated,symptoms but ambulatory,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 75, bmi: 28.68, treatment arm: FOLFOX, bowel obstruction: Yes, chemotherapy cycles: 10, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type","The patient is a 75-year-old white female with a BMI of 28.68. She is receiving the FOLFOX treatment regimen and has experienced a bowel obstruction. She has completed 10 cycles of chemotherapy. The histology shows well-differentiated cancer cells. Despite experiencing symptoms, the patient is still able to be ambulatory. The KRAS biomarker indicates that the cancer is wild-type."
1703,white,female,74,20.8,FOLFIRI,No,Yes,No,No,12,well differentiated,fully active,interminate,No,No,No,No,No,0,"race: white, sex: female, age: 74, bmi: 20.8, treatment arm: FOLFIRI, serious adverse effect: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: interminate","The patient is a 74-year-old white female with a BMI of 20.8. She is receiving treatment with the FOLFIRI regimen and has experienced a serious adverse effect. She has completed 12 cycles of chemotherapy. The histology of her cancer is well-differentiated. Despite the adverse effect, her performance status is fully active. The KRAS biomarker status is indeterminate."
1704,white,male,49,31.07,FOLFOX + Cetuximab,No,No,No,No,12,poorly differentiated,symptoms but ambulatory,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 49, bmi: 31.07, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: poorly differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type","The patient is a 49-year-old white male with a BMI of 31.07. He is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. His histology shows poorly differentiated cancer. Despite experiencing symptoms, he is still able to be ambulatory. The KRAS biomarker indicates that he has a wild-type status."
1705,white,female,62,31.57,FOLFOX,No,No,No,No,12,poorly differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 62, bmi: 31.57, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 62-year-old white female with a BMI of 31.57. She is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. Her histology indicates poorly differentiated cancer. Despite this, her performance status is fully active. Additionally, her KRAS biomarker shows that it is wild-type."
1706,white,female,60,37.11,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,fully active,mutant,No,No,No,No,No,0,"race: white, sex: female, age: 60, bmi: 37.11, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant",The patient is a 60-year-old white female with a BMI of 37.11. She is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cancer cells. The patient has a fully active performance status. The KRAS biomarker analysis indicates a mutant status.
1707,white,female,42,45.79,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,symptoms but ambulatory,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 42, bmi: 45.79, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type","The patient is a 42-year-old white female with a BMI of 45.79. She is receiving treatment with FOLFOX and Cetuximab and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cells. Despite experiencing symptoms, she is still able to walk around (ambulatory). The KRAS biomarker analysis indicates that she has a wild-type KRAS gene."
1708,white,male,75,25.96,FOLFOX,No,No,No,No,12,well differentiated,symptoms but ambulatory,interminate,No,No,No,No,No,0,"race: white, sex: male, age: 75, bmi: 25.96, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: interminate","The patient is a 75-year-old white male with a BMI of 25.96. He is undergoing treatment with the FOLFOX chemotherapy regimen and has completed 12 cycles so far. The histology of his cancer is well-differentiated. Despite experiencing symptoms, he is still able to be ambulatory. The KRAS biomarker status is indeterminate for this patient."
1709,white,female,58,23.18,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,Yes,No,No,1,"race: white, sex: female, age: 58, bmi: 23.18, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type, adverse effect: diarrhea: Yes","The patient is a 58-year-old white female with a BMI of 23.18. She is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cancer, and she has a fully active performance status. The KRAS biomarker indicates that she has a wild-type gene. The patient is experiencing diarrhea as an adverse effect of the treatment."
1710,white,male,52,27.75,FOLFOX + Cetuximab,No,Yes,No,Yes,8,well differentiated,fully active,mutant,Yes,No,No,No,No,0,"race: white, sex: male, age: 52, bmi: 27.75, treatment arm: FOLFOX + Cetuximab, serious adverse effect: Yes, bowel perforation: Yes, chemotherapy cycles: 8, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant, adverse effect: thrombosis: Yes","The patient is a 52-year-old white male with a BMI of 27.75. He is receiving treatment with FOLFOX + Cetuximab and has experienced a serious adverse effect in the form of a bowel perforation. He has completed 8 cycles of chemotherapy. The histology shows well-differentiated cells, and his performance status is fully active. The KRAS biomarker is mutant, and he has also experienced an adverse effect of thrombosis."
1711,white,male,67,23.02,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 67, bmi: 23.02, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type",The patient is a 67-year-old white male with a BMI of 23.02. He is receiving treatment in the FOLFOX + Cetuximab treatment arm and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer cells. The patient has a fully active performance status and his KRAS biomarker is wild-type.
1712,black,female,65,30.15,FOLFOX + Cetuximab,Yes,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: black, sex: female, age: 65, bmi: 30.15, treatment arm: FOLFOX + Cetuximab, adherence: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type",The patient is a 65-year-old Black female with a BMI of 30.15. She is receiving treatment with FOLFOX + Cetuximab and has been adherent to the treatment plan. She has completed 12 cycles of chemotherapy. The histology shows that the cancer is well-differentiated. The patient has a fully active performance status. The KRAS biomarker is wild-type.
1713,white,male,37,22.28,FOLFOX,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 37, bmi: 22.28, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 37-year-old white male with a BMI of 22.28. He is receiving the FOLFOX treatment arm and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cells, and he has a fully active performance status. The KRAS biomarker indicates that he has a wild-type status."
1714,black,female,49,21.71,FOLFOX,Yes,No,Yes,No,12,well differentiated,fully active,mutant,No,No,Yes,No,No,0,"race: black, sex: female, age: 49, bmi: 21.71, treatment arm: FOLFOX, adherence: Yes, bowel obstruction: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant, adverse effect: diarrhea: Yes","The patient is a 49-year-old Black female with a BMI of 21.71 who is receiving the FOLFOX treatment regimen. She has been adherent to her treatment. She has experienced a bowel obstruction and has completed 12 cycles of chemotherapy. The histology shows that the cancer is well-differentiated. Despite the bowel obstruction, her performance status is fully active. The KRAS biomarker testing revealed a mutant status. The patient has also experienced diarrhea as an adverse effect of the treatment."
1715,white,female,52,27.53,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 52, bmi: 27.53, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 52-year-old white female with a BMI of 27.53. She is receiving treatment in the FOLFOX + Cetuximab treatment arm and is scheduled for 12 chemotherapy cycles. Her histology shows well-differentiated cells, and she has a fully active performance status. Additionally, her KRAS biomarker indicates that it is wild-type."
1716,white,female,72,23.5,FOLFOX + Cetuximab,No,No,Yes,No,6,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 72, bmi: 23.5, treatment arm: FOLFOX + Cetuximab, bowel obstruction: Yes, chemotherapy cycles: 6, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","This patient is a 72-year-old white female with a BMI of 23.5. She is receiving treatment with FOLFOX + Cetuximab for her cancer. She has experienced a bowel obstruction and has completed 6 cycles of chemotherapy. The histology of her cancer is well-differentiated. Despite her condition, she has a fully active performance status. Her KRAS biomarker status is wild-type."
1717,black,female,54,36.29,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,fully active,interminate,No,No,No,No,No,0,"race: black, sex: female, age: 54, bmi: 36.29, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: interminate",The patient is a 54-year-old Black female with a BMI of 36.29. She is receiving treatment in the FOLFOX + Cetuximab treatment arm and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cancer cells. The patient has a fully active performance status and her KRAS biomarker status is indeterminate.
1718,white,female,50,28.05,FOLFOX,No,No,Yes,No,12,well differentiated,symptoms but ambulatory,mutant,No,No,No,No,No,0,"race: white, sex: female, age: 50, bmi: 28.05, treatment arm: FOLFOX, bowel obstruction: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: mutant","The patient is a 50-year-old white female with a BMI of 28.05 who is undergoing treatment with FOLFOX chemotherapy. She has experienced a bowel obstruction and has completed 12 cycles of chemotherapy. The histology shows well-differentiated cells, and her performance status indicates that she has symptoms but is still able to walk around. Additionally, the KRAS biomarker testing revealed a mutant status."
1719,other,male,43,29.38,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: other, sex: male, age: 43, bmi: 29.38, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 43-year-old male of a race categorized as ""other"" with a BMI of 29.38. He is receiving treatment in the FOLFOX + Cetuximab treatment arm and has completed 12 cycles of chemotherapy. The histology indicates well-differentiated cancer, and the patient's performance status is fully active. The KRAS biomarker shows that the patient has a wild-type status."
1720,white,male,55,28.58,FOLFOX + Cetuximab,No,No,Yes,No,12,well differentiated,symptoms but ambulatory,wild-type,Yes,No,No,Yes,No,0,"race: white, sex: male, age: 55, bmi: 28.58, treatment arm: FOLFOX + Cetuximab, bowel obstruction: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type, adverse effect: thrombosis: Yes, adverse effect: infection: Yes","The patient is a 55-year-old white male with a BMI of 28.58 who is receiving treatment with FOLFOX + Cetuximab. He has a bowel obstruction and has completed 12 cycles of chemotherapy. The histology shows well-differentiated cells, and his performance status is symptomatic but still able to walk around. His KRAS biomarker is wild-type. The patient has experienced adverse effects including thrombosis and infection."
1721,black,male,60,35.17,FOLFOX + Cetuximab,No,Yes,No,No,12,well differentiated,symptoms but ambulatory,mutant,No,No,No,No,No,0,"race: black, sex: male, age: 60, bmi: 35.17, treatment arm: FOLFOX + Cetuximab, serious adverse effect: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: mutant","The patient is a 60-year-old Black male with a BMI of 35.17. He is receiving treatment with FOLFOX + Cetuximab and has experienced a serious adverse effect. He has completed 12 cycles of chemotherapy. Histologically, the tumor is well-differentiated. Despite experiencing symptoms, the patient is still able to ambulate. The KRAS biomarker testing revealed a mutant status."
1722,white,male,43,47.38,FOLFOX,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 43, bmi: 47.38, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type",The patient is a 43-year-old white male with a BMI of 47.38. He is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer cells. The patient has a fully active performance status and his KRAS biomarker is wild-type.
1723,white,male,57,40.68,FOLFOX,No,No,No,No,12,well differentiated,symptoms but ambulatory,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 57, bmi: 40.68, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type","The patient is a 57-year-old white male with a BMI of 40.68. He is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. The histology shows well-differentiated cancer cells. Despite experiencing symptoms, the patient is still able to walk around (ambulatory). The KRAS biomarker analysis indicates that the patient has a wild-type KRAS status."
1724,white,female,44,20.6,FOLFOX,No,No,No,No,10,well differentiated,fully active,wild-type,No,No,Yes,No,No,0,"race: white, sex: female, age: 44, bmi: 20.6, treatment arm: FOLFOX, chemotherapy cycles: 10, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type, adverse effect: diarrhea: Yes",The patient is a 44-year-old white female with a BMI of 20.6 who is receiving the FOLFOX treatment regimen. She has completed 10 cycles of chemotherapy. Her histology shows well-differentiated cancer cells. The patient has a fully active performance status and her KRAS biomarker is wild-type. She is experiencing diarrhea as an adverse effect of the treatment.
1725,white,male,67,29.98,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 67, bmi: 29.98, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 67-year-old white male with a BMI of 29.98. He is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. His cancer histology is well-differentiated, and he has a fully active performance status. The KRAS biomarker analysis indicates that he has a wild-type KRAS status."
1726,other,female,60,26.27,FOLFOX + Cetuximab,No,No,No,No,12,poorly differentiated,fully active,wild-type,No,No,No,No,No,0,"race: other, sex: female, age: 60, bmi: 26.27, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 60-year-old female of a race other than Caucasian. She has a BMI of 26.27 and is receiving treatment with FOLFOX + Cetuximab. She is scheduled for 12 cycles of chemotherapy. The histology of her cancer is poorly differentiated. Despite her diagnosis, she has a fully active performance status. Additionally, her KRAS biomarker status is wild-type."
1727,white,female,61,26.25,FOLFOX + Cetuximab,Yes,No,Yes,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 61, bmi: 26.25, treatment arm: FOLFOX + Cetuximab, adherence: Yes, bowel obstruction: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 61-year-old white female with a BMI of 26.25. She is receiving treatment in the FOLFOX + Cetuximab treatment arm and has been adherent to her treatment. She has experienced a bowel obstruction. The patient has completed 12 cycles of chemotherapy and has well-differentiated histology. Her performance status is fully active, and her KRAS biomarker is wild-type."
1728,white,female,45,23.84,FOLFOX + Cetuximab,No,Yes,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 45, bmi: 23.84, treatment arm: FOLFOX + Cetuximab, serious adverse effect: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 45-year-old white female with a BMI of 23.84. She is receiving treatment with FOLFOX + Cetuximab and has experienced a serious adverse effect. She has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cells, and her performance status is fully active. The KRAS biomarker indicates that she has a wild-type status."
1729,black,male,37,20.9,FOLFOX,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,1,"race: black, sex: male, age: 37, bmi: 20.9, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type",The patient is a 37-year-old Black male with a BMI of 20.9. He is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer cells. The patient has a fully active performance status and his KRAS biomarker is wild-type.
1730,white,male,57,39.84,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,1,"race: white, sex: male, age: 57, bmi: 39.84, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 57-year-old white male with a BMI of 39.84. He is receiving treatment in the FOLFOX + Cetuximab treatment arm and is scheduled for 12 chemotherapy cycles. His cancer histology is well-differentiated, and he has a fully active performance status. The KRAS biomarker analysis shows that he has a wild-type KRAS status."
1731,white,female,45,24.17,FOLFOX,No,Yes,No,No,12,well differentiated,fully active,mutant,No,No,No,No,No,0,"race: white, sex: female, age: 45, bmi: 24.17, treatment arm: FOLFOX, serious adverse effect: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 45-year-old white female with a BMI of 24.17. She is receiving treatment with the FOLFOX chemotherapy regimen and has experienced a serious adverse effect. She has completed 12 cycles of chemotherapy. The histology of her cancer is well-differentiated. Despite the adverse effect, her performance status is fully active. Additionally, the KRAS biomarker testing revealed a mutant status."
1732,white,male,46,36.42,FOLFOX + Cetuximab,No,No,Yes,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 46, bmi: 36.42, treatment arm: FOLFOX + Cetuximab, bowel obstruction: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type",The patient is a 46-year-old white male with a BMI of 36.42. He is receiving treatment in the FOLFOX + Cetuximab treatment arm. He has a bowel obstruction and has completed 12 cycles of chemotherapy. The histology shows well-differentiated cells. The patient has a fully active performance status. The KRAS biomarker indicates that he has a wild-type status.
1733,white,female,76,27.18,FOLFOX + Cetuximab,No,No,No,No,11,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 76, bmi: 27.18, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 11, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 76-year-old white female with a BMI of 27.18. She is currently receiving treatment in the FOLFOX + Cetuximab treatment arm and has completed 11 cycles of chemotherapy. Her histology shows well-differentiated cancer cells. Despite her age, she has a fully active performance status. Additionally, her KRAS biomarker indicates that it is wild-type."
1734,white,male,59,24.3,FOLFIRI,Yes,Yes,No,Yes,9,well differentiated,fully active,mutant,No,No,Yes,No,No,0,"race: white, sex: male, age: 59, bmi: 24.3, treatment arm: FOLFIRI, adherence: Yes, serious adverse effect: Yes, bowel perforation: Yes, chemotherapy cycles: 9, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant, adverse effect: diarrhea: Yes","The patient is a 59-year-old white male with a BMI of 24.3 who is receiving treatment with the FOLFIRI regimen. He has been adherent to the treatment. Unfortunately, he experienced a serious adverse effect in the form of a bowel perforation after completing 9 cycles of chemotherapy. The histology of his cancer is well differentiated, and his performance status is fully active. The KRAS biomarker testing revealed a mutant status. Additionally, he has been experiencing diarrhea as an adverse effect of the treatment."
1735,white,female,41,23.05,FOLFOX,No,Yes,No,No,12,well differentiated,fully active,mutant,No,No,No,No,No,0,"race: white, sex: female, age: 41, bmi: 23.05, treatment arm: FOLFOX, serious adverse effect: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 41-year-old white female with a BMI of 23.05. She is receiving the FOLFOX treatment arm for her well-differentiated histology. She has experienced a serious adverse effect during her 12 chemotherapy cycles. Despite this, her performance status is fully active. Additionally, the KRAS biomarker testing revealed a mutant status."
1736,black,female,40,22.04,FOLFOX,No,No,No,No,6,well differentiated,fully active,mutant,No,No,No,No,No,1,"race: black, sex: female, age: 40, bmi: 22.04, treatment arm: FOLFOX, chemotherapy cycles: 6, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 40-year-old Black female with a BMI of 22.04. She is receiving the FOLFOX treatment arm and has completed 6 cycles of chemotherapy. Her histology shows well-differentiated cells, and she has a fully active performance status. The KRAS biomarker analysis indicates a mutant status."
1737,white,male,68,28.42,FOLFOX,No,No,No,No,12,well differentiated,symptoms but ambulatory,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 68, bmi: 28.42, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type","The patient is a 68-year-old white male with a BMI of 28.42. He is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer cells. Despite experiencing symptoms, he is still able to walk around (ambulatory). The KRAS biomarker analysis indicates that he has a wild-type KRAS status."
1738,white,male,64,34.37,FOLFOX,No,Yes,No,No,12,poorly differentiated,fully active,interminate,No,No,No,No,No,0,"race: white, sex: male, age: 64, bmi: 34.37, treatment arm: FOLFOX, serious adverse effect: Yes, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: interminate","The patient is a 64-year-old white male with a BMI of 34.37. He is receiving the FOLFOX treatment arm and has experienced a serious adverse effect. He has undergone 12 cycles of chemotherapy. The histology shows poorly differentiated cancer cells. Despite this, his performance status is fully active. The KRAS biomarker status is indeterminate."
1739,white,male,51,42.09,FOLFOX + Cetuximab,No,No,No,No,12,poorly differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 51, bmi: 42.09, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 51-year-old white male with a BMI of 42.09. He is receiving treatment in the FOLFOX + Cetuximab treatment arm and is scheduled for 12 chemotherapy cycles. The histology indicates poorly differentiated cancer. Despite this, the patient has a fully active performance status. The KRAS biomarker shows that the patient has a wild-type status."
1740,white,male,34,27.39,FOLFOX,No,No,No,No,12,well differentiated,symptoms but ambulatory,mutant,No,No,No,No,No,0,"race: white, sex: male, age: 34, bmi: 27.39, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: mutant","The patient is a 34-year-old white male with a BMI of 27.39. He is receiving the FOLFOX treatment regimen and is scheduled for 12 cycles of chemotherapy. His histology shows well-differentiated cells. Despite experiencing symptoms, he is still able to walk around (ambulatory). The KRAS biomarker analysis indicates a mutant status."
1741,white,male,63,36.61,FOLFOX,No,No,No,No,12,well differentiated,fully active,mutant,No,No,No,No,No,0,"race: white, sex: male, age: 63, bmi: 36.61, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 63-year-old white male with a BMI of 36.61. He is receiving the FOLFOX treatment arm and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cells, and he has a fully active performance status. The KRAS biomarker analysis indicates a mutant status."
1742,white,male,73,25.4,FOLFOX + Cetuximab,Yes,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 73, bmi: 25.4, treatment arm: FOLFOX + Cetuximab, adherence: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type",The patient is a 73-year-old white male with a BMI of 25.4. He is receiving treatment in the FOLFOX + Cetuximab treatment arm and has been adherent to the treatment. He has completed 12 chemotherapy cycles. The histology shows well-differentiated cancer cells. The patient has a fully active performance status. His KRAS biomarker is wild-type.
1743,black,female,71,27.48,FOLFOX,No,Yes,No,No,10,poorly differentiated,symptoms but ambulatory,wild-type,No,No,No,No,No,0,"race: black, sex: female, age: 71, bmi: 27.48, treatment arm: FOLFOX, serious adverse effect: Yes, chemotherapy cycles: 10, histology: poorly differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type","The patient is a 71-year-old Black female with a BMI of 27.48. She is receiving the FOLFOX treatment arm and has experienced a serious adverse effect. She has undergone 10 cycles of chemotherapy. The histology of her cancer is poorly differentiated. Despite experiencing symptoms, she is still ambulatory. Her KRAS biomarker shows that it is wild-type."
1744,white,female,42,31.22,FOLFOX + Cetuximab,No,No,No,No,3,poorly differentiated,symptoms but ambulatory,wild-type,No,No,No,Yes,No,0,"race: white, sex: female, age: 42, bmi: 31.22, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 3, histology: poorly differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type, adverse effect: infection: Yes","The patient is a 42-year-old white female with a BMI of 31.22. She is currently undergoing treatment with FOLFOX + Cetuximab and has completed 3 cycles of chemotherapy. Her histology shows poorly differentiated cancer cells. Despite experiencing symptoms, she is still able to be ambulatory. The KRAS biomarker testing revealed that she has a wild-type KRAS status. Additionally, she has developed an infection as an adverse effect of the treatment."
1745,white,male,55,25.26,FOLFOX + Cetuximab,No,No,Yes,No,2,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 55, bmi: 25.26, treatment arm: FOLFOX + Cetuximab, bowel obstruction: Yes, chemotherapy cycles: 2, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type",The patient is a 55-year-old white male with a BMI of 25.26. He is receiving treatment in the FOLFOX + Cetuximab treatment arm. He has a bowel obstruction and has completed 2 cycles of chemotherapy. The histology shows well-differentiated cells. The patient has a fully active performance status. His KRAS biomarker is wild-type.
1746,white,male,55,27.13,FOLFOX + Cetuximab,No,No,Yes,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 55, bmi: 27.13, treatment arm: FOLFOX + Cetuximab, bowel obstruction: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type",The patient is a 55-year-old white male with a BMI of 27.13. He is receiving treatment in the FOLFOX + Cetuximab treatment arm. He has a bowel obstruction and has completed 12 cycles of chemotherapy. The histology shows well-differentiated cells. The patient has a fully active performance status and has a wild-type KRAS biomarker.
1747,white,male,75,28.17,FOLFOX,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 75, bmi: 28.17, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 75-year-old white male with a BMI of 28.17. He is receiving treatment with the FOLFOX chemotherapy regimen and has completed 12 cycles. His cancer histology is well-differentiated, and he has a fully active performance status. The KRAS biomarker analysis shows that he has a wild-type KRAS status."
1748,white,male,52,27.07,FOLFOX + Cetuximab,No,No,No,No,11,well differentiated,fully active,wild-type,No,No,No,Yes,No,0,"race: white, sex: male, age: 52, bmi: 27.07, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 11, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type, adverse effect: infection: Yes","The patient is a 52-year-old white male with a BMI of 27.07. He is receiving treatment with FOLFOX + Cetuximab and has completed 11 cycles of chemotherapy. His cancer histology is well-differentiated, and he has a fully active performance status. His KRAS biomarker is wild-type. The patient has experienced an infection as an adverse effect."
1749,other,female,48,24.97,FOLFOX,Yes,No,No,No,12,well differentiated,symptoms but ambulatory,wild-type,No,No,No,No,No,0,"race: other, sex: female, age: 48, bmi: 24.97, treatment arm: FOLFOX, adherence: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type","The patient is a 48-year-old female of a race other than specified, with a BMI of 24.97. She is receiving treatment in the FOLFOX arm and has been adherent to the chemotherapy regimen for 12 cycles. The histology shows well-differentiated cells, and her performance status indicates that she has symptoms but is still ambulatory. The KRAS biomarker analysis reveals a wild-type result."
1750,white,male,58,28.72,FOLFOX,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 58, bmi: 28.72, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 58-year-old white male with a BMI of 28.72. He is receiving treatment with the FOLFOX chemotherapy regimen and is scheduled for 12 cycles. His cancer histology is well-differentiated, and he has a fully active performance status. The KRAS biomarker testing revealed that he has a wild-type KRAS status."
1751,white,male,64,31.87,FOLFOX + Cetuximab,No,No,Yes,No,12,well differentiated,fully active,wild-type,No,Yes,No,No,No,0,"race: white, sex: male, age: 64, bmi: 31.87, treatment arm: FOLFOX + Cetuximab, bowel obstruction: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type, adverse effect: hypersensitivity: Yes","This patient is a 64-year-old white male with a BMI of 31.87. He is receiving treatment with FOLFOX + Cetuximab for his well-differentiated histology. He has experienced a bowel obstruction and has completed 12 cycles of chemotherapy. Despite the adverse effect of hypersensitivity, he has a fully active performance status. Additionally, his KRAS biomarker is wild-type."
1752,white,male,36,30.62,FOLFOX + Cetuximab,No,No,No,No,12,poorly differentiated,fully active,wild-type,Yes,No,No,No,No,0,"race: white, sex: male, age: 36, bmi: 30.62, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type, adverse effect: thrombosis: Yes","The patient is a 36-year-old white male with a BMI of 30.62. He is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. His cancer histology is poorly differentiated, and he has a fully active performance status. The KRAS biomarker testing showed that he has a wild-type KRAS status. The patient has experienced an adverse effect of thrombosis."
1753,white,female,59,39.56,FOLFOX,No,No,No,No,8,well differentiated,fully active,mutant,No,No,No,No,No,0,"race: white, sex: female, age: 59, bmi: 39.56, treatment arm: FOLFOX, chemotherapy cycles: 8, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 59-year-old white female with a BMI of 39.56. She is receiving the FOLFOX treatment regimen and has completed 8 cycles of chemotherapy. Her histology shows well-differentiated cancer cells. Despite her cancer diagnosis, she has a fully active performance status. The patient's KRAS biomarker is mutant."
1754,white,female,72,30.82,FOLFOX + Cetuximab,No,Yes,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,1,"race: white, sex: female, age: 72, bmi: 30.82, treatment arm: FOLFOX + Cetuximab, serious adverse effect: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 72-year-old white female with a BMI of 30.82. She is receiving treatment with FOLFOX + Cetuximab and has experienced a serious adverse effect. She has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cells, and her performance status is fully active. The KRAS biomarker indicates that she has a wild-type status."
1755,white,male,63,27.95,FOLFOX,No,No,No,No,12,poorly differentiated,symptoms but ambulatory,mutant,No,No,No,No,No,1,"race: white, sex: male, age: 63, bmi: 27.95, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: poorly differentiated, performance status: symptoms but ambulatory, KRAS biomarker: mutant","The patient is a 63-year-old white male with a BMI of 27.95. He is undergoing treatment with the FOLFOX chemotherapy regimen and has completed 12 cycles. The histology of his cancer is poorly differentiated. Despite experiencing symptoms, he is still able to ambulate. The KRAS biomarker testing revealed a mutant status."
1756,other,female,65,31.87,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: other, sex: female, age: 65, bmi: 31.87, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 65-year-old female of a race categorized as ""other"" with a BMI of 31.87. She is receiving treatment in the FOLFOX + Cetuximab treatment arm and is scheduled for 12 chemotherapy cycles. The histology indicates that the cancer is well-differentiated. The patient has a fully active performance status. Additionally, the KRAS biomarker testing revealed that the patient has a wild-type KRAS status."
1757,white,female,73,29.13,FOLFOX,No,Yes,No,No,12,poorly differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 73, bmi: 29.13, treatment arm: FOLFOX, serious adverse effect: Yes, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 73-year-old white female with a BMI of 29.13. She is receiving the FOLFOX treatment arm for her poorly differentiated histology. She has experienced a serious adverse effect during her 12 chemotherapy cycles. Despite this, her performance status is fully active. The KRAS biomarker shows that she has a wild-type status."
1758,black,male,43,27.56,FOLFOX + Cetuximab,No,No,Yes,No,12,well differentiated,fully active,mutant,No,No,No,No,No,0,"race: black, sex: male, age: 43, bmi: 27.56, treatment arm: FOLFOX + Cetuximab, bowel obstruction: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 43-year-old Black male with a BMI of 27.56. He is receiving treatment with FOLFOX + Cetuximab for his well-differentiated histology. He has experienced a bowel obstruction and has completed 12 cycles of chemotherapy. Despite this, his performance status is fully active. The patient's KRAS biomarker status is mutant."
1759,white,female,67,19.51,FOLFOX,No,Yes,Yes,No,12,well differentiated,fully active,wild-type,No,No,Yes,No,No,0,"race: white, sex: female, age: 67, bmi: 19.51, treatment arm: FOLFOX, serious adverse effect: Yes, bowel obstruction: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type, adverse effect: diarrhea: Yes","The patient is a 67-year-old white female with a BMI of 19.51 who is undergoing treatment with FOLFOX chemotherapy. She has experienced a serious adverse effect in the form of a bowel obstruction. Despite this, she has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cells, and her performance status is fully active. The KRAS biomarker indicates that she has a wild-type gene. Additionally, she has experienced diarrhea as an adverse effect."
1760,white,male,68,24.26,FOLFOX,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 68, bmi: 24.26, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type",The patient is a 68-year-old white male with a BMI of 24.26. He is receiving the FOLFOX treatment arm and has completed 12 cycles of chemotherapy. The histology shows well-differentiated cancer cells. The patient has a fully active performance status. The KRAS biomarker indicates that the patient has a wild-type KRAS gene.
1761,black,male,63,29.38,FOLFOX + Cetuximab,No,No,No,No,3,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: black, sex: male, age: 63, bmi: 29.38, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 3, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 63-year-old Black male with a BMI of 29.38. He is currently receiving treatment with FOLFOX + Cetuximab and has completed 3 cycles of chemotherapy. His cancer histology is well-differentiated, and he has a fully active performance status. The KRAS biomarker testing shows that he has a wild-type KRAS status."
1762,other,female,52,34.51,FOLFOX,No,No,Yes,No,12,well differentiated,fully active,mutant,No,No,No,No,No,0,"race: other, sex: female, age: 52, bmi: 34.51, treatment arm: FOLFOX, bowel obstruction: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 52-year-old female of a race other than specified, with a BMI of 34.51. She is undergoing treatment with the FOLFOX regimen and has experienced a bowel obstruction. She has completed 12 cycles of chemotherapy. The histology shows well-differentiated cells, and her performance status is fully active. The KRAS biomarker is mutant in this case."
1763,white,male,61,27.87,FOLFOX,No,No,No,No,11,well differentiated,fully active,wild-type,No,Yes,Yes,No,No,0,"race: white, sex: male, age: 61, bmi: 27.87, treatment arm: FOLFOX, chemotherapy cycles: 11, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type, adverse effect: hypersensitivity: Yes, adverse effect: diarrhea: Yes","The patient is a 61-year-old white male with a BMI of 27.87. He is receiving the FOLFOX treatment regimen and has completed 11 cycles of chemotherapy. His cancer histology is well-differentiated, and he has a fully active performance status. The KRAS biomarker testing showed that he has a wild-type KRAS status. He has experienced adverse effects of hypersensitivity and diarrhea during his treatment."
1764,white,male,35,22.22,FOLFIRI,Yes,No,No,No,12,well differentiated,fully active,mutant,No,No,No,No,No,1,"race: white, sex: male, age: 35, bmi: 22.22, treatment arm: FOLFIRI, adherence: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant",The patient is a 35-year-old white male with a BMI of 22.22. He is receiving the FOLFIRI treatment regimen and has been adherent to the treatment. He has completed 12 cycles of chemotherapy. The histology shows well-differentiated cancer cells. The patient has a fully active performance status. The KRAS biomarker indicates a mutant status.
1765,white,female,36,21.64,FOLFOX,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 36, bmi: 21.64, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type",The patient is a 36-year-old white female with a BMI of 21.64. She is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cancer cells. She has a fully active performance status and her KRAS biomarker is wild-type.
1766,other,female,65,35.76,FOLFOX + Cetuximab,No,Yes,No,No,5,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: other, sex: female, age: 65, bmi: 35.76, treatment arm: FOLFOX + Cetuximab, serious adverse effect: Yes, chemotherapy cycles: 5, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 65-year-old female of a race categorized as ""other"" with a BMI of 35.76. She is currently undergoing treatment with FOLFOX + Cetuximab. Unfortunately, she has experienced a serious adverse effect. She has completed 5 cycles of chemotherapy. Her histology shows that the cancer is well-differentiated. Despite the adverse effect, her performance status is fully active. Additionally, her KRAS biomarker status is wild-type."
1767,white,female,43,28.52,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 43, bmi: 28.52, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 43-year-old white female with a BMI of 28.52. She is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cells, and she has a fully active performance status. The KRAS biomarker indicates that she has a wild-type gene."
1768,white,female,38,22.95,FOLFOX,Yes,No,No,No,12,well differentiated,symptoms but ambulatory,wild-type,No,No,Yes,No,No,0,"race: white, sex: female, age: 38, bmi: 22.95, treatment arm: FOLFOX, adherence: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type, adverse effect: diarrhea: Yes","The patient is a 38-year-old white female with a BMI of 22.95. She is receiving treatment with the FOLFOX regimen and has been adherent to her chemotherapy cycles, completing 12 cycles so far. Her histology shows well-differentiated cancer cells. Despite experiencing symptoms, she is still able to be ambulatory. The KRAS biomarker testing revealed that she has a wild-type KRAS status. The patient has reported experiencing diarrhea as an adverse effect of the treatment."
1769,white,male,55,22.93,FOLFOX,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 55, bmi: 22.93, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 55-year-old white male with a BMI of 22.93. He is receiving treatment with the FOLFOX chemotherapy regimen and has completed 12 cycles. His cancer histology is well-differentiated, and he has a fully active performance status. The KRAS biomarker testing showed that he has a wild-type KRAS status."
1770,white,male,46,31.12,FOLFOX + Cetuximab,Yes,No,No,No,6,poorly differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 46, bmi: 31.12, treatment arm: FOLFOX + Cetuximab, adherence: Yes, chemotherapy cycles: 6, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 46-year-old white male with a BMI of 31.12. He is receiving treatment in the FOLFOX + Cetuximab treatment arm and has been adherent to the treatment. He has completed 6 cycles of chemotherapy. The histology of his cancer is poorly differentiated. Despite this, his performance status is fully active. Additionally, his KRAS biomarker status is wild-type."
1771,white,male,46,20.2,FOLFOX,Yes,Yes,No,No,12,well differentiated,symptoms but ambulatory,wild-type,Yes,No,No,No,No,0,"race: white, sex: male, age: 46, bmi: 20.2, treatment arm: FOLFOX, adherence: Yes, serious adverse effect: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type, adverse effect: thrombosis: Yes","The patient is a 46-year-old white male with a BMI of 20.2 who is receiving the FOLFOX treatment regimen. He has been adherent to the treatment and has completed 12 chemotherapy cycles. The histology shows well-differentiated cancer cells, and the patient's performance status is characterized by experiencing symptoms but still being ambulatory. The KRAS biomarker indicates a wild-type status. The patient has experienced a serious adverse effect in the form of thrombosis."
1772,white,female,40,40.77,FOLFOX,Yes,No,No,No,12,well differentiated,symptoms but ambulatory,mutant,No,No,No,No,No,0,"race: white, sex: female, age: 40, bmi: 40.77, treatment arm: FOLFOX, adherence: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: mutant","The patient is a 40-year-old white female with a BMI of 40.77. She is receiving the FOLFOX treatment regimen and has been adherent to her chemotherapy cycles, completing a total of 12 cycles. Her histology shows well-differentiated cancer cells. Despite experiencing symptoms, she is still able to be ambulatory. The KRAS biomarker analysis revealed a mutant status."
1773,white,female,60,33.59,FOLFOX,No,No,No,No,12,well differentiated,symptoms but ambulatory,mutant,No,No,No,No,No,0,"race: white, sex: female, age: 60, bmi: 33.59, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: mutant","The patient is a 60-year-old white female with a BMI of 33.59. She is receiving the FOLFOX treatment arm and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cancer cells. Despite experiencing symptoms, she is still able to be ambulatory. The KRAS biomarker analysis indicates a mutant status."
1774,white,female,35,28.09,FOLFOX + Cetuximab,No,No,No,No,1,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 35, bmi: 28.09, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 1, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type",The patient is a 35-year-old white female with a BMI of 28.09. She is receiving treatment in the FOLFOX + Cetuximab treatment arm and has completed one cycle of chemotherapy. Her histology shows well-differentiated cancer cells. The patient has a fully active performance status and her KRAS biomarker is wild-type.
1775,white,male,53,34.43,FOLFOX,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 53, bmi: 34.43, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type",The patient is a 53-year-old white male with a BMI of 34.43. He is undergoing treatment with the FOLFOX chemotherapy regimen and has completed 12 cycles. His histology shows well-differentiated cancer cells. The patient has a fully active performance status and his KRAS biomarker is wild-type.
1776,white,male,74,31.97,FOLFOX,No,No,No,No,12,well differentiated,fully active,mutant,No,No,No,No,No,0,"race: white, sex: male, age: 74, bmi: 31.97, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 74-year-old white male with a BMI of 31.97. He is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer cells. Despite his age, he has a fully active performance status. The KRAS biomarker testing revealed a mutant status."
1777,white,male,74,26.92,FOLFOX + Cetuximab,No,No,No,Yes,3,well differentiated,fully active,wild-type,No,No,Yes,No,No,0,"race: white, sex: male, age: 74, bmi: 26.92, treatment arm: FOLFOX + Cetuximab, bowel perforation: Yes, chemotherapy cycles: 3, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type, adverse effect: diarrhea: Yes","The patient is a 74-year-old white male with a BMI of 26.92 who is receiving treatment with FOLFOX + Cetuximab. He has experienced a bowel perforation and has completed 3 cycles of chemotherapy. The histology shows that the cancer is well-differentiated. Despite the bowel perforation, the patient's performance status is fully active. His KRAS biomarker indicates that it is wild-type. He is also experiencing diarrhea as an adverse effect of the treatment."
1778,white,male,57,49.43,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,symptoms but ambulatory,wild-type,Yes,No,No,No,No,0,"race: white, sex: male, age: 57, bmi: 49.43, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type, adverse effect: thrombosis: Yes","The patient is a 57-year-old white male with a BMI of 49.43. He is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. His cancer histology is well-differentiated, and he has symptoms but is still able to be ambulatory. The KRAS biomarker testing showed that he has a wild-type KRAS status. Additionally, the patient has experienced an adverse effect of thrombosis."
1779,white,female,64,24.65,FOLFOX + Cetuximab,Yes,No,No,No,5,poorly differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 64, bmi: 24.65, treatment arm: FOLFOX + Cetuximab, adherence: Yes, chemotherapy cycles: 5, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 64-year-old white female with a BMI of 24.65. She is currently receiving treatment in the FOLFOX + Cetuximab treatment arm and has been adherent to her medication. She has completed 5 cycles of chemotherapy. Her histology shows poorly differentiated cells, and her performance status is fully active. The KRAS biomarker indicates that she has a wild-type status."
1780,white,male,58,23.65,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,fully active,interminate,No,No,No,No,No,0,"race: white, sex: male, age: 58, bmi: 23.65, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: interminate","The patient is a 58-year-old white male with a BMI of 23.65. He is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cells, and he has a fully active performance status. The KRAS biomarker status is indeterminate for this patient."
1781,white,male,71,32.35,FOLFOX,No,No,No,No,8,poorly differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 71, bmi: 32.35, treatment arm: FOLFOX, chemotherapy cycles: 8, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 71-year-old white male with a BMI of 32.35. He is receiving treatment with the FOLFOX chemotherapy regimen and has completed 8 cycles. His cancer histology is poorly differentiated. Despite his age, he has a fully active performance status. The KRAS biomarker testing revealed that he has a wild-type KRAS status."
1782,white,male,50,28.15,FOLFOX,No,Yes,No,No,11,poorly differentiated,fully active,mutant,No,No,No,No,No,0,"race: white, sex: male, age: 50, bmi: 28.15, treatment arm: FOLFOX, serious adverse effect: Yes, chemotherapy cycles: 11, histology: poorly differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 50-year-old white male with a BMI of 28.15. He is undergoing treatment with the FOLFOX regimen and has experienced a serious adverse effect. He has completed 11 cycles of chemotherapy. The histology of his cancer is poorly differentiated. Despite this, his performance status is fully active. The KRAS biomarker testing revealed a mutant status."
1783,white,male,41,23.39,FOLFOX,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 41, bmi: 23.39, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type",The patient is a 41-year-old white male with a BMI of 23.39. He is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. His cancer histology is well-differentiated. The patient has a fully active performance status and has a wild-type KRAS biomarker.
1784,white,male,39,38.92,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,symptoms but ambulatory,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 39, bmi: 38.92, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type","The patient is a 39-year-old white male with a BMI of 38.92. He is receiving treatment with FOLFOX + Cetuximab and is scheduled for 12 chemotherapy cycles. His histology shows well-differentiated cancer. Despite experiencing symptoms, he is still able to walk around (ambulatory). His KRAS biomarker is wild-type."
1785,white,male,63,29.41,FOLFOX,No,No,No,No,10,poorly differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 63, bmi: 29.41, treatment arm: FOLFOX, chemotherapy cycles: 10, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 63-year-old white male with a BMI of 29.41. He is receiving the FOLFOX treatment regimen and has completed 10 cycles of chemotherapy. His histology shows poorly differentiated cancer cells. Despite this, his performance status is fully active. Additionally, his KRAS biomarker status is wild-type."
1786,other,female,44,23.37,FOLFOX + Cetuximab,No,No,No,No,12,poorly differentiated,fully active,wild-type,No,No,No,No,No,0,"race: other, sex: female, age: 44, bmi: 23.37, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 44-year-old female of a race categorized as ""other"" with a BMI of 23.37. She is receiving treatment in the FOLFOX + Cetuximab treatment arm and is scheduled for 12 chemotherapy cycles. The histology of her condition is poorly differentiated. Despite this, her performance status is fully active. Additionally, the KRAS biomarker indicates that she has a wild-type status."
1787,white,male,72,25.47,FOLFOX,No,Yes,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,1,"race: white, sex: male, age: 72, bmi: 25.47, treatment arm: FOLFOX, serious adverse effect: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 72-year-old white male with a BMI of 25.47. He is undergoing treatment with the FOLFOX regimen and has experienced a serious adverse effect. He has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer cells. Despite his age, he has a fully active performance status. The KRAS biomarker analysis indicates that he has a wild-type KRAS gene."
1788,white,female,66,30.2,FOLFOX,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 66, bmi: 30.2, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type",The patient is a 66-year-old white female with a BMI of 30.2. She is receiving the FOLFOX treatment regimen and is scheduled for 12 chemotherapy cycles. Her histology shows well-differentiated cells. The patient has a fully active performance status and her KRAS biomarker is wild-type.
1789,white,female,71,23.98,FOLFOX,No,No,No,No,12,well differentiated,symptoms but ambulatory,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 71, bmi: 23.98, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type","The patient is a 71-year-old white female with a BMI of 23.98. She is undergoing treatment with the FOLFOX chemotherapy regimen and has completed 12 cycles. Her histology shows well-differentiated cancer cells. Despite experiencing symptoms, she is still able to be ambulatory. The KRAS biomarker analysis indicates that she has a wild-type KRAS status."
1790,white,male,60,23.81,FOLFOX + Cetuximab,No,No,No,Yes,12,well differentiated,symptoms but ambulatory,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 60, bmi: 23.81, treatment arm: FOLFOX + Cetuximab, bowel perforation: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type","The patient is a 60-year-old white male with a BMI of 23.81. He is receiving treatment with FOLFOX + Cetuximab and has experienced a bowel perforation. He has completed 12 cycles of chemotherapy. The histology shows well-differentiated cells. Despite experiencing symptoms, the patient is still able to be ambulatory. The KRAS biomarker indicates that the patient has a wild-type status."
1791,white,female,62,30.29,FOLFOX + Cetuximab,Yes,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 62, bmi: 30.29, treatment arm: FOLFOX + Cetuximab, adherence: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type",The patient is a 62-year-old white female with a BMI of 30.29. She is receiving treatment with FOLFOX + Cetuximab and has been adherent to the treatment. She has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cancer cells. The patient has a fully active performance status. Her KRAS biomarker is wild-type.
1792,black,male,48,33.67,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: black, sex: male, age: 48, bmi: 33.67, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type",The patient is a 48-year-old Black male with a BMI of 33.67. He is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer cells. The patient has a fully active performance status and his KRAS biomarker is wild-type.
1793,white,male,75,26.64,FOLFOX + Cetuximab,No,Yes,No,No,12,poorly differentiated,fully active,wild-type,Yes,No,Yes,No,No,1,"race: white, sex: male, age: 75, bmi: 26.64, treatment arm: FOLFOX + Cetuximab, serious adverse effect: Yes, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type, adverse effect: thrombosis: Yes, adverse effect: diarrhea: Yes","The patient is a 75-year-old white male with a BMI of 26.64. He is receiving treatment with FOLFOX + Cetuximab and has experienced a serious adverse effect. He has completed 12 cycles of chemotherapy. His histology shows poorly differentiated cells. Despite this, his performance status is fully active. The KRAS biomarker is wild-type. The patient has also experienced adverse effects in the form of thrombosis and diarrhea."
1794,white,male,76,27.22,FOLFOX + Cetuximab,No,No,No,Yes,1,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 76, bmi: 27.22, treatment arm: FOLFOX + Cetuximab, bowel perforation: Yes, chemotherapy cycles: 1, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","This patient is a 76-year-old white male with a BMI of 27.22. He is currently receiving treatment in the FOLFOX + Cetuximab treatment arm. He has experienced a bowel perforation and has completed one cycle of chemotherapy. The histology of his cancer is well-differentiated. Despite the bowel perforation, his performance status is fully active. Additionally, his KRAS biomarker status is wild-type."
1795,white,male,62,27.56,FOLFOX + Cetuximab,No,No,Yes,No,12,poorly differentiated,fully active,wild-type,No,Yes,No,No,No,1,"race: white, sex: male, age: 62, bmi: 27.56, treatment arm: FOLFOX + Cetuximab, bowel obstruction: Yes, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type, adverse effect: hypersensitivity: Yes","This patient is a 62-year-old white male with a BMI of 27.56. He is receiving treatment with FOLFOX + Cetuximab for his bowel obstruction. He has completed 12 cycles of chemotherapy. The histology of his cancer is poorly differentiated. Despite his condition, his performance status is fully active. His KRAS biomarker is wild-type. He has experienced a hypersensitivity adverse effect during treatment."
1796,white,female,47,23.29,FOLFOX,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 47, bmi: 23.29, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 47-year-old white female with a BMI of 23.29. She is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. Her cancer histology is well-differentiated, and she has a fully active performance status. The KRAS biomarker analysis indicates that she has a wild-type KRAS status."
1797,white,female,42,27.55,FOLFOX + Cetuximab,No,Yes,No,No,12,well differentiated,symptoms but ambulatory,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 42, bmi: 27.55, treatment arm: FOLFOX + Cetuximab, serious adverse effect: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type","The patient is a 42-year-old white female with a BMI of 27.55. She is undergoing treatment with FOLFOX + Cetuximab and has experienced a serious adverse effect. She has completed 12 cycles of chemotherapy. The histology shows that the cancer is well-differentiated. Despite experiencing symptoms, she is still able to be ambulatory. The KRAS biomarker indicates that she has a wild-type status."
1798,white,male,43,32.59,FOLFOX,Yes,Yes,No,No,12,poorly differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 43, bmi: 32.59, treatment arm: FOLFOX, adherence: Yes, serious adverse effect: Yes, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 43-year-old white male with a BMI of 32.59. He is receiving the FOLFOX treatment regimen and has been adherent to the treatment. Unfortunately, he has experienced a serious adverse effect. He has completed 12 cycles of chemotherapy and his histology shows poorly differentiated cells. Despite this, his performance status is fully active. His KRAS biomarker is wild-type."
1799,white,female,72,24.61,FOLFOX,No,Yes,No,No,2,well differentiated,fully active,mutant,No,No,No,No,No,0,"race: white, sex: female, age: 72, bmi: 24.61, treatment arm: FOLFOX, serious adverse effect: Yes, chemotherapy cycles: 2, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 72-year-old white female with a BMI of 24.61. She is receiving the FOLFOX treatment regimen and has experienced a serious adverse effect. She has completed 2 cycles of chemotherapy and her histology shows well-differentiated cells. Despite the adverse effect, her performance status is fully active. Additionally, the KRAS biomarker testing revealed a mutant status."
1800,white,female,64,18.1,FOLFOX,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 64, bmi: 18.1, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 64-year-old white female with a BMI of 18.1. She is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. The histology of her cancer is well-differentiated. Despite undergoing treatment, her performance status is fully active. Additionally, her KRAS biomarker status is wild-type."
1801,white,female,62,31.39,FOLFOX,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 62, bmi: 31.39, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 62-year-old white female with a BMI of 31.39. She is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cancer cells. Despite her cancer diagnosis, she has a fully active performance status. The KRAS biomarker analysis indicates that she has a wild-type KRAS gene."
1802,white,female,67,30.66,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,symptoms but ambulatory,wild-type,No,No,Yes,No,No,0,"race: white, sex: female, age: 67, bmi: 30.66, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type, adverse effect: diarrhea: Yes","The patient is a 67-year-old white female with a BMI of 30.66. She is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cancer, and she has symptoms but is still able to walk around (ambulatory). The KRAS biomarker indicates that she has a wild-type gene. She is experiencing diarrhea as an adverse effect of the treatment."
1803,white,female,72,29.78,FOLFOX + Cetuximab,No,Yes,No,No,12,well differentiated,fully active,mutant,No,No,No,No,No,0,"race: white, sex: female, age: 72, bmi: 29.78, treatment arm: FOLFOX + Cetuximab, serious adverse effect: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 72-year-old white female with a BMI of 29.78. She is receiving treatment with FOLFOX + Cetuximab and has experienced a serious adverse effect. She has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cells, and her performance status is fully active. The KRAS biomarker indicates a mutant status."
1804,white,male,57,18.82,FOLFOX + Cetuximab,No,Yes,No,No,12,well differentiated,fully active,mutant,No,No,No,No,No,0,"race: white, sex: male, age: 57, bmi: 18.82, treatment arm: FOLFOX + Cetuximab, serious adverse effect: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 57-year-old white male with a BMI of 18.82. He is undergoing treatment with FOLFOX + Cetuximab and has experienced a serious adverse effect. He has completed 12 cycles of chemotherapy. His histology shows well-differentiated cells, and his performance status is fully active. The KRAS biomarker analysis indicates a mutant status."
1805,white,male,73,26.07,FOLFIRI (KRAS mutant),No,No,Yes,No,12,well differentiated,symptoms but ambulatory,mutant,No,No,No,No,No,0,"race: white, sex: male, age: 73, bmi: 26.07, treatment arm: FOLFIRI (KRAS mutant), bowel obstruction: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: mutant","This patient is a 73-year-old white male with a BMI of 26.07. He is receiving treatment with the FOLFIRI regimen for his KRAS mutant status. He has a bowel obstruction and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer. Despite experiencing symptoms, he is still able to be ambulatory."
1806,black,male,56,24.96,FOLFOX + Cetuximab,Yes,No,No,No,12,well differentiated,symptoms but ambulatory,wild-type,No,No,No,No,No,0,"race: black, sex: male, age: 56, bmi: 24.96, treatment arm: FOLFOX + Cetuximab, adherence: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type","The patient is a 56-year-old Black male with a BMI of 24.96. He is receiving treatment with FOLFOX + Cetuximab and has been adherent to the treatment. He has completed 12 cycles of chemotherapy. The histology shows well-differentiated cancer. Despite experiencing symptoms, the patient is still able to be ambulatory. The KRAS biomarker indicates that the patient has a wild-type status."
1807,white,male,35,37.38,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,Yes,No,No,1,"race: white, sex: male, age: 35, bmi: 37.38, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type, adverse effect: diarrhea: Yes","The patient is a 35-year-old white male with a BMI of 37.38. He is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. His cancer histology is well-differentiated, and he has a fully active performance status. The KRAS biomarker testing showed that he has a wild-type KRAS status. The patient is experiencing diarrhea as an adverse effect of the treatment."
1808,white,male,55,28.54,FOLFIRI,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 55, bmi: 28.54, treatment arm: FOLFIRI, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type",The patient is a 55-year-old white male with a BMI of 28.54. He is receiving treatment with the FOLFIRI chemotherapy regimen and has completed 12 cycles. His cancer histology is well differentiated. The patient has a fully active performance status and has a wild-type KRAS biomarker.
1809,white,male,41,34.62,FOLFOX,No,No,No,No,12,poorly differentiated,symptoms but ambulatory,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 41, bmi: 34.62, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: poorly differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type","The patient is a 41-year-old white male with a BMI of 34.62. He is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. His histology shows poorly differentiated cancer cells. Despite experiencing symptoms, he is still able to walk around (ambulatory). The KRAS biomarker analysis indicates that he has a wild-type KRAS status."
1810,white,female,52,26.68,FOLFOX,No,No,No,No,3,well differentiated,fully active,wild-type,No,No,Yes,Yes,No,0,"race: white, sex: female, age: 52, bmi: 26.68, treatment arm: FOLFOX, chemotherapy cycles: 3, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type, adverse effect: diarrhea: Yes, adverse effect: infection: Yes","The patient is a 52-year-old white female with a BMI of 26.68. She is currently receiving the FOLFOX treatment regimen and has completed 3 cycles of chemotherapy. Her histology shows well-differentiated cancer cells. Despite experiencing diarrhea and infection as adverse effects, her performance status remains fully active. Additionally, her KRAS biomarker status is wild-type."
1811,white,female,59,18.82,FOLFOX + Cetuximab,No,Yes,Yes,No,2,poorly differentiated,fully active,wild-type,No,Yes,No,Yes,No,0,"race: white, sex: female, age: 59, bmi: 18.82, treatment arm: FOLFOX + Cetuximab, serious adverse effect: Yes, bowel obstruction: Yes, chemotherapy cycles: 2, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type, adverse effect: hypersensitivity: Yes, adverse effect: infection: Yes","The patient is a 59-year-old white female with a BMI of 18.82. She is receiving treatment in the FOLFOX + Cetuximab treatment arm. She has experienced a serious adverse effect, specifically a bowel obstruction, after completing 2 cycles of chemotherapy. The histology of her cancer is poorly differentiated. Despite the adverse effects, her performance status is fully active. Her KRAS biomarker is wild-type. Additionally, she has experienced hypersensitivity and infection as adverse effects during her treatment."
1812,white,male,56,26.16,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,symptoms but ambulatory,wild-type,No,Yes,No,No,No,0,"race: white, sex: male, age: 56, bmi: 26.16, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type, adverse effect: hypersensitivity: Yes","The patient is a 56-year-old white male with a BMI of 26.16. He is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer, and he has symptoms but is still ambulatory. The KRAS biomarker indicates that he is wild-type. He has experienced a hypersensitivity adverse effect."
1813,white,male,62,25.95,FOLFOX + Cetuximab,No,No,Yes,No,8,poorly differentiated,fully active,wild-type,No,No,No,Yes,No,0,"race: white, sex: male, age: 62, bmi: 25.95, treatment arm: FOLFOX + Cetuximab, bowel obstruction: Yes, chemotherapy cycles: 8, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type, adverse effect: infection: Yes","The patient is a 62-year-old white male with a BMI of 25.95 who is receiving treatment with FOLFOX + Cetuximab. He has a bowel obstruction and has completed 8 cycles of chemotherapy. The histology of his cancer is poorly differentiated. Despite these challenges, his performance status is fully active. His KRAS biomarker is wild-type. The patient has experienced an infection as an adverse effect of his treatment."
1814,white,female,69,22.75,FOLFIRI (KRAS mutant),No,No,No,No,12,poorly differentiated,symptoms but ambulatory,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 69, bmi: 22.75, treatment arm: FOLFIRI (KRAS mutant), chemotherapy cycles: 12, histology: poorly differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type","The patient is a 69-year-old white female with a BMI of 22.75. She is receiving the FOLFIRI treatment regimen for her KRAS mutant status. She has undergone 12 cycles of chemotherapy. Her histology shows poorly differentiated cancer cells. Despite experiencing symptoms, she is still able to move around. Her KRAS biomarker is wild-type."
1815,white,male,63,35.99,FOLFOX,No,No,No,Yes,12,well differentiated,fully active,mutant,No,No,No,No,No,0,"race: white, sex: male, age: 63, bmi: 35.99, treatment arm: FOLFOX, bowel perforation: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 63-year-old white male with a BMI of 35.99. He is receiving the FOLFOX treatment arm for his cancer. He has experienced a bowel perforation and has completed 12 cycles of chemotherapy. The histology of his cancer is well-differentiated. Despite his condition, he has a fully active performance status. The KRAS biomarker testing revealed a mutant status."
1816,white,female,43,22.55,FOLFOX,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 43, bmi: 22.55, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 43-year-old white female with a BMI of 22.55. She is receiving the FOLFOX treatment arm and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cells, and her performance status is fully active. The KRAS biomarker indicates that she has a wild-type status."
1817,white,male,62,34.48,FOLFOX,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 62, bmi: 34.48, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type",The patient is a 62-year-old white male with a BMI of 34.48. He is receiving the FOLFOX treatment arm and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer cells. The patient has a fully active performance status and his KRAS biomarker is wild-type.
1818,other,female,71,21.6,FOLFOX + Cetuximab,No,Yes,Yes,No,12,poorly differentiated,fully active,wild-type,No,No,No,No,No,0,"race: other, sex: female, age: 71, bmi: 21.6, treatment arm: FOLFOX + Cetuximab, serious adverse effect: Yes, bowel obstruction: Yes, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type","This patient is a 71-year-old female of a race categorized as ""other"" with a BMI of 21.6. She is receiving treatment in the FOLFOX + Cetuximab treatment arm. Unfortunately, she has experienced a serious adverse effect, specifically a bowel obstruction. She has completed 12 cycles of chemotherapy and her histology shows poorly differentiated cells. Despite these challenges, her performance status is fully active. Additionally, her KRAS biomarker is wild-type."
1819,white,male,68,26.72,FOLFOX + Cetuximab,No,Yes,No,No,12,poorly differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 68, bmi: 26.72, treatment arm: FOLFOX + Cetuximab, serious adverse effect: Yes, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 68-year-old white male with a BMI of 26.72. He is undergoing treatment with FOLFOX + Cetuximab and has experienced a serious adverse effect. He has completed 12 cycles of chemotherapy. The histology of his cancer is poorly differentiated. Despite these challenges, his performance status is fully active. His KRAS biomarker status is wild-type."
1820,white,female,64,23.83,FOLFIRI,No,Yes,No,No,8,poorly differentiated,fully active,wild-type,Yes,No,No,No,No,0,"race: white, sex: female, age: 64, bmi: 23.83, treatment arm: FOLFIRI, serious adverse effect: Yes, chemotherapy cycles: 8, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type, adverse effect: thrombosis: Yes","The patient is a 64-year-old white female with a BMI of 23.83 who is undergoing treatment with FOLFIRI chemotherapy. She has experienced a serious adverse effect during the treatment, specifically thrombosis. She has completed 8 cycles of chemotherapy and her histology shows poorly differentiated cells. Despite the adverse effect, her performance status is fully active. Additionally, her KRAS biomarker is wild-type."
1821,white,male,63,31.26,FOLFOX,No,Yes,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 63, bmi: 31.26, treatment arm: FOLFOX, serious adverse effect: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 63-year-old white male with a BMI of 31.26. He is undergoing treatment with the FOLFOX regimen and has experienced a serious adverse effect. He has completed 12 cycles of chemotherapy. The histology shows that the cancer is well-differentiated. Despite the treatment, the patient's performance status is fully active. The KRAS biomarker analysis indicates that the patient has a wild-type KRAS status."
1822,white,female,66,21.12,FOLFIRI + Cetuximab,Yes,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,1,"race: white, sex: female, age: 66, bmi: 21.12, treatment arm: FOLFIRI + Cetuximab, adherence: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 66-year-old white female with a BMI of 21.12. She is receiving treatment in the FOLFIRI + Cetuximab treatment arm and has been adherent to her chemotherapy regimen for 12 cycles. Her histology shows well-differentiated cancer, and she has a fully active performance status. Additionally, her KRAS biomarker is wild-type."
1823,white,male,67,44.1,FOLFOX,No,No,No,No,12,well differentiated,fully active,mutant,No,No,No,No,No,0,"race: white, sex: male, age: 67, bmi: 44.1, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 67-year-old white male with a BMI of 44.1. He is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer cells. Despite his age, he has a fully active performance status. The KRAS biomarker testing revealed a mutant status."
1824,white,female,66,32.24,FOLFOX + Cetuximab,No,No,No,No,9,well differentiated,fully active,mutant,No,No,No,No,No,0,"race: white, sex: female, age: 66, bmi: 32.24, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 9, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant",The patient is a 66-year-old white female with a BMI of 32.24. She is receiving treatment with FOLFOX + Cetuximab and has completed 9 cycles of chemotherapy. Her histology shows well-differentiated cancer. She has a fully active performance status. The KRAS biomarker indicates that she has a mutant status.
1825,white,male,47,27.59,FOLFOX + Cetuximab,No,No,No,No,12,poorly differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 47, bmi: 27.59, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 47-year-old white male with a BMI of 27.59. He is receiving treatment in the FOLFOX + Cetuximab treatment arm and is scheduled for 12 chemotherapy cycles. His histology shows poorly differentiated cancer cells. Despite this, his performance status is fully active. Additionally, his KRAS biomarker indicates that he has a wild-type KRAS gene."
1826,white,male,69,28.96,FOLFIRI,No,Yes,No,No,12,well differentiated,fully active,wild-type,Yes,No,No,No,No,0,"race: white, sex: male, age: 69, bmi: 28.96, treatment arm: FOLFIRI, serious adverse effect: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type, adverse effect: thrombosis: Yes","The patient is a 69-year-old white male with a BMI of 28.96 who is undergoing treatment with the FOLFIRI chemotherapy regimen. He has experienced a serious adverse effect during the treatment. He has completed 12 cycles of chemotherapy. The histology of his cancer is well-differentiated. Despite the adverse effect, his performance status is fully active. His KRAS biomarker is wild-type. Additionally, he has experienced thrombosis as an adverse effect."
1827,white,male,74,24.29,FOLFOX + Cetuximab,No,No,No,No,3,well differentiated,symptoms but ambulatory,wild-type,No,No,Yes,No,No,0,"race: white, sex: male, age: 74, bmi: 24.29, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 3, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type, adverse effect: diarrhea: Yes",The patient is a 74-year-old white male with a BMI of 24.29 who is receiving treatment with FOLFOX + Cetuximab for his well-differentiated cancer. He has completed 3 cycles of chemotherapy and has a performance status of experiencing symptoms but still able to walk around. His KRAS biomarker is wild-type. The patient is experiencing diarrhea as an adverse effect of the treatment.
1828,white,female,63,38.21,FOLFOX,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,Yes,No,No,0,"race: white, sex: female, age: 63, bmi: 38.21, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type, adverse effect: diarrhea: Yes","This patient is a 63-year-old white female with a BMI of 38.21. She is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cancer cells. Despite experiencing diarrhea as an adverse effect, her performance status is fully active. Additionally, her KRAS biomarker is wild-type."
1829,white,male,46,20.37,FOLFIRI + Cetuximab,No,No,No,No,12,well differentiated,fully active,mutant,No,No,No,No,No,0,"race: white, sex: male, age: 46, bmi: 20.37, treatment arm: FOLFIRI + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant",The patient is a 46-year-old white male with a BMI of 20.37. He is receiving treatment in the FOLFIRI + Cetuximab treatment arm and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer cells. The patient has a fully active performance status. The KRAS biomarker analysis indicates a mutant status.
1830,white,male,75,28.03,FOLFOX + Cetuximab,No,No,No,No,11,well differentiated,fully active,mutant,No,No,No,No,No,0,"race: white, sex: male, age: 75, bmi: 28.03, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 11, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 75-year-old white male with a BMI of 28.03. He is receiving treatment with FOLFOX + Cetuximab and has completed 11 cycles of chemotherapy. His cancer histology is well differentiated. Despite his age, he has a fully active performance status. The KRAS biomarker testing revealed a mutant status."
1831,white,female,48,30.16,FOLFOX,No,No,No,No,12,well differentiated,fully active,mutant,Yes,No,No,No,No,0,"race: white, sex: female, age: 48, bmi: 30.16, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant, adverse effect: thrombosis: Yes","The patient is a 48-year-old white female with a BMI of 30.16. She is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cancer cells. Despite her fully active performance status, she has a mutant KRAS biomarker. Additionally, she has experienced thrombosis as an adverse effect."
1832,white,female,54,18,FOLFOX + Cetuximab,No,No,Yes,No,6,well differentiated,symptoms but ambulatory,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 54, bmi: 18.0, treatment arm: FOLFOX + Cetuximab, bowel obstruction: Yes, chemotherapy cycles: 6, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type","The patient is a 54-year-old white female with a BMI of 18.0. She is receiving treatment with FOLFOX + Cetuximab for her well-differentiated histology. She has experienced a bowel obstruction and has completed 6 cycles of chemotherapy. Despite experiencing symptoms, she is still able to be ambulatory. Her KRAS biomarker status is wild-type."
1833,white,male,48,26.58,FOLFOX + Cetuximab,No,No,Yes,No,12,poorly differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 48, bmi: 26.58, treatment arm: FOLFOX + Cetuximab, bowel obstruction: Yes, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 48-year-old white male with a BMI of 26.58. He is receiving treatment in the FOLFOX + Cetuximab treatment arm. He has a bowel obstruction and has completed 12 cycles of chemotherapy. The histology of his cancer is poorly differentiated. Despite these challenges, his performance status is fully active. His KRAS biomarker status is wild-type."
1834,white,female,46,26.8,FOLFOX,No,Yes,No,No,12,poorly differentiated,symptoms but ambulatory,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 46, bmi: 26.8, treatment arm: FOLFOX, serious adverse effect: Yes, chemotherapy cycles: 12, histology: poorly differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type","The patient is a 46-year-old white female with a BMI of 26.8. She is receiving the FOLFOX treatment regimen and has experienced a serious adverse effect. She has completed 12 cycles of chemotherapy. The histology of her cancer is poorly differentiated. Despite experiencing symptoms, she is still able to be ambulatory. Her KRAS biomarker status is wild-type."
1835,white,male,74,29.1,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,fully active,mutant,No,No,No,No,No,0,"race: white, sex: male, age: 74, bmi: 29.1, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 74-year-old white male with a BMI of 29.1. He is receiving treatment in the FOLFOX + Cetuximab treatment arm and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer cells. Despite his age, he has a fully active performance status. The KRAS biomarker analysis indicates that he has a mutant KRAS status."
1836,white,female,56,22.41,FOLFOX + Cetuximab,Yes,No,No,No,4,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 56, bmi: 22.41, treatment arm: FOLFOX + Cetuximab, adherence: Yes, chemotherapy cycles: 4, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 56-year-old white female with a BMI of 22.41. She is currently receiving treatment in the FOLFOX + Cetuximab treatment arm and has been adherent to her medication. She has completed 4 cycles of chemotherapy. Her histology shows well-differentiated cancer cells. The patient has a fully active performance status. Additionally, her KRAS biomarker is wild-type."
1837,white,male,61,37.08,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,symptoms but ambulatory,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 61, bmi: 37.08, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type","The patient is a 61-year-old white male with a BMI of 37.08. He is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. His cancer histology is well differentiated. Despite experiencing symptoms, he is still able to walk around (ambulatory). His KRAS biomarker status is wild-type."
1838,white,male,40,27.27,FOLFOX + Cetuximab,No,No,No,No,12,poorly differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 40, bmi: 27.27, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 40-year-old white male with a BMI of 27.27. He is receiving treatment with FOLFOX + Cetuximab and is scheduled for 12 cycles of chemotherapy. His cancer histology is poorly differentiated. Despite his diagnosis, he has a fully active performance status. Additionally, the KRAS biomarker testing revealed that he has a wild-type KRAS status."
1839,white,female,43,23.46,FOLFOX + Cetuximab,No,No,No,No,11,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 43, bmi: 23.46, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 11, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 43-year-old white female with a BMI of 23.46. She is receiving treatment in the FOLFOX + Cetuximab treatment arm and has completed 11 cycles of chemotherapy. Her histology shows well-differentiated cells, and she has a fully active performance status. The KRAS biomarker indicates that she has a wild-type mutation."
1840,white,male,52,26.29,FOLFOX + Cetuximab,No,No,No,No,0,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 52, bmi: 26.29, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 0, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type",The patient is a 52-year-old white male with a BMI of 26.29. He is enrolled in the FOLFOX + Cetuximab treatment arm but has not started chemotherapy cycles yet. His histology shows well-differentiated cancer cells. The patient has a fully active performance status and his KRAS biomarker is wild-type.
1841,black,female,65,24.1,FOLFOX + Cetuximab,No,No,No,No,1,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: black, sex: female, age: 65, bmi: 24.1, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 1, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 65-year-old Black female with a BMI of 24.1. She is currently receiving treatment with FOLFOX + Cetuximab and has completed one cycle of chemotherapy. Her cancer histology is well-differentiated, and she has a fully active performance status. Additionally, her KRAS biomarker status is wild-type."
1842,white,female,51,27.78,FOLFOX + Cetuximab,Yes,No,No,Yes,0,poorly differentiated,symptoms but ambulatory,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 51, bmi: 27.78, treatment arm: FOLFOX + Cetuximab, adherence: Yes, bowel perforation: Yes, chemotherapy cycles: 0, histology: poorly differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type","This patient is a 51-year-old white female with a BMI of 27.78. She is enrolled in the treatment arm receiving FOLFOX + Cetuximab and has been adherent to the treatment. She has experienced a bowel perforation. Despite having not started any chemotherapy cycles yet, her histology shows poorly differentiated cancer. She has symptoms but is still able to be ambulatory. Her KRAS biomarker status is wild-type."
1843,white,female,51,23.48,FOLFOX,No,No,No,No,12,poorly differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 51, bmi: 23.48, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 51-year-old white female with a BMI of 23.48. She is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. The histology of her cancer is poorly differentiated. Despite her diagnosis, she maintains a fully active performance status. Additionally, her KRAS biomarker status is wild-type."
1844,black,female,65,26.23,FOLFOX,No,No,No,No,11,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: black, sex: female, age: 65, bmi: 26.23, treatment arm: FOLFOX, chemotherapy cycles: 11, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","This patient is a 65-year-old Black female with a BMI of 26.23. She is receiving the FOLFOX treatment regimen and has completed 11 cycles of chemotherapy. The histology of her cancer is well-differentiated. Despite undergoing treatment, her performance status is fully active. Additionally, her KRAS biomarker status is wild-type."
1845,white,female,41,30.55,FOLFOX,No,No,No,No,5,well differentiated,symptoms but ambulatory,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 41, bmi: 30.55, treatment arm: FOLFOX, chemotherapy cycles: 5, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type","The patient is a 41-year-old white female with a BMI of 30.55. She is receiving the FOLFOX treatment regimen and has completed 5 cycles of chemotherapy. Her histology shows well-differentiated cancer cells. Despite experiencing symptoms, she is still able to be ambulatory. The KRAS biomarker analysis indicates that she has a wild-type KRAS status."
1846,white,female,43,23.04,FOLFOX + Cetuximab,No,No,No,No,8,poorly differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 43, bmi: 23.04, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 8, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 43-year-old white female with a BMI of 23.04. She is receiving treatment in the FOLFOX + Cetuximab treatment arm and has completed 8 cycles of chemotherapy. Her histology shows poorly differentiated cancer cells. Despite this, her performance status is fully active. Additionally, her KRAS biomarker indicates that it is wild-type."
1847,white,male,42,33.45,FOLFOX,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 42, bmi: 33.45, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type",The patient is a 42-year-old white male with a BMI of 33.45. He is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. His cancer histology is well differentiated. The patient has a fully active performance status and his KRAS biomarker is wild-type.
1848,white,female,68,24.8,FOLFOX + Cetuximab,No,No,Yes,No,11,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 68, bmi: 24.8, treatment arm: FOLFOX + Cetuximab, bowel obstruction: Yes, chemotherapy cycles: 11, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 68-year-old white female with a BMI of 24.8. She is receiving treatment with FOLFOX + Cetuximab for her cancer. She has experienced a bowel obstruction and has completed 11 cycles of chemotherapy. The histology of her cancer is well-differentiated. Despite her condition, she has a fully active performance status. Additionally, her KRAS biomarker is wild-type."
1849,white,female,73,33.17,FOLFOX,No,No,No,No,12,poorly differentiated,fully active,mutant,No,No,Yes,No,No,0,"race: white, sex: female, age: 73, bmi: 33.17, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: mutant, adverse effect: diarrhea: Yes","The patient is a 73-year-old white female with a BMI of 33.17. She is undergoing treatment with FOLFOX chemotherapy and has completed 12 cycles. The histology of her cancer is poorly differentiated. Despite this, her performance status is fully active. The KRAS biomarker testing revealed a mutant status. The patient is experiencing diarrhea as an adverse effect of the treatment."
1850,white,female,61,24.63,FOLFOX,Yes,No,Yes,Yes,2,well differentiated,symptoms but ambulatory,mutant,No,No,No,No,No,0,"race: white, sex: female, age: 61, bmi: 24.63, treatment arm: FOLFOX, adherence: Yes, bowel obstruction: Yes, bowel perforation: Yes, chemotherapy cycles: 2, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: mutant","The patient is a 61-year-old white female with a BMI of 24.63. She is receiving treatment in the FOLFOX treatment arm and has been adherent to her treatment. She has experienced both a bowel obstruction and a bowel perforation. She has completed 2 cycles of chemotherapy. The histology shows that the cancer is well differentiated. Despite experiencing symptoms, she is still able to be ambulatory. The KRAS biomarker testing revealed a mutant status."
1851,white,male,65,26.36,FOLFIRI (KRAS mutant),No,No,No,No,12,poorly differentiated,fully active,interminate,No,No,No,No,No,0,"race: white, sex: male, age: 65, bmi: 26.36, treatment arm: FOLFIRI (KRAS mutant), chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: interminate","The patient is a 65-year-old white male with a BMI of 26.36. He is receiving treatment with the FOLFIRI regimen for KRAS mutant cancer. He has completed 12 cycles of chemotherapy. The histology of his cancer is poorly differentiated. Despite his cancer diagnosis, his performance status is fully active. The KRAS biomarker status is indeterminate."
1852,other,female,55,29.12,FOLFOX,No,No,No,No,7,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: other, sex: female, age: 55, bmi: 29.12, treatment arm: FOLFOX, chemotherapy cycles: 7, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 55-year-old female of a race categorized as ""other"" with a BMI of 29.12. She is currently undergoing treatment with the FOLFOX chemotherapy regimen and has completed 7 cycles. The histology of her cancer is well-differentiated. Despite her cancer diagnosis, she maintains a fully active performance status. Additionally, her KRAS biomarker status is wild-type."
1853,white,female,40,23.64,FOLFOX,No,No,Yes,No,12,poorly differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 40, bmi: 23.64, treatment arm: FOLFOX, bowel obstruction: Yes, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 40-year-old white female with a BMI of 23.64. She is receiving treatment with the FOLFOX regimen and has experienced a bowel obstruction. She has completed 12 cycles of chemotherapy. The histology of her cancer is poorly differentiated. Despite these challenges, her performance status is fully active. Her KRAS biomarker status is wild-type."
1854,white,male,59,26.24,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,symptoms but ambulatory,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 59, bmi: 26.24, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type","The patient is a 59-year-old white male with a BMI of 26.24. He is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer. Despite experiencing symptoms, he is still able to be ambulatory. The KRAS biomarker analysis indicates that he has a wild-type KRAS gene."
1855,white,female,42,22.66,FOLFOX,No,Yes,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 42, bmi: 22.66, treatment arm: FOLFOX, serious adverse effect: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type",The patient is a 42-year-old white female with a BMI of 22.66. She is receiving the FOLFOX treatment regimen and has experienced a serious adverse effect. She has completed 12 cycles of chemotherapy. The histology shows that the cancer is well-differentiated. The patient has a fully active performance status. Her KRAS biomarker indicates that it is wild-type.
1856,white,female,49,26.56,FOLFOX,Yes,No,No,No,12,poorly differentiated,fully active,mutant,No,No,No,No,No,0,"race: white, sex: female, age: 49, bmi: 26.56, treatment arm: FOLFOX, adherence: Yes, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 49-year-old white female with a BMI of 26.56. She is receiving treatment in the FOLFOX arm and has been adherent to her chemotherapy regimen, completing 12 cycles. Her histology shows poorly differentiated cancer cells. Despite this, her performance status is fully active. Additionally, the KRAS biomarker testing revealed a mutant status."
1857,white,male,50,35.66,FOLFOX + Cetuximab,No,No,No,No,12,poorly differentiated,fully active,mutant,No,No,Yes,No,No,0,"race: white, sex: male, age: 50, bmi: 35.66, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: mutant, adverse effect: diarrhea: Yes","The patient is a 50-year-old white male with a BMI of 35.66. He is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. His histology shows poorly differentiated cancer, and he has a fully active performance status. The KRAS biomarker is mutant. The patient is experiencing diarrhea as an adverse effect of the treatment."
1858,white,male,76,27.5,FOLFOX,No,No,No,No,4,well differentiated,symptoms but ambulatory,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 76, bmi: 27.5, treatment arm: FOLFOX, chemotherapy cycles: 4, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type","The patient is a 76-year-old white male with a BMI of 27.5. He is receiving the FOLFOX treatment regimen and has completed 4 cycles of chemotherapy. His cancer histology is well-differentiated. Despite experiencing symptoms, he is still able to ambulate. The KRAS biomarker analysis shows that he has a wild-type KRAS status."
1859,white,male,70,29.86,FOLFOX + Cetuximab,No,Yes,No,No,12,well differentiated,fully active,wild-type,No,No,Yes,Yes,No,0,"race: white, sex: male, age: 70, bmi: 29.86, treatment arm: FOLFOX + Cetuximab, serious adverse effect: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type, adverse effect: diarrhea: Yes, adverse effect: infection: Yes","The patient is a 70-year-old white male with a BMI of 29.86. He is receiving treatment with FOLFOX + Cetuximab and has experienced a serious adverse effect. He has completed 12 cycles of chemotherapy. His histology shows well-differentiated cells, and he has a fully active performance status. The KRAS biomarker is wild-type. He has experienced adverse effects of diarrhea and infection."
1860,white,female,47,31.8,FOLFOX,No,No,Yes,No,0,well differentiated,symptoms but ambulatory,mutant,No,No,No,No,No,0,"race: white, sex: female, age: 47, bmi: 31.8, treatment arm: FOLFOX, bowel obstruction: Yes, chemotherapy cycles: 0, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: mutant","This patient is a 47-year-old white female with a BMI of 31.8. She is enrolled in the FOLFOX treatment arm and is currently experiencing a bowel obstruction. She has not undergone any chemotherapy cycles yet. The histology of her cancer is well-differentiated. Despite experiencing symptoms, she is still able to be ambulatory. The KRAS biomarker testing revealed a mutant status."
1861,white,female,49,41.98,FOLFOX,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 49, bmi: 41.98, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 49-year-old white female with a BMI of 41.98. She is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cancer cells. Despite her cancer diagnosis, she has a fully active performance status. Additionally, her KRAS biomarker is wild-type."
1862,white,male,51,48.35,FOLFIRI + Cetuximab,No,No,No,No,12,well differentiated,symptoms but ambulatory,wild-type,No,No,No,No,No,1,"race: white, sex: male, age: 51, bmi: 48.35, treatment arm: FOLFIRI + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type","The patient is a 51-year-old white male with a BMI of 48.35. He is receiving treatment with FOLFIRI + Cetuximab and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer. Despite experiencing symptoms, he is still able to walk around (ambulatory). The KRAS biomarker analysis indicates that he has a wild-type KRAS gene."
1863,white,male,42,28.47,FOLFOX,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 42, bmi: 28.47, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 42-year-old white male with a BMI of 28.47. He is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. The histology shows well-differentiated cancer cells. The patient's performance status is fully active, and the KRAS biomarker indicates that he has a wild-type status."
1864,black,female,55,40.88,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,fully active,wild-type,Yes,No,No,No,No,0,"race: black, sex: female, age: 55, bmi: 40.88, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type, adverse effect: thrombosis: Yes","This patient is a 55-year-old Black female with a BMI of 40.88 who is receiving treatment with FOLFOX + Cetuximab for her well-differentiated cancer. She has undergone 12 cycles of chemotherapy and has a fully active performance status. Her KRAS biomarker is wild-type. Additionally, she has experienced the adverse effect of thrombosis."
1865,white,male,70,26.64,FOLFOX + Cetuximab,No,No,Yes,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 70, bmi: 26.64, treatment arm: FOLFOX + Cetuximab, bowel obstruction: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","This patient is a 70-year-old white male with a BMI of 26.64. He is receiving treatment with FOLFOX + Cetuximab for his colorectal cancer. He has experienced a bowel obstruction and has completed 12 cycles of chemotherapy. The histology of his cancer is well differentiated. Despite his condition, his performance status is fully active. His KRAS biomarker status is wild-type."
1866,white,female,51,28.93,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,Yes,No,No,0,"race: white, sex: female, age: 51, bmi: 28.93, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type, adverse effect: diarrhea: Yes","The patient is a 51-year-old white female with a BMI of 28.93. She is receiving treatment with FOLFOX + Cetuximab and has completed 12 chemotherapy cycles. Her histology shows well-differentiated cancer, and she has a fully active performance status. The KRAS biomarker is wild-type. The patient is experiencing diarrhea as an adverse effect of the treatment."
1867,white,male,66,33.87,FOLFOX,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 66, bmi: 33.87, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type",The patient is a 66-year-old white male with a BMI of 33.87. He is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. His cancer histology is well-differentiated. The patient has a fully active performance status and his KRAS biomarker is wild-type.
1868,white,female,43,33.86,FOLFOX,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 43, bmi: 33.86, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type",The patient is a 43-year-old white female with a BMI of 33.86. She is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. Her cancer histology is well differentiated. She has a fully active performance status and her KRAS biomarker is wild-type.
1869,white,female,62,28.42,FOLFOX + Cetuximab,No,No,No,No,3,well differentiated,symptoms but ambulatory,wild-type,No,No,No,Yes,No,0,"race: white, sex: female, age: 62, bmi: 28.42, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 3, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type, adverse effect: infection: Yes","The patient is a 62-year-old white female with a BMI of 28.42. She is receiving treatment with FOLFOX + Cetuximab and has completed 3 cycles of chemotherapy. Her histology shows well-differentiated cancer. Despite experiencing symptoms, she is still able to be ambulatory. Her KRAS biomarker is wild-type. The patient has developed an infection as an adverse effect of the treatment."
1870,white,male,68,30.02,FOLFIRI,No,No,No,No,12,well differentiated,symptoms but ambulatory,mutant,No,No,No,No,No,0,"race: white, sex: male, age: 68, bmi: 30.02, treatment arm: FOLFIRI, chemotherapy cycles: 12, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: mutant","The patient is a 68-year-old white male with a BMI of 30.02. He is undergoing treatment with FOLFIRI chemotherapy regimen and has completed 12 cycles. His cancer histology is well-differentiated. Despite experiencing symptoms, he is still able to ambulate. The patient's KRAS biomarker status is mutant."
1871,white,male,59,32.28,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,fully active,mutant,Yes,Yes,No,No,No,1,"race: white, sex: male, age: 59, bmi: 32.28, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant, adverse effect: thrombosis: Yes, adverse effect: hypersensitivity: Yes","The patient is a 59-year-old white male with a BMI of 32.28. He is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. His cancer histology is well-differentiated, and he has a fully active performance status. The KRAS biomarker testing showed a mutant result. The patient has experienced adverse effects of thrombosis and hypersensitivity during treatment."
1872,white,female,41,20.05,FOLFOX,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 41, bmi: 20.05, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type",The patient is a 41-year-old white female with a BMI of 20.05. She is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cancer cells. The patient has a fully active performance status and her KRAS biomarker is wild-type.
1873,other,female,47,19.04,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: other, sex: female, age: 47, bmi: 19.04, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 47-year-old female of a race other than specified. She has a BMI of 19.04 and is receiving treatment with the FOLFOX + Cetuximab regimen. She is scheduled for 12 cycles of chemotherapy. The histology indicates that the cancer is well-differentiated. The patient has a fully active performance status. Additionally, the KRAS biomarker testing shows that the patient has a wild-type KRAS status."
1874,white,female,58,39.74,FOLFOX + Cetuximab,No,No,Yes,No,9,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 58, bmi: 39.74, treatment arm: FOLFOX + Cetuximab, bowel obstruction: Yes, chemotherapy cycles: 9, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 58-year-old white female with a BMI of 39.74. She is receiving treatment with FOLFOX + Cetuximab for her cancer. She has experienced a bowel obstruction and has completed 9 cycles of chemotherapy. The histology of her cancer is well-differentiated. Despite her condition, her performance status is fully active. Additionally, her KRAS biomarker status is wild-type."
1875,white,male,68,22.82,FOLFOX + Cetuximab,No,No,Yes,No,0,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 68, bmi: 22.82, treatment arm: FOLFOX + Cetuximab, bowel obstruction: Yes, chemotherapy cycles: 0, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 68-year-old white male with a BMI of 22.82. He is enrolled in the FOLFOX + Cetuximab treatment arm. He is currently experiencing a bowel obstruction. The patient has not undergone any chemotherapy cycles yet. His histology shows well-differentiated cells. Despite the bowel obstruction, his performance status is fully active. The KRAS biomarker analysis indicates that he has a wild-type KRAS status."
1876,white,female,42,25.37,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,fully active,mutant,No,No,No,No,No,0,"race: white, sex: female, age: 42, bmi: 25.37, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 42-year-old white female with a BMI of 25.37. She is receiving treatment in the FOLFOX + Cetuximab treatment arm and is scheduled for 12 chemotherapy cycles. Her histology shows well-differentiated cells, and she has a fully active performance status. The KRAS biomarker analysis indicates a mutant status."
1877,white,male,42,41.93,FOLFOX,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 42, bmi: 41.93, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type",The patient is a 42-year-old white male with a BMI of 41.93. He is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer cells. The patient has a fully active performance status. His KRAS biomarker status is wild-type.
1878,white,male,56,27.82,FOLFOX + Cetuximab,No,No,Yes,Yes,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 56, bmi: 27.82, treatment arm: FOLFOX + Cetuximab, bowel obstruction: Yes, bowel perforation: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 56-year-old white male with a BMI of 27.82. He is receiving treatment with FOLFOX + Cetuximab for his cancer. He has experienced both a bowel obstruction and a bowel perforation. He is undergoing 12 cycles of chemotherapy. The histology of his cancer is well-differentiated. Despite his bowel issues, his performance status is fully active. His KRAS biomarker status is wild-type."
1879,other,female,43,18.24,FOLFOX,No,No,No,Yes,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: other, sex: female, age: 43, bmi: 18.24, treatment arm: FOLFOX, bowel perforation: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 43-year-old female of a race categorized as ""other"" with a BMI of 18.24. She is receiving treatment in the FOLFOX regimen and has experienced a bowel perforation. She has completed 12 cycles of chemotherapy. The histology of her condition is well-differentiated. Despite the bowel perforation, her performance status is fully active. The KRAS biomarker analysis indicates that she has a wild-type KRAS gene."
1880,white,male,36,19.59,FOLFIRI + Cetuximab,Yes,No,Yes,No,10,poorly differentiated,fully active,wild-type,No,No,No,No,No,1,"race: white, sex: male, age: 36, bmi: 19.59, treatment arm: FOLFIRI + Cetuximab, adherence: Yes, bowel obstruction: Yes, chemotherapy cycles: 10, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 36-year-old white male with a BMI of 19.59. He is receiving treatment in the FOLFIRI + Cetuximab treatment arm and has been adherent to the treatment. He is currently experiencing a bowel obstruction and has completed 10 cycles of chemotherapy. The histology shows poorly differentiated cancer cells. Despite the bowel obstruction, the patient's performance status is fully active. The KRAS biomarker indicates that the cancer is wild-type."
1881,white,male,53,36.96,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 53, bmi: 36.96, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 53-year-old white male with a BMI of 36.96. He is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. His cancer histology is well-differentiated, and he has a fully active performance status. The KRAS biomarker analysis indicates that he has a wild-type KRAS status."
1882,other,male,67,19.65,FOLFOX,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: other, sex: male, age: 67, bmi: 19.65, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 67-year-old male of a race categorized as ""other"" with a BMI of 19.65. He is undergoing treatment with the FOLFOX regimen and has completed 12 cycles of chemotherapy. The histology indicates that the cancer is well-differentiated. The patient's performance status is fully active, and the KRAS biomarker shows that it is wild-type."
1883,white,male,62,49.49,FOLFOX,No,No,Yes,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 62, bmi: 49.49, treatment arm: FOLFOX, bowel obstruction: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 62-year-old white male with a BMI of 49.49. He is receiving the FOLFOX treatment regimen and has experienced a bowel obstruction. He has completed 12 cycles of chemotherapy. The histology of his cancer is well differentiated. Despite the bowel obstruction, his performance status is fully active. The KRAS biomarker testing revealed that he has a wild-type KRAS status."
1884,black,male,64,28.76,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,symptoms but ambulatory,wild-type,No,No,No,No,No,0,"race: black, sex: male, age: 64, bmi: 28.76, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type","The patient is a 64-year-old Black male with a BMI of 28.76. He is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cells. Despite experiencing symptoms, he is still able to walk around (ambulatory). The KRAS biomarker analysis indicates that he has a wild-type KRAS status."
1885,white,female,57,19.11,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 57, bmi: 19.11, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 57-year-old white female with a BMI of 19.11. She is receiving treatment in the FOLFOX + Cetuximab treatment arm and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cancer cells. Despite her cancer diagnosis, she has a fully active performance status. Additionally, her KRAS biomarker is wild-type."
1886,white,male,45,25.8,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 45, bmi: 25.8, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 45-year-old white male with a BMI of 25.8. He is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. His cancer histology is well-differentiated, and he has a fully active performance status. The KRAS biomarker analysis shows that he has a wild-type KRAS status."
1887,white,male,63,24.75,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,fully active,mutant,No,No,No,No,No,0,"race: white, sex: male, age: 63, bmi: 24.75, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 63-year-old white male with a BMI of 24.75. He is receiving treatment in the FOLFOX + Cetuximab treatment arm and is scheduled for 12 chemotherapy cycles. His histology shows well-differentiated cells, and he has a fully active performance status. The KRAS biomarker analysis indicates a mutant status."
1888,black,male,58,26.42,FOLFOX + Cetuximab,No,No,No,No,6,well differentiated,fully active,wild-type,No,No,No,Yes,No,0,"race: black, sex: male, age: 58, bmi: 26.42, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 6, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type, adverse effect: infection: Yes","The patient is a 58-year-old Black male with a BMI of 26.42. He is receiving treatment with FOLFOX + Cetuximab and has completed 6 cycles of chemotherapy. His histology shows well-differentiated cells, and he has a fully active performance status. The KRAS biomarker is wild-type. The patient has experienced an infection as an adverse effect of treatment."
1889,white,male,41,28.63,FOLFOX,No,No,Yes,No,12,well differentiated,symptoms but ambulatory,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 41, bmi: 28.63, treatment arm: FOLFOX, bowel obstruction: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type","The patient is a 41-year-old white male with a BMI of 28.63. He is receiving the FOLFOX treatment regimen and has a bowel obstruction. He has completed 12 cycles of chemotherapy. The histology shows well-differentiated cancer cells. Despite experiencing symptoms, he is still able to be ambulatory. The KRAS biomarker indicates that he has a wild-type status."
1890,white,female,55,34.31,FOLFOX,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 55, bmi: 34.31, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 55-year-old white female with a BMI of 34.31. She is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cancer cells. Despite her cancer diagnosis, she has a fully active performance status. Additionally, her KRAS biomarker indicates that it is wild-type."
1891,white,male,76,28.22,FOLFOX,No,No,No,No,12,poorly differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 76, bmi: 28.22, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 76-year-old white male with a BMI of 28.22. He is undergoing treatment with the FOLFOX chemotherapy regimen and has completed 12 cycles. His histology shows poorly differentiated cancer cells. Despite his age, he has a fully active performance status. The KRAS biomarker analysis indicates that he has a wild-type KRAS gene."
1892,other,female,58,26.44,FOLFOX,Yes,No,No,No,12,well differentiated,fully active,mutant,No,No,No,No,No,0,"race: other, sex: female, age: 58, bmi: 26.44, treatment arm: FOLFOX, adherence: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 58-year-old female of a race categorized as ""other"" with a BMI of 26.44. She is undergoing treatment with the FOLFOX regimen and has been adherent to the treatment. She has completed 12 cycles of chemotherapy. The histology of her cancer is well-differentiated. Despite her cancer diagnosis, she maintains a fully active performance status. The KRAS biomarker analysis has revealed a mutant status."
1893,white,male,51,25.28,FOLFIRI,No,No,Yes,No,12,well differentiated,symptoms but ambulatory,mutant,Yes,No,No,No,No,0,"race: white, sex: male, age: 51, bmi: 25.28, treatment arm: FOLFIRI, bowel obstruction: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: mutant, adverse effect: thrombosis: Yes","The patient is a 51-year-old white male with a BMI of 25.28 who is undergoing treatment with the FOLFIRI regimen. He has experienced a bowel obstruction and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer cells. Despite experiencing symptoms, he is still able to be ambulatory. The patient's KRAS biomarker is mutant, and he has also developed thrombosis as an adverse effect of treatment."
1894,white,male,47,26.56,FOLFOX + Cetuximab,No,No,Yes,No,12,well differentiated,fully active,mutant,Yes,No,No,No,No,0,"race: white, sex: male, age: 47, bmi: 26.56, treatment arm: FOLFOX + Cetuximab, bowel obstruction: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant, adverse effect: thrombosis: Yes","The patient is a 47-year-old white male with a BMI of 26.56. He is receiving treatment with FOLFOX + Cetuximab for his well-differentiated histology. He has experienced a bowel obstruction and has undergone 12 cycles of chemotherapy. Despite this, his performance status remains fully active. The patient has a mutant KRAS biomarker and has also experienced thrombosis as an adverse effect."
1895,white,female,52,28.26,FOLFOX,No,No,No,No,3,well differentiated,fully active,interminate,No,No,No,No,No,0,"race: white, sex: female, age: 52, bmi: 28.26, treatment arm: FOLFOX, chemotherapy cycles: 3, histology: well differentiated, performance status: fully active, KRAS biomarker: interminate","The patient is a 52-year-old white female with a BMI of 28.26. She is currently receiving the FOLFOX treatment regimen and has completed 3 cycles of chemotherapy. Her histology shows well-differentiated cancer cells. Despite her cancer diagnosis, she has a fully active performance status. The KRAS biomarker status is indeterminate for this patient."
1896,white,female,66,26.25,FOLFOX,Yes,No,No,Yes,12,poorly differentiated,fully active,mutant,No,No,Yes,No,No,0,"race: white, sex: female, age: 66, bmi: 26.25, treatment arm: FOLFOX, adherence: Yes, bowel perforation: Yes, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: mutant, adverse effect: diarrhea: Yes","The patient is a 66-year-old white female with a BMI of 26.25 who is receiving the FOLFOX treatment regimen. She has been adherent to her treatment and has completed 12 cycles of chemotherapy. The histology of her cancer is poorly differentiated, and she has a fully active performance status. The KRAS biomarker testing revealed a mutant status. The patient has experienced a bowel perforation and is also experiencing diarrhea as an adverse effect of the treatment."
1897,other,male,44,26.37,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: other, sex: male, age: 44, bmi: 26.37, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 44-year-old male of a race categorized as ""other"" with a BMI of 26.37. He is undergoing treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cells, and he has a fully active performance status. Additionally, the KRAS biomarker indicates that he has a wild-type status."
1898,other,female,48,22.68,FOLFOX,No,No,No,No,2,well differentiated,fully active,mutant,No,No,No,No,No,0,"race: other, sex: female, age: 48, bmi: 22.68, treatment arm: FOLFOX, chemotherapy cycles: 2, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 48-year-old female of a race categorized as ""other"" with a BMI of 22.68. She is currently undergoing treatment with the FOLFOX chemotherapy regimen and has completed 2 cycles so far. The histology of her cancer is well differentiated. Despite her cancer diagnosis, she has a fully active performance status. Additionally, the KRAS biomarker testing has revealed a mutant status."
1899,white,male,48,26.88,FOLFOX + Cetuximab,Yes,No,Yes,Yes,2,poorly differentiated,fully active,wild-type,No,No,No,No,No,1,"race: white, sex: male, age: 48, bmi: 26.88, treatment arm: FOLFOX + Cetuximab, adherence: Yes, bowel obstruction: Yes, bowel perforation: Yes, chemotherapy cycles: 2, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 48-year-old white male with a BMI of 26.88 who is currently receiving treatment in the FOLFOX + Cetuximab treatment arm. He is adherent to his treatment regimen. The patient has experienced both bowel obstruction and bowel perforation. He has completed 2 cycles of chemotherapy. His histology shows poorly differentiated cells. Despite his health challenges, the patient has a fully active performance status. His KRAS biomarker indicates that he has a wild-type mutation."
1900,white,male,43,24.78,FOLFOX,Yes,No,Yes,No,12,poorly differentiated,fully active,mutant,No,No,No,No,No,0,"race: white, sex: male, age: 43, bmi: 24.78, treatment arm: FOLFOX, adherence: Yes, bowel obstruction: Yes, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 43-year-old white male with a BMI of 24.78. He is receiving treatment in the FOLFOX treatment arm and has been adherent to the prescribed treatment. He has experienced a bowel obstruction. The patient has completed 12 cycles of chemotherapy. The histology of the cancer is poorly differentiated. Despite the challenges, the patient has a fully active performance status. The KRAS biomarker testing revealed a mutant status."
1901,white,female,46,26.06,FOLFOX + Cetuximab,Yes,No,Yes,No,12,well differentiated,fully active,mutant,No,No,No,No,No,0,"race: white, sex: female, age: 46, bmi: 26.06, treatment arm: FOLFOX + Cetuximab, adherence: Yes, bowel obstruction: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 46-year-old white female with a BMI of 26.06. She is receiving treatment in the FOLFOX + Cetuximab treatment arm and has been adherent to her treatment. She has experienced a bowel obstruction and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cells, and her performance status is fully active. Additionally, the KRAS biomarker indicates a mutant status."
1902,other,female,52,20.61,FOLFOX,No,No,No,No,12,well differentiated,symptoms but ambulatory,mutant,No,No,No,No,No,0,"race: other, sex: female, age: 52, bmi: 20.61, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: mutant","The patient is a 52-year-old female of a race categorized as ""other"" with a BMI of 20.61. She is undergoing treatment with the FOLFOX regimen and has completed 12 cycles of chemotherapy. The histology of her cancer is well-differentiated. Despite experiencing symptoms, she is still able to ambulate. Additionally, the KRAS biomarker testing revealed a mutation in the patient."
1903,white,male,58,23.43,FOLFOX + Cetuximab,No,No,No,No,12,poorly differentiated,fully active,mutant,No,No,No,No,No,0,"race: white, sex: male, age: 58, bmi: 23.43, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 58-year-old white male with a BMI of 23.43. He is undergoing treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. His cancer histology is poorly differentiated, and he has a fully active performance status. The KRAS biomarker analysis shows that he has a mutant KRAS status."
1904,white,female,66,25.38,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,symptoms but ambulatory,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 66, bmi: 25.38, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type","The patient is a 66-year-old white female with a BMI of 25.38. She is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cancer cells. Despite experiencing symptoms, she is still able to walk around (ambulatory). The KRAS biomarker indicates that she has a wild-type mutation."
1905,other,female,59,22.68,FOLFOX + Cetuximab,Yes,No,Yes,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: other, sex: female, age: 59, bmi: 22.68, treatment arm: FOLFOX + Cetuximab, adherence: Yes, bowel obstruction: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 59-year-old female of a race categorized as ""other"" with a BMI of 22.68. She is receiving treatment in the FOLFOX + Cetuximab treatment arm and has been adherent to her treatment. She has experienced a bowel obstruction. The patient has completed 12 cycles of chemotherapy and has well-differentiated histology. Her performance status is fully active, and her KRAS biomarker is wild-type."
1906,white,female,46,28.73,FOLFOX,No,Yes,Yes,No,12,well differentiated,fully active,mutant,No,No,No,No,No,1,"race: white, sex: female, age: 46, bmi: 28.73, treatment arm: FOLFOX, serious adverse effect: Yes, bowel obstruction: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 46-year-old white female with a BMI of 28.73. She is undergoing treatment with the FOLFOX regimen and has experienced a serious adverse effect, specifically a bowel obstruction. She has completed 12 cycles of chemotherapy. The histology shows that the cancer is well-differentiated. Despite the adverse effect, her performance status is fully active. Additionally, the KRAS biomarker testing revealed a mutant status."
1907,white,female,36,29.09,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 36, bmi: 29.09, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 36-year-old white female with a BMI of 29.09. She is receiving treatment with FOLFOX + Cetuximab and is scheduled for 12 chemotherapy cycles. Her cancer histology is well-differentiated, and she has a fully active performance status. Additionally, her KRAS biomarker status is wild-type."
1908,black,female,64,32.08,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,fully active,mutant,No,No,No,No,No,0,"race: black, sex: female, age: 64, bmi: 32.08, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 64-year-old Black female with a BMI of 32.08. She is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cancer cells. Despite her age, she has a fully active performance status. Additionally, the KRAS biomarker testing revealed a mutant status."
1909,white,male,59,35.35,FOLFOX + Cetuximab,Yes,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 59, bmi: 35.35, treatment arm: FOLFOX + Cetuximab, adherence: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 59-year-old white male with a BMI of 35.35. He is receiving treatment in the FOLFOX + Cetuximab treatment arm and has been adherent to the treatment. He has completed 12 chemotherapy cycles. His histology shows well-differentiated cells, and he has a fully active performance status. The KRAS biomarker indicates that he has a wild-type mutation."
1910,white,female,66,21.73,FOLFOX,No,No,No,No,0,well differentiated,fully active,mutant,No,No,No,No,No,0,"race: white, sex: female, age: 66, bmi: 21.73, treatment arm: FOLFOX, chemotherapy cycles: 0, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant",The patient is a 66-year-old white female with a BMI of 21.73. She is enrolled in the FOLFOX treatment arm but has not started chemotherapy cycles yet. Her histology shows well-differentiated cancer cells. The patient has a fully active performance status. The KRAS biomarker testing revealed a mutant status.
1911,white,male,45,34.16,FOLFOX + Cetuximab,No,No,Yes,No,12,poorly differentiated,fully active,mutant,Yes,No,No,No,No,0,"race: white, sex: male, age: 45, bmi: 34.16, treatment arm: FOLFOX + Cetuximab, bowel obstruction: Yes, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: mutant, adverse effect: thrombosis: Yes","The patient is a 45-year-old white male with a BMI of 34.16. He is receiving treatment with FOLFOX + Cetuximab for his poorly differentiated histology. He has experienced a bowel obstruction and thrombosis as adverse effects during his 12 chemotherapy cycles. Despite these challenges, his performance status remains fully active. Additionally, his KRAS biomarker is mutant."
1912,white,male,46,29.33,FOLFOX,No,No,No,No,1,well differentiated,symptoms but ambulatory,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 46, bmi: 29.33, treatment arm: FOLFOX, chemotherapy cycles: 1, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type","The patient is a 46-year-old white male with a BMI of 29.33. He is receiving treatment with the FOLFOX chemotherapy regimen and has completed one cycle so far. His cancer histology is well-differentiated. Despite experiencing symptoms, he is still able to be ambulatory. The KRAS biomarker testing showed that he has a wild-type KRAS status."
1913,white,male,57,33.83,FOLFIRI (KRAS mutant),Yes,No,Yes,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,1,"race: white, sex: male, age: 57, bmi: 33.83, treatment arm: FOLFIRI (KRAS mutant), adherence: Yes, bowel obstruction: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 57-year-old white male with a BMI of 33.83. He is receiving the FOLFIRI treatment regimen for his KRAS mutant status and has been adherent to the treatment. He has experienced a bowel obstruction. The patient has completed 12 cycles of chemotherapy and has well-differentiated histology. Despite the bowel obstruction, his performance status is fully active. His KRAS biomarker is wild-type."
1914,white,male,54,25.21,FOLFIRI + Cetuximab,No,Yes,No,No,8,well differentiated,fully active,mutant,No,No,Yes,No,No,0,"race: white, sex: male, age: 54, bmi: 25.21, treatment arm: FOLFIRI + Cetuximab, serious adverse effect: Yes, chemotherapy cycles: 8, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant, adverse effect: diarrhea: Yes","The patient is a 54-year-old white male with a BMI of 25.21. He is receiving the FOLFIRI + Cetuximab treatment regimen and has experienced a serious adverse effect. He has completed 8 cycles of chemotherapy. His histology shows well-differentiated cells, and his performance status is fully active. The KRAS biomarker indicates a mutant status. Additionally, he is experiencing diarrhea as an adverse effect of the treatment."
1915,white,male,64,28.39,FOLFOX,No,No,No,No,12,well differentiated,fully active,mutant,No,No,No,No,No,0,"race: white, sex: male, age: 64, bmi: 28.39, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 64-year-old white male with a BMI of 28.39. He is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. His cancer histology is well-differentiated. Despite his age, he has a fully active performance status. The KRAS biomarker testing revealed a mutant status."
1916,white,male,44,23.99,FOLFOX + Cetuximab,No,No,No,No,12,poorly differentiated,in bed less than 50% of the time,mutant,No,No,No,No,No,1,"race: white, sex: male, age: 44, bmi: 23.99, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: poorly differentiated, performance status: in bed less than 50% of the time, KRAS biomarker: mutant","The patient is a 44-year-old white male with a BMI of 23.99. He is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. His histology shows poorly differentiated cancer cells. The patient's performance status indicates that he is in bed less than 50% of the time. Additionally, the KRAS biomarker testing revealed a mutant status."
1917,white,male,40,28.33,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,fully active,mutant,No,No,No,No,No,0,"race: white, sex: male, age: 40, bmi: 28.33, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant",The patient is a 40-year-old white male with a BMI of 28.33. He is receiving treatment with FOLFOX + Cetuximab and is scheduled for 12 chemotherapy cycles. The histology shows well-differentiated cancer cells. The patient has a fully active performance status. The KRAS biomarker analysis indicates a mutant status.
1918,white,male,43,30.27,FOLFOX,No,No,No,No,12,well differentiated,fully active,mutant,No,No,No,No,No,0,"race: white, sex: male, age: 43, bmi: 30.27, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 43-year-old white male with a BMI of 30.27. He is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer cells. The patient has a fully active performance status. Additionally, the KRAS biomarker testing revealed a mutant result."
1919,white,female,69,42.72,FOLFOX + Cetuximab,No,Yes,Yes,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 69, bmi: 42.72, treatment arm: FOLFOX + Cetuximab, serious adverse effect: Yes, bowel obstruction: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 69-year-old white female with a BMI of 42.72. She is receiving treatment with FOLFOX + Cetuximab. She experienced a serious adverse effect and developed a bowel obstruction. She has completed 12 cycles of chemotherapy. The histology shows well-differentiated cells. Despite these challenges, her performance status is fully active. The KRAS biomarker indicates that she has a wild-type mutation."
1920,black,female,56,27.04,FOLFOX,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: black, sex: female, age: 56, bmi: 27.04, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 56-year-old Black female with a BMI of 27.04. She is receiving the FOLFOX treatment arm and has completed 12 cycles of chemotherapy. The histology shows well-differentiated cells, and her performance status is fully active. The KRAS biomarker indicates that she has a wild-type status."
1921,white,male,64,24.38,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,symptoms but ambulatory,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 64, bmi: 24.38, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type","The patient is a 64-year-old white male with a BMI of 24.38. He is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. His cancer histology is well-differentiated. Despite experiencing symptoms, he is still able to ambulate. His KRAS biomarker status is wild-type."
1922,white,male,38,25.28,FOLFOX,No,No,No,No,12,well differentiated,symptoms but ambulatory,mutant,No,No,No,No,No,0,"race: white, sex: male, age: 38, bmi: 25.28, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: mutant","The patient is a 38-year-old white male with a BMI of 25.28. He is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer cells. Despite experiencing symptoms, he is still able to walk around (ambulatory). The KRAS biomarker testing revealed a mutation in the KRAS gene."
1923,white,male,35,32.65,FOLFOX,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 35, bmi: 32.65, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 35-year-old white male with a BMI of 32.65. He is receiving the FOLFOX treatment regimen and is scheduled for 12 cycles of chemotherapy. His cancer histology is well-differentiated, and he has a fully active performance status. The KRAS biomarker testing revealed that he has a wild-type KRAS status."
1924,white,female,52,19.61,FOLFOX + Cetuximab,No,No,No,No,12,poorly differentiated,fully active,wild-type,No,No,No,No,No,1,"race: white, sex: female, age: 52, bmi: 19.61, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 52-year-old white female with a BMI of 19.61. She is undergoing treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. Her histology shows poorly differentiated cancer cells. Despite this, her performance status is fully active. Additionally, her KRAS biomarker is wild-type."
1925,white,female,48,27.24,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,fully active,mutant,No,No,Yes,No,No,0,"race: white, sex: female, age: 48, bmi: 27.24, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant, adverse effect: diarrhea: Yes","The patient is a 48-year-old white female with a BMI of 27.24. She is receiving treatment with FOLFOX + Cetuximab and has completed 12 chemotherapy cycles. Her histology shows well-differentiated cancer, and she has a fully active performance status. The KRAS biomarker analysis indicates a mutant status. The patient is experiencing diarrhea as an adverse effect of the treatment."
1926,white,male,70,31.14,FOLFOX,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 70, bmi: 31.14, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 70-year-old white male with a BMI of 31.14. He is receiving the FOLFOX treatment arm and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cells, and he has a fully active performance status. The KRAS biomarker indicates that he has a wild-type status."
1927,white,female,53,19.72,FOLFOX + Cetuximab,No,No,Yes,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 53, bmi: 19.72, treatment arm: FOLFOX + Cetuximab, bowel obstruction: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 53-year-old white female with a BMI of 19.72. She is receiving treatment with FOLFOX + Cetuximab for her cancer. She has experienced a bowel obstruction and has completed 12 cycles of chemotherapy. The histology of her cancer is well differentiated. Despite her bowel obstruction, her performance status is fully active. Her KRAS biomarker status is wild-type."
1928,white,male,76,32.65,FOLFOX,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 76, bmi: 32.65, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 76-year-old white male with a BMI of 32.65. He is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. His cancer histology is well differentiated, and he has a fully active performance status. The KRAS biomarker analysis shows that he has a wild-type KRAS status."
1929,white,male,62,24.5,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,fully active,mutant,No,No,No,No,No,1,"race: white, sex: male, age: 62, bmi: 24.5, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 62-year-old white male with a BMI of 24.5. He is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cells, and he has a fully active performance status. The KRAS biomarker indicates a mutant status."
1930,black,female,56,26.82,FOLFOX + Cetuximab,No,No,Yes,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: black, sex: female, age: 56, bmi: 26.82, treatment arm: FOLFOX + Cetuximab, bowel obstruction: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 56-year-old Black female with a BMI of 26.82. She is receiving treatment with FOLFOX + Cetuximab for her well-differentiated histology. She has experienced a bowel obstruction and has completed 12 cycles of chemotherapy. Despite this, her performance status is fully active. Her KRAS biomarker status is wild-type."
1931,white,male,76,31.82,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 76, bmi: 31.82, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 76-year-old white male with a BMI of 31.82. He is receiving treatment in the FOLFOX + Cetuximab treatment arm and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cells, and he has a fully active performance status. The KRAS biomarker analysis indicates that he has a wild-type KRAS status."
1932,white,female,63,21.47,FOLFOX + Cetuximab,No,No,No,No,12,poorly differentiated,symptoms but ambulatory,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 63, bmi: 21.47, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: poorly differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type","The patient is a 63-year-old white female with a BMI of 21.47. She is receiving treatment in the FOLFOX + Cetuximab treatment arm and is scheduled for 12 chemotherapy cycles. Her histology shows poorly differentiated cancer cells. Despite experiencing symptoms, she is still able to walk around (ambulatory). The KRAS biomarker analysis indicates that she has a wild-type KRAS gene."
1933,white,male,67,22.75,FOLFOX,No,No,No,No,9,poorly differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 67, bmi: 22.75, treatment arm: FOLFOX, chemotherapy cycles: 9, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 67-year-old white male with a BMI of 22.75. He is receiving the FOLFOX treatment arm and has completed 9 cycles of chemotherapy. His histology shows poorly differentiated cancer cells. Despite this, his performance status is fully active. The KRAS biomarker analysis indicates that he has a wild-type KRAS gene."
1934,white,female,66,18.93,FOLFOX + Cetuximab,No,No,No,No,12,poorly differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 66, bmi: 18.93, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 66-year-old white female with a BMI of 18.93. She is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. Her cancer histology is poorly differentiated. Despite her cancer diagnosis, she has a fully active performance status. The KRAS biomarker testing revealed that she has a wild-type KRAS status."
1935,white,female,57,21.71,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 57, bmi: 21.71, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 57-year-old white female with a BMI of 21.71. She is receiving treatment in the FOLFOX + Cetuximab treatment arm and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cancer cells. Despite her cancer diagnosis, she has a fully active performance status. Additionally, her KRAS biomarker is wild-type."
1936,white,female,52,30.12,FOLFOX + Cetuximab,No,No,Yes,No,12,well differentiated,fully active,wild-type,Yes,No,No,No,No,0,"race: white, sex: female, age: 52, bmi: 30.12, treatment arm: FOLFOX + Cetuximab, bowel obstruction: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type, adverse effect: thrombosis: Yes","This patient is a 52-year-old white female with a BMI of 30.12. She is receiving treatment with FOLFOX + Cetuximab for her well-differentiated histology. She has experienced a bowel obstruction and has undergone 12 cycles of chemotherapy. Despite the adverse effect of thrombosis, her performance status remains fully active. Additionally, her KRAS biomarker status is wild-type."
1937,other,female,65,38.79,FOLFOX,Yes,No,No,No,12,well differentiated,symptoms but ambulatory,interminate,No,No,No,No,No,0,"race: other, sex: female, age: 65, bmi: 38.79, treatment arm: FOLFOX, adherence: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: interminate","The patient is a 65-year-old female of a race categorized as ""other"" with a BMI of 38.79. She is undergoing treatment with the FOLFOX regimen and has been adherent to the treatment. She has completed 12 cycles of chemotherapy. The histology of her condition is well-differentiated. Despite experiencing symptoms, she is still able to be ambulatory. The KRAS biomarker status is indeterminate for this patient."
1938,white,male,44,25.47,FOLFOX,Yes,No,Yes,No,12,poorly differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 44, bmi: 25.47, treatment arm: FOLFOX, adherence: Yes, bowel obstruction: Yes, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 44-year-old white male with a BMI of 25.47. He is receiving the FOLFOX treatment regimen and has been adherent to the treatment. He has experienced a bowel obstruction. The patient has completed 12 cycles of chemotherapy and has a histology of poorly differentiated cancer. Despite these challenges, his performance status is fully active. Additionally, the KRAS biomarker analysis shows that he has a wild-type KRAS status."
1939,white,female,63,25.15,FOLFOX,No,No,No,No,12,poorly differentiated,fully active,mutant,No,No,No,No,No,0,"race: white, sex: female, age: 63, bmi: 25.15, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 63-year-old white female with a BMI of 25.15. She is undergoing treatment with the FOLFOX chemotherapy regimen and has completed 12 cycles. The histology of her cancer is poorly differentiated. Despite this, her performance status is fully active. Additionally, the KRAS biomarker testing revealed a mutant status."
1940,white,female,56,30.11,FOLFOX + Cetuximab,No,No,No,No,3,well differentiated,symptoms but ambulatory,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 56, bmi: 30.11, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 3, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type","The patient is a 56-year-old white female with a BMI of 30.11. She is currently receiving treatment in the FOLFOX + Cetuximab treatment arm and has completed 3 cycles of chemotherapy. Her histology shows well-differentiated cancer cells. Despite experiencing symptoms, she is still able to walk around (ambulatory). The KRAS biomarker analysis indicates that she has a wild-type KRAS status."
1941,white,male,67,22.69,FOLFOX + Cetuximab,No,No,No,No,11,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 67, bmi: 22.69, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 11, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 67-year-old white male with a BMI of 22.69. He is undergoing treatment with FOLFOX + Cetuximab and has completed 11 cycles of chemotherapy. His histology shows well-differentiated cancer, and he has a fully active performance status. The KRAS biomarker analysis indicates that he has a wild-type KRAS status."
1942,white,female,50,23.45,FOLFOX,No,No,No,No,9,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 50, bmi: 23.45, treatment arm: FOLFOX, chemotherapy cycles: 9, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type",The patient is a 50-year-old white female with a BMI of 23.45. She is receiving the FOLFOX treatment regimen and has completed 9 cycles of chemotherapy. The histology shows well-differentiated cancer cells. The patient has a fully active performance status. The KRAS biomarker analysis indicates that she has a wild-type KRAS status.
1943,white,female,50,26.9,FOLFOX,No,Yes,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 50, bmi: 26.9, treatment arm: FOLFOX, serious adverse effect: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 50-year-old white female with a BMI of 26.9. She is receiving the FOLFOX treatment regimen and has experienced a serious adverse effect. She has completed 12 cycles of chemotherapy. The histology shows that the cancer is well-differentiated. Despite the treatment, her performance status is fully active. The KRAS biomarker analysis indicates that she has a wild-type KRAS status."
1944,other,female,56,28.34,FOLFOX,No,No,No,No,6,well differentiated,symptoms but ambulatory,wild-type,No,No,No,No,No,0,"race: other, sex: female, age: 56, bmi: 28.34, treatment arm: FOLFOX, chemotherapy cycles: 6, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type","The patient is a 56-year-old female of a race classified as ""other"" with a BMI of 28.34. She is undergoing treatment with the FOLFOX chemotherapy regimen and has completed 6 cycles. The histology of her condition is well-differentiated. Despite experiencing symptoms, she is still able to be ambulatory. The KRAS biomarker analysis indicates that she has a wild-type KRAS status."
1945,white,female,56,31.52,FOLFOX,No,No,No,No,12,poorly differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 56, bmi: 31.52, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 56-year-old white female with a BMI of 31.52. She is receiving treatment with the FOLFOX chemotherapy regimen and is scheduled for 12 cycles. Her histology shows poorly differentiated cancer cells. Despite this, her performance status is fully active. Additionally, her KRAS biomarker indicates that it is wild-type."
1946,white,female,45,29.79,FOLFOX,No,No,Yes,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 45, bmi: 29.79, treatment arm: FOLFOX, bowel obstruction: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 45-year-old white female with a BMI of 29.79. She is receiving treatment with the FOLFOX regimen for her well-differentiated histology. She has experienced a bowel obstruction and has completed 12 cycles of chemotherapy. Despite the bowel obstruction, her performance status is fully active. Her KRAS biomarker status is wild-type."
1947,white,male,59,33.14,FOLFOX,Yes,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 59, bmi: 33.14, treatment arm: FOLFOX, adherence: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type",The patient is a 59-year-old white male with a BMI of 33.14. He is receiving the FOLFOX treatment regimen and has been adherent to the treatment. He has completed 12 cycles of chemotherapy. The histology shows well-differentiated cancer cells. The patient has a fully active performance status. The KRAS biomarker indicates that he has a wild-type gene.
1948,white,male,44,34.51,FOLFOX + Cetuximab,No,No,Yes,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 44, bmi: 34.51, treatment arm: FOLFOX + Cetuximab, bowel obstruction: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","This patient is a 44-year-old white male with a BMI of 34.51. He is receiving treatment with FOLFOX + Cetuximab for his well-differentiated histology. He has experienced a bowel obstruction and has completed 12 cycles of chemotherapy. Despite the bowel obstruction, his performance status is fully active. His KRAS biomarker status is wild-type."
1949,other,female,59,25.33,FOLFOX,No,No,No,No,12,well differentiated,symptoms but ambulatory,wild-type,No,No,No,No,No,0,"race: other, sex: female, age: 59, bmi: 25.33, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type","The patient is a 59-year-old female of a race categorized as ""other"" with a BMI of 25.33. She is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. The histology of her cancer is well-differentiated. Despite experiencing symptoms, she is still able to ambulate, indicating a relatively good performance status. Additionally, her KRAS biomarker status is wild-type."
1950,white,female,54,26.66,FOLFOX,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 54, bmi: 26.66, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type",The patient is a 54-year-old white female with a BMI of 26.66. She is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cancer cells. The patient has a fully active performance status and her KRAS biomarker is wild-type.
1951,white,male,54,25.74,FOLFIRI,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 54, bmi: 25.74, treatment arm: FOLFIRI, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 54-year-old white male with a BMI of 25.74. He is receiving the FOLFIRI treatment regimen and has completed 12 cycles of chemotherapy. His cancer histology is well differentiated, and he has a fully active performance status. The KRAS biomarker analysis shows that he has a wild-type KRAS status."
1952,white,male,64,25.96,FOLFOX,No,No,No,No,12,poorly differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 64, bmi: 25.96, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 64-year-old white male with a BMI of 25.96. He is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. His cancer histology is poorly differentiated. Despite his cancer diagnosis, he has a fully active performance status. Additionally, his KRAS biomarker status is wild-type."
1953,white,male,66,25.12,FOLFOX,No,No,No,No,12,well differentiated,symptoms but ambulatory,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 66, bmi: 25.12, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type","The patient is a 66-year-old white male with a BMI of 25.12. He is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. His cancer histology is well-differentiated. Despite experiencing symptoms, he is still able to be ambulatory. The KRAS biomarker analysis shows that he has a wild-type KRAS status."
1954,black,male,64,31.87,FOLFOX,No,No,No,No,12,poorly differentiated,fully active,wild-type,No,No,No,No,No,1,"race: black, sex: male, age: 64, bmi: 31.87, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 64-year-old Black male with a BMI of 31.87. He is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. His histology shows poorly differentiated cancer cells. Despite this, his performance status is fully active. Additionally, his KRAS biomarker indicates that he has a wild-type status."
1955,white,male,67,24.78,FOLFOX,No,Yes,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 67, bmi: 24.78, treatment arm: FOLFOX, serious adverse effect: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 67-year-old white male with a BMI of 24.78. He is receiving the FOLFOX treatment regimen and has experienced a serious adverse effect. He has completed 12 cycles of chemotherapy. The histology of his condition is well-differentiated. Despite the adverse effect, his performance status is fully active. The KRAS biomarker analysis indicates that he has a wild-type KRAS status."
1956,white,female,58,22.23,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 58, bmi: 22.23, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 58-year-old white female with a BMI of 22.23. She is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. Her cancer histology is well-differentiated, and she has a fully active performance status. The KRAS biomarker analysis shows that she has a wild-type KRAS status."
1957,white,male,68,27.69,FOLFOX,No,No,No,No,4,well differentiated,symptoms but ambulatory,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 68, bmi: 27.69, treatment arm: FOLFOX, chemotherapy cycles: 4, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type","The patient is a 68-year-old white male with a BMI of 27.69. He is currently receiving the FOLFOX treatment regimen and has completed 4 cycles of chemotherapy. His histology shows well-differentiated cancer cells. Despite experiencing symptoms, he is still able to be ambulatory. The KRAS biomarker analysis indicates that he has a wild-type KRAS status."
1958,other,female,63,22.18,FOLFIRI,No,Yes,No,No,7,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: other, sex: female, age: 63, bmi: 22.18, treatment arm: FOLFIRI, serious adverse effect: Yes, chemotherapy cycles: 7, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 63-year-old female of a race other than specified, with a BMI of 22.18. She is undergoing treatment with the FOLFIRI chemotherapy regimen and has experienced a serious adverse effect. She has completed 7 cycles of chemotherapy. The histology of her condition is well-differentiated. Despite the adverse effect, her performance status is fully active. The KRAS biomarker analysis indicates that she has a wild-type KRAS status."
1959,white,male,62,31.77,FOLFOX,No,No,No,No,12,poorly differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 62, bmi: 31.77, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 62-year-old white male with a BMI of 31.77. He is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. His cancer histology is poorly differentiated. Despite his diagnosis, he has a fully active performance status. Additionally, his KRAS biomarker status is wild-type."
1960,white,female,74,38.01,FOLFOX,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 74, bmi: 38.01, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 74-year-old white female with a BMI of 38.01. She is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. Her cancer histology is well differentiated. Despite her age, she has a fully active performance status. The KRAS biomarker testing revealed that she has a wild-type KRAS status."
1961,white,male,42,41.6,FOLFOX,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 42, bmi: 41.6, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type",The patient is a 42-year-old white male with a BMI of 41.6. He is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. His cancer histology is well differentiated. The patient has a fully active performance status and his KRAS biomarker is wild-type.
1962,white,female,61,36.58,FOLFOX,No,No,No,No,8,well differentiated,fully active,wild-type,No,No,Yes,No,No,0,"race: white, sex: female, age: 61, bmi: 36.58, treatment arm: FOLFOX, chemotherapy cycles: 8, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type, adverse effect: diarrhea: Yes","The patient is a 61-year-old white female with a BMI of 36.58. She is receiving the FOLFOX treatment arm and has completed 8 cycles of chemotherapy. Her histology shows well-differentiated cells, and her performance status is fully active. The KRAS biomarker indicates she has a wild-type status. The patient is experiencing diarrhea as an adverse effect."
1963,white,female,69,33.19,FOLFOX + Cetuximab,No,Yes,No,No,12,well differentiated,fully active,wild-type,No,No,Yes,No,No,0,"race: white, sex: female, age: 69, bmi: 33.19, treatment arm: FOLFOX + Cetuximab, serious adverse effect: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type, adverse effect: diarrhea: Yes","The patient is a 69-year-old white female with a BMI of 33.19. She is receiving treatment with FOLFOX + Cetuximab and has experienced a serious adverse effect. She has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cells, and her performance status is fully active. The KRAS biomarker indicates she is wild-type. Additionally, she has experienced diarrhea as an adverse effect of her treatment."
1964,white,male,58,28.13,FOLFOX + Cetuximab,Yes,No,Yes,No,12,well differentiated,fully active,mutant,No,No,No,No,No,0,"race: white, sex: male, age: 58, bmi: 28.13, treatment arm: FOLFOX + Cetuximab, adherence: Yes, bowel obstruction: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 58-year-old white male with a BMI of 28.13. He is receiving treatment in the FOLFOX + Cetuximab treatment arm and has been adherent to the treatment. He has experienced a bowel obstruction and has completed 12 cycles of chemotherapy. The histology shows well-differentiated cells, and his performance status is fully active. The KRAS biomarker indicates a mutant status."
1965,white,male,63,25.96,FOLFOX + Cetuximab,No,No,No,No,3,well differentiated,symptoms but ambulatory,wild-type,No,No,Yes,No,No,0,"race: white, sex: male, age: 63, bmi: 25.96, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 3, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type, adverse effect: diarrhea: Yes","The patient is a 63-year-old white male with a BMI of 25.96. He is currently receiving treatment with FOLFOX + Cetuximab and has completed 3 cycles of chemotherapy. His cancer histology is well-differentiated, and he has symptoms but is still able to ambulate. The KRAS biomarker testing showed that he has a wild-type result. The patient is experiencing diarrhea as an adverse effect of the treatment."
1966,black,female,68,28.3,FOLFOX + Cetuximab,No,No,No,Yes,7,well differentiated,fully active,wild-type,No,No,No,Yes,No,0,"race: black, sex: female, age: 68, bmi: 28.3, treatment arm: FOLFOX + Cetuximab, bowel perforation: Yes, chemotherapy cycles: 7, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type, adverse effect: infection: Yes","This patient is a 68-year-old Black female with a BMI of 28.3. She is receiving treatment with FOLFOX + Cetuximab and has experienced a bowel perforation. She has completed 7 cycles of chemotherapy and her histology shows well-differentiated cells. Despite the bowel perforation, her performance status is fully active. Her KRAS biomarker is wild-type. Additionally, she has experienced an infection as an adverse effect of treatment."
1967,white,male,44,22.72,FOLFOX,No,No,No,No,12,poorly differentiated,fully active,mutant,No,No,No,No,No,0,"race: white, sex: male, age: 44, bmi: 22.72, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 44-year-old white male with a BMI of 22.72. He is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. The histology of his cancer is poorly differentiated. Despite his cancer diagnosis, he has a fully active performance status. Additionally, the KRAS biomarker testing revealed a mutant status."
1968,white,female,59,20.87,FOLFOX + Cetuximab,No,No,No,No,12,poorly differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 59, bmi: 20.87, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 59-year-old white female with a BMI of 20.87. She is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. Her histology shows poorly differentiated cancer. Despite this, her performance status is fully active. Additionally, her KRAS biomarker indicates that it is wild-type."
1969,white,female,63,20.58,FOLFIRI (KRAS mutant),No,No,Yes,No,2,well differentiated,fully active,mutant,Yes,No,No,No,No,0,"race: white, sex: female, age: 63, bmi: 20.58, treatment arm: FOLFIRI (KRAS mutant), bowel obstruction: Yes, chemotherapy cycles: 2, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant, adverse effect: thrombosis: Yes","The patient is a 63-year-old white female with a BMI of 20.58. She is receiving the FOLFIRI treatment arm for her KRAS mutant status. She has experienced a bowel obstruction and has completed 2 cycles of chemotherapy. Her histology shows well-differentiated cells, and her performance status is fully active. The patient has a mutant KRAS biomarker and has experienced thrombosis as an adverse effect."
1970,white,female,51,26.33,FOLFOX,No,No,No,No,8,poorly differentiated,fully active,wild-type,Yes,No,No,No,No,1,"race: white, sex: female, age: 51, bmi: 26.33, treatment arm: FOLFOX, chemotherapy cycles: 8, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type, adverse effect: thrombosis: Yes","The patient is a 51-year-old white female with a BMI of 26.33. She is undergoing treatment with FOLFOX chemotherapy regimen and has completed 8 cycles. The histology of her cancer is poorly differentiated. Despite this, her performance status is fully active. The KRAS biomarker testing revealed that she has a wild-type KRAS status. Additionally, she has experienced an adverse effect of thrombosis."
1971,white,female,44,33.41,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,fully active,mutant,No,No,No,No,No,0,"race: white, sex: female, age: 44, bmi: 33.41, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 44-year-old white female with a BMI of 33.41. She is receiving treatment in the FOLFOX + Cetuximab treatment arm and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cells, and she has a fully active performance status. The KRAS biomarker analysis indicates a mutant status."
1972,white,female,72,22.73,FOLFIRI,No,Yes,No,No,5,well differentiated,symptoms but ambulatory,wild-type,No,No,No,No,No,1,"race: white, sex: female, age: 72, bmi: 22.73, treatment arm: FOLFIRI, serious adverse effect: Yes, chemotherapy cycles: 5, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type","The patient is a 72-year-old white female with a BMI of 22.73. She is undergoing treatment with the FOLFIRI regimen and has experienced a serious adverse effect. She has completed 5 cycles of chemotherapy. The histology shows well-differentiated cancer cells. Despite experiencing symptoms, she is still able to be ambulatory. The KRAS biomarker indicates that she has a wild-type status."
1973,white,male,42,35,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 42, bmi: 35.0, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 42-year-old white male with a BMI of 35.0. He is receiving treatment in the FOLFOX + Cetuximab treatment arm and is scheduled for 12 chemotherapy cycles. His cancer histology is well-differentiated, and he has a fully active performance status. The KRAS biomarker analysis shows that he has a wild-type KRAS status."
1974,black,male,60,25.72,FOLFIRI + Cetuximab,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: black, sex: male, age: 60, bmi: 25.72, treatment arm: FOLFIRI + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 60-year-old Black male with a BMI of 25.72. He is receiving treatment with FOLFIRI + Cetuximab and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer cells. Despite his cancer diagnosis, he has a fully active performance status. Additionally, his KRAS biomarker status is wild-type."
1975,white,female,57,29.93,FOLFOX + Cetuximab,No,No,No,Yes,12,poorly differentiated,symptoms but ambulatory,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 57, bmi: 29.93, treatment arm: FOLFOX + Cetuximab, bowel perforation: Yes, chemotherapy cycles: 12, histology: poorly differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type","The patient is a 57-year-old white female with a BMI of 29.93. She is receiving treatment with FOLFOX + Cetuximab and has experienced a bowel perforation. She has completed 12 cycles of chemotherapy. The histology of her cancer is poorly differentiated. Despite experiencing symptoms, she is still able to be ambulatory. Her KRAS biomarker status is wild-type."
1976,white,female,35,42.34,FOLFOX,No,No,No,No,6,well differentiated,symptoms but ambulatory,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 35, bmi: 42.34, treatment arm: FOLFOX, chemotherapy cycles: 6, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type","The patient is a 35-year-old white female with a BMI of 42.34. She is receiving the FOLFOX treatment regimen and has completed 6 cycles of chemotherapy. Her histology shows well-differentiated cancer cells. Despite experiencing symptoms, she is still able to be ambulatory. The KRAS biomarker analysis indicates that she has a wild-type KRAS status."
1977,white,male,50,32.38,FOLFOX + Cetuximab,No,No,No,No,0,poorly differentiated,fully active,interminate,No,No,No,No,No,1,"race: white, sex: male, age: 50, bmi: 32.38, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 0, histology: poorly differentiated, performance status: fully active, KRAS biomarker: interminate","The patient is a 50-year-old white male with a BMI of 32.38. He is enrolled in the treatment arm receiving FOLFOX + Cetuximab but has not started chemotherapy cycles yet. His histology shows poorly differentiated cancer, and he has a fully active performance status. The KRAS biomarker status is indeterminate for this patient."
1978,other,male,63,28.92,FOLFOX + Cetuximab,No,No,Yes,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: other, sex: male, age: 63, bmi: 28.92, treatment arm: FOLFOX + Cetuximab, bowel obstruction: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 63-year-old male of a race categorized as ""other"" with a BMI of 28.92. He is receiving treatment with FOLFOX + Cetuximab and has experienced a bowel obstruction. He has completed 12 cycles of chemotherapy. The histology of his condition is well-differentiated. Despite the bowel obstruction, his performance status is fully active. Additionally, his KRAS biomarker status is wild-type."
1979,white,male,55,25.42,FOLFOX,Yes,No,No,No,12,poorly differentiated,in bed less than 50% of the time,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 55, bmi: 25.42, treatment arm: FOLFOX, adherence: Yes, chemotherapy cycles: 12, histology: poorly differentiated, performance status: in bed less than 50% of the time, KRAS biomarker: wild-type",The patient is a 55-year-old white male with a BMI of 25.42. He is receiving the FOLFOX treatment regimen and has adhered to the treatment. He has completed 12 cycles of chemotherapy. The histology shows poorly differentiated cancer cells. His performance status indicates that he is in bed less than 50% of the time. The KRAS biomarker analysis shows that he has a wild-type KRAS gene.
1980,white,male,60,27.04,FOLFOX + Cetuximab,No,No,No,No,5,poorly differentiated,fully active,wild-type,No,No,Yes,No,No,0,"race: white, sex: male, age: 60, bmi: 27.04, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 5, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type, adverse effect: diarrhea: Yes","The patient is a 60-year-old white male with a BMI of 27.04. He is receiving treatment with FOLFOX + Cetuximab and has completed 5 cycles of chemotherapy. The histology of his cancer is poorly differentiated. Despite this, his performance status is fully active. His KRAS biomarker status is wild-type. The patient is experiencing diarrhea as an adverse effect of the treatment."
1981,white,female,55,25.96,FOLFOX,Yes,No,No,No,3,well differentiated,symptoms but ambulatory,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 55, bmi: 25.96, treatment arm: FOLFOX, adherence: Yes, chemotherapy cycles: 3, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type","The patient is a 55-year-old white female with a BMI of 25.96. She is receiving the FOLFOX treatment regimen and has been adherent to her chemotherapy. She has completed 3 cycles of chemotherapy. Her histology shows well-differentiated cancer cells. Despite experiencing symptoms, she is still able to be ambulatory. The KRAS biomarker analysis indicates that she has a wild-type KRAS status."
1982,white,female,62,31.83,FOLFIRI,No,Yes,No,No,12,well differentiated,symptoms but ambulatory,wild-type,No,No,No,No,No,1,"race: white, sex: female, age: 62, bmi: 31.83, treatment arm: FOLFIRI, serious adverse effect: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type","The patient is a 62-year-old white female with a BMI of 31.83. She is undergoing treatment with the FOLFIRI chemotherapy regimen and has experienced a serious adverse effect. She has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cells. Despite experiencing symptoms, she is still able to be ambulatory. The KRAS biomarker analysis indicates that she has a wild-type KRAS status."
1983,white,female,67,27.26,FOLFIRI + Cetuximab,Yes,Yes,No,No,12,poorly differentiated,fully active,wild-type,No,No,Yes,No,No,0,"race: white, sex: female, age: 67, bmi: 27.26, treatment arm: FOLFIRI + Cetuximab, adherence: Yes, serious adverse effect: Yes, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type, adverse effect: diarrhea: Yes","The patient is a 67-year-old white female with a BMI of 27.26. She is receiving treatment with FOLFIRI + Cetuximab and has been adherent to the treatment. She experienced a serious adverse effect during the treatment. She has completed 12 cycles of chemotherapy. The histology of her cancer is poorly differentiated. Despite this, her performance status is fully active. Her KRAS biomarker is wild-type. She has also experienced diarrhea as an adverse effect of the treatment."
1984,white,male,76,26.39,FOLFOX + Cetuximab,No,No,No,No,1,poorly differentiated,symptoms but ambulatory,wild-type,No,No,Yes,No,No,0,"race: white, sex: male, age: 76, bmi: 26.39, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 1, histology: poorly differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type, adverse effect: diarrhea: Yes","The patient is a 76-year-old white male with a BMI of 26.39. He is currently receiving treatment with FOLFOX + Cetuximab and has completed one cycle of chemotherapy. His histology shows poorly differentiated cancer cells. Despite experiencing symptoms, he is still able to walk around (ambulatory). His KRAS biomarker is wild-type. The patient is experiencing diarrhea as an adverse effect of the treatment."
1985,white,female,51,42.94,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 51, bmi: 42.94, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 51-year-old white female with a BMI of 42.94. She is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. Her cancer histology is well-differentiated, and she has a fully active performance status. The KRAS biomarker testing showed that she has a wild-type KRAS status."
1986,white,male,68,26.97,FOLFOX,No,No,No,No,12,poorly differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 68, bmi: 26.97, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 68-year-old white male with a BMI of 26.97. He is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. His histology shows poorly differentiated cancer cells. Despite this, his performance status is fully active. Additionally, the KRAS biomarker analysis indicates that he has a wild-type KRAS gene."
1987,white,male,45,24.39,FOLFOX,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 45, bmi: 24.39, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 45-year-old white male with a BMI of 24.39. He is receiving treatment with the FOLFOX chemotherapy regimen and has completed 12 cycles so far. His cancer histology is well differentiated, and he has a fully active performance status. Additionally, the KRAS biomarker testing showed that he has a wild-type KRAS status."
1988,white,male,41,35.3,FOLFOX + Cetuximab,Yes,No,No,No,12,poorly differentiated,fully active,interminate,No,No,No,No,No,0,"race: white, sex: male, age: 41, bmi: 35.3, treatment arm: FOLFOX + Cetuximab, adherence: Yes, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: interminate","The patient is a 41-year-old white male with a BMI of 35.3. He is currently receiving treatment in the FOLFOX + Cetuximab treatment arm and has been adherent to the treatment regimen. He has completed 12 cycles of chemotherapy. The histology of his cancer is poorly differentiated. Despite his cancer diagnosis, he has a fully active performance status. The KRAS biomarker status for this patient is indeterminate."
1989,white,female,67,26.24,FOLFOX,No,Yes,No,No,4,well differentiated,fully active,wild-type,No,No,Yes,No,No,0,"race: white, sex: female, age: 67, bmi: 26.24, treatment arm: FOLFOX, serious adverse effect: Yes, chemotherapy cycles: 4, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type, adverse effect: diarrhea: Yes","The patient is a 67-year-old white female with a BMI of 26.24. She is receiving the FOLFOX treatment regimen and has experienced a serious adverse effect. She has completed 4 cycles of chemotherapy. The histology shows that the cancer is well-differentiated. Despite the serious adverse effect, the patient's performance status is fully active. The KRAS biomarker indicates that she has a wild-type mutation. Additionally, she has experienced diarrhea as an adverse effect."
1990,white,female,39,27.55,FOLFOX + Cetuximab,No,No,Yes,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 39, bmi: 27.55, treatment arm: FOLFOX + Cetuximab, bowel obstruction: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 39-year-old white female with a BMI of 27.55. She is receiving treatment with FOLFOX + Cetuximab for her well-differentiated histology. She has experienced a bowel obstruction and has completed 12 cycles of chemotherapy. Despite the bowel obstruction, her performance status is fully active. Her KRAS biomarker status is wild-type."
1991,white,male,46,27.78,FOLFOX,Yes,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 46, bmi: 27.78, treatment arm: FOLFOX, adherence: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type",The patient is a 46-year-old white male with a BMI of 27.78. He is receiving treatment with the FOLFOX regimen and has been adherent to the treatment. He has completed 12 cycles of chemotherapy. The histology shows well-differentiated cancer cells. The patient has a fully active performance status. The KRAS biomarker is wild-type.
1992,white,male,73,25.78,FOLFIRI + Cetuximab,No,No,No,No,12,well differentiated,fully active,mutant,No,No,Yes,No,No,0,"race: white, sex: male, age: 73, bmi: 25.78, treatment arm: FOLFIRI + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant, adverse effect: diarrhea: Yes","The patient is a 73-year-old white male with a BMI of 25.78. He is receiving treatment with FOLFIRI + Cetuximab and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer cells. Despite his age, he has a fully active performance status. The KRAS biomarker testing revealed a mutant status. The patient is experiencing diarrhea as an adverse effect of the treatment."
1993,other,female,72,28.79,FOLFOX + Cetuximab,No,No,No,No,12,poorly differentiated,symptoms but ambulatory,wild-type,No,No,No,No,No,0,"race: other, sex: female, age: 72, bmi: 28.79, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: poorly differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type","The patient is a 72-year-old female of a race other than specified, with a BMI of 28.79. She is undergoing treatment with the FOLFOX + Cetuximab regimen and has completed 12 cycles of chemotherapy. The histology of her condition is poorly differentiated. Despite experiencing symptoms, she is still able to walk around (ambulatory). Her KRAS biomarker status is wild-type."
1994,white,male,71,30.41,FOLFOX,No,No,No,No,12,well differentiated,fully active,mutant,No,No,No,No,No,0,"race: white, sex: male, age: 71, bmi: 30.41, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant",The patient is a 71-year-old white male with a BMI of 30.41. He is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. The histology shows well-differentiated cancer cells. The patient has a fully active performance status. The KRAS biomarker analysis indicates a mutant status.
1995,white,male,69,20.3,FOLFOX + Cetuximab,No,No,Yes,No,7,well differentiated,symptoms but ambulatory,wild-type,No,No,No,No,No,1,"race: white, sex: male, age: 69, bmi: 20.3, treatment arm: FOLFOX + Cetuximab, bowel obstruction: Yes, chemotherapy cycles: 7, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type","The patient is a 69-year-old white male with a BMI of 20.3. He is currently receiving treatment with FOLFOX + Cetuximab for his cancer. He has experienced a bowel obstruction and has completed 7 cycles of chemotherapy. The histology of his cancer is well-differentiated. Despite experiencing symptoms, he is still able to be ambulatory. His KRAS biomarker status is wild-type."
1996,other,male,63,26.15,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,Yes,No,No,0,"race: other, sex: male, age: 63, bmi: 26.15, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type, adverse effect: diarrhea: Yes","The patient is a 63-year-old male of a race other than specified, with a BMI of 26.15. He is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cells, and he has a fully active performance status. The KRAS biomarker indicates that he is wild-type. The patient is experiencing diarrhea as an adverse effect of the treatment."
1997,white,female,68,37.82,FOLFOX,Yes,Yes,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,1,"race: white, sex: female, age: 68, bmi: 37.82, treatment arm: FOLFOX, adherence: Yes, serious adverse effect: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 68-year-old white female with a BMI of 37.82. She is receiving the FOLFOX treatment regimen and has been adherent to the treatment. However, she has experienced a serious adverse effect. She has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cancer cells. Despite her age, she has a fully active performance status. Additionally, her KRAS biomarker indicates that it is wild-type."
1998,white,male,60,28.58,FOLFOX,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 60, bmi: 28.58, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 60-year-old white male with a BMI of 28.58. He is receiving the FOLFOX treatment regimen and is scheduled for 12 cycles of chemotherapy. His cancer histology is well-differentiated, and he has a fully active performance status. The KRAS biomarker analysis shows that he has a wild-type KRAS status."
1999,other,male,60,22.5,FOLFOX + Cetuximab,Yes,No,No,Yes,0,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: other, sex: male, age: 60, bmi: 22.5, treatment arm: FOLFOX + Cetuximab, adherence: Yes, bowel perforation: Yes, chemotherapy cycles: 0, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 60-year-old male of a race categorized as ""other"" with a BMI of 22.5. He is enrolled in the treatment arm receiving FOLFOX + Cetuximab. The patient has been adherent to the treatment. He has experienced a bowel perforation. However, he has not undergone any chemotherapy cycles yet. The histology shows well-differentiated cells. The patient's performance status is fully active. The KRAS biomarker indicates that he has a wild-type status."
2000,white,male,56,21.54,FOLFOX + Cetuximab,No,No,No,Yes,12,well differentiated,symptoms but ambulatory,wild-type,No,No,Yes,No,No,0,"race: white, sex: male, age: 56, bmi: 21.54, treatment arm: FOLFOX + Cetuximab, bowel perforation: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type, adverse effect: diarrhea: Yes","The patient is a 56-year-old white male with a BMI of 21.54. He is receiving treatment with FOLFOX + Cetuximab and has experienced a bowel perforation. He has completed 12 cycles of chemotherapy and has well-differentiated histology. Despite experiencing symptoms, he is still able to be ambulatory. His KRAS biomarker is wild-type. He is also experiencing diarrhea as an adverse effect of the treatment."
2001,black,female,45,55.22,FOLFOX,No,No,No,No,12,well differentiated,symptoms but ambulatory,mutant,Yes,No,No,No,No,0,"race: black, sex: female, age: 45, bmi: 55.22, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: mutant, adverse effect: thrombosis: Yes","The patient is a 45-year-old Black female with a BMI of 55.22. She is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cancer cells. Despite experiencing symptoms, she is still able to be ambulatory. The KRAS biomarker testing revealed a mutant status. Additionally, the patient has experienced thrombosis as an adverse effect."
2002,white,male,39,22.6,FOLFOX + Cetuximab,No,No,No,No,12,poorly differentiated,symptoms but ambulatory,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 39, bmi: 22.6, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: poorly differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type","The patient is a 39-year-old white male with a BMI of 22.6. He is receiving treatment in the FOLFOX + Cetuximab treatment arm and has completed 12 cycles of chemotherapy. His histology shows poorly differentiated cancer cells. Despite experiencing symptoms, he is still able to be ambulatory. The KRAS biomarker analysis indicates that he has a wild-type KRAS status."
2003,white,male,66,31.88,FOLFOX + Cetuximab,No,No,No,No,12,poorly differentiated,symptoms but ambulatory,wild-type,No,Yes,No,No,No,0,"race: white, sex: male, age: 66, bmi: 31.88, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: poorly differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type, adverse effect: hypersensitivity: Yes","The patient is a 66-year-old white male with a BMI of 31.88. He is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. His histology shows poorly differentiated cancer. Despite experiencing symptoms, he is still able to be ambulatory. His KRAS biomarker is wild-type. The patient has developed a hypersensitivity reaction as an adverse effect to the treatment."
2004,white,female,57,23.6,FOLFOX + Cetuximab,No,Yes,No,No,12,poorly differentiated,fully active,mutant,No,No,No,No,No,0,"race: white, sex: female, age: 57, bmi: 23.6, treatment arm: FOLFOX + Cetuximab, serious adverse effect: Yes, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 57-year-old white female with a BMI of 23.6. She is receiving treatment with FOLFOX + Cetuximab and has experienced a serious adverse effect. She has completed 12 cycles of chemotherapy. The histology of her cancer is poorly differentiated. Despite this, her performance status is fully active. Additionally, her KRAS biomarker is mutant."
2005,white,female,45,31.52,FOLFIRI,Yes,No,No,No,12,well differentiated,fully active,mutant,No,No,No,No,No,0,"race: white, sex: female, age: 45, bmi: 31.52, treatment arm: FOLFIRI, adherence: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 45-year-old white female with a BMI of 31.52. She is receiving treatment with the FOLFIRI regimen and has been adherent to the treatment. She has completed 12 cycles of chemotherapy. The histology of her cancer is well-differentiated. Despite undergoing treatment, her performance status is fully active. The KRAS biomarker testing revealed a mutant status."
2006,black,male,66,40.72,FOLFOX,No,Yes,No,No,12,well differentiated,fully active,mutant,No,No,No,No,No,0,"race: black, sex: male, age: 66, bmi: 40.72, treatment arm: FOLFOX, serious adverse effect: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 66-year-old Black male with a BMI of 40.72. He is undergoing treatment with the FOLFOX chemotherapy regimen and has experienced a serious adverse effect. He has completed 12 cycles of chemotherapy. The histology shows that the cancer is well-differentiated. Despite the treatment, the patient's performance status is fully active. The KRAS biomarker analysis indicates that the patient has a mutant KRAS status."
2007,white,female,43,26.68,FOLFOX,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 43, bmi: 26.68, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type",The patient is a 43-year-old white female with a BMI of 26.68. She is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cells. The patient has a fully active performance status. Her KRAS biomarker is wild-type.
2008,white,male,55,38.44,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,fully active,mutant,No,No,No,No,No,0,"race: white, sex: male, age: 55, bmi: 38.44, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant",The patient is a 55-year-old white male with a BMI of 38.44. He is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer cells. The patient has a fully active performance status and carries a mutant KRAS biomarker.
2009,white,male,70,28.94,FOLFOX + Cetuximab,No,No,No,No,9,poorly differentiated,symptoms but ambulatory,wild-type,No,No,Yes,Yes,No,0,"race: white, sex: male, age: 70, bmi: 28.94, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 9, histology: poorly differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type, adverse effect: diarrhea: Yes, adverse effect: infection: Yes","The patient is a 70-year-old white male with a BMI of 28.94 who is receiving treatment with FOLFOX + Cetuximab. He has completed 9 cycles of chemotherapy and has been diagnosed with poorly differentiated histology. Despite experiencing symptoms, he is still able to be ambulatory. His KRAS biomarker status is wild-type. He has reported experiencing diarrhea and infection as adverse effects of the treatment."
2010,white,male,40,33.56,FOLFIRI + Cetuximab,Yes,No,No,Yes,9,poorly differentiated,fully active,wild-type,No,Yes,No,No,No,0,"race: white, sex: male, age: 40, bmi: 33.56, treatment arm: FOLFIRI + Cetuximab, adherence: Yes, bowel perforation: Yes, chemotherapy cycles: 9, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type, adverse effect: hypersensitivity: Yes","The patient is a 40-year-old white male with a BMI of 33.56. He is receiving treatment with FOLFIRI + Cetuximab and has been adherent to the treatment. He experienced a bowel perforation and has completed 9 cycles of chemotherapy. The histology shows poorly differentiated cells. Despite the adverse effect of hypersensitivity, the patient's performance status remains fully active. The KRAS biomarker indicates that he has a wild-type mutation."
2011,white,male,71,34.58,FOLFOX + Cetuximab,No,No,No,No,3,well differentiated,fully active,wild-type,No,No,Yes,No,No,0,"race: white, sex: male, age: 71, bmi: 34.58, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 3, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type, adverse effect: diarrhea: Yes","The patient is a 71-year-old white male with a BMI of 34.58. He is currently receiving treatment with FOLFOX + Cetuximab and has completed 3 cycles of chemotherapy. His histology shows well-differentiated cancer, and he has a fully active performance status. The KRAS biomarker testing revealed that he has a wild-type KRAS status. The patient is experiencing diarrhea as an adverse effect of the treatment."
2012,white,male,37,32.94,FOLFOX + Cetuximab,Yes,No,No,Yes,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 37, bmi: 32.94, treatment arm: FOLFOX + Cetuximab, adherence: Yes, bowel perforation: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 37-year-old white male with a BMI of 32.94. He is receiving treatment in the FOLFOX + Cetuximab treatment arm and has been adherent to the treatment. He experienced a bowel perforation and has completed 12 cycles of chemotherapy. The histology shows well-differentiated cells, and the patient has a fully active performance status. His KRAS biomarker is wild-type."
2013,white,male,47,35.76,FOLFOX,No,No,No,Yes,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 47, bmi: 35.76, treatment arm: FOLFOX, bowel perforation: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 47-year-old white male with a BMI of 35.76. He is receiving the FOLFOX treatment arm for his bowel perforation. He has completed 12 cycles of chemotherapy and has well-differentiated histology. Despite his bowel perforation, his performance status is fully active. His KRAS biomarker is wild-type."
2014,white,female,59,49.73,FOLFOX,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 59, bmi: 49.73, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 59-year-old white female with a BMI of 49.73. She is receiving the FOLFOX treatment arm and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cells, and she has a fully active performance status. The KRAS biomarker analysis indicates that she has a wild-type KRAS gene."
2015,white,male,72,25.59,FOLFOX + Cetuximab,Yes,Yes,No,No,12,well differentiated,fully active,wild-type,Yes,No,Yes,No,No,0,"race: white, sex: male, age: 72, bmi: 25.59, treatment arm: FOLFOX + Cetuximab, adherence: Yes, serious adverse effect: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type, adverse effect: thrombosis: Yes, adverse effect: diarrhea: Yes",The patient is a 72-year-old white male with a BMI of 25.59. He is receiving treatment with FOLFOX + Cetuximab and has been adherent to the treatment regimen. He experienced a serious adverse effect during the treatment. He completed 12 cycles of chemotherapy and has well-differentiated histology. His performance status is fully active. The KRAS biomarker indicates he is wild-type. He also experienced adverse effects of thrombosis and diarrhea during the treatment.
2016,black,male,68,33.36,FOLFOX + Cetuximab,No,Yes,No,No,12,well differentiated,fully active,mutant,Yes,No,No,No,No,0,"race: black, sex: male, age: 68, bmi: 33.36, treatment arm: FOLFOX + Cetuximab, serious adverse effect: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant, adverse effect: thrombosis: Yes","The patient is a 68-year-old Black male with a BMI of 33.36. He is receiving treatment with FOLFOX + Cetuximab and has experienced a serious adverse effect. He has completed 12 cycles of chemotherapy. The histology shows that the cancer is well-differentiated. Despite the serious adverse effect, the patient's performance status is fully active. The KRAS biomarker is mutant, and the patient has also experienced thrombosis as an adverse effect."
2017,white,female,36,31.25,FOLFOX,No,Yes,No,No,12,well differentiated,fully active,mutant,No,No,No,No,No,0,"race: white, sex: female, age: 36, bmi: 31.25, treatment arm: FOLFOX, serious adverse effect: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant",The patient is a 36-year-old white female with a BMI of 31.25. She is receiving the FOLFOX treatment regimen and has experienced a serious adverse effect. She has completed 12 cycles of chemotherapy. The histology shows well-differentiated cancer cells. The patient has a fully active performance status. The KRAS biomarker indicates a mutant status.
2018,white,female,52,19.88,FOLFOX,No,Yes,No,No,12,well differentiated,fully active,mutant,No,No,Yes,No,No,1,"race: white, sex: female, age: 52, bmi: 19.88, treatment arm: FOLFOX, serious adverse effect: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant, adverse effect: diarrhea: Yes","The patient is a 52-year-old white female with a BMI of 19.88 who is receiving the FOLFOX treatment regimen. She has experienced a serious adverse effect during her 12 cycles of chemotherapy. Her histology shows that the cancer is well-differentiated, and her performance status is fully active. The KRAS biomarker testing revealed a mutant status. Additionally, she has experienced diarrhea as an adverse effect of the treatment."
2019,white,male,46,31.15,FOLFOX + Cetuximab,No,No,No,No,12,poorly differentiated,fully active,mutant,No,No,No,No,No,1,"race: white, sex: male, age: 46, bmi: 31.15, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 46-year-old white male with a BMI of 31.15. He is receiving treatment with FOLFOX + Cetuximab and is scheduled for 12 cycles of chemotherapy. His histology shows poorly differentiated cancer cells. Despite his diagnosis, the patient has a fully active performance status. Additionally, the KRAS biomarker testing revealed a mutant status."
2020,white,male,52,27.38,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,symptoms but ambulatory,mutant,No,No,Yes,No,No,0,"race: white, sex: male, age: 52, bmi: 27.38, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: mutant, adverse effect: diarrhea: Yes","The patient is a 52-year-old white male with a BMI of 27.38. He is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer. Despite experiencing symptoms, he is still able to walk around (ambulatory). The KRAS biomarker testing revealed a mutant status. The patient is experiencing diarrhea as an adverse effect of the treatment."
2021,black,female,74,29.2,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,symptoms but ambulatory,wild-type,No,No,No,No,No,0,"race: black, sex: female, age: 74, bmi: 29.2, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type","The patient is a 74-year-old Black female with a BMI of 29.2. She is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cancer. Despite experiencing symptoms, she is still able to ambulate. The KRAS biomarker indicates that she has a wild-type status."
2022,black,female,72,22.95,FOLFOX + Cetuximab,No,Yes,No,No,11,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: black, sex: female, age: 72, bmi: 22.95, treatment arm: FOLFOX + Cetuximab, serious adverse effect: Yes, chemotherapy cycles: 11, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 72-year-old Black female with a BMI of 22.95. She is receiving treatment with FOLFOX + Cetuximab and has experienced a serious adverse effect. She has completed 11 cycles of chemotherapy. Her histology shows well-differentiated cells. Despite her age, she has a fully active performance status. Additionally, her KRAS biomarker is wild-type."
2023,white,male,54,25.83,FOLFOX,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 54, bmi: 25.83, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type",The patient is a 54-year-old white male with a BMI of 25.83. He is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. The histology shows well-differentiated cancer cells. The patient has a fully active performance status. The KRAS biomarker indicates that he has a wild-type KRAS gene.
2024,white,female,57,22.39,FOLFOX + Cetuximab,No,No,No,No,4,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 57, bmi: 22.39, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 4, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 57-year-old white female with a BMI of 22.39. She is receiving treatment with FOLFOX + Cetuximab and has completed 4 cycles of chemotherapy. Her histology shows well-differentiated cancer, and she has a fully active performance status. The KRAS biomarker indicates that she has a wild-type status."
2025,white,male,53,36.11,FOLFOX + Cetuximab,No,No,No,No,5,well differentiated,fully active,wild-type,No,No,No,No,No,1,"race: white, sex: male, age: 53, bmi: 36.11, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 5, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 53-year-old white male with a BMI of 36.11. He is receiving treatment in the FOLFOX + Cetuximab treatment arm and has completed 5 cycles of chemotherapy. His histology shows well-differentiated cancer cells. Despite his cancer diagnosis, he has a fully active performance status. Additionally, his KRAS biomarker is wild-type."
2026,white,female,74,27.24,FOLFOX + Cetuximab,No,No,No,Yes,12,well differentiated,in bed less than 50% of the time,mutant,No,No,No,No,No,0,"race: white, sex: female, age: 74, bmi: 27.24, treatment arm: FOLFOX + Cetuximab, bowel perforation: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: in bed less than 50% of the time, KRAS biomarker: mutant",The patient is a 74-year-old white female with a BMI of 27.24. She is receiving treatment with FOLFOX + Cetuximab and has experienced a bowel perforation. She has completed 12 cycles of chemotherapy. The histology shows well-differentiated cancer. Her performance status indicates that she is in bed less than 50% of the time. The KRAS biomarker analysis revealed a mutant status.
2027,white,male,72,26.32,FOLFOX + Cetuximab,No,No,No,No,3,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 72, bmi: 26.32, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 3, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 72-year-old white male with a BMI of 26.32. He is receiving treatment with FOLFOX + Cetuximab and has completed 3 cycles of chemotherapy. His cancer histology is well differentiated, and he has a fully active performance status. The KRAS biomarker analysis shows that he has a wild-type KRAS status."
2028,white,female,50,38.83,FOLFOX,No,No,No,Yes,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 50, bmi: 38.83, treatment arm: FOLFOX, bowel perforation: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 50-year-old white female with a BMI of 38.83. She is undergoing treatment with the FOLFOX regimen and has experienced a bowel perforation. She has completed 12 cycles of chemotherapy. The histology of her cancer is well-differentiated. Despite the bowel perforation, her performance status is fully active. The KRAS biomarker analysis shows that she has a wild-type KRAS status."
2029,white,female,53,37.4,FOLFOX + Cetuximab,No,No,No,No,11,well differentiated,symptoms but ambulatory,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 53, bmi: 37.4, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 11, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type","This patient is a 53-year-old white female with a BMI of 37.4. She is receiving treatment with FOLFOX + Cetuximab and has completed 11 cycles of chemotherapy. Her histology shows well-differentiated cancer. Despite experiencing symptoms, she is still able to be ambulatory. Additionally, her KRAS biomarker is wild-type."
2030,white,male,76,29.22,FOLFOX + Cetuximab,No,Yes,No,No,11,well differentiated,fully active,wild-type,No,No,No,No,No,1,"race: white, sex: male, age: 76, bmi: 29.22, treatment arm: FOLFOX + Cetuximab, serious adverse effect: Yes, chemotherapy cycles: 11, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","This patient is a 76-year-old white male with a BMI of 29.22. He is undergoing treatment with FOLFOX + Cetuximab and has experienced a serious adverse effect. He has completed 11 cycles of chemotherapy. The histology of his cancer is well-differentiated. Despite his age, he has a fully active performance status. His KRAS biomarker status is wild-type."
2031,white,male,76,33.02,FOLFOX,No,No,No,No,11,well differentiated,fully active,mutant,No,No,Yes,No,No,0,"race: white, sex: male, age: 76, bmi: 33.02, treatment arm: FOLFOX, chemotherapy cycles: 11, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant, adverse effect: diarrhea: Yes","The patient is a 76-year-old white male with a BMI of 33.02 who is undergoing treatment with the FOLFOX chemotherapy regimen. He has completed 11 cycles of chemotherapy. His cancer histology is well differentiated. Despite his age, he has a fully active performance status. The KRAS biomarker testing revealed a mutant status. The patient is experiencing diarrhea as an adverse effect of the treatment."
2032,white,male,68,24.1,FOLFOX,No,Yes,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 68, bmi: 24.1, treatment arm: FOLFOX, serious adverse effect: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type",The patient is a 68-year-old white male with a BMI of 24.1. He is receiving the FOLFOX treatment regimen and has experienced a serious adverse effect. He has completed 12 cycles of chemotherapy. The histology shows that the cancer is well-differentiated. The patient's performance status is fully active. The KRAS biomarker indicates that he has a wild-type mutation.
2033,white,female,54,25.5,FOLFOX,Yes,No,No,No,12,poorly differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 54, bmi: 25.5, treatment arm: FOLFOX, adherence: Yes, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 54-year-old white female with a BMI of 25.5. She is receiving treatment with FOLFOX and has been adherent to the chemotherapy regimen for 12 cycles. The histology of her cancer is poorly differentiated. Despite this, her performance status is fully active. Additionally, her KRAS biomarker status is wild-type."
2034,white,male,67,25.52,FOLFOX,No,No,Yes,No,11,well differentiated,fully active,interminate,No,No,No,No,No,1,"race: white, sex: male, age: 67, bmi: 25.52, treatment arm: FOLFOX, bowel obstruction: Yes, chemotherapy cycles: 11, histology: well differentiated, performance status: fully active, KRAS biomarker: interminate","The patient is a 67-year-old white male with a BMI of 25.52. He is receiving treatment with FOLFOX chemotherapy regimen and has experienced a bowel obstruction. He has completed 11 cycles of chemotherapy. The histology of his cancer is well-differentiated. Despite the bowel obstruction, his performance status is fully active. The KRAS biomarker status is indeterminate."
2035,other,male,36,20.48,FOLFOX,No,No,No,No,12,poorly differentiated,fully active,interminate,No,No,No,No,No,0,"race: other, sex: male, age: 36, bmi: 20.48, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: interminate","The patient is a 36-year-old male of a race categorized as ""other"" with a BMI of 20.48. He is undergoing treatment with the FOLFOX chemotherapy regimen and has completed 12 cycles. The histology of his condition is poorly differentiated. Despite this, his performance status is fully active. The KRAS biomarker status is indeterminate."
2036,white,female,70,25.5,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,fully active,mutant,No,No,No,No,No,0,"race: white, sex: female, age: 70, bmi: 25.5, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 70-year-old white female with a BMI of 25.5. She is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. Her cancer histology is well-differentiated, and she has a fully active performance status. The KRAS biomarker testing revealed a mutant status."
2037,white,male,55,40.46,FOLFOX + Cetuximab,No,No,No,No,1,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 55, bmi: 40.46, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 1, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 55-year-old white male with a BMI of 40.46. He is currently receiving treatment in the FOLFOX + Cetuximab treatment arm and has completed one cycle of chemotherapy. His cancer histology is well-differentiated, and he has a fully active performance status. Additionally, the KRAS biomarker testing revealed that he has a wild-type KRAS status."
2038,white,female,53,21.04,FOLFOX + Cetuximab,Yes,No,No,No,6,well differentiated,symptoms but ambulatory,wild-type,No,No,Yes,Yes,No,1,"race: white, sex: female, age: 53, bmi: 21.04, treatment arm: FOLFOX + Cetuximab, adherence: Yes, chemotherapy cycles: 6, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type, adverse effect: diarrhea: Yes, adverse effect: infection: Yes","The patient is a 53-year-old white female with a BMI of 21.04. She is receiving treatment with FOLFOX + Cetuximab and has been adherent to the treatment. She has completed 6 cycles of chemotherapy. Histologically, her cancer is well-differentiated. Despite experiencing symptoms, she is still ambulatory. Her KRAS biomarker is wild-type. She has experienced adverse effects of diarrhea and infection during her treatment."
2039,white,male,46,29.44,FOLFOX + Cetuximab,Yes,No,No,No,12,poorly differentiated,fully active,wild-type,No,No,Yes,No,No,0,"race: white, sex: male, age: 46, bmi: 29.44, treatment arm: FOLFOX + Cetuximab, adherence: Yes, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type, adverse effect: diarrhea: Yes","The patient is a 46-year-old white male with a BMI of 29.44. He is receiving treatment with FOLFOX + Cetuximab and has been adherent to the treatment. He has completed 12 cycles of chemotherapy. The histology of his cancer is poorly differentiated. Despite this, his performance status is fully active. His KRAS biomarker is wild-type. He is experiencing diarrhea as an adverse effect of the treatment."
2040,white,male,63,23.35,FOLFOX,No,Yes,Yes,No,3,well differentiated,symptoms but ambulatory,mutant,No,No,No,No,No,0,"race: white, sex: male, age: 63, bmi: 23.35, treatment arm: FOLFOX, serious adverse effect: Yes, bowel obstruction: Yes, chemotherapy cycles: 3, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: mutant","The patient is a 63-year-old white male with a BMI of 23.35. He is receiving the FOLFOX treatment regimen and has experienced a serious adverse effect, specifically a bowel obstruction. He has completed 3 cycles of chemotherapy. The histology shows well-differentiated cells. Despite experiencing symptoms, the patient is still able to be ambulatory. The KRAS biomarker analysis revealed a mutant status."
2041,white,male,74,23.72,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 74, bmi: 23.72, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 74-year-old white male with a BMI of 23.72. He is receiving treatment in the FOLFOX + Cetuximab treatment arm and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer cells. Despite his age, he has a fully active performance status. Additionally, his KRAS biomarker indicates that he has a wild-type gene."
2042,white,male,44,28.18,FOLFOX + Cetuximab,No,No,No,No,10,well differentiated,fully active,mutant,No,No,No,No,No,0,"race: white, sex: male, age: 44, bmi: 28.18, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 10, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 44-year-old white male with a BMI of 28.18. He is receiving treatment in the FOLFOX + Cetuximab treatment arm and has completed 10 cycles of chemotherapy. His histology shows well-differentiated cells, and he has a fully active performance status. The KRAS biomarker indicates that he has a mutant status."
2043,white,male,41,22.57,FOLFOX,No,No,No,No,12,well differentiated,fully active,mutant,No,No,No,No,No,0,"race: white, sex: male, age: 41, bmi: 22.57, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant",The patient is a 41-year-old white male with a BMI of 22.57. He is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer cells. The patient has a fully active performance status and has a mutant KRAS biomarker.
2044,white,male,66,27.35,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,fully active,mutant,No,No,No,No,No,0,"race: white, sex: male, age: 66, bmi: 27.35, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant",The patient is a 66-year-old white male with a BMI of 27.35. He is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. His cancer histology is well differentiated. The patient has a fully active performance status and has a mutant KRAS biomarker.
2045,white,female,42,37.9,FOLFOX + Cetuximab,No,No,Yes,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 42, bmi: 37.9, treatment arm: FOLFOX + Cetuximab, bowel obstruction: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 42-year-old white female with a BMI of 37.9. She is receiving treatment with FOLFOX + Cetuximab for her well-differentiated histology. She has experienced a bowel obstruction and has completed 12 cycles of chemotherapy. Despite the bowel obstruction, her performance status is fully active. Additionally, her KRAS biomarker status is wild-type."
2046,white,female,50,19.49,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,Yes,No,No,0,"race: white, sex: female, age: 50, bmi: 19.49, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type, adverse effect: diarrhea: Yes","The patient is a 50-year-old white female with a BMI of 19.49. She is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. Her cancer histology is well-differentiated, and she has a fully active performance status. The KRAS biomarker testing showed that she has a wild-type KRAS status. The patient is experiencing diarrhea as an adverse effect of the treatment."
2047,white,male,46,32.71,FOLFOX,No,Yes,No,No,7,well differentiated,symptoms but ambulatory,mutant,Yes,No,No,No,No,0,"race: white, sex: male, age: 46, bmi: 32.71, treatment arm: FOLFOX, serious adverse effect: Yes, chemotherapy cycles: 7, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: mutant, adverse effect: thrombosis: Yes","The patient is a 46-year-old white male with a BMI of 32.71 who is receiving the FOLFOX treatment regimen. He has experienced a serious adverse effect during treatment. He has completed 7 cycles of chemotherapy. The histology indicates that the cancer is well-differentiated. Despite experiencing symptoms, the patient is still able to be ambulatory. The KRAS biomarker testing revealed a mutant result. Additionally, the patient has developed thrombosis as an adverse effect."
2048,white,male,36,24.78,FOLFOX + Cetuximab,No,No,No,No,12,poorly differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 36, bmi: 24.78, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 36-year-old white male with a BMI of 24.78. He is receiving treatment in the FOLFOX + Cetuximab treatment arm and has completed 12 cycles of chemotherapy. His histology shows poorly differentiated cancer cells. Despite this, his performance status is fully active. Additionally, his KRAS biomarker status is wild-type."
2049,white,male,76,26.21,FOLFOX,No,No,Yes,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 76, bmi: 26.21, treatment arm: FOLFOX, bowel obstruction: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 76-year-old white male with a BMI of 26.21. He is receiving treatment with FOLFOX chemotherapy regimen and has experienced a bowel obstruction. He has completed 12 cycles of chemotherapy. The histology of his cancer is well differentiated. Despite his age, he has a fully active performance status. His KRAS biomarker status is wild-type."
2050,black,male,69,26.71,FOLFOX,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: black, sex: male, age: 69, bmi: 26.71, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type",The patient is a 69-year-old Black male with a BMI of 26.71. He is receiving the FOLFOX treatment arm and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer cells. The patient has a fully active performance status. His KRAS biomarker is wild-type.
2051,white,female,47,23.43,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 47, bmi: 23.43, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type",The patient is a 47-year-old white female with a BMI of 23.43. She is undergoing treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cancer cells. She has a fully active performance status. The KRAS biomarker analysis indicates that she has a wild-type KRAS gene.
2052,white,male,41,31.61,FOLFOX,Yes,No,Yes,No,3,well differentiated,symptoms but ambulatory,mutant,No,No,No,No,No,1,"race: white, sex: male, age: 41, bmi: 31.61, treatment arm: FOLFOX, adherence: Yes, bowel obstruction: Yes, chemotherapy cycles: 3, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: mutant","The patient is a 41-year-old white male with a BMI of 31.61. He is receiving treatment with FOLFOX chemotherapy and has been adherent to the treatment. He is currently experiencing a bowel obstruction and has completed 3 cycles of chemotherapy. The histology shows well-differentiated cancer cells. Despite experiencing symptoms, the patient is still able to be ambulatory. The KRAS biomarker testing revealed a mutant status."
2053,other,female,53,21.2,FOLFOX,No,Yes,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: other, sex: female, age: 53, bmi: 21.2, treatment arm: FOLFOX, serious adverse effect: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 53-year-old female of a race other than Caucasian, with a BMI of 21.2. She is receiving the FOLFOX treatment regimen and has experienced a serious adverse effect. She has completed 12 cycles of chemotherapy. The histology of her cancer is well-differentiated. Despite her treatment, she has a fully active performance status. The KRAS biomarker testing revealed that she has a wild-type KRAS status."
2054,white,male,54,34.51,FOLFOX + Cetuximab,No,Yes,No,No,11,well differentiated,symptoms but ambulatory,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 54, bmi: 34.51, treatment arm: FOLFOX + Cetuximab, serious adverse effect: Yes, chemotherapy cycles: 11, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type","The patient is a 54-year-old white male with a BMI of 34.51. He is receiving treatment with FOLFOX + Cetuximab and has experienced a serious adverse effect. He has completed 11 cycles of chemotherapy. The histology shows well-differentiated cells. Despite experiencing symptoms, the patient is still able to be ambulatory. The KRAS biomarker indicates that it is wild-type."
2055,white,male,65,29.05,FOLFIRI + Cetuximab,No,No,No,No,12,well differentiated,symptoms but ambulatory,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 65, bmi: 29.05, treatment arm: FOLFIRI + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type","The patient is a 65-year-old white male with a BMI of 29.05. He is undergoing treatment with FOLFIRI + Cetuximab and has completed 12 cycles of chemotherapy. His cancer histology is well-differentiated. Despite experiencing symptoms, he is still able to ambulate. His KRAS biomarker status is wild-type."
2056,white,male,70,25.55,FOLFOX,No,Yes,No,No,3,well differentiated,fully active,mutant,No,No,No,No,No,0,"race: white, sex: male, age: 70, bmi: 25.55, treatment arm: FOLFOX, serious adverse effect: Yes, chemotherapy cycles: 3, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 70-year-old white male with a BMI of 25.55. He is receiving the FOLFOX treatment regimen and has experienced a serious adverse effect. He has completed 3 cycles of chemotherapy. The histology shows well-differentiated cancer cells. Despite the adverse effect, the patient's performance status is fully active. The KRAS biomarker analysis indicates a mutant status."
2057,white,male,66,29.25,FOLFOX + Cetuximab,No,No,No,No,1,well differentiated,symptoms but ambulatory,mutant,No,No,No,No,No,0,"race: white, sex: male, age: 66, bmi: 29.25, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 1, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: mutant","The patient is a 66-year-old white male with a BMI of 29.25. He is receiving treatment with FOLFOX + Cetuximab and has completed one cycle of chemotherapy. His histology shows well-differentiated cancer. Despite experiencing symptoms, he is still able to walk around (ambulatory). The KRAS biomarker analysis revealed a mutant status."
2058,white,female,71,30.12,FOLFOX + Cetuximab,No,No,No,No,3,poorly differentiated,fully active,wild-type,No,No,Yes,No,No,0,"race: white, sex: female, age: 71, bmi: 30.12, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 3, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type, adverse effect: diarrhea: Yes","The patient is a 71-year-old white female with a BMI of 30.12. She is currently receiving treatment with FOLFOX + Cetuximab and has completed 3 cycles of chemotherapy. Her cancer histology is poorly differentiated, and she has a fully active performance status. The KRAS biomarker testing showed that she has a wild-type KRAS status. The patient has experienced diarrhea as an adverse effect of the treatment."
2059,black,female,73,32.94,FOLFOX + Cetuximab,Yes,No,No,No,11,well differentiated,symptoms but ambulatory,wild-type,No,No,Yes,Yes,No,1,"race: black, sex: female, age: 73, bmi: 32.94, treatment arm: FOLFOX + Cetuximab, adherence: Yes, chemotherapy cycles: 11, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type, adverse effect: diarrhea: Yes, adverse effect: infection: Yes","The patient is a 73-year-old Black female with a BMI of 32.94. She is receiving treatment with FOLFOX + Cetuximab and has been adherent to the treatment. She has completed 11 chemotherapy cycles. Histologically, her cancer is well-differentiated. Despite experiencing symptoms, she is still ambulatory. Her KRAS biomarker status is wild-type. The patient has reported experiencing diarrhea and infection as adverse effects of the treatment."
2060,white,male,52,24.57,FOLFOX,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 52, bmi: 24.57, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 52-year-old white male with a BMI of 24.57. He is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cells, and he has a fully active performance status. The KRAS biomarker analysis indicates that he has a wild-type KRAS status."
2061,white,male,51,27.84,FOLFIRI,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 51, bmi: 27.84, treatment arm: FOLFIRI, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 51-year-old white male with a BMI of 27.84. He is undergoing treatment with the FOLFIRI chemotherapy regimen and has completed 12 cycles. His cancer histology is well-differentiated, and he has a fully active performance status. The KRAS biomarker analysis shows that he has a wild-type KRAS status."
2062,white,female,45,26.53,FOLFOX,No,No,No,No,12,well differentiated,fully active,mutant,No,No,No,No,No,0,"race: white, sex: female, age: 45, bmi: 26.53, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 45-year-old white female with a BMI of 26.53. She is undergoing treatment with the FOLFOX chemotherapy regimen and has completed 12 cycles. Her cancer histology is well-differentiated, and she has a fully active performance status. The KRAS biomarker testing revealed a mutant status."
2063,white,male,69,25.64,FOLFOX,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 69, bmi: 25.64, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 69-year-old white male with a BMI of 25.64. He is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cells, and he has a fully active performance status. The KRAS biomarker analysis indicates that he has a wild-type KRAS gene."
2064,black,female,62,42.85,FOLFOX + Cetuximab,No,No,No,No,12,poorly differentiated,fully active,mutant,No,No,No,Yes,No,0,"race: black, sex: female, age: 62, bmi: 42.85, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: mutant, adverse effect: infection: Yes","The patient is a 62-year-old Black female with a BMI of 42.85. She is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. Her histology shows poorly differentiated cancer cells. Despite this, her performance status is fully active. The KRAS biomarker testing revealed a mutant status. The patient has experienced an adverse effect in the form of an infection."
2065,white,male,52,27.81,FOLFOX + Cetuximab,Yes,No,No,No,12,poorly differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 52, bmi: 27.81, treatment arm: FOLFOX + Cetuximab, adherence: Yes, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 52-year-old white male with a BMI of 27.81. He is receiving treatment in the FOLFOX + Cetuximab treatment arm and has been adherent to the treatment. He has completed 12 chemotherapy cycles. The histology of his cancer is poorly differentiated. Despite this, his performance status is fully active. His KRAS biomarker status is wild-type."
2066,white,male,50,29.2,FOLFOX,No,No,No,No,12,well differentiated,fully active,mutant,No,No,No,No,No,0,"race: white, sex: male, age: 50, bmi: 29.2, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant",The patient is a 50-year-old white male with a BMI of 29.2. He is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. His cancer histology is well differentiated. The patient has a fully active performance status. The KRAS biomarker testing revealed a mutant status.
2067,white,female,75,26.14,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,symptoms but ambulatory,wild-type,No,No,Yes,No,No,1,"race: white, sex: female, age: 75, bmi: 26.14, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type, adverse effect: diarrhea: Yes","The patient is a 75-year-old white female with a BMI of 26.14. She is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cancer. Despite experiencing symptoms, she is still able to be ambulatory. Her KRAS biomarker is wild-type. She has reported experiencing diarrhea as an adverse effect of her treatment."
2068,white,female,46,21.01,FOLFOX,No,Yes,No,No,5,well differentiated,fully active,mutant,No,No,No,No,No,0,"race: white, sex: female, age: 46, bmi: 21.01, treatment arm: FOLFOX, serious adverse effect: Yes, chemotherapy cycles: 5, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant",The patient is a 46-year-old white female with a BMI of 21.01. She is receiving the FOLFOX treatment regimen and has experienced a serious adverse effect. She has completed 5 cycles of chemotherapy. The histology shows that the cancer is well-differentiated. The patient has a fully active performance status. The KRAS biomarker indicates that it is mutant.
2069,white,female,70,29.82,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,fully active,interminate,No,No,No,No,No,0,"race: white, sex: female, age: 70, bmi: 29.82, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: interminate","The patient is a 70-year-old white female with a BMI of 29.82. She is undergoing treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cells, and she has a fully active performance status. The KRAS biomarker status is indeterminate."
2070,white,male,64,35.68,FOLFOX,No,Yes,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 64, bmi: 35.68, treatment arm: FOLFOX, serious adverse effect: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 64-year-old white male with a BMI of 35.68. He is undergoing treatment with the FOLFOX chemotherapy regimen and has experienced a serious adverse effect. He has completed 12 cycles of chemotherapy. The histology of his cancer is well-differentiated. Despite the adverse effect, his performance status is fully active. His KRAS biomarker status is wild-type."
2071,white,female,62,26.95,FOLFOX,Yes,No,No,No,7,well differentiated,fully active,wild-type,No,No,No,No,No,1,"race: white, sex: female, age: 62, bmi: 26.95, treatment arm: FOLFOX, adherence: Yes, chemotherapy cycles: 7, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 62-year-old white female with a BMI of 26.95. She is receiving the FOLFOX treatment regimen and has been adherent to her chemotherapy cycles, completing 7 cycles so far. Her histology shows well-differentiated cancer cells. Despite her cancer diagnosis, she has a fully active performance status. The KRAS biomarker analysis indicates that she has a wild-type KRAS status."
2072,white,female,74,31.31,FOLFOX,No,No,No,No,9,poorly differentiated,fully active,wild-type,No,No,Yes,No,No,0,"race: white, sex: female, age: 74, bmi: 31.31, treatment arm: FOLFOX, chemotherapy cycles: 9, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type, adverse effect: diarrhea: Yes","The patient is a 74-year-old white female with a BMI of 31.31. She is receiving the FOLFOX treatment regimen and has completed 9 cycles of chemotherapy. Her histology shows poorly differentiated cancer cells. Despite this, her performance status is fully active. The KRAS biomarker testing revealed that she has a wild-type KRAS gene. The patient is experiencing diarrhea as an adverse effect of the treatment."
2073,white,female,45,33.49,FOLFOX,No,No,No,No,2,poorly differentiated,symptoms but ambulatory,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 45, bmi: 33.49, treatment arm: FOLFOX, chemotherapy cycles: 2, histology: poorly differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type","The patient is a 45-year-old white female with a BMI of 33.49. She is currently receiving the FOLFOX treatment regimen and has completed 2 cycles of chemotherapy. Her histology shows poorly differentiated cancer cells. Despite experiencing symptoms, she is still able to be ambulatory. The KRAS biomarker analysis indicates that she has a wild-type KRAS status."
2074,black,male,43,27.76,FOLFIRI (KRAS mutant),No,No,Yes,No,12,well differentiated,fully active,mutant,No,No,No,No,No,1,"race: black, sex: male, age: 43, bmi: 27.76, treatment arm: FOLFIRI (KRAS mutant), bowel obstruction: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 43-year-old Black male with a BMI of 27.76. He is receiving the FOLFIRI treatment regimen for his KRAS mutant status. He has a bowel obstruction and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cells. Despite his condition, he has a fully active performance status."
2075,other,female,75,28.9,FOLFOX,No,Yes,No,No,12,poorly differentiated,fully active,mutant,No,No,No,No,No,0,"race: other, sex: female, age: 75, bmi: 28.9, treatment arm: FOLFOX, serious adverse effect: Yes, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 75-year-old female of a race other than Caucasian, with a BMI of 28.9. She is receiving the FOLFOX treatment regimen and has experienced a serious adverse effect. She has completed 12 cycles of chemotherapy. The histology of her cancer is poorly differentiated. Despite these challenges, her performance status is fully active. Additionally, the KRAS biomarker testing revealed a mutant status."
2076,black,female,45,33.77,FOLFOX,No,No,No,No,3,well differentiated,fully active,mutant,No,No,No,No,Yes,0,"race: black, sex: female, age: 45, bmi: 33.77, treatment arm: FOLFOX, chemotherapy cycles: 3, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant, adverse effect: infarction: Yes",The patient is a 45-year-old Black female with a BMI of 33.77. She is receiving the FOLFOX treatment regimen and has completed 3 cycles of chemotherapy. The histology shows well-differentiated cancer cells. The patient has a fully active performance status. The KRAS biomarker is mutant. The patient has experienced an infarction as an adverse effect.
2077,white,female,73,24.5,FOLFOX + Cetuximab,No,No,No,No,5,well differentiated,fully active,mutant,No,No,Yes,No,No,0,"race: white, sex: female, age: 73, bmi: 24.5, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 5, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant, adverse effect: diarrhea: Yes","The patient is a 73-year-old white female with a BMI of 24.5. She is receiving treatment with FOLFOX + Cetuximab and has completed 5 cycles of chemotherapy. Her histology shows well-differentiated cancer, and she has a fully active performance status. The KRAS biomarker testing revealed a mutant status. The patient is experiencing diarrhea as an adverse effect of the treatment."
2078,white,male,55,45.16,FOLFOX,No,No,No,No,12,well differentiated,symptoms but ambulatory,wild-type,No,No,Yes,No,No,0,"race: white, sex: male, age: 55, bmi: 45.16, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type, adverse effect: diarrhea: Yes","The patient is a 55-year-old white male with a BMI of 45.16. He is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer cells. Despite experiencing symptoms, he is still able to be ambulatory. The KRAS biomarker testing revealed that he has a wild-type KRAS status. The patient has reported experiencing diarrhea as an adverse effect of the treatment."
2079,white,female,73,20.06,FOLFOX,No,No,No,No,12,poorly differentiated,fully active,wild-type,No,No,Yes,Yes,No,0,"race: white, sex: female, age: 73, bmi: 20.06, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type, adverse effect: diarrhea: Yes, adverse effect: infection: Yes","The patient is a 73-year-old white female with a BMI of 20.06. She is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. Her histology shows poorly differentiated cancer cells. Despite this, her performance status is fully active. The KRAS biomarker analysis indicates that she has a wild-type KRAS status. The patient has experienced adverse effects of diarrhea and infection during her treatment."
2080,white,female,55,38.95,FOLFOX,Yes,No,No,No,12,well differentiated,symptoms but ambulatory,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 55, bmi: 38.95, treatment arm: FOLFOX, adherence: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type","The patient is a 55-year-old white female with a BMI of 38.95. She is receiving the FOLFOX treatment regimen and has been adherent to her chemotherapy. She has completed 12 cycles of chemotherapy. The histology of her cancer is well-differentiated. Despite experiencing symptoms, she is still able to be ambulatory. Her KRAS biomarker status is wild-type."
2081,white,female,46,25.06,FOLFOX + Cetuximab,Yes,No,No,No,12,well differentiated,symptoms but ambulatory,wild-type,No,No,Yes,No,No,0,"race: white, sex: female, age: 46, bmi: 25.06, treatment arm: FOLFOX + Cetuximab, adherence: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type, adverse effect: diarrhea: Yes","The patient is a 46-year-old white female with a BMI of 25.06 who is receiving treatment with FOLFOX + Cetuximab. She has been adherent to her treatment and has completed 12 chemotherapy cycles. Her histology shows well-differentiated cells, and she has symptoms but is still able to be ambulatory. The KRAS biomarker is wild-type. She is experiencing diarrhea as an adverse effect of the treatment."
2082,white,male,61,48.88,FOLFOX + Cetuximab,Yes,No,No,Yes,12,poorly differentiated,symptoms but ambulatory,mutant,No,No,Yes,No,No,0,"race: white, sex: male, age: 61, bmi: 48.88, treatment arm: FOLFOX + Cetuximab, adherence: Yes, bowel perforation: Yes, chemotherapy cycles: 12, histology: poorly differentiated, performance status: symptoms but ambulatory, KRAS biomarker: mutant, adverse effect: diarrhea: Yes","The patient is a 61-year-old white male with a BMI of 48.88 who is undergoing treatment with FOLFOX + Cetuximab. He has been adherent to his treatment regimen and has completed 12 cycles of chemotherapy. The histology of his cancer is poorly differentiated, and he has a mutant KRAS biomarker. Despite experiencing symptoms, he is still able to be ambulatory. The patient has also developed a bowel perforation and is experiencing diarrhea as an adverse effect of the treatment."
2083,white,male,65,24.43,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 65, bmi: 24.43, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 65-year-old white male with a BMI of 24.43. He is receiving treatment in the FOLFOX + Cetuximab treatment arm and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer cells. Despite his age, he has a fully active performance status. Additionally, his KRAS biomarker is wild-type."
2084,white,male,45,28.96,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,symptoms but ambulatory,wild-type,No,No,No,Yes,No,0,"race: white, sex: male, age: 45, bmi: 28.96, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type, adverse effect: infection: Yes","The patient is a 45-year-old white male with a BMI of 28.96. He is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. His cancer histology is well-differentiated, and he has symptoms but is still able to be ambulatory. His KRAS biomarker is wild-type. The patient has experienced an infection as an adverse effect of the treatment."
2085,white,female,56,24.05,FOLFOX,No,No,No,No,12,poorly differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 56, bmi: 24.05, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 56-year-old white female with a BMI of 24.05. She is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. Her histology shows poorly differentiated cells. Despite this, her performance status is fully active. Additionally, her KRAS biomarker is wild-type."
2086,white,male,54,27.58,FOLFOX,No,No,No,No,6,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 54, bmi: 27.58, treatment arm: FOLFOX, chemotherapy cycles: 6, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type",The patient is a 54-year-old white male with a BMI of 27.58. He is receiving the FOLFOX treatment regimen and has completed 6 cycles of chemotherapy. His histology shows well-differentiated cancer cells. The patient has a fully active performance status and his KRAS biomarker is wild-type.
2087,white,female,40,20.96,FOLFOX + Cetuximab,No,Yes,No,No,12,well differentiated,fully active,mutant,No,No,Yes,No,No,0,"race: white, sex: female, age: 40, bmi: 20.96, treatment arm: FOLFOX + Cetuximab, serious adverse effect: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant, adverse effect: diarrhea: Yes","This patient is a 40-year-old white female with a BMI of 20.96. She is receiving treatment with FOLFOX + Cetuximab for her well-differentiated histology. Despite being fully active with a good performance status, she has experienced a serious adverse effect during her 12 chemotherapy cycles. The patient's KRAS biomarker is mutant, and she has also experienced diarrhea as an adverse effect of her treatment."
2088,white,male,69,20.28,FOLFOX + Cetuximab,No,No,No,No,5,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 69, bmi: 20.28, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 5, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 69-year-old white male with a BMI of 20.28. He is currently undergoing treatment with FOLFOX + Cetuximab and has completed 5 cycles of chemotherapy. His cancer histology is well differentiated, and he has a fully active performance status. The KRAS biomarker analysis shows that he has a wild-type KRAS status."
2089,white,female,44,26.62,FOLFOX,Yes,No,No,No,3,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 44, bmi: 26.62, treatment arm: FOLFOX, adherence: Yes, chemotherapy cycles: 3, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type",The patient is a 44-year-old white female with a BMI of 26.62. She is receiving treatment in the FOLFOX chemotherapy arm and has been adherent to the treatment. She has completed 3 cycles of chemotherapy. The histology shows well-differentiated cancer cells. The patient has a fully active performance status. The KRAS biomarker indicates that she has a wild-type KRAS gene.
2090,white,female,44,49,FOLFOX + Cetuximab,No,Yes,No,No,11,well differentiated,symptoms but ambulatory,wild-type,No,No,No,Yes,No,1,"race: white, sex: female, age: 44, bmi: 49.0, treatment arm: FOLFOX + Cetuximab, serious adverse effect: Yes, chemotherapy cycles: 11, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type, adverse effect: infection: Yes","The patient is a 44-year-old white female with a BMI of 49.0 who is receiving treatment with FOLFOX + Cetuximab. She has experienced a serious adverse effect during her 11 chemotherapy cycles. Her histology shows well-differentiated cells, and she has symptoms but is still able to be ambulatory. The patient's KRAS biomarker is wild-type. Additionally, she has developed an infection as an adverse effect of her treatment."
2091,white,male,55,29.59,FOLFOX,Yes,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 55, bmi: 29.59, treatment arm: FOLFOX, adherence: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type",The patient is a 55-year-old white male with a BMI of 29.59. He is receiving the FOLFOX treatment regimen and has been adherent to the treatment. He has completed 12 cycles of chemotherapy. The histology shows well-differentiated cancer cells. The patient has a fully active performance status. His KRAS biomarker is wild-type.
2092,white,female,56,34.12,FOLFOX,No,No,No,No,12,well differentiated,fully active,interminate,No,No,No,No,No,0,"race: white, sex: female, age: 56, bmi: 34.12, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: interminate",The patient is a 56-year-old white female with a BMI of 34.12. She is receiving treatment with the FOLFOX chemotherapy regimen and has completed 12 cycles. The histology of her cancer is well-differentiated. She has a fully active performance status. The KRAS biomarker status is indeterminate.
2093,white,female,51,25.72,FOLFOX + Cetuximab,Yes,No,No,No,1,poorly differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 51, bmi: 25.72, treatment arm: FOLFOX + Cetuximab, adherence: Yes, chemotherapy cycles: 1, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 51-year-old white female with a BMI of 25.72. She is currently receiving treatment in the FOLFOX + Cetuximab treatment arm and has been adherent to the prescribed regimen. She has completed one cycle of chemotherapy. The histology of her cancer is poorly differentiated. Despite her diagnosis, she maintains a fully active performance status. Additionally, her KRAS biomarker status is wild-type."
2094,white,female,61,50.87,FOLFOX + Cetuximab,No,No,Yes,No,7,well differentiated,fully active,wild-type,No,Yes,No,No,No,0,"race: white, sex: female, age: 61, bmi: 50.87, treatment arm: FOLFOX + Cetuximab, bowel obstruction: Yes, chemotherapy cycles: 7, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type, adverse effect: hypersensitivity: Yes","This patient is a 61-year-old white female with a BMI of 50.87 who is receiving treatment with FOLFOX + Cetuximab. She has experienced a bowel obstruction and has completed 7 cycles of chemotherapy. Her histology shows well-differentiated cells, and her performance status is fully active. The KRAS biomarker indicates she has a wild-type gene. She has also experienced a hypersensitivity adverse effect."
2095,white,female,49,39.82,FOLFOX,Yes,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 49, bmi: 39.82, treatment arm: FOLFOX, adherence: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 49-year-old white female with a BMI of 39.82. She is receiving the FOLFOX treatment regimen and has been adherent to her chemotherapy cycles, completing a total of 12 cycles. Her histology shows well-differentiated cancer cells. She has a fully active performance status and her KRAS biomarker is wild-type."
2096,white,male,65,32.91,FOLFOX,No,No,No,No,12,well differentiated,symptoms but ambulatory,wild-type,Yes,No,No,No,No,0,"race: white, sex: male, age: 65, bmi: 32.91, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type, adverse effect: thrombosis: Yes","The patient is a 65-year-old white male with a BMI of 32.91. He is undergoing treatment with the FOLFOX chemotherapy regimen and has completed 12 cycles. His cancer histology is well-differentiated, and he has a performance status of experiencing symptoms but still able to walk around. The KRAS biomarker testing showed that he has a wild-type KRAS status. Additionally, the patient has experienced an adverse effect of thrombosis."
2097,white,male,46,24.66,FOLFOX,No,No,No,No,12,well differentiated,symptoms but ambulatory,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 46, bmi: 24.66, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type","The patient is a 46-year-old white male with a BMI of 24.66. He is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer cells. Despite experiencing symptoms, he is still able to be ambulatory. The KRAS biomarker analysis indicates that he has a wild-type KRAS status."
2098,white,female,67,38.94,FOLFIRI (KRAS mutant),Yes,No,No,No,12,poorly differentiated,fully active,wild-type,No,No,No,No,No,1,"race: white, sex: female, age: 67, bmi: 38.94, treatment arm: FOLFIRI (KRAS mutant), adherence: Yes, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 67-year-old white female with a BMI of 38.94. She is receiving the FOLFIRI treatment regimen for her KRAS mutant status. She has been adherent to her treatment and has completed 12 cycles of chemotherapy. Her cancer histology is poorly differentiated. Despite her diagnosis, she has a fully active performance status. It is important to note that her KRAS biomarker is wild-type."
2099,white,male,34,25.66,FOLFOX,No,No,No,No,12,well differentiated,fully active,mutant,No,No,No,No,No,0,"race: white, sex: male, age: 34, bmi: 25.66, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 34-year-old white male with a BMI of 25.66. He is receiving treatment in the FOLFOX chemotherapy arm and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cells. The patient has a fully active performance status. Additionally, the KRAS biomarker analysis indicates a mutant status."
2100,white,male,46,32.55,FOLFOX,No,Yes,No,No,12,well differentiated,symptoms but ambulatory,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 46, bmi: 32.55, treatment arm: FOLFOX, serious adverse effect: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type","The patient is a 46-year-old white male with a BMI of 32.55. He is receiving the FOLFOX treatment regimen and has experienced a serious adverse effect. He has completed 12 cycles of chemotherapy. The histology shows well-differentiated cancer cells. Despite experiencing symptoms, the patient is still able to be ambulatory. The KRAS biomarker indicates that the patient has a wild-type status."
2101,white,male,72,37.46,FOLFOX + Cetuximab,No,No,Yes,No,12,poorly differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 72, bmi: 37.46, treatment arm: FOLFOX + Cetuximab, bowel obstruction: Yes, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type","This patient is a 72-year-old white male with a BMI of 37.46. He is receiving treatment with FOLFOX + Cetuximab for his cancer. He has a bowel obstruction and has completed 12 cycles of chemotherapy. The histology of his cancer is poorly differentiated. Despite his condition, his performance status is fully active. His KRAS biomarker status is wild-type."
2102,white,male,76,22.26,FOLFOX,No,No,No,No,9,well differentiated,fully active,mutant,No,No,No,No,No,0,"race: white, sex: male, age: 76, bmi: 22.26, treatment arm: FOLFOX, chemotherapy cycles: 9, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 76-year-old white male with a BMI of 22.26. He is receiving treatment in the FOLFOX chemotherapy arm and has completed 9 cycles of chemotherapy. The histology of his cancer is well-differentiated. Despite his age, he has a fully active performance status. The KRAS biomarker testing revealed a mutant status."
2103,black,male,54,22.82,FOLFIRI + Cetuximab,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: black, sex: male, age: 54, bmi: 22.82, treatment arm: FOLFIRI + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 54-year-old Black male with a BMI of 22.82. He is receiving treatment with FOLFIRI + Cetuximab and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer, and he has a fully active performance status. Additionally, his KRAS biomarker is wild-type."
2104,white,female,71,22.17,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,Yes,No,0,"race: white, sex: female, age: 71, bmi: 22.17, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type, adverse effect: infection: Yes","The patient is a 71-year-old white female with a BMI of 22.17. She is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cells, and she has a fully active performance status. The KRAS biomarker indicates that she is wild-type. The patient has experienced an adverse effect in the form of an infection."
2105,white,male,41,31.35,FOLFOX,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 41, bmi: 31.35, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type",The patient is a 41-year-old white male with a BMI of 31.35. He is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer cells. The patient has a fully active performance status and his KRAS biomarker is wild-type.
2106,other,female,58,33.4,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,fully active,wild-type,No,Yes,No,No,No,0,"race: other, sex: female, age: 58, bmi: 33.4, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type, adverse effect: hypersensitivity: Yes","The patient is a 58-year-old female of a race categorized as ""other"" with a BMI of 33.4. She is receiving treatment in the FOLFOX + Cetuximab treatment arm and has completed 12 cycles of chemotherapy. The histology of her cancer is well-differentiated, and her performance status is fully active. The KRAS biomarker testing revealed that she has a wild-type KRAS status. She has experienced a hypersensitivity adverse effect during her treatment."
2107,white,female,64,27.8,FOLFOX + Cetuximab,No,No,No,No,2,well differentiated,symptoms but ambulatory,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 64, bmi: 27.8, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 2, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type","The patient is a 64-year-old white female with a BMI of 27.8. She is currently receiving treatment with FOLFOX + Cetuximab and has completed 2 cycles of chemotherapy. Her cancer histology is well-differentiated. Despite experiencing symptoms, she is still able to be ambulatory. The KRAS biomarker testing revealed that she has a wild-type KRAS status."
2108,white,female,59,44.32,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,fully active,interminate,No,No,No,No,No,0,"race: white, sex: female, age: 59, bmi: 44.32, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: interminate",The patient is a 59-year-old white female with a BMI of 44.32. She is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cancer cells. She has a fully active performance status. The KRAS biomarker status is indeterminate.
2109,other,male,76,22.44,FOLFOX,Yes,No,No,No,12,poorly differentiated,symptoms but ambulatory,wild-type,No,No,No,No,No,0,"race: other, sex: male, age: 76, bmi: 22.44, treatment arm: FOLFOX, adherence: Yes, chemotherapy cycles: 12, histology: poorly differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type","The patient is a 76-year-old male of a race categorized as ""other"" with a BMI of 22.44. He is receiving treatment in the FOLFOX treatment arm and has been adherent to the prescribed chemotherapy regimen for 12 cycles. The histology of his cancer is poorly differentiated. Despite experiencing symptoms, the patient is still able to be ambulatory. His KRAS biomarker status is wild-type."
2110,white,female,55,23.26,FOLFIRI,No,Yes,No,No,6,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 55, bmi: 23.26, treatment arm: FOLFIRI, serious adverse effect: Yes, chemotherapy cycles: 6, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 55-year-old white female with a BMI of 23.26. She is undergoing treatment with the FOLFIRI regimen and has experienced a serious adverse effect. She has completed 6 cycles of chemotherapy. The histology shows well-differentiated cancer cells. Despite the adverse effect, her performance status is fully active. The KRAS biomarker indicates that she has a wild-type mutation."
2111,white,female,41,34.15,FOLFOX + Cetuximab,No,No,No,No,7,well differentiated,fully active,mutant,No,No,No,No,No,0,"race: white, sex: female, age: 41, bmi: 34.15, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 7, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 41-year-old white female with a BMI of 34.15. She is receiving treatment in the FOLFOX + Cetuximab treatment arm and has completed 7 cycles of chemotherapy. Her histology shows well-differentiated cancer cells. Despite her cancer diagnosis, she has a fully active performance status. The KRAS biomarker testing revealed a mutant status."
2112,black,male,51,27.55,FOLFIRI + Cetuximab,No,No,No,No,12,well differentiated,fully active,interminate,No,No,No,No,No,0,"race: black, sex: male, age: 51, bmi: 27.55, treatment arm: FOLFIRI + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: interminate",The patient is a 51-year-old Black male with a BMI of 27.55. He is receiving treatment with FOLFIRI + Cetuximab and has completed 12 cycles of chemotherapy. The histology shows well-differentiated cancer cells. The patient has a fully active performance status. The KRAS biomarker status is indeterminate.
2113,white,male,64,37.51,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 64, bmi: 37.51, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type",The patient is a 64-year-old white male with a BMI of 37.51. He is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer cells. The patient has a fully active performance status and has a wild-type KRAS biomarker.
2114,white,male,54,30.15,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 54, bmi: 30.15, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 54-year-old white male with a BMI of 30.15. He is receiving treatment in the FOLFOX + Cetuximab treatment arm and is scheduled for 12 chemotherapy cycles. His histology shows well-differentiated cells, and he has a performance status of fully active. The KRAS biomarker analysis indicates that he has a wild-type KRAS gene."
2115,white,female,41,27.4,FOLFOX,Yes,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 41, bmi: 27.4, treatment arm: FOLFOX, adherence: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 41-year-old white female with a BMI of 27.4. She is receiving the FOLFOX treatment regimen and has been adherent to her chemotherapy cycles, completing a total of 12 cycles. Her histology shows well-differentiated cancer cells. The patient has a fully active performance status and her KRAS biomarker is wild-type."
2116,white,male,51,33.15,FOLFOX,No,No,No,No,3,well differentiated,fully active,wild-type,Yes,No,Yes,No,No,0,"race: white, sex: male, age: 51, bmi: 33.15, treatment arm: FOLFOX, chemotherapy cycles: 3, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type, adverse effect: thrombosis: Yes, adverse effect: diarrhea: Yes","The patient is a 51-year-old white male with a BMI of 33.15. He is receiving the FOLFOX treatment arm and has completed 3 cycles of chemotherapy. His histology shows well-differentiated cancer cells, and he has a fully active performance status. The KRAS biomarker is wild-type. The patient has experienced adverse effects of thrombosis and diarrhea."
2117,white,female,71,33.8,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,fully active,mutant,No,No,Yes,No,No,1,"race: white, sex: female, age: 71, bmi: 33.8, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant, adverse effect: diarrhea: Yes","The patient is a 71-year-old white female with a BMI of 33.8 who is undergoing treatment with FOLFOX + Cetuximab for colorectal cancer. She has completed 12 cycles of chemotherapy. The histology of her cancer is well differentiated, and her performance status is fully active. The KRAS biomarker testing showed a mutant result. The patient is experiencing diarrhea as an adverse effect of the treatment."
2118,white,male,72,24.19,FOLFOX + Cetuximab,No,No,No,No,11,well differentiated,fully active,wild-type,No,Yes,No,No,No,0,"race: white, sex: male, age: 72, bmi: 24.19, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 11, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type, adverse effect: hypersensitivity: Yes","The patient is a 72-year-old white male with a BMI of 24.19. He is receiving treatment with FOLFOX + Cetuximab and has completed 11 cycles of chemotherapy. His histology shows well-differentiated cancer cells. Despite his age, he has a fully active performance status. The KRAS biomarker testing revealed that he has a wild-type KRAS status. The patient has experienced a hypersensitivity adverse effect during treatment."
2119,white,male,43,35.83,FOLFIRI,No,No,No,No,12,poorly differentiated,fully active,mutant,No,No,No,No,No,0,"race: white, sex: male, age: 43, bmi: 35.83, treatment arm: FOLFIRI, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 43-year-old white male with a BMI of 35.83. He is receiving the FOLFIRI treatment regimen and has completed 12 cycles of chemotherapy. His cancer histology is poorly differentiated. Despite his cancer diagnosis, he has a fully active performance status. The patient's KRAS biomarker status is mutant."
2120,white,female,40,31.62,FOLFIRI (KRAS mutant),No,No,No,No,12,well differentiated,fully active,interminate,No,No,No,No,No,0,"race: white, sex: female, age: 40, bmi: 31.62, treatment arm: FOLFIRI (KRAS mutant), chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: interminate",The patient is a 40-year-old white female with a BMI of 31.62. She is receiving the FOLFIRI treatment regimen for her KRAS mutant status. She has completed 12 cycles of chemotherapy. The histology shows well-differentiated cells. Her performance status is fully active. The KRAS biomarker status is indeterminate.
2121,white,male,44,28.16,FOLFOX,No,No,No,No,8,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 44, bmi: 28.16, treatment arm: FOLFOX, chemotherapy cycles: 8, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type",The patient is a 44-year-old white male with a BMI of 28.16. He is receiving the FOLFOX treatment regimen and has completed 8 cycles of chemotherapy. His cancer histology is well differentiated. The patient has a fully active performance status and his KRAS biomarker is wild-type.
2122,white,female,60,26.37,FOLFOX,Yes,No,No,No,12,poorly differentiated,symptoms but ambulatory,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 60, bmi: 26.37, treatment arm: FOLFOX, adherence: Yes, chemotherapy cycles: 12, histology: poorly differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type","The patient is a 60-year-old white female with a BMI of 26.37. She is receiving the FOLFOX treatment regimen and has been adherent to the treatment. She has completed 12 cycles of chemotherapy. The histology of her cancer is poorly differentiated. Despite experiencing symptoms, she is still able to be ambulatory. Her KRAS biomarker status is wild-type."
2123,white,male,34,26.52,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 34, bmi: 26.52, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type",The patient is a 34-year-old white male with a BMI of 26.52. He is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer cells. The patient has a fully active performance status and his KRAS biomarker is wild-type.
2124,white,female,45,30.62,FOLFOX + Cetuximab,No,No,Yes,No,12,poorly differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 45, bmi: 30.62, treatment arm: FOLFOX + Cetuximab, bowel obstruction: Yes, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type","This patient is a 45-year-old white female with a BMI of 30.62. She is receiving treatment with FOLFOX + Cetuximab for her bowel obstruction. She has undergone 12 cycles of chemotherapy. The histology of her cancer is poorly differentiated. Despite her condition, she has a fully active performance status. Her KRAS biomarker status is wild-type."
2125,other,female,55,21.7,FOLFOX,No,No,No,No,12,well differentiated,symptoms but ambulatory,wild-type,No,No,No,No,No,0,"race: other, sex: female, age: 55, bmi: 21.7, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type","The patient is a 55-year-old female of a race categorized as ""other"" with a BMI of 21.7. She is undergoing treatment with the FOLFOX chemotherapy regimen and has completed 12 cycles. The histology of her condition is well-differentiated. Despite experiencing symptoms, she is still able to be ambulatory. Additionally, her KRAS biomarker status is wild-type."
2126,white,female,53,21.6,FOLFOX,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 53, bmi: 21.6, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type",The patient is a 53-year-old white female with a BMI of 21.6. She is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cancer cells. She has a fully active performance status and her KRAS biomarker is wild-type.
2127,white,female,49,25.68,FOLFOX,No,No,No,No,6,well differentiated,symptoms but ambulatory,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 49, bmi: 25.68, treatment arm: FOLFOX, chemotherapy cycles: 6, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type","The patient is a 49-year-old white female with a BMI of 25.68. She is receiving the FOLFOX treatment regimen and has completed 6 cycles of chemotherapy. Her histology shows well-differentiated cancer cells. Despite experiencing symptoms, she is still able to be ambulatory. The KRAS biomarker analysis indicates that she has a wild-type KRAS status."
2128,white,male,51,31.85,FOLFOX,No,No,No,No,12,well differentiated,symptoms but ambulatory,mutant,No,No,No,No,No,0,"race: white, sex: male, age: 51, bmi: 31.85, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: mutant","The patient is a 51-year-old white male with a BMI of 31.85. He is undergoing treatment with the FOLFOX chemotherapy regimen and has completed 12 cycles. His histology shows well-differentiated cancer cells. Despite experiencing symptoms, he is still able to be ambulatory. The patient's KRAS biomarker status is mutant."
2129,white,male,67,23.24,FOLFOX,No,No,No,No,12,poorly differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 67, bmi: 23.24, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 67-year-old white male with a BMI of 23.24. He is undergoing treatment with the FOLFOX chemotherapy regimen and has completed 12 cycles so far. His histology shows poorly differentiated cancer cells. Despite this, his performance status is fully active, indicating that he is able to carry out daily activities without limitations. Additionally, his KRAS biomarker status is wild-type."
2130,white,female,73,25.83,FOLFOX + Cetuximab,No,Yes,No,No,9,poorly differentiated,symptoms but ambulatory,interminate,No,No,No,No,No,1,"race: white, sex: female, age: 73, bmi: 25.83, treatment arm: FOLFOX + Cetuximab, serious adverse effect: Yes, chemotherapy cycles: 9, histology: poorly differentiated, performance status: symptoms but ambulatory, KRAS biomarker: interminate","The patient is a 73-year-old white female with a BMI of 25.83. She is receiving treatment with FOLFOX + Cetuximab for her cancer. Unfortunately, she has experienced a serious adverse effect from the treatment. She has completed 9 cycles of chemotherapy. The histology of her cancer is poorly differentiated. Despite experiencing symptoms, she is still able to be ambulatory. Her KRAS biomarker status is indeterminate."
2131,white,male,49,32.07,FOLFOX,No,No,No,No,12,well differentiated,symptoms but ambulatory,mutant,No,No,No,No,No,0,"race: white, sex: male, age: 49, bmi: 32.07, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: mutant","The patient is a 49-year-old white male with a BMI of 32.07. He is undergoing treatment with the FOLFOX chemotherapy regimen and has completed 12 cycles. His histology shows well-differentiated cancer cells. Despite experiencing symptoms, he is still able to ambulate. The KRAS biomarker analysis revealed a mutant status."
2132,white,female,75,29.14,FOLFOX + Cetuximab,No,Yes,Yes,No,12,well differentiated,symptoms but ambulatory,wild-type,No,No,No,Yes,No,0,"race: white, sex: female, age: 75, bmi: 29.14, treatment arm: FOLFOX + Cetuximab, serious adverse effect: Yes, bowel obstruction: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type, adverse effect: infection: Yes","The patient is a 75-year-old white female with a BMI of 29.14. She is receiving treatment with FOLFOX + Cetuximab and has experienced a serious adverse effect, specifically a bowel obstruction. She has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cells, and her performance status indicates that she has symptoms but is still able to be ambulatory. Additionally, her KRAS biomarker is wild-type. The patient has also experienced an infection as an adverse effect."
2133,white,male,73,27.2,FOLFOX,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 73, bmi: 27.2, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 73-year-old white male with a BMI of 27.2. He is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. His cancer histology is well-differentiated. Despite his age, he has a fully active performance status. Additionally, his KRAS biomarker status is wild-type."
2134,white,male,52,36.08,FOLFOX + Cetuximab,No,No,No,No,3,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 52, bmi: 36.08, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 3, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 52-year-old white male with a BMI of 36.08. He is receiving treatment with FOLFOX + Cetuximab and has completed 3 cycles of chemotherapy. His cancer histology is well-differentiated, and he has a fully active performance status. The KRAS biomarker analysis shows that he has a wild-type KRAS status."
2135,white,male,73,26.53,FOLFOX + Cetuximab,No,No,No,Yes,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 73, bmi: 26.53, treatment arm: FOLFOX + Cetuximab, bowel perforation: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","This patient is a 73-year-old white male with a BMI of 26.53. He is receiving treatment with FOLFOX + Cetuximab for his colorectal cancer. He has experienced a bowel perforation and has completed 12 cycles of chemotherapy. The histology of his cancer is well-differentiated. Despite his condition, his performance status is fully active. His KRAS biomarker status is wild-type."
2136,white,female,71,31.64,FOLFOX + Cetuximab,No,No,No,No,1,well differentiated,fully active,wild-type,No,Yes,No,No,No,0,"race: white, sex: female, age: 71, bmi: 31.64, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 1, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type, adverse effect: hypersensitivity: Yes","The patient is a 71-year-old white female with a BMI of 31.64. She is currently undergoing treatment with FOLFOX + Cetuximab and has completed one cycle of chemotherapy. Her histology shows well-differentiated cancer cells. Despite her age, she has a fully active performance status. The KRAS biomarker testing revealed that she has a wild-type KRAS gene. The patient experienced a hypersensitivity reaction as an adverse effect to the treatment."
2137,white,female,55,22.22,FOLFIRI + Cetuximab,No,No,No,No,12,well differentiated,fully active,mutant,No,No,No,No,No,1,"race: white, sex: female, age: 55, bmi: 22.22, treatment arm: FOLFIRI + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 55-year-old white female with a BMI of 22.22. She is receiving treatment in the FOLFIRI + Cetuximab treatment arm and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cancer cells. The patient has a fully active performance status. Additionally, her KRAS biomarker is mutant."
2138,white,male,70,23.53,FOLFOX + Cetuximab,No,No,Yes,No,2,poorly differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 70, bmi: 23.53, treatment arm: FOLFOX + Cetuximab, bowel obstruction: Yes, chemotherapy cycles: 2, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 70-year-old white male with a BMI of 23.53. He is currently receiving treatment in the FOLFOX + Cetuximab treatment arm. He has experienced a bowel obstruction and has completed 2 cycles of chemotherapy. The histology of his cancer is poorly differentiated. Despite these challenges, his performance status is fully active. His KRAS biomarker status is wild-type."
2139,white,male,40,25.33,FOLFOX + Cetuximab,Yes,No,No,No,12,well differentiated,fully active,wild-type,No,No,Yes,No,No,0,"race: white, sex: male, age: 40, bmi: 25.33, treatment arm: FOLFOX + Cetuximab, adherence: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type, adverse effect: diarrhea: Yes","The patient is a 40-year-old white male with a BMI of 25.33. He is receiving treatment in the FOLFOX + Cetuximab treatment arm and has been adherent to the treatment. He has completed 12 chemotherapy cycles. His histology shows well-differentiated cells, and his performance status is fully active. The KRAS biomarker is wild-type. The patient has experienced diarrhea as an adverse effect of the treatment."
2140,white,female,40,57.73,FOLFOX + Cetuximab,No,No,Yes,No,12,well differentiated,in bed less than 50% of the time,wild-type,No,No,No,Yes,No,0,"race: white, sex: female, age: 40, bmi: 57.73, treatment arm: FOLFOX + Cetuximab, bowel obstruction: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: in bed less than 50% of the time, KRAS biomarker: wild-type, adverse effect: infection: Yes","The patient is a 40-year-old white female with a BMI of 57.73 who is receiving treatment with FOLFOX + Cetuximab. She has a bowel obstruction and has completed 12 cycles of chemotherapy. The histology shows well-differentiated cells, and her performance status indicates that she is in bed less than 50% of the time. Her KRAS biomarker is wild-type. Additionally, she has experienced an infection as an adverse effect of treatment."
2141,white,male,62,37.53,FOLFOX + Cetuximab,No,No,Yes,Yes,12,poorly differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 62, bmi: 37.53, treatment arm: FOLFOX + Cetuximab, bowel obstruction: Yes, bowel perforation: Yes, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type","This patient is a 62-year-old white male with a BMI of 37.53. He is receiving treatment with FOLFOX + Cetuximab for his cancer. He has experienced both a bowel obstruction and a bowel perforation. He has completed 12 cycles of chemotherapy. The histology of his cancer is poorly differentiated. Despite his health challenges, his performance status is fully active. His KRAS biomarker status is wild-type."
2142,white,male,71,25.31,FOLFIRI,No,Yes,No,No,12,well differentiated,fully active,interminate,No,No,No,No,No,0,"race: white, sex: male, age: 71, bmi: 25.31, treatment arm: FOLFIRI, serious adverse effect: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: interminate","The patient is a 71-year-old white male with a BMI of 25.31. He is undergoing treatment with the FOLFIRI regimen and has experienced a serious adverse effect. He has completed 12 cycles of chemotherapy. The histology of his condition is well-differentiated. Despite the adverse effect, his performance status is fully active. The KRAS biomarker status is indeterminate."
2143,white,female,51,25.81,FOLFOX,Yes,No,Yes,No,12,well differentiated,symptoms but ambulatory,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 51, bmi: 25.81, treatment arm: FOLFOX, adherence: Yes, bowel obstruction: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type","The patient is a 51-year-old white female with a BMI of 25.81. She is receiving treatment with FOLFOX chemotherapy and has been adherent to the treatment. She has experienced a bowel obstruction. The patient has completed 12 cycles of chemotherapy and her histology shows well-differentiated cells. Despite experiencing symptoms, she is still able to be ambulatory. The KRAS biomarker testing revealed that she has a wild-type KRAS status."
2144,white,female,46,24.8,FOLFOX,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 46, bmi: 24.8, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type",The patient is a 46-year-old white female with a BMI of 24.8. She is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. The histology shows well-differentiated cancer cells. The patient has a fully active performance status. The KRAS biomarker indicates that the tumor is wild-type.
2145,white,female,42,28.23,FOLFOX,No,No,No,No,6,well differentiated,fully active,mutant,No,No,No,No,No,0,"race: white, sex: female, age: 42, bmi: 28.23, treatment arm: FOLFOX, chemotherapy cycles: 6, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 42-year-old white female with a BMI of 28.23. She is receiving the FOLFOX treatment regimen and has completed 6 cycles of chemotherapy. Her histology shows well-differentiated cells, and her performance status is fully active. The KRAS biomarker analysis indicates a mutant status."
2146,white,male,58,31.18,FOLFOX + Cetuximab,No,No,No,No,6,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 58, bmi: 31.18, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 6, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type",The patient is a 58-year-old white male with a BMI of 31.18. He is receiving treatment in the FOLFOX + Cetuximab treatment arm and has completed 6 cycles of chemotherapy. His cancer histology is well differentiated. The patient has a fully active performance status and has a wild-type KRAS biomarker.
2147,white,female,57,32.88,FOLFIRI (KRAS mutant),No,Yes,No,No,12,well differentiated,fully active,mutant,No,No,No,No,No,0,"race: white, sex: female, age: 57, bmi: 32.88, treatment arm: FOLFIRI (KRAS mutant), serious adverse effect: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant","This patient is a 57-year-old white female with a BMI of 32.88. She is receiving the FOLFIRI treatment regimen for her KRAS mutant status. She has experienced a serious adverse effect during her 12 chemotherapy cycles. The histology of her cancer is well-differentiated, and her performance status is fully active."
2148,white,female,34,25.35,FOLFOX,Yes,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 34, bmi: 25.35, treatment arm: FOLFOX, adherence: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type",The patient is a 34-year-old white female with a BMI of 25.35. She is receiving treatment with the FOLFOX chemotherapy regimen and has been adherent to her treatment. She has completed 12 cycles of chemotherapy. The histology of her cancer is well-differentiated. The patient has a fully active performance status. Her KRAS biomarker status is wild-type.
2149,white,female,66,41.06,FOLFOX + Cetuximab,No,No,Yes,No,12,poorly differentiated,fully active,wild-type,No,No,No,No,No,1,"race: white, sex: female, age: 66, bmi: 41.06, treatment arm: FOLFOX + Cetuximab, bowel obstruction: Yes, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type","This patient is a 66-year-old white female with a BMI of 41.06. She is receiving treatment with FOLFOX + Cetuximab for her bowel obstruction. She has undergone 12 cycles of chemotherapy. The histology of her cancer is poorly differentiated. Despite her condition, she has a fully active performance status. Her KRAS biomarker is wild-type."
2150,white,female,41,32.98,FOLFOX + Cetuximab,No,No,Yes,Yes,12,well differentiated,fully active,mutant,No,No,No,No,No,0,"race: white, sex: female, age: 41, bmi: 32.98, treatment arm: FOLFOX + Cetuximab, bowel obstruction: Yes, bowel perforation: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant","This patient is a 41-year-old white female with a BMI of 32.98. She is receiving treatment with FOLFOX + Cetuximab for her cancer. She has experienced both a bowel obstruction and a bowel perforation. She is scheduled to undergo 12 cycles of chemotherapy. The histology of her cancer is well-differentiated. Despite her medical challenges, her performance status is fully active. Additionally, the KRAS biomarker testing revealed a mutant status."
2151,white,male,55,28.41,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 55, bmi: 28.41, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type",The patient is a 55-year-old white male with a BMI of 28.41. He is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer cells. The patient has a fully active performance status. His KRAS biomarker is wild-type.
2152,white,male,61,41.76,FOLFOX,No,No,No,No,12,poorly differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 61, bmi: 41.76, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 61-year-old white male with a BMI of 41.76. He is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. His histology shows poorly differentiated cancer cells. Despite this, his performance status is fully active. Additionally, his KRAS biomarker indicates that it is wild-type."
2153,white,male,58,26.26,FOLFOX + Cetuximab,No,Yes,No,No,12,well differentiated,symptoms but ambulatory,mutant,No,No,No,No,No,0,"race: white, sex: male, age: 58, bmi: 26.26, treatment arm: FOLFOX + Cetuximab, serious adverse effect: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: mutant","The patient is a 58-year-old white male with a BMI of 26.26. He is receiving treatment in the FOLFOX + Cetuximab treatment arm and has experienced a serious adverse effect. He has completed 12 cycles of chemotherapy. The histology shows well-differentiated cells. Despite experiencing symptoms, the patient is still ambulatory. The KRAS biomarker indicates a mutant status."
2154,white,female,43,35.8,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,symptoms but ambulatory,mutant,No,No,No,No,No,0,"race: white, sex: female, age: 43, bmi: 35.8, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: mutant","The patient is a 43-year-old white female with a BMI of 35.8. She is receiving treatment in the FOLFOX + Cetuximab treatment arm and is scheduled for 12 chemotherapy cycles. Her histology shows well-differentiated cells. Despite experiencing symptoms, she is still able to ambulate. The KRAS biomarker analysis revealed a mutant status."
2155,white,male,74,32.09,FOLFOX + Cetuximab,No,No,No,No,10,well differentiated,fully active,mutant,No,Yes,No,No,No,0,"race: white, sex: male, age: 74, bmi: 32.09, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 10, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant, adverse effect: hypersensitivity: Yes","The patient is a 74-year-old white male with a BMI of 32.09. He is receiving treatment with FOLFOX + Cetuximab and has completed 10 cycles of chemotherapy. His histology shows well-differentiated cancer cells, and he has a fully active performance status. The KRAS biomarker analysis revealed a mutant status. The patient has experienced a hypersensitivity adverse effect."
2156,white,female,71,29.09,FOLFOX + Cetuximab,No,No,No,No,12,poorly differentiated,symptoms but ambulatory,mutant,No,No,Yes,No,No,0,"race: white, sex: female, age: 71, bmi: 29.09, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: poorly differentiated, performance status: symptoms but ambulatory, KRAS biomarker: mutant, adverse effect: diarrhea: Yes","The patient is a 71-year-old white female with a BMI of 29.09. She is receiving treatment with FOLFOX + Cetuximab and has completed 12 chemotherapy cycles. Her histology shows poorly differentiated cancer cells. Despite experiencing symptoms, she is still able to ambulate. The KRAS biomarker testing revealed a mutant status. The patient is experiencing diarrhea as an adverse effect of the treatment."
2157,white,female,73,25.96,FOLFIRI (KRAS mutant),Yes,Yes,No,Yes,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 73, bmi: 25.96, treatment arm: FOLFIRI (KRAS mutant), adherence: Yes, serious adverse effect: Yes, bowel perforation: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 73-year-old white female with a BMI of 25.96. She is receiving the FOLFIRI treatment regimen for her KRAS mutant status and has been adherent to the treatment. Unfortunately, she experienced a serious adverse effect in the form of a bowel perforation. Despite this, she completed 12 cycles of chemotherapy. Her histology shows well-differentiated cancer, and her performance status is fully active. It is worth noting that her KRAS biomarker is wild-type."
2158,white,female,60,25.26,FOLFOX + Cetuximab,No,Yes,No,No,8,well differentiated,fully active,mutant,No,No,No,No,No,1,"race: white, sex: female, age: 60, bmi: 25.26, treatment arm: FOLFOX + Cetuximab, serious adverse effect: Yes, chemotherapy cycles: 8, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 60-year-old white female with a BMI of 25.26. She is receiving treatment with FOLFOX + Cetuximab and has experienced a serious adverse effect. She has completed 8 cycles of chemotherapy. Her histology shows well-differentiated cells, and her performance status is fully active. The KRAS biomarker indicates a mutant status."
2159,white,female,67,23.48,FOLFIRI,No,No,No,No,11,well differentiated,fully active,mutant,No,No,No,No,No,0,"race: white, sex: female, age: 67, bmi: 23.48, treatment arm: FOLFIRI, chemotherapy cycles: 11, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 67-year-old white female with a BMI of 23.48. She is currently receiving the FOLFIRI treatment regimen and has completed 11 cycles of chemotherapy. The histology of her cancer is well differentiated. Despite her age, she has a fully active performance status. The KRAS biomarker testing revealed a mutant status."
2160,white,female,43,36.59,FOLFOX + Cetuximab,No,No,No,Yes,12,well differentiated,symptoms but ambulatory,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 43, bmi: 36.59, treatment arm: FOLFOX + Cetuximab, bowel perforation: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type","The patient is a 43-year-old white female with a BMI of 36.59. She is receiving treatment with FOLFOX + Cetuximab for her well-differentiated histology. She experienced a bowel perforation and has undergone 12 cycles of chemotherapy. Despite experiencing symptoms, she is still ambulatory. Her KRAS biomarker status is wild-type."
2161,white,female,59,32,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,fully active,wild-type,No,Yes,No,No,No,0,"race: white, sex: female, age: 59, bmi: 32.0, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type, adverse effect: hypersensitivity: Yes","The patient is a 59-year-old white female with a BMI of 32.0. She is receiving treatment with FOLFOX + Cetuximab and has completed 12 chemotherapy cycles. Her histology shows well-differentiated cells, and she has a fully active performance status. The KRAS biomarker indicates she is wild-type. She has experienced a hypersensitivity adverse effect."
2162,black,female,42,44.16,FOLFOX,No,No,Yes,No,12,well differentiated,in bed less than 50% of the time,mutant,No,No,No,No,No,0,"race: black, sex: female, age: 42, bmi: 44.16, treatment arm: FOLFOX, bowel obstruction: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: in bed less than 50% of the time, KRAS biomarker: mutant","The patient is a 42-year-old Black female with a BMI of 44.16. She is receiving the FOLFOX treatment arm for her well-differentiated histology. She has experienced a bowel obstruction and has completed 12 cycles of chemotherapy. Her performance status indicates that she is in bed less than 50% of the time. Additionally, she has a mutant KRAS biomarker."
2163,black,male,45,27.74,FOLFOX,No,Yes,Yes,No,12,well differentiated,fully active,wild-type,No,No,Yes,No,No,0,"race: black, sex: male, age: 45, bmi: 27.74, treatment arm: FOLFOX, serious adverse effect: Yes, bowel obstruction: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type, adverse effect: diarrhea: Yes","The patient is a 45-year-old Black male with a BMI of 27.74. He is undergoing treatment with the FOLFOX regimen and has experienced a serious adverse effect, specifically a bowel obstruction. He has completed 12 cycles of chemotherapy. The histology of his cancer is well-differentiated, and his performance status is fully active. The KRAS biomarker testing revealed a wild-type result. Additionally, he has experienced diarrhea as an adverse effect."
2164,white,female,56,27.32,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,fully active,mutant,No,No,No,No,No,0,"race: white, sex: female, age: 56, bmi: 27.32, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 56-year-old white female with a BMI of 27.32. She is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cancer cells. Despite her cancer diagnosis, she has a fully active performance status. Additionally, the KRAS biomarker analysis revealed a mutant status."
2165,white,female,48,22.11,FOLFOX + Cetuximab,No,Yes,No,No,5,poorly differentiated,fully active,wild-type,Yes,No,Yes,No,No,0,"race: white, sex: female, age: 48, bmi: 22.11, treatment arm: FOLFOX + Cetuximab, serious adverse effect: Yes, chemotherapy cycles: 5, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type, adverse effect: thrombosis: Yes, adverse effect: diarrhea: Yes","The patient is a 48-year-old white female with a BMI of 22.11. She is receiving treatment with FOLFOX + Cetuximab and has experienced a serious adverse effect. She has completed 5 cycles of chemotherapy. The histology of her cancer is poorly differentiated. Despite this, her performance status is fully active. Her KRAS biomarker is wild-type. She has also experienced adverse effects in the form of thrombosis and diarrhea."
2166,white,female,50,36.54,FOLFOX,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 50, bmi: 36.54, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type",The patient is a 50-year-old white female with a BMI of 36.54. She is receiving the FOLFOX treatment arm and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cancer cells. The patient has a fully active performance status and her KRAS biomarker is wild-type.
2167,white,female,61,44.44,FOLFOX,No,Yes,No,No,11,poorly differentiated,fully active,mutant,No,No,No,No,No,0,"race: white, sex: female, age: 61, bmi: 44.44, treatment arm: FOLFOX, serious adverse effect: Yes, chemotherapy cycles: 11, histology: poorly differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 61-year-old white female with a BMI of 44.44. She is receiving the FOLFOX treatment arm for her cancer. She has experienced a serious adverse effect from the treatment. So far, she has completed 11 cycles of chemotherapy. The histology of her cancer is poorly differentiated. Despite her condition, she has a fully active performance status. Additionally, the KRAS biomarker testing revealed that she has a mutant KRAS status."
2168,white,male,66,43.03,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 66, bmi: 43.03, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 66-year-old white male with a BMI of 43.03. He is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. His cancer histology is well differentiated. Despite his age, he has a fully active performance status. Additionally, his KRAS biomarker status is wild-type."
2169,white,male,44,38.33,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 44, bmi: 38.33, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 44-year-old white male with a BMI of 38.33. He is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. His cancer histology is well-differentiated, and he has a fully active performance status. The KRAS biomarker analysis shows that he has a wild-type KRAS status."
2170,white,male,60,26.36,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 60, bmi: 26.36, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 60-year-old white male with a BMI of 26.36. He is receiving treatment with FOLFOX + Cetuximab and is scheduled for 12 cycles of chemotherapy. His cancer histology is well-differentiated, and he has a fully active performance status. Additionally, his KRAS biomarker status is wild-type."
2171,white,female,36,20.9,FOLFOX,No,No,No,No,12,poorly differentiated,fully active,mutant,No,No,No,No,No,0,"race: white, sex: female, age: 36, bmi: 20.9, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 36-year-old white female with a BMI of 20.9. She is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. Her cancer histology is poorly differentiated. Despite this, her performance status is fully active. The KRAS biomarker analysis revealed a mutant status."
2172,white,female,61,30.85,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,Yes,No,No,0,"race: white, sex: female, age: 61, bmi: 30.85, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type, adverse effect: diarrhea: Yes","The patient is a 61-year-old white female with a BMI of 30.85. She is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. Her cancer histology is well-differentiated, and she has a fully active performance status. The KRAS biomarker testing showed that she has a wild-type KRAS status. She is experiencing diarrhea as an adverse effect of the treatment."
2173,white,male,42,31.66,FOLFOX,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 42, bmi: 31.66, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type",The patient is a 42-year-old white male with a BMI of 31.66. He is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer cells. The patient has a fully active performance status and his KRAS biomarker is wild-type.
2174,black,male,52,28.88,FOLFOX,No,No,No,Yes,12,well differentiated,symptoms but ambulatory,mutant,No,No,No,No,No,0,"race: black, sex: male, age: 52, bmi: 28.88, treatment arm: FOLFOX, bowel perforation: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: mutant","The patient is a 52-year-old Black male with a BMI of 28.88. He is receiving the FOLFOX treatment arm and has experienced a bowel perforation. He has undergone 12 cycles of chemotherapy. The histology shows well-differentiated cancer cells. Despite experiencing symptoms, the patient is still able to be ambulatory. The KRAS biomarker indicates a mutant status."
2175,white,female,67,27.32,FOLFOX + Cetuximab,No,No,No,No,12,poorly differentiated,fully active,interminate,No,No,No,No,No,0,"race: white, sex: female, age: 67, bmi: 27.32, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: interminate","The patient is a 67-year-old white female with a BMI of 27.32. She is receiving treatment in the FOLFOX + Cetuximab treatment arm and is scheduled for 12 chemotherapy cycles. Her histology shows poorly differentiated cancer cells. Despite this, her performance status is fully active. The KRAS biomarker status is indeterminate for this patient."
2176,white,male,55,28.88,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 55, bmi: 28.88, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 55-year-old white male with a BMI of 28.88. He is receiving treatment in the FOLFOX + Cetuximab treatment arm and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cells, and he has a fully active performance status. The KRAS biomarker indicates that he has a wild-type mutation."
2177,white,male,44,23.97,FOLFOX,Yes,No,No,No,12,well differentiated,symptoms but ambulatory,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 44, bmi: 23.97, treatment arm: FOLFOX, adherence: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type","The patient is a 44-year-old white male with a BMI of 23.97. He is receiving the FOLFOX treatment regimen and has been adherent to the treatment. He has completed 12 cycles of chemotherapy. The histology shows that the cancer is well-differentiated. Despite experiencing symptoms, the patient is still able to be ambulatory. The KRAS biomarker indicates that it is wild-type."
2178,white,male,74,22.16,FOLFOX + Cetuximab,Yes,No,Yes,Yes,12,well differentiated,symptoms but ambulatory,mutant,No,No,Yes,No,No,1,"race: white, sex: male, age: 74, bmi: 22.16, treatment arm: FOLFOX + Cetuximab, adherence: Yes, bowel obstruction: Yes, bowel perforation: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: mutant, adverse effect: diarrhea: Yes","The patient is a 74-year-old white male with a BMI of 22.16. He is receiving treatment with FOLFOX + Cetuximab and has been adherent to the treatment. He has experienced bowel obstruction and perforation. He has completed 12 cycles of chemotherapy. Histologically, the cancer is well-differentiated. Despite experiencing symptoms, the patient is still ambulatory. The KRAS biomarker is mutant. The patient has also experienced diarrhea as an adverse effect of the treatment."
2179,white,male,40,36.58,FOLFOX,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,Yes,No,0,"race: white, sex: male, age: 40, bmi: 36.58, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type, adverse effect: infection: Yes",The patient is a 40-year-old white male with a BMI of 36.58 who is receiving the FOLFOX treatment arm for his well-differentiated histology. He has completed 12 cycles of chemotherapy and has a fully active performance status. His KRAS biomarker is wild-type. The patient has experienced an infection as an adverse effect.
2180,white,male,42,30.51,FOLFOX,No,Yes,No,No,12,well differentiated,fully active,wild-type,No,Yes,No,No,No,0,"race: white, sex: male, age: 42, bmi: 30.51, treatment arm: FOLFOX, serious adverse effect: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type, adverse effect: hypersensitivity: Yes","The patient is a 42-year-old white male with a BMI of 30.51. He is receiving the FOLFOX treatment regimen and has experienced a serious adverse effect. He has completed 12 cycles of chemotherapy and has well-differentiated histology. Despite the serious adverse effect, his performance status is fully active. His KRAS biomarker is wild-type, and he has also experienced a hypersensitivity adverse effect."
2181,white,female,41,26.32,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,fully active,mutant,No,No,No,No,No,0,"race: white, sex: female, age: 41, bmi: 26.32, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant",The patient is a 41-year-old white female with a BMI of 26.32. She is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. The histology shows well-differentiated cancer cells. The patient has a fully active performance status. The KRAS biomarker indicates a mutant status.
2182,white,male,59,28.88,FOLFOX + Cetuximab,No,No,Yes,No,8,poorly differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 59, bmi: 28.88, treatment arm: FOLFOX + Cetuximab, bowel obstruction: Yes, chemotherapy cycles: 8, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 59-year-old white male with a BMI of 28.88. He is receiving treatment in the FOLFOX + Cetuximab treatment arm. He has a bowel obstruction and has completed 8 cycles of chemotherapy. The histology shows poorly differentiated cells. Despite the bowel obstruction, the patient's performance status is fully active. The KRAS biomarker indicates that the patient has a wild-type KRAS gene."
2183,white,female,66,26.16,FOLFIRI,No,No,No,No,1,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 66, bmi: 26.16, treatment arm: FOLFIRI, chemotherapy cycles: 1, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type",The patient is a 66-year-old white female with a BMI of 26.16. She is receiving treatment with the FOLFIRI chemotherapy regimen and has completed one cycle so far. Her cancer histology is well-differentiated. She has a fully active performance status. The KRAS biomarker testing showed that she has a wild-type KRAS status.
2184,white,female,62,22.98,FOLFOX,No,No,No,No,10,poorly differentiated,fully active,mutant,No,No,No,No,No,0,"race: white, sex: female, age: 62, bmi: 22.98, treatment arm: FOLFOX, chemotherapy cycles: 10, histology: poorly differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 62-year-old white female with a BMI of 22.98. She is receiving the FOLFOX treatment regimen and has completed 10 cycles of chemotherapy. The histology of her cancer is poorly differentiated. Despite this, her performance status is fully active. Additionally, the KRAS biomarker testing revealed a mutant status."
2185,white,male,74,23.76,FOLFOX,Yes,No,Yes,Yes,12,well differentiated,symptoms but ambulatory,mutant,Yes,No,Yes,No,No,0,"race: white, sex: male, age: 74, bmi: 23.76, treatment arm: FOLFOX, adherence: Yes, bowel obstruction: Yes, bowel perforation: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: mutant, adverse effect: thrombosis: Yes, adverse effect: diarrhea: Yes","This patient is a 74-year-old white male with a BMI of 23.76. He is receiving treatment with FOLFOX and has been adherent to the treatment. He has experienced a bowel obstruction and perforation. He has completed 12 cycles of chemotherapy. The histology shows well-differentiated cancer cells. Despite experiencing symptoms, he is still able to be ambulatory. The KRAS biomarker is mutant in this patient. He has also experienced adverse effects in the form of thrombosis and diarrhea."
2186,white,female,67,23.1,FOLFIRI (KRAS mutant),No,No,No,No,12,well differentiated,fully active,mutant,No,No,No,No,No,0,"race: white, sex: female, age: 67, bmi: 23.1, treatment arm: FOLFIRI (KRAS mutant), chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 67-year-old white female with a BMI of 23.1. She is receiving the FOLFIRI treatment regimen for her KRAS mutant status. She has completed 12 cycles of chemotherapy. Her cancer histology is well-differentiated, and she has a fully active performance status."
2187,white,female,41,33.01,FOLFIRI,No,No,No,No,12,well differentiated,fully active,interminate,No,No,No,No,No,1,"race: white, sex: female, age: 41, bmi: 33.01, treatment arm: FOLFIRI, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: interminate",The patient is a 41-year-old white female with a BMI of 33.01. She is receiving the FOLFIRI treatment regimen and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cancer cells. The patient has a fully active performance status. The KRAS biomarker status is indeterminate.
2188,white,female,35,34.12,FOLFOX,No,No,Yes,No,12,poorly differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 35, bmi: 34.12, treatment arm: FOLFOX, bowel obstruction: Yes, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 35-year-old white female with a BMI of 34.12. She is receiving the FOLFOX treatment regimen and has experienced a bowel obstruction. She has completed 12 cycles of chemotherapy. The histology of her cancer is poorly differentiated. Despite her condition, her performance status is fully active. The KRAS biomarker analysis shows that she has a wild-type KRAS gene."
2189,white,female,40,22.13,FOLFOX + Cetuximab,Yes,Yes,No,No,12,poorly differentiated,fully active,wild-type,No,No,Yes,Yes,No,0,"race: white, sex: female, age: 40, bmi: 22.13, treatment arm: FOLFOX + Cetuximab, adherence: Yes, serious adverse effect: Yes, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type, adverse effect: diarrhea: Yes, adverse effect: infection: Yes","The patient is a 40-year-old white female with a BMI of 22.13. She is receiving treatment with FOLFOX + Cetuximab and has been adherent to the treatment. She experienced serious adverse effects during the 12 chemotherapy cycles, including diarrhea and infection. The histology of her condition is poorly differentiated, and her performance status is fully active. Her KRAS biomarker is wild-type."
2190,white,male,48,30.75,FOLFOX + Cetuximab,No,Yes,No,No,5,well differentiated,fully active,wild-type,No,No,No,Yes,No,0,"race: white, sex: male, age: 48, bmi: 30.75, treatment arm: FOLFOX + Cetuximab, serious adverse effect: Yes, chemotherapy cycles: 5, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type, adverse effect: infection: Yes","The patient is a 48-year-old white male with a BMI of 30.75. He is receiving treatment with FOLFOX + Cetuximab and has experienced a serious adverse effect. He has completed 5 cycles of chemotherapy. His histology shows well-differentiated cells, and he has a fully active performance status. The KRAS biomarker indicates that he is wild-type. Additionally, he has developed an infection as an adverse effect of the treatment."
2191,white,male,54,30.56,FOLFOX,No,No,Yes,No,12,poorly differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 54, bmi: 30.56, treatment arm: FOLFOX, bowel obstruction: Yes, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 54-year-old white male with a BMI of 30.56. He is receiving treatment with the FOLFOX regimen for his bowel obstruction. He has completed 12 cycles of chemotherapy. The histology of his cancer is poorly differentiated. Despite his condition, he has a fully active performance status. The KRAS biomarker testing revealed that he has the wild-type KRAS gene."
2192,other,male,55,28.69,FOLFIRI,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: other, sex: male, age: 55, bmi: 28.69, treatment arm: FOLFIRI, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 55-year-old male of a race categorized as ""other"" with a BMI of 28.69. He is undergoing treatment with the FOLFIRI chemotherapy regimen and has completed 12 cycles. The histology of his cancer is well-differentiated. Despite his cancer diagnosis, he has a fully active performance status. Additionally, his KRAS biomarker status is wild-type."
2193,white,male,67,23.59,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,fully active,mutant,No,No,No,No,No,0,"race: white, sex: male, age: 67, bmi: 23.59, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant",The patient is a 67-year-old white male with a BMI of 23.59. He is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. His cancer histology is well differentiated. The patient has a fully active performance status. His KRAS biomarker status is mutant.
2194,white,male,71,24.95,FOLFOX + Cetuximab,No,Yes,No,No,1,well differentiated,symptoms but ambulatory,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 71, bmi: 24.95, treatment arm: FOLFOX + Cetuximab, serious adverse effect: Yes, chemotherapy cycles: 1, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type","The patient is a 71-year-old white male with a BMI of 24.95. He is receiving treatment with FOLFOX + Cetuximab. Unfortunately, he has experienced a serious adverse effect after completing one cycle of chemotherapy. His histology shows well-differentiated cells, and his performance status indicates that he has symptoms but is still able to be ambulatory. The KRAS biomarker analysis shows that he has a wild-type KRAS status."
2195,white,male,66,29.92,FOLFOX,No,No,Yes,No,12,poorly differentiated,symptoms but ambulatory,wild-type,No,No,No,No,No,1,"race: white, sex: male, age: 66, bmi: 29.92, treatment arm: FOLFOX, bowel obstruction: Yes, chemotherapy cycles: 12, histology: poorly differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type","The patient is a 66-year-old white male with a BMI of 29.92. He is receiving the FOLFOX treatment regimen for his cancer. He has experienced a bowel obstruction and has completed 12 cycles of chemotherapy. The histology of his cancer is poorly differentiated. Despite experiencing symptoms, he is still able to be ambulatory. His KRAS biomarker status is wild-type."
2196,white,male,55,26.35,FOLFOX + Cetuximab,No,Yes,No,Yes,12,well differentiated,fully active,wild-type,Yes,No,No,Yes,No,0,"race: white, sex: male, age: 55, bmi: 26.35, treatment arm: FOLFOX + Cetuximab, serious adverse effect: Yes, bowel perforation: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type, adverse effect: thrombosis: Yes, adverse effect: infection: Yes","The patient is a 55-year-old white male with a BMI of 26.35. He is receiving treatment with FOLFOX + Cetuximab and has experienced a serious adverse effect, specifically a bowel perforation. He has completed 12 cycles of chemotherapy and has well-differentiated histology. Despite the serious adverse effect, his performance status is fully active. His KRAS biomarker is wild-type. Additionally, he has experienced adverse effects of thrombosis and infection."
2197,white,female,41,26.29,FOLFOX,No,No,No,No,12,well differentiated,fully active,interminate,No,No,No,No,No,0,"race: white, sex: female, age: 41, bmi: 26.29, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: interminate",The patient is a 41-year-old white female with a BMI of 26.29. She is undergoing treatment with the FOLFOX regimen and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cells. She has a fully active performance status. The KRAS biomarker status is indeterminate.
2198,white,male,73,27.94,FOLFOX + Cetuximab,No,No,No,No,9,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 73, bmi: 27.94, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 9, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 73-year-old white male with a BMI of 27.94. He is receiving treatment in the FOLFOX + Cetuximab treatment arm and has completed 9 cycles of chemotherapy. His histology shows well-differentiated cancer cells. Despite his age, he has a fully active performance status. The KRAS biomarker analysis indicates that he has a wild-type KRAS gene."
2199,white,female,70,32.17,FOLFOX + Cetuximab,No,Yes,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 70, bmi: 32.17, treatment arm: FOLFOX + Cetuximab, serious adverse effect: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 70-year-old white female with a BMI of 32.17. She is receiving treatment with FOLFOX + Cetuximab and has experienced a serious adverse effect. She has completed 12 cycles of chemotherapy. The histology shows that the cancer is well-differentiated. Despite the treatment, her performance status is fully active. The KRAS biomarker indicates that she has a wild-type mutation."
2200,white,female,45,26.84,FOLFOX,No,Yes,Yes,No,12,poorly differentiated,fully active,wild-type,No,No,Yes,No,No,1,"race: white, sex: female, age: 45, bmi: 26.84, treatment arm: FOLFOX, serious adverse effect: Yes, bowel obstruction: Yes, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type, adverse effect: diarrhea: Yes","The patient is a 45-year-old white female with a BMI of 26.84 who is receiving the FOLFOX treatment regimen. She has experienced a serious adverse effect in the form of bowel obstruction. She has completed 12 cycles of chemotherapy and her histology shows poorly differentiated cells. Despite these challenges, her performance status is fully active. The KRAS biomarker analysis indicates that she has a wild-type KRAS status. Additionally, she has experienced diarrhea as an adverse effect during her treatment."
2201,white,male,56,26.3,FOLFOX + Cetuximab,No,No,No,No,0,well differentiated,fully active,mutant,No,No,No,No,No,0,"race: white, sex: male, age: 56, bmi: 26.3, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 0, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 56-year-old white male with a BMI of 26.3. He is enrolled in the treatment arm receiving FOLFOX + Cetuximab but has not started chemotherapy cycles yet. His histology shows well-differentiated cancer, and he has a fully active performance status. The KRAS biomarker analysis indicates a mutant status."
2202,white,male,73,33.41,FOLFOX + Cetuximab,No,No,No,No,4,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 73, bmi: 33.41, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 4, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 73-year-old white male with a BMI of 33.41. He is receiving treatment with FOLFOX + Cetuximab and has completed 4 cycles of chemotherapy. His cancer histology is well differentiated, and he has a fully active performance status. The KRAS biomarker testing indicates that he has a wild-type KRAS status."
2203,white,male,36,23.59,FOLFOX,Yes,No,Yes,No,12,poorly differentiated,symptoms but ambulatory,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 36, bmi: 23.59, treatment arm: FOLFOX, adherence: Yes, bowel obstruction: Yes, chemotherapy cycles: 12, histology: poorly differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type","The patient is a 36-year-old white male with a BMI of 23.59. He is receiving the FOLFOX treatment regimen and has been adherent to the treatment. The patient has experienced a bowel obstruction and has completed 12 cycles of chemotherapy. His histology shows poorly differentiated cells. Despite experiencing symptoms, the patient is still able to be ambulatory. The KRAS biomarker analysis indicates that the patient has a wild-type KRAS status."
2204,white,male,37,23.23,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,fully active,mutant,No,No,No,No,No,0,"race: white, sex: male, age: 37, bmi: 23.23, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 37-year-old white male with a BMI of 23.23. He is receiving treatment in the FOLFOX + Cetuximab treatment arm and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cells, and he has a fully active performance status. The KRAS biomarker analysis indicates a mutant status."
2205,black,female,34,33.46,FOLFOX + Cetuximab,No,Yes,No,No,10,well differentiated,fully active,wild-type,No,Yes,Yes,No,No,0,"race: black, sex: female, age: 34, bmi: 33.46, treatment arm: FOLFOX + Cetuximab, serious adverse effect: Yes, chemotherapy cycles: 10, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type, adverse effect: hypersensitivity: Yes, adverse effect: diarrhea: Yes","The patient is a 34-year-old Black female with a BMI of 33.46. She is receiving treatment with FOLFOX + Cetuximab and has experienced a serious adverse effect. She has completed 10 cycles of chemotherapy. Her histology shows well-differentiated cells, and her performance status is fully active. The KRAS biomarker is wild-type. She has experienced adverse effects including hypersensitivity and diarrhea."
2206,white,female,45,23.77,FOLFIRI,No,No,Yes,No,12,well differentiated,fully active,mutant,No,No,No,No,No,1,"race: white, sex: female, age: 45, bmi: 23.77, treatment arm: FOLFIRI, bowel obstruction: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 45-year-old white female with a BMI of 23.77. She is receiving treatment with the FOLFIRI regimen and has experienced a bowel obstruction. She has completed 12 cycles of chemotherapy. The histology of her cancer is well differentiated. Despite the bowel obstruction, her performance status is fully active. The KRAS biomarker testing revealed a mutant status."
2207,white,male,72,26.37,FOLFOX,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 72, bmi: 26.37, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type",The patient is a 72-year-old white male with a BMI of 26.37. He is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. The histology indicates that the cancer is well-differentiated. The patient has a fully active performance status. The KRAS biomarker testing shows that he has a wild-type KRAS status.
2208,white,male,55,24.33,FOLFOX + Cetuximab,No,No,No,No,11,well differentiated,fully active,mutant,No,No,No,No,No,0,"race: white, sex: male, age: 55, bmi: 24.33, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 11, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 55-year-old white male with a BMI of 24.33. He is undergoing treatment with FOLFOX + Cetuximab and has completed 11 cycles of chemotherapy. His cancer histology is well differentiated, and he has a fully active performance status. The KRAS biomarker testing revealed a mutant status."
2209,white,female,57,24.43,FOLFOX + Cetuximab,Yes,Yes,Yes,No,12,well differentiated,fully active,wild-type,No,No,Yes,No,No,0,"race: white, sex: female, age: 57, bmi: 24.43, treatment arm: FOLFOX + Cetuximab, adherence: Yes, serious adverse effect: Yes, bowel obstruction: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type, adverse effect: diarrhea: Yes","The patient is a 57-year-old white female with a BMI of 24.43. She is receiving treatment with FOLFOX + Cetuximab and has been adherent to the treatment. Unfortunately, she experienced a serious adverse effect in the form of a bowel obstruction. She has completed 12 cycles of chemotherapy and her histology shows well-differentiated cells. Despite the adverse effect, her performance status remains fully active. The KRAS biomarker analysis revealed that she has a wild-type KRAS status. Additionally, she has also experienced diarrhea as an adverse effect of the treatment."
2210,white,female,46,20.43,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,fully active,mutant,No,No,No,No,No,0,"race: white, sex: female, age: 46, bmi: 20.43, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 46-year-old white female with a BMI of 20.43. She is receiving treatment in the FOLFOX + Cetuximab treatment arm and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cells, and she has a fully active performance status. The KRAS biomarker analysis indicates a mutant status."
2211,white,female,51,28.91,FOLFOX,No,Yes,No,No,9,well differentiated,fully active,mutant,No,No,No,No,No,0,"race: white, sex: female, age: 51, bmi: 28.91, treatment arm: FOLFOX, serious adverse effect: Yes, chemotherapy cycles: 9, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 51-year-old white female with a BMI of 28.91. She is receiving the FOLFOX treatment regimen and has experienced a serious adverse effect. She has completed 9 cycles of chemotherapy. The histology of her condition is well-differentiated. Despite the adverse effect, her performance status is fully active. Additionally, the KRAS biomarker analysis shows that she has a mutant KRAS status."
2212,white,female,62,28.36,FOLFOX + Cetuximab,No,Yes,No,No,2,poorly differentiated,fully active,wild-type,No,No,No,No,No,1,"race: white, sex: female, age: 62, bmi: 28.36, treatment arm: FOLFOX + Cetuximab, serious adverse effect: Yes, chemotherapy cycles: 2, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 62-year-old white female with a BMI of 28.36. She is receiving treatment with FOLFOX + Cetuximab and has experienced a serious adverse effect. She has completed 2 cycles of chemotherapy. Her histology shows poorly differentiated cells. Despite this, her performance status is fully active. The KRAS biomarker indicates that she has a wild-type status."
2213,white,male,48,32.25,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,Yes,No,No,0,"race: white, sex: male, age: 48, bmi: 32.25, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type, adverse effect: diarrhea: Yes","The patient is a 48-year-old white male with a BMI of 32.25. He is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer, and he has a fully active performance status. The KRAS biomarker indicates that he is wild-type. The patient is experiencing diarrhea as an adverse effect of the treatment."
2214,white,male,51,25.57,FOLFOX + Cetuximab,No,Yes,No,No,11,poorly differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 51, bmi: 25.57, treatment arm: FOLFOX + Cetuximab, serious adverse effect: Yes, chemotherapy cycles: 11, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 51-year-old white male with a BMI of 25.57. He is receiving treatment with FOLFOX + Cetuximab. He experienced a serious adverse effect during the treatment. He has completed 11 cycles of chemotherapy. The histology of his cancer is poorly differentiated. Despite his condition, he has a fully active performance status. His KRAS biomarker is wild-type."
2215,white,female,45,21.72,FOLFOX + Cetuximab,No,Yes,No,No,4,well differentiated,symptoms but ambulatory,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 45, bmi: 21.72, treatment arm: FOLFOX + Cetuximab, serious adverse effect: Yes, chemotherapy cycles: 4, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type","The patient is a 45-year-old white female with a BMI of 21.72. She is receiving treatment with FOLFOX + Cetuximab. She has experienced a serious adverse effect. She has completed 4 cycles of chemotherapy. Her histology shows well-differentiated cells. Despite experiencing symptoms, she is still able to be ambulatory. Her KRAS biomarker is wild-type."
2216,white,male,68,25.54,FOLFIRI (KRAS mutant),No,No,No,No,0,well differentiated,fully active,wild-type,No,No,No,No,No,1,"race: white, sex: male, age: 68, bmi: 25.54, treatment arm: FOLFIRI (KRAS mutant), chemotherapy cycles: 0, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 68-year-old white male with a BMI of 25.54. He is in the FOLFIRI treatment arm for his KRAS mutant status. He has not started any chemotherapy cycles yet. His histology shows well-differentiated cells, and he has a fully active performance status. His KRAS biomarker is wild-type."
2217,white,female,55,24.29,FOLFOX,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 55, bmi: 24.29, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type",The patient is a 55-year-old white female with a BMI of 24.29. She is undergoing treatment with the FOLFOX chemotherapy regimen and has completed 12 cycles. Her cancer histology is well differentiated. She has a fully active performance status. The KRAS biomarker testing showed that she has a wild-type KRAS status.
2218,white,male,66,25.46,FOLFOX + Cetuximab,No,No,No,No,2,well differentiated,fully active,mutant,No,No,No,No,No,0,"race: white, sex: male, age: 66, bmi: 25.46, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 2, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 66-year-old white male with a BMI of 25.46. He is currently receiving treatment with FOLFOX + Cetuximab and has completed 2 cycles of chemotherapy. His histology shows well-differentiated cancer cells. Despite his age, he has a fully active performance status. The KRAS biomarker analysis indicates that he has a mutant KRAS status."
2219,white,male,50,30.43,FOLFOX + Cetuximab,No,Yes,No,No,12,well differentiated,symptoms but ambulatory,mutant,No,No,No,No,No,0,"race: white, sex: male, age: 50, bmi: 30.43, treatment arm: FOLFOX + Cetuximab, serious adverse effect: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: mutant","The patient is a 50-year-old white male with a BMI of 30.43. He is receiving treatment with FOLFOX + Cetuximab and has experienced a serious adverse effect. He has completed 12 cycles of chemotherapy. His histology shows well-differentiated cells. Despite experiencing symptoms, he is still able to be ambulatory. The KRAS biomarker analysis indicates a mutant status."
2220,white,female,49,27.96,FOLFOX,No,No,No,No,12,well differentiated,fully active,mutant,No,No,No,No,No,0,"race: white, sex: female, age: 49, bmi: 27.96, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant",The patient is a 49-year-old white female with a BMI of 27.96. She is receiving treatment with the FOLFOX chemotherapy regimen and has completed 12 cycles. Her cancer histology is well differentiated. The patient has a fully active performance status. The KRAS biomarker testing revealed a mutant status.
2221,white,male,50,26.8,FOLFOX + Cetuximab,No,No,Yes,No,12,well differentiated,symptoms but ambulatory,mutant,No,No,No,No,No,1,"race: white, sex: male, age: 50, bmi: 26.8, treatment arm: FOLFOX + Cetuximab, bowel obstruction: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: mutant","The patient is a 50-year-old white male with a BMI of 26.8. He is receiving treatment with FOLFOX + Cetuximab for his well-differentiated histology. He has experienced a bowel obstruction and has completed 12 cycles of chemotherapy. Despite experiencing symptoms, he is still able to be ambulatory. The KRAS biomarker for this patient is mutant."
2222,white,female,44,31.64,FOLFIRI,No,No,No,No,12,well differentiated,fully active,mutant,No,No,No,No,No,0,"race: white, sex: female, age: 44, bmi: 31.64, treatment arm: FOLFIRI, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 44-year-old white female with a BMI of 31.64. She is receiving the FOLFIRI treatment regimen and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cancer cells. Despite her cancer diagnosis, she has a fully active performance status. Additionally, her KRAS biomarker indicates a mutant status."
2223,white,male,70,35.02,FOLFIRI (KRAS mutant),No,No,No,No,12,poorly differentiated,fully active,wild-type,No,No,No,No,No,1,"race: white, sex: male, age: 70, bmi: 35.02, treatment arm: FOLFIRI (KRAS mutant), chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 70-year-old white male with a BMI of 35.02. He is receiving treatment with FOLFIRI for KRAS mutant cancer. He has completed 12 cycles of chemotherapy. The histology of his cancer is poorly differentiated. Despite his age, he has a fully active performance status. His KRAS biomarker is wild-type."
2224,white,female,41,35.03,FOLFOX + Cetuximab,No,No,No,No,1,well differentiated,symptoms but ambulatory,wild-type,No,Yes,No,No,No,0,"race: white, sex: female, age: 41, bmi: 35.03, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 1, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type, adverse effect: hypersensitivity: Yes","The patient is a 41-year-old white female with a BMI of 35.03. She is receiving treatment in the FOLFOX + Cetuximab treatment arm and has completed one cycle of chemotherapy. Her histology shows well-differentiated cancer, and she has symptoms but is still able to walk around (ambulatory). The KRAS biomarker indicates that she has a wild-type gene. She has experienced a hypersensitivity adverse effect."
2225,white,female,49,21.14,FOLFOX,No,No,No,No,12,well differentiated,fully active,mutant,No,No,No,No,No,0,"race: white, sex: female, age: 49, bmi: 21.14, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 49-year-old white female with a BMI of 21.14. She is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cancer cells. Despite her cancer diagnosis, she has a fully active performance status. The KRAS biomarker testing revealed a mutant status."
2226,white,female,66,31.63,FOLFOX,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 66, bmi: 31.63, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type",The patient is a 66-year-old white female with a BMI of 31.63. She is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. The histology shows well-differentiated cancer cells. The patient has a fully active performance status. The KRAS biomarker testing indicates that she has a wild-type KRAS status.
2227,white,female,66,34.41,FOLFOX + Cetuximab,No,No,No,No,12,poorly differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 66, bmi: 34.41, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 66-year-old white female with a BMI of 34.41. She is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. Her cancer histology is poorly differentiated. Despite this, she has a fully active performance status. Additionally, her KRAS biomarker status is wild-type."
2228,white,female,46,32.84,FOLFOX,No,No,No,No,12,well differentiated,symptoms but ambulatory,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 46, bmi: 32.84, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type","The patient is a 46-year-old white female with a BMI of 32.84. She is receiving the FOLFOX treatment regimen and is scheduled for 12 cycles of chemotherapy. Her histology shows well-differentiated cancer cells. Despite experiencing symptoms, she is still able to be ambulatory. The KRAS biomarker analysis indicates that she has a wild-type KRAS gene."
2229,white,female,37,24.2,FOLFOX + Cetuximab,No,No,Yes,No,12,well differentiated,fully active,wild-type,No,Yes,No,No,No,0,"race: white, sex: female, age: 37, bmi: 24.2, treatment arm: FOLFOX + Cetuximab, bowel obstruction: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type, adverse effect: hypersensitivity: Yes",The patient is a 37-year-old white female with a BMI of 24.2. She is receiving treatment with FOLFOX + Cetuximab and has experienced a bowel obstruction. She has completed 12 cycles of chemotherapy. The histology shows that the cancer is well-differentiated. The patient has a fully active performance status and her KRAS biomarker is wild-type. She has also experienced hypersensitivity as an adverse effect.
2230,black,male,52,24.26,FOLFOX,No,No,No,No,12,well differentiated,symptoms but ambulatory,wild-type,No,No,No,No,No,0,"race: black, sex: male, age: 52, bmi: 24.26, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type","The patient is a 52-year-old Black male with a BMI of 24.26. He is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer cells. Despite experiencing symptoms, he is still able to walk around (ambulatory). The KRAS biomarker analysis indicates that he has a wild-type KRAS status."
2231,white,male,35,41.94,FOLFOX,No,No,No,No,8,poorly differentiated,fully active,mutant,No,No,No,No,No,1,"race: white, sex: male, age: 35, bmi: 41.94, treatment arm: FOLFOX, chemotherapy cycles: 8, histology: poorly differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 35-year-old white male with a BMI of 41.94. He is receiving the FOLFOX treatment regimen and has completed 8 cycles of chemotherapy. His histology shows poorly differentiated cancer cells. Despite this, his performance status is fully active. The KRAS biomarker analysis indicates that he has a mutant KRAS status."
2232,black,male,36,28.34,FOLFOX,No,No,No,No,3,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: black, sex: male, age: 36, bmi: 28.34, treatment arm: FOLFOX, chemotherapy cycles: 3, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type",The patient is a 36-year-old Black male with a BMI of 28.34. He is receiving the FOLFOX treatment arm and has completed 3 cycles of chemotherapy. His histology shows well-differentiated cancer cells. The patient has a fully active performance status and his KRAS biomarker is wild-type.
2233,black,female,51,36.78,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,fully active,mutant,No,No,No,No,No,0,"race: black, sex: female, age: 51, bmi: 36.78, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant",The patient is a 51-year-old Black female with a BMI of 36.78. She is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. The histology shows well-differentiated cancer cells. The patient has a fully active performance status. The KRAS biomarker indicates a mutant status.
2234,white,female,39,28.55,FOLFOX + Cetuximab,No,Yes,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 39, bmi: 28.55, treatment arm: FOLFOX + Cetuximab, serious adverse effect: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 39-year-old white female with a BMI of 28.55. She is receiving treatment with FOLFOX + Cetuximab and has experienced a serious adverse effect. She has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cells, and her performance status is fully active. The KRAS biomarker indicates that she has a wild-type status."
2235,white,male,56,29.92,FOLFOX + Cetuximab,No,Yes,No,No,12,well differentiated,fully active,mutant,Yes,Yes,No,No,No,0,"race: white, sex: male, age: 56, bmi: 29.92, treatment arm: FOLFOX + Cetuximab, serious adverse effect: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant, adverse effect: thrombosis: Yes, adverse effect: hypersensitivity: Yes","The patient is a 56-year-old white male with a BMI of 29.92. He is receiving treatment with FOLFOX + Cetuximab and has experienced serious adverse effects. He has undergone 12 cycles of chemotherapy. His histology shows well-differentiated cells, and he has a fully active performance status. The KRAS biomarker is mutant in this patient. He has also experienced adverse effects such as thrombosis and hypersensitivity reactions."
2236,white,female,47,35.68,FOLFOX,No,No,No,No,12,well differentiated,symptoms but ambulatory,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 47, bmi: 35.68, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type","The patient is a 47-year-old white female with a BMI of 35.68. She is undergoing treatment with FOLFOX chemotherapy and has completed 12 cycles. The histology shows well-differentiated cancer cells. Despite experiencing symptoms, the patient is still able to walk around (ambulatory). The KRAS biomarker analysis indicates that the patient has a wild-type KRAS status."
2237,white,female,40,22.34,FOLFOX,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 40, bmi: 22.34, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type",The patient is a 40-year-old white female with a BMI of 22.34. She is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cancer cells. The patient has a fully active performance status and her KRAS biomarker is wild-type.
2238,white,female,69,28.1,FOLFOX + Cetuximab,No,No,No,No,7,well differentiated,fully active,mutant,No,No,No,No,No,0,"race: white, sex: female, age: 69, bmi: 28.1, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 7, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 69-year-old white female with a BMI of 28.1. She is currently receiving treatment in the FOLFOX + Cetuximab treatment arm and has completed 7 cycles of chemotherapy. Her histology shows well-differentiated cancer cells. Despite her age, she has a fully active performance status. The KRAS biomarker analysis indicates that she has a mutant KRAS status."
2239,white,male,62,21.87,FOLFOX + Cetuximab,Yes,No,No,No,1,well differentiated,symptoms but ambulatory,mutant,No,No,No,No,No,0,"race: white, sex: male, age: 62, bmi: 21.87, treatment arm: FOLFOX + Cetuximab, adherence: Yes, chemotherapy cycles: 1, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: mutant","The patient is a 62-year-old white male with a BMI of 21.87. He is currently receiving treatment in the FOLFOX + Cetuximab treatment arm and has been adherent to the treatment. He has completed 1 cycle of chemotherapy. His histology shows well-differentiated cancer cells. Despite experiencing symptoms, he is still able to be ambulatory. The KRAS biomarker analysis indicates that he has a mutant KRAS status."
2240,other,female,64,22.09,FOLFOX + Cetuximab,No,No,No,No,10,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: other, sex: female, age: 64, bmi: 22.09, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 10, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 64-year-old female of a race categorized as ""other"" with a BMI of 22.09. She is receiving treatment in the FOLFOX + Cetuximab treatment arm and has completed 10 cycles of chemotherapy. Her histology shows well-differentiated cancer cells. Despite her age, she has a fully active performance status. Additionally, her KRAS biomarker indicates that it is wild-type."
2241,other,female,59,28.76,FOLFOX + Cetuximab,No,Yes,No,No,12,well differentiated,fully active,interminate,No,No,No,No,No,0,"race: other, sex: female, age: 59, bmi: 28.76, treatment arm: FOLFOX + Cetuximab, serious adverse effect: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: interminate","The patient is a 59-year-old female of a race categorized as ""other"" with a BMI of 28.76. She is undergoing treatment with the FOLFOX + Cetuximab regimen and has experienced a serious adverse effect. She has completed 12 cycles of chemotherapy. The histology of her condition is well-differentiated, and her performance status is fully active. The KRAS biomarker status is indeterminate."
2242,white,female,71,25.64,FOLFOX + Cetuximab,No,Yes,No,No,11,poorly differentiated,fully active,wild-type,No,No,No,No,No,1,"race: white, sex: female, age: 71, bmi: 25.64, treatment arm: FOLFOX + Cetuximab, serious adverse effect: Yes, chemotherapy cycles: 11, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type","This patient is a 71-year-old white female with a BMI of 25.64. She is receiving treatment with FOLFOX + Cetuximab and has experienced a serious adverse effect. She has completed 11 cycles of chemotherapy. The histology of her cancer is poorly differentiated. Despite her cancer diagnosis, her performance status is fully active. Additionally, her KRAS biomarker is wild-type."
2243,white,male,41,26.57,FOLFOX + Cetuximab,No,No,No,No,12,poorly differentiated,symptoms but ambulatory,wild-type,No,Yes,No,No,No,0,"race: white, sex: male, age: 41, bmi: 26.57, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: poorly differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type, adverse effect: hypersensitivity: Yes","The patient is a 41-year-old white male with a BMI of 26.57. He is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. His histology shows poorly differentiated cancer. Despite experiencing symptoms, he is still able to be ambulatory. His KRAS biomarker is wild-type. The patient has reported experiencing hypersensitivity as an adverse effect."
2244,white,male,43,26.71,FOLFOX,No,Yes,No,No,12,well differentiated,fully active,interminate,No,No,No,No,No,0,"race: white, sex: male, age: 43, bmi: 26.71, treatment arm: FOLFOX, serious adverse effect: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: interminate","The patient is a 43-year-old white male with a BMI of 26.71. He is receiving treatment with the FOLFOX chemotherapy regimen and has experienced a serious adverse effect. He has completed 12 cycles of chemotherapy. The histology of his condition is well-differentiated. Despite the serious adverse effect, his performance status is fully active. The KRAS biomarker status is indeterminate."
2245,white,male,49,30.94,FOLFOX,No,No,No,No,12,well differentiated,symptoms but ambulatory,mutant,No,No,No,No,No,1,"race: white, sex: male, age: 49, bmi: 30.94, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: mutant","The patient is a 49-year-old white male with a BMI of 30.94. He is receiving the FOLFOX treatment arm and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer cells. Despite experiencing symptoms, he is still able to walk around (ambulatory). The KRAS biomarker analysis indicates a mutant status."
2246,white,female,65,36.85,FOLFOX + Cetuximab,No,No,No,No,12,poorly differentiated,fully active,wild-type,No,No,Yes,No,No,1,"race: white, sex: female, age: 65, bmi: 36.85, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type, adverse effect: diarrhea: Yes","The patient is a 65-year-old white female with a BMI of 36.85. She is receiving treatment with FOLFOX + Cetuximab and has completed 12 chemotherapy cycles. Her histology shows poorly differentiated cancer, and her performance status is fully active. The KRAS biomarker is wild-type. The patient is experiencing diarrhea as an adverse effect of the treatment."
2247,white,male,46,36.59,FOLFOX,No,Yes,No,No,7,well differentiated,fully active,mutant,Yes,No,No,No,No,1,"race: white, sex: male, age: 46, bmi: 36.59, treatment arm: FOLFOX, serious adverse effect: Yes, chemotherapy cycles: 7, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant, adverse effect: thrombosis: Yes","The patient is a 46-year-old white male with a BMI of 36.59. He is receiving the FOLFOX treatment regimen and has experienced a serious adverse effect. He has completed 7 cycles of chemotherapy. The histology shows well-differentiated cancer cells. Despite the serious adverse effect, the patient's performance status is fully active. The KRAS biomarker is mutant. Additionally, the patient has experienced thrombosis as an adverse effect."
2248,white,female,73,23.33,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 73, bmi: 23.33, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","This patient is a 73-year-old white female with a BMI of 23.33. She is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. Her cancer histology is well differentiated, and she has a fully active performance status. Additionally, her KRAS biomarker is wild-type."
2249,other,male,36,21.12,FOLFIRI + Cetuximab,Yes,No,Yes,No,12,well differentiated,fully active,mutant,No,No,No,No,No,0,"race: other, sex: male, age: 36, bmi: 21.12, treatment arm: FOLFIRI + Cetuximab, adherence: Yes, bowel obstruction: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 36-year-old male of a race categorized as ""other"" with a BMI of 21.12. He is undergoing treatment with FOLFIRI + Cetuximab and has been adherent to the treatment. The patient has experienced a bowel obstruction and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cells, and he has a fully active performance status. Additionally, the patient has a mutant KRAS biomarker."
2250,white,male,38,30.87,FOLFOX + Cetuximab,Yes,No,No,No,12,poorly differentiated,fully active,wild-type,No,Yes,No,No,No,0,"race: white, sex: male, age: 38, bmi: 30.87, treatment arm: FOLFOX + Cetuximab, adherence: Yes, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type, adverse effect: hypersensitivity: Yes","The patient is a 38-year-old white male with a BMI of 30.87. He is receiving treatment with FOLFOX + Cetuximab and has been adherent to the treatment. He has completed 12 chemotherapy cycles. His histology shows poorly differentiated cancer cells. Despite this, his performance status is fully active. The KRAS biomarker testing revealed that he has a wild-type KRAS status. The patient has experienced a hypersensitivity adverse effect during treatment."
2251,black,female,57,22.48,FOLFOX + Cetuximab,Yes,Yes,No,No,12,well differentiated,symptoms but ambulatory,mutant,No,No,No,No,No,0,"race: black, sex: female, age: 57, bmi: 22.48, treatment arm: FOLFOX + Cetuximab, adherence: Yes, serious adverse effect: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: mutant","The patient is a 57-year-old Black female with a BMI of 22.48. She is receiving treatment with FOLFOX + Cetuximab and has been adherent to the treatment. However, she experienced a serious adverse effect. She has completed 12 cycles of chemotherapy. The histology shows that the cancer is well-differentiated. Despite experiencing symptoms, she is still ambulatory. The KRAS biomarker indicates that it is mutant."
2252,white,female,50,20.68,FOLFOX,Yes,Yes,No,No,12,well differentiated,fully active,wild-type,No,No,Yes,No,No,0,"race: white, sex: female, age: 50, bmi: 20.68, treatment arm: FOLFOX, adherence: Yes, serious adverse effect: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type, adverse effect: diarrhea: Yes","The patient is a 50-year-old white female with a BMI of 20.68. She is receiving the FOLFOX treatment regimen and has been adherent to the treatment. She experienced a serious adverse effect during the treatment. She completed 12 cycles of chemotherapy. The histology of her cancer is well-differentiated. Her performance status is fully active. The KRAS biomarker testing showed that she has a wild-type KRAS status. Additionally, she experienced diarrhea as an adverse effect during the treatment."
2253,white,female,55,28.28,FOLFIRI,No,No,No,No,12,well differentiated,fully active,mutant,No,No,No,No,No,1,"race: white, sex: female, age: 55, bmi: 28.28, treatment arm: FOLFIRI, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant",The patient is a 55-year-old white female with a BMI of 28.28. She is receiving the FOLFIRI treatment regimen and has completed 12 cycles of chemotherapy. The histology shows well-differentiated cancer cells. The patient has a fully active performance status. The KRAS biomarker testing revealed a mutant status.
2254,other,male,47,21.71,FOLFOX,No,No,No,No,1,poorly differentiated,fully active,wild-type,No,No,No,No,No,0,"race: other, sex: male, age: 47, bmi: 21.71, treatment arm: FOLFOX, chemotherapy cycles: 1, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 47-year-old male of ""other"" race with a BMI of 21.71. He is currently receiving treatment in the FOLFOX chemotherapy arm and has completed one cycle of chemotherapy. The histology of his cancer is poorly differentiated. Despite this, his performance status is fully active, indicating that he is able to carry out his daily activities without limitations. Additionally, his KRAS biomarker status is wild-type."
2255,white,male,52,29.14,FOLFOX,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 52, bmi: 29.14, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type",The patient is a 52-year-old white male with a BMI of 29.14. He is receiving treatment with FOLFOX chemotherapy regimen and has completed 12 cycles. The histology shows well-differentiated cancer cells. The patient has a fully active performance status. The KRAS biomarker analysis indicates that the patient has a wild-type KRAS status.
2256,white,male,36,30.85,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 36, bmi: 30.85, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 36-year-old white male with a BMI of 30.85. He is receiving treatment in the FOLFOX + Cetuximab treatment arm and is scheduled for 12 chemotherapy cycles. His cancer histology is well differentiated, and he has a fully active performance status. The KRAS biomarker analysis shows that he has a wild-type KRAS status."
2257,white,female,61,34.52,FOLFOX + Cetuximab,No,Yes,No,No,12,well differentiated,symptoms but ambulatory,wild-type,No,No,Yes,Yes,No,0,"race: white, sex: female, age: 61, bmi: 34.52, treatment arm: FOLFOX + Cetuximab, serious adverse effect: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type, adverse effect: diarrhea: Yes, adverse effect: infection: Yes","This patient is a 61-year-old white female with a BMI of 34.52. She is receiving treatment with FOLFOX + Cetuximab and has experienced a serious adverse effect. She has completed 12 cycles of chemotherapy and her histology shows well-differentiated cells. Despite experiencing symptoms, she is still ambulatory. Her KRAS biomarker is wild-type. She has also experienced adverse effects such as diarrhea and infection."
2258,white,male,43,24.26,FOLFOX + Cetuximab,No,No,No,No,2,well differentiated,fully active,mutant,No,Yes,No,No,No,0,"race: white, sex: male, age: 43, bmi: 24.26, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 2, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant, adverse effect: hypersensitivity: Yes","The patient is a 43-year-old white male with a BMI of 24.26. He is currently receiving treatment in the FOLFOX + Cetuximab treatment arm and has completed 2 cycles of chemotherapy. His histology shows well-differentiated cells, and he has a fully active performance status. The KRAS biomarker analysis indicates a mutant status. The patient has experienced a hypersensitivity adverse effect."
2259,black,male,66,31.42,FOLFOX + Cetuximab,No,No,No,No,7,well differentiated,symptoms but ambulatory,mutant,No,Yes,No,No,No,1,"race: black, sex: male, age: 66, bmi: 31.42, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 7, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: mutant, adverse effect: hypersensitivity: Yes","The patient is a 66-year-old Black male with a BMI of 31.42. He is receiving treatment with FOLFOX + Cetuximab and has completed 7 cycles of chemotherapy. His histology shows well-differentiated cancer. Despite experiencing symptoms, he is still able to be ambulatory. The KRAS biomarker testing revealed a mutant result. The patient has experienced a hypersensitivity adverse effect during treatment."
2260,white,female,47,35.71,FOLFOX,No,No,No,No,12,well differentiated,fully active,mutant,No,No,No,No,No,0,"race: white, sex: female, age: 47, bmi: 35.71, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 47-year-old white female with a BMI of 35.71. She is receiving the FOLFOX treatment arm and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cancer cells. Despite her cancer diagnosis, she has a fully active performance status. The KRAS biomarker analysis revealed a mutant status."
2261,white,female,58,22.22,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 58, bmi: 22.22, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 58-year-old white female with a BMI of 22.22. She is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cancer, and she has a fully active performance status. The KRAS biomarker indicates that she has a wild-type status."
2262,white,female,59,32.24,FOLFOX,No,Yes,Yes,No,11,poorly differentiated,fully active,mutant,No,No,Yes,Yes,No,0,"race: white, sex: female, age: 59, bmi: 32.24, treatment arm: FOLFOX, serious adverse effect: Yes, bowel obstruction: Yes, chemotherapy cycles: 11, histology: poorly differentiated, performance status: fully active, KRAS biomarker: mutant, adverse effect: diarrhea: Yes, adverse effect: infection: Yes","This patient is a 59-year-old white female with a BMI of 32.24 who is receiving the FOLFOX treatment regimen. She has experienced a serious adverse effect, specifically a bowel obstruction, after completing 11 cycles of chemotherapy. The histology of her cancer is poorly differentiated. Despite these challenges, her performance status is fully active. The KRAS biomarker testing revealed a mutant status. Additionally, she has experienced adverse effects such as diarrhea and infection."
2263,white,male,62,31.47,FOLFOX,No,No,No,No,12,well differentiated,fully active,mutant,No,No,No,No,No,0,"race: white, sex: male, age: 62, bmi: 31.47, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 62-year-old white male with a BMI of 31.47. He is undergoing treatment with the FOLFOX chemotherapy regimen and has completed 12 cycles. His cancer histology is well differentiated. Despite his age, he has a fully active performance status. The KRAS biomarker testing revealed a mutant status."
2264,white,female,41,33.39,FOLFOX,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 41, bmi: 33.39, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 41-year-old white female with a BMI of 33.39. She is receiving the FOLFOX treatment regimen and is scheduled for 12 cycles of chemotherapy. The histology of her cancer is well-differentiated. Despite undergoing treatment, her performance status is fully active. Additionally, her KRAS biomarker status is wild-type."
2265,white,female,50,40.1,FOLFOX,Yes,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 50, bmi: 40.1, treatment arm: FOLFOX, adherence: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 50-year-old white female with a BMI of 40.1. She is receiving the FOLFOX treatment regimen and has been adherent to her chemotherapy cycles, completing a total of 12 cycles. Her histology shows well-differentiated cancer cells. The patient has a fully active performance status and her KRAS biomarker is wild-type."
2266,white,male,58,28.3,FOLFOX + Cetuximab,Yes,Yes,No,No,12,well differentiated,symptoms but ambulatory,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 58, bmi: 28.3, treatment arm: FOLFOX + Cetuximab, adherence: Yes, serious adverse effect: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type","The patient is a 58-year-old white male with a BMI of 28.3. He is receiving treatment with FOLFOX + Cetuximab and has been adherent to the treatment. However, he experienced a serious adverse effect during the course of 12 chemotherapy cycles. His histology shows well-differentiated cells, and he has symptoms but is still ambulatory based on his performance status. The KRAS biomarker analysis indicates that he has a wild-type KRAS status."
2267,white,male,72,33.88,FOLFOX + Cetuximab,No,No,No,No,1,well differentiated,fully active,wild-type,No,No,Yes,No,No,0,"race: white, sex: male, age: 72, bmi: 33.88, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 1, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type, adverse effect: diarrhea: Yes","The patient is a 72-year-old white male with a BMI of 33.88. He is currently receiving treatment with FOLFOX + Cetuximab and has completed one cycle of chemotherapy. His cancer histology is well differentiated, and he has a fully active performance status. The KRAS biomarker testing showed that he has a wild-type KRAS status. The patient is experiencing diarrhea as an adverse effect of the treatment."
2268,black,female,65,33.08,FOLFOX,Yes,No,No,No,12,well differentiated,fully active,mutant,No,No,No,No,No,0,"race: black, sex: female, age: 65, bmi: 33.08, treatment arm: FOLFOX, adherence: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 65-year-old Black female with a BMI of 33.08. She is receiving the FOLFOX treatment regimen and has been adherent to her chemotherapy cycles, completing a total of 12 cycles. Her histology shows well-differentiated cancer cells. Despite her age, she has a fully active performance status. The KRAS biomarker analysis indicates that she has a mutant KRAS status."
2269,white,female,59,27.22,FOLFOX + Cetuximab,No,No,No,No,9,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 59, bmi: 27.22, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 9, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 59-year-old white female with a BMI of 27.22. She is receiving treatment with FOLFOX + Cetuximab and has completed 9 cycles of chemotherapy. Her histology shows well-differentiated cancer, and she has a fully active performance status. The KRAS biomarker indicates that she has a wild-type gene."
2270,white,female,71,18.48,FOLFOX + Cetuximab,No,No,No,No,2,poorly differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 71, bmi: 18.48, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 2, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 71-year-old white female with a BMI of 18.48. She is currently receiving treatment with FOLFOX and Cetuximab and has completed 2 cycles of chemotherapy. Her cancer histology is poorly differentiated. Despite her age, she has a fully active performance status. Additionally, her KRAS biomarker status is wild-type."
2271,other,male,44,34.4,FOLFOX,No,No,No,No,6,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: other, sex: male, age: 44, bmi: 34.4, treatment arm: FOLFOX, chemotherapy cycles: 6, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 44-year-old male of a race categorized as ""other"" with a BMI of 34.4. He is undergoing treatment with the FOLFOX chemotherapy regimen and has completed 6 cycles. The histology of his cancer is well-differentiated. He has a fully active performance status. His KRAS biomarker status is wild-type."
2272,other,male,58,27.5,FOLFOX,Yes,No,Yes,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: other, sex: male, age: 58, bmi: 27.5, treatment arm: FOLFOX, adherence: Yes, bowel obstruction: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 58-year-old male of a race categorized as ""other"" with a BMI of 27.5. He is receiving treatment in the FOLFOX treatment arm and has been adherent to the prescribed treatment. The patient has experienced a bowel obstruction. He has completed 12 cycles of chemotherapy. The histology of his condition is well-differentiated. Despite the bowel obstruction, his performance status is fully active. The KRAS biomarker analysis shows that he has a wild-type KRAS status."
2273,white,male,40,20.76,FOLFOX,No,No,Yes,No,12,well differentiated,fully active,wild-type,No,Yes,No,No,No,0,"race: white, sex: male, age: 40, bmi: 20.76, treatment arm: FOLFOX, bowel obstruction: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type, adverse effect: hypersensitivity: Yes","The patient is a 40-year-old white male with a BMI of 20.76. He is receiving treatment with FOLFOX for his well-differentiated histology. He has experienced a bowel obstruction and has completed 12 cycles of chemotherapy. Despite the adverse effect of hypersensitivity, his performance status remains fully active. Additionally, his KRAS biomarker is wild-type."
2274,white,female,61,28.57,FOLFOX,No,No,No,No,12,well differentiated,fully active,mutant,No,No,No,No,No,0,"race: white, sex: female, age: 61, bmi: 28.57, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant",The patient is a 61-year-old white female with a BMI of 28.57. She is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cancer cells. The patient has a fully active performance status. The KRAS biomarker analysis indicates a mutant status.
2275,white,male,45,25.81,FOLFOX,No,No,No,No,8,poorly differentiated,fully active,mutant,No,No,No,No,No,0,"race: white, sex: male, age: 45, bmi: 25.81, treatment arm: FOLFOX, chemotherapy cycles: 8, histology: poorly differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 45-year-old white male with a BMI of 25.81. He is receiving treatment with the FOLFOX chemotherapy regimen and has completed 8 cycles so far. His cancer histology is poorly differentiated. Despite his diagnosis, he has a fully active performance status. The patient's KRAS biomarker is mutant."
2276,white,male,69,36.76,FOLFOX + Cetuximab,No,No,No,No,0,well differentiated,fully active,mutant,No,No,No,No,No,0,"race: white, sex: male, age: 69, bmi: 36.76, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 0, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 69-year-old white male with a BMI of 36.76. He is enrolled in the FOLFOX + Cetuximab treatment arm but has not started chemotherapy cycles yet. His histology shows well-differentiated cancer cells. Despite his age, he has a fully active performance status. The KRAS biomarker analysis indicates a mutant status."
2277,white,female,74,31.85,FOLFOX + Cetuximab,No,No,Yes,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,1,"race: white, sex: female, age: 74, bmi: 31.85, treatment arm: FOLFOX + Cetuximab, bowel obstruction: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 74-year-old white female with a BMI of 31.85. She is undergoing treatment with FOLFOX + Cetuximab for her cancer. She has experienced a bowel obstruction and has completed 12 cycles of chemotherapy. The histology of her cancer is well differentiated. Despite her age, she has a fully active performance status. Her KRAS biomarker is wild-type."
2278,white,male,48,28.54,FOLFOX,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 48, bmi: 28.54, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type",The patient is a 48-year-old white male with a BMI of 28.54. He is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer cells. The patient has a fully active performance status and his KRAS biomarker is wild-type.
2279,white,male,46,26.68,FOLFOX + Cetuximab,No,No,No,No,12,poorly differentiated,fully active,mutant,No,No,No,No,No,0,"race: white, sex: male, age: 46, bmi: 26.68, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 46-year-old white male with a BMI of 26.68. He is receiving treatment in the FOLFOX + Cetuximab treatment arm and has completed 12 chemotherapy cycles. His histology shows poorly differentiated cancer cells. Despite this, his performance status is fully active. The KRAS biomarker analysis indicates a mutant status."
2280,white,female,48,33.9,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,symptoms but ambulatory,wild-type,No,No,No,Yes,No,0,"race: white, sex: female, age: 48, bmi: 33.9, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type, adverse effect: infection: Yes","The patient is a 48-year-old white female with a BMI of 33.9. She is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cancer, and she has symptoms but is still able to walk around (ambulatory). The KRAS biomarker is wild-type. The patient has experienced an infection as an adverse effect of the treatment."
2281,white,female,52,24.78,FOLFOX + Cetuximab,No,No,No,No,3,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 52, bmi: 24.78, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 3, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type",The patient is a 52-year-old white female with a BMI of 24.78. She is receiving treatment in the FOLFOX + Cetuximab treatment arm and has completed 3 cycles of chemotherapy. Her histology shows well-differentiated cancer cells. The patient has a fully active performance status and her KRAS biomarker is wild-type.
2282,white,female,41,41.84,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,Yes,No,No,0,"race: white, sex: female, age: 41, bmi: 41.84, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type, adverse effect: diarrhea: Yes",The patient is a 41-year-old white female with a BMI of 41.84 who is undergoing treatment with FOLFOX + Cetuximab for well-differentiated histology. She has completed 12 cycles of chemotherapy and has a fully active performance status. Her KRAS biomarker is wild-type. She is experiencing diarrhea as an adverse effect of the treatment.
2283,white,male,56,32.33,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,symptoms but ambulatory,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 56, bmi: 32.33, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type","The patient is a 56-year-old white male with a BMI of 32.33. He is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer cells. Despite experiencing symptoms, he is still able to be ambulatory. The KRAS biomarker analysis indicates that he has a wild-type KRAS gene."
2284,white,male,66,21.88,FOLFOX,No,No,No,No,12,well differentiated,symptoms but ambulatory,wild-type,No,No,Yes,No,No,0,"race: white, sex: male, age: 66, bmi: 21.88, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type, adverse effect: diarrhea: Yes",The patient is a 66-year-old white male with a BMI of 21.88 who is receiving the FOLFOX treatment regimen for his well-differentiated histology. He has completed 12 cycles of chemotherapy and has a performance status of experiencing symptoms but still able to walk around. His KRAS biomarker is wild-type. The patient is experiencing diarrhea as an adverse effect of the treatment.
2285,white,male,55,30.03,FOLFOX,No,No,Yes,No,12,well differentiated,fully active,wild-type,No,No,No,Yes,No,0,"race: white, sex: male, age: 55, bmi: 30.03, treatment arm: FOLFOX, bowel obstruction: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type, adverse effect: infection: Yes","The patient is a 55-year-old white male with a BMI of 30.03 who is undergoing treatment with the FOLFOX chemotherapy regimen. He has experienced a bowel obstruction and has completed 12 cycles of chemotherapy. The histology of his cancer is well-differentiated, and his performance status is fully active. His KRAS biomarker is wild-type. Additionally, he has experienced an infection as an adverse effect during his treatment."
2286,white,male,70,25.45,FOLFOX + Cetuximab,No,No,No,No,9,poorly differentiated,fully active,mutant,No,No,Yes,No,No,0,"race: white, sex: male, age: 70, bmi: 25.45, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 9, histology: poorly differentiated, performance status: fully active, KRAS biomarker: mutant, adverse effect: diarrhea: Yes","The patient is a 70-year-old white male with a BMI of 25.45. He is currently receiving treatment with FOLFOX + Cetuximab and has completed 9 cycles of chemotherapy. His histology shows poorly differentiated cancer cells. Despite this, his performance status is fully active. The patient's KRAS biomarker is mutant. He is experiencing diarrhea as an adverse effect of the treatment."
2287,black,male,65,36.64,FOLFOX + Cetuximab,No,Yes,No,No,6,well differentiated,symptoms but ambulatory,mutant,No,No,No,No,No,0,"race: black, sex: male, age: 65, bmi: 36.64, treatment arm: FOLFOX + Cetuximab, serious adverse effect: Yes, chemotherapy cycles: 6, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: mutant","The patient is a 65-year-old Black male with a BMI of 36.64. He is receiving treatment in the FOLFOX + Cetuximab treatment arm. He experienced a serious adverse effect during the treatment. He completed 6 cycles of chemotherapy. The histology shows well-differentiated cells. Despite experiencing symptoms, the patient is still able to be ambulatory. The KRAS biomarker indicates a mutant status."
2288,white,male,51,27.28,FOLFIRI + Cetuximab,No,Yes,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 51, bmi: 27.28, treatment arm: FOLFIRI + Cetuximab, serious adverse effect: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 51-year-old white male with a BMI of 27.28. He is receiving treatment with FOLFIRI + Cetuximab and has experienced a serious adverse effect. He has completed 12 cycles of chemotherapy. His histology shows well-differentiated cells. Despite the adverse effect, his performance status is fully active. His KRAS biomarker is wild-type."
2289,white,male,70,22.87,FOLFIRI (KRAS mutant),No,Yes,No,No,8,well differentiated,fully active,wild-type,No,No,Yes,No,No,1,"race: white, sex: male, age: 70, bmi: 22.87, treatment arm: FOLFIRI (KRAS mutant), serious adverse effect: Yes, chemotherapy cycles: 8, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type, adverse effect: diarrhea: Yes","The patient is a 70-year-old white male with a BMI of 22.87. He is receiving the FOLFIRI treatment regimen for his well-differentiated histology cancer with a KRAS wild-type biomarker. Despite being fully active with no performance status issues, he has experienced a serious adverse effect of diarrhea during his 8 cycles of chemotherapy."
2290,white,male,47,25.72,FOLFOX,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 47, bmi: 25.72, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 47-year-old white male with a BMI of 25.72. He is receiving the FOLFOX treatment regimen and is scheduled for 12 cycles of chemotherapy. His cancer histology is well-differentiated, and he has a fully active performance status. The KRAS biomarker testing revealed that he has a wild-type KRAS status."
2291,white,male,62,30.36,FOLFOX,No,No,No,No,12,poorly differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 62, bmi: 30.36, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 62-year-old white male with a BMI of 30.36. He is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. His histology shows poorly differentiated cancer cells. Despite this, his performance status is fully active. Additionally, his KRAS biomarker indicates that he has a wild-type KRAS gene."
2292,black,male,55,31.62,FOLFIRI + Cetuximab,Yes,No,No,No,0,well differentiated,fully active,mutant,No,No,No,No,No,1,"race: black, sex: male, age: 55, bmi: 31.62, treatment arm: FOLFIRI + Cetuximab, adherence: Yes, chemotherapy cycles: 0, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant",The patient is a 55-year-old Black male with a BMI of 31.62. He is enrolled in the treatment arm receiving FOLFIRI + Cetuximab for his cancer treatment. He has been adherent to the treatment plan. The patient has not started any chemotherapy cycles yet. His cancer histology is well differentiated. He has a fully active performance status. The KRAS biomarker analysis showed a mutant status.
2293,white,male,51,32.08,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,fully active,wild-type,Yes,No,No,No,No,1,"race: white, sex: male, age: 51, bmi: 32.08, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type, adverse effect: thrombosis: Yes","The patient is a 51-year-old white male with a BMI of 32.08. He is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. His cancer histology is well-differentiated, and he has a fully active performance status. The KRAS biomarker testing showed that he has a wild-type KRAS status. The patient has experienced an adverse effect of thrombosis."
2294,other,male,43,25.4,FOLFOX + Cetuximab,No,No,No,No,0,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: other, sex: male, age: 43, bmi: 25.4, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 0, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 43-year-old male of a race categorized as ""other"" with a BMI of 25.4. He is enrolled in the treatment arm receiving FOLFOX + Cetuximab but has not yet started chemotherapy cycles. His histology shows well-differentiated cells, and he has a fully active performance status. The KRAS biomarker analysis indicates that he has a wild-type KRAS status."
2295,white,male,76,29.48,FOLFOX + Cetuximab,Yes,No,No,No,12,well differentiated,fully active,mutant,No,No,No,No,No,0,"race: white, sex: male, age: 76, bmi: 29.48, treatment arm: FOLFOX + Cetuximab, adherence: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant",The patient is a 76-year-old white male with a BMI of 29.48. He is receiving treatment with FOLFOX + Cetuximab and has been adherent to the treatment. He has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer cells. The patient has a fully active performance status. The KRAS biomarker analysis indicates a mutant status.
2296,white,male,58,42.07,FOLFOX,Yes,No,No,No,12,well differentiated,symptoms but ambulatory,mutant,No,No,No,No,No,1,"race: white, sex: male, age: 58, bmi: 42.07, treatment arm: FOLFOX, adherence: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: mutant","The patient is a 58-year-old white male with a BMI of 42.07. He is receiving treatment in the FOLFOX arm and has been adherent to the chemotherapy regimen for 12 cycles. His histology shows well-differentiated cancer. Despite experiencing symptoms, he is still able to be ambulatory. The KRAS biomarker analysis indicates a mutant status."
2297,other,female,55,31.95,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: other, sex: female, age: 55, bmi: 31.95, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 55-year-old female of a race categorized as ""other"" with a BMI of 31.95. She is receiving treatment in the FOLFOX + Cetuximab treatment arm and is scheduled for 12 chemotherapy cycles. The histology indicates that the cancer is well-differentiated. The patient has a fully active performance status. Additionally, the KRAS biomarker shows that it is wild-type."
2298,white,male,52,29.2,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,fully active,mutant,No,No,No,No,No,0,"race: white, sex: male, age: 52, bmi: 29.2, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 52-year-old white male with a BMI of 29.2. He is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. His cancer histology is well-differentiated, and he has a fully active performance status. The KRAS biomarker testing revealed a mutant status."
2299,white,male,63,25.76,FOLFOX + Cetuximab,Yes,Yes,No,No,1,well differentiated,fully active,wild-type,No,No,No,No,Yes,0,"race: white, sex: male, age: 63, bmi: 25.76, treatment arm: FOLFOX + Cetuximab, adherence: Yes, serious adverse effect: Yes, chemotherapy cycles: 1, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type, adverse effect: infarction: Yes","The patient is a 63-year-old white male with a BMI of 25.76. He is receiving treatment with FOLFOX + Cetuximab and has been adherent to the treatment. He experienced a serious adverse effect after the first chemotherapy cycle, specifically an infarction. The histology of his condition is well-differentiated, and his performance status is fully active. His KRAS biomarker status is wild-type."
2300,white,male,55,28.46,FOLFOX,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 55, bmi: 28.46, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 55-year-old white male with a BMI of 28.46. He is undergoing treatment with the FOLFOX chemotherapy regimen and has completed 12 cycles. His cancer histology is well-differentiated, and he has a fully active performance status. The KRAS biomarker testing showed that he has a wild-type KRAS status."
2301,other,female,65,19.49,FOLFOX,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,Yes,No,0,"race: other, sex: female, age: 65, bmi: 19.49, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type, adverse effect: infection: Yes","The patient is a 65-year-old female of a race categorized as ""other"" with a BMI of 19.49. She is receiving treatment with the FOLFOX chemotherapy regimen and has completed 12 cycles. The histology of her cancer is well-differentiated, and her performance status is fully active. The KRAS biomarker testing indicates that she has a wild-type KRAS status. The patient has experienced an adverse effect in the form of an infection."
2302,white,female,55,26.25,FOLFOX,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 55, bmi: 26.25, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 55-year-old white female with a BMI of 26.25. She is undergoing treatment with the FOLFOX chemotherapy regimen and has completed 12 cycles. Her cancer histology is well-differentiated, and she has a fully active performance status. Additionally, her KRAS biomarker status is wild-type."
2303,other,male,44,29.24,FOLFOX + Cetuximab,No,Yes,No,No,12,well differentiated,symptoms but ambulatory,wild-type,No,No,No,Yes,No,0,"race: other, sex: male, age: 44, bmi: 29.24, treatment arm: FOLFOX + Cetuximab, serious adverse effect: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type, adverse effect: infection: Yes","The patient is a 44-year-old male of a race categorized as ""other"" with a BMI of 29.24. He is undergoing treatment with FOLFOX + Cetuximab and has experienced a serious adverse effect. He has completed 12 cycles of chemotherapy. The histology shows that the cancer is well-differentiated. Despite experiencing symptoms, the patient is still able to be ambulatory. The KRAS biomarker indicates that it is wild-type. Additionally, the patient has also developed an infection as an adverse effect."
2304,white,male,53,26.81,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 53, bmi: 26.81, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type",The patient is a 53-year-old white male with a BMI of 26.81. He is receiving treatment in the FOLFOX + Cetuximab treatment arm and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer cells. The patient has a fully active performance status and has a wild-type KRAS biomarker.
2305,white,female,38,33.3,FOLFOX + Cetuximab,No,No,Yes,No,1,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 38, bmi: 33.3, treatment arm: FOLFOX + Cetuximab, bowel obstruction: Yes, chemotherapy cycles: 1, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 38-year-old white female with a BMI of 33.3. She is currently receiving treatment with FOLFOX + Cetuximab for her bowel obstruction. She has completed one cycle of chemotherapy. The histology of her condition is well differentiated. Despite the bowel obstruction, her performance status is fully active. Additionally, her KRAS biomarker status is wild-type."
2306,white,male,37,24.31,FOLFOX,No,Yes,Yes,No,12,poorly differentiated,fully active,interminate,No,No,No,No,No,0,"race: white, sex: male, age: 37, bmi: 24.31, treatment arm: FOLFOX, serious adverse effect: Yes, bowel obstruction: Yes, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: interminate","The patient is a 37-year-old white male with a BMI of 24.31. He is receiving treatment with the FOLFOX regimen and has experienced a serious adverse effect, specifically a bowel obstruction. He has completed 12 cycles of chemotherapy. The histology of his cancer is poorly differentiated. Despite these challenges, his performance status is fully active. The KRAS biomarker status is indeterminate for this patient."
2307,white,male,45,29.79,FOLFIRI + Cetuximab,No,No,No,No,12,well differentiated,symptoms but ambulatory,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 45, bmi: 29.79, treatment arm: FOLFIRI + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type","The patient is a 45-year-old white male with a BMI of 29.79. He is receiving treatment with FOLFIRI + Cetuximab and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer cells. Despite experiencing symptoms, he is still able to be ambulatory. The KRAS biomarker indicates that he has a wild-type status."
2308,white,female,41,18.24,FOLFOX + Cetuximab,Yes,No,Yes,Yes,0,poorly differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 41, bmi: 18.24, treatment arm: FOLFOX + Cetuximab, adherence: Yes, bowel obstruction: Yes, bowel perforation: Yes, chemotherapy cycles: 0, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 41-year-old white female with a BMI of 18.24. She is currently enrolled in the FOLFOX + Cetuximab treatment arm and is adherent to her treatment. She has experienced both bowel obstruction and bowel perforation. Despite having not started any chemotherapy cycles yet, her histology shows poorly differentiated cells. The patient's performance status is fully active, and her KRAS biomarker indicates that she has a wild-type status."
2309,white,male,56,24.25,FOLFOX,Yes,Yes,No,No,5,poorly differentiated,symptoms but ambulatory,wild-type,Yes,No,No,No,No,1,"race: white, sex: male, age: 56, bmi: 24.25, treatment arm: FOLFOX, adherence: Yes, serious adverse effect: Yes, chemotherapy cycles: 5, histology: poorly differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type, adverse effect: thrombosis: Yes","The patient is a 56-year-old white male with a BMI of 24.25. He is receiving the FOLFOX treatment regimen and has been adherent to the treatment. He has experienced a serious adverse effect in the form of thrombosis after completing 5 cycles of chemotherapy. His cancer histology is poorly differentiated, and he has a performance status of experiencing symptoms but still being able to ambulate. The KRAS biomarker testing showed that he has a wild-type KRAS status."
2310,white,male,70,37.3,FOLFOX,No,No,No,No,12,well differentiated,symptoms but ambulatory,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 70, bmi: 37.3, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type","The patient is a 70-year-old white male with a BMI of 37.3. He is undergoing treatment with the FOLFOX chemotherapy regimen and has completed 12 cycles. His histology shows well-differentiated cancer cells. Despite experiencing symptoms, he is still able to be ambulatory. The KRAS biomarker analysis indicates that he has a wild-type KRAS status."
2311,black,female,75,29.62,FOLFOX,No,Yes,No,No,11,well differentiated,fully active,mutant,No,No,No,No,No,0,"race: black, sex: female, age: 75, bmi: 29.62, treatment arm: FOLFOX, serious adverse effect: Yes, chemotherapy cycles: 11, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 75-year-old Black female with a BMI of 29.62 who is receiving the FOLFOX treatment. She has experienced a serious adverse effect during her 11 cycles of chemotherapy. Her histology shows well-differentiated cells, and she has a fully active performance status. The KRAS biomarker analysis indicates a mutant status."
2312,white,female,58,26.82,FOLFOX,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,Yes,No,No,0,"race: white, sex: female, age: 58, bmi: 26.82, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type, adverse effect: diarrhea: Yes","The patient is a 58-year-old white female with a BMI of 26.82. She is receiving the FOLFOX treatment arm for her well-differentiated histology. She has completed 12 cycles of chemotherapy. Her performance status is fully active, and her KRAS biomarker is wild-type. She is experiencing diarrhea as an adverse effect."
2313,white,male,72,23.15,FOLFOX,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 72, bmi: 23.15, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type",The patient is a 72-year-old white male with a BMI of 23.15. He is receiving the FOLFOX treatment arm and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer cells. The patient has a fully active performance status and his KRAS biomarker is wild-type.
2314,white,male,49,29.67,FOLFOX,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 49, bmi: 29.67, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 49-year-old white male with a BMI of 29.67. He is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cells, and he has a fully active performance status. The KRAS biomarker analysis indicates that he has a wild-type KRAS status."
2315,white,male,51,24.92,FOLFOX + Cetuximab,Yes,No,No,No,12,poorly differentiated,fully active,wild-type,No,No,No,Yes,No,0,"race: white, sex: male, age: 51, bmi: 24.92, treatment arm: FOLFOX + Cetuximab, adherence: Yes, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type, adverse effect: infection: Yes","The patient is a 51-year-old white male with a BMI of 24.92. He is receiving treatment in the FOLFOX + Cetuximab treatment arm and has been adherent to the treatment. He has completed 12 chemotherapy cycles. The histology of his cancer is poorly differentiated. Despite this, his performance status is fully active. His KRAS biomarker status is wild-type. He has experienced an adverse effect in the form of an infection."
2316,white,female,44,24.04,FOLFOX,No,No,No,No,12,well differentiated,fully active,mutant,No,No,No,No,No,0,"race: white, sex: female, age: 44, bmi: 24.04, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 44-year-old white female with a BMI of 24.04. She is receiving the FOLFOX treatment arm and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cells, and she has a fully active performance status. The KRAS biomarker analysis indicates a mutant status."
2317,black,male,37,25.68,FOLFOX + Cetuximab,No,No,Yes,No,12,well differentiated,fully active,mutant,No,No,No,No,No,0,"race: black, sex: male, age: 37, bmi: 25.68, treatment arm: FOLFOX + Cetuximab, bowel obstruction: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant",The patient is a 37-year-old Black male with a BMI of 25.68. He is receiving treatment with FOLFOX + Cetuximab for bowel obstruction. He has completed 12 cycles of chemotherapy. The histology shows well-differentiated cells. The patient has a fully active performance status. The KRAS biomarker indicates a mutant status.
2318,white,female,62,25.07,FOLFOX,No,No,No,Yes,12,well differentiated,symptoms but ambulatory,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 62, bmi: 25.07, treatment arm: FOLFOX, bowel perforation: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type","This patient is a 62-year-old white female with a BMI of 25.07. She is receiving treatment with the FOLFOX regimen for her cancer. She has experienced a bowel perforation and has undergone 12 cycles of chemotherapy. The histology of her cancer is well-differentiated. Despite experiencing symptoms, she is still able to be ambulatory. Her KRAS biomarker status is wild-type."
2319,white,female,45,29.74,FOLFOX + Cetuximab,No,Yes,No,No,12,well differentiated,symptoms but ambulatory,mutant,Yes,No,No,Yes,No,0,"race: white, sex: female, age: 45, bmi: 29.74, treatment arm: FOLFOX + Cetuximab, serious adverse effect: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: mutant, adverse effect: thrombosis: Yes, adverse effect: infection: Yes","The patient is a 45-year-old white female with a BMI of 29.74 who is undergoing treatment with FOLFOX + Cetuximab. She has experienced serious adverse effects during the treatment, including thrombosis and infection. The patient has completed 12 cycles of chemotherapy and has a well-differentiated histology. Despite experiencing symptoms, she is still able to be ambulatory. Additionally, the patient's KRAS biomarker is mutant."
2320,other,female,50,41.44,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,symptoms but ambulatory,mutant,No,No,No,No,No,0,"race: other, sex: female, age: 50, bmi: 41.44, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: mutant","The patient is a 50-year-old female of a race categorized as ""other"" with a BMI of 41.44. She is receiving treatment in the FOLFOX + Cetuximab treatment arm and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated characteristics. Despite experiencing symptoms, she is still able to ambulate. The KRAS biomarker analysis indicates a mutant status."
2321,white,female,60,34.62,FOLFOX,No,No,No,No,12,well differentiated,symptoms but ambulatory,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 60, bmi: 34.62, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type","The patient is a 60-year-old white female with a BMI of 34.62. She is receiving the FOLFOX treatment arm and has completed 12 cycles of chemotherapy. The histology shows well-differentiated cancer cells. Despite experiencing symptoms, the patient is still able to be ambulatory. The KRAS biomarker indicates that the cancer cells are wild-type."
2322,white,female,58,33.92,FOLFOX + Cetuximab,Yes,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 58, bmi: 33.92, treatment arm: FOLFOX + Cetuximab, adherence: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 58-year-old white female with a BMI of 33.92. She is receiving treatment in the FOLFOX + Cetuximab treatment arm and has been adherent to her chemotherapy regimen for 12 cycles. Her histology shows well-differentiated cells, and she has a fully active performance status. Additionally, her KRAS biomarker is wild-type."
2323,other,male,61,25.6,FOLFOX,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: other, sex: male, age: 61, bmi: 25.6, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 61-year-old male of a race categorized as ""other"" with a BMI of 25.6. He is undergoing treatment with the FOLFOX chemotherapy regimen and has completed 12 cycles. The histology of his cancer is well-differentiated. Despite his age, he has a fully active performance status. Additionally, his KRAS biomarker status is wild-type."
2324,white,male,53,28.57,FOLFOX,Yes,No,No,No,12,well differentiated,symptoms but ambulatory,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 53, bmi: 28.57, treatment arm: FOLFOX, adherence: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type","The patient is a 53-year-old white male with a BMI of 28.57. He is receiving treatment in the FOLFOX treatment arm and has been adherent to the chemotherapy regimen for 12 cycles. His histology shows well-differentiated cancer cells. Despite experiencing symptoms, he is still able to be ambulatory. The KRAS biomarker analysis indicates that he has a wild-type KRAS status."
2325,white,female,67,27.1,FOLFOX,No,Yes,No,No,12,poorly differentiated,symptoms but ambulatory,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 67, bmi: 27.1, treatment arm: FOLFOX, serious adverse effect: Yes, chemotherapy cycles: 12, histology: poorly differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type","The patient is a 67-year-old white female with a BMI of 27.1 who is undergoing treatment with the FOLFOX chemotherapy regimen. She has experienced a serious adverse effect from the treatment. She has completed 12 cycles of chemotherapy. The histology of her cancer is poorly differentiated. Despite experiencing symptoms, she is still able to be ambulatory. Her KRAS biomarker status is wild-type."
2326,white,male,50,24.57,FOLFIRI,No,No,No,No,12,well differentiated,symptoms but ambulatory,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 50, bmi: 24.57, treatment arm: FOLFIRI, chemotherapy cycles: 12, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type","The patient is a 50-year-old white male with a BMI of 24.57. He is receiving the FOLFIRI treatment regimen and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer cells. Despite experiencing symptoms, he is still able to walk around (ambulatory). The KRAS biomarker analysis indicates that he has a wild-type KRAS gene."
2327,white,male,73,48.84,FOLFOX,No,Yes,No,No,12,well differentiated,in bed less than 50% of the time,mutant,No,No,No,No,No,1,"race: white, sex: male, age: 73, bmi: 48.84, treatment arm: FOLFOX, serious adverse effect: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: in bed less than 50% of the time, KRAS biomarker: mutant",The patient is a 73-year-old white male with a BMI of 48.84 who is receiving the FOLFOX treatment regimen. He has experienced a serious adverse effect from the treatment. He has completed 12 cycles of chemotherapy. The histology shows that the cancer is well-differentiated. His performance status indicates that he is in bed less than 50% of the time. The KRAS biomarker testing revealed a mutant result.
2328,white,male,52,30.73,FOLFOX,No,Yes,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 52, bmi: 30.73, treatment arm: FOLFOX, serious adverse effect: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 52-year-old white male with a BMI of 30.73. He is receiving the FOLFOX treatment arm for his well-differentiated histology. He has experienced a serious adverse effect during his 12 chemotherapy cycles. Despite this, his performance status is fully active. His KRAS biomarker is wild-type."
2329,white,male,58,28.27,FOLFOX + Cetuximab,No,No,No,No,10,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 58, bmi: 28.27, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 10, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 58-year-old white male with a BMI of 28.27. He is receiving treatment with FOLFOX + Cetuximab and has completed 10 cycles of chemotherapy. His cancer histology is well-differentiated, and he has a fully active performance status. The KRAS biomarker testing showed that he has a wild-type KRAS status."
2330,white,female,59,24.09,FOLFOX,Yes,No,Yes,Yes,12,well differentiated,fully active,interminate,No,No,No,No,No,0,"race: white, sex: female, age: 59, bmi: 24.09, treatment arm: FOLFOX, adherence: Yes, bowel obstruction: Yes, bowel perforation: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: interminate","The patient is a 59-year-old white female with a BMI of 24.09. She is receiving treatment with the FOLFOX regimen and has been adherent to the treatment. She has experienced both a bowel obstruction and a bowel perforation. The patient has completed 12 cycles of chemotherapy and her histology shows well-differentiated cells. Despite the bowel issues, her performance status is fully active. The KRAS biomarker status is indeterminate for this patient."
2331,white,male,53,25.8,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,Yes,No,No,0,"race: white, sex: male, age: 53, bmi: 25.8, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type, adverse effect: diarrhea: Yes","The patient is a 53-year-old white male with a BMI of 25.8. He is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer, and he has a fully active performance status. The KRAS biomarker analysis indicates that he has a wild-type status. The patient is experiencing diarrhea as an adverse effect of the treatment."
2332,white,female,73,23.82,FOLFOX,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 73, bmi: 23.82, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 73-year-old white female with a BMI of 23.82. She is receiving treatment with the FOLFOX chemotherapy regimen and has completed 12 cycles. The histology of her cancer is well-differentiated. Despite her age, she has a fully active performance status. Her KRAS biomarker status is wild-type."
2333,white,male,47,26.45,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,symptoms but ambulatory,wild-type,No,Yes,Yes,No,No,0,"race: white, sex: male, age: 47, bmi: 26.45, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type, adverse effect: hypersensitivity: Yes, adverse effect: diarrhea: Yes","The patient is a 47-year-old white male with a BMI of 26.45. He is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. His cancer histology is well-differentiated, and he has symptoms but is still able to walk around (ambulatory). The KRAS biomarker is wild-type. The patient has experienced hypersensitivity and diarrhea as adverse effects during treatment."
2334,white,female,59,31,FOLFOX,No,No,Yes,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 59, bmi: 31.0, treatment arm: FOLFOX, bowel obstruction: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","This patient is a 59-year-old white female with a BMI of 31.0. She is receiving the FOLFOX treatment regimen and has experienced a bowel obstruction. She has completed 12 cycles of chemotherapy. The histology of her cancer is well differentiated. Despite the bowel obstruction, her performance status is fully active. The KRAS biomarker testing revealed that she has a wild-type KRAS gene."
2335,white,male,40,37.97,FOLFIRI,No,No,No,No,12,well differentiated,fully active,mutant,No,No,No,No,No,1,"race: white, sex: male, age: 40, bmi: 37.97, treatment arm: FOLFIRI, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant",The patient is a 40-year-old white male with a BMI of 37.97. He is receiving the FOLFIRI treatment arm and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer cells. The patient has a fully active performance status. The KRAS biomarker indicates a mutant status.
2336,white,male,56,30.04,FOLFIRI,No,No,No,Yes,12,well differentiated,fully active,wild-type,No,No,No,No,No,1,"race: white, sex: male, age: 56, bmi: 30.04, treatment arm: FOLFIRI, bowel perforation: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 56-year-old white male with a BMI of 30.04. He is receiving treatment with the FOLFIRI regimen and has experienced a bowel perforation. He has completed 12 cycles of chemotherapy. The histology of his cancer is well differentiated. Despite the bowel perforation, his performance status is fully active. His KRAS biomarker status is wild-type."
2337,white,female,65,22.81,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 65, bmi: 22.81, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 65-year-old white female with a BMI of 22.81. She is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. Her cancer histology is well-differentiated, and she has a fully active performance status. The KRAS biomarker analysis shows that she has a wild-type KRAS status."
2338,white,male,56,37.13,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 56, bmi: 37.13, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 56-year-old white male with a BMI of 37.13. He is receiving treatment in the FOLFOX + Cetuximab treatment arm and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cells, and he has a fully active performance status. The KRAS biomarker indicates that he has a wild-type status."
2339,white,male,66,32.56,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,symptoms but ambulatory,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 66, bmi: 32.56, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type","The patient is a 66-year-old white male with a BMI of 32.56. He is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer. Despite experiencing symptoms, he is still able to walk around (ambulatory). The KRAS biomarker indicates that he has a wild-type gene."
2340,white,male,74,22.86,FOLFOX,No,No,No,No,12,poorly differentiated,fully active,mutant,No,No,No,No,No,0,"race: white, sex: male, age: 74, bmi: 22.86, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 74-year-old white male with a BMI of 22.86. He is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. His histology shows poorly differentiated cancer cells. Despite this, his performance status is fully active. Additionally, the KRAS biomarker analysis indicates a mutant status."
2341,black,male,40,25.88,FOLFOX,No,No,No,No,12,poorly differentiated,fully active,wild-type,No,No,No,No,No,0,"race: black, sex: male, age: 40, bmi: 25.88, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 40-year-old Black male with a BMI of 25.88. He is receiving the FOLFOX treatment arm and has completed 12 cycles of chemotherapy. The histology shows poorly differentiated cancer cells. Despite this, his performance status is fully active. The KRAS biomarker indicates that he has a wild-type gene."
2342,white,male,51,36.15,FOLFOX + Cetuximab,No,No,No,No,9,well differentiated,symptoms but ambulatory,mutant,No,No,No,No,No,0,"race: white, sex: male, age: 51, bmi: 36.15, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 9, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: mutant","The patient is a 51-year-old white male with a BMI of 36.15. He is receiving treatment with FOLFOX + Cetuximab and has completed 9 cycles of chemotherapy. His histology shows well-differentiated cancer. Despite experiencing symptoms, he is still able to be ambulatory. The KRAS biomarker analysis indicates a mutant status."
2343,white,female,53,25.52,FOLFOX,No,No,No,No,12,poorly differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 53, bmi: 25.52, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 53-year-old white female with a BMI of 25.52. She is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. Her histology shows poorly differentiated cancer cells. Despite this, her performance status is fully active. Additionally, her KRAS biomarker indicates that it is wild-type."
2344,white,male,50,25.72,FOLFOX,Yes,No,No,No,10,well differentiated,fully active,mutant,No,No,No,No,No,0,"race: white, sex: male, age: 50, bmi: 25.72, treatment arm: FOLFOX, adherence: Yes, chemotherapy cycles: 10, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 50-year-old white male with a BMI of 25.72. He is receiving treatment in the FOLFOX treatment arm and has been adherent to the chemotherapy regimen for 10 cycles. His histology shows well-differentiated cells, and he has a fully active performance status. The KRAS biomarker analysis indicates a mutant status."
2345,white,female,53,42.06,FOLFIRI + Cetuximab,No,No,No,No,12,poorly differentiated,fully active,wild-type,No,No,Yes,No,No,0,"race: white, sex: female, age: 53, bmi: 42.06, treatment arm: FOLFIRI + Cetuximab, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type, adverse effect: diarrhea: Yes","The patient is a 53-year-old white female with a BMI of 42.06. She is receiving treatment with FOLFIRI + Cetuximab and has completed 12 cycles of chemotherapy. Her histology shows poorly differentiated cancer cells. Despite this, her performance status is fully active. The KRAS biomarker indicates that she has a wild-type gene. She is experiencing diarrhea as an adverse effect of her treatment."
2346,white,female,55,43.25,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,symptoms but ambulatory,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 55, bmi: 43.25, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type","The patient is a 55-year-old white female with a BMI of 43.25. She is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cancer. Despite experiencing symptoms, she is still able to be ambulatory. The KRAS biomarker testing revealed that she has a wild-type KRAS status."
2347,white,female,71,43.28,FOLFOX,No,No,No,Yes,12,well differentiated,fully active,mutant,No,No,No,No,No,0,"race: white, sex: female, age: 71, bmi: 43.28, treatment arm: FOLFOX, bowel perforation: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 71-year-old white female with a BMI of 43.28. She is receiving the FOLFOX treatment regimen and has experienced a bowel perforation. She has completed 12 cycles of chemotherapy. The histology of her cancer is well differentiated. Despite these challenges, her performance status is fully active. Additionally, the KRAS biomarker testing revealed a mutant status."
2348,white,male,37,38.03,FOLFOX,No,No,No,No,12,well differentiated,fully active,mutant,No,No,No,No,No,0,"race: white, sex: male, age: 37, bmi: 38.03, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant",The patient is a 37-year-old white male with a BMI of 38.03. He is receiving the FOLFOX treatment arm and has completed 12 cycles of chemotherapy. The histology shows well-differentiated cancer cells. The patient has a fully active performance status. The KRAS biomarker indicates a mutant status.
2349,white,male,63,24.83,FOLFOX,No,No,No,No,12,poorly differentiated,fully active,mutant,No,No,No,No,No,0,"race: white, sex: male, age: 63, bmi: 24.83, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 63-year-old white male with a BMI of 24.83. He is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. His histology shows poorly differentiated cancer cells. Despite this, his performance status is fully active. Additionally, the patient has a mutant KRAS biomarker."
2350,other,female,48,24.06,FOLFOX + Cetuximab,No,No,No,No,0,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: other, sex: female, age: 48, bmi: 24.06, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 0, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 48-year-old female of a race categorized as ""other"" with a BMI of 24.06. She is enrolled in the treatment arm receiving FOLFOX + Cetuximab but has not started any chemotherapy cycles yet. Her histology shows well-differentiated cells, and she has a fully active performance status. Additionally, her KRAS biomarker status is wild-type."
2351,white,female,45,27.98,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,symptoms but ambulatory,interminate,No,No,No,No,No,0,"race: white, sex: female, age: 45, bmi: 27.98, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: interminate","The patient is a 45-year-old white female with a BMI of 27.98. She is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cancer. Despite experiencing symptoms, she is still able to walk around (ambulatory). The KRAS biomarker status is indeterminate for this patient."
2352,white,female,59,23.54,FOLFOX,Yes,No,Yes,No,12,well differentiated,symptoms but ambulatory,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 59, bmi: 23.54, treatment arm: FOLFOX, adherence: Yes, bowel obstruction: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type","The patient is a 59-year-old white female with a BMI of 23.54. She is receiving treatment with FOLFOX for her well-differentiated histology. Despite experiencing symptoms, she is still able to be ambulatory. She has completed 12 cycles of chemotherapy and has adhered to her treatment regimen. Additionally, she has a wild-type KRAS biomarker and is currently dealing with a bowel obstruction."
2353,white,male,58,29.56,FOLFOX,No,Yes,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 58, bmi: 29.56, treatment arm: FOLFOX, serious adverse effect: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 58-year-old white male with a BMI of 29.56. He is receiving the FOLFOX treatment arm for his well-differentiated histology. He has experienced a serious adverse effect during his 12 chemotherapy cycles. Despite this, his performance status is fully active. His KRAS biomarker is wild-type."
2354,white,female,62,42.9,FOLFOX + Cetuximab,No,No,Yes,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 62, bmi: 42.9, treatment arm: FOLFOX + Cetuximab, bowel obstruction: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 62-year-old white female with a BMI of 42.9. She is receiving treatment with FOLFOX + Cetuximab for her well-differentiated histology. She has experienced a bowel obstruction and has completed 12 cycles of chemotherapy. Despite the bowel obstruction, her performance status is fully active. The KRAS biomarker indicates that she has a wild-type status."
2355,white,female,68,23.43,FOLFOX + Cetuximab,No,No,Yes,No,12,well differentiated,symptoms but ambulatory,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 68, bmi: 23.43, treatment arm: FOLFOX + Cetuximab, bowel obstruction: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type","The patient is a 68-year-old white female with a BMI of 23.43. She is receiving treatment with FOLFOX + Cetuximab for her cancer. She has experienced a bowel obstruction and has completed 12 cycles of chemotherapy. The histology of her cancer is well-differentiated. Despite experiencing symptoms, she is still able to be ambulatory. Her KRAS biomarker status is wild-type."
2356,black,male,51,29.41,FOLFOX + Cetuximab,No,No,No,No,2,well differentiated,symptoms but ambulatory,wild-type,No,No,No,No,No,0,"race: black, sex: male, age: 51, bmi: 29.41, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 2, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type","The patient is a 51-year-old Black male with a BMI of 29.41. He is currently receiving treatment with FOLFOX + Cetuximab and has completed 2 cycles of chemotherapy. His cancer histology is well-differentiated. Despite experiencing symptoms, he is still able to be ambulatory. The KRAS biomarker testing revealed that he has a wild-type KRAS status."
2357,white,male,69,26.84,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,fully active,interminate,No,No,No,No,No,0,"race: white, sex: male, age: 69, bmi: 26.84, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: interminate","The patient is a 69-year-old white male with a BMI of 26.84. He is receiving treatment in the FOLFOX + Cetuximab treatment arm and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer cells. Despite his age, he has a fully active performance status. The KRAS biomarker status is indeterminate for this patient."
2358,white,male,73,23.03,FOLFOX + Cetuximab,Yes,No,No,No,3,well differentiated,fully active,wild-type,No,No,Yes,No,No,0,"race: white, sex: male, age: 73, bmi: 23.03, treatment arm: FOLFOX + Cetuximab, adherence: Yes, chemotherapy cycles: 3, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type, adverse effect: diarrhea: Yes","The patient is a 73-year-old white male with a BMI of 23.03. He is currently receiving treatment with FOLFOX + Cetuximab and has been adherent to the treatment. He has completed 3 cycles of chemotherapy. His histology shows well-differentiated cancer cells. Despite experiencing diarrhea as an adverse effect, his performance status is fully active. Additionally, his KRAS biomarker is wild-type."
2359,white,male,41,29.23,FOLFOX + Cetuximab,No,No,Yes,No,12,well differentiated,fully active,wild-type,Yes,No,No,No,No,0,"race: white, sex: male, age: 41, bmi: 29.23, treatment arm: FOLFOX + Cetuximab, bowel obstruction: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type, adverse effect: thrombosis: Yes","This patient is a 41-year-old white male with a BMI of 29.23. He is receiving treatment with FOLFOX + Cetuximab for his well-differentiated histology. He has experienced a bowel obstruction and has undergone 12 cycles of chemotherapy. Despite these challenges, his performance status is fully active. His KRAS biomarker is wild-type. Additionally, he has experienced the adverse effect of thrombosis."
2360,white,female,61,25.71,FOLFOX,Yes,No,No,Yes,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 61, bmi: 25.71, treatment arm: FOLFOX, adherence: Yes, bowel perforation: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 61-year-old white female with a BMI of 25.71. She is receiving the FOLFOX treatment regimen and has been adherent to the treatment. She experienced a bowel perforation and has completed 12 cycles of chemotherapy. The histology shows well-differentiated cells, and her performance status is fully active. The KRAS biomarker indicates that she has a wild-type mutation."
2361,white,male,74,29.87,FOLFOX,No,No,No,No,12,well differentiated,fully active,mutant,No,No,No,No,No,0,"race: white, sex: male, age: 74, bmi: 29.87, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 74-year-old white male with a BMI of 29.87. He is receiving treatment with the FOLFOX chemotherapy regimen and has completed 12 cycles. His cancer histology is well-differentiated. Despite his age, he has a fully active performance status. The KRAS biomarker testing revealed a mutant status."
2362,white,female,64,21.48,FOLFOX,No,No,No,No,12,well differentiated,symptoms but ambulatory,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 64, bmi: 21.48, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type","The patient is a 64-year-old white female with a BMI of 21.48. She is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cancer cells. Despite experiencing symptoms, she is still able to be ambulatory. Additionally, her KRAS biomarker indicates that it is wild-type."
2363,white,female,50,24.1,FOLFOX + Cetuximab,No,No,No,No,12,poorly differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 50, bmi: 24.1, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 50-year-old white female with a BMI of 24.1. She is receiving treatment with FOLFOX + Cetuximab and is scheduled for 12 chemotherapy cycles. Her cancer histology is poorly differentiated. Despite her diagnosis, she has a fully active performance status. Additionally, her KRAS biomarker status is wild-type."
2364,white,male,64,36.22,FOLFOX,No,No,No,No,12,well differentiated,fully active,wild-type,Yes,No,No,No,No,0,"race: white, sex: male, age: 64, bmi: 36.22, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type, adverse effect: thrombosis: Yes","The patient is a 64-year-old white male with a BMI of 36.22. He is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. His cancer histology is well-differentiated, and he has a fully active performance status. The KRAS biomarker testing showed that he has a wild-type KRAS status. The patient has experienced an adverse effect of thrombosis."
2365,black,male,41,22.88,FOLFIRI,No,No,Yes,No,12,well differentiated,symptoms but ambulatory,wild-type,No,No,No,No,No,0,"race: black, sex: male, age: 41, bmi: 22.88, treatment arm: FOLFIRI, bowel obstruction: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type","The patient is a 41-year-old Black male with a BMI of 22.88. He is receiving the FOLFIRI treatment arm for his well-differentiated histology. He has experienced a bowel obstruction and has completed 12 cycles of chemotherapy. Despite experiencing symptoms, he is still ambulatory. His KRAS biomarker shows that he is wild-type."
2366,white,female,64,25.54,FOLFIRI (KRAS mutant),No,Yes,No,No,10,well differentiated,fully active,interminate,No,No,No,No,No,0,"race: white, sex: female, age: 64, bmi: 25.54, treatment arm: FOLFIRI (KRAS mutant), serious adverse effect: Yes, chemotherapy cycles: 10, histology: well differentiated, performance status: fully active, KRAS biomarker: interminate","This patient is a 64-year-old white female with a BMI of 25.54. She is receiving the FOLFIRI treatment regimen for her KRAS mutant cancer. She has experienced a serious adverse effect from the treatment. So far, she has completed 10 cycles of chemotherapy. Her cancer histology is well differentiated. Despite her treatment, she has a fully active performance status. The KRAS biomarker status is currently indeterminate."
2367,white,male,50,26.58,FOLFOX + Cetuximab,Yes,No,Yes,No,12,well differentiated,symptoms but ambulatory,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 50, bmi: 26.58, treatment arm: FOLFOX + Cetuximab, adherence: Yes, bowel obstruction: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type","The patient is a 50-year-old white male with a BMI of 26.58. He is receiving treatment with FOLFOX + Cetuximab and is adherent to the treatment. He has experienced a bowel obstruction. The patient has completed 12 cycles of chemotherapy. His histology shows well-differentiated cells. Despite experiencing symptoms, he is still able to be ambulatory. The KRAS biomarker indicates that he has a wild-type status."
2368,white,male,68,25.8,FOLFOX,No,No,No,No,12,poorly differentiated,symptoms but ambulatory,wild-type,No,No,No,No,No,1,"race: white, sex: male, age: 68, bmi: 25.8, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: poorly differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type","The patient is a 68-year-old white male with a BMI of 25.8. He is receiving treatment with the FOLFOX chemotherapy regimen and is scheduled for 12 cycles. The histology of his cancer is poorly differentiated. Despite experiencing symptoms, he is still able to ambulate. His KRAS biomarker status is wild-type."
2369,white,male,47,30.19,FOLFOX,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 47, bmi: 30.19, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 47-year-old white male with a BMI of 30.19. He is receiving treatment with the FOLFOX chemotherapy regimen and is scheduled to undergo 12 cycles. His cancer histology is well-differentiated, and he has a fully active performance status. The KRAS biomarker analysis indicates that he has a wild-type KRAS status."
2370,white,male,38,19.59,FOLFOX,Yes,No,Yes,Yes,10,poorly differentiated,symptoms but ambulatory,wild-type,No,No,No,No,No,1,"race: white, sex: male, age: 38, bmi: 19.59, treatment arm: FOLFOX, adherence: Yes, bowel obstruction: Yes, bowel perforation: Yes, chemotherapy cycles: 10, histology: poorly differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type","The patient is a 38-year-old white male with a BMI of 19.59. He is receiving treatment with FOLFOX chemotherapy and has been adherent to the treatment. The patient has experienced bowel obstruction and perforation. He has completed 10 cycles of chemotherapy. Histologically, the cancer is poorly differentiated. Despite experiencing symptoms, the patient is still able to be ambulatory. The KRAS biomarker shows that the cancer is wild-type."
2371,white,female,39,20.28,FOLFOX + Cetuximab,No,Yes,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 39, bmi: 20.28, treatment arm: FOLFOX + Cetuximab, serious adverse effect: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 39-year-old white female with a BMI of 20.28. She is undergoing treatment with FOLFOX + Cetuximab and has experienced a serious adverse effect. She has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cells. Despite the adverse effect, her performance status is fully active. The KRAS biomarker indicates that she has a wild-type gene."
2372,white,male,45,39,FOLFOX,No,No,No,No,12,well differentiated,fully active,mutant,No,No,No,No,No,0,"race: white, sex: male, age: 45, bmi: 39.0, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant",The patient is a 45-year-old white male with a BMI of 39.0. He is receiving treatment in the FOLFOX chemotherapy arm and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer cells. The patient has a fully active performance status. The KRAS biomarker analysis indicates a mutant status.
2373,white,male,53,30.22,FOLFOX,Yes,No,No,No,12,poorly differentiated,fully active,wild-type,No,No,No,Yes,No,1,"race: white, sex: male, age: 53, bmi: 30.22, treatment arm: FOLFOX, adherence: Yes, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type, adverse effect: infection: Yes","The patient is a 53-year-old white male with a BMI of 30.22. He is receiving the FOLFOX treatment regimen and has been adherent to the prescribed chemotherapy cycles, completing all 12 cycles. His tumor histology is poorly differentiated. Despite this, his performance status is fully active. The KRAS biomarker testing showed that he has a wild-type KRAS status. Unfortunately, he has experienced an infection as an adverse effect during his treatment."
2374,white,male,68,31.7,FOLFOX,Yes,No,Yes,Yes,12,well differentiated,symptoms but ambulatory,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 68, bmi: 31.7, treatment arm: FOLFOX, adherence: Yes, bowel obstruction: Yes, bowel perforation: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type","The patient is a 68-year-old white male with a BMI of 31.7. He is receiving treatment in the FOLFOX treatment arm and has been adherent to the treatment. The patient has experienced bowel obstruction and perforation. He has completed 12 cycles of chemotherapy. Histologically, the cancer is well-differentiated. Despite experiencing symptoms, the patient is still ambulatory. The KRAS biomarker shows that it is wild-type."
2375,white,male,55,18.65,FOLFOX,No,No,Yes,No,12,poorly differentiated,symptoms but ambulatory,mutant,No,No,No,No,No,0,"race: white, sex: male, age: 55, bmi: 18.65, treatment arm: FOLFOX, bowel obstruction: Yes, chemotherapy cycles: 12, histology: poorly differentiated, performance status: symptoms but ambulatory, KRAS biomarker: mutant","The patient is a 55-year-old white male with a BMI of 18.65. He is receiving the FOLFOX treatment regimen for his bowel obstruction. He has undergone 12 cycles of chemotherapy. The histology of his cancer is poorly differentiated. Despite experiencing symptoms, he is still able to be ambulatory. The KRAS biomarker testing revealed a mutant status."
2376,white,female,51,25.43,FOLFOX + Cetuximab,No,No,No,No,2,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 51, bmi: 25.43, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 2, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 51-year-old white female with a BMI of 25.43. She is currently receiving treatment in the FOLFOX + Cetuximab treatment arm and has completed 2 cycles of chemotherapy. Her histology shows well-differentiated cancer cells. Despite her cancer diagnosis, she has a fully active performance status. Additionally, her KRAS biomarker indicates that it is wild-type."
2377,white,female,45,23.35,FOLFOX,No,Yes,No,No,12,well differentiated,fully active,wild-type,No,No,No,Yes,No,0,"race: white, sex: female, age: 45, bmi: 23.35, treatment arm: FOLFOX, serious adverse effect: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type, adverse effect: infection: Yes","The patient is a 45-year-old white female with a BMI of 23.35. She is undergoing treatment with FOLFOX chemotherapy regimen and has experienced a serious adverse effect. She has completed 12 cycles of chemotherapy and her histology shows well-differentiated cells. Despite the serious adverse effect, her performance status is fully active. The KRAS biomarker testing revealed that she has a wild-type KRAS status. Additionally, she has also experienced an infection as an adverse effect during her treatment."
2378,white,female,41,43.12,FOLFOX,No,No,No,No,4,well differentiated,symptoms but ambulatory,mutant,No,No,No,No,No,1,"race: white, sex: female, age: 41, bmi: 43.12, treatment arm: FOLFOX, chemotherapy cycles: 4, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: mutant","The patient is a 41-year-old white female with a BMI of 43.12. She is undergoing treatment with FOLFOX chemotherapy and has completed 4 cycles so far. Her histology shows well-differentiated cancer cells. Despite experiencing symptoms, she is still able to be ambulatory. The KRAS biomarker analysis indicates a mutant status."
2379,white,male,43,30.79,FOLFOX,No,No,No,No,12,well differentiated,symptoms but ambulatory,mutant,No,No,No,No,No,0,"race: white, sex: male, age: 43, bmi: 30.79, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: mutant","The patient is a 43-year-old white male with a BMI of 30.79. He is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. His cancer histology is well-differentiated. Despite experiencing symptoms, he is still able to ambulate. The KRAS biomarker testing revealed a mutant status."
2380,white,female,52,27.48,FOLFOX,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 52, bmi: 27.48, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 52-year-old white female with a BMI of 27.48. She is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cancer cells. Despite her cancer diagnosis, she has a fully active performance status. The KRAS biomarker analysis indicates that she has a wild-type KRAS gene."
2381,white,male,59,31.71,FOLFOX,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 59, bmi: 31.71, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type",The patient is a 59-year-old white male with a BMI of 31.71. He is receiving treatment with the FOLFOX chemotherapy regimen and has completed 12 cycles. His cancer histology is well differentiated. The patient has a fully active performance status and his KRAS biomarker status is wild-type.
2382,white,female,66,50.45,FOLFOX,No,No,No,No,0,poorly differentiated,symptoms but ambulatory,wild-type,No,No,No,No,No,1,"race: white, sex: female, age: 66, bmi: 50.45, treatment arm: FOLFOX, chemotherapy cycles: 0, histology: poorly differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type","The patient is a 66-year-old white female with a BMI of 50.45. She is enrolled in the FOLFOX treatment arm but has not started chemotherapy cycles yet. Her histology shows poorly differentiated cancer cells. Despite experiencing symptoms, she is still able to walk around (ambulatory). The KRAS biomarker analysis indicates that she has a wild-type KRAS status."
2383,white,male,63,24.54,FOLFOX,No,No,No,No,12,poorly differentiated,fully active,interminate,No,No,No,No,No,0,"race: white, sex: male, age: 63, bmi: 24.54, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: interminate","The patient is a 63-year-old white male with a BMI of 24.54. He is undergoing treatment with the FOLFOX chemotherapy regimen and has completed 12 cycles. His histology shows poorly differentiated cancer cells. Despite this, his performance status is fully active. The KRAS biomarker status is indeterminate."
2384,white,female,49,31.24,FOLFOX,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 49, bmi: 31.24, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 49-year-old white female with a BMI of 31.24. She is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cancer cells. Despite her cancer diagnosis, she has a fully active performance status. The KRAS biomarker analysis indicates that she has a wild-type KRAS gene."
2385,white,female,54,54.29,FOLFOX,No,No,No,No,12,well differentiated,fully active,mutant,No,No,No,No,No,0,"race: white, sex: female, age: 54, bmi: 54.29, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 54-year-old white female with a high BMI of 54.29. She is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. Her cancer histology is well-differentiated, and she has a fully active performance status. The KRAS biomarker testing revealed a mutant status."
2386,white,male,46,42.38,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,symptoms but ambulatory,mutant,No,No,No,Yes,No,0,"race: white, sex: male, age: 46, bmi: 42.38, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: mutant, adverse effect: infection: Yes","The patient is a 46-year-old white male with a BMI of 42.38. He is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer. Despite experiencing symptoms, he is still able to ambulate. The KRAS biomarker is mutant in this patient. He has developed an infection as an adverse effect of the treatment."
2387,white,male,58,31.3,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 58, bmi: 31.3, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type",The patient is a 58-year-old white male with a BMI of 31.3. He is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer cells. The patient has a fully active performance status and has a wild-type KRAS biomarker.
2388,white,male,67,24.31,FOLFOX,No,No,No,No,12,well differentiated,fully active,wild-type,No,Yes,No,No,No,0,"race: white, sex: male, age: 67, bmi: 24.31, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type, adverse effect: hypersensitivity: Yes","The patient is a 67-year-old white male with a BMI of 24.31. He is receiving the FOLFOX treatment arm and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cells, and he has a fully active performance status. The KRAS biomarker is wild-type. The patient has experienced a hypersensitivity adverse effect."
2389,white,female,67,22.07,FOLFOX,No,No,No,No,12,well differentiated,fully active,mutant,No,No,No,No,No,0,"race: white, sex: female, age: 67, bmi: 22.07, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 67-year-old white female with a BMI of 22.07. She is receiving treatment with the FOLFOX chemotherapy regimen and has completed 12 cycles. Her histology shows well-differentiated cancer cells. Despite her age, she has a fully active performance status. The KRAS biomarker testing revealed a mutant status."
2390,white,female,46,27.53,FOLFOX,No,No,No,No,10,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 46, bmi: 27.53, treatment arm: FOLFOX, chemotherapy cycles: 10, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type",The patient is a 46-year-old white female with a BMI of 27.53. She is receiving the FOLFOX treatment regimen and has completed 10 cycles of chemotherapy. The histology shows well-differentiated cancer cells. The patient has a fully active performance status. The KRAS biomarker indicates that the patient has a wild-type KRAS gene.
2391,white,female,53,28.28,FOLFOX + Cetuximab,No,No,No,No,12,poorly differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 53, bmi: 28.28, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 53-year-old white female with a BMI of 28.28. She is receiving treatment in the FOLFOX + Cetuximab treatment arm and is scheduled for 12 chemotherapy cycles. Her histology indicates poorly differentiated cancer. Despite this, her performance status is fully active. Additionally, her KRAS biomarker status is wild-type."
2392,white,male,40,39.41,FOLFIRI (KRAS mutant),No,No,No,No,10,well differentiated,fully active,wild-type,Yes,No,No,No,No,0,"race: white, sex: male, age: 40, bmi: 39.41, treatment arm: FOLFIRI (KRAS mutant), chemotherapy cycles: 10, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type, adverse effect: thrombosis: Yes",The patient is a 40-year-old white male with a BMI of 39.41. He is receiving FOLFIRI treatment for his well-differentiated cancer with a KRAS mutation. He has completed 10 cycles of chemotherapy and has a fully active performance status. His KRAS biomarker is wild-type. The patient has experienced thrombosis as an adverse effect.
2393,other,male,40,23.02,FOLFOX,No,No,No,No,11,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: other, sex: male, age: 40, bmi: 23.02, treatment arm: FOLFOX, chemotherapy cycles: 11, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 40-year-old male of a race categorized as ""other"" with a BMI of 23.02. He is currently receiving treatment in the FOLFOX chemotherapy arm and has completed 11 cycles of chemotherapy. The histology of his cancer is well-differentiated. Despite undergoing treatment, the patient maintains a fully active performance status. Additionally, the KRAS biomarker analysis indicates that the patient has a wild-type KRAS status."
2394,white,female,47,22.34,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,symptoms but ambulatory,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 47, bmi: 22.34, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type","The patient is a 47-year-old white female with a BMI of 22.34. She is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cancer. Despite experiencing symptoms, she is still able to be ambulatory. The KRAS biomarker analysis indicates that she has a wild-type KRAS status."
2395,white,female,56,35.77,FOLFOX,No,No,No,Yes,12,well differentiated,fully active,interminate,No,No,No,No,No,0,"race: white, sex: female, age: 56, bmi: 35.77, treatment arm: FOLFOX, bowel perforation: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: interminate","The patient is a 56-year-old white female with a BMI of 35.77. She is receiving the FOLFOX treatment regimen and has experienced a bowel perforation. She has completed 12 cycles of chemotherapy. The histology of her condition is well-differentiated. Despite the bowel perforation, her performance status is fully active. Her KRAS biomarker status is indeterminate."
2396,white,male,74,24.86,FOLFOX,No,No,No,No,6,poorly differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 74, bmi: 24.86, treatment arm: FOLFOX, chemotherapy cycles: 6, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 74-year-old white male with a BMI of 24.86. He is receiving the FOLFOX treatment regimen and has completed 6 cycles of chemotherapy. His histology shows poorly differentiated cells. Despite this, his performance status is fully active. Additionally, the KRAS biomarker indicates that he has a wild-type status."
2397,other,male,44,36.73,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,symptoms but ambulatory,wild-type,No,No,No,No,No,0,"race: other, sex: male, age: 44, bmi: 36.73, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type","The patient is a 44-year-old male of a race categorized as ""other"" with a BMI of 36.73. He is undergoing treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. His histology shows well-differentiated characteristics. Despite experiencing symptoms, the patient is still able to be ambulatory. Additionally, his KRAS biomarker indicates a wild-type status."
2398,white,female,65,31.14,FOLFOX,No,No,No,No,12,poorly differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 65, bmi: 31.14, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 65-year-old white female with a BMI of 31.14. She is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. Her histology shows poorly differentiated cancer cells. Despite this, her performance status is fully active. Additionally, her KRAS biomarker indicates that it is wild-type."
2399,white,male,45,26.71,FOLFOX,No,No,No,No,12,poorly differentiated,fully active,mutant,No,No,No,No,No,0,"race: white, sex: male, age: 45, bmi: 26.71, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 45-year-old white male with a BMI of 26.71. He is receiving the FOLFOX treatment regimen and is scheduled for 12 chemotherapy cycles. The histology indicates poorly differentiated cancer cells. Despite this, the patient has a fully active performance status. The KRAS biomarker testing revealed a mutant status."
2400,white,female,66,40.57,FOLFIRI + Cetuximab,No,No,Yes,No,9,well differentiated,symptoms but ambulatory,mutant,No,No,No,No,No,0,"race: white, sex: female, age: 66, bmi: 40.57, treatment arm: FOLFIRI + Cetuximab, bowel obstruction: Yes, chemotherapy cycles: 9, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: mutant","The patient is a 66-year-old white female with a BMI of 40.57. She is receiving treatment with FOLFIRI + Cetuximab for her well-differentiated histology. She has experienced a bowel obstruction and has completed 9 cycles of chemotherapy. Despite experiencing symptoms, she is still able to be ambulatory. Additionally, the patient's KRAS biomarker is mutant."
2401,white,male,72,22.22,FOLFOX,No,Yes,No,No,12,poorly differentiated,symptoms but ambulatory,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 72, bmi: 22.22, treatment arm: FOLFOX, serious adverse effect: Yes, chemotherapy cycles: 12, histology: poorly differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type","The patient is a 72-year-old white male with a BMI of 22.22. He is undergoing treatment with the FOLFOX chemotherapy regimen and has experienced a serious adverse effect. He has completed 12 cycles of chemotherapy. The histology of his cancer is poorly differentiated. Despite experiencing symptoms, he is still able to be ambulatory. His KRAS biomarker status is wild-type."
2402,white,female,68,31.89,FOLFOX,No,No,No,No,4,well differentiated,fully active,wild-type,No,No,Yes,No,No,0,"race: white, sex: female, age: 68, bmi: 31.89, treatment arm: FOLFOX, chemotherapy cycles: 4, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type, adverse effect: diarrhea: Yes","The patient is a 68-year-old white female with a BMI of 31.89. She is receiving the FOLFOX treatment regimen and has completed 4 cycles of chemotherapy. Her histology shows well-differentiated cancer, and she has a fully active performance status. The KRAS biomarker testing revealed a wild-type result. The patient is experiencing diarrhea as an adverse effect of the treatment."
2403,white,male,64,24.62,FOLFOX + Cetuximab,No,Yes,No,No,12,poorly differentiated,fully active,wild-type,No,Yes,No,No,No,0,"race: white, sex: male, age: 64, bmi: 24.62, treatment arm: FOLFOX + Cetuximab, serious adverse effect: Yes, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type, adverse effect: hypersensitivity: Yes","The patient is a 64-year-old white male with a BMI of 24.62. He is receiving treatment with FOLFOX + Cetuximab and has experienced a serious adverse effect. He has completed 12 cycles of chemotherapy. His histology shows poorly differentiated cells. Despite this, his performance status is fully active. The KRAS biomarker indicates that he has a wild-type gene. Additionally, he has experienced a hypersensitivity adverse effect."
2404,white,female,62,18.4,FOLFOX + Cetuximab,No,No,No,Yes,12,well differentiated,fully active,mutant,No,No,Yes,No,No,0,"race: white, sex: female, age: 62, bmi: 18.4, treatment arm: FOLFOX + Cetuximab, bowel perforation: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant, adverse effect: diarrhea: Yes","This patient is a 62-year-old white female with a BMI of 18.4. She is receiving treatment with FOLFOX + Cetuximab for her well-differentiated cancer. She has experienced a bowel perforation and has undergone 12 cycles of chemotherapy. Despite these challenges, her performance status is fully active. The patient has a mutant KRAS biomarker and is experiencing diarrhea as an adverse effect of her treatment."
2405,white,female,41,32.98,FOLFOX,No,Yes,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,Yes,0,"race: white, sex: female, age: 41, bmi: 32.98, treatment arm: FOLFOX, serious adverse effect: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type, adverse effect: infarction: Yes","This patient is a 41-year-old white female with a BMI of 32.98 who is receiving the FOLFOX treatment regimen. She has experienced a serious adverse effect during her 12 cycles of chemotherapy. Her histology shows that the cancer is well-differentiated. Despite the adverse effects, her performance status is fully active. Additionally, her KRAS biomarker indicates that it is wild-type. She has also experienced an infarction as an adverse effect."
2406,white,male,51,28.68,FOLFOX,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 51, bmi: 28.68, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 51-year-old white male with a BMI of 28.68. He is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. His cancer histology is well-differentiated, and he has a fully active performance status. The KRAS biomarker testing revealed that he has a wild-type KRAS status."
2407,white,female,45,24.67,FOLFOX,No,Yes,No,No,12,well differentiated,symptoms but ambulatory,mutant,No,No,No,No,No,0,"race: white, sex: female, age: 45, bmi: 24.67, treatment arm: FOLFOX, serious adverse effect: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: mutant","The patient is a 45-year-old white female with a BMI of 24.67. She is receiving the FOLFOX treatment regimen and has experienced a serious adverse effect. She has undergone 12 cycles of chemotherapy. The histology shows well-differentiated cancer cells. Despite experiencing symptoms, she is still able to be ambulatory. The KRAS biomarker analysis indicates a mutant status."
2408,white,male,64,24.48,FOLFIRI (KRAS mutant),No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 64, bmi: 24.48, treatment arm: FOLFIRI (KRAS mutant), chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 64-year-old white male with a BMI of 24.48. He is undergoing treatment with FOLFIRI for KRAS mutant cancer. He has completed 12 cycles of chemotherapy. The histology of his cancer is well differentiated. Despite his cancer diagnosis, he has a fully active performance status. His KRAS biomarker is wild-type."
2409,white,male,63,22.93,FOLFOX + Cetuximab,Yes,Yes,No,Yes,12,well differentiated,symptoms but ambulatory,wild-type,No,No,Yes,No,No,0,"race: white, sex: male, age: 63, bmi: 22.93, treatment arm: FOLFOX + Cetuximab, adherence: Yes, serious adverse effect: Yes, bowel perforation: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type, adverse effect: diarrhea: Yes","The patient is a 63-year-old white male with a BMI of 22.93 who is receiving treatment with FOLFOX + Cetuximab. He has been adherent to the treatment regimen. Unfortunately, he experienced a serious adverse effect in the form of a bowel perforation. Despite this complication, he completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer, and his performance status indicates that he has symptoms but is still ambulatory. The KRAS biomarker testing revealed a wild-type result. Additionally, he has been experiencing diarrhea as an adverse effect of the treatment."
2410,white,male,44,32.67,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,symptoms but ambulatory,mutant,No,No,No,No,No,0,"race: white, sex: male, age: 44, bmi: 32.67, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: mutant","The patient is a 44-year-old white male with a BMI of 32.67. He is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. His cancer histology is well-differentiated. Despite experiencing symptoms, he is still able to be ambulatory. The KRAS biomarker testing revealed a mutant status."
2411,white,female,57,20.72,FOLFIRI (KRAS mutant),Yes,No,Yes,No,12,well differentiated,symptoms but ambulatory,mutant,No,No,No,No,No,0,"race: white, sex: female, age: 57, bmi: 20.72, treatment arm: FOLFIRI (KRAS mutant), adherence: Yes, bowel obstruction: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: mutant","The patient is a 57-year-old white female with a BMI of 20.72. She is receiving treatment with the FOLFIRI regimen for her KRAS mutant status. She has been adherent to her treatment. The patient has experienced a bowel obstruction. She has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cells. Despite experiencing symptoms, she is still able to be ambulatory."
2412,other,female,55,26.54,FOLFOX + Cetuximab,No,No,No,No,1,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: other, sex: female, age: 55, bmi: 26.54, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 1, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 55-year-old female of a race categorized as ""other"" with a BMI of 26.54. She is currently undergoing treatment with the FOLFOX + Cetuximab regimen and has completed one cycle of chemotherapy. The histology of her condition is well-differentiated, and she has a fully active performance status. Additionally, her KRAS biomarker status is wild-type."
2413,white,female,38,49.57,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,symptoms but ambulatory,wild-type,No,Yes,No,No,No,0,"race: white, sex: female, age: 38, bmi: 49.57, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type, adverse effect: hypersensitivity: Yes","The patient is a 38-year-old white female with a BMI of 49.57 who is receiving treatment with FOLFOX + Cetuximab. She has completed 12 cycles of chemotherapy and has well-differentiated histology. Despite experiencing symptoms, she is still able to walk around. Her KRAS biomarker is wild-type. She has experienced a hypersensitivity adverse effect."
2414,white,female,54,34.97,FOLFOX + Cetuximab,No,Yes,No,No,12,poorly differentiated,fully active,wild-type,Yes,No,No,No,No,0,"race: white, sex: female, age: 54, bmi: 34.97, treatment arm: FOLFOX + Cetuximab, serious adverse effect: Yes, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type, adverse effect: thrombosis: Yes","The patient is a 54-year-old white female with a BMI of 34.97. She is receiving treatment with FOLFOX + Cetuximab and has experienced a serious adverse effect. She has undergone 12 cycles of chemotherapy. The histology of her condition is poorly differentiated. Despite this, her performance status is fully active. Her KRAS biomarker is wild-type. Additionally, she has experienced thrombosis as an adverse effect."
2415,white,female,66,40.68,FOLFOX,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 66, bmi: 40.68, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type",The patient is a 66-year-old white female with a BMI of 40.68. She is undergoing treatment with the FOLFOX chemotherapy regimen and has completed 12 cycles. The histology shows well-differentiated cancer cells. The patient has a fully active performance status. The KRAS biomarker analysis indicates that she has a wild-type KRAS status.
2416,white,male,64,21.44,FOLFOX,No,No,No,No,12,well differentiated,symptoms but ambulatory,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 64, bmi: 21.44, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type","The patient is a 64-year-old white male with a BMI of 21.44. He is undergoing treatment with the FOLFOX chemotherapy regimen and has completed 12 cycles. His cancer histology is well-differentiated. Despite experiencing symptoms, he is still able to walk around (ambulatory). The KRAS biomarker analysis shows that he has a wild-type KRAS status."
2417,white,male,58,24.81,FOLFOX,No,Yes,No,No,4,well differentiated,fully active,wild-type,Yes,No,No,No,No,1,"race: white, sex: male, age: 58, bmi: 24.81, treatment arm: FOLFOX, serious adverse effect: Yes, chemotherapy cycles: 4, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type, adverse effect: thrombosis: Yes","The patient is a 58-year-old white male with a BMI of 24.81. He is receiving the FOLFOX treatment regimen and has experienced a serious adverse effect. He has completed 4 cycles of chemotherapy. His histology shows well-differentiated cells, and he has a fully active performance status. The KRAS biomarker is wild-type. Additionally, he has experienced thrombosis as an adverse effect."
2418,white,male,55,31.45,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,symptoms but ambulatory,mutant,No,Yes,No,No,No,1,"race: white, sex: male, age: 55, bmi: 31.45, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: mutant, adverse effect: hypersensitivity: Yes","The patient is a 55-year-old white male with a BMI of 31.45. He is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. His cancer histology is well differentiated, and he has symptoms but is still able to walk around (ambulatory). The KRAS biomarker testing showed a mutant result. The patient experienced a hypersensitivity adverse effect during treatment."
2419,white,male,62,24.26,FOLFOX + Cetuximab,No,No,Yes,No,12,poorly differentiated,symptoms but ambulatory,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 62, bmi: 24.26, treatment arm: FOLFOX + Cetuximab, bowel obstruction: Yes, chemotherapy cycles: 12, histology: poorly differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type","This patient is a 62-year-old white male with a BMI of 24.26. He is receiving treatment with FOLFOX + Cetuximab for his cancer. He has experienced a bowel obstruction and has undergone 12 cycles of chemotherapy. The histology of his cancer is poorly differentiated. Despite experiencing symptoms, he is still able to be ambulatory. His KRAS biomarker status is wild-type."
2420,white,male,45,40.19,FOLFOX,No,No,No,No,12,well differentiated,symptoms but ambulatory,wild-type,No,Yes,No,No,No,0,"race: white, sex: male, age: 45, bmi: 40.19, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type, adverse effect: hypersensitivity: Yes","The patient is a 45-year-old white male with a BMI of 40.19. He is receiving the FOLFOX treatment arm and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer cells. Despite experiencing symptoms, he is still able to ambulate. The KRAS biomarker analysis indicates that he has a wild-type KRAS status. Additionally, the patient has experienced a hypersensitivity adverse effect."
2421,white,female,75,28.45,FOLFOX + Cetuximab,No,Yes,No,No,12,poorly differentiated,fully active,wild-type,No,No,Yes,No,No,0,"race: white, sex: female, age: 75, bmi: 28.45, treatment arm: FOLFOX + Cetuximab, serious adverse effect: Yes, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type, adverse effect: diarrhea: Yes","This 75-year-old white female patient with a BMI of 28.45 is undergoing treatment with FOLFOX + Cetuximab for her poorly differentiated cancer. She has experienced a serious adverse effect during her 12 chemotherapy cycles. Despite this, she maintains a fully active performance status. Her KRAS biomarker is wild-type. Additionally, she has experienced diarrhea as an adverse effect of her treatment."
2422,white,female,71,23.98,FOLFOX + Cetuximab,No,Yes,No,No,7,well differentiated,fully active,mutant,No,No,Yes,No,No,0,"race: white, sex: female, age: 71, bmi: 23.98, treatment arm: FOLFOX + Cetuximab, serious adverse effect: Yes, chemotherapy cycles: 7, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant, adverse effect: diarrhea: Yes","This patient is a 71-year-old white female with a BMI of 23.98. She is receiving treatment with FOLFOX + Cetuximab and has experienced a serious adverse effect. She has completed 7 cycles of chemotherapy. Her histology shows well-differentiated cancer, and her performance status is fully active. The KRAS biomarker testing revealed a mutant status. Additionally, she has experienced diarrhea as an adverse effect of her treatment."
2423,white,female,51,36.91,FOLFOX,No,No,No,No,12,poorly differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 51, bmi: 36.91, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 51-year-old white female with a BMI of 36.91. She is receiving the FOLFOX treatment arm and has completed 12 cycles of chemotherapy. Her histology shows poorly differentiated cancer cells. Despite this, her performance status is fully active. Additionally, her KRAS biomarker is wild-type."
2424,white,male,41,28.13,FOLFOX + Cetuximab,No,No,No,No,12,poorly differentiated,fully active,wild-type,No,No,No,No,No,1,"race: white, sex: male, age: 41, bmi: 28.13, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 41-year-old white male with a BMI of 28.13. He is receiving treatment in the FOLFOX + Cetuximab treatment arm and has completed 12 cycles of chemotherapy. His histology shows poorly differentiated cancer cells. Despite this, his performance status is fully active. Additionally, his KRAS biomarker indicates that it is wild-type."
2425,other,female,51,26.2,FOLFOX,No,No,No,No,12,well differentiated,fully active,mutant,No,No,No,No,No,0,"race: other, sex: female, age: 51, bmi: 26.2, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 51-year-old female of a race categorized as ""other"" with a BMI of 26.2. She is undergoing treatment with the FOLFOX chemotherapy regimen and has completed 12 cycles. The histology of her condition is well-differentiated. Despite her treatment, she maintains a fully active performance status. Additionally, the KRAS biomarker testing has revealed a mutant status."
2426,white,male,55,27.55,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 55, bmi: 27.55, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type",The patient is a 55-year-old white male with a BMI of 27.55. He is receiving treatment in the FOLFOX + Cetuximab treatment arm and is scheduled for 12 chemotherapy cycles. His histology shows well-differentiated cells. The patient has a fully active performance status and his KRAS biomarker is wild-type.
2427,black,female,41,27,FOLFOX,No,No,No,No,1,well differentiated,symptoms but ambulatory,mutant,No,No,No,No,No,0,"race: black, sex: female, age: 41, bmi: 27.0, treatment arm: FOLFOX, chemotherapy cycles: 1, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: mutant","The patient is a 41-year-old Black female with a BMI of 27.0. She is receiving the FOLFOX treatment regimen and has completed one cycle of chemotherapy. Her histology shows well-differentiated cancer cells. Despite experiencing symptoms, she is still able to be ambulatory. The KRAS biomarker testing revealed a mutant status."
2428,white,male,69,33.02,FOLFOX + Cetuximab,Yes,Yes,No,No,2,well differentiated,fully active,wild-type,No,Yes,No,No,Yes,0,"race: white, sex: male, age: 69, bmi: 33.02, treatment arm: FOLFOX + Cetuximab, adherence: Yes, serious adverse effect: Yes, chemotherapy cycles: 2, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type, adverse effect: hypersensitivity: Yes, adverse effect: infarction: Yes","The patient is a 69-year-old white male with a BMI of 33.02. He is receiving treatment in the FOLFOX + Cetuximab treatment arm and has been adherent to the treatment. After completing 2 chemotherapy cycles, he experienced serious adverse effects including hypersensitivity and infarction. His histology shows well-differentiated cells, and his performance status is fully active. The KRAS biomarker analysis revealed that he has a wild-type KRAS status."
2429,white,male,59,23.88,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 59, bmi: 23.88, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type",The patient is a 59-year-old white male with a BMI of 23.88. He is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer cells. The patient has a fully active performance status and his KRAS biomarker is wild-type.
2430,black,female,65,21.41,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,symptoms but ambulatory,interminate,No,No,No,No,No,1,"race: black, sex: female, age: 65, bmi: 21.41, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: interminate","The patient is a 65-year-old Black female with a BMI of 21.41. She is receiving treatment in the FOLFOX + Cetuximab treatment arm and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cancer. Despite experiencing symptoms, she is still able to be ambulatory. The KRAS biomarker status is indeterminate for this patient."
2431,white,male,74,22.1,FOLFOX,Yes,No,No,No,12,well differentiated,symptoms but ambulatory,wild-type,Yes,No,No,No,No,0,"race: white, sex: male, age: 74, bmi: 22.1, treatment arm: FOLFOX, adherence: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type, adverse effect: thrombosis: Yes","The patient is a 74-year-old white male with a BMI of 22.1. He is receiving the FOLFOX treatment regimen and has been adherent to the therapy for 12 chemotherapy cycles. His histology shows well-differentiated cancer cells. Despite experiencing symptoms, he is still able to be ambulatory. The KRAS biomarker indicates that he has a wild-type status. The patient has also experienced thrombosis as an adverse effect of the treatment."
2432,white,male,41,25.73,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 41, bmi: 25.73, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type",The patient is a 41-year-old white male with a BMI of 25.73. He is receiving treatment in the FOLFOX + Cetuximab treatment arm and is scheduled for 12 chemotherapy cycles. His histology shows well-differentiated cancer cells. The patient has a fully active performance status. His KRAS biomarker status is wild-type.
2433,black,male,38,26.06,FOLFOX,No,No,Yes,No,12,poorly differentiated,fully active,wild-type,No,No,No,No,No,1,"race: black, sex: male, age: 38, bmi: 26.06, treatment arm: FOLFOX, bowel obstruction: Yes, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 38-year-old Black male with a BMI of 26.06. He is receiving the FOLFOX treatment arm for his bowel obstruction. He has undergone 12 cycles of chemotherapy. The histology shows poorly differentiated cells. Despite this, his performance status is fully active. The KRAS biomarker indicates that he has a wild-type status."
2434,white,male,67,30.77,FOLFOX,No,No,No,No,12,well differentiated,fully active,mutant,No,No,No,No,No,0,"race: white, sex: male, age: 67, bmi: 30.77, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant",The patient is a 67-year-old white male with a BMI of 30.77. He is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. His cancer histology is well-differentiated. The patient has a fully active performance status. The KRAS biomarker testing revealed a mutant status.
2435,white,female,52,20.63,FOLFOX + Cetuximab,No,No,No,No,1,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 52, bmi: 20.63, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 1, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 52-year-old white female with a BMI of 20.63. She is currently receiving treatment in the FOLFOX + Cetuximab treatment arm and has completed one cycle of chemotherapy. Her histology shows well-differentiated cells, and she has a fully active performance status. Additionally, her KRAS biomarker status is wild-type."
2436,white,male,40,28.31,FOLFIRI (KRAS mutant),No,Yes,No,No,5,well differentiated,fully active,mutant,No,No,No,No,No,0,"race: white, sex: male, age: 40, bmi: 28.31, treatment arm: FOLFIRI (KRAS mutant), serious adverse effect: Yes, chemotherapy cycles: 5, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 40-year-old white male with a BMI of 28.31. He is receiving the FOLFIRI treatment regimen for his KRAS mutant status. Unfortunately, he has experienced a serious adverse effect. He has completed 5 cycles of chemotherapy. His histology shows well-differentiated cells. Despite the adverse effect, his performance status is fully active."
2437,white,male,39,22.94,FOLFOX + Cetuximab,No,No,No,No,12,poorly differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 39, bmi: 22.94, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 39-year-old white male with a BMI of 22.94. He is receiving treatment in the FOLFOX + Cetuximab treatment arm and has completed 12 cycles of chemotherapy. His histology shows poorly differentiated cancer cells. Despite this, his performance status is fully active. Additionally, the KRAS biomarker indicates that he has a wild-type gene."
2438,white,male,55,31.27,FOLFOX,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 55, bmi: 31.27, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type",The patient is a 55-year-old white male with a BMI of 31.27. He is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. The histology indicates that the cancer is well-differentiated. The patient has a fully active performance status. The KRAS biomarker testing showed that he has a wild-type KRAS status.
2439,black,male,68,29.96,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,fully active,wild-type,Yes,No,No,No,No,0,"race: black, sex: male, age: 68, bmi: 29.96, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type, adverse effect: thrombosis: Yes","The patient is a 68-year-old Black male with a BMI of 29.96. He is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer, and he has a fully active performance status. The KRAS biomarker is wild-type. The patient has experienced an adverse effect of thrombosis."
2440,white,male,70,30.93,FOLFIRI,No,No,No,No,12,poorly differentiated,fully active,wild-type,No,No,No,No,No,1,"race: white, sex: male, age: 70, bmi: 30.93, treatment arm: FOLFIRI, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 70-year-old white male with a BMI of 30.93. He is receiving the FOLFIRI treatment regimen and has completed 12 cycles of chemotherapy. His histology shows poorly differentiated cancer cells. Despite his age, he has a fully active performance status. The KRAS biomarker analysis indicates that he has a wild-type KRAS status."
2441,white,female,48,29.67,FOLFOX,No,No,No,No,12,poorly differentiated,symptoms but ambulatory,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 48, bmi: 29.67, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: poorly differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type","The patient is a 48-year-old white female with a BMI of 29.67. She is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. Her histology shows poorly differentiated cells. Despite experiencing symptoms, she is still able to walk around (ambulatory). The KRAS biomarker analysis indicates that she has a wild-type KRAS status."
2442,white,female,67,33.8,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 67, bmi: 33.8, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 67-year-old white female with a BMI of 33.8. She is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cancer, and she has a fully active performance status. Additionally, her KRAS biomarker is wild-type."
2443,white,male,60,28.97,FOLFOX,No,No,No,No,12,poorly differentiated,fully active,mutant,No,No,No,No,No,0,"race: white, sex: male, age: 60, bmi: 28.97, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 60-year-old white male with a BMI of 28.97. He is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. His histology shows poorly differentiated cancer cells. Despite this, his performance status is fully active. The KRAS biomarker testing revealed a mutant status."
2444,white,male,66,36.96,FOLFOX,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 66, bmi: 36.96, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type",The patient is a 66-year-old white male with a BMI of 36.96. He is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. His cancer histology is well differentiated. The patient has a fully active performance status and his KRAS biomarker is wild-type.
2445,white,female,75,28.1,FOLFOX + Cetuximab,Yes,No,No,No,3,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 75, bmi: 28.1, treatment arm: FOLFOX + Cetuximab, adherence: Yes, chemotherapy cycles: 3, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 75-year-old white female with a BMI of 28.1. She is currently receiving treatment in the FOLFOX + Cetuximab treatment arm and has been adherent to her treatment. She has completed 3 cycles of chemotherapy. Her histology shows well-differentiated cancer cells. Despite her age, she has a fully active performance status. Additionally, her KRAS biomarker indicates that it is wild-type."
2446,white,female,54,24.39,FOLFOX + Cetuximab,No,Yes,No,No,12,poorly differentiated,fully active,mutant,No,No,No,No,No,0,"race: white, sex: female, age: 54, bmi: 24.39, treatment arm: FOLFOX + Cetuximab, serious adverse effect: Yes, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 54-year-old white female with a BMI of 24.39. She is receiving treatment in the FOLFOX + Cetuximab treatment arm and has experienced a serious adverse effect. She has completed 12 chemotherapy cycles and has a histology of poorly differentiated cancer. Despite this, her performance status is fully active. Additionally, her KRAS biomarker is mutant."
2447,white,female,40,22.33,FOLFOX,No,No,No,No,12,well differentiated,fully active,mutant,No,No,No,No,No,0,"race: white, sex: female, age: 40, bmi: 22.33, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant",The patient is a 40-year-old white female with a BMI of 22.33. She is receiving the FOLFOX treatment arm and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cancer cells. She has a fully active performance status. The KRAS biomarker testing revealed a mutant status.
2448,white,female,47,26.67,FOLFOX + Cetuximab,Yes,No,No,No,10,poorly differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 47, bmi: 26.67, treatment arm: FOLFOX + Cetuximab, adherence: Yes, chemotherapy cycles: 10, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 47-year-old white female with a BMI of 26.67. She is receiving treatment in the FOLFOX + Cetuximab treatment arm and has been adherent to her chemotherapy regimen for 10 cycles. Her histology shows poorly differentiated cancer cells. Despite this, her performance status is fully active. Additionally, her KRAS biomarker indicates that she has a wild-type status."
2449,white,male,43,27.65,FOLFOX,No,No,No,No,9,well differentiated,symptoms but ambulatory,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 43, bmi: 27.65, treatment arm: FOLFOX, chemotherapy cycles: 9, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type","The patient is a 43-year-old white male with a BMI of 27.65. He is receiving the FOLFOX treatment regimen and has completed 9 cycles of chemotherapy. His histology shows well-differentiated cancer cells. Despite experiencing symptoms, he is still able to be ambulatory. The KRAS biomarker analysis indicates that he has a wild-type KRAS status."
2450,white,female,76,29.01,FOLFOX,No,No,No,No,4,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 76, bmi: 29.01, treatment arm: FOLFOX, chemotherapy cycles: 4, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 76-year-old white female with a BMI of 29.01. She is receiving the FOLFOX treatment regimen and has completed 4 cycles of chemotherapy. Her cancer histology is well-differentiated. Despite her age, she has a fully active performance status. The KRAS biomarker testing revealed that she has a wild-type KRAS status."
2451,white,male,42,26.89,FOLFOX + Cetuximab,No,No,No,No,9,well differentiated,fully active,mutant,No,No,No,No,No,0,"race: white, sex: male, age: 42, bmi: 26.89, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 9, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant",The patient is a 42-year-old white male with a BMI of 26.89. He is receiving treatment in the FOLFOX + Cetuximab treatment arm and has completed 9 cycles of chemotherapy. His histology shows well-differentiated cells. The patient has a fully active performance status. The KRAS biomarker analysis indicates a mutant status.
2452,white,male,59,28.18,FOLFOX + Cetuximab,No,No,No,No,6,poorly differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 59, bmi: 28.18, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 6, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 59-year-old white male with a BMI of 28.18. He is receiving treatment in the FOLFOX + Cetuximab treatment arm and has completed 6 cycles of chemotherapy. His histology shows poorly differentiated cancer cells. Despite this, his performance status is fully active. Additionally, his KRAS biomarker indicates that he has a wild-type mutation."
2453,white,male,37,30.87,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,fully active,wild-type,Yes,No,No,No,No,0,"race: white, sex: male, age: 37, bmi: 30.87, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type, adverse effect: thrombosis: Yes","The patient is a 37-year-old white male with a BMI of 30.87. He is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. His cancer histology is well-differentiated, and he has a fully active performance status. The KRAS biomarker testing showed that he has a wild-type KRAS status. The patient has experienced an adverse effect of thrombosis."
2454,white,male,45,24.42,FOLFOX,No,No,No,No,12,poorly differentiated,fully active,mutant,No,No,No,No,No,0,"race: white, sex: male, age: 45, bmi: 24.42, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 45-year-old white male with a BMI of 24.42. He is undergoing treatment with the FOLFOX chemotherapy regimen and has completed 12 cycles. His cancer histology is poorly differentiated. Despite his diagnosis, he has a fully active performance status. Additionally, the patient's KRAS biomarker status is mutant."
2455,white,male,59,33.35,FOLFOX + Cetuximab,Yes,Yes,No,No,12,well differentiated,symptoms but ambulatory,mutant,No,Yes,No,No,No,0,"race: white, sex: male, age: 59, bmi: 33.35, treatment arm: FOLFOX + Cetuximab, adherence: Yes, serious adverse effect: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: mutant, adverse effect: hypersensitivity: Yes","The patient is a 59-year-old white male with a BMI of 33.35 who is receiving treatment with FOLFOX + Cetuximab. He has been adherent to the treatment regimen and has completed 12 cycles of chemotherapy. The patient's histology shows well-differentiated cancer, and he has a mutant KRAS biomarker. Despite experiencing serious adverse effects, the patient is still ambulatory with symptoms. He has also developed hypersensitivity as an adverse effect to the treatment."
2456,white,male,50,26.7,FOLFOX + Cetuximab,No,No,Yes,No,12,well differentiated,fully active,mutant,No,No,No,No,No,0,"race: white, sex: male, age: 50, bmi: 26.7, treatment arm: FOLFOX + Cetuximab, bowel obstruction: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 50-year-old white male with a BMI of 26.7. He is receiving treatment with FOLFOX + Cetuximab for his well-differentiated histology. He has experienced a bowel obstruction and has completed 12 cycles of chemotherapy. Despite this, his performance status is fully active. Additionally, the patient has a mutant KRAS biomarker."
2457,white,female,40,27.28,FOLFIRI + Cetuximab,No,No,Yes,No,12,well differentiated,fully active,mutant,No,No,No,No,No,0,"race: white, sex: female, age: 40, bmi: 27.28, treatment arm: FOLFIRI + Cetuximab, bowel obstruction: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 40-year-old white female with a BMI of 27.28. She is receiving treatment with FOLFIRI + Cetuximab and has experienced a bowel obstruction. She has completed 12 cycles of chemotherapy. The histology shows well-differentiated cells, and her performance status is fully active. The KRAS biomarker indicates a mutant status."
2458,white,female,64,21.9,FOLFOX,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 64, bmi: 21.9, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 64-year-old white female with a BMI of 21.9. She is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cancer cells. Despite her cancer diagnosis, she has a fully active performance status. Additionally, her KRAS biomarker indicates that she has the wild-type version of the gene."
2459,white,female,67,27.14,FOLFOX + Cetuximab,No,No,Yes,No,12,well differentiated,fully active,mutant,No,No,No,No,No,0,"race: white, sex: female, age: 67, bmi: 27.14, treatment arm: FOLFOX + Cetuximab, bowel obstruction: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 67-year-old white female with a BMI of 27.14. She is receiving treatment with FOLFOX + Cetuximab for her well-differentiated histology. She has experienced a bowel obstruction and has completed 12 cycles of chemotherapy. Despite the bowel obstruction, her performance status is fully active. Additionally, the KRAS biomarker shows a mutant status."
2460,white,male,56,31.06,FOLFOX,No,No,No,No,12,well differentiated,symptoms but ambulatory,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 56, bmi: 31.06, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type","The patient is a 56-year-old white male with a BMI of 31.06. He is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer cells. Despite experiencing symptoms, he is still able to be ambulatory. The KRAS biomarker analysis indicates that he has a wild-type KRAS status."
2461,white,male,49,22.76,FOLFOX,No,No,No,No,3,poorly differentiated,fully active,wild-type,No,No,Yes,No,No,0,"race: white, sex: male, age: 49, bmi: 22.76, treatment arm: FOLFOX, chemotherapy cycles: 3, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type, adverse effect: diarrhea: Yes","The patient is a 49-year-old white male with a BMI of 22.76. He is currently receiving the FOLFOX treatment regimen and has completed 3 cycles of chemotherapy. His histology shows poorly differentiated cancer cells. Despite this, his performance status is fully active. The KRAS biomarker analysis indicates that he has a wild-type KRAS gene. The patient is experiencing diarrhea as an adverse effect of the treatment."
2462,white,female,44,20.22,FOLFOX,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 44, bmi: 20.22, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 44-year-old white female with a BMI of 20.22. She is receiving treatment in the FOLFOX chemotherapy arm and is scheduled for 12 cycles. Her histology shows well-differentiated cancer cells. Despite her diagnosis, she maintains a fully active performance status. Additionally, her KRAS biomarker indicates that she has the wild-type variant."
2463,white,male,67,28.47,FOLFOX + Cetuximab,No,Yes,No,No,2,well differentiated,fully active,wild-type,No,No,Yes,No,No,0,"race: white, sex: male, age: 67, bmi: 28.47, treatment arm: FOLFOX + Cetuximab, serious adverse effect: Yes, chemotherapy cycles: 2, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type, adverse effect: diarrhea: Yes","The patient is a 67-year-old white male with a BMI of 28.47. He is receiving treatment with FOLFOX + Cetuximab and has experienced a serious adverse effect. He has completed 2 cycles of chemotherapy. The histology shows that the cancer is well-differentiated. Despite the serious adverse effect, the patient's performance status is fully active. The KRAS biomarker indicates that it is wild-type. Additionally, the patient has experienced diarrhea as an adverse effect."
2464,white,female,57,25.61,FOLFIRI,No,No,No,No,12,well differentiated,fully active,mutant,No,No,No,No,No,0,"race: white, sex: female, age: 57, bmi: 25.61, treatment arm: FOLFIRI, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 57-year-old white female with a BMI of 25.61. She is undergoing treatment with the FOLFIRI chemotherapy regimen and has completed 12 cycles. Her cancer histology is well-differentiated. Despite her cancer diagnosis, she has a fully active performance status. The KRAS biomarker testing revealed a mutant status."
2465,white,female,60,22.03,FOLFOX,No,No,No,No,12,well differentiated,fully active,mutant,No,No,No,No,No,0,"race: white, sex: female, age: 60, bmi: 22.03, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 60-year-old white female with a BMI of 22.03. She is receiving the FOLFOX treatment regimen for her cancer, with a planned total of 12 chemotherapy cycles. The histology of her cancer is well-differentiated. Despite undergoing treatment, she has a fully active performance status. Additionally, the KRAS biomarker testing revealed a mutant status."
2466,white,female,56,24.64,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,fully active,mutant,No,No,No,No,No,0,"race: white, sex: female, age: 56, bmi: 24.64, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant",The patient is a 56-year-old white female with a BMI of 24.64. She is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. The histology shows well-differentiated cancer cells. The patient has a fully active performance status. The KRAS biomarker indicates a mutant status.
2467,white,male,48,23.52,FOLFOX + Cetuximab,No,No,Yes,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 48, bmi: 23.52, treatment arm: FOLFOX + Cetuximab, bowel obstruction: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 48-year-old white male with a BMI of 23.52. He is undergoing treatment with FOLFOX + Cetuximab for his well-differentiated histology. He has experienced a bowel obstruction and has completed 12 cycles of chemotherapy. Despite this, his performance status is fully active. His KRAS biomarker is wild-type."
2468,white,female,47,24.8,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 47, bmi: 24.8, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type",The patient is a 47-year-old white female with a BMI of 24.8. She is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cancer cells. She has a fully active performance status and her KRAS biomarker is wild-type.
2469,white,female,35,22.41,FOLFOX,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 35, bmi: 22.41, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type",The patient is a 35-year-old white female with a BMI of 22.41. She is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. The histology of her cancer is well-differentiated. She has a fully active performance status. The KRAS biomarker testing showed that she has a wild-type KRAS status.
2470,white,male,72,28.37,FOLFIRI (KRAS mutant),No,No,No,No,12,well differentiated,fully active,wild-type,No,No,Yes,No,No,1,"race: white, sex: male, age: 72, bmi: 28.37, treatment arm: FOLFIRI (KRAS mutant), chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type, adverse effect: diarrhea: Yes","The patient is a 72-year-old white male with a BMI of 28.37. He is receiving the FOLFIRI treatment regimen for his well-differentiated histology. Despite being fully active with a wild-type KRAS biomarker, he is experiencing diarrhea as an adverse effect of the chemotherapy."
2471,white,female,54,29.28,FOLFOX + Cetuximab,No,No,No,No,12,poorly differentiated,fully active,wild-type,No,No,Yes,No,No,0,"race: white, sex: female, age: 54, bmi: 29.28, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type, adverse effect: diarrhea: Yes","The patient is a 54-year-old white female with a BMI of 29.28. She is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. Her histology shows poorly differentiated cancer cells. Despite this, her performance status is fully active. The KRAS biomarker test results indicate that she has a wild-type KRAS gene. The patient is experiencing diarrhea as an adverse effect of the treatment."
2472,other,female,34,17.5,FOLFOX + Cetuximab,No,Yes,No,No,12,poorly differentiated,fully active,mutant,No,No,No,No,No,0,"race: other, sex: female, age: 34, bmi: 17.5, treatment arm: FOLFOX + Cetuximab, serious adverse effect: Yes, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 34-year-old female of a race categorized as ""other"" with a BMI of 17.5. She is receiving treatment in the FOLFOX + Cetuximab treatment arm and has experienced a serious adverse effect. She has undergone 12 cycles of chemotherapy. Histologically, her cancer is poorly differentiated. Despite this, her performance status is fully active. Additionally, the KRAS biomarker testing revealed a mutant status."
2473,white,male,41,24.33,FOLFOX,No,Yes,No,No,12,poorly differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 41, bmi: 24.33, treatment arm: FOLFOX, serious adverse effect: Yes, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 41-year-old white male with a BMI of 24.33. He is undergoing treatment with the FOLFOX chemotherapy regimen and has experienced a serious adverse effect. He has completed 12 cycles of chemotherapy. The histology of his cancer is poorly differentiated. Despite this, his performance status is fully active. The KRAS biomarker testing revealed that he has a wild-type KRAS status."
2474,other,male,49,32.49,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: other, sex: male, age: 49, bmi: 32.49, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 49-year-old male of a race categorized as ""other"" with a BMI of 32.49. He is undergoing treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. The histology of his condition is well-differentiated. Despite his cancer treatment, he maintains a fully active performance status. Additionally, the KRAS biomarker analysis indicates that he has a wild-type KRAS gene."
2475,white,male,74,25.95,FOLFOX + Cetuximab,No,No,Yes,No,12,well differentiated,fully active,wild-type,No,No,No,Yes,No,1,"race: white, sex: male, age: 74, bmi: 25.95, treatment arm: FOLFOX + Cetuximab, bowel obstruction: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type, adverse effect: infection: Yes","The patient is a 74-year-old white male with a BMI of 25.95 who is receiving treatment with FOLFOX + Cetuximab. He has a bowel obstruction and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cells, and he has a fully active performance status. The KRAS biomarker is wild-type. The patient has experienced an infection as an adverse effect."
2476,white,male,69,21.99,FOLFOX,No,No,No,No,12,well differentiated,fully active,mutant,No,No,No,No,No,0,"race: white, sex: male, age: 69, bmi: 21.99, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 69-year-old white male with a BMI of 21.99. He is receiving treatment in the FOLFOX chemotherapy arm and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer cells. Despite his age, he has a fully active performance status. Additionally, the KRAS biomarker testing revealed a mutant status."
2477,white,male,69,29.48,FOLFOX,No,No,No,Yes,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 69, bmi: 29.48, treatment arm: FOLFOX, bowel perforation: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 69-year-old white male with a BMI of 29.48. He is undergoing treatment with the FOLFOX regimen and has experienced a bowel perforation. He has completed 12 cycles of chemotherapy. The histology of his cancer is well-differentiated. Despite his condition, he has a fully active performance status. His KRAS biomarker status is wild-type."
2478,white,male,54,32.05,FOLFOX,Yes,No,No,No,4,well differentiated,symptoms but ambulatory,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 54, bmi: 32.05, treatment arm: FOLFOX, adherence: Yes, chemotherapy cycles: 4, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type","The patient is a 54-year-old white male with a BMI of 32.05. He is receiving the FOLFOX treatment regimen and has been adherent to the treatment. He has completed 4 cycles of chemotherapy. The histology shows well-differentiated cancer cells. Despite experiencing symptoms, the patient is still able to ambulate. The KRAS biomarker analysis indicates a wild-type result."
2479,white,female,62,32.89,FOLFOX,No,No,No,No,12,well differentiated,fully active,mutant,No,No,No,No,No,0,"race: white, sex: female, age: 62, bmi: 32.89, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 62-year-old white female with a BMI of 32.89. She is receiving the FOLFOX treatment arm and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cancer cells. Despite her cancer diagnosis, she has a fully active performance status. The KRAS biomarker testing revealed a mutant status."
2480,white,male,64,39.53,FOLFOX,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 64, bmi: 39.53, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type",The patient is a 64-year-old white male with a BMI of 39.53. He is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer cells. The patient has a fully active performance status and his KRAS biomarker is wild-type.
2481,white,male,75,28.18,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,fully active,mutant,No,No,No,Yes,No,0,"race: white, sex: male, age: 75, bmi: 28.18, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant, adverse effect: infection: Yes","The patient is a 75-year-old white male with a BMI of 28.18. He is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer. Despite his age, he has a fully active performance status. The patient's KRAS biomarker is mutant. He has experienced an adverse effect in the form of an infection."
2482,white,male,66,31.05,FOLFOX,No,No,No,No,10,poorly differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 66, bmi: 31.05, treatment arm: FOLFOX, chemotherapy cycles: 10, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 66-year-old white male with a BMI of 31.05. He is receiving the FOLFOX treatment regimen and has completed 10 cycles of chemotherapy. His histology shows poorly differentiated cancer cells. Despite this, his performance status is fully active. Additionally, his KRAS biomarker indicates that it is wild-type."
2483,white,male,51,29.31,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 51, bmi: 29.31, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type",The patient is a 51-year-old white male with a BMI of 29.31. He is receiving treatment in the FOLFOX + Cetuximab treatment arm and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cells. The patient has a fully active performance status and his KRAS biomarker is wild-type.
2484,other,male,70,28.52,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: other, sex: male, age: 70, bmi: 28.52, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 70-year-old male of a race categorized as ""other"" with a BMI of 28.52. He is receiving treatment in the FOLFOX + Cetuximab treatment arm and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cells, and he has a fully active performance status. Additionally, the KRAS biomarker indicates that he has a wild-type status."
2485,white,male,66,28.98,FOLFIRI (KRAS mutant),No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 66, bmi: 28.98, treatment arm: FOLFIRI (KRAS mutant), chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 66-year-old white male with a BMI of 28.98. He is receiving treatment with FOLFIRI due to having a KRAS mutant status. He has completed 12 cycles of chemotherapy. The histology shows well-differentiated cancer cells. Despite his age, the patient has a fully active performance status. His KRAS biomarker is wild-type."
2486,white,female,41,23.8,FOLFOX,Yes,No,No,No,12,poorly differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 41, bmi: 23.8, treatment arm: FOLFOX, adherence: Yes, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 41-year-old white female with a BMI of 23.8. She is receiving the FOLFOX treatment regimen and has been adherent to the treatment. She has completed 12 cycles of chemotherapy. Histologically, her cancer is poorly differentiated. Despite this, her performance status is fully active. The KRAS biomarker analysis indicates that she has a wild-type KRAS status."
2487,black,female,44,28.82,FOLFOX,Yes,No,No,No,12,poorly differentiated,symptoms but ambulatory,wild-type,No,No,No,No,No,0,"race: black, sex: female, age: 44, bmi: 28.82, treatment arm: FOLFOX, adherence: Yes, chemotherapy cycles: 12, histology: poorly differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type","The patient is a 44-year-old Black female with a BMI of 28.82. She is receiving the FOLFOX treatment regimen and has been adherent to her chemotherapy cycles, completing 12 cycles so far. Her histology shows poorly differentiated cancer cells. Despite experiencing symptoms, she is still able to be ambulatory. The KRAS biomarker analysis indicates that she has a wild-type KRAS status."
2488,white,female,73,16.12,FOLFOX + Cetuximab,No,Yes,Yes,No,2,poorly differentiated,symptoms but ambulatory,wild-type,No,No,Yes,No,No,1,"race: white, sex: female, age: 73, bmi: 16.12, treatment arm: FOLFOX + Cetuximab, serious adverse effect: Yes, bowel obstruction: Yes, chemotherapy cycles: 2, histology: poorly differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type, adverse effect: diarrhea: Yes","The patient is a 73-year-old white female with a low BMI of 16.12. She is receiving treatment with FOLFOX + Cetuximab. Unfortunately, she has experienced a serious adverse effect in the form of a bowel obstruction after completing 2 cycles of chemotherapy. The histology of her cancer is poorly differentiated. Despite experiencing symptoms, she is still able to be ambulatory. Her KRAS biomarker shows that it is wild-type. Additionally, she is also experiencing diarrhea as an adverse effect of the treatment."
2489,white,female,60,39.37,FOLFOX,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 60, bmi: 39.37, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type",The patient is a 60-year-old white female with a BMI of 39.37. She is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. The histology shows well-differentiated cancer cells. The patient has a fully active performance status. The KRAS biomarker indicates that she has a wild-type mutation.
2490,white,male,73,29.78,FOLFOX + Cetuximab,No,No,No,No,12,poorly differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 73, bmi: 29.78, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 73-year-old white male with a BMI of 29.78. He is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. His cancer histology is poorly differentiated, and he has a fully active performance status. The KRAS biomarker analysis shows that he has a wild-type KRAS status."
2491,black,male,53,22.22,FOLFOX,No,Yes,No,No,12,poorly differentiated,fully active,wild-type,No,No,Yes,No,No,0,"race: black, sex: male, age: 53, bmi: 22.22, treatment arm: FOLFOX, serious adverse effect: Yes, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type, adverse effect: diarrhea: Yes","The patient is a 53-year-old Black male with a BMI of 22.22 who is undergoing treatment with FOLFOX chemotherapy. He has experienced a serious adverse effect during the treatment. He has completed 12 cycles of chemotherapy and has been diagnosed with poorly differentiated histology. Despite the adverse effect, his performance status is fully active. The KRAS biomarker testing showed that he has a wild-type KRAS status. Additionally, he has experienced diarrhea as an adverse effect during the treatment."
2492,white,female,39,20.28,FOLFOX,No,No,No,No,11,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 39, bmi: 20.28, treatment arm: FOLFOX, chemotherapy cycles: 11, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type",The patient is a 39-year-old white female with a BMI of 20.28. She is undergoing treatment with FOLFOX chemotherapy and has completed 11 cycles so far. The histology of her cancer is well-differentiated. She has a fully active performance status. The KRAS biomarker testing revealed that she has a wild-type KRAS status.
2493,other,female,49,46.71,FOLFOX + Cetuximab,Yes,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,Yes,No,0,"race: other, sex: female, age: 49, bmi: 46.71, treatment arm: FOLFOX + Cetuximab, adherence: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type, adverse effect: infection: Yes","The patient is a 49-year-old female of a race other than Caucasian. She has a high BMI of 46.71 and is currently undergoing treatment with FOLFOX + Cetuximab. She has been adherent to her treatment regimen and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cancer cells, and she has a fully active performance status. The KRAS biomarker testing indicates that she has a wild-type KRAS gene. Unfortunately, she has experienced an infection as an adverse effect during her treatment."
2494,white,male,74,23.05,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 74, bmi: 23.05, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type",The patient is a 74-year-old white male with a BMI of 23.05. He is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer cells. The patient has a fully active performance status and has a wild-type KRAS biomarker.
2495,white,female,65,40.85,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,symptoms but ambulatory,mutant,No,No,No,No,No,0,"race: white, sex: female, age: 65, bmi: 40.85, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: mutant","The patient is a 65-year-old white female with a BMI of 40.85. She is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cancer. Despite experiencing symptoms, she is still able to walk around (ambulatory). The KRAS biomarker testing revealed a mutant status."
2496,white,female,55,27.34,FOLFOX,No,No,No,No,0,poorly differentiated,fully active,mutant,No,No,No,No,No,0,"race: white, sex: female, age: 55, bmi: 27.34, treatment arm: FOLFOX, chemotherapy cycles: 0, histology: poorly differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 55-year-old white female with a BMI of 27.34. She is in the FOLFOX treatment arm and has not undergone any chemotherapy cycles yet. Her histology shows poorly differentiated cells. Despite this, her performance status is fully active. The KRAS biomarker analysis indicates a mutant status."
2497,white,male,61,31.43,FOLFOX + Cetuximab,No,No,No,No,12,poorly differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 61, bmi: 31.43, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 61-year-old white male with a BMI of 31.43. He is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. The histology of his cancer is poorly differentiated. Despite his diagnosis, the patient has a fully active performance status. His KRAS biomarker status is wild-type."
2498,white,female,64,33.19,FOLFOX + Cetuximab,No,No,No,No,9,poorly differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 64, bmi: 33.19, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 9, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 64-year-old white female with a BMI of 33.19. She is receiving treatment in the FOLFOX + Cetuximab treatment arm and has completed 9 cycles of chemotherapy. Her histology shows poorly differentiated cancer cells. Despite this, her performance status is fully active. Additionally, her KRAS biomarker indicates that she has a wild-type gene."
2499,black,male,56,36.89,FOLFOX,No,No,No,No,12,well differentiated,fully active,mutant,No,No,No,No,No,0,"race: black, sex: male, age: 56, bmi: 36.89, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 56-year-old Black male with a BMI of 36.89. He is receiving the FOLFOX treatment arm and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cells, and he has a fully active performance status. The KRAS biomarker analysis indicates a mutant status."
2500,white,female,43,21.16,FOLFOX + Cetuximab,No,No,Yes,Yes,2,poorly differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 43, bmi: 21.16, treatment arm: FOLFOX + Cetuximab, bowel obstruction: Yes, bowel perforation: Yes, chemotherapy cycles: 2, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 43-year-old white female with a BMI of 21.16. She is currently receiving treatment in the FOLFOX + Cetuximab treatment arm. She has experienced both a bowel obstruction and a bowel perforation. So far, she has completed 2 cycles of chemotherapy. The histology of her cancer is poorly differentiated. Despite these challenges, her performance status is fully active. Additionally, her KRAS biomarker status is wild-type."
2501,white,female,50,32.78,FOLFOX,No,Yes,No,No,11,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 50, bmi: 32.78, treatment arm: FOLFOX, serious adverse effect: Yes, chemotherapy cycles: 11, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 50-year-old white female with a BMI of 32.78 who is undergoing treatment with the FOLFOX chemotherapy regimen. She has experienced a serious adverse effect during her 11 chemotherapy cycles. The histology of her cancer is well differentiated. Despite the adverse effect, her performance status is fully active. The KRAS biomarker testing revealed that she has a wild-type KRAS status."
2502,white,female,67,29.74,FOLFOX,No,No,No,No,2,well differentiated,fully active,wild-type,No,No,Yes,No,No,0,"race: white, sex: female, age: 67, bmi: 29.74, treatment arm: FOLFOX, chemotherapy cycles: 2, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type, adverse effect: diarrhea: Yes","The patient is a 67-year-old white female with a BMI of 29.74. She is currently receiving the FOLFOX treatment regimen and has completed 2 cycles of chemotherapy. Her histology shows well-differentiated cancer cells. Despite experiencing diarrhea as an adverse effect, her performance status is fully active. Additionally, her KRAS biomarker indicates that she has a wild-type gene."
2503,white,female,60,25.02,FOLFOX + Cetuximab,No,No,No,No,3,well differentiated,fully active,mutant,No,Yes,No,No,No,0,"race: white, sex: female, age: 60, bmi: 25.02, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 3, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant, adverse effect: hypersensitivity: Yes","The patient is a 60-year-old white female with a BMI of 25.02. She is currently receiving treatment in the FOLFOX + Cetuximab treatment arm and has completed 3 cycles of chemotherapy. Her histology shows well-differentiated cancer, and she has a fully active performance status. The KRAS biomarker indicates a mutant status. The patient has experienced a hypersensitivity adverse effect."
2504,white,female,43,20.02,FOLFOX + Cetuximab,No,Yes,Yes,No,12,poorly differentiated,fully active,interminate,No,No,No,No,No,0,"race: white, sex: female, age: 43, bmi: 20.02, treatment arm: FOLFOX + Cetuximab, serious adverse effect: Yes, bowel obstruction: Yes, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: interminate","The patient is a 43-year-old white female with a BMI of 20.02. She is receiving treatment with FOLFOX + Cetuximab and has experienced a serious adverse effect, specifically a bowel obstruction. She has completed 12 cycles of chemotherapy. The histology of her condition is poorly differentiated. Despite these challenges, her performance status is fully active. The KRAS biomarker status is indeterminate for this patient."
2505,white,female,49,21.83,FOLFOX,Yes,No,Yes,No,0,poorly differentiated,in bed less than 50% of the time,interminate,No,No,No,No,No,0,"race: white, sex: female, age: 49, bmi: 21.83, treatment arm: FOLFOX, adherence: Yes, bowel obstruction: Yes, chemotherapy cycles: 0, histology: poorly differentiated, performance status: in bed less than 50% of the time, KRAS biomarker: interminate",The patient is a 49-year-old white female with a BMI of 21.83. She is in the FOLFOX treatment arm and is adherent to her treatment. She is currently experiencing a bowel obstruction. The patient has not yet undergone any chemotherapy cycles. Her histology shows poorly differentiated cells. She has a performance status of being in bed less than 50% of the time. The KRAS biomarker status is indeterminate.
2506,white,female,71,23.24,FOLFOX,No,No,No,No,12,well differentiated,fully active,interminate,No,No,No,No,No,0,"race: white, sex: female, age: 71, bmi: 23.24, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: interminate",The patient is a 71-year-old white female with a BMI of 23.24. She is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cancer cells. The patient has a fully active performance status. The KRAS biomarker status is indeterminate.
2507,white,male,37,24.05,FOLFOX + Cetuximab,No,Yes,Yes,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 37, bmi: 24.05, treatment arm: FOLFOX + Cetuximab, serious adverse effect: Yes, bowel obstruction: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","This patient is a 37-year-old white male with a BMI of 24.05. He is receiving treatment with FOLFOX + Cetuximab for his cancer. Unfortunately, he has experienced a serious adverse effect, specifically a bowel obstruction. He has completed 12 cycles of chemotherapy. The histology of his cancer is well-differentiated. Despite the adverse effects, his performance status is fully active. His KRAS biomarker status is wild-type."
2508,white,male,59,39.34,FOLFOX,No,No,No,No,8,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 59, bmi: 39.34, treatment arm: FOLFOX, chemotherapy cycles: 8, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type",The patient is a 59-year-old white male with a BMI of 39.34. He is undergoing treatment with the FOLFOX chemotherapy regimen and has completed 8 cycles so far. The histology of his cancer is well-differentiated. He has a fully active performance status. His KRAS biomarker status is wild-type.
2509,white,female,63,20.81,FOLFOX,No,Yes,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 63, bmi: 20.81, treatment arm: FOLFOX, serious adverse effect: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 63-year-old white female with a BMI of 20.81. She is receiving the FOLFOX treatment regimen and has experienced a serious adverse effect. She has completed 12 cycles of chemotherapy. The histology shows that the cancer is well-differentiated. Despite the adverse effect, her performance status is fully active. The KRAS biomarker indicates that she has a wild-type mutation."
2510,white,female,70,22.01,FOLFIRI + Cetuximab,No,No,No,No,4,well differentiated,fully active,mutant,No,No,No,No,No,0,"race: white, sex: female, age: 70, bmi: 22.01, treatment arm: FOLFIRI + Cetuximab, chemotherapy cycles: 4, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 70-year-old white female with a BMI of 22.01. She is undergoing treatment with FOLFIRI + Cetuximab and has completed 4 cycles of chemotherapy. Her cancer histology is well differentiated. Despite her age, she has a fully active performance status. The KRAS biomarker testing revealed a mutant status."
2511,white,female,70,25.03,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,Yes,No,No,0,"race: white, sex: female, age: 70, bmi: 25.03, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type, adverse effect: diarrhea: Yes","The patient is a 70-year-old white female with a BMI of 25.03. She is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cancer, and she has a fully active performance status. The KRAS biomarker indicates she has a wild-type status. She is experiencing diarrhea as an adverse effect of the treatment."
2512,white,female,42,22.68,FOLFOX + Cetuximab,No,Yes,No,No,2,poorly differentiated,symptoms but ambulatory,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 42, bmi: 22.68, treatment arm: FOLFOX + Cetuximab, serious adverse effect: Yes, chemotherapy cycles: 2, histology: poorly differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type","This patient is a 42-year-old white female with a BMI of 22.68. She is receiving treatment with FOLFOX + Cetuximab and has experienced a serious adverse effect. She has completed 2 cycles of chemotherapy. Her histology shows poorly differentiated cells. Despite experiencing symptoms, she is still able to be ambulatory. Her KRAS biomarker status is wild-type."
2513,white,female,46,21.18,FOLFOX,No,No,Yes,Yes,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 46, bmi: 21.18, treatment arm: FOLFOX, bowel obstruction: Yes, bowel perforation: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 46-year-old white female with a BMI of 21.18. She is receiving treatment with the FOLFOX regimen and has experienced both a bowel obstruction and perforation. She has completed 12 cycles of chemotherapy. The histology of her condition is well differentiated. Despite the bowel issues, her performance status is fully active. The KRAS biomarker analysis indicates that she has a wild-type KRAS status."
2514,white,male,59,19.67,FOLFOX,No,No,No,No,1,well differentiated,fully active,mutant,No,No,No,No,No,0,"race: white, sex: male, age: 59, bmi: 19.67, treatment arm: FOLFOX, chemotherapy cycles: 1, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant",The patient is a 59-year-old white male with a BMI of 19.67. He is currently on the FOLFOX treatment arm and has completed 1 cycle of chemotherapy. His histology shows well-differentiated cells. The patient has a fully active performance status. The KRAS biomarker analysis indicates a mutant status.
2515,white,male,62,27.67,FOLFOX,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 62, bmi: 27.67, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 62-year-old white male with a BMI of 27.67. He is receiving treatment in the FOLFOX chemotherapy arm and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer cells. Despite his cancer diagnosis, he has a fully active performance status. Additionally, his KRAS biomarker is wild-type."
2516,white,female,58,25.1,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 58, bmi: 25.1, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type",The patient is a 58-year-old white female with a BMI of 25.1. She is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cancer cells. The patient has a fully active performance status and her KRAS biomarker is wild-type.
2517,white,female,54,26.06,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 54, bmi: 26.06, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 54-year-old white female with a BMI of 26.06. She is receiving treatment in the FOLFOX + Cetuximab treatment arm and is scheduled for 12 chemotherapy cycles. Her histology shows well-differentiated cells, and she has a fully active performance status. Additionally, her KRAS biomarker is wild-type."
2518,white,male,74,26.37,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,in bed less than 50% of the time,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 74, bmi: 26.37, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: in bed less than 50% of the time, KRAS biomarker: wild-type","The patient is a 74-year-old white male with a BMI of 26.37. He is receiving treatment in the FOLFOX + Cetuximab treatment arm and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer cells. The patient's performance status indicates that he is in bed less than 50% of the time. Additionally, his KRAS biomarker status is wild-type."
2519,white,male,59,26.94,FOLFOX + Cetuximab,No,No,No,No,8,poorly differentiated,fully active,wild-type,No,No,No,No,No,1,"race: white, sex: male, age: 59, bmi: 26.94, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 8, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 59-year-old white male with a BMI of 26.94. He is receiving treatment with FOLFOX + Cetuximab and has completed 8 cycles of chemotherapy. His cancer histology is poorly differentiated, and he has a fully active performance status. The KRAS biomarker analysis shows that he has a wild-type KRAS status."
2520,white,female,55,24.77,FOLFOX,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 55, bmi: 24.77, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 55-year-old white female with a BMI of 24.77. She is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. Her cancer histology is well-differentiated, and she has a fully active performance status. The KRAS biomarker analysis shows that she has a wild-type KRAS status."
2521,white,male,52,22.98,FOLFOX,Yes,No,Yes,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,1,"race: white, sex: male, age: 52, bmi: 22.98, treatment arm: FOLFOX, adherence: Yes, bowel obstruction: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 52-year-old white male with a BMI of 22.98. He is receiving treatment with the FOLFOX regimen and has been adherent to the treatment. He has experienced a bowel obstruction. The patient has completed 12 cycles of chemotherapy. Histologically, the cancer is well-differentiated. His performance status is fully active. The KRAS biomarker shows that he has a wild-type mutation."
2522,white,female,63,33.95,FOLFIRI + Cetuximab,Yes,No,Yes,No,12,poorly differentiated,fully active,interminate,No,No,No,No,No,0,"race: white, sex: female, age: 63, bmi: 33.95, treatment arm: FOLFIRI + Cetuximab, adherence: Yes, bowel obstruction: Yes, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: interminate","The patient is a 63-year-old white female with a BMI of 33.95. She is currently receiving treatment in the FOLFIRI + Cetuximab treatment arm and has been adherent to her treatment. She is experiencing a bowel obstruction and has completed 12 cycles of chemotherapy. Her histology shows poorly differentiated cells. Despite these challenges, her performance status is fully active. The KRAS biomarker status is indeterminate for this patient."
2523,black,female,42,38.17,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,fully active,mutant,No,No,No,No,No,0,"race: black, sex: female, age: 42, bmi: 38.17, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant",The patient is a 42-year-old Black female with a BMI of 38.17. She is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cancer cells. She has a fully active performance status. The KRAS biomarker analysis indicates a mutant status.
2524,white,male,54,29.24,FOLFOX,No,No,No,No,7,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 54, bmi: 29.24, treatment arm: FOLFOX, chemotherapy cycles: 7, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type",The patient is a 54-year-old white male with a BMI of 29.24. He is receiving the FOLFOX treatment regimen and has completed 7 cycles of chemotherapy. His histology shows well-differentiated cancer cells. The patient has a fully active performance status and his KRAS biomarker is wild-type.
2525,white,female,56,27.55,FOLFOX + Cetuximab,No,Yes,No,No,12,well differentiated,fully active,wild-type,Yes,No,Yes,Yes,No,0,"race: white, sex: female, age: 56, bmi: 27.55, treatment arm: FOLFOX + Cetuximab, serious adverse effect: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type, adverse effect: thrombosis: Yes, adverse effect: diarrhea: Yes, adverse effect: infection: Yes","The patient is a 56-year-old white female with a BMI of 27.55 who is undergoing treatment with FOLFOX + Cetuximab. She has experienced a serious adverse effect during treatment. She has completed 12 chemotherapy cycles and has well-differentiated histology. Her performance status is fully active. The KRAS biomarker is wild-type. She has experienced adverse effects including thrombosis, diarrhea, and infection."
2526,other,female,64,20.33,FOLFOX,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: other, sex: female, age: 64, bmi: 20.33, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 64-year-old female of a race categorized as ""other"" with a BMI of 20.33. She is receiving treatment with the FOLFOX chemotherapy regimen and has completed 12 cycles. Her histology shows well-differentiated cancer cells. The patient has a fully active performance status and her KRAS biomarker is wild-type."
2527,white,female,45,15.86,FOLFOX + Cetuximab,Yes,No,Yes,No,12,poorly differentiated,fully active,wild-type,No,No,Yes,No,No,0,"race: white, sex: female, age: 45, bmi: 15.86, treatment arm: FOLFOX + Cetuximab, adherence: Yes, bowel obstruction: Yes, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type, adverse effect: diarrhea: Yes","The patient is a 45-year-old white female with a BMI of 15.86. She is receiving treatment with FOLFOX + Cetuximab and has been adherent to the treatment plan. She has experienced a bowel obstruction and has completed 12 cycles of chemotherapy. The histology of her cancer is poorly differentiated. Despite these challenges, her performance status is fully active. Her KRAS biomarker is wild-type. She has experienced diarrhea as an adverse effect of the treatment."
2528,white,male,68,41.4,FOLFOX,No,No,No,No,12,well differentiated,fully active,mutant,Yes,No,No,No,No,0,"race: white, sex: male, age: 68, bmi: 41.4, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant, adverse effect: thrombosis: Yes","The patient is a 68-year-old white male with a BMI of 41.4. He is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer cells. Despite his age, he has a fully active performance status. The KRAS biomarker testing revealed a mutant status. The patient has experienced an adverse effect of thrombosis."
2529,white,male,65,26.44,FOLFOX + Cetuximab,No,No,No,No,2,well differentiated,fully active,wild-type,No,No,No,Yes,No,0,"race: white, sex: male, age: 65, bmi: 26.44, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 2, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type, adverse effect: infection: Yes","The patient is a 65-year-old white male with a BMI of 26.44. He is currently receiving treatment with FOLFOX + Cetuximab and has completed 2 cycles of chemotherapy. The histology shows well-differentiated cancer cells. Despite experiencing an infection, the patient's performance status is fully active. The KRAS biomarker indicates that the patient has a wild-type gene."
2530,white,female,59,23.92,FOLFOX,No,No,No,No,12,well differentiated,fully active,mutant,No,No,No,No,No,0,"race: white, sex: female, age: 59, bmi: 23.92, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant",The patient is a 59-year-old white female with a BMI of 23.92. She is undergoing treatment with the FOLFOX chemotherapy regimen and has completed 12 cycles. Her histology shows well-differentiated cancer cells. The patient has a fully active performance status. The KRAS biomarker testing revealed a mutant status.
2531,white,male,46,26.66,FOLFOX + Cetuximab,Yes,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,1,"race: white, sex: male, age: 46, bmi: 26.66, treatment arm: FOLFOX + Cetuximab, adherence: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type",The patient is a 46-year-old white male with a BMI of 26.66. He is receiving treatment in the FOLFOX + Cetuximab treatment arm and has been adherent to the treatment. He has completed 12 chemotherapy cycles. The histology shows that the cancer is well-differentiated. The patient has a fully active performance status. The KRAS biomarker indicates that it is wild-type.
2532,white,male,42,34.29,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,fully active,mutant,No,No,No,No,No,0,"race: white, sex: male, age: 42, bmi: 34.29, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 42-year-old white male with a BMI of 34.29. He is receiving treatment in the FOLFOX + Cetuximab treatment arm and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cells, and he has a fully active performance status. The KRAS biomarker analysis indicates a mutant status."
2533,white,female,64,22.22,FOLFIRI + Cetuximab,Yes,No,No,Yes,12,well differentiated,symptoms but ambulatory,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 64, bmi: 22.22, treatment arm: FOLFIRI + Cetuximab, adherence: Yes, bowel perforation: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type","The patient is a 64-year-old white female with a BMI of 22.22. She is receiving treatment in the FOLFIRI + Cetuximab treatment arm and has been adherent to her treatment. She experienced a bowel perforation and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cells. Despite experiencing symptoms, she is still able to be ambulatory. Her KRAS biomarker indicates that it is wild-type."
2534,white,male,35,35.67,FOLFOX + Cetuximab,No,No,No,No,4,poorly differentiated,symptoms but ambulatory,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 35, bmi: 35.67, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 4, histology: poorly differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type","The patient is a 35-year-old white male with a BMI of 35.67. He is receiving treatment with FOLFOX + Cetuximab and has completed 4 cycles of chemotherapy. His histology shows poorly differentiated cancer. Despite experiencing symptoms, he is still able to ambulate. His KRAS biomarker indicates that it is wild-type."
2535,white,female,51,37.91,FOLFOX,No,No,No,No,12,well differentiated,symptoms but ambulatory,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 51, bmi: 37.91, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type","The patient is a 51-year-old white female with a BMI of 37.91. She is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cancer cells. Despite experiencing symptoms, she is still ambulatory. The KRAS biomarker analysis indicates that she has a wild-type KRAS status."
2536,white,male,40,23.99,FOLFOX + Cetuximab,No,No,No,No,11,well differentiated,fully active,interminate,No,No,No,No,No,0,"race: white, sex: male, age: 40, bmi: 23.99, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 11, histology: well differentiated, performance status: fully active, KRAS biomarker: interminate","The patient is a 40-year-old white male with a BMI of 23.99. He is receiving treatment in the FOLFOX + Cetuximab treatment arm and has completed 11 chemotherapy cycles. His histology shows well-differentiated cells, and he has a fully active performance status. The KRAS biomarker status is indeterminate."
2537,white,female,47,24.72,FOLFIRI + Cetuximab,No,No,No,No,12,well differentiated,symptoms but ambulatory,mutant,No,No,No,No,No,0,"race: white, sex: female, age: 47, bmi: 24.72, treatment arm: FOLFIRI + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: mutant","The patient is a 47-year-old white female with a BMI of 24.72. She is receiving treatment with FOLFIRI + Cetuximab and has completed 12 cycles of chemotherapy. The histology indicates well-differentiated cancer. Despite experiencing symptoms, the patient is still able to be ambulatory. The KRAS biomarker shows a mutant status."
2538,white,male,70,23.81,FOLFOX,No,No,No,No,12,poorly differentiated,symptoms but ambulatory,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 70, bmi: 23.81, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: poorly differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type","The patient is a 70-year-old white male with a BMI of 23.81. He is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. The histology of his cancer is poorly differentiated. Despite experiencing symptoms, he is still able to ambulate. His KRAS biomarker status is wild-type."
2539,white,male,59,25.8,FOLFOX,No,Yes,No,No,12,well differentiated,fully active,wild-type,No,No,Yes,No,No,0,"race: white, sex: male, age: 59, bmi: 25.8, treatment arm: FOLFOX, serious adverse effect: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type, adverse effect: diarrhea: Yes","The patient is a 59-year-old white male with a BMI of 25.8. He is receiving the FOLFOX treatment regimen and has experienced a serious adverse effect. He has completed 12 cycles of chemotherapy. The histology shows well-differentiated cancer cells. Despite the serious adverse effect, the patient's performance status is fully active. His KRAS biomarker is wild-type. Additionally, he has experienced diarrhea as an adverse effect of the treatment."
2540,white,male,42,32.23,FOLFOX,No,Yes,No,No,12,well differentiated,symptoms but ambulatory,wild-type,Yes,No,No,Yes,No,0,"race: white, sex: male, age: 42, bmi: 32.23, treatment arm: FOLFOX, serious adverse effect: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type, adverse effect: thrombosis: Yes, adverse effect: infection: Yes","The patient is a 42-year-old white male with a BMI of 32.23 who is receiving the FOLFOX treatment regimen. He has experienced serious adverse effects during the treatment, including thrombosis and infection. The patient has undergone 12 cycles of chemotherapy and has well-differentiated histology. Despite experiencing symptoms, he is still able to be ambulatory. His KRAS biomarker status is wild-type."
2541,white,female,63,37.45,FOLFOX,No,No,No,No,12,poorly differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 63, bmi: 37.45, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 63-year-old white female with a BMI of 37.45. She is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. Her histology shows poorly differentiated cells. Despite this, her performance status is fully active. Additionally, her KRAS biomarker indicates that she has a wild-type status."
2542,white,male,67,28.69,FOLFIRI (KRAS mutant),No,No,No,No,12,well differentiated,fully active,mutant,No,No,No,No,No,0,"race: white, sex: male, age: 67, bmi: 28.69, treatment arm: FOLFIRI (KRAS mutant), chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 67-year-old white male with a BMI of 28.69. He is receiving treatment with the FOLFIRI regimen for KRAS mutant cancer. He has completed 12 cycles of chemotherapy. His cancer histology is well-differentiated, and he has a fully active performance status."
2543,white,female,45,29.76,FOLFOX,Yes,Yes,No,No,12,poorly differentiated,symptoms but ambulatory,wild-type,No,No,Yes,No,No,0,"race: white, sex: female, age: 45, bmi: 29.76, treatment arm: FOLFOX, adherence: Yes, serious adverse effect: Yes, chemotherapy cycles: 12, histology: poorly differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type, adverse effect: diarrhea: Yes","The patient is a 45-year-old white female with a BMI of 29.76. She is receiving the FOLFOX treatment regimen and has been adherent to the treatment. She experienced a serious adverse effect during the treatment. The patient completed 12 cycles of chemotherapy and has a histology of poorly differentiated cancer. Despite experiencing symptoms, she is still able to be ambulatory. Her KRAS biomarker is wild-type. Additionally, she has experienced diarrhea as an adverse effect during the treatment."
2544,black,female,51,35.58,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: black, sex: female, age: 51, bmi: 35.58, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 51-year-old Black female with a BMI of 35.58. She is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. The histology shows well-differentiated cancer cells. The patient's performance status is fully active, and her KRAS biomarker is wild-type."
2545,white,female,44,41.87,FOLFIRI (KRAS mutant),No,No,No,No,12,well differentiated,fully active,mutant,No,No,No,No,No,0,"race: white, sex: female, age: 44, bmi: 41.87, treatment arm: FOLFIRI (KRAS mutant), chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 44-year-old white female with a BMI of 41.87. She is receiving treatment in the FOLFIRI chemotherapy arm for KRAS mutant status. She has completed 12 cycles of chemotherapy. The histology indicates well-differentiated cancer. Despite her cancer diagnosis, she has a fully active performance status."
2546,white,male,43,32.41,FOLFOX,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 43, bmi: 32.41, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type",The patient is a 43-year-old white male with a BMI of 32.41. He is receiving the FOLFOX treatment arm and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cells. The patient has a fully active performance status and his KRAS biomarker is wild-type.
2547,white,male,50,27.41,FOLFOX,No,Yes,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 50, bmi: 27.41, treatment arm: FOLFOX, serious adverse effect: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 50-year-old white male with a BMI of 27.41. He is receiving the FOLFOX treatment arm for his well-differentiated histology. He has experienced a serious adverse effect during his 12 chemotherapy cycles. Despite this, his performance status is fully active. His KRAS biomarker is wild-type."
2548,other,male,61,29.27,FOLFIRI (KRAS mutant),No,Yes,No,No,12,well differentiated,fully active,mutant,No,No,No,No,No,0,"race: other, sex: male, age: 61, bmi: 29.27, treatment arm: FOLFIRI (KRAS mutant), serious adverse effect: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 61-year-old male of a race categorized as ""other"" with a BMI of 29.27. He is undergoing treatment with the FOLFIRI regimen for his KRAS mutant status. Unfortunately, he has experienced a serious adverse effect during the treatment. He has completed 12 cycles of chemotherapy. His histology shows well-differentiated cells, and his performance status is fully active despite the adverse effect."
2549,white,male,71,25.22,FOLFOX + Cetuximab,No,Yes,No,No,10,well differentiated,symptoms but ambulatory,wild-type,No,No,No,No,No,1,"race: white, sex: male, age: 71, bmi: 25.22, treatment arm: FOLFOX + Cetuximab, serious adverse effect: Yes, chemotherapy cycles: 10, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type","The patient is a 71-year-old white male with a BMI of 25.22. He is receiving treatment with FOLFOX + Cetuximab and has experienced a serious adverse effect. He has completed 10 cycles of chemotherapy. His histology shows well-differentiated cells. Despite experiencing symptoms, he is still able to be ambulatory. His KRAS biomarker is wild-type."
2550,white,female,69,30.47,FOLFOX + Cetuximab,Yes,No,No,No,4,poorly differentiated,fully active,wild-type,No,No,Yes,No,No,0,"race: white, sex: female, age: 69, bmi: 30.47, treatment arm: FOLFOX + Cetuximab, adherence: Yes, chemotherapy cycles: 4, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type, adverse effect: diarrhea: Yes","The patient is a 69-year-old white female with a BMI of 30.47. She is currently receiving treatment in the FOLFOX + Cetuximab treatment arm and has been adherent to her treatment. She has completed 4 chemotherapy cycles. Her histology shows poorly differentiated cancer cells. Despite this, her performance status is fully active. The KRAS biomarker indicates that she has a wild-type gene. The patient has experienced diarrhea as an adverse effect of the treatment."
2551,white,male,49,43.12,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,fully active,interminate,No,No,No,No,No,1,"race: white, sex: male, age: 49, bmi: 43.12, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: interminate",The patient is a 49-year-old white male with a BMI of 43.12. He is receiving treatment in the FOLFOX + Cetuximab treatment arm and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer cells. The patient has a fully active performance status. The KRAS biomarker status is indeterminate.
2552,white,male,41,44.56,FOLFOX + Cetuximab,No,No,No,No,9,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 41, bmi: 44.56, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 9, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type",The patient is a 41-year-old white male with a BMI of 44.56. He is receiving treatment with FOLFOX + Cetuximab and has completed 9 cycles of chemotherapy. His histology shows well-differentiated cancer cells. The patient has a fully active performance status and his KRAS biomarker is wild-type.
2553,white,female,63,30.2,FOLFOX,No,No,Yes,No,1,well differentiated,fully active,mutant,No,No,No,No,No,0,"race: white, sex: female, age: 63, bmi: 30.2, treatment arm: FOLFOX, bowel obstruction: Yes, chemotherapy cycles: 1, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 63-year-old white female with a BMI of 30.2. She is currently receiving treatment with FOLFOX for her well-differentiated histology. She has experienced a bowel obstruction and has completed one cycle of chemotherapy. Despite this, her performance status is fully active. Additionally, her KRAS biomarker is mutant."
2554,white,male,41,31.35,FOLFOX + Cetuximab,No,Yes,No,No,12,well differentiated,symptoms but ambulatory,mutant,No,No,No,No,No,1,"race: white, sex: male, age: 41, bmi: 31.35, treatment arm: FOLFOX + Cetuximab, serious adverse effect: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: mutant","The patient is a 41-year-old white male with a BMI of 31.35. He is receiving treatment with FOLFOX + Cetuximab and has experienced a serious adverse effect. He has completed 12 cycles of chemotherapy. The histology shows well-differentiated cells. Despite experiencing symptoms, the patient is still able to be ambulatory. The KRAS biomarker indicates a mutant status."
2555,white,female,64,25.68,FOLFOX,No,No,No,No,12,well differentiated,fully active,mutant,No,No,No,No,No,0,"race: white, sex: female, age: 64, bmi: 25.68, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 64-year-old white female with a BMI of 25.68. She is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. Her cancer histology is well-differentiated, and she has a fully active performance status. The KRAS biomarker testing revealed a mutant status."
2556,white,male,40,29.03,FOLFOX,No,No,No,No,12,well differentiated,symptoms but ambulatory,wild-type,No,No,Yes,No,No,0,"race: white, sex: male, age: 40, bmi: 29.03, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type, adverse effect: diarrhea: Yes",The patient is a 40-year-old white male with a BMI of 29.03 who is receiving the FOLFOX treatment arm for his well-differentiated histology. He has completed 12 cycles of chemotherapy and has a performance status of experiencing symptoms but still able to walk around. His KRAS biomarker is wild-type. The patient is experiencing diarrhea as an adverse effect of the treatment.
2557,white,female,76,23.36,FOLFOX,No,No,No,No,12,poorly differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 76, bmi: 23.36, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 76-year-old white female with a BMI of 23.36. She is undergoing treatment with the FOLFOX chemotherapy regimen and has completed 12 cycles. Her cancer histology is poorly differentiated. Despite her age, she has a fully active performance status. The KRAS biomarker testing revealed that she has a wild-type KRAS status."
2558,white,male,57,23.2,FOLFOX + Cetuximab,No,No,No,No,10,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 57, bmi: 23.2, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 10, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 57-year-old white male with a BMI of 23.2. He is receiving treatment with FOLFOX + Cetuximab and has completed 10 cycles of chemotherapy. His cancer histology is well-differentiated, and he has a fully active performance status. The KRAS biomarker analysis shows that he has a wild-type KRAS status."
2559,white,female,35,34.21,FOLFOX,No,No,No,No,12,well differentiated,symptoms but ambulatory,mutant,No,No,No,No,No,0,"race: white, sex: female, age: 35, bmi: 34.21, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: mutant","The patient is a 35-year-old white female with a BMI of 34.21. She is receiving treatment with FOLFOX chemotherapy and has completed 12 cycles. Her histology shows well-differentiated cancer cells. Despite experiencing symptoms, she is still able to walk around (ambulatory). The KRAS biomarker testing revealed a mutation."
2560,white,female,64,22.81,FOLFOX,Yes,No,No,Yes,12,well differentiated,fully active,mutant,No,No,No,No,No,0,"race: white, sex: female, age: 64, bmi: 22.81, treatment arm: FOLFOX, adherence: Yes, bowel perforation: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 64-year-old white female with a BMI of 22.81. She is receiving treatment with the FOLFOX regimen and has been adherent to the treatment. She experienced a bowel perforation during the course of treatment. She completed 12 cycles of chemotherapy. The histology of her cancer is well differentiated. Despite the bowel perforation, her performance status is fully active. The KRAS biomarker testing revealed a mutant status."
2561,white,male,63,30.73,FOLFOX,No,No,No,No,12,poorly differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 63, bmi: 30.73, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 63-year-old white male with a BMI of 30.73. He is undergoing treatment with the FOLFOX chemotherapy regimen and has completed 12 cycles. His cancer histology is poorly differentiated. Despite his cancer diagnosis, he has a fully active performance status. Additionally, his KRAS biomarker status is wild-type."
2562,white,female,63,26.06,FOLFOX + Cetuximab,No,Yes,No,No,12,well differentiated,fully active,mutant,No,Yes,No,No,No,0,"race: white, sex: female, age: 63, bmi: 26.06, treatment arm: FOLFOX + Cetuximab, serious adverse effect: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant, adverse effect: hypersensitivity: Yes","The patient is a 63-year-old white female with a BMI of 26.06. She is receiving treatment with FOLFOX + Cetuximab and has experienced a serious adverse effect. She has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cells, and her performance status is fully active. The KRAS biomarker indicates a mutant status. Additionally, she has experienced a hypersensitivity adverse effect."
2563,white,male,41,29.54,FOLFOX,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 41, bmi: 29.54, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 41-year-old white male with a BMI of 29.54. He is undergoing treatment with the FOLFOX chemotherapy regimen and has completed 12 cycles so far. His histology shows well-differentiated cancer cells. Despite his cancer diagnosis, he has a fully active performance status. The KRAS biomarker analysis indicates that he has a wild-type KRAS gene."
2564,white,male,49,30.07,FOLFOX,No,No,No,No,1,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 49, bmi: 30.07, treatment arm: FOLFOX, chemotherapy cycles: 1, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type",The patient is a 49-year-old white male with a BMI of 30.07. He is receiving the FOLFOX treatment regimen and has completed one cycle of chemotherapy. His cancer histology is well-differentiated. The patient has a fully active performance status. His KRAS biomarker status is wild-type.
2565,white,female,57,23.6,FOLFOX,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 57, bmi: 23.6, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 57-year-old white female with a BMI of 23.6. She is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. Her cancer histology is well-differentiated, and she has a fully active performance status. The KRAS biomarker analysis shows that she has a wild-type KRAS status."
2566,white,female,65,18.75,FOLFOX + Cetuximab,No,No,No,No,12,poorly differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 65, bmi: 18.75, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 65-year-old white female with a BMI of 18.75. She is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. Her cancer histology is poorly differentiated. Despite her diagnosis, she has a fully active performance status. Additionally, her KRAS biomarker status is wild-type."
2567,white,female,38,19.84,FOLFIRI,Yes,No,No,No,12,well differentiated,symptoms but ambulatory,wild-type,No,No,No,No,No,1,"race: white, sex: female, age: 38, bmi: 19.84, treatment arm: FOLFIRI, adherence: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type","The patient is a 38-year-old white female with a BMI of 19.84. She is receiving treatment with the FOLFIRI regimen and has been adherent to the treatment. She has completed 12 cycles of chemotherapy. The histology of her cancer is well-differentiated. Despite experiencing symptoms, she is still able to be ambulatory. Her KRAS biomarker status is wild-type."
2568,white,male,70,27.19,FOLFOX + Cetuximab,No,Yes,No,No,5,poorly differentiated,symptoms but ambulatory,wild-type,No,No,Yes,No,No,1,"race: white, sex: male, age: 70, bmi: 27.19, treatment arm: FOLFOX + Cetuximab, serious adverse effect: Yes, chemotherapy cycles: 5, histology: poorly differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type, adverse effect: diarrhea: Yes","The patient is a 70-year-old white male with a BMI of 27.19 who is receiving treatment with FOLFOX + Cetuximab. He has experienced a serious adverse effect during his treatment, specifically diarrhea. He has completed 5 cycles of chemotherapy and has a histology of poorly differentiated cancer. Despite experiencing symptoms, he is still able to be ambulatory. His KRAS biomarker shows that he is wild-type."
2569,white,male,43,39.51,FOLFOX,Yes,No,No,No,12,well differentiated,symptoms but ambulatory,interminate,No,No,No,No,No,0,"race: white, sex: male, age: 43, bmi: 39.51, treatment arm: FOLFOX, adherence: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: interminate","The patient is a 43-year-old white male with a BMI of 39.51. He is receiving the FOLFOX treatment regimen and has been adherent to the treatment. He has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer cells. Despite experiencing symptoms, he is still able to ambulate. The KRAS biomarker status is indeterminate for this patient."
2570,white,female,73,27.55,FOLFOX,No,No,Yes,No,12,poorly differentiated,fully active,interminate,No,No,No,No,No,0,"race: white, sex: female, age: 73, bmi: 27.55, treatment arm: FOLFOX, bowel obstruction: Yes, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: interminate","The patient is a 73-year-old white female with a BMI of 27.55. She is receiving the FOLFOX treatment regimen and has experienced a bowel obstruction. She has completed 12 cycles of chemotherapy. The histology of her cancer is poorly differentiated. Despite these challenges, her performance status is fully active. The KRAS biomarker status is indeterminate."
2571,black,female,40,24.98,FOLFOX,No,No,No,No,3,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: black, sex: female, age: 40, bmi: 24.98, treatment arm: FOLFOX, chemotherapy cycles: 3, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type",The patient is a 40-year-old Black female with a BMI of 24.98. She is receiving the FOLFOX treatment regimen and has completed 3 cycles of chemotherapy. The histology of her cancer is well-differentiated. She has a fully active performance status. The KRAS biomarker testing revealed that she has a wild-type KRAS status.
2572,white,female,57,29.16,FOLFOX + Cetuximab,No,No,No,No,11,poorly differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 57, bmi: 29.16, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 11, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 57-year-old white female with a BMI of 29.16. She is receiving treatment with FOLFOX + Cetuximab and has completed 11 cycles of chemotherapy. Her histology shows poorly differentiated cancer cells. Despite this, her performance status is fully active. Additionally, her KRAS biomarker status is wild-type."
2573,white,female,57,28.56,FOLFOX + Cetuximab,No,No,No,No,8,well differentiated,fully active,mutant,No,No,No,No,No,0,"race: white, sex: female, age: 57, bmi: 28.56, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 8, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant",The patient is a 57-year-old white female with a BMI of 28.56. She is receiving treatment with FOLFOX + Cetuximab and has completed 8 cycles of chemotherapy. Her histology shows well-differentiated cancer cells. The patient has a fully active performance status. The KRAS biomarker indicates that she has a mutant form of the gene.
2574,white,male,42,35.15,FOLFOX + Cetuximab,No,No,No,No,12,poorly differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 42, bmi: 35.15, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 42-year-old white male with a BMI of 35.15. He is receiving treatment with FOLFOX + Cetuximab and is scheduled for 12 cycles of chemotherapy. His histology shows poorly differentiated cancer cells. Despite this, his performance status is fully active. Additionally, his KRAS biomarker indicates that it is wild-type."
2575,black,male,42,27.17,FOLFOX,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: black, sex: male, age: 42, bmi: 27.17, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type",The patient is a 42-year-old Black male with a BMI of 27.17. He is receiving the FOLFOX treatment arm and has completed 12 cycles of chemotherapy. The histology shows well-differentiated cancer cells. The patient has a fully active performance status. The KRAS biomarker indicates that the patient has a wild-type KRAS gene.
2576,black,male,40,23.84,FOLFOX + Cetuximab,No,No,No,No,9,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: black, sex: male, age: 40, bmi: 23.84, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 9, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type",The patient is a 40-year-old Black male with a BMI of 23.84. He is receiving treatment with FOLFOX + Cetuximab and has completed 9 cycles of chemotherapy. His histology shows well-differentiated cancer cells. The patient has a fully active performance status and his KRAS biomarker is wild-type.
2577,white,female,75,27.28,FOLFIRI,No,No,No,No,2,poorly differentiated,fully active,wild-type,No,No,No,No,No,1,"race: white, sex: female, age: 75, bmi: 27.28, treatment arm: FOLFIRI, chemotherapy cycles: 2, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 75-year-old white female with a BMI of 27.28. She is currently receiving the FOLFIRI treatment regimen and has completed 2 cycles of chemotherapy. The histology of her cancer is poorly differentiated. Despite her age, she has a fully active performance status. Additionally, her KRAS biomarker status is wild-type."
2578,white,male,37,29.8,FOLFOX + Cetuximab,Yes,No,No,Yes,12,poorly differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 37, bmi: 29.8, treatment arm: FOLFOX + Cetuximab, adherence: Yes, bowel perforation: Yes, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 37-year-old white male with a BMI of 29.8. He is receiving treatment with FOLFOX + Cetuximab and has been adherent to the treatment. He experienced a bowel perforation and has completed 12 cycles of chemotherapy. The histology shows poorly differentiated cells. Despite the bowel perforation, the patient's performance status is fully active. The KRAS biomarker indicates that it is wild-type."
2579,black,female,58,29.48,FOLFOX + Cetuximab,Yes,No,No,Yes,12,well differentiated,fully active,mutant,No,No,No,No,No,0,"race: black, sex: female, age: 58, bmi: 29.48, treatment arm: FOLFOX + Cetuximab, adherence: Yes, bowel perforation: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 58-year-old Black female with a BMI of 29.48. She is receiving treatment with FOLFOX + Cetuximab and has been adherent to the treatment. She experienced a bowel perforation and has completed 12 cycles of chemotherapy. The histology shows well-differentiated cells, and her performance status is fully active. The KRAS biomarker indicates a mutant status."
2580,white,female,52,42.68,FOLFOX,No,No,No,No,12,well differentiated,fully active,mutant,No,No,No,No,No,0,"race: white, sex: female, age: 52, bmi: 42.68, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 52-year-old white female with a BMI of 42.68. She is receiving treatment with the FOLFOX chemotherapy regimen and is scheduled for 12 cycles. The histology of her cancer is well differentiated. Despite her high BMI, her performance status is fully active. The KRAS biomarker testing revealed a mutant status."
2581,black,female,61,31.3,FOLFOX + Cetuximab,No,Yes,No,No,12,well differentiated,fully active,mutant,No,No,No,Yes,No,0,"race: black, sex: female, age: 61, bmi: 31.3, treatment arm: FOLFOX + Cetuximab, serious adverse effect: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant, adverse effect: infection: Yes","The patient is a 61-year-old Black female with a BMI of 31.3. She is receiving treatment with FOLFOX + Cetuximab and has experienced a serious adverse effect. She has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cells, and her performance status is fully active. The KRAS biomarker is mutant. Additionally, she has experienced an infection as an adverse effect."
2582,white,male,46,44.02,FOLFOX,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 46, bmi: 44.02, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 46-year-old white male with a BMI of 44.02. He is receiving treatment with the FOLFOX chemotherapy regimen and has completed 12 cycles. His cancer histology is well-differentiated, and he has a fully active performance status. The KRAS biomarker analysis shows that he has a wild-type KRAS status."
2583,white,female,55,27.53,FOLFOX + Cetuximab,Yes,No,No,No,12,well differentiated,fully active,wild-type,Yes,No,No,No,No,0,"race: white, sex: female, age: 55, bmi: 27.53, treatment arm: FOLFOX + Cetuximab, adherence: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type, adverse effect: thrombosis: Yes","The patient is a 55-year-old white female with a BMI of 27.53. She is receiving treatment in the FOLFOX + Cetuximab treatment arm and has been adherent to her chemotherapy cycles, completing 12 cycles so far. Her histology shows well-differentiated cells, and she has a fully active performance status. The KRAS biomarker indicates that she is wild-type. Unfortunately, she has experienced a thrombosis as an adverse effect during her treatment."
2584,black,male,76,36.57,FOLFOX,No,No,No,No,12,well differentiated,fully active,mutant,No,No,No,No,No,0,"race: black, sex: male, age: 76, bmi: 36.57, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 76-year-old Black male with a BMI of 36.57. He is receiving the FOLFOX treatment arm and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer cells. Despite his age, he has a fully active performance status. The KRAS biomarker analysis indicates a mutant status."
2585,white,female,72,23.19,FOLFOX,No,Yes,No,No,12,well differentiated,fully active,mutant,No,No,No,No,No,0,"race: white, sex: female, age: 72, bmi: 23.19, treatment arm: FOLFOX, serious adverse effect: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 72-year-old white female with a BMI of 23.19. She is undergoing treatment with the FOLFOX regimen and has experienced a serious adverse effect. She has completed 12 cycles of chemotherapy. The histology shows that the cancer is well-differentiated. Despite the treatment, the patient's performance status is fully active. The KRAS biomarker analysis indicates that the patient has a mutant KRAS status."
2586,white,female,61,23.36,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 61, bmi: 23.36, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type",The patient is a 61-year-old white female with a BMI of 23.36. She is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. The histology shows well-differentiated cancer cells. The patient has a fully active performance status. The KRAS biomarker indicates that the patient has a wild-type gene.
2587,white,male,70,31.05,FOLFOX,No,No,No,No,0,well differentiated,symptoms but ambulatory,wild-type,No,No,No,No,No,1,"race: white, sex: male, age: 70, bmi: 31.05, treatment arm: FOLFOX, chemotherapy cycles: 0, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type","This patient is a 70-year-old white male with a BMI of 31.05. He is enrolled in the FOLFOX treatment arm but has not started chemotherapy cycles yet. His histology shows well-differentiated cancer cells. Despite experiencing symptoms, he is still able to be ambulatory. The KRAS biomarker analysis indicates that he has a wild-type KRAS gene."
2588,white,male,47,30.01,FOLFOX,No,No,No,No,12,poorly differentiated,fully active,wild-type,No,No,No,Yes,No,0,"race: white, sex: male, age: 47, bmi: 30.01, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type, adverse effect: infection: Yes","The patient is a 47-year-old white male with a BMI of 30.01. He is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. His histology shows poorly differentiated cancer cells. Despite this, his performance status is fully active. The KRAS biomarker indicates that he has a wild-type gene. The patient has experienced an adverse effect in the form of an infection."
2589,white,male,56,29.89,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 56, bmi: 29.89, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 56-year-old white male with a BMI of 29.89. He is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. His cancer histology is well-differentiated, and he has a fully active performance status. The KRAS biomarker analysis shows that he has a wild-type KRAS status."
2590,white,female,62,23.83,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 62, bmi: 23.83, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type",The patient is a 62-year-old white female with a BMI of 23.83. She is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. Her cancer histology is well-differentiated. The patient has a fully active performance status and her KRAS biomarker is wild-type.
2591,white,male,38,26.92,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,fully active,mutant,No,No,No,No,No,0,"race: white, sex: male, age: 38, bmi: 26.92, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 38-year-old white male with a BMI of 26.92. He is receiving treatment with FOLFOX + Cetuximab and is scheduled for 12 cycles of chemotherapy. His cancer histology is well-differentiated, and he has a fully active performance status. The KRAS biomarker analysis shows a mutant status."
2592,black,female,56,37.47,FOLFOX,No,No,No,No,12,well differentiated,fully active,interminate,No,No,No,No,No,0,"race: black, sex: female, age: 56, bmi: 37.47, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: interminate",The patient is a 56-year-old Black female with a BMI of 37.47. She is receiving the FOLFOX treatment arm and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cells. She has a fully active performance status. The KRAS biomarker status is indeterminate.
2593,white,male,49,26.26,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 49, bmi: 26.26, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 49-year-old white male with a BMI of 26.26. He is receiving treatment in the FOLFOX + Cetuximab treatment arm and is scheduled for 12 chemotherapy cycles. His histology shows well-differentiated cancer, and he has a fully active performance status. Additionally, his KRAS biomarker is wild-type."
2594,white,female,50,26.68,FOLFIRI + Cetuximab,Yes,No,No,No,12,poorly differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 50, bmi: 26.68, treatment arm: FOLFIRI + Cetuximab, adherence: Yes, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 50-year-old white female with a BMI of 26.68. She is receiving treatment in the FOLFIRI + Cetuximab treatment arm and has been adherent to her chemotherapy regimen for 12 cycles. Her histology shows poorly differentiated cancer cells. Despite this, her performance status is fully active. Additionally, her KRAS biomarker indicates that it is wild-type."
2595,white,male,47,27.05,FOLFOX + Cetuximab,No,No,Yes,No,12,well differentiated,fully active,wild-type,No,No,Yes,No,No,0,"race: white, sex: male, age: 47, bmi: 27.05, treatment arm: FOLFOX + Cetuximab, bowel obstruction: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type, adverse effect: diarrhea: Yes","The patient is a 47-year-old white male with a BMI of 27.05. He is receiving treatment with FOLFOX + Cetuximab for bowel obstruction. He has completed 12 cycles of chemotherapy and has well-differentiated histology. Despite experiencing diarrhea as an adverse effect, his performance status is fully active. Additionally, his KRAS biomarker status is wild-type."
2596,white,male,49,26.07,FOLFOX + Cetuximab,No,No,No,Yes,1,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 49, bmi: 26.07, treatment arm: FOLFOX + Cetuximab, bowel perforation: Yes, chemotherapy cycles: 1, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","This patient is a 49-year-old white male with a BMI of 26.07. He is receiving treatment with FOLFOX + Cetuximab for his cancer. He has experienced a bowel perforation and has completed one cycle of chemotherapy. The histology of his cancer is well differentiated. Despite the bowel perforation, his performance status is fully active. His KRAS biomarker status is wild-type."
2597,white,female,44,21.45,FOLFOX + Cetuximab,Yes,No,Yes,Yes,2,poorly differentiated,symptoms but ambulatory,wild-type,No,No,No,No,No,1,"race: white, sex: female, age: 44, bmi: 21.45, treatment arm: FOLFOX + Cetuximab, adherence: Yes, bowel obstruction: Yes, bowel perforation: Yes, chemotherapy cycles: 2, histology: poorly differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type","The patient is a 44-year-old white female with a BMI of 21.45. She is receiving treatment with FOLFOX + Cetuximab and is adherent to her treatment. She has experienced a bowel obstruction and perforation. She has completed 2 cycles of chemotherapy. The histology of her cancer is poorly differentiated. Despite experiencing symptoms, she is still able to be ambulatory. Her KRAS biomarker status is wild-type."
2598,black,male,68,23.55,FOLFOX + Cetuximab,No,No,No,No,7,poorly differentiated,symptoms but ambulatory,interminate,No,No,No,No,No,0,"race: black, sex: male, age: 68, bmi: 23.55, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 7, histology: poorly differentiated, performance status: symptoms but ambulatory, KRAS biomarker: interminate","The patient is a 68-year-old Black male with a BMI of 23.55. He is currently receiving treatment in the FOLFOX + Cetuximab treatment arm and has completed 7 cycles of chemotherapy. His histology shows poorly differentiated cancer cells. Despite experiencing symptoms, he is still able to walk around (ambulatory). The KRAS biomarker status is indeterminate for this patient."
2599,white,male,72,25.76,FOLFIRI,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,1,"race: white, sex: male, age: 72, bmi: 25.76, treatment arm: FOLFIRI, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 72-year-old white male with a BMI of 25.76. He is receiving treatment with the FOLFIRI chemotherapy regimen and has completed 12 cycles. His cancer histology is well-differentiated, and he has a fully active performance status. The KRAS biomarker testing shows that he has a wild-type KRAS status."
2600,white,male,61,20.44,FOLFOX + Cetuximab,No,No,No,No,12,poorly differentiated,fully active,mutant,No,No,No,No,No,1,"race: white, sex: male, age: 61, bmi: 20.44, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 61-year-old white male with a BMI of 20.44. He is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. The histology of his condition is poorly differentiated. Despite this, his performance status is fully active. Additionally, the KRAS biomarker indicates that he has a mutant status."
2601,black,female,75,33.16,FOLFOX + Cetuximab,No,Yes,No,No,12,well differentiated,in bed less than 50% of the time,wild-type,No,No,No,No,No,0,"race: black, sex: female, age: 75, bmi: 33.16, treatment arm: FOLFOX + Cetuximab, serious adverse effect: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: in bed less than 50% of the time, KRAS biomarker: wild-type",The patient is a 75-year-old Black female with a BMI of 33.16. She is undergoing treatment with FOLFOX + Cetuximab and has experienced a serious adverse effect. She has completed 12 cycles of chemotherapy. The histology shows well-differentiated cancer. Her performance status indicates that she is in bed less than 50% of the time. The KRAS biomarker analysis revealed that she has a wild-type KRAS status.
2602,white,female,43,27.1,FOLFOX,No,No,No,No,6,poorly differentiated,symptoms but ambulatory,mutant,No,No,Yes,No,No,0,"race: white, sex: female, age: 43, bmi: 27.1, treatment arm: FOLFOX, chemotherapy cycles: 6, histology: poorly differentiated, performance status: symptoms but ambulatory, KRAS biomarker: mutant, adverse effect: diarrhea: Yes","The patient is a 43-year-old white female with a BMI of 27.1 who is undergoing treatment with the FOLFOX chemotherapy regimen. She has completed 6 cycles of chemotherapy. Her cancer histology is poorly differentiated. Despite experiencing symptoms, she is still able to be ambulatory. The KRAS biomarker testing revealed a mutant result. The patient is experiencing diarrhea as an adverse effect of the treatment."
2603,white,female,48,23.02,FOLFOX + Cetuximab,No,No,No,No,12,poorly differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 48, bmi: 23.02, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 48-year-old white female with a BMI of 23.02. She is receiving treatment in the FOLFOX + Cetuximab treatment arm and is scheduled for 12 chemotherapy cycles. The histology of her condition is poorly differentiated. Despite this, her performance status is fully active. Additionally, the KRAS biomarker indicates that she has a wild-type status."
2604,white,male,39,27.13,FOLFOX + Cetuximab,No,No,No,No,3,well differentiated,fully active,wild-type,No,Yes,No,No,No,0,"race: white, sex: male, age: 39, bmi: 27.13, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 3, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type, adverse effect: hypersensitivity: Yes","The patient is a 39-year-old white male with a BMI of 27.13. He is receiving treatment with FOLFOX + Cetuximab and has completed 3 chemotherapy cycles. His histology shows well-differentiated cancer, and he has a fully active performance status. The KRAS biomarker is wild-type. The patient has experienced a hypersensitivity adverse effect."
2605,white,female,47,25.26,FOLFIRI (KRAS mutant),No,No,No,No,2,poorly differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 47, bmi: 25.26, treatment arm: FOLFIRI (KRAS mutant), chemotherapy cycles: 2, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 47-year-old white female with a BMI of 25.26. She is receiving treatment with FOLFIRI for KRAS mutant cancer. She has completed 2 cycles of chemotherapy. The histology of her cancer is poorly differentiated. Despite her diagnosis, she has a fully active performance status. Her KRAS biomarker is wild-type."
2606,black,female,53,24.1,FOLFOX,No,No,No,No,12,well differentiated,fully active,mutant,No,Yes,No,No,No,0,"race: black, sex: female, age: 53, bmi: 24.1, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant, adverse effect: hypersensitivity: Yes",The patient is a 53-year-old Black female with a BMI of 24.1 who is receiving the FOLFOX treatment regimen for her well-differentiated histology. She has completed 12 cycles of chemotherapy and has a fully active performance status. The KRAS biomarker testing revealed a mutant status. The patient has experienced hypersensitivity as an adverse effect during her treatment.
2607,white,female,59,19.63,FOLFOX + Cetuximab,No,No,Yes,No,6,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 59, bmi: 19.63, treatment arm: FOLFOX + Cetuximab, bowel obstruction: Yes, chemotherapy cycles: 6, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 59-year-old white female with a BMI of 19.63. She is receiving treatment in the FOLFOX + Cetuximab treatment arm. She has a bowel obstruction and has completed 6 cycles of chemotherapy. The histology shows that the cancer is well-differentiated. Despite the bowel obstruction, her performance status is fully active. The KRAS biomarker indicates that she has a wild-type mutation."
2608,white,male,40,27.41,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,1,"race: white, sex: male, age: 40, bmi: 27.41, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 40-year-old white male with a BMI of 27.41. He is receiving treatment in the FOLFOX + Cetuximab treatment arm and is scheduled for 12 chemotherapy cycles. His histology indicates well-differentiated cancer, and he has a fully active performance status. The KRAS biomarker testing shows that he has a wild-type KRAS status."
2609,other,male,35,36.67,FOLFOX + Cetuximab,No,No,Yes,No,1,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: other, sex: male, age: 35, bmi: 36.67, treatment arm: FOLFOX + Cetuximab, bowel obstruction: Yes, chemotherapy cycles: 1, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 35-year-old male of a race categorized as ""other"" with a BMI of 36.67. He is currently receiving treatment in the FOLFOX + Cetuximab treatment arm. The patient is experiencing a bowel obstruction and has completed one cycle of chemotherapy. Histology results indicate that the cancer is well-differentiated. Despite the bowel obstruction, the patient's performance status is fully active. The KRAS biomarker testing revealed a wild-type result."
2610,white,female,53,28.69,FOLFOX + Cetuximab,No,No,No,No,12,poorly differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 53, bmi: 28.69, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 53-year-old white female with a BMI of 28.69. She is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. Her histology shows poorly differentiated cancer cells. Despite this, her performance status is fully active. Additionally, her KRAS biomarker indicates that it is wild-type."
2611,white,female,65,24.42,FOLFOX + Cetuximab,No,No,No,No,12,poorly differentiated,fully active,mutant,No,No,No,No,No,0,"race: white, sex: female, age: 65, bmi: 24.42, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 65-year-old white female with a BMI of 24.42. She is receiving treatment in the FOLFOX + Cetuximab treatment arm and has completed 12 cycles of chemotherapy. Her histology shows poorly differentiated cancer cells. Despite this, her performance status is fully active. The KRAS biomarker analysis indicates a mutant status."
2612,white,female,60,29.94,FOLFOX,No,No,No,No,12,well differentiated,fully active,mutant,No,No,No,No,No,0,"race: white, sex: female, age: 60, bmi: 29.94, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 60-year-old white female with a BMI of 29.94. She is receiving the FOLFOX treatment arm and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cells, and she has a fully active performance status. The KRAS biomarker indicates a mutant status."
2613,white,female,70,22.17,FOLFOX + Cetuximab,No,No,No,No,3,well differentiated,fully active,wild-type,No,No,Yes,No,No,1,"race: white, sex: female, age: 70, bmi: 22.17, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 3, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type, adverse effect: diarrhea: Yes","The patient is a 70-year-old white female with a BMI of 22.17. She is receiving treatment with FOLFOX + Cetuximab and has completed 3 cycles of chemotherapy. Her histology shows well-differentiated cancer, and she has a fully active performance status. The KRAS biomarker indicates that she is wild-type. She is experiencing diarrhea as an adverse effect of the treatment."
2614,white,female,69,21.99,FOLFOX,No,Yes,Yes,No,12,well differentiated,fully active,mutant,Yes,No,No,No,No,0,"race: white, sex: female, age: 69, bmi: 21.99, treatment arm: FOLFOX, serious adverse effect: Yes, bowel obstruction: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant, adverse effect: thrombosis: Yes","The patient is a 69-year-old white female with a BMI of 21.99. She is receiving the FOLFOX treatment regimen and has experienced a serious adverse effect in the form of a bowel obstruction. She has completed 12 cycles of chemotherapy. The histology of her condition is well-differentiated, and her performance status is fully active. The KRAS biomarker testing revealed a mutant status. Additionally, she has also experienced the adverse effect of thrombosis."
2615,white,male,37,24.01,FOLFOX + Cetuximab,No,No,No,Yes,2,poorly differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 37, bmi: 24.01, treatment arm: FOLFOX + Cetuximab, bowel perforation: Yes, chemotherapy cycles: 2, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 37-year-old white male with a BMI of 24.01. He is receiving treatment with FOLFOX + Cetuximab for his colorectal cancer. He has experienced a bowel perforation and has completed 2 cycles of chemotherapy. The histology of his cancer is poorly differentiated. Despite these challenges, his performance status is fully active. Additionally, his KRAS biomarker status is wild-type."
2616,white,male,75,25.53,FOLFOX + Cetuximab,No,Yes,Yes,No,9,well differentiated,symptoms but ambulatory,mutant,No,No,Yes,No,No,1,"race: white, sex: male, age: 75, bmi: 25.53, treatment arm: FOLFOX + Cetuximab, serious adverse effect: Yes, bowel obstruction: Yes, chemotherapy cycles: 9, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: mutant, adverse effect: diarrhea: Yes","The patient is a 75-year-old white male with a BMI of 25.53. He is receiving treatment with FOLFOX + Cetuximab. He has experienced a serious adverse effect, specifically a bowel obstruction. He has completed 9 cycles of chemotherapy. The histology shows well-differentiated cells. Despite experiencing symptoms, the patient is still ambulatory. The KRAS biomarker indicates a mutant status. Additionally, the patient has also experienced diarrhea as an adverse effect."
2617,white,female,43,37.6,FOLFIRI,No,Yes,No,No,12,poorly differentiated,symptoms but ambulatory,wild-type,No,No,Yes,No,No,0,"race: white, sex: female, age: 43, bmi: 37.6, treatment arm: FOLFIRI, serious adverse effect: Yes, chemotherapy cycles: 12, histology: poorly differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type, adverse effect: diarrhea: Yes","The patient is a 43-year-old white female with a BMI of 37.6 who is receiving the FOLFIRI treatment regimen. She has experienced a serious adverse effect during her 12 chemotherapy cycles. Her cancer histology is poorly differentiated, and her performance status indicates that she has symptoms but is still able to be ambulatory. The KRAS biomarker testing revealed that she has a wild-type KRAS status. Additionally, she has experienced diarrhea as an adverse effect of her treatment."
2618,white,female,59,23.05,FOLFOX,No,No,Yes,No,12,poorly differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 59, bmi: 23.05, treatment arm: FOLFOX, bowel obstruction: Yes, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 59-year-old white female with a BMI of 23.05. She is receiving the FOLFOX treatment arm for her bowel obstruction. She has completed 12 chemotherapy cycles and her histology shows poorly differentiated cells. Despite her condition, her performance status is fully active. The KRAS biomarker analysis indicates that she has a wild-type KRAS status."
2619,white,female,53,26.57,FOLFOX + Cetuximab,No,Yes,No,No,12,well differentiated,fully active,wild-type,No,No,Yes,No,No,0,"race: white, sex: female, age: 53, bmi: 26.57, treatment arm: FOLFOX + Cetuximab, serious adverse effect: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type, adverse effect: diarrhea: Yes",The patient is a 53-year-old white female with a BMI of 26.57. She is receiving treatment with FOLFOX + Cetuximab and has experienced a serious adverse effect. She has completed 12 cycles of chemotherapy. The histology shows that the cancer is well-differentiated. The patient has a fully active performance status and her KRAS biomarker is wild-type. She has also experienced diarrhea as an adverse effect of the treatment.
2620,white,male,41,36.12,FOLFOX + Cetuximab,No,Yes,No,No,3,poorly differentiated,fully active,mutant,Yes,No,No,No,No,0,"race: white, sex: male, age: 41, bmi: 36.12, treatment arm: FOLFOX + Cetuximab, serious adverse effect: Yes, chemotherapy cycles: 3, histology: poorly differentiated, performance status: fully active, KRAS biomarker: mutant, adverse effect: thrombosis: Yes","The patient is a 41-year-old white male with a BMI of 36.12. He is currently receiving treatment with FOLFOX + Cetuximab. Unfortunately, he has experienced a serious adverse effect. He has completed 3 cycles of chemotherapy. The histology of his cancer is poorly differentiated. Despite this, his performance status is fully active. His KRAS biomarker is mutant. Additionally, he has developed thrombosis as an adverse effect."
2621,white,male,66,23.84,FOLFOX + Cetuximab,No,No,No,Yes,12,well differentiated,fully active,mutant,No,No,No,No,No,0,"race: white, sex: male, age: 66, bmi: 23.84, treatment arm: FOLFOX + Cetuximab, bowel perforation: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 66-year-old white male with a BMI of 23.84. He is receiving treatment with FOLFOX + Cetuximab. He experienced a bowel perforation and has undergone 12 cycles of chemotherapy. The histology shows well-differentiated cells. Despite the bowel perforation, his performance status is fully active. The KRAS biomarker indicates a mutant status."
2622,white,female,56,30.72,FOLFOX + Cetuximab,No,Yes,No,Yes,11,poorly differentiated,fully active,wild-type,No,Yes,Yes,No,No,0,"race: white, sex: female, age: 56, bmi: 30.72, treatment arm: FOLFOX + Cetuximab, serious adverse effect: Yes, bowel perforation: Yes, chemotherapy cycles: 11, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type, adverse effect: hypersensitivity: Yes, adverse effect: diarrhea: Yes","The patient is a 56-year-old white female with a BMI of 30.72. She is receiving treatment with FOLFOX + Cetuximab and has experienced a serious adverse effect in the form of a bowel perforation. She has completed 11 cycles of chemotherapy and her histology shows poorly differentiated cells. Despite these challenges, her performance status is fully active. Her KRAS biomarker is wild-type. Additionally, she has experienced adverse effects in the form of hypersensitivity and diarrhea."
2623,black,female,63,36.23,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,symptoms but ambulatory,wild-type,No,Yes,No,No,No,0,"race: black, sex: female, age: 63, bmi: 36.23, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type, adverse effect: hypersensitivity: Yes","The patient is a 63-year-old Black female with a BMI of 36.23. She is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. Her cancer histology is well-differentiated, and she has symptoms but is still able to be ambulatory. The KRAS biomarker testing showed that she has a wild-type KRAS status. She experienced a hypersensitivity adverse effect during treatment."
2624,white,female,44,19.76,FOLFOX + Cetuximab,No,Yes,No,No,12,well differentiated,fully active,wild-type,No,No,Yes,No,No,0,"race: white, sex: female, age: 44, bmi: 19.76, treatment arm: FOLFOX + Cetuximab, serious adverse effect: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type, adverse effect: diarrhea: Yes","The patient is a 44-year-old white female with a BMI of 19.76. She is receiving treatment with FOLFOX + Cetuximab and has experienced a serious adverse effect. She has completed 12 cycles of chemotherapy. Histologically, her cancer is well-differentiated. Despite the serious adverse effect, her performance status is fully active. Her KRAS biomarker is wild-type. Additionally, she has experienced diarrhea as an adverse effect."
2625,white,female,74,20.62,FOLFOX,No,No,No,Yes,12,poorly differentiated,symptoms but ambulatory,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 74, bmi: 20.62, treatment arm: FOLFOX, bowel perforation: Yes, chemotherapy cycles: 12, histology: poorly differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type","The patient is a 74-year-old white female with a BMI of 20.62. She is receiving the FOLFOX treatment arm for her bowel perforation. She has undergone 12 chemotherapy cycles and her histology shows poorly differentiated cells. Despite experiencing symptoms, she is still able to be ambulatory. Her KRAS biomarker indicates that she has a wild-type status."
2626,other,female,41,26.14,FOLFOX + Cetuximab,No,No,No,No,10,well differentiated,fully active,wild-type,No,Yes,Yes,No,No,0,"race: other, sex: female, age: 41, bmi: 26.14, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 10, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type, adverse effect: hypersensitivity: Yes, adverse effect: diarrhea: Yes","The patient is a 41-year-old female of a race classified as ""other"" with a BMI of 26.14. She is undergoing treatment with the FOLFOX + Cetuximab regimen and has completed 10 cycles of chemotherapy. The histology of her condition is well-differentiated, and her performance status is fully active. The KRAS biomarker testing revealed a wild-type result. The patient has experienced adverse effects during treatment, including hypersensitivity and diarrhea."
2627,white,male,35,27.32,FOLFOX,Yes,No,No,No,3,poorly differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 35, bmi: 27.32, treatment arm: FOLFOX, adherence: Yes, chemotherapy cycles: 3, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 35-year-old white male with a BMI of 27.32. He is receiving the FOLFOX treatment regimen and has been adherent to the treatment. He has completed 3 cycles of chemotherapy. The histology of his cancer is poorly differentiated. Despite his diagnosis, he has a fully active performance status. His KRAS biomarker status is wild-type."
2628,white,male,59,30.48,FOLFIRI,No,No,No,No,8,well differentiated,fully active,wild-type,No,No,No,No,No,1,"race: white, sex: male, age: 59, bmi: 30.48, treatment arm: FOLFIRI, chemotherapy cycles: 8, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 59-year-old white male with a BMI of 30.48. He is undergoing treatment with the FOLFIRI chemotherapy regimen and has completed 8 cycles. His cancer histology is well differentiated, and he has a fully active performance status. The KRAS biomarker analysis shows that he has a wild-type KRAS status."
2629,black,male,57,17.11,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: black, sex: male, age: 57, bmi: 17.11, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 57-year-old Black male with a low BMI of 17.11. He is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer cells. Despite his cancer diagnosis, he has a fully active performance status. Additionally, his KRAS biomarker is wild-type."
2630,white,male,46,21.39,FOLFOX + Cetuximab,Yes,No,No,No,12,well differentiated,symptoms but ambulatory,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 46, bmi: 21.39, treatment arm: FOLFOX + Cetuximab, adherence: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type","The patient is a 46-year-old white male with a BMI of 21.39. He is receiving treatment in the FOLFOX + Cetuximab treatment arm and has been adherent to the treatment. He has completed 12 chemotherapy cycles. The histology shows well-differentiated cancer cells. Despite experiencing symptoms, the patient is still ambulatory. The KRAS biomarker indicates that the patient has a wild-type KRAS gene."
2631,white,female,48,25.41,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 48, bmi: 25.41, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 48-year-old white female with a BMI of 25.41. She is receiving treatment with FOLFOX + Cetuximab and is scheduled for 12 chemotherapy cycles. Her cancer histology is well-differentiated, and she has a fully active performance status. The KRAS biomarker testing indicates that she has a wild-type KRAS status."
2632,other,male,53,31.6,FOLFOX,No,Yes,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: other, sex: male, age: 53, bmi: 31.6, treatment arm: FOLFOX, serious adverse effect: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 53-year-old male of a race categorized as ""other"" with a BMI of 31.6. He is undergoing treatment with the FOLFOX regimen and has experienced a serious adverse effect. He has completed 12 cycles of chemotherapy. The histology of his cancer is well-differentiated. Despite the adverse effect, his performance status is fully active. The KRAS biomarker analysis shows that he has a wild-type KRAS status."
2633,black,male,45,20.99,FOLFIRI,Yes,No,Yes,Yes,12,well differentiated,symptoms but ambulatory,wild-type,No,No,No,No,No,1,"race: black, sex: male, age: 45, bmi: 20.99, treatment arm: FOLFIRI, adherence: Yes, bowel obstruction: Yes, bowel perforation: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type","The patient is a 45-year-old Black male with a BMI of 20.99. He is receiving the FOLFIRI treatment regimen and has been adherent to the treatment. He has experienced both a bowel obstruction and a bowel perforation. The patient has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer cells. Despite experiencing symptoms, he is still able to be ambulatory. The KRAS biomarker analysis indicates that he has a wild-type KRAS status."
2634,white,male,70,31.39,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,Yes,No,0,"race: white, sex: male, age: 70, bmi: 31.39, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type, adverse effect: infection: Yes","The patient is a 70-year-old white male with a BMI of 31.39. He is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. His cancer histology is well-differentiated, and he has a fully active performance status. The KRAS biomarker testing showed that he is wild-type. The patient has experienced an adverse effect in the form of an infection."
2635,white,male,69,37.06,FOLFOX + Cetuximab,Yes,No,No,Yes,8,well differentiated,fully active,wild-type,No,No,Yes,No,No,0,"race: white, sex: male, age: 69, bmi: 37.06, treatment arm: FOLFOX + Cetuximab, adherence: Yes, bowel perforation: Yes, chemotherapy cycles: 8, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type, adverse effect: diarrhea: Yes","The patient is a 69-year-old white male with a BMI of 37.06. He is receiving treatment with FOLFOX + Cetuximab and has been adherent to the treatment. He experienced a bowel perforation and has completed 8 cycles of chemotherapy. His histology shows well-differentiated cells, and his performance status is fully active. The KRAS biomarker indicates that he is wild-type. He has also experienced diarrhea as an adverse effect of the treatment."
2636,other,female,39,29.41,FOLFOX,No,No,No,No,12,poorly differentiated,fully active,wild-type,No,No,No,No,No,0,"race: other, sex: female, age: 39, bmi: 29.41, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 39-year-old female of a race categorized as ""other"" with a BMI of 29.41. She is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. The histology of her cancer is poorly differentiated. Despite her diagnosis, she maintains a fully active performance status. Additionally, her KRAS biomarker status is wild-type."
2637,white,female,63,22.87,FOLFOX,No,Yes,Yes,No,12,well differentiated,symptoms but ambulatory,mutant,No,No,No,No,No,0,"race: white, sex: female, age: 63, bmi: 22.87, treatment arm: FOLFOX, serious adverse effect: Yes, bowel obstruction: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: mutant","The patient is a 63-year-old white female with a BMI of 22.87. She is receiving the FOLFOX treatment regimen and has experienced a serious adverse effect, specifically a bowel obstruction. She has completed 12 cycles of chemotherapy. The histology shows that the cancer is well-differentiated. Despite experiencing symptoms, she is still able to be ambulatory. The KRAS biomarker testing revealed a mutant status."
2638,white,female,76,25.3,FOLFOX,No,No,No,No,12,well differentiated,fully active,mutant,No,No,No,No,No,1,"race: white, sex: female, age: 76, bmi: 25.3, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 76-year-old white female with a BMI of 25.3. She is receiving the FOLFOX treatment arm and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cells, and she has a fully active performance status. The KRAS biomarker analysis indicates a mutant status."
2639,white,female,63,24.93,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,fully active,mutant,No,No,No,No,No,0,"race: white, sex: female, age: 63, bmi: 24.93, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 63-year-old white female with a BMI of 24.93. She is receiving treatment in the FOLFOX + Cetuximab treatment arm and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cancer cells. Despite her cancer diagnosis, she has a fully active performance status. The patient's KRAS biomarker indicates a mutant status."
2640,white,male,67,26.76,FOLFOX,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 67, bmi: 26.76, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 67-year-old white male with a BMI of 26.76. He is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. His cancer histology is well-differentiated, and he has a fully active performance status. The KRAS biomarker testing indicates that he has a wild-type KRAS status."
2641,white,female,38,22.64,FOLFOX + Cetuximab,No,Yes,No,No,12,well differentiated,symptoms but ambulatory,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 38, bmi: 22.64, treatment arm: FOLFOX + Cetuximab, serious adverse effect: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type","The patient is a 38-year-old white female with a BMI of 22.64. She is receiving treatment with FOLFOX + Cetuximab and has experienced a serious adverse effect. She has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cells. Despite experiencing symptoms, she is still able to be ambulatory. Her KRAS biomarker status is wild-type."
2642,white,female,70,21.91,FOLFOX,No,Yes,No,No,12,poorly differentiated,fully active,mutant,No,No,No,No,No,0,"race: white, sex: female, age: 70, bmi: 21.91, treatment arm: FOLFOX, serious adverse effect: Yes, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 70-year-old white female with a BMI of 21.91. She is receiving the FOLFOX treatment regimen and has experienced a serious adverse effect. She has completed 12 cycles of chemotherapy. The histology of her cancer is poorly differentiated. Despite this, her performance status is fully active. Additionally, the KRAS biomarker testing revealed a mutant status."
2643,white,male,55,22.5,FOLFOX + Cetuximab,No,Yes,No,No,12,well differentiated,fully active,mutant,No,No,No,No,No,0,"race: white, sex: male, age: 55, bmi: 22.5, treatment arm: FOLFOX + Cetuximab, serious adverse effect: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 55-year-old white male with a BMI of 22.5. He is receiving treatment with FOLFOX + Cetuximab and has experienced a serious adverse effect. He has completed 12 cycles of chemotherapy. His histology shows well-differentiated cells, and his performance status is fully active. The KRAS biomarker indicates a mutant status."
2644,white,male,66,29,FOLFOX,No,No,Yes,No,9,poorly differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 66, bmi: 29.0, treatment arm: FOLFOX, bowel obstruction: Yes, chemotherapy cycles: 9, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 66-year-old white male with a BMI of 29.0. He is receiving treatment with FOLFOX chemotherapy regimen and has experienced a bowel obstruction. He has completed 9 cycles of chemotherapy. The histology of his cancer is poorly differentiated. Despite these challenges, his performance status is fully active. The KRAS biomarker testing revealed that he has a wild-type KRAS status."
2645,white,female,64,25.63,FOLFOX,No,No,No,No,12,well differentiated,symptoms but ambulatory,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 64, bmi: 25.63, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type","The patient is a 64-year-old white female with a BMI of 25.63. She is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cells. Despite experiencing symptoms, she is still able to be ambulatory. The KRAS biomarker analysis indicates that she has a wild-type KRAS status."
2646,white,male,75,29.56,FOLFIRI,No,Yes,No,No,8,well differentiated,symptoms but ambulatory,mutant,No,No,No,No,No,0,"race: white, sex: male, age: 75, bmi: 29.56, treatment arm: FOLFIRI, serious adverse effect: Yes, chemotherapy cycles: 8, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: mutant","The patient is a 75-year-old white male with a BMI of 29.56. He is receiving the FOLFIRI treatment regimen and has experienced a serious adverse effect. He has completed 8 cycles of chemotherapy. His histology shows well-differentiated cells. Despite experiencing symptoms, he is still able to be ambulatory. The KRAS biomarker analysis indicates a mutant status."
2647,white,female,47,41.26,FOLFOX,No,No,No,No,12,well differentiated,symptoms but ambulatory,mutant,No,No,No,No,No,0,"race: white, sex: female, age: 47, bmi: 41.26, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: mutant","The patient is a 47-year-old white female with a BMI of 41.26. She is undergoing treatment with the FOLFOX chemotherapy regimen and has completed 12 cycles. The histology shows well-differentiated cancer cells. Despite experiencing symptoms, the patient is still able to be ambulatory. The KRAS biomarker analysis revealed a mutant status."
2648,white,male,58,20.18,FOLFOX,Yes,No,No,No,12,well differentiated,fully active,mutant,No,No,No,No,No,0,"race: white, sex: male, age: 58, bmi: 20.18, treatment arm: FOLFOX, adherence: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 58-year-old white male with a BMI of 20.18. He is receiving the FOLFOX treatment regimen and has been adherent to the prescribed chemotherapy cycles, completing 12 cycles so far. His histology shows well-differentiated cancer cells. The patient has a fully active performance status. The KRAS biomarker analysis indicates a mutant status."
2649,white,female,54,25.33,FOLFIRI + Cetuximab,No,Yes,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 54, bmi: 25.33, treatment arm: FOLFIRI + Cetuximab, serious adverse effect: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","This patient is a 54-year-old white female with a BMI of 25.33. She is receiving treatment with FOLFIRI + Cetuximab and has experienced a serious adverse effect. She has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cells, and her performance status is fully active. The KRAS biomarker indicates that she has a wild-type mutation."
2650,white,female,41,26.71,FOLFOX,No,No,Yes,No,12,poorly differentiated,fully active,mutant,No,No,No,No,No,0,"race: white, sex: female, age: 41, bmi: 26.71, treatment arm: FOLFOX, bowel obstruction: Yes, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 41-year-old white female with a BMI of 26.71. She is receiving treatment with FOLFOX chemotherapy regimen and has experienced a bowel obstruction. She has completed 12 cycles of chemotherapy. The histology of her cancer is poorly differentiated. Despite these challenges, her performance status is fully active. Additionally, the KRAS biomarker testing revealed a mutant status."
2651,white,female,40,25.59,FOLFOX,Yes,Yes,No,No,12,well differentiated,fully active,mutant,No,No,No,No,No,0,"race: white, sex: female, age: 40, bmi: 25.59, treatment arm: FOLFOX, adherence: Yes, serious adverse effect: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 40-year-old white female with a BMI of 25.59. She is receiving the FOLFOX treatment regimen and has been adherent to the treatment. She experienced a serious adverse effect during the course of her 12 chemotherapy cycles. The histology of her cancer is well differentiated. Despite the treatment, her performance status remains fully active. Additionally, her KRAS biomarker is identified as mutant."
2652,white,male,55,24.54,FOLFOX + Cetuximab,Yes,Yes,No,No,12,well differentiated,symptoms but ambulatory,mutant,No,No,No,No,No,0,"race: white, sex: male, age: 55, bmi: 24.54, treatment arm: FOLFOX + Cetuximab, adherence: Yes, serious adverse effect: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: mutant","The patient is a 55-year-old white male with a BMI of 24.54. He is receiving treatment with FOLFOX + Cetuximab and has been adherent to the treatment. However, he experienced a serious adverse effect during the course of 12 chemotherapy cycles. His histology shows well-differentiated cells, and he has symptoms but is still ambulatory based on his performance status. Additionally, the KRAS biomarker indicates a mutant status."
2653,white,male,39,28.2,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,symptoms but ambulatory,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 39, bmi: 28.2, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type","The patient is a 39-year-old white male with a BMI of 28.2. He is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer cells. Despite experiencing symptoms, he is still able to walk around (ambulatory). His KRAS biomarker indicates that he has a wild-type gene."
2654,white,female,69,26.72,FOLFOX,No,No,No,No,12,well differentiated,symptoms but ambulatory,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 69, bmi: 26.72, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type","The patient is a 69-year-old white female with a BMI of 26.72. She is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cancer cells. Despite experiencing symptoms, she is still able to walk around (ambulatory). Additionally, her KRAS biomarker status is wild-type."
2655,black,male,68,51.33,FOLFOX,No,No,No,No,12,well differentiated,symptoms but ambulatory,mutant,No,No,No,No,No,0,"race: black, sex: male, age: 68, bmi: 51.33, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: mutant","The patient is a 68-year-old Black male with a BMI of 51.33. He is receiving the FOLFOX treatment arm and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer cells. Despite experiencing symptoms, he is still able to walk around (ambulatory). The KRAS biomarker analysis indicates that he has a mutant KRAS status."
2656,white,female,59,31.6,FOLFOX,Yes,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 59, bmi: 31.6, treatment arm: FOLFOX, adherence: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 59-year-old white female with a BMI of 31.6. She is receiving the FOLFOX treatment regimen and has been adherent to her chemotherapy cycles, completing a total of 12 cycles. Her histology shows well-differentiated cells, and she has a fully active performance status. Additionally, her KRAS biomarker is wild-type."
2657,white,male,50,34.23,FOLFOX + Cetuximab,No,No,No,No,12,poorly differentiated,fully active,wild-type,No,No,Yes,No,No,0,"race: white, sex: male, age: 50, bmi: 34.23, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type, adverse effect: diarrhea: Yes","The patient is a 50-year-old white male with a BMI of 34.23. He is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. His histology shows poorly differentiated cancer cells. Despite this, his performance status is fully active. The KRAS biomarker testing revealed that he has a wild-type KRAS status. The patient is experiencing diarrhea as an adverse effect of the treatment."
2658,white,male,61,25.16,FOLFOX,No,No,No,No,1,well differentiated,symptoms but ambulatory,wild-type,No,No,No,No,No,1,"race: white, sex: male, age: 61, bmi: 25.16, treatment arm: FOLFOX, chemotherapy cycles: 1, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type","The patient is a 61-year-old white male with a BMI of 25.16. He is currently undergoing treatment with the FOLFOX chemotherapy regimen and has completed one cycle so far. His cancer histology shows well-differentiated cells. Despite experiencing symptoms, he is still able to be ambulatory. The KRAS biomarker analysis indicates that he has a wild-type KRAS status."
2659,white,female,65,35.86,FOLFOX + Cetuximab,No,No,No,No,0,poorly differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 65, bmi: 35.86, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 0, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 65-year-old white female with a BMI of 35.86. She is enrolled in the FOLFOX + Cetuximab treatment arm but has not started chemotherapy cycles yet. Her histology shows poorly differentiated cancer cells. Despite this, she has a fully active performance status. The KRAS biomarker indicates that she has a wild-type gene."
2660,white,female,71,24.24,FOLFIRI + Cetuximab,No,No,No,No,4,well differentiated,fully active,interminate,No,No,No,No,No,1,"race: white, sex: female, age: 71, bmi: 24.24, treatment arm: FOLFIRI + Cetuximab, chemotherapy cycles: 4, histology: well differentiated, performance status: fully active, KRAS biomarker: interminate","The patient is a 71-year-old white female with a BMI of 24.24. She is currently receiving treatment with FOLFIRI + Cetuximab and has completed 4 cycles of chemotherapy. Her histology shows well-differentiated cancer cells. Despite her age, she has a fully active performance status. The KRAS biomarker status is indeterminate for this patient."
2661,white,male,57,25.68,FOLFOX,No,No,No,No,12,well differentiated,symptoms but ambulatory,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 57, bmi: 25.68, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type","The patient is a 57-year-old white male with a BMI of 25.68. He is undergoing treatment with the FOLFOX chemotherapy regimen and has completed 12 cycles. His histology shows well-differentiated cancer cells. Despite experiencing symptoms, he is still able to be ambulatory. His KRAS biomarker status is wild-type."
2662,other,male,58,26.71,FOLFOX,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: other, sex: male, age: 58, bmi: 26.71, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 58-year-old male of a race classified as ""other"" with a BMI of 26.71. He is receiving treatment with the FOLFOX chemotherapy regimen and has completed 12 cycles. His cancer histology is well-differentiated, and he has a fully active performance status. Additionally, his KRAS biomarker status is wild-type."
2663,white,male,66,31.94,FOLFOX + Cetuximab,No,No,No,No,1,well differentiated,symptoms but ambulatory,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 66, bmi: 31.94, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 1, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type","The patient is a 66-year-old white male with a BMI of 31.94. He is currently undergoing treatment with FOLFOX + Cetuximab and has completed one cycle of chemotherapy. His histology shows well-differentiated cancer cells. Despite experiencing symptoms, he is still able to be ambulatory. The KRAS biomarker analysis indicates that he has a wild-type KRAS status."
2664,white,female,55,32.98,FOLFOX,Yes,No,No,Yes,0,poorly differentiated,fully active,interminate,No,No,No,No,No,0,"race: white, sex: female, age: 55, bmi: 32.98, treatment arm: FOLFOX, adherence: Yes, bowel perforation: Yes, chemotherapy cycles: 0, histology: poorly differentiated, performance status: fully active, KRAS biomarker: interminate","This patient is a 55-year-old white female with a BMI of 32.98. She is enrolled in the FOLFOX treatment arm and has been adherent to her treatment. She has experienced a bowel perforation and has not yet undergone any chemotherapy cycles. Her histology shows poorly differentiated cells, and her performance status is fully active. The KRAS biomarker status is indeterminate for this patient."
2665,white,female,60,20.68,FOLFIRI + Cetuximab,No,No,No,No,12,poorly differentiated,fully active,mutant,No,No,No,No,No,0,"race: white, sex: female, age: 60, bmi: 20.68, treatment arm: FOLFIRI + Cetuximab, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 60-year-old white female with a BMI of 20.68. She is receiving treatment with FOLFIRI + Cetuximab and has completed 12 cycles of chemotherapy. Her histology shows poorly differentiated cancer cells. Despite this, her performance status is fully active. Additionally, the KRAS biomarker analysis indicates a mutant status."
2666,white,female,41,25.22,FOLFOX,No,Yes,No,No,12,poorly differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 41, bmi: 25.22, treatment arm: FOLFOX, serious adverse effect: Yes, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 41-year-old white female with a BMI of 25.22. She is receiving the FOLFOX treatment regimen and has experienced a serious adverse effect. She has completed 12 cycles of chemotherapy. The histology of her cancer is poorly differentiated. Despite this, her performance status is fully active. Additionally, her KRAS biomarker status is wild-type."
2667,white,female,47,24.46,FOLFOX,No,No,No,No,12,well differentiated,symptoms but ambulatory,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 47, bmi: 24.46, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type","The patient is a 47-year-old white female with a BMI of 24.46. She is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cancer cells. Despite experiencing symptoms, she is still able to be ambulatory. The KRAS biomarker analysis indicates that she has a wild-type KRAS gene."
2668,black,male,62,26.05,FOLFOX,No,No,Yes,No,12,poorly differentiated,fully active,mutant,No,No,No,No,No,0,"race: black, sex: male, age: 62, bmi: 26.05, treatment arm: FOLFOX, bowel obstruction: Yes, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 62-year-old Black male with a BMI of 26.05. He is receiving the FOLFOX treatment regimen and has experienced a bowel obstruction. He has completed 12 cycles of chemotherapy. The histology of his cancer is poorly differentiated. Despite his condition, his performance status is fully active. The KRAS biomarker testing revealed a mutant result."
2669,white,male,65,25.49,FOLFOX,No,No,No,No,12,poorly differentiated,symptoms but ambulatory,wild-type,No,No,No,No,No,1,"race: white, sex: male, age: 65, bmi: 25.49, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: poorly differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type","The patient is a 65-year-old white male with a BMI of 25.49. He is undergoing treatment with the FOLFOX chemotherapy regimen and has completed 12 cycles. His histology shows poorly differentiated cancer cells. Despite experiencing symptoms, he is still able to walk around (ambulatory). The KRAS biomarker analysis indicates that he has a wild-type KRAS status."
2670,white,female,66,25.78,FOLFOX,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 66, bmi: 25.78, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type",The patient is a 66-year-old white female with a BMI of 25.78. She is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cancer cells. The patient has a fully active performance status and her KRAS biomarker is wild-type.
2671,other,male,56,21.38,FOLFOX,No,No,Yes,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: other, sex: male, age: 56, bmi: 21.38, treatment arm: FOLFOX, bowel obstruction: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 56-year-old male of a race other than Caucasian. He has a BMI of 21.38 and is undergoing treatment with the FOLFOX chemotherapy regimen. He has experienced a bowel obstruction and has completed 12 cycles of chemotherapy. The histology of his cancer is well-differentiated. Despite the bowel obstruction, his performance status is fully active. His KRAS biomarker status is wild-type."
2672,white,male,67,28.04,FOLFOX + Cetuximab,Yes,No,No,No,12,well differentiated,fully active,interminate,No,No,No,No,No,0,"race: white, sex: male, age: 67, bmi: 28.04, treatment arm: FOLFOX + Cetuximab, adherence: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: interminate",The patient is a 67-year-old white male with a BMI of 28.04. He is receiving treatment in the FOLFOX + Cetuximab treatment arm and has been adherent to the treatment. He has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer cells. The patient has a fully active performance status. The KRAS biomarker status is indeterminate.
2673,white,male,76,24.93,FOLFOX,No,No,No,No,12,well differentiated,fully active,mutant,No,No,No,No,No,0,"race: white, sex: male, age: 76, bmi: 24.93, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 76-year-old white male with a BMI of 24.93. He is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer cells. Despite his age, he has a fully active performance status. The KRAS biomarker testing revealed a mutant status."
2674,white,male,46,26.4,FOLFOX + Cetuximab,No,No,No,No,6,well differentiated,symptoms but ambulatory,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 46, bmi: 26.4, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 6, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type","The patient is a 46-year-old white male with a BMI of 26.4. He is receiving treatment with FOLFOX + Cetuximab and has completed 6 cycles of chemotherapy. His cancer histology is well-differentiated. Despite experiencing symptoms, he is still able to be ambulatory. The KRAS biomarker analysis shows that he has a wild-type KRAS status."
2675,white,male,58,33.49,FOLFOX,No,No,Yes,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 58, bmi: 33.49, treatment arm: FOLFOX, bowel obstruction: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","This patient is a 58-year-old white male with a BMI of 33.49. He is receiving treatment with the FOLFOX regimen and has experienced a bowel obstruction. He has completed 12 cycles of chemotherapy. The histology of his cancer is well differentiated. Despite the bowel obstruction, his performance status is fully active. His KRAS biomarker status is wild-type."
2676,black,female,58,27.39,FOLFOX,No,No,No,No,8,well differentiated,symptoms but ambulatory,mutant,No,No,No,No,No,1,"race: black, sex: female, age: 58, bmi: 27.39, treatment arm: FOLFOX, chemotherapy cycles: 8, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: mutant","The patient is a 58-year-old Black female with a BMI of 27.39. She is receiving the FOLFOX treatment regimen and has completed 8 cycles of chemotherapy. Her histology shows well-differentiated cancer cells. Despite experiencing symptoms, she is still able to walk around (ambulatory). The KRAS biomarker testing revealed a mutant result."
2677,white,female,74,30.66,FOLFOX,No,No,No,No,12,poorly differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 74, bmi: 30.66, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 74-year-old white female with a BMI of 30.66. She is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. Her histology shows poorly differentiated cancer cells. Despite this, her performance status is fully active. Additionally, her KRAS biomarker indicates that it is wild-type."
2678,white,male,57,26.66,FOLFOX,Yes,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 57, bmi: 26.66, treatment arm: FOLFOX, adherence: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type",The patient is a 57-year-old white male with a BMI of 26.66. He is receiving the FOLFOX treatment regimen and has been adherent to the treatment. He has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer cells. The patient has a fully active performance status. His KRAS biomarker is wild-type.
2679,white,female,70,31.92,FOLFOX + Cetuximab,No,No,No,No,12,poorly differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 70, bmi: 31.92, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 70-year-old white female with a BMI of 31.92. She is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. Her cancer histology is poorly differentiated, and she has a fully active performance status. The KRAS biomarker analysis indicates that she has a wild-type KRAS status."
2680,white,male,62,22.31,FOLFOX,Yes,No,No,Yes,6,poorly differentiated,symptoms but ambulatory,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 62, bmi: 22.31, treatment arm: FOLFOX, adherence: Yes, bowel perforation: Yes, chemotherapy cycles: 6, histology: poorly differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type","The patient is a 62-year-old white male with a BMI of 22.31. He is receiving treatment with the FOLFOX regimen and has been adherent to the treatment. He experienced a bowel perforation during the course of treatment. He completed 6 cycles of chemotherapy. The histology of his cancer is poorly differentiated. Despite experiencing symptoms, he is still able to be ambulatory. His KRAS biomarker status is wild-type."
2681,black,male,53,33.22,FOLFOX,No,No,No,No,12,well differentiated,symptoms but ambulatory,mutant,No,No,No,No,No,0,"race: black, sex: male, age: 53, bmi: 33.22, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: mutant","The patient is a 53-year-old Black male with a BMI of 33.22. He is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer cells. Despite experiencing symptoms, he is still able to walk around (ambulatory). The KRAS biomarker testing revealed a mutant status."
2682,white,male,53,27.76,FOLFOX,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 53, bmi: 27.76, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 53-year-old white male with a BMI of 27.76. He is receiving the FOLFOX treatment arm and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cells, and he has a fully active performance status. The KRAS biomarker analysis indicates that he has a wild-type KRAS status."
2683,other,male,65,27.26,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,Yes,No,No,0,"race: other, sex: male, age: 65, bmi: 27.26, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type, adverse effect: diarrhea: Yes","The patient is a 65-year-old male of a race categorized as ""other"" with a BMI of 27.26. He is undergoing treatment with the FOLFOX + Cetuximab regimen and has completed 12 cycles of chemotherapy. The histology of the cancer is well-differentiated, and the patient's performance status is fully active. The KRAS biomarker status is wild-type. The patient is experiencing diarrhea as an adverse effect of the treatment."
2684,white,female,55,22.54,FOLFOX,No,No,No,No,12,poorly differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 55, bmi: 22.54, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 55-year-old white female with a BMI of 22.54. She is undergoing treatment with the FOLFOX chemotherapy regimen and has completed 12 cycles. Her cancer histology is poorly differentiated. Despite her diagnosis, she has a fully active performance status. Additionally, her KRAS biomarker status is wild-type."
2685,white,female,43,22.84,FOLFOX + Cetuximab,No,Yes,No,No,12,well differentiated,fully active,mutant,No,No,Yes,No,No,0,"race: white, sex: female, age: 43, bmi: 22.84, treatment arm: FOLFOX + Cetuximab, serious adverse effect: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant, adverse effect: diarrhea: Yes","The patient is a 43-year-old white female with a BMI of 22.84. She is receiving treatment with FOLFOX + Cetuximab and has experienced a serious adverse effect. She has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cells, and she has a fully active performance status. The KRAS biomarker indicates a mutant status. Additionally, she has experienced diarrhea as an adverse effect."
2686,white,male,37,31.53,FOLFOX,No,Yes,No,No,12,poorly differentiated,symptoms but ambulatory,wild-type,Yes,No,No,No,No,0,"race: white, sex: male, age: 37, bmi: 31.53, treatment arm: FOLFOX, serious adverse effect: Yes, chemotherapy cycles: 12, histology: poorly differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type, adverse effect: thrombosis: Yes","The patient is a 37-year-old white male with a BMI of 31.53. He is receiving treatment with FOLFOX chemotherapy regimen and has experienced a serious adverse effect. He has completed 12 cycles of chemotherapy. The histology of his cancer is poorly differentiated. Despite experiencing symptoms, he is still able to be ambulatory. The KRAS biomarker testing revealed that he has a wild-type KRAS status. Additionally, he has developed thrombosis as an adverse effect of the treatment."
2687,white,female,47,31.22,FOLFOX + Cetuximab,No,No,No,No,12,poorly differentiated,symptoms but ambulatory,wild-type,No,No,No,Yes,No,0,"race: white, sex: female, age: 47, bmi: 31.22, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: poorly differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type, adverse effect: infection: Yes","The patient is a 47-year-old white female with a BMI of 31.22. She is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. Her histology shows poorly differentiated cancer cells. Despite experiencing symptoms, she is still able to be ambulatory. The KRAS biomarker testing indicates that she has a wild-type KRAS gene. The patient has developed an infection as an adverse effect of the treatment."
2688,white,male,74,33.11,FOLFOX,No,No,Yes,No,12,well differentiated,symptoms but ambulatory,wild-type,No,No,No,No,No,1,"race: white, sex: male, age: 74, bmi: 33.11, treatment arm: FOLFOX, bowel obstruction: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type","The patient is a 74-year-old white male with a BMI of 33.11. He is receiving the FOLFOX treatment regimen and has experienced a bowel obstruction. He has completed 12 cycles of chemotherapy. The histology indicates that the cancer is well-differentiated. Despite experiencing symptoms, the patient is still able to be ambulatory. The KRAS biomarker shows that the cancer is wild-type."
2689,white,female,73,22.07,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 73, bmi: 22.07, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 73-year-old white female with a BMI of 22.07. She is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cancer, and she has a fully active performance status. The KRAS biomarker indicates that she has a wild-type status."
2690,other,female,68,19.42,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,symptoms but ambulatory,wild-type,No,No,No,No,No,0,"race: other, sex: female, age: 68, bmi: 19.42, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type","The patient is a 68-year-old female of a race categorized as ""other"" with a BMI of 19.42. She is receiving treatment in the FOLFOX + Cetuximab treatment arm and has completed 12 cycles of chemotherapy. The histology indicates that the cancer is well-differentiated. Despite experiencing symptoms, the patient is still able to be ambulatory. Additionally, the KRAS biomarker shows that it is wild-type."
2691,other,male,57,22.32,FOLFOX + Cetuximab,No,No,Yes,No,2,poorly differentiated,fully active,wild-type,No,No,No,No,No,0,"race: other, sex: male, age: 57, bmi: 22.32, treatment arm: FOLFOX + Cetuximab, bowel obstruction: Yes, chemotherapy cycles: 2, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 57-year-old male of a race categorized as ""other"" with a BMI of 22.32. He is receiving treatment in the FOLFOX + Cetuximab treatment arm. The patient has a bowel obstruction and has completed 2 cycles of chemotherapy. The histology indicates poorly differentiated cancer. Despite these challenges, the patient has a fully active performance status. The KRAS biomarker shows that it is wild-type."
2692,white,male,49,23.4,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,symptoms but ambulatory,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 49, bmi: 23.4, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type","The patient is a 49-year-old white male with a BMI of 23.4. He is receiving treatment in the FOLFOX + Cetuximab treatment arm and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer cells. Despite experiencing symptoms, he is still able to walk around (ambulatory). His KRAS biomarker indicates that he has a wild-type gene."
2693,white,female,72,35.3,FOLFOX + Cetuximab,Yes,Yes,No,No,12,poorly differentiated,fully active,wild-type,No,No,Yes,No,No,0,"race: white, sex: female, age: 72, bmi: 35.3, treatment arm: FOLFOX + Cetuximab, adherence: Yes, serious adverse effect: Yes, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type, adverse effect: diarrhea: Yes","The patient is a 72-year-old white female with a BMI of 35.3 who is receiving treatment with FOLFOX + Cetuximab. She has been adherent to her treatment and has completed 12 cycles of chemotherapy. The histology of her cancer is poorly differentiated. Despite experiencing a serious adverse effect of diarrhea, her performance status remains fully active. Her KRAS biomarker status is wild-type."
2694,white,male,49,42.61,FOLFOX + Cetuximab,No,Yes,No,No,9,well differentiated,symptoms but ambulatory,mutant,No,No,No,No,No,1,"race: white, sex: male, age: 49, bmi: 42.61, treatment arm: FOLFOX + Cetuximab, serious adverse effect: Yes, chemotherapy cycles: 9, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: mutant","The patient is a 49-year-old white male with a BMI of 42.61. He is receiving treatment with FOLFOX + Cetuximab and has experienced a serious adverse effect. He has completed 9 cycles of chemotherapy. The histology shows that the cancer is well-differentiated. Despite experiencing symptoms, the patient is still able to be ambulatory. The KRAS biomarker analysis indicates that the patient has a mutant KRAS status."
2695,white,male,50,29.1,FOLFOX + Cetuximab,No,No,No,No,2,well differentiated,symptoms but ambulatory,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 50, bmi: 29.1, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 2, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type","The patient is a 50-year-old white male with a BMI of 29.1. He is receiving treatment in the FOLFOX + Cetuximab treatment arm and has completed 2 cycles of chemotherapy. His histology shows well-differentiated cancer cells. Despite experiencing symptoms, he is still able to walk around (ambulatory). His KRAS biomarker status is wild-type."
2696,white,male,74,27.59,FOLFOX + Cetuximab,No,No,No,No,10,poorly differentiated,fully active,wild-type,No,No,No,Yes,No,0,"race: white, sex: male, age: 74, bmi: 27.59, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 10, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type, adverse effect: infection: Yes","The patient is a 74-year-old white male with a BMI of 27.59. He is receiving treatment with FOLFOX + Cetuximab and has completed 10 cycles of chemotherapy. His histology shows poorly differentiated cancer cells. Despite this, his performance status is fully active. The KRAS biomarker indicates that he has a wild-type gene. The patient has experienced an adverse effect in the form of an infection."
2697,white,male,64,31.87,FOLFOX + Cetuximab,No,No,No,No,0,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 64, bmi: 31.87, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 0, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 64-year-old white male with a BMI of 31.87. He is enrolled in the treatment arm receiving FOLFOX + Cetuximab but has not started chemotherapy cycles yet. His histology shows well-differentiated cancer, and he has a fully active performance status. The KRAS biomarker analysis indicates that he has a wild-type KRAS status."
2698,white,female,66,24.16,FOLFOX,No,No,No,No,4,poorly differentiated,symptoms but ambulatory,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 66, bmi: 24.16, treatment arm: FOLFOX, chemotherapy cycles: 4, histology: poorly differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type","The patient is a 66-year-old white female with a BMI of 24.16. She is receiving the FOLFOX treatment arm and has completed 4 cycles of chemotherapy. Her histology shows poorly differentiated cancer cells. Despite experiencing symptoms, she is still able to walk around (ambulatory). The KRAS biomarker indicates that she has a wild-type KRAS gene."
2699,white,female,68,35.7,FOLFOX + Cetuximab,Yes,No,No,Yes,12,poorly differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 68, bmi: 35.7, treatment arm: FOLFOX + Cetuximab, adherence: Yes, bowel perforation: Yes, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 68-year-old white female with a BMI of 35.7. She is part of the treatment arm receiving FOLFOX + Cetuximab and has been adherent to the treatment. She experienced a bowel perforation and completed 12 cycles of chemotherapy. The histology shows poorly differentiated cells, and her performance status is fully active. The KRAS biomarker indicates that she has a wild-type mutation."
2700,other,female,59,28,FOLFOX + Cetuximab,No,No,No,No,1,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: other, sex: female, age: 59, bmi: 28.0, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 1, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 59-year-old female of a race categorized as ""other"" with a BMI of 28.0. She is currently receiving treatment in the FOLFOX + Cetuximab treatment arm and has completed one cycle of chemotherapy. The histology of her condition is well-differentiated, and her performance status is fully active. Additionally, the KRAS biomarker analysis indicates that she has a wild-type KRAS status."
2701,white,female,69,23.4,FOLFOX,No,No,No,No,12,well differentiated,fully active,mutant,No,No,No,No,No,0,"race: white, sex: female, age: 69, bmi: 23.4, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 69-year-old white female with a BMI of 23.4. She is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cancer cells. Despite her age, she has a fully active performance status. The KRAS biomarker testing revealed a mutant status."
2702,white,female,65,28.64,FOLFOX,Yes,No,No,No,12,well differentiated,symptoms but ambulatory,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 65, bmi: 28.64, treatment arm: FOLFOX, adherence: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type","The patient is a 65-year-old white female with a BMI of 28.64. She is receiving the FOLFOX treatment regimen and has been adherent to her chemotherapy cycles, completing a total of 12 cycles. Her histology shows well-differentiated cancer cells. Despite experiencing symptoms, she is still able to be ambulatory. The KRAS biomarker testing revealed that she has a wild-type KRAS status."
2703,white,male,52,35.95,FOLFOX,No,Yes,No,No,11,poorly differentiated,fully active,wild-type,Yes,Yes,No,No,No,0,"race: white, sex: male, age: 52, bmi: 35.95, treatment arm: FOLFOX, serious adverse effect: Yes, chemotherapy cycles: 11, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type, adverse effect: thrombosis: Yes, adverse effect: hypersensitivity: Yes","The patient is a 52-year-old white male with a BMI of 35.95 who is receiving the FOLFOX treatment regimen. He has experienced serious adverse effects during his 11 chemotherapy cycles, including thrombosis and hypersensitivity reactions. His cancer histology is poorly differentiated, and his performance status is fully active. The KRAS biomarker testing revealed a wild-type result."
2704,white,female,58,40.74,FOLFIRI (KRAS mutant),No,Yes,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 58, bmi: 40.74, treatment arm: FOLFIRI (KRAS mutant), serious adverse effect: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","This patient is a 58-year-old white female with a BMI of 40.74. She is receiving the FOLFIRI treatment regimen for her KRAS mutant status. She has experienced a serious adverse effect during her 12 cycles of chemotherapy. Her histology shows well-differentiated cells, and her performance status is fully active. It is important to note that her KRAS biomarker is wild-type."
2705,white,male,57,25.16,FOLFIRI,No,No,No,No,12,well differentiated,symptoms but ambulatory,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 57, bmi: 25.16, treatment arm: FOLFIRI, chemotherapy cycles: 12, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type","The patient is a 57-year-old white male with a BMI of 25.16. He is receiving treatment with the FOLFIRI chemotherapy regimen and has completed 12 cycles. His cancer histology is well-differentiated. Despite experiencing symptoms, he is still able to be ambulatory. The KRAS biomarker testing revealed that he has a wild-type KRAS status."
2706,white,female,55,37.02,FOLFOX + Cetuximab,Yes,No,Yes,Yes,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 55, bmi: 37.02, treatment arm: FOLFOX + Cetuximab, adherence: Yes, bowel obstruction: Yes, bowel perforation: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 55-year-old white female with a BMI of 37.02. She is receiving treatment with FOLFOX + Cetuximab and has been adherent to the treatment. She has experienced both bowel obstruction and bowel perforation. The patient has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cancer cells. Despite the bowel issues, her performance status is fully active. The KRAS biomarker indicates that she has a wild-type mutation."
2707,white,female,74,24.95,FOLFOX + Cetuximab,No,Yes,No,No,4,well differentiated,fully active,wild-type,No,No,Yes,No,No,0,"race: white, sex: female, age: 74, bmi: 24.95, treatment arm: FOLFOX + Cetuximab, serious adverse effect: Yes, chemotherapy cycles: 4, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type, adverse effect: diarrhea: Yes","The patient is a 74-year-old white female with a BMI of 24.95. She is receiving treatment with FOLFOX + Cetuximab and has experienced a serious adverse effect. She has completed 4 cycles of chemotherapy. Her histology shows well-differentiated cells, and she has a fully active performance status. The KRAS biomarker indicates she is wild-type. Additionally, she has experienced diarrhea as an adverse effect of the treatment."
2708,white,male,67,27.56,FOLFOX + Cetuximab,No,No,Yes,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,1,"race: white, sex: male, age: 67, bmi: 27.56, treatment arm: FOLFOX + Cetuximab, bowel obstruction: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 67-year-old white male with a BMI of 27.56. He is receiving treatment with FOLFOX + Cetuximab for his well-differentiated histology. He has experienced a bowel obstruction and has completed 12 cycles of chemotherapy. Despite this, his performance status is fully active. Additionally, his KRAS biomarker status is wild-type."
2709,white,male,74,24.84,FOLFOX,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,Yes,No,No,0,"race: white, sex: male, age: 74, bmi: 24.84, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type, adverse effect: diarrhea: Yes","The patient is a 74-year-old white male with a BMI of 24.84. He is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer cells. Despite his age, he has a fully active performance status. The KRAS biomarker analysis indicates that he has a wild-type KRAS gene. The patient is experiencing diarrhea as an adverse effect of the treatment."
2710,white,female,61,26.43,FOLFOX,No,No,Yes,No,12,poorly differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 61, bmi: 26.43, treatment arm: FOLFOX, bowel obstruction: Yes, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 61-year-old white female with a BMI of 26.43. She is receiving treatment with the FOLFOX regimen and has experienced a bowel obstruction. She has completed 12 cycles of chemotherapy. The histology of her cancer is poorly differentiated. Despite these challenges, her performance status is fully active. Additionally, her KRAS biomarker status is wild-type."
2711,white,male,42,25.96,FOLFIRI,No,Yes,No,No,12,well differentiated,fully active,wild-type,No,No,Yes,No,No,1,"race: white, sex: male, age: 42, bmi: 25.96, treatment arm: FOLFIRI, serious adverse effect: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type, adverse effect: diarrhea: Yes","The patient is a 42-year-old white male with a BMI of 25.96 who is receiving the FOLFIRI treatment regimen. He has experienced a serious adverse effect during his 12 chemotherapy cycles. His histology shows well-differentiated cells, and his performance status is fully active. The KRAS biomarker indicates he has a wild-type status. Additionally, he has experienced diarrhea as an adverse effect."
2712,white,female,41,23.31,FOLFOX,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 41, bmi: 23.31, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type",The patient is a 41-year-old white female with a BMI of 23.31. She is receiving treatment with the FOLFOX chemotherapy regimen and has completed 12 cycles. The histology of her cancer is well-differentiated. She has a fully active performance status and her KRAS biomarker is wild-type.
2713,white,female,41,18.78,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 41, bmi: 18.78, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type",The patient is a 41-year-old white female with a BMI of 18.78. She is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. Her cancer histology is well-differentiated. She has a fully active performance status. The KRAS biomarker testing shows that she has a wild-type KRAS status.
2714,white,male,72,21.32,FOLFOX,No,No,Yes,No,11,poorly differentiated,fully active,mutant,No,No,No,No,No,0,"race: white, sex: male, age: 72, bmi: 21.32, treatment arm: FOLFOX, bowel obstruction: Yes, chemotherapy cycles: 11, histology: poorly differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 72-year-old white male with a BMI of 21.32. He is receiving the FOLFOX treatment arm for his bowel obstruction. He has completed 11 cycles of chemotherapy. The histology shows poorly differentiated cancer cells. Despite this, his performance status is fully active. The KRAS biomarker analysis indicates a mutant status."
2715,white,female,57,25.59,FOLFIRI,Yes,No,Yes,No,12,well differentiated,symptoms but ambulatory,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 57, bmi: 25.59, treatment arm: FOLFIRI, adherence: Yes, bowel obstruction: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type","The patient is a 57-year-old white female with a BMI of 25.59. She is receiving treatment in the FOLFIRI treatment arm and has been adherent to her chemotherapy. She is currently experiencing a bowel obstruction. So far, she has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cells. Despite experiencing symptoms, she is still able to be ambulatory. Her KRAS biomarker status is wild-type."
2716,white,male,76,23.65,FOLFOX + Cetuximab,No,Yes,No,No,12,well differentiated,fully active,wild-type,No,No,Yes,No,No,0,"race: white, sex: male, age: 76, bmi: 23.65, treatment arm: FOLFOX + Cetuximab, serious adverse effect: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type, adverse effect: diarrhea: Yes","The patient is a 76-year-old white male with a BMI of 23.65. He is receiving treatment with FOLFOX + Cetuximab and has experienced a serious adverse effect. He has completed 12 cycles of chemotherapy. His histology shows well-differentiated cells, and his performance status is fully active. His KRAS biomarker is wild-type. Additionally, he has experienced diarrhea as an adverse effect of the treatment."
2717,black,female,71,38.3,FOLFOX,No,No,No,No,4,well differentiated,fully active,mutant,No,No,Yes,No,No,0,"race: black, sex: female, age: 71, bmi: 38.3, treatment arm: FOLFOX, chemotherapy cycles: 4, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant, adverse effect: diarrhea: Yes","The patient is a 71-year-old Black female with a BMI of 38.3 who is receiving the FOLFOX treatment regimen for chemotherapy. She has completed 4 cycles of chemotherapy and her histology shows well-differentiated cells. Despite experiencing diarrhea as an adverse effect, her performance status is fully active. Additionally, the KRAS biomarker testing revealed a mutant status."
2718,white,female,72,19.99,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,symptoms but ambulatory,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 72, bmi: 19.99, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type","The patient is a 72-year-old white female with a BMI of 19.99. She is receiving treatment with FOLFOX and Cetuximab and has completed 12 cycles of chemotherapy. Her cancer histology is well-differentiated. Despite experiencing symptoms, she is still able to walk around (ambulatory). Her KRAS biomarker status is wild-type."
2719,white,male,47,27.25,FOLFOX,No,No,No,No,6,well differentiated,fully active,mutant,No,No,No,No,No,0,"race: white, sex: male, age: 47, bmi: 27.25, treatment arm: FOLFOX, chemotherapy cycles: 6, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant",The patient is a 47-year-old white male with a BMI of 27.25. He is receiving the FOLFOX treatment regimen and has completed 6 cycles of chemotherapy. His histology shows well-differentiated cancer cells. The patient has a fully active performance status. The KRAS biomarker analysis indicates a mutant status.
2720,white,male,63,28.51,FOLFOX,No,No,No,No,12,poorly differentiated,fully active,mutant,No,Yes,No,No,No,0,"race: white, sex: male, age: 63, bmi: 28.51, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: mutant, adverse effect: hypersensitivity: Yes","The patient is a 63-year-old white male with a BMI of 28.51. He is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. His histology shows poorly differentiated cancer cells. Despite this, his performance status is fully active. The KRAS biomarker testing revealed a mutant status. The patient has experienced a hypersensitivity adverse effect."
2721,white,female,59,19.68,FOLFOX,No,No,Yes,No,12,poorly differentiated,symptoms but ambulatory,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 59, bmi: 19.68, treatment arm: FOLFOX, bowel obstruction: Yes, chemotherapy cycles: 12, histology: poorly differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type","The patient is a 59-year-old white female with a BMI of 19.68. She is receiving the FOLFOX treatment regimen and has experienced a bowel obstruction. She has completed 12 cycles of chemotherapy. The histology of her cancer is poorly differentiated. Despite experiencing symptoms, she is still able to be ambulatory. Her KRAS biomarker status is wild-type."
2722,white,male,56,26.97,FOLFOX + Cetuximab,Yes,No,No,No,12,well differentiated,fully active,wild-type,No,No,Yes,No,No,0,"race: white, sex: male, age: 56, bmi: 26.97, treatment arm: FOLFOX + Cetuximab, adherence: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type, adverse effect: diarrhea: Yes","The patient is a 56-year-old white male with a BMI of 26.97 who is undergoing treatment with FOLFOX + Cetuximab. He has been adherent to the treatment and has completed 12 chemotherapy cycles. His histology shows well-differentiated cancer, and he has a fully active performance status. The KRAS biomarker indicates that he is wild-type. The patient has experienced diarrhea as an adverse effect of the treatment."
2723,white,male,43,39.12,FOLFOX,Yes,No,No,No,12,well differentiated,fully active,mutant,No,No,No,No,No,0,"race: white, sex: male, age: 43, bmi: 39.12, treatment arm: FOLFOX, adherence: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 43-year-old white male with a BMI of 39.12. He is receiving treatment with FOLFOX chemotherapy and has been adherent to the treatment for 12 cycles. The histology shows well-differentiated cancer cells, and the patient's performance status is fully active. The KRAS biomarker analysis indicates a mutant status."
2724,white,female,39,32.3,FOLFOX + Cetuximab,Yes,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 39, bmi: 32.3, treatment arm: FOLFOX + Cetuximab, adherence: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 39-year-old white female with a BMI of 32.3. She is receiving treatment in the FOLFOX + Cetuximab treatment arm and has been adherent to her chemotherapy regimen for 12 cycles. Her histology shows well-differentiated cells, and she has a fully active performance status. Additionally, her KRAS biomarker is wild-type."
2725,white,male,73,28.98,FOLFIRI,No,Yes,No,No,8,well differentiated,fully active,wild-type,No,No,No,No,No,1,"race: white, sex: male, age: 73, bmi: 28.98, treatment arm: FOLFIRI, serious adverse effect: Yes, chemotherapy cycles: 8, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 73-year-old white male with a BMI of 28.98. He is receiving the FOLFIRI treatment regimen and has experienced a serious adverse effect. He has completed 8 cycles of chemotherapy. The histology shows well-differentiated cancer cells. Despite the adverse effect, the patient's performance status is fully active. The KRAS biomarker indicates that the patient has a wild-type KRAS gene."
2726,white,female,59,32.59,FOLFOX + Cetuximab,Yes,No,Yes,No,12,poorly differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 59, bmi: 32.59, treatment arm: FOLFOX + Cetuximab, adherence: Yes, bowel obstruction: Yes, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 59-year-old white female with a BMI of 32.59. She is receiving treatment in the FOLFOX + Cetuximab treatment arm and has been adherent to her treatment. She has experienced a bowel obstruction. The patient has completed 12 cycles of chemotherapy. Histologically, her cancer is poorly differentiated. Despite these challenges, she has a fully active performance status. Additionally, her KRAS biomarker is wild-type."
2727,white,female,65,24.54,FOLFOX,No,No,No,No,7,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 65, bmi: 24.54, treatment arm: FOLFOX, chemotherapy cycles: 7, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type",The patient is a 65-year-old white female with a BMI of 24.54. She is receiving the FOLFOX treatment regimen and has completed 7 cycles of chemotherapy. Her histology shows well-differentiated cancer cells. The patient has a fully active performance status and her KRAS biomarker is wild-type.
2728,white,female,59,36.05,FOLFOX,No,No,No,No,4,well differentiated,fully active,wild-type,No,No,Yes,No,No,0,"race: white, sex: female, age: 59, bmi: 36.05, treatment arm: FOLFOX, chemotherapy cycles: 4, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type, adverse effect: diarrhea: Yes",The patient is a 59-year-old white female with a BMI of 36.05 who is receiving the FOLFOX treatment regimen for her well-differentiated histology. She has completed 4 cycles of chemotherapy and has a fully active performance status. Her KRAS biomarker is wild-type. The patient is experiencing diarrhea as an adverse effect of the treatment.
2729,other,male,53,18.5,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: other, sex: male, age: 53, bmi: 18.5, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 53-year-old male of a race categorized as ""other"" with a BMI of 18.5. He is receiving treatment in the FOLFOX + Cetuximab treatment arm and is scheduled for 12 chemotherapy cycles. His histology indicates well-differentiated cancer cells. The patient has a fully active performance status and his KRAS biomarker is wild-type."
2730,white,male,75,31.48,FOLFOX,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 75, bmi: 31.48, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 75-year-old white male with a BMI of 31.48. He is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. His cancer histology is well differentiated, and he has a fully active performance status. The KRAS biomarker analysis shows that he has a wild-type KRAS status."
2731,white,male,66,24.42,FOLFIRI (KRAS mutant),No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 66, bmi: 24.42, treatment arm: FOLFIRI (KRAS mutant), chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 66-year-old white male with a BMI of 24.42. He is receiving the FOLFIRI treatment regimen for his KRAS mutant status. He has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer cells. Despite his cancer diagnosis, he has a fully active performance status. His KRAS biomarker is wild-type."
2732,white,female,68,50.38,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,symptoms but ambulatory,wild-type,Yes,No,No,Yes,No,0,"race: white, sex: female, age: 68, bmi: 50.38, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type, adverse effect: thrombosis: Yes, adverse effect: infection: Yes","The patient is a 68-year-old white female with a BMI of 50.38. She is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. The histology shows well-differentiated cancer, and her performance status indicates that she has symptoms but is still able to walk around. Her KRAS biomarker is wild-type. She has experienced adverse effects of thrombosis and infection."
2733,white,female,67,23.94,FOLFIRI (KRAS mutant),No,No,No,No,1,well differentiated,fully active,mutant,No,No,No,No,No,1,"race: white, sex: female, age: 67, bmi: 23.94, treatment arm: FOLFIRI (KRAS mutant), chemotherapy cycles: 1, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 67-year-old white female with a BMI of 23.94. She is receiving treatment with the FOLFIRI regimen for KRAS mutant cancer. She has completed one cycle of chemotherapy. The histology of her cancer is well differentiated. Despite her diagnosis, she has a fully active performance status."
2734,white,male,46,31.2,FOLFOX + Cetuximab,No,Yes,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,Yes,0,"race: white, sex: male, age: 46, bmi: 31.2, treatment arm: FOLFOX + Cetuximab, serious adverse effect: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type, adverse effect: infarction: Yes","The patient is a 46-year-old white male with a BMI of 31.2. He is receiving treatment with FOLFOX + Cetuximab and has experienced a serious adverse effect. He has completed 12 cycles of chemotherapy. His histology shows well-differentiated cells, and his performance status is fully active. The KRAS biomarker is wild-type. Additionally, he has experienced an infarction as an adverse effect."
2735,white,male,62,29.53,FOLFOX,No,No,No,No,12,poorly differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 62, bmi: 29.53, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 62-year-old white male with a BMI of 29.53. He is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. His cancer histology is poorly differentiated. Despite his cancer diagnosis, he has a fully active performance status. Additionally, his KRAS biomarker status is wild-type."
2736,white,male,36,18.37,FOLFIRI + Cetuximab,No,No,No,No,12,poorly differentiated,fully active,mutant,No,No,No,No,No,0,"race: white, sex: male, age: 36, bmi: 18.37, treatment arm: FOLFIRI + Cetuximab, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 36-year-old white male with a BMI of 18.37. He is receiving treatment in the FOLFIRI + Cetuximab treatment arm and has completed 12 cycles of chemotherapy. His histology shows poorly differentiated cancer cells. Despite this, his performance status is fully active. The KRAS biomarker analysis indicates a mutant status."
2737,white,male,45,26.89,FOLFOX,No,No,Yes,No,9,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 45, bmi: 26.89, treatment arm: FOLFOX, bowel obstruction: Yes, chemotherapy cycles: 9, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 45-year-old white male with a BMI of 26.89. He is receiving treatment with the FOLFOX regimen for his bowel obstruction. He has completed 9 cycles of chemotherapy. The histology shows well-differentiated cancer cells. Despite the bowel obstruction, his performance status is fully active. The KRAS biomarker analysis indicates a wild-type result."
2738,white,male,43,30.2,FOLFOX,No,No,No,No,12,well differentiated,fully active,mutant,No,No,No,No,No,0,"race: white, sex: male, age: 43, bmi: 30.2, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant",The patient is a 43-year-old white male with a BMI of 30.2. He is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer cells. The patient has a fully active performance status and has a mutant KRAS biomarker.
2739,white,male,58,30.52,FOLFIRI (KRAS mutant),No,No,Yes,No,12,well differentiated,fully active,mutant,No,No,No,No,No,1,"race: white, sex: male, age: 58, bmi: 30.52, treatment arm: FOLFIRI (KRAS mutant), bowel obstruction: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 58-year-old white male with a BMI of 30.52. He is receiving treatment with the FOLFIRI regimen for his KRAS mutant status. He has a bowel obstruction and has completed 12 cycles of chemotherapy. The histology shows well-differentiated cells, and his performance status is fully active."
2740,other,male,63,30.3,FOLFOX,No,No,No,No,12,well differentiated,fully active,interminate,No,No,No,No,No,1,"race: other, sex: male, age: 63, bmi: 30.3, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: interminate","The patient is a 63-year-old male of a race categorized as ""other"" with a BMI of 30.3. He is receiving the FOLFOX treatment arm and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cells, and he has a fully active performance status. The KRAS biomarker status is indeterminate for this patient."
2741,white,female,75,31.87,FOLFOX,Yes,No,No,No,12,poorly differentiated,fully active,wild-type,No,No,Yes,No,No,1,"race: white, sex: female, age: 75, bmi: 31.87, treatment arm: FOLFOX, adherence: Yes, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type, adverse effect: diarrhea: Yes","The patient is a 75-year-old white female with a BMI of 31.87. She is receiving the FOLFOX treatment regimen and has been adherent to her chemotherapy cycles, completing 12 cycles so far. Her cancer histology is poorly differentiated. Despite this, her performance status is fully active. The KRAS biomarker testing revealed that she has a wild-type KRAS status. She has experienced diarrhea as an adverse effect during her treatment."
2742,white,male,35,32.96,FOLFOX,Yes,No,No,No,12,poorly differentiated,symptoms but ambulatory,mutant,No,No,Yes,Yes,No,1,"race: white, sex: male, age: 35, bmi: 32.96, treatment arm: FOLFOX, adherence: Yes, chemotherapy cycles: 12, histology: poorly differentiated, performance status: symptoms but ambulatory, KRAS biomarker: mutant, adverse effect: diarrhea: Yes, adverse effect: infection: Yes","The patient is a 35-year-old white male with a BMI of 32.96. He is receiving the FOLFOX treatment regimen and has been adherent to the chemotherapy cycles, completing 12 cycles so far. His cancer histology is poorly differentiated. Despite experiencing symptoms, he is still able to be ambulatory. The KRAS biomarker testing revealed a mutant status. The patient has experienced adverse effects of diarrhea and infection during the course of treatment."
2743,white,male,64,22.49,FOLFOX + Cetuximab,Yes,No,No,No,7,well differentiated,fully active,wild-type,No,No,No,Yes,No,0,"race: white, sex: male, age: 64, bmi: 22.49, treatment arm: FOLFOX + Cetuximab, adherence: Yes, chemotherapy cycles: 7, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type, adverse effect: infection: Yes",The patient is a 64-year-old white male with a BMI of 22.49. He is receiving treatment with FOLFOX + Cetuximab and has been adherent to the treatment. He has completed 7 cycles of chemotherapy. His histology shows well-differentiated cancer. The patient has a fully active performance status. His KRAS biomarker is wild-type. He has experienced an infection as an adverse effect during his treatment.
2744,white,male,43,29.65,FOLFOX,No,No,No,No,12,poorly differentiated,symptoms but ambulatory,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 43, bmi: 29.65, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: poorly differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type","The patient is a 43-year-old white male with a BMI of 29.65. He is receiving treatment with the FOLFOX chemotherapy regimen and has completed 12 cycles. His histology shows poorly differentiated cancer cells. Despite experiencing symptoms, he is still able to be ambulatory. The KRAS biomarker analysis indicates that he has a wild-type KRAS status."
2745,white,female,62,22.25,FOLFOX,No,No,Yes,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 62, bmi: 22.25, treatment arm: FOLFOX, bowel obstruction: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 62-year-old white female with a BMI of 22.25. She is receiving the FOLFOX treatment regimen and has experienced a bowel obstruction. She has completed 12 cycles of chemotherapy. The histology of her cancer is well differentiated. Despite the bowel obstruction, her performance status is fully active. The KRAS biomarker status is wild-type."
2746,white,female,58,21.93,FOLFIRI,No,No,Yes,No,12,well differentiated,fully active,mutant,No,No,No,No,No,0,"race: white, sex: female, age: 58, bmi: 21.93, treatment arm: FOLFIRI, bowel obstruction: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 58-year-old white female with a BMI of 21.93. She is receiving treatment with the FOLFIRI regimen and has experienced a bowel obstruction. She has completed 12 cycles of chemotherapy. The histology of her cancer is well-differentiated. Despite the bowel obstruction, her performance status is fully active. The KRAS biomarker analysis shows that she has a mutant KRAS status."
2747,white,male,74,28.4,FOLFOX,No,No,No,No,12,poorly differentiated,fully active,wild-type,No,No,Yes,No,No,0,"race: white, sex: male, age: 74, bmi: 28.4, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type, adverse effect: diarrhea: Yes","The patient is a 74-year-old white male with a BMI of 28.4. He is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. His cancer histology is poorly differentiated. Despite this, his performance status is fully active. The KRAS biomarker testing revealed that he has a wild-type KRAS status. The patient is experiencing diarrhea as an adverse effect of the treatment."
2748,black,female,39,24.91,FOLFOX,No,No,Yes,No,12,well differentiated,symptoms but ambulatory,wild-type,Yes,No,No,No,No,0,"race: black, sex: female, age: 39, bmi: 24.91, treatment arm: FOLFOX, bowel obstruction: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type, adverse effect: thrombosis: Yes","The patient is a 39-year-old Black female with a BMI of 24.91 who is undergoing treatment with the FOLFOX chemotherapy regimen. She has experienced a bowel obstruction and has completed 12 cycles of chemotherapy. The histology of her cancer is well-differentiated, and her performance status is characterized by symptoms but she is still able to be ambulatory. The KRAS biomarker testing revealed that she has a wild-type KRAS status. Additionally, she has experienced an adverse effect of thrombosis."
2749,white,male,55,34.42,FOLFOX + Cetuximab,Yes,No,No,No,7,poorly differentiated,fully active,wild-type,No,No,No,No,No,1,"race: white, sex: male, age: 55, bmi: 34.42, treatment arm: FOLFOX + Cetuximab, adherence: Yes, chemotherapy cycles: 7, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 55-year-old white male with a BMI of 34.42. He is currently receiving treatment in the FOLFOX + Cetuximab treatment arm and has been adherent to the treatment regimen. He has completed 7 cycles of chemotherapy. The histology of his cancer is poorly differentiated. Despite this, his performance status is fully active. Additionally, his KRAS biomarker status is wild-type."
2750,white,male,49,20.95,FOLFOX + Cetuximab,Yes,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 49, bmi: 20.95, treatment arm: FOLFOX + Cetuximab, adherence: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type",The patient is a 49-year-old white male with a BMI of 20.95. He is undergoing treatment with FOLFOX + Cetuximab and has been adherent to the treatment. He has completed 12 chemotherapy cycles. His histology shows well-differentiated cancer cells. The patient has a fully active performance status. His KRAS biomarker is wild-type.
2751,white,female,51,40.12,FOLFOX + Cetuximab,No,No,No,No,10,well differentiated,fully active,mutant,No,No,Yes,No,No,0,"race: white, sex: female, age: 51, bmi: 40.12, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 10, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant, adverse effect: diarrhea: Yes","The patient is a 51-year-old white female with a BMI of 40.12. She is receiving treatment with FOLFOX + Cetuximab and has completed 10 cycles of chemotherapy. Her cancer histology is well-differentiated, and she has a fully active performance status. The KRAS biomarker testing revealed a mutant status. The patient is experiencing diarrhea as an adverse effect of the treatment."
2752,white,female,59,28.5,FOLFOX + Cetuximab,No,No,No,Yes,12,well differentiated,fully active,mutant,No,No,No,No,No,0,"race: white, sex: female, age: 59, bmi: 28.5, treatment arm: FOLFOX + Cetuximab, bowel perforation: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 59-year-old white female with a BMI of 28.5. She is receiving treatment with FOLFOX + Cetuximab and has experienced a bowel perforation. She has completed 12 cycles of chemotherapy. The histology of her cancer is well differentiated. Despite the bowel perforation, her performance status is fully active. The KRAS biomarker indicates that she has a mutant status."
2753,white,female,53,43.49,FOLFOX,Yes,Yes,No,No,12,poorly differentiated,fully active,wild-type,Yes,No,No,No,No,0,"race: white, sex: female, age: 53, bmi: 43.49, treatment arm: FOLFOX, adherence: Yes, serious adverse effect: Yes, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type, adverse effect: thrombosis: Yes","This patient is a 53-year-old white female with a BMI of 43.49 who is receiving the FOLFOX treatment regimen. She has been adherent to her treatment and has completed 12 cycles of chemotherapy. The histology of her cancer is poorly differentiated, and her performance status is fully active. Her KRAS biomarker is wild-type. She has experienced a serious adverse effect in the form of thrombosis."
2754,white,female,49,23.63,FOLFOX,No,No,No,No,12,poorly differentiated,fully active,wild-type,No,No,Yes,No,No,0,"race: white, sex: female, age: 49, bmi: 23.63, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type, adverse effect: diarrhea: Yes","The patient is a 49-year-old white female with a BMI of 23.63. She is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. Her histology shows poorly differentiated cancer cells. Despite this, her performance status is fully active. The KRAS biomarker analysis indicates she has a wild-type KRAS status. The patient has experienced diarrhea as an adverse effect of the treatment."
2755,white,female,76,33.01,FOLFOX + Cetuximab,Yes,No,Yes,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 76, bmi: 33.01, treatment arm: FOLFOX + Cetuximab, adherence: Yes, bowel obstruction: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 76-year-old white female with a BMI of 33.01. She is receiving treatment in the FOLFOX + Cetuximab treatment arm and has been adherent to her treatment. She has experienced a bowel obstruction. The patient has completed 12 cycles of chemotherapy and her histology shows well-differentiated cells. Despite the bowel obstruction, her performance status is fully active. Her KRAS biomarker is wild-type."
2756,other,female,64,31.32,FOLFOX + Cetuximab,No,No,No,Yes,11,poorly differentiated,symptoms but ambulatory,wild-type,No,No,No,No,No,0,"race: other, sex: female, age: 64, bmi: 31.32, treatment arm: FOLFOX + Cetuximab, bowel perforation: Yes, chemotherapy cycles: 11, histology: poorly differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type","The patient is a 64-year-old female of a race categorized as ""other"" with a BMI of 31.32. She is undergoing treatment with FOLFOX + Cetuximab and has experienced a bowel perforation. She has completed 11 cycles of chemotherapy. The histology of her cancer is poorly differentiated. Despite experiencing symptoms, she is still able to be ambulatory. Her KRAS biomarker status is wild-type."
2757,white,male,40,28.24,FOLFOX,Yes,No,No,No,12,well differentiated,fully active,mutant,No,No,No,No,No,0,"race: white, sex: male, age: 40, bmi: 28.24, treatment arm: FOLFOX, adherence: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant",The patient is a 40-year-old white male with a BMI of 28.24. He is receiving the FOLFOX treatment regimen and has been adherent to the treatment. He has completed 12 cycles of chemotherapy. The histology shows well-differentiated cancer cells. The patient has a fully active performance status. The KRAS biomarker testing revealed a mutant status.
2758,white,female,61,34.97,FOLFOX,No,No,No,No,12,poorly differentiated,fully active,wild-type,No,No,No,No,No,1,"race: white, sex: female, age: 61, bmi: 34.97, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 61-year-old white female with a BMI of 34.97. She is undergoing treatment with the FOLFOX chemotherapy regimen and has completed 12 cycles. The histology of her cancer is poorly differentiated. Despite her diagnosis, she has a fully active performance status. Additionally, her KRAS biomarker status is wild-type."
2759,white,male,46,30.17,FOLFOX,No,No,Yes,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 46, bmi: 30.17, treatment arm: FOLFOX, bowel obstruction: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 46-year-old white male with a BMI of 30.17. He is receiving the FOLFOX treatment regimen for his well-differentiated histology. He has experienced a bowel obstruction and has completed 12 cycles of chemotherapy. Despite the bowel obstruction, his performance status is fully active. The KRAS biomarker testing showed that he has a wild-type KRAS status."
2760,white,female,34,36.23,FOLFOX + Cetuximab,No,No,Yes,No,1,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 34, bmi: 36.23, treatment arm: FOLFOX + Cetuximab, bowel obstruction: Yes, chemotherapy cycles: 1, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 34-year-old white female with a BMI of 36.23. She is currently receiving treatment in the FOLFOX + Cetuximab treatment arm. She has experienced a bowel obstruction and has completed one cycle of chemotherapy. The histology shows that the cancer is well-differentiated. Despite the bowel obstruction, her performance status is fully active. The KRAS biomarker indicates that she has a wild-type mutation."
2761,white,female,57,19.44,FOLFOX + Cetuximab,No,Yes,No,No,12,well differentiated,symptoms but ambulatory,mutant,No,No,Yes,No,No,0,"race: white, sex: female, age: 57, bmi: 19.44, treatment arm: FOLFOX + Cetuximab, serious adverse effect: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: mutant, adverse effect: diarrhea: Yes","The patient is a 57-year-old white female with a BMI of 19.44. She is receiving treatment in the FOLFOX + Cetuximab treatment arm and has experienced a serious adverse effect. She has undergone 12 chemotherapy cycles and has well-differentiated histology. Despite experiencing symptoms, she is still ambulatory. The KRAS biomarker shows a mutant status. Additionally, she has experienced diarrhea as an adverse effect."
2762,white,female,49,23.35,FOLFOX,Yes,No,No,No,12,well differentiated,fully active,mutant,No,No,No,No,No,0,"race: white, sex: female, age: 49, bmi: 23.35, treatment arm: FOLFOX, adherence: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 49-year-old white female with a BMI of 23.35. She is receiving treatment with the FOLFOX regimen and has been adherent to her chemotherapy cycles, completing a total of 12 cycles. Her histology shows well-differentiated cancer cells. The patient has a fully active performance status. The KRAS biomarker analysis indicates a mutant status."
2763,black,male,47,30.32,FOLFOX + Cetuximab,No,No,No,No,12,poorly differentiated,fully active,wild-type,No,No,No,No,No,0,"race: black, sex: male, age: 47, bmi: 30.32, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 47-year-old Black male with a BMI of 30.32. He is receiving treatment with FOLFOX + Cetuximab and is scheduled for 12 chemotherapy cycles. His cancer histology is poorly differentiated, and he has a fully active performance status. The KRAS biomarker analysis shows that he has a wild-type KRAS status."
2764,white,female,47,25.2,FOLFOX,No,No,No,No,2,well differentiated,symptoms but ambulatory,mutant,No,No,No,No,No,1,"race: white, sex: female, age: 47, bmi: 25.2, treatment arm: FOLFOX, chemotherapy cycles: 2, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: mutant","The patient is a 47-year-old white female with a BMI of 25.2. She is currently receiving the FOLFOX treatment regimen and has completed 2 cycles of chemotherapy. Her histology shows well-differentiated cancer cells. Despite experiencing symptoms, she is still able to be ambulatory. Additionally, the patient's KRAS biomarker indicates a mutant status."
2765,white,male,63,29.07,FOLFOX,No,No,No,No,12,well differentiated,fully active,mutant,No,No,No,No,No,0,"race: white, sex: male, age: 63, bmi: 29.07, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 63-year-old white male with a BMI of 29.07. He is receiving the FOLFOX treatment arm and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cells, and he has a fully active performance status. The KRAS biomarker analysis indicates a mutant status."
2766,white,male,64,30.28,FOLFOX,No,No,No,No,12,well differentiated,fully active,mutant,No,No,No,No,No,0,"race: white, sex: male, age: 64, bmi: 30.28, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 64-year-old white male with a BMI of 30.28. He is receiving treatment with the FOLFOX chemotherapy regimen and has completed 12 cycles. His cancer histology is well differentiated, and he has a fully active performance status. The KRAS biomarker testing revealed a mutant status."
2767,white,male,43,22.19,FOLFOX,No,No,Yes,No,12,poorly differentiated,fully active,wild-type,No,No,No,No,No,1,"race: white, sex: male, age: 43, bmi: 22.19, treatment arm: FOLFOX, bowel obstruction: Yes, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 43-year-old white male with a BMI of 22.19. He is receiving treatment with the FOLFOX regimen for his bowel obstruction. He has undergone 12 cycles of chemotherapy. The histology of his cancer is poorly differentiated. Despite his condition, he has a fully active performance status. The KRAS biomarker analysis shows that he has a wild-type KRAS gene."
2768,white,male,53,36.73,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,Yes,No,No,0,"race: white, sex: male, age: 53, bmi: 36.73, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type, adverse effect: diarrhea: Yes",The patient is a 53-year-old white male with a BMI of 36.73. He is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer cells. The patient has a fully active performance status and his KRAS biomarker is wild-type. He is experiencing diarrhea as an adverse effect of the treatment.
2769,white,male,56,36.01,FOLFOX + Cetuximab,Yes,No,No,No,12,well differentiated,symptoms but ambulatory,mutant,No,No,No,No,No,0,"race: white, sex: male, age: 56, bmi: 36.01, treatment arm: FOLFOX + Cetuximab, adherence: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: mutant","The patient is a 56-year-old white male with a BMI of 36.01. He is receiving treatment in the FOLFOX + Cetuximab treatment arm and has been adherent to the treatment. He has completed 12 chemotherapy cycles. His histology shows well-differentiated cancer. Despite experiencing symptoms, he is still able to be ambulatory. The KRAS biomarker analysis indicates a mutant status."
2770,white,female,75,33.23,FOLFOX + Cetuximab,No,Yes,No,Yes,4,poorly differentiated,fully active,wild-type,No,No,No,No,No,1,"race: white, sex: female, age: 75, bmi: 33.23, treatment arm: FOLFOX + Cetuximab, serious adverse effect: Yes, bowel perforation: Yes, chemotherapy cycles: 4, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 75-year-old white female with a BMI of 33.23. She is receiving treatment with FOLFOX + Cetuximab. Unfortunately, she experienced a serious adverse effect in the form of a bowel perforation after completing 4 cycles of chemotherapy. The histology of her cancer is poorly differentiated. Despite these challenges, her performance status is fully active. The KRAS biomarker testing revealed that she has a wild-type KRAS status."
2771,white,male,64,22.94,FOLFOX + Cetuximab,No,No,No,No,12,poorly differentiated,symptoms but ambulatory,mutant,No,No,No,No,No,1,"race: white, sex: male, age: 64, bmi: 22.94, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: poorly differentiated, performance status: symptoms but ambulatory, KRAS biomarker: mutant","The patient is a 64-year-old white male with a BMI of 22.94. He is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. His histology shows poorly differentiated cancer cells. Despite experiencing symptoms, he is still able to be ambulatory. The KRAS biomarker analysis revealed a mutant status."
2772,other,female,60,31.85,FOLFOX,No,No,No,No,12,well differentiated,fully active,mutant,No,No,No,No,No,0,"race: other, sex: female, age: 60, bmi: 31.85, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 60-year-old female of a race categorized as ""other"" with a BMI of 31.85. She is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cancer cells. Despite her cancer diagnosis, she maintains a fully active performance status. The KRAS biomarker testing revealed a mutant status."
2773,white,female,58,38.98,FOLFOX,No,No,No,No,7,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 58, bmi: 38.98, treatment arm: FOLFOX, chemotherapy cycles: 7, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 58-year-old white female with a BMI of 38.98. She is currently undergoing treatment with the FOLFOX chemotherapy regimen and has completed 7 cycles so far. Her cancer histology shows that it is well-differentiated. Despite her cancer diagnosis, she has a fully active performance status. Additionally, her KRAS biomarker status is wild-type."
2774,white,female,53,28.73,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,symptoms but ambulatory,wild-type,No,No,Yes,No,No,0,"race: white, sex: female, age: 53, bmi: 28.73, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type, adverse effect: diarrhea: Yes","This patient is a 53-year-old white female with a BMI of 28.73. She is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. Her cancer histology is well-differentiated, and she has symptoms but is still able to be ambulatory. Her KRAS biomarker status is wild-type. She is experiencing diarrhea as an adverse effect of her treatment."
2775,white,female,72,22.04,FOLFOX,No,No,No,No,12,poorly differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 72, bmi: 22.04, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 72-year-old white female with a BMI of 22.04. She is undergoing treatment with the FOLFOX chemotherapy regimen and has completed 12 cycles. The histology of her cancer is poorly differentiated. Despite this, her performance status is fully active. Additionally, her KRAS biomarker status is wild-type."
2776,white,male,41,21.71,FOLFOX + Cetuximab,No,Yes,Yes,No,12,well differentiated,fully active,wild-type,No,No,Yes,No,No,0,"race: white, sex: male, age: 41, bmi: 21.71, treatment arm: FOLFOX + Cetuximab, serious adverse effect: Yes, bowel obstruction: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type, adverse effect: diarrhea: Yes","The patient is a 41-year-old white male with a BMI of 21.71. He is receiving treatment with FOLFOX + Cetuximab and has experienced a serious adverse effect, specifically a bowel obstruction. He has completed 12 cycles of chemotherapy. The histology shows that the cancer is well-differentiated. Despite the adverse effects, the patient's performance status is fully active. The KRAS biomarker indicates that it is wild-type. Additionally, the patient has experienced diarrhea as an adverse effect of the treatment."
2777,white,male,39,22.64,FOLFOX,No,No,No,No,12,well differentiated,fully active,interminate,No,No,No,No,No,0,"race: white, sex: male, age: 39, bmi: 22.64, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: interminate",The patient is a 39-year-old white male with a BMI of 22.64. He is receiving treatment with the FOLFOX chemotherapy regimen and has completed 12 cycles. His histology shows well-differentiated cancer cells. The patient has a fully active performance status. The KRAS biomarker status is indeterminate.
2778,white,female,45,30.24,FOLFOX + Cetuximab,No,No,No,No,0,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 45, bmi: 30.24, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 0, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 45-year-old white female with a BMI of 30.24. She is enrolled in the FOLFOX + Cetuximab treatment arm but has not started chemotherapy cycles yet. Her histology shows well-differentiated cancer, and she has a fully active performance status. The KRAS biomarker analysis indicates that she has a wild-type KRAS status."
2779,white,female,62,40.82,FOLFOX + Cetuximab,No,No,Yes,No,12,well differentiated,symptoms but ambulatory,mutant,No,No,No,No,No,0,"race: white, sex: female, age: 62, bmi: 40.82, treatment arm: FOLFOX + Cetuximab, bowel obstruction: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: mutant","The patient is a 62-year-old white female with a BMI of 40.82. She is receiving treatment with FOLFOX + Cetuximab for her well-differentiated histology. She has experienced a bowel obstruction and has completed 12 cycles of chemotherapy. Despite experiencing symptoms, she is still able to ambulate. The patient's KRAS biomarker status is mutant."
2780,black,male,46,27.25,FOLFOX + Cetuximab,No,No,No,No,2,well differentiated,symptoms but ambulatory,wild-type,No,No,No,No,No,0,"race: black, sex: male, age: 46, bmi: 27.25, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 2, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type","The patient is a 46-year-old Black male with a BMI of 27.25. He is currently receiving treatment with FOLFOX + Cetuximab and has completed 2 cycles of chemotherapy. His histology shows well-differentiated cancer cells. Despite experiencing symptoms, he is still able to be ambulatory. The KRAS biomarker analysis indicates that he has a wild-type KRAS status."
2781,white,female,42,25.98,FOLFOX + Cetuximab,No,No,Yes,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 42, bmi: 25.98, treatment arm: FOLFOX + Cetuximab, bowel obstruction: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 42-year-old white female with a BMI of 25.98. She is receiving treatment with FOLFOX + Cetuximab for her well-differentiated histology. She has experienced a bowel obstruction and has completed 12 cycles of chemotherapy. Despite this, her performance status is fully active. Additionally, her KRAS biomarker status is wild-type."
2782,white,male,58,30.39,FOLFOX,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 58, bmi: 30.39, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type",The patient is a 58-year-old white male with a BMI of 30.39. He is receiving treatment with the FOLFOX chemotherapy regimen and has completed 12 cycles. His cancer histology is well differentiated. The patient has a fully active performance status and his KRAS biomarker is wild-type.
2783,black,male,71,29.78,FOLFOX + Cetuximab,No,No,No,No,12,poorly differentiated,fully active,mutant,No,No,No,No,No,0,"race: black, sex: male, age: 71, bmi: 29.78, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 71-year-old Black male with a BMI of 29.78. He is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. His histology shows poorly differentiated cancer cells. Despite this, his performance status is fully active. Additionally, the KRAS biomarker analysis indicates a mutant status."
2784,white,female,44,26.56,FOLFOX,No,No,No,No,12,poorly differentiated,fully active,wild-type,Yes,No,Yes,No,No,0,"race: white, sex: female, age: 44, bmi: 26.56, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type, adverse effect: thrombosis: Yes, adverse effect: diarrhea: Yes","The patient is a 44-year-old white female with a BMI of 26.56. She is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. Her histology shows poorly differentiated cancer cells. Despite this, her performance status is fully active. The KRAS biomarker analysis indicates that she has a wild-type KRAS status. The patient has experienced adverse effects during treatment, including thrombosis and diarrhea."
2785,white,female,43,36.1,FOLFOX,Yes,No,No,Yes,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 43, bmi: 36.1, treatment arm: FOLFOX, adherence: Yes, bowel perforation: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 43-year-old white female with a BMI of 36.1. She is receiving treatment in the FOLFOX treatment arm and has been adherent to her treatment. She experienced a bowel perforation during her treatment. She has completed 12 chemotherapy cycles. The histology of her cancer is well-differentiated. Despite the bowel perforation, her performance status is fully active. Her KRAS biomarker status is wild-type."
2786,white,female,49,30.61,FOLFOX,No,No,No,No,12,well differentiated,symptoms but ambulatory,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 49, bmi: 30.61, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type","The patient is a 49-year-old white female with a BMI of 30.61. She is undergoing treatment with the FOLFOX chemotherapy regimen and has completed 12 cycles. The histology of her cancer is well-differentiated. Despite experiencing symptoms, she is still able to be ambulatory. The KRAS biomarker analysis shows that she has a wild-type KRAS status."
2787,white,female,35,17.33,FOLFOX + Cetuximab,No,No,Yes,No,6,well differentiated,fully active,wild-type,No,No,No,Yes,No,0,"race: white, sex: female, age: 35, bmi: 17.33, treatment arm: FOLFOX + Cetuximab, bowel obstruction: Yes, chemotherapy cycles: 6, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type, adverse effect: infection: Yes","The patient is a 35-year-old white female with a BMI of 17.33. She is receiving treatment with FOLFOX + Cetuximab for her well-differentiated histology. She has experienced a bowel obstruction and has completed 6 cycles of chemotherapy. Despite this, her performance status remains fully active. Her KRAS biomarker is wild-type. Unfortunately, she has also developed an infection as an adverse effect of her treatment."
2788,white,male,46,26.12,FOLFOX + Cetuximab,Yes,No,Yes,Yes,3,well differentiated,fully active,mutant,No,No,No,No,No,1,"race: white, sex: male, age: 46, bmi: 26.12, treatment arm: FOLFOX + Cetuximab, adherence: Yes, bowel obstruction: Yes, bowel perforation: Yes, chemotherapy cycles: 3, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 46-year-old white male with a BMI of 26.12. He is currently receiving treatment in the FOLFOX + Cetuximab treatment arm and is adherent to the prescribed regimen. He has experienced both a bowel obstruction and a bowel perforation. So far, he has completed 3 cycles of chemotherapy. The histology of his condition is well-differentiated, and his performance status is fully active. Additionally, the KRAS biomarker testing revealed a mutant status."
2789,white,male,75,25.8,FOLFOX + Cetuximab,No,Yes,No,No,12,poorly differentiated,fully active,mutant,No,No,No,No,No,0,"race: white, sex: male, age: 75, bmi: 25.8, treatment arm: FOLFOX + Cetuximab, serious adverse effect: Yes, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 75-year-old white male with a BMI of 25.8. He is receiving treatment with FOLFOX + Cetuximab and has experienced a serious adverse effect. He has completed 12 cycles of chemotherapy. The histology of his cancer is poorly differentiated. Despite these challenges, his performance status is fully active. Additionally, the KRAS biomarker testing revealed a mutant status."
2790,white,male,64,26.44,FOLFOX,Yes,No,Yes,No,10,well differentiated,symptoms but ambulatory,mutant,No,No,No,No,No,0,"race: white, sex: male, age: 64, bmi: 26.44, treatment arm: FOLFOX, adherence: Yes, bowel obstruction: Yes, chemotherapy cycles: 10, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: mutant","The patient is a 64-year-old white male with a BMI of 26.44. He is receiving the FOLFOX treatment regimen and has been adherent to the treatment. He has experienced a bowel obstruction and has completed 10 cycles of chemotherapy. The histology shows well-differentiated cancer cells. Despite experiencing symptoms, the patient is still able to be ambulatory. The KRAS biomarker indicates a mutant status in this patient."
2791,white,female,73,27.54,FOLFOX + Cetuximab,No,No,Yes,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,1,"race: white, sex: female, age: 73, bmi: 27.54, treatment arm: FOLFOX + Cetuximab, bowel obstruction: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 73-year-old white female with a BMI of 27.54. She is receiving treatment with FOLFOX + Cetuximab and has experienced a bowel obstruction. She has completed 12 cycles of chemotherapy. The histology indicates that the cancer is well-differentiated. Despite the bowel obstruction, her performance status is fully active. The KRAS biomarker shows that she has a wild-type status."
2792,white,female,46,25.45,FOLFOX,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 46, bmi: 25.45, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type",The patient is a 46-year-old white female with a BMI of 25.45. She is undergoing treatment with the FOLFOX chemotherapy regimen and has completed 12 cycles. The histology shows well-differentiated cancer cells. The patient has a fully active performance status. The KRAS biomarker analysis indicates that she has a wild-type KRAS gene.
2793,white,male,44,25.86,FOLFOX + Cetuximab,No,Yes,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 44, bmi: 25.86, treatment arm: FOLFOX + Cetuximab, serious adverse effect: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","This patient is a 44-year-old white male with a BMI of 25.86. He is receiving treatment with FOLFOX + Cetuximab and has experienced a serious adverse effect. He has completed 12 cycles of chemotherapy. His histology shows well-differentiated cells, and he has a fully active performance status. Additionally, his KRAS biomarker is wild-type."
2794,white,female,54,26.4,FOLFOX + Cetuximab,No,No,No,No,12,poorly differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 54, bmi: 26.4, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 54-year-old white female with a BMI of 26.4. She is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. Her histology shows poorly differentiated cancer cells. Despite this, her performance status is fully active. Additionally, her KRAS biomarker is wild-type."
2795,white,male,62,28.69,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,fully active,mutant,No,No,No,Yes,No,0,"race: white, sex: male, age: 62, bmi: 28.69, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant, adverse effect: infection: Yes","The patient is a 62-year-old white male with a BMI of 28.69 who is receiving treatment with FOLFOX + Cetuximab for 12 chemotherapy cycles. His histology shows well-differentiated cancer, and he has a fully active performance status. The KRAS biomarker is mutant in this patient. He has experienced an adverse effect in the form of an infection."
2796,white,male,73,24.23,FOLFIRI + Cetuximab,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,1,"race: white, sex: male, age: 73, bmi: 24.23, treatment arm: FOLFIRI + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 73-year-old white male with a BMI of 24.23. He is undergoing treatment with FOLFIRI + Cetuximab and has completed 12 cycles of chemotherapy. His cancer histology is well-differentiated, and he has a fully active performance status. The KRAS biomarker analysis shows that he has a wild-type KRAS status."
2797,white,male,60,26.36,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 60, bmi: 26.36, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 60-year-old white male with a BMI of 26.36. He is receiving treatment in the FOLFOX + Cetuximab treatment arm and is scheduled for 12 cycles of chemotherapy. His histology shows well-differentiated cancer cells. Despite his cancer diagnosis, he has a fully active performance status. The KRAS biomarker analysis indicates that he has a wild-type KRAS gene."
2798,other,female,37,24.71,FOLFOX,No,No,No,No,12,poorly differentiated,fully active,wild-type,No,Yes,No,No,No,0,"race: other, sex: female, age: 37, bmi: 24.71, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type, adverse effect: hypersensitivity: Yes","The patient is a 37-year-old female of a race categorized as ""other"" with a BMI of 24.71. She is receiving treatment with the FOLFOX chemotherapy regimen and has completed 12 cycles. The histology of her cancer is poorly differentiated. Despite this, her performance status is fully active. The KRAS biomarker testing indicates that she has a wild-type KRAS status. The patient has experienced a hypersensitivity adverse effect."
2799,white,male,36,30.99,FOLFIRI,Yes,No,No,Yes,11,poorly differentiated,fully active,mutant,No,No,Yes,No,No,1,"race: white, sex: male, age: 36, bmi: 30.99, treatment arm: FOLFIRI, adherence: Yes, bowel perforation: Yes, chemotherapy cycles: 11, histology: poorly differentiated, performance status: fully active, KRAS biomarker: mutant, adverse effect: diarrhea: Yes","The patient is a 36-year-old white male with a BMI of 30.99 who is receiving the FOLFIRI treatment regimen. He has been adherent to his treatment and has completed 11 cycles of chemotherapy. The patient's histology shows poorly differentiated cancer cells. Despite experiencing a bowel perforation, his performance status remains fully active. The KRAS biomarker testing revealed a mutant status. The patient has also experienced diarrhea as an adverse effect of the treatment."
2800,white,female,69,24.98,FOLFOX + Cetuximab,No,No,Yes,No,12,poorly differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 69, bmi: 24.98, treatment arm: FOLFOX + Cetuximab, bowel obstruction: Yes, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 69-year-old white female with a BMI of 24.98. She is currently receiving treatment with FOLFOX + Cetuximab for her cancer. She has experienced a bowel obstruction and has completed 12 cycles of chemotherapy. The histology of her cancer is poorly differentiated. Despite these challenges, her performance status is fully active. Additionally, her KRAS biomarker status is wild-type."
2801,white,male,69,32.24,FOLFOX,No,No,No,No,12,well differentiated,fully active,mutant,No,No,No,No,No,0,"race: white, sex: male, age: 69, bmi: 32.24, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 69-year-old white male with a BMI of 32.24. He is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer cells. Despite his age, he has a fully active performance status. The KRAS biomarker analysis indicates that he has a mutant KRAS status."
2802,white,male,47,32.83,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 47, bmi: 32.83, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 47-year-old white male with a BMI of 32.83. He is receiving treatment in the FOLFOX + Cetuximab treatment arm and is scheduled for 12 chemotherapy cycles. His histology shows well-differentiated cancer cells. Despite his cancer diagnosis, he has a fully active performance status. Additionally, his KRAS biomarker indicates that it is wild-type."
2803,white,male,50,26.15,FOLFOX,Yes,No,No,No,12,poorly differentiated,symptoms but ambulatory,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 50, bmi: 26.15, treatment arm: FOLFOX, adherence: Yes, chemotherapy cycles: 12, histology: poorly differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type","The patient is a 50-year-old white male with a BMI of 26.15. He is receiving the FOLFOX treatment regimen and has been adherent to the treatment. He has completed 12 cycles of chemotherapy. His histology shows poorly differentiated cancer cells. Despite experiencing symptoms, he is still ambulatory. The KRAS biomarker testing revealed that he has a wild-type KRAS status."
2804,white,male,62,28.87,FOLFOX,No,No,Yes,No,12,well differentiated,fully active,mutant,No,No,No,No,No,1,"race: white, sex: male, age: 62, bmi: 28.87, treatment arm: FOLFOX, bowel obstruction: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 62-year-old white male with a BMI of 28.87. He is receiving the FOLFOX treatment regimen and has experienced a bowel obstruction. He has completed 12 cycles of chemotherapy. The histology of his cancer is well differentiated. Despite the bowel obstruction, his performance status is fully active. The KRAS biomarker testing revealed a mutant status."
2805,white,female,67,44.95,FOLFOX,No,No,No,No,12,well differentiated,fully active,wild-type,No,Yes,No,No,No,0,"race: white, sex: female, age: 67, bmi: 44.95, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type, adverse effect: hypersensitivity: Yes","The patient is a 67-year-old white female with a BMI of 44.95. She is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cells, and she has a fully active performance status. The KRAS biomarker indicates that she is wild-type. The patient has experienced a hypersensitivity adverse effect."
2806,white,male,63,32.19,FOLFOX,No,No,No,No,12,well differentiated,fully active,wild-type,No,Yes,No,No,No,0,"race: white, sex: male, age: 63, bmi: 32.19, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type, adverse effect: hypersensitivity: Yes","The patient is a 63-year-old white male with a BMI of 32.19. He is receiving the FOLFOX treatment arm and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cells, and his performance status is fully active. The KRAS biomarker indicates he is wild-type. The patient has experienced a hypersensitivity adverse effect."
2807,white,male,62,29.62,FOLFIRI (KRAS mutant),No,No,No,No,12,poorly differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 62, bmi: 29.62, treatment arm: FOLFIRI (KRAS mutant), chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 62-year-old white male with a BMI of 29.62. He is receiving treatment with FOLFIRI due to having a KRAS mutant status. He has completed 12 cycles of chemotherapy. The histology of his cancer is poorly differentiated. Despite this, his performance status is fully active. It is important to note that his KRAS biomarker is wild-type."
2808,white,female,49,18.78,FOLFOX + Cetuximab,No,Yes,No,No,12,well differentiated,symptoms but ambulatory,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 49, bmi: 18.78, treatment arm: FOLFOX + Cetuximab, serious adverse effect: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type","This patient is a 49-year-old white female with a BMI of 18.78. She is undergoing treatment with FOLFOX + Cetuximab and has experienced a serious adverse effect. She has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cancer cells. Despite experiencing symptoms, she is still able to be ambulatory. Her KRAS biomarker status is wild-type."
2809,white,female,62,29.96,FOLFOX,Yes,No,Yes,No,10,well differentiated,symptoms but ambulatory,wild-type,No,No,No,No,No,1,"race: white, sex: female, age: 62, bmi: 29.96, treatment arm: FOLFOX, adherence: Yes, bowel obstruction: Yes, chemotherapy cycles: 10, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type","The patient is a 62-year-old white female with a BMI of 29.96. She is receiving the FOLFOX treatment regimen and has been adherent to her treatment. She has experienced a bowel obstruction and has completed 10 cycles of chemotherapy. Her histology shows well-differentiated cancer cells. Despite experiencing symptoms, she is still able to be ambulatory. Her KRAS biomarker status is wild-type."
2810,white,male,43,28.92,FOLFOX,No,No,No,No,1,well differentiated,fully active,mutant,No,No,No,No,No,0,"race: white, sex: male, age: 43, bmi: 28.92, treatment arm: FOLFOX, chemotherapy cycles: 1, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 43-year-old white male with a BMI of 28.92. He is currently receiving the FOLFOX treatment regimen and has completed one cycle of chemotherapy. The histology of his cancer is well-differentiated. Despite undergoing treatment, his performance status is fully active. Additionally, the patient's KRAS biomarker status indicates that it is mutant."
2811,white,female,58,37.94,FOLFOX,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 58, bmi: 37.94, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 58-year-old white female with a BMI of 37.94. She is undergoing treatment with the FOLFOX regimen and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cancer cells. Despite her cancer diagnosis, she has a fully active performance status. The KRAS biomarker testing revealed that she has a wild-type KRAS gene."
2812,white,female,40,24.58,FOLFOX,No,Yes,No,No,9,well differentiated,fully active,wild-type,No,No,Yes,Yes,No,0,"race: white, sex: female, age: 40, bmi: 24.58, treatment arm: FOLFOX, serious adverse effect: Yes, chemotherapy cycles: 9, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type, adverse effect: diarrhea: Yes, adverse effect: infection: Yes","The patient is a 40-year-old white female with a BMI of 24.58 who is receiving the FOLFOX treatment regimen. She has experienced a serious adverse effect during her 9 chemotherapy cycles. Her histology shows well-differentiated cells, and her performance status is fully active. The KRAS biomarker indicates she has a wild-type status. She has also experienced adverse effects of diarrhea and infection."
2813,white,male,56,21,FOLFOX,No,No,No,No,12,well differentiated,symptoms but ambulatory,mutant,No,No,No,No,No,0,"race: white, sex: male, age: 56, bmi: 21.0, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: mutant","The patient is a 56-year-old white male with a BMI of 21.0. He is receiving treatment with the FOLFOX chemotherapy regimen and has completed 12 cycles. His cancer histology is well-differentiated. Despite experiencing symptoms, he is still able to walk around (ambulatory). The KRAS biomarker testing revealed a mutation."
2814,white,female,41,30.48,FOLFOX,No,No,No,No,12,poorly differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 41, bmi: 30.48, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 41-year-old white female with a BMI of 30.48. She is receiving the FOLFOX treatment regimen and is scheduled for 12 cycles of chemotherapy. Her histology shows poorly differentiated cancer cells. Despite this, her performance status is fully active. Additionally, her KRAS biomarker indicates that it is wild-type."
2815,white,female,42,25.22,FOLFOX,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 42, bmi: 25.22, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type",The patient is a 42-year-old white female with a BMI of 25.22. She is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. The histology shows well-differentiated cancer cells. The patient has a fully active performance status and her KRAS biomarker is wild-type.
2816,white,male,62,27.55,FOLFOX + Cetuximab,No,No,No,No,12,poorly differentiated,symptoms but ambulatory,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 62, bmi: 27.55, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: poorly differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type","The patient is a 62-year-old white male with a BMI of 27.55. He is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. His histology shows poorly differentiated cancer cells. Despite experiencing symptoms, he is still able to ambulate. His KRAS biomarker status is wild-type."
2817,white,male,44,28.77,FOLFOX,No,No,Yes,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,1,"race: white, sex: male, age: 44, bmi: 28.77, treatment arm: FOLFOX, bowel obstruction: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type",The patient is a 44-year-old white male with a BMI of 28.77. He is receiving the FOLFOX treatment regimen and has experienced a bowel obstruction. He has completed 12 cycles of chemotherapy. The histology shows well-differentiated cancer cells. The patient has a fully active performance status. His KRAS biomarker indicates that it is wild-type.
2818,white,male,67,27.78,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,fully active,mutant,No,No,No,Yes,No,0,"race: white, sex: male, age: 67, bmi: 27.78, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant, adverse effect: infection: Yes","The patient is a 67-year-old white male with a BMI of 27.78. He is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer cells. Despite being fully active, he has tested positive for a mutant KRAS biomarker. Additionally, he has experienced an infection as an adverse effect of his treatment."
2819,white,female,76,20.36,FOLFOX,No,No,No,No,2,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 76, bmi: 20.36, treatment arm: FOLFOX, chemotherapy cycles: 2, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 76-year-old white female with a BMI of 20.36. She is currently undergoing treatment with the FOLFOX chemotherapy regimen and has completed 2 cycles so far. Her cancer histology is well-differentiated, and she has a fully active performance status. Additionally, her KRAS biomarker status is wild-type."
2820,white,male,50,25.38,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 50, bmi: 25.38, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 50-year-old white male with a BMI of 25.38. He is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. His cancer histology is well differentiated, and he has a fully active performance status. The KRAS biomarker testing showed that he has a wild-type KRAS status."
2821,white,male,64,46.7,FOLFOX + Cetuximab,Yes,No,Yes,No,12,poorly differentiated,symptoms but ambulatory,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 64, bmi: 46.7, treatment arm: FOLFOX + Cetuximab, adherence: Yes, bowel obstruction: Yes, chemotherapy cycles: 12, histology: poorly differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type","The patient is a 64-year-old white male with a BMI of 46.7. He is undergoing treatment with FOLFOX + Cetuximab and has been adherent to the treatment. He has experienced a bowel obstruction and has completed 12 cycles of chemotherapy. The histology shows poorly differentiated cancer cells. Despite experiencing symptoms, the patient is still ambulatory. The KRAS biomarker indicates that he has a wild-type mutation."
2822,other,male,68,29.62,FOLFOX + Cetuximab,No,Yes,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: other, sex: male, age: 68, bmi: 29.62, treatment arm: FOLFOX + Cetuximab, serious adverse effect: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 68-year-old male of a race categorized as ""other"" with a BMI of 29.62. He is undergoing treatment with FOLFOX + Cetuximab and has experienced a serious adverse effect. He has completed 12 cycles of chemotherapy. The histology shows that the cancer cells are well-differentiated. Despite the treatment, the patient's performance status is fully active. The KRAS biomarker indicates that the patient has a wild-type KRAS gene."
2823,white,female,54,25.85,FOLFOX,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 54, bmi: 25.85, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type",The patient is a 54-year-old white female with a BMI of 25.85. She is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. Her cancer histology is well differentiated. She has a fully active performance status. The KRAS biomarker analysis shows that she has a wild-type KRAS status.
2824,white,male,60,27.81,FOLFOX + Cetuximab,No,Yes,Yes,No,12,poorly differentiated,symptoms but ambulatory,mutant,No,No,No,No,No,1,"race: white, sex: male, age: 60, bmi: 27.81, treatment arm: FOLFOX + Cetuximab, serious adverse effect: Yes, bowel obstruction: Yes, chemotherapy cycles: 12, histology: poorly differentiated, performance status: symptoms but ambulatory, KRAS biomarker: mutant","The patient is a 60-year-old white male with a BMI of 27.81. He is undergoing treatment with FOLFOX + Cetuximab and has experienced a serious adverse effect, specifically a bowel obstruction. He has completed 12 cycles of chemotherapy. The histology of his condition is poorly differentiated. Despite experiencing symptoms, he is still able to be ambulatory. Additionally, the KRAS biomarker shows that it is mutant."
2825,other,male,43,22.81,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: other, sex: male, age: 43, bmi: 22.81, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 43-year-old male of a race categorized as ""other"" with a BMI of 22.81. He is receiving treatment in the FOLFOX + Cetuximab treatment arm and is scheduled for 12 chemotherapy cycles. His histology indicates well-differentiated cancer, and he has a fully active performance status. Additionally, the KRAS biomarker testing revealed a wild-type result."
2826,white,female,52,36.47,FOLFOX,Yes,Yes,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 52, bmi: 36.47, treatment arm: FOLFOX, adherence: Yes, serious adverse effect: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 52-year-old white female with a BMI of 36.47. She is receiving treatment with the FOLFOX regimen and has been adherent to the treatment. She experienced a serious adverse effect during the course of her 12 chemotherapy cycles. The histology of her cancer is well-differentiated. Despite the adverse effect, her performance status is fully active. The KRAS biomarker testing revealed that she has a wild-type KRAS status."
2827,white,female,42,23.46,FOLFOX + Cetuximab,No,No,No,No,5,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 42, bmi: 23.46, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 5, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type",The patient is a 42-year-old white female with a BMI of 23.46. She is receiving treatment in the FOLFOX + Cetuximab treatment arm and has completed 5 cycles of chemotherapy. Her histology shows well-differentiated cancer cells. The patient has a fully active performance status and her KRAS biomarker is wild-type.
2828,white,female,71,28.91,FOLFOX,No,No,Yes,No,12,poorly differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 71, bmi: 28.91, treatment arm: FOLFOX, bowel obstruction: Yes, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 71-year-old white female with a BMI of 28.91. She is receiving the FOLFOX treatment regimen and has experienced a bowel obstruction. She has completed 12 cycles of chemotherapy. The histology of her cancer is poorly differentiated. Despite these challenges, her performance status is fully active. The KRAS biomarker testing revealed that she has a wild-type KRAS status."
2829,white,male,69,33.96,FOLFOX + Cetuximab,No,No,Yes,No,1,poorly differentiated,symptoms but ambulatory,wild-type,No,No,No,No,Yes,0,"race: white, sex: male, age: 69, bmi: 33.96, treatment arm: FOLFOX + Cetuximab, bowel obstruction: Yes, chemotherapy cycles: 1, histology: poorly differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type, adverse effect: infarction: Yes","The patient is a 69-year-old white male with a BMI of 33.96. He is receiving treatment with FOLFOX + Cetuximab for his poorly differentiated histology. He has experienced a bowel obstruction and has completed one cycle of chemotherapy. Despite experiencing symptoms, he is still able to ambulate. His KRAS biomarker is wild-type. Additionally, he has suffered from an infarction as an adverse effect."
2830,white,female,44,29.07,FOLFOX,No,Yes,No,No,4,poorly differentiated,symptoms but ambulatory,wild-type,No,No,Yes,Yes,No,0,"race: white, sex: female, age: 44, bmi: 29.07, treatment arm: FOLFOX, serious adverse effect: Yes, chemotherapy cycles: 4, histology: poorly differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type, adverse effect: diarrhea: Yes, adverse effect: infection: Yes","The patient is a 44-year-old white female with a BMI of 29.07. She is receiving the FOLFOX treatment regimen and has experienced a serious adverse effect. She has completed 4 cycles of chemotherapy. The histology of her cancer is poorly differentiated. Despite experiencing symptoms, she is still able to be ambulatory. Her KRAS biomarker is wild-type. She has also experienced adverse effects in the form of diarrhea and infection."
2831,white,female,62,38.98,FOLFOX + Cetuximab,Yes,Yes,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 62, bmi: 38.98, treatment arm: FOLFOX + Cetuximab, adherence: Yes, serious adverse effect: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 62-year-old white female with a BMI of 38.98. She is receiving treatment with FOLFOX + Cetuximab and has been adherent to the treatment. However, she experienced a serious adverse effect during the treatment. She completed 12 cycles of chemotherapy. The histology of her cancer is well-differentiated, and her performance status is fully active. Her KRAS biomarker status is wild-type."
2832,white,male,43,29.05,FOLFOX + Cetuximab,No,No,No,No,2,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 43, bmi: 29.05, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 2, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 43-year-old white male with a BMI of 29.05. He is receiving treatment with FOLFOX + Cetuximab and has completed 2 cycles of chemotherapy. His cancer histology is well-differentiated, and he has a fully active performance status. The KRAS biomarker analysis shows that he has a wild-type KRAS status."
2833,white,male,52,27.82,FOLFOX,No,Yes,No,No,1,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 52, bmi: 27.82, treatment arm: FOLFOX, serious adverse effect: Yes, chemotherapy cycles: 1, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 52-year-old white male with a BMI of 27.82. He is receiving the FOLFOX treatment arm for his well-differentiated histology. He has experienced a serious adverse effect after one cycle of chemotherapy. Despite this, his performance status is fully active. His KRAS biomarker is wild-type."
2834,white,male,60,27.74,FOLFIRI,No,No,No,No,12,well differentiated,symptoms but ambulatory,wild-type,No,No,No,No,No,1,"race: white, sex: male, age: 60, bmi: 27.74, treatment arm: FOLFIRI, chemotherapy cycles: 12, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type","The patient is a 60-year-old white male with a BMI of 27.74. He is undergoing treatment with the FOLFIRI chemotherapy regimen and has completed 12 cycles. His cancer histology is well-differentiated. Despite experiencing symptoms, he is still able to ambulate. The KRAS biomarker analysis shows that he has a wild-type KRAS status."
2835,white,male,55,29.26,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,Yes,No,0,"race: white, sex: male, age: 55, bmi: 29.26, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type, adverse effect: infection: Yes","The patient is a 55-year-old white male with a BMI of 29.26. He is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer, and he has a fully active performance status. The KRAS biomarker indicates he is wild-type. The patient has experienced an infection as an adverse effect during treatment."
2836,white,female,42,19.55,FOLFOX,No,No,Yes,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 42, bmi: 19.55, treatment arm: FOLFOX, bowel obstruction: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 42-year-old white female with a BMI of 19.55. She is receiving the FOLFOX treatment regimen for her well-differentiated histology. She has experienced a bowel obstruction and has completed 12 cycles of chemotherapy. Despite the bowel obstruction, her performance status is fully active. The KRAS biomarker analysis shows that she has a wild-type KRAS status."
2837,white,female,53,21.99,FOLFIRI,No,No,Yes,No,12,well differentiated,symptoms but ambulatory,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 53, bmi: 21.99, treatment arm: FOLFIRI, bowel obstruction: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type","The patient is a 53-year-old white female with a BMI of 21.99. She is receiving the FOLFIRI treatment arm for her well-differentiated histology. She has experienced a bowel obstruction and has completed 12 cycles of chemotherapy. Despite experiencing symptoms, she is still able to be ambulatory. Her KRAS biomarker status is wild-type."
2838,white,male,64,28.89,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,fully active,mutant,No,No,No,No,No,0,"race: white, sex: male, age: 64, bmi: 28.89, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 64-year-old white male with a BMI of 28.89. He is undergoing treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. His cancer histology is well-differentiated, and he has a fully active performance status. The KRAS biomarker analysis shows a mutant status."
2839,white,male,76,21.07,FOLFIRI + Cetuximab,No,No,No,No,3,poorly differentiated,symptoms but ambulatory,wild-type,No,No,No,Yes,No,1,"race: white, sex: male, age: 76, bmi: 21.07, treatment arm: FOLFIRI + Cetuximab, chemotherapy cycles: 3, histology: poorly differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type, adverse effect: infection: Yes","The patient is a 76-year-old white male with a BMI of 21.07. He is currently receiving treatment with FOLFIRI + Cetuximab and has completed 3 cycles of chemotherapy. His histology shows poorly differentiated cancer cells. Despite experiencing symptoms, he is still able to be ambulatory. His KRAS biomarker status is wild-type. The patient has developed an infection as an adverse effect of the treatment."
2840,white,female,40,28.73,FOLFOX,No,No,No,No,8,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 40, bmi: 28.73, treatment arm: FOLFOX, chemotherapy cycles: 8, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 40-year-old white female with a BMI of 28.73. She is receiving the FOLFOX treatment arm and has completed 8 cycles of chemotherapy. Her histology shows well-differentiated cells, and she has a fully active performance status. The KRAS biomarker analysis indicates that she has a wild-type KRAS status."
2841,white,male,39,30.98,FOLFOX + Cetuximab,No,No,Yes,No,2,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 39, bmi: 30.98, treatment arm: FOLFOX + Cetuximab, bowel obstruction: Yes, chemotherapy cycles: 2, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type",The patient is a 39-year-old white male with a BMI of 30.98. He is receiving treatment in the FOLFOX + Cetuximab treatment arm. He has experienced a bowel obstruction and has completed 2 cycles of chemotherapy. The histology shows well-differentiated cells. The patient has a fully active performance status. His KRAS biomarker is wild-type.
2842,white,female,70,43.23,FOLFOX,No,No,No,No,12,poorly differentiated,symptoms but ambulatory,interminate,No,No,No,No,No,0,"race: white, sex: female, age: 70, bmi: 43.23, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: poorly differentiated, performance status: symptoms but ambulatory, KRAS biomarker: interminate","The patient is a 70-year-old white female with a BMI of 43.23. She is receiving the FOLFOX treatment arm for her poorly differentiated histology. She has undergone 12 cycles of chemotherapy. Despite experiencing symptoms, she is still able to ambulate. Her KRAS biomarker status is indeterminate."
2843,other,male,50,45.41,FOLFOX,No,No,No,No,5,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: other, sex: male, age: 50, bmi: 45.41, treatment arm: FOLFOX, chemotherapy cycles: 5, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 50-year-old male of a race other than specified, with a BMI of 45.41. He is undergoing treatment with the FOLFOX chemotherapy regimen and has completed 5 cycles. His histology shows well-differentiated cells, and he has a fully active performance status. The KRAS biomarker analysis indicates that he has a wild-type KRAS status."
2844,white,male,72,31.14,FOLFOX + Cetuximab,No,No,No,No,5,well differentiated,fully active,wild-type,Yes,No,No,No,No,0,"race: white, sex: male, age: 72, bmi: 31.14, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 5, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type, adverse effect: thrombosis: Yes","The patient is a 72-year-old white male with a BMI of 31.14. He is currently receiving treatment with FOLFOX + Cetuximab and has completed 5 cycles of chemotherapy. His histology shows well-differentiated cancer cells. Despite his age, he has a fully active performance status. The KRAS biomarker analysis indicates that he has a wild-type KRAS gene. Unfortunately, he has experienced an adverse effect in the form of thrombosis."
2845,white,female,44,21.09,FOLFOX + Cetuximab,No,Yes,No,No,12,well differentiated,fully active,wild-type,No,No,Yes,No,No,0,"race: white, sex: female, age: 44, bmi: 21.09, treatment arm: FOLFOX + Cetuximab, serious adverse effect: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type, adverse effect: diarrhea: Yes","This patient is a 44-year-old white female with a BMI of 21.09. She is receiving treatment with FOLFOX + Cetuximab and has experienced a serious adverse effect. She has completed 12 cycles of chemotherapy. Her histology shows that the cancer is well-differentiated. Despite the adverse effects, her performance status is fully active. The KRAS biomarker testing revealed that she has a wild-type KRAS status. Additionally, she has experienced diarrhea as an adverse effect of the treatment."
2846,other,male,60,24.59,FOLFOX,No,No,No,No,6,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: other, sex: male, age: 60, bmi: 24.59, treatment arm: FOLFOX, chemotherapy cycles: 6, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 60-year-old male of a race categorized as ""other"" with a BMI of 24.59. He is undergoing treatment with the FOLFOX chemotherapy regimen and has completed 6 cycles of chemotherapy. The histology of his cancer is well-differentiated. He has a fully active performance status. His KRAS biomarker status is wild-type."
2847,white,female,52,37.4,FOLFOX,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,Yes,No,No,0,"race: white, sex: female, age: 52, bmi: 37.4, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type, adverse effect: diarrhea: Yes","The patient is a 52-year-old white female with a BMI of 37.4. She is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cancer cells. Despite experiencing diarrhea as an adverse effect, her performance status is fully active. Additionally, her KRAS biomarker indicates that it is wild-type."
2848,white,female,53,35.69,FOLFOX + Cetuximab,No,No,Yes,No,12,poorly differentiated,fully active,wild-type,No,No,Yes,No,No,0,"race: white, sex: female, age: 53, bmi: 35.69, treatment arm: FOLFOX + Cetuximab, bowel obstruction: Yes, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type, adverse effect: diarrhea: Yes",This patient is a 53-year-old white female with a BMI of 35.69. She is receiving treatment with FOLFOX + Cetuximab for her poorly differentiated histology. She has experienced a bowel obstruction and is fully active with a wild-type KRAS biomarker. She has undergone 12 cycles of chemotherapy and is experiencing diarrhea as an adverse effect of her treatment.
2849,white,female,53,25,FOLFOX + Cetuximab,No,Yes,No,No,12,well differentiated,fully active,mutant,No,No,No,No,No,0,"race: white, sex: female, age: 53, bmi: 25.0, treatment arm: FOLFOX + Cetuximab, serious adverse effect: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 53-year-old white female with a BMI of 25.0. She is receiving treatment with FOLFOX + Cetuximab and has experienced a serious adverse effect. She has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cells, and her performance status is fully active. The KRAS biomarker indicates a mutant status."
2850,white,female,46,25.82,FOLFOX,No,No,No,No,5,poorly differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 46, bmi: 25.82, treatment arm: FOLFOX, chemotherapy cycles: 5, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 46-year-old white female with a BMI of 25.82. She is receiving the FOLFOX treatment regimen and has completed 5 cycles of chemotherapy. The histology of her cancer is poorly differentiated. Despite her diagnosis, she has a fully active performance status. Additionally, her KRAS biomarker status is wild-type."
2851,other,male,59,19.15,FOLFOX,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: other, sex: male, age: 59, bmi: 19.15, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 59-year-old male of a race categorized as ""other"" with a BMI of 19.15. He is receiving treatment in the FOLFOX chemotherapy arm and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer cells. The patient has a fully active performance status and his KRAS biomarker is wild-type."
2852,white,male,71,29.73,FOLFIRI (KRAS mutant),No,No,No,No,12,poorly differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 71, bmi: 29.73, treatment arm: FOLFIRI (KRAS mutant), chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 71-year-old white male with a BMI of 29.73. He is receiving treatment with the FOLFIRI regimen for KRAS mutant cancer. He has completed 12 cycles of chemotherapy. The histology of his cancer is poorly differentiated. Despite his diagnosis, his performance status is fully active. His KRAS biomarker status is wild-type."
2853,white,male,48,24.62,FOLFOX + Cetuximab,No,Yes,No,No,12,poorly differentiated,fully active,mutant,No,No,No,No,No,0,"race: white, sex: male, age: 48, bmi: 24.62, treatment arm: FOLFOX + Cetuximab, serious adverse effect: Yes, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 48-year-old white male with a BMI of 24.62. He is receiving treatment with FOLFOX + Cetuximab and has experienced a serious adverse effect. He has completed 12 cycles of chemotherapy. The histology of his cancer is poorly differentiated. Despite this, his performance status is fully active. Additionally, the KRAS biomarker testing revealed a mutant status."
2854,white,female,73,37.26,FOLFOX + Cetuximab,No,Yes,No,No,12,poorly differentiated,fully active,wild-type,No,No,Yes,No,No,0,"race: white, sex: female, age: 73, bmi: 37.26, treatment arm: FOLFOX + Cetuximab, serious adverse effect: Yes, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type, adverse effect: diarrhea: Yes","The patient is a 73-year-old white female with a BMI of 37.26. She is receiving treatment with FOLFOX + Cetuximab and has experienced a serious adverse effect. She has undergone 12 cycles of chemotherapy. The histology of her cancer is poorly differentiated. Despite this, her performance status is fully active. Her KRAS biomarker is wild-type. She has also experienced diarrhea as an adverse effect of treatment."
2855,white,male,46,32.97,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,fully active,mutant,Yes,No,Yes,No,No,0,"race: white, sex: male, age: 46, bmi: 32.97, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant, adverse effect: thrombosis: Yes, adverse effect: diarrhea: Yes","The patient is a 46-year-old white male with a BMI of 32.97. He is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. His cancer histology is well-differentiated, and he has a fully active performance status. The KRAS biomarker testing revealed a mutant status. The patient has experienced adverse effects of thrombosis and diarrhea during the course of treatment."
2856,white,female,58,22.59,FOLFOX,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 58, bmi: 22.59, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type",The patient is a 58-year-old white female with a BMI of 22.59. She is receiving treatment with the FOLFOX chemotherapy regimen and has completed 12 cycles. The histology of her cancer is well-differentiated. She has a fully active performance status. The KRAS biomarker testing revealed that she has a wild-type KRAS status.
2857,white,male,74,33.58,FOLFOX,No,No,No,No,12,well differentiated,fully active,mutant,No,No,No,No,No,0,"race: white, sex: male, age: 74, bmi: 33.58, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 74-year-old white male with a BMI of 33.58. He is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. His cancer histology is well-differentiated, and he has a fully active performance status. The KRAS biomarker testing revealed a mutant status."
2858,white,female,41,39.09,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,symptoms but ambulatory,mutant,No,No,No,No,No,0,"race: white, sex: female, age: 41, bmi: 39.09, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: mutant","The patient is a 41-year-old white female with a BMI of 39.09. She is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. Her cancer histology is well-differentiated. Despite experiencing symptoms, she is still able to ambulate. The KRAS biomarker testing revealed a mutant status."
2859,white,female,54,32.41,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 54, bmi: 32.41, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 54-year-old white female with a BMI of 32.41. She is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cells, and she has a fully active performance status. The KRAS biomarker indicates that she has a wild-type status."
2860,white,male,49,20.99,FOLFOX + Cetuximab,No,Yes,No,No,12,poorly differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 49, bmi: 20.99, treatment arm: FOLFOX + Cetuximab, serious adverse effect: Yes, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 49-year-old white male with a BMI of 20.99. He is receiving treatment with FOLFOX + Cetuximab and has experienced a serious adverse effect. He has undergone 12 cycles of chemotherapy. The histology of his condition is poorly differentiated. Despite this, his performance status is fully active. His KRAS biomarker is wild-type."
2861,other,male,49,23.58,FOLFOX,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: other, sex: male, age: 49, bmi: 23.58, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 49-year-old male of a race other than specified, with a BMI of 23.58. He is undergoing treatment with the FOLFOX chemotherapy regimen and has completed 12 cycles. His histology shows well-differentiated cancer cells. The patient has a fully active performance status and his KRAS biomarker is wild-type."
2862,white,male,43,34.23,FOLFOX + Cetuximab,No,Yes,No,No,7,well differentiated,symptoms but ambulatory,mutant,No,No,No,No,No,0,"race: white, sex: male, age: 43, bmi: 34.23, treatment arm: FOLFOX + Cetuximab, serious adverse effect: Yes, chemotherapy cycles: 7, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: mutant","The patient is a 43-year-old white male with a BMI of 34.23. He is receiving treatment with FOLFOX + Cetuximab and has experienced a serious adverse effect. He has completed 7 cycles of chemotherapy. His histology shows well-differentiated cells. Despite experiencing symptoms, he is still able to be ambulatory. The KRAS biomarker analysis indicates a mutant status."
2863,white,male,63,24.84,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 63, bmi: 24.84, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type",The patient is a 63-year-old white male with a BMI of 24.84. He is receiving treatment in the FOLFOX + Cetuximab treatment arm and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer cells. The patient has a fully active performance status and his KRAS biomarker is wild-type.
2864,white,male,56,22.29,FOLFOX,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 56, bmi: 22.29, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 56-year-old white male with a BMI of 22.29. He is receiving treatment with the FOLFOX chemotherapy regimen and has completed 12 cycles. His cancer histology is well-differentiated, and he has a fully active performance status. The KRAS biomarker testing showed that he has a wild-type KRAS status."
2865,white,male,61,28.88,FOLFOX,No,No,No,No,12,well differentiated,fully active,interminate,No,No,No,No,No,0,"race: white, sex: male, age: 61, bmi: 28.88, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: interminate","The patient is a 61-year-old white male with a BMI of 28.88. He is receiving treatment with the FOLFOX chemotherapy regimen and has completed 12 cycles. His cancer histology is well-differentiated, and he has a fully active performance status. The KRAS biomarker status is indeterminate."
2866,white,male,41,32.07,FOLFOX + Cetuximab,No,No,No,No,6,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 41, bmi: 32.07, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 6, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type",The patient is a 41-year-old white male with a BMI of 32.07. He is receiving treatment in the FOLFOX + Cetuximab treatment arm and has completed 6 cycles of chemotherapy. His histology shows well-differentiated cancer cells. The patient has a fully active performance status. His KRAS biomarker is wild-type.
2867,white,male,63,34.97,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 63, bmi: 34.97, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 63-year-old white male with a BMI of 34.97. He is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. His cancer histology is well-differentiated, and he has a fully active performance status. The KRAS biomarker analysis shows that he has a wild-type KRAS status."
2868,white,female,45,22.82,FOLFOX + Cetuximab,No,No,Yes,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 45, bmi: 22.82, treatment arm: FOLFOX + Cetuximab, bowel obstruction: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 45-year-old white female with a BMI of 22.82. She is receiving treatment with FOLFOX + Cetuximab for her well-differentiated histology. She has experienced a bowel obstruction and has completed 12 cycles of chemotherapy. Despite the bowel obstruction, her performance status is fully active. Additionally, her KRAS biomarker status is wild-type."
2869,black,male,46,18.44,FOLFOX,Yes,No,Yes,No,8,well differentiated,symptoms but ambulatory,wild-type,No,No,No,No,No,0,"race: black, sex: male, age: 46, bmi: 18.44, treatment arm: FOLFOX, adherence: Yes, bowel obstruction: Yes, chemotherapy cycles: 8, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type","The patient is a 46-year-old Black male with a BMI of 18.44. He is receiving the FOLFOX treatment regimen and has been adherent to the treatment. He is currently experiencing a bowel obstruction. So far, he has completed 8 cycles of chemotherapy. The histology shows that the cancer is well-differentiated. Despite experiencing symptoms, the patient is still able to be ambulatory. The KRAS biomarker indicates that he has a wild-type status."
2870,white,male,56,31.57,FOLFOX,No,Yes,No,No,12,well differentiated,fully active,mutant,No,No,No,No,No,0,"race: white, sex: male, age: 56, bmi: 31.57, treatment arm: FOLFOX, serious adverse effect: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 56-year-old white male with a BMI of 31.57. He is receiving the FOLFOX treatment regimen and has experienced a serious adverse effect. He has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer cells. Despite his treatment, he has a fully active performance status. The KRAS biomarker analysis indicates a mutant status."
2871,white,male,76,23.35,FOLFOX,No,No,No,No,11,well differentiated,fully active,interminate,No,No,No,No,No,0,"race: white, sex: male, age: 76, bmi: 23.35, treatment arm: FOLFOX, chemotherapy cycles: 11, histology: well differentiated, performance status: fully active, KRAS biomarker: interminate","The patient is a 76-year-old white male with a BMI of 23.35. He is currently receiving treatment with the FOLFOX chemotherapy regimen and has completed 11 cycles so far. His cancer histology is well-differentiated, and he has a performance status of fully active. The KRAS biomarker status is indeterminate for this patient."
2872,white,male,73,25.33,FOLFIRI,No,No,No,No,12,well differentiated,symptoms but ambulatory,mutant,No,No,No,No,No,1,"race: white, sex: male, age: 73, bmi: 25.33, treatment arm: FOLFIRI, chemotherapy cycles: 12, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: mutant","The patient is a 73-year-old white male with a BMI of 25.33. He is undergoing treatment with FOLFIRI chemotherapy regimen and has completed 12 cycles. His histology shows well-differentiated cancer cells. Despite experiencing symptoms, he is still able to walk around (ambulatory). The patient's KRAS biomarker indicates a mutant status."
2873,white,female,43,19.95,FOLFIRI (KRAS mutant),No,No,No,No,12,well differentiated,fully active,wild-type,No,No,Yes,No,No,0,"race: white, sex: female, age: 43, bmi: 19.95, treatment arm: FOLFIRI (KRAS mutant), chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type, adverse effect: diarrhea: Yes","The patient is a 43-year-old white female with a BMI of 19.95. She is receiving the FOLFIRI treatment regimen for her well-differentiated cancer with a KRAS mutation. She has completed 12 cycles of chemotherapy. Her performance status is fully active, and her KRAS biomarker is wild-type. She is experiencing diarrhea as an adverse effect of the treatment."
2874,white,male,50,43.98,FOLFOX + Cetuximab,No,Yes,No,No,12,well differentiated,in bed less than 50% of the time,wild-type,Yes,No,No,No,Yes,1,"race: white, sex: male, age: 50, bmi: 43.98, treatment arm: FOLFOX + Cetuximab, serious adverse effect: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: in bed less than 50% of the time, KRAS biomarker: wild-type, adverse effect: thrombosis: Yes, adverse effect: infarction: Yes","The patient is a 50-year-old white male with a BMI of 43.98. He is receiving treatment with FOLFOX + Cetuximab and has experienced serious adverse effects during the treatment. He has completed 12 cycles of chemotherapy. The histology shows that the cancer is well-differentiated. The patient's performance status indicates that he is in bed less than 50% of the time. The KRAS biomarker is wild-type. Additionally, the patient has experienced adverse effects such as thrombosis and infarction."
2875,white,male,57,30.07,FOLFOX,No,No,No,No,12,well differentiated,symptoms but ambulatory,wild-type,No,No,Yes,No,No,0,"race: white, sex: male, age: 57, bmi: 30.07, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type, adverse effect: diarrhea: Yes",The patient is a 57-year-old white male with a BMI of 30.07 who is receiving the FOLFOX treatment regimen for his well-differentiated histology. He has completed 12 cycles of chemotherapy and has a performance status of experiencing symptoms but still able to walk around. His KRAS biomarker is wild-type. The patient is experiencing diarrhea as an adverse effect of the treatment.
2876,white,female,48,31.46,FOLFOX,No,No,No,No,12,poorly differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 48, bmi: 31.46, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 48-year-old white female with a BMI of 31.46. She is undergoing treatment with the FOLFOX chemotherapy regimen and has completed 12 cycles. The histology of her cancer is poorly differentiated. Despite her diagnosis, she has a fully active performance status. Her KRAS biomarker status is wild-type."
2877,white,female,46,23.83,FOLFOX,No,No,No,No,12,well differentiated,fully active,mutant,No,No,No,No,No,0,"race: white, sex: female, age: 46, bmi: 23.83, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant",The patient is a 46-year-old white female with a BMI of 23.83. She is receiving treatment with the FOLFOX chemotherapy regimen and has completed 12 cycles. The histology of her cancer is well-differentiated. She has a fully active performance status. The KRAS biomarker testing revealed a mutant status.
2878,white,female,61,30.2,FOLFOX + Cetuximab,No,No,No,No,12,poorly differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 61, bmi: 30.2, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 61-year-old white female with a BMI of 30.2. She is receiving treatment in the FOLFOX + Cetuximab treatment arm and has completed 12 cycles of chemotherapy. Her histology shows poorly differentiated cancer cells. Despite this, her performance status is fully active. Additionally, her KRAS biomarker status is wild-type."
2879,white,female,65,19.84,FOLFIRI (KRAS mutant),No,No,No,No,9,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 65, bmi: 19.84, treatment arm: FOLFIRI (KRAS mutant), chemotherapy cycles: 9, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 65-year-old white female with a BMI of 19.84. She is receiving the FOLFIRI treatment regimen for KRAS mutant cancer and has completed 9 cycles of chemotherapy. Her cancer histology is well-differentiated, and she has a fully active performance status. The KRAS biomarker for her cancer is wild-type."
2880,white,female,72,25.51,FOLFOX + Cetuximab,No,No,No,No,3,poorly differentiated,symptoms but ambulatory,wild-type,No,No,No,No,No,1,"race: white, sex: female, age: 72, bmi: 25.51, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 3, histology: poorly differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type","The patient is a 72-year-old white female with a BMI of 25.51. She is currently undergoing treatment with FOLFOX + Cetuximab and has completed 3 cycles of chemotherapy. Her histology shows poorly differentiated cancer cells. Despite experiencing symptoms, she is still able to walk around (ambulatory). Her KRAS biomarker status is wild-type."
2881,white,male,63,29.78,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 63, bmi: 29.78, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 63-year-old white male with a BMI of 29.78. He is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. His cancer histology is well-differentiated, and he has a fully active performance status. The KRAS biomarker analysis shows that he has a wild-type KRAS status."
2882,white,male,75,27.96,FOLFIRI (KRAS mutant),No,Yes,No,No,12,poorly differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 75, bmi: 27.96, treatment arm: FOLFIRI (KRAS mutant), serious adverse effect: Yes, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 75-year-old white male with a BMI of 27.96. He is receiving the FOLFIRI treatment regimen for his KRAS mutant status. Unfortunately, he has experienced a serious adverse effect. He has completed 12 cycles of chemotherapy. His histology shows poorly differentiated cells. Despite these challenges, his performance status is fully active. It is worth noting that his KRAS biomarker is wild-type."
2883,white,female,71,30.69,FOLFIRI (KRAS mutant),No,No,No,No,12,well differentiated,fully active,mutant,No,No,No,No,No,1,"race: white, sex: female, age: 71, bmi: 30.69, treatment arm: FOLFIRI (KRAS mutant), chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 71-year-old white female with a BMI of 30.69. She is receiving treatment with the FOLFIRI regimen for KRAS mutant cancer. She has completed 12 cycles of chemotherapy. The histology of her cancer is well-differentiated. Despite her age, she has a fully active performance status."
2884,white,male,49,36.06,FOLFIRI (KRAS mutant),No,No,No,No,12,well differentiated,fully active,wild-type,No,No,Yes,Yes,No,0,"race: white, sex: male, age: 49, bmi: 36.06, treatment arm: FOLFIRI (KRAS mutant), chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type, adverse effect: diarrhea: Yes, adverse effect: infection: Yes","The patient is a 49-year-old white male with a BMI of 36.06. He is receiving FOLFIRI treatment for his well-differentiated cancer, with a KRAS mutation. He has completed 12 cycles of chemotherapy and has a fully active performance status. His KRAS biomarker is wild-type. He is experiencing adverse effects of diarrhea and infection."
2885,white,female,67,35.01,FOLFOX,No,Yes,No,No,12,well differentiated,symptoms but ambulatory,mutant,No,No,No,No,No,0,"race: white, sex: female, age: 67, bmi: 35.01, treatment arm: FOLFOX, serious adverse effect: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: mutant","The patient is a 67-year-old white female with a BMI of 35.01. She is receiving the FOLFOX treatment arm for her well-differentiated histology. She has experienced a serious adverse effect during her 12 chemotherapy cycles. Despite having symptoms, she is still ambulatory. Additionally, the patient has a mutant KRAS biomarker."
2886,white,female,60,36.76,FOLFOX + Cetuximab,No,No,No,No,1,well differentiated,fully active,mutant,No,No,No,No,No,0,"race: white, sex: female, age: 60, bmi: 36.76, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 1, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 60-year-old white female with a BMI of 36.76. She is currently receiving treatment in the FOLFOX + Cetuximab treatment arm and has completed one cycle of chemotherapy. Her histology shows well-differentiated cancer cells. Despite her age, she has a fully active performance status. Additionally, the KRAS biomarker testing revealed a mutant status."
2887,white,female,53,24.97,FOLFOX,No,No,No,No,3,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 53, bmi: 24.97, treatment arm: FOLFOX, chemotherapy cycles: 3, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type",The patient is a 53-year-old white female with a BMI of 24.97. She is receiving the FOLFOX treatment regimen and has completed 3 cycles of chemotherapy. Her histology shows well-differentiated cancer cells. She has a fully active performance status and her KRAS biomarker is wild-type.
2888,white,female,66,37.82,FOLFOX + Cetuximab,No,Yes,No,No,12,well differentiated,fully active,mutant,No,No,No,No,No,0,"race: white, sex: female, age: 66, bmi: 37.82, treatment arm: FOLFOX + Cetuximab, serious adverse effect: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 66-year-old white female with a BMI of 37.82. She is receiving treatment with FOLFOX + Cetuximab and has experienced a serious adverse effect. She has completed 12 chemotherapy cycles. The histology shows that the cancer is well-differentiated. Despite the treatment, her performance status is fully active. The KRAS biomarker indicates that she has a mutant form."
2889,black,male,55,20.63,FOLFOX + Cetuximab,No,No,Yes,No,6,well differentiated,fully active,mutant,No,No,No,No,No,0,"race: black, sex: male, age: 55, bmi: 20.63, treatment arm: FOLFOX + Cetuximab, bowel obstruction: Yes, chemotherapy cycles: 6, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant",The patient is a 55-year-old Black male with a BMI of 20.63. He is receiving treatment in the FOLFOX + Cetuximab treatment arm. He has a bowel obstruction and has completed 6 cycles of chemotherapy. The histology shows well-differentiated cells. The patient has a fully active performance status. The KRAS biomarker is mutant in this case.
2890,white,female,63,25.8,FOLFOX,No,No,No,No,12,poorly differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 63, bmi: 25.8, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 63-year-old white female with a BMI of 25.8. She is undergoing treatment with the FOLFOX chemotherapy regimen and has completed 12 cycles. The histology of her cancer is poorly differentiated. Despite her diagnosis, she has a fully active performance status. Additionally, her KRAS biomarker status is wild-type."
2891,white,male,69,23.02,FOLFOX + Cetuximab,Yes,No,Yes,No,4,poorly differentiated,symptoms but ambulatory,mutant,No,No,Yes,No,No,0,"race: white, sex: male, age: 69, bmi: 23.02, treatment arm: FOLFOX + Cetuximab, adherence: Yes, bowel obstruction: Yes, chemotherapy cycles: 4, histology: poorly differentiated, performance status: symptoms but ambulatory, KRAS biomarker: mutant, adverse effect: diarrhea: Yes","The patient is a 69-year-old white male with a BMI of 23.02. He is receiving treatment with FOLFOX + Cetuximab and is adherent to the treatment. He has a bowel obstruction and has completed 4 cycles of chemotherapy. The histology shows poorly differentiated cancer cells. Despite experiencing symptoms, the patient is ambulatory. The KRAS biomarker is mutant. The patient is experiencing diarrhea as an adverse effect of the treatment."
2892,white,male,66,27.43,FOLFOX + Cetuximab,No,No,No,No,12,poorly differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 66, bmi: 27.43, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 66-year-old white male with a BMI of 27.43. He is receiving treatment in the FOLFOX + Cetuximab treatment arm and has completed 12 cycles of chemotherapy. His histology shows poorly differentiated cancer cells. Despite this, his performance status is fully active. Additionally, his KRAS biomarker status is wild-type."
2893,white,female,49,27.53,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,fully active,wild-type,No,Yes,No,No,No,0,"race: white, sex: female, age: 49, bmi: 27.53, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type, adverse effect: hypersensitivity: Yes","The patient is a 49-year-old white female with a BMI of 27.53 who is receiving treatment with FOLFOX + Cetuximab. She has completed 12 cycles of chemotherapy and has well-differentiated histology. Her performance status is fully active, and her KRAS biomarker is wild-type. She has experienced a hypersensitivity adverse effect."
2894,white,male,72,39,FOLFOX,No,Yes,No,No,12,well differentiated,fully active,mutant,No,No,No,No,No,0,"race: white, sex: male, age: 72, bmi: 39.0, treatment arm: FOLFOX, serious adverse effect: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 72-year-old white male with a BMI of 39.0. He is receiving the FOLFOX treatment regimen and has experienced a serious adverse effect. He has completed 12 cycles of chemotherapy. The histology of his cancer is well differentiated. Despite his age, he has a fully active performance status. The KRAS biomarker testing revealed a mutant status."
2895,white,female,73,20.19,FOLFIRI (KRAS mutant),Yes,No,Yes,No,12,well differentiated,fully active,mutant,No,No,No,No,No,0,"race: white, sex: female, age: 73, bmi: 20.19, treatment arm: FOLFIRI (KRAS mutant), adherence: Yes, bowel obstruction: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 73-year-old white female with a BMI of 20.19. She is receiving treatment in the FOLFIRI treatment arm for her KRAS mutant status. She has been adherent to her treatment. The patient has experienced a bowel obstruction and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cells. Despite the bowel obstruction, her performance status is fully active."
2896,white,male,59,28.06,FOLFOX,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 59, bmi: 28.06, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type",The patient is a 59-year-old white male with a BMI of 28.06. He is receiving the FOLFOX treatment arm and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cells. The patient has a fully active performance status. His KRAS biomarker is wild-type.
2897,white,female,63,30.9,FOLFOX,No,No,No,No,12,well differentiated,fully active,interminate,No,No,No,No,No,0,"race: white, sex: female, age: 63, bmi: 30.9, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: interminate",The patient is a 63-year-old white female with a BMI of 30.9. She is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cancer cells. The patient has a fully active performance status. The KRAS biomarker status is indeterminate.
2898,white,female,61,25.05,FOLFOX + Cetuximab,No,No,No,Yes,2,poorly differentiated,symptoms but ambulatory,wild-type,No,Yes,Yes,No,No,0,"race: white, sex: female, age: 61, bmi: 25.05, treatment arm: FOLFOX + Cetuximab, bowel perforation: Yes, chemotherapy cycles: 2, histology: poorly differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type, adverse effect: hypersensitivity: Yes, adverse effect: diarrhea: Yes","The patient is a 61-year-old white female with a BMI of 25.05. She is currently undergoing treatment with FOLFOX + Cetuximab for her poorly differentiated histology. She has experienced a bowel perforation and has completed 2 cycles of chemotherapy. Despite experiencing symptoms, she is still able to be ambulatory. Her KRAS biomarker is wild-type. She has also had adverse effects of hypersensitivity and diarrhea."
2899,white,male,63,28.32,FOLFOX,No,No,Yes,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 63, bmi: 28.32, treatment arm: FOLFOX, bowel obstruction: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 63-year-old white male with a BMI of 28.32. He is receiving the FOLFOX treatment regimen for his well-differentiated histology. He has experienced a bowel obstruction and has completed 12 cycles of chemotherapy. Despite the bowel obstruction, his performance status is fully active. His KRAS biomarker status is wild-type."
2900,white,female,49,22.46,FOLFOX + Cetuximab,Yes,No,No,No,2,poorly differentiated,in bed less than 50% of the time,wild-type,No,No,No,No,No,1,"race: white, sex: female, age: 49, bmi: 22.46, treatment arm: FOLFOX + Cetuximab, adherence: Yes, chemotherapy cycles: 2, histology: poorly differentiated, performance status: in bed less than 50% of the time, KRAS biomarker: wild-type","The patient is a 49-year-old white female with a BMI of 22.46. She is currently receiving treatment in the FOLFOX + Cetuximab treatment arm and has been adherent to her medication. She has completed 2 cycles of chemotherapy. The histology of her cancer is poorly differentiated. Her performance status indicates that she is in bed less than 50% of the time. Additionally, her KRAS biomarker status is wild-type."
2901,white,female,66,32.34,FOLFOX,No,Yes,No,No,8,poorly differentiated,symptoms but ambulatory,wild-type,No,No,Yes,Yes,No,0,"race: white, sex: female, age: 66, bmi: 32.34, treatment arm: FOLFOX, serious adverse effect: Yes, chemotherapy cycles: 8, histology: poorly differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type, adverse effect: diarrhea: Yes, adverse effect: infection: Yes","The patient is a 66-year-old white female with a BMI of 32.34 who is receiving the FOLFOX treatment regimen. She has experienced serious adverse effects during her 8 cycles of chemotherapy, including diarrhea and infection. Her cancer histology is poorly differentiated, and her KRAS biomarker status is wild-type. Despite experiencing symptoms, she is still able to be ambulatory."
2902,white,male,51,27.55,FOLFOX,No,Yes,No,No,12,well differentiated,fully active,mutant,No,No,No,No,No,0,"race: white, sex: male, age: 51, bmi: 27.55, treatment arm: FOLFOX, serious adverse effect: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 51-year-old white male with a BMI of 27.55. He is receiving the FOLFOX treatment regimen and has experienced a serious adverse effect. He has completed 12 cycles of chemotherapy. The histology shows well-differentiated cancer cells. Despite the adverse effect, his performance status is fully active. The KRAS biomarker analysis indicates a mutant status."
2903,white,female,49,21.46,FOLFOX + Cetuximab,No,No,Yes,No,12,well differentiated,fully active,interminate,No,No,No,No,No,0,"race: white, sex: female, age: 49, bmi: 21.46, treatment arm: FOLFOX + Cetuximab, bowel obstruction: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: interminate","This patient is a 49-year-old white female with a BMI of 21.46. She is receiving treatment with FOLFOX + Cetuximab for her cancer. She has experienced a bowel obstruction and has completed 12 cycles of chemotherapy. The histology of her cancer is well-differentiated. Despite her condition, her performance status is fully active. Her KRAS biomarker status is indeterminate."
2904,white,female,72,21.12,FOLFOX,No,Yes,Yes,No,12,poorly differentiated,symptoms but ambulatory,wild-type,No,No,No,No,No,1,"race: white, sex: female, age: 72, bmi: 21.12, treatment arm: FOLFOX, serious adverse effect: Yes, bowel obstruction: Yes, chemotherapy cycles: 12, histology: poorly differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type","The patient is a 72-year-old white female with a BMI of 21.12. She is undergoing treatment with the FOLFOX regimen and has experienced a serious adverse effect, specifically a bowel obstruction. She has completed 12 cycles of chemotherapy. The histology of her cancer is poorly differentiated. Despite experiencing symptoms, she is still able to be ambulatory. Her KRAS biomarker status is wild-type."
2905,white,female,39,19.4,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 39, bmi: 19.4, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 39-year-old white female with a BMI of 19.4. She is receiving treatment in the FOLFOX + Cetuximab treatment arm and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cells, and she has a fully active performance status. The KRAS biomarker analysis indicates that she has a wild-type KRAS status."
2906,white,male,76,31.97,FOLFOX,Yes,No,No,No,5,well differentiated,fully active,mutant,No,No,No,No,No,0,"race: white, sex: male, age: 76, bmi: 31.97, treatment arm: FOLFOX, adherence: Yes, chemotherapy cycles: 5, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant",The patient is a 76-year-old white male with a BMI of 31.97. He is receiving the FOLFOX treatment regimen and has been adherent to the treatment. He has completed 5 cycles of chemotherapy. The histology shows well-differentiated cancer cells. The patient has a fully active performance status. The KRAS biomarker testing revealed a mutant status.
2907,black,male,59,16.91,FOLFOX + Cetuximab,No,No,Yes,Yes,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: black, sex: male, age: 59, bmi: 16.91, treatment arm: FOLFOX + Cetuximab, bowel obstruction: Yes, bowel perforation: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 59-year-old Black male with a low BMI of 16.91. He is receiving treatment with FOLFOX + Cetuximab for his condition. He has experienced both a bowel obstruction and a bowel perforation. The patient has completed 12 cycles of chemotherapy. His histology shows that the cancer is well-differentiated. Despite his health challenges, his performance status is fully active. Additionally, the KRAS biomarker indicates that he has a wild-type mutation."
2908,white,male,69,30.55,FOLFOX,No,No,No,No,0,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 69, bmi: 30.55, treatment arm: FOLFOX, chemotherapy cycles: 0, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 69-year-old white male with a BMI of 30.55. He is in the FOLFOX treatment arm and has not undergone any chemotherapy cycles yet. His histology shows well-differentiated cells, and he has a fully active performance status. The KRAS biomarker indicates that he has a wild-type status."
2909,white,female,70,29.83,FOLFIRI,No,Yes,No,No,1,poorly differentiated,symptoms but ambulatory,mutant,No,No,No,No,No,1,"race: white, sex: female, age: 70, bmi: 29.83, treatment arm: FOLFIRI, serious adverse effect: Yes, chemotherapy cycles: 1, histology: poorly differentiated, performance status: symptoms but ambulatory, KRAS biomarker: mutant","The patient is a 70-year-old white female with a BMI of 29.83. She is receiving the FOLFIRI treatment regimen and has experienced a serious adverse effect after one cycle of chemotherapy. The histology of her cancer is poorly differentiated. Despite experiencing symptoms, she is still able to ambulate. Additionally, her KRAS biomarker is mutant."
2910,white,female,60,25.49,FOLFOX,No,No,No,No,10,well differentiated,fully active,mutant,No,No,No,No,No,0,"race: white, sex: female, age: 60, bmi: 25.49, treatment arm: FOLFOX, chemotherapy cycles: 10, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 60-year-old white female with a BMI of 25.49. She is receiving the FOLFOX treatment regimen and has completed 10 cycles of chemotherapy. Her histology shows well-differentiated cancer cells. Despite her cancer diagnosis, she has a fully active performance status. The KRAS biomarker testing revealed a mutant status."
2911,white,female,70,22.48,FOLFOX + Cetuximab,No,Yes,No,No,1,well differentiated,in bed less than 50% of the time,mutant,No,No,No,No,No,1,"race: white, sex: female, age: 70, bmi: 22.48, treatment arm: FOLFOX + Cetuximab, serious adverse effect: Yes, chemotherapy cycles: 1, histology: well differentiated, performance status: in bed less than 50% of the time, KRAS biomarker: mutant",The patient is a 70-year-old white female with a BMI of 22.48. She is receiving treatment with FOLFOX + Cetuximab and has experienced a serious adverse effect. She has completed one cycle of chemotherapy. The histology shows well-differentiated cells. Her performance status indicates that she is in bed less than 50% of the time. The KRAS biomarker test revealed a mutant result.
2912,white,male,35,31.2,FOLFOX,No,No,No,No,12,well differentiated,symptoms but ambulatory,mutant,Yes,No,No,No,No,0,"race: white, sex: male, age: 35, bmi: 31.2, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: mutant, adverse effect: thrombosis: Yes","The patient is a 35-year-old white male with a BMI of 31.2. He is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. His cancer histology is well-differentiated, and he has symptoms but is still able to walk around (ambulatory). The KRAS biomarker testing showed a mutation. The patient has experienced thrombosis as an adverse effect."
2913,white,male,46,27.56,FOLFOX,No,Yes,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,1,"race: white, sex: male, age: 46, bmi: 27.56, treatment arm: FOLFOX, serious adverse effect: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 46-year-old white male with a BMI of 27.56. He is receiving the FOLFOX treatment regimen and has experienced a serious adverse effect. He has completed 12 cycles of chemotherapy. The histology of his condition is well-differentiated. Despite the adverse effect, his performance status is fully active. The KRAS biomarker analysis indicates that he has a wild-type status."
2914,white,male,50,27.02,FOLFOX,No,Yes,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 50, bmi: 27.02, treatment arm: FOLFOX, serious adverse effect: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 50-year-old white male with a BMI of 27.02. He is undergoing treatment with the FOLFOX chemotherapy regimen and has experienced a serious adverse effect. He has completed 12 cycles of chemotherapy and has well-differentiated histology. Despite the adverse effect, his performance status is fully active. His KRAS biomarker status is wild-type."
2915,white,male,52,26.14,FOLFOX,Yes,No,Yes,No,12,poorly differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 52, bmi: 26.14, treatment arm: FOLFOX, adherence: Yes, bowel obstruction: Yes, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 52-year-old white male with a BMI of 26.14. He is receiving the FOLFOX treatment regimen and has been adherent to the treatment. He has experienced a bowel obstruction. The patient has completed 12 cycles of chemotherapy. His histology shows poorly differentiated cancer cells. Despite these challenges, his performance status is fully active. The KRAS biomarker analysis indicates that he has a wild-type KRAS status."
2916,white,male,58,34.19,FOLFOX,Yes,No,No,No,12,well differentiated,symptoms but ambulatory,wild-type,No,No,Yes,No,No,0,"race: white, sex: male, age: 58, bmi: 34.19, treatment arm: FOLFOX, adherence: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type, adverse effect: diarrhea: Yes","The patient is a 58-year-old white male with a BMI of 34.19. He is receiving the FOLFOX treatment regimen and has been adherent to the treatment. He has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer cells. Despite experiencing symptoms, he is still able to be ambulatory. His KRAS biomarker status is wild-type. He has reported experiencing diarrhea as an adverse effect of the treatment."
2917,white,female,42,23.58,FOLFOX,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 42, bmi: 23.58, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 42-year-old white female with a BMI of 23.58. She is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. Her cancer histology is well-differentiated, and she has a fully active performance status. The KRAS biomarker testing revealed that she has a wild-type KRAS status."
2918,black,male,76,27.12,FOLFOX,No,No,Yes,No,3,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: black, sex: male, age: 76, bmi: 27.12, treatment arm: FOLFOX, bowel obstruction: Yes, chemotherapy cycles: 3, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 76-year-old Black male with a BMI of 27.12. He is currently receiving treatment with the FOLFOX regimen for his cancer. He has experienced a bowel obstruction and has completed 3 cycles of chemotherapy. The histology of his cancer is well-differentiated. Despite his age, he has a fully active performance status. The KRAS biomarker analysis shows that he has a wild-type KRAS status."
2919,white,female,58,21.3,FOLFOX,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 58, bmi: 21.3, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type",The patient is a 58-year-old white female with a BMI of 21.3. She is receiving treatment with the FOLFOX chemotherapy regimen and has completed 12 cycles. Her cancer histology is well-differentiated. She has a fully active performance status. The KRAS biomarker testing showed that she has a wild-type KRAS status.
2920,black,female,51,24.49,FOLFOX,No,No,No,No,12,well differentiated,fully active,mutant,No,No,No,No,No,0,"race: black, sex: female, age: 51, bmi: 24.49, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant",The patient is a 51-year-old Black female with a BMI of 24.49. She is undergoing treatment with the FOLFOX chemotherapy regimen and has completed 12 cycles. The histology of her cancer is well differentiated. She has a fully active performance status. The KRAS biomarker analysis shows a mutant status.
2921,white,female,66,34.84,FOLFOX + Cetuximab,No,Yes,No,No,12,well differentiated,fully active,wild-type,No,No,Yes,No,No,0,"race: white, sex: female, age: 66, bmi: 34.84, treatment arm: FOLFOX + Cetuximab, serious adverse effect: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type, adverse effect: diarrhea: Yes","This patient is a 66-year-old white female with a BMI of 34.84 who is undergoing treatment with FOLFOX + Cetuximab for a well-differentiated histology. She has experienced a serious adverse effect during her 12 chemotherapy cycles. Despite this, her performance status remains fully active. The KRAS biomarker indicates she is wild-type. Additionally, she has experienced diarrhea as an adverse effect of her treatment."
2922,white,female,69,28.67,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,fully active,wild-type,No,Yes,Yes,No,No,1,"race: white, sex: female, age: 69, bmi: 28.67, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type, adverse effect: hypersensitivity: Yes, adverse effect: diarrhea: Yes","The patient is a 69-year-old white female with a BMI of 28.67. She is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cells, and she has a fully active performance status. The KRAS biomarker indicates she is wild-type. The patient has experienced hypersensitivity and diarrhea as adverse effects during treatment."
2923,white,male,68,28.55,FOLFOX,No,No,Yes,No,12,well differentiated,fully active,wild-type,Yes,No,No,No,No,0,"race: white, sex: male, age: 68, bmi: 28.55, treatment arm: FOLFOX, bowel obstruction: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type, adverse effect: thrombosis: Yes","The patient is a 68-year-old white male with a BMI of 28.55. He is receiving the FOLFOX treatment regimen for his well-differentiated histology. He has experienced a bowel obstruction and has completed 12 cycles of chemotherapy. Despite this, he has a fully active performance status. His KRAS biomarker is wild-type. Additionally, he has developed thrombosis as an adverse effect."
2924,black,male,46,26.32,FOLFOX + Cetuximab,No,No,Yes,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: black, sex: male, age: 46, bmi: 26.32, treatment arm: FOLFOX + Cetuximab, bowel obstruction: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 46-year-old Black male with a BMI of 26.32. He is receiving treatment with FOLFOX + Cetuximab for his well-differentiated histology. He has experienced a bowel obstruction and has completed 12 cycles of chemotherapy. Despite the bowel obstruction, his performance status is fully active. His KRAS biomarker status is wild-type."
2925,white,female,43,47.26,FOLFOX + Cetuximab,No,No,No,No,12,poorly differentiated,symptoms but ambulatory,mutant,No,No,No,No,No,0,"race: white, sex: female, age: 43, bmi: 47.26, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: poorly differentiated, performance status: symptoms but ambulatory, KRAS biomarker: mutant","The patient is a 43-year-old white female with a BMI of 47.26. She is receiving treatment in the FOLFOX + Cetuximab treatment arm and has completed 12 cycles of chemotherapy. Her histology shows poorly differentiated cancer cells. Despite experiencing symptoms, she is still able to be ambulatory. The KRAS biomarker analysis revealed a mutant status."
2926,white,male,67,38.82,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,symptoms but ambulatory,wild-type,No,Yes,No,No,No,0,"race: white, sex: male, age: 67, bmi: 38.82, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type, adverse effect: hypersensitivity: Yes","The patient is a 67-year-old white male with a BMI of 38.82. He is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer. Despite experiencing symptoms, he is still able to walk around (ambulatory). The KRAS biomarker testing revealed that he has a wild-type KRAS status. The patient has experienced a hypersensitivity adverse effect during treatment."
2927,white,female,65,32.3,FOLFIRI (KRAS mutant),No,No,No,No,12,well differentiated,fully active,mutant,No,No,No,No,No,0,"race: white, sex: female, age: 65, bmi: 32.3, treatment arm: FOLFIRI (KRAS mutant), chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 65-year-old white female with a BMI of 32.3. She is receiving the FOLFIRI treatment regimen for her KRAS mutant status. She has completed 12 cycles of chemotherapy. Her cancer histology is well-differentiated. Despite her cancer diagnosis, she has a fully active performance status."
2928,white,male,74,29.35,FOLFOX + Cetuximab,No,No,Yes,No,12,well differentiated,fully active,wild-type,No,No,No,Yes,No,0,"race: white, sex: male, age: 74, bmi: 29.35, treatment arm: FOLFOX + Cetuximab, bowel obstruction: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type, adverse effect: infection: Yes","The patient is a 74-year-old white male with a BMI of 29.35. He is receiving treatment with FOLFOX + Cetuximab and has experienced a bowel obstruction. He has completed 12 cycles of chemotherapy. The histology shows that the cancer is well-differentiated. Despite the bowel obstruction, his performance status is fully active. The KRAS biomarker indicates that he has a wild-type mutation. Additionally, he has experienced an infection as an adverse effect of treatment."
2929,white,female,52,29.1,FOLFOX + Cetuximab,No,No,No,No,12,poorly differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 52, bmi: 29.1, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 52-year-old white female with a BMI of 29.1. She is receiving treatment with FOLFOX + Cetuximab and is scheduled for 12 chemotherapy cycles. Her cancer histology is poorly differentiated. Despite her diagnosis, she has a fully active performance status. Additionally, her KRAS biomarker status is wild-type."
2930,white,male,60,25.68,FOLFOX,No,No,No,No,12,poorly differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 60, bmi: 25.68, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 60-year-old white male with a BMI of 25.68. He is receiving treatment with the FOLFOX regimen and has completed 12 cycles of chemotherapy. His cancer histology is poorly differentiated. Despite his cancer diagnosis, he has a fully active performance status. The KRAS biomarker testing revealed that he has a wild-type KRAS status."
2931,white,female,63,19.89,FOLFOX,No,No,Yes,No,1,well differentiated,fully active,wild-type,No,No,Yes,No,No,0,"race: white, sex: female, age: 63, bmi: 19.89, treatment arm: FOLFOX, bowel obstruction: Yes, chemotherapy cycles: 1, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type, adverse effect: diarrhea: Yes","The patient is a 63-year-old white female with a BMI of 19.89. She is currently receiving treatment with FOLFOX for her well-differentiated histology. She has experienced a bowel obstruction and is in her first cycle of chemotherapy. Despite this, her performance status is fully active. Her KRAS biomarker is wild-type. She is also experiencing diarrhea as an adverse effect of her treatment."
2932,white,male,40,27.36,FOLFOX,No,No,No,No,12,well differentiated,symptoms but ambulatory,mutant,No,No,Yes,No,No,0,"race: white, sex: male, age: 40, bmi: 27.36, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: mutant, adverse effect: diarrhea: Yes","The patient is a 40-year-old white male with a BMI of 27.36 who is undergoing treatment with the FOLFOX chemotherapy regimen. He has completed 12 cycles of chemotherapy and has well-differentiated histology. Despite experiencing symptoms, he is still able to walk around (ambulatory). The KRAS biomarker testing revealed a mutant status. The patient is experiencing diarrhea as an adverse effect of the treatment."
2933,white,male,46,33.98,FOLFOX + Cetuximab,No,Yes,No,No,12,well differentiated,symptoms but ambulatory,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 46, bmi: 33.98, treatment arm: FOLFOX + Cetuximab, serious adverse effect: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type","The patient is a 46-year-old white male with a BMI of 33.98. He is receiving treatment with FOLFOX + Cetuximab and has experienced a serious adverse effect. He has completed 12 cycles of chemotherapy. The histology shows that the cancer is well-differentiated. Despite experiencing symptoms, the patient is still able to be ambulatory. The KRAS biomarker indicates that the cancer is wild-type."
2934,white,female,67,29.61,FOLFOX + Cetuximab,No,Yes,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 67, bmi: 29.61, treatment arm: FOLFOX + Cetuximab, serious adverse effect: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 67-year-old white female with a BMI of 29.61. She is receiving treatment with FOLFOX + Cetuximab and has experienced a serious adverse effect. She has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cells. Despite the adverse effect, her performance status is fully active. The KRAS biomarker indicates that she has a wild-type mutation."
2935,white,male,44,21.05,FOLFOX + Cetuximab,No,No,No,No,12,poorly differentiated,symptoms but ambulatory,mutant,No,No,No,No,No,0,"race: white, sex: male, age: 44, bmi: 21.05, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: poorly differentiated, performance status: symptoms but ambulatory, KRAS biomarker: mutant","The patient is a 44-year-old white male with a BMI of 21.05. He is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. His histology shows poorly differentiated cancer. Despite experiencing symptoms, he is still able to be ambulatory. The KRAS biomarker analysis indicates a mutant status."
2936,white,male,76,32.14,FOLFOX,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 76, bmi: 32.14, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 76-year-old white male with a BMI of 32.14. He is receiving treatment with the FOLFOX chemotherapy regimen and has completed 12 cycles. His cancer histology is well differentiated. Despite his age, he has a fully active performance status. The KRAS biomarker testing revealed that he has a wild-type KRAS status."
2937,white,female,45,20.51,FOLFOX + Cetuximab,No,Yes,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 45, bmi: 20.51, treatment arm: FOLFOX + Cetuximab, serious adverse effect: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 45-year-old white female with a BMI of 20.51. She is receiving treatment with FOLFOX + Cetuximab and has experienced a serious adverse effect. She has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cancer cells. Despite the treatment, her performance status is fully active. The KRAS biomarker indicates that she has a wild-type mutation."
2938,white,male,71,36.98,FOLFOX,No,No,No,No,12,well differentiated,fully active,mutant,No,No,No,No,No,0,"race: white, sex: male, age: 71, bmi: 36.98, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant",The patient is a 71-year-old white male with a BMI of 36.98. He is receiving treatment with the FOLFOX regimen and has completed 12 cycles of chemotherapy. The histology shows well-differentiated cancer cells. The patient has a fully active performance status. The KRAS biomarker testing revealed a mutant status.
2939,white,female,42,18.94,FOLFOX,No,No,Yes,No,12,well differentiated,fully active,mutant,No,No,No,No,No,0,"race: white, sex: female, age: 42, bmi: 18.94, treatment arm: FOLFOX, bowel obstruction: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 42-year-old white female with a BMI of 18.94. She is receiving the FOLFOX treatment regimen and has experienced a bowel obstruction. She has completed 12 cycles of chemotherapy. The histology shows well-differentiated cancer cells. Despite the bowel obstruction, her performance status is fully active. The KRAS biomarker testing revealed a mutant status."
2940,white,male,38,35.38,FOLFOX + Cetuximab,No,No,No,No,12,poorly differentiated,fully active,wild-type,No,No,No,Yes,No,0,"race: white, sex: male, age: 38, bmi: 35.38, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type, adverse effect: infection: Yes","The patient is a 38-year-old white male with a BMI of 35.38. He is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. The histology of his cancer is poorly differentiated. Despite this, his performance status is fully active. His KRAS biomarker status is wild-type. He has experienced an infection as an adverse effect during his treatment."
2941,white,female,42,28.93,FOLFOX,No,No,No,No,12,poorly differentiated,symptoms but ambulatory,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 42, bmi: 28.93, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: poorly differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type","The patient is a 42-year-old white female with a BMI of 28.93. She is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. Her histology shows poorly differentiated cancer cells. Despite experiencing symptoms, she is still able to move around (ambulatory). The KRAS biomarker testing revealed that she has a wild-type KRAS status."
2942,white,male,62,39.84,FOLFOX + Cetuximab,No,No,No,No,12,poorly differentiated,fully active,mutant,No,No,Yes,No,No,0,"race: white, sex: male, age: 62, bmi: 39.84, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: mutant, adverse effect: diarrhea: Yes","The patient is a 62-year-old white male with a BMI of 39.84. He is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. His histology shows poorly differentiated cancer cells. Despite this, his performance status is fully active. The KRAS biomarker testing revealed a mutant status. The patient is experiencing diarrhea as an adverse effect of the treatment."
2943,other,female,50,28.91,FOLFOX,No,No,No,No,12,well differentiated,fully active,mutant,No,No,No,No,No,0,"race: other, sex: female, age: 50, bmi: 28.91, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 50-year-old female of a race categorized as ""other"" with a BMI of 28.91. She is undergoing treatment with the FOLFOX chemotherapy regimen and has completed 12 cycles. The histology of her cancer is well-differentiated. Despite her diagnosis, she maintains a fully active performance status. The KRAS biomarker testing revealed a mutant status."
2944,white,male,65,35.08,FOLFOX,No,No,No,No,11,well differentiated,symptoms but ambulatory,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 65, bmi: 35.08, treatment arm: FOLFOX, chemotherapy cycles: 11, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type","The patient is a 65-year-old white male with a BMI of 35.08. He is receiving treatment with the FOLFOX chemotherapy regimen and has completed 11 cycles so far. His histology shows well-differentiated cancer cells. Despite experiencing symptoms, he is still able to walk around (ambulatory). His KRAS biomarker status is wild-type."
2945,white,female,53,32.28,FOLFOX + Cetuximab,No,Yes,No,No,2,well differentiated,symptoms but ambulatory,wild-type,No,Yes,No,No,No,0,"race: white, sex: female, age: 53, bmi: 32.28, treatment arm: FOLFOX + Cetuximab, serious adverse effect: Yes, chemotherapy cycles: 2, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type, adverse effect: hypersensitivity: Yes","The patient is a 53-year-old white female with a BMI of 32.28. She is receiving treatment with FOLFOX + Cetuximab and has experienced a serious adverse effect. She has completed 2 cycles of chemotherapy. Her histology shows well-differentiated cells, and she has symptoms but is still ambulatory. Her KRAS biomarker is wild-type. Additionally, she has experienced a hypersensitivity adverse effect."
2946,white,male,38,22.04,FOLFOX,No,No,No,No,12,well differentiated,symptoms but ambulatory,wild-type,No,Yes,No,No,No,0,"race: white, sex: male, age: 38, bmi: 22.04, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type, adverse effect: hypersensitivity: Yes","The patient is a 38-year-old white male with a BMI of 22.04. He is receiving the FOLFOX treatment arm and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cells, and he has symptoms but is still ambulatory in terms of performance status. The KRAS biomarker indicates that he has a wild-type status. The patient has experienced a hypersensitivity adverse effect."
2947,white,female,65,24.45,FOLFOX,No,No,No,No,12,well differentiated,fully active,interminate,No,No,No,No,No,0,"race: white, sex: female, age: 65, bmi: 24.45, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: interminate",The patient is a 65-year-old white female with a BMI of 24.45. She is undergoing treatment with the FOLFOX chemotherapy regimen and has completed 12 cycles. Her histology shows well-differentiated cancer cells. The patient has a fully active performance status. The KRAS biomarker status is indeterminate.
2948,white,male,55,26.83,FOLFOX,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 55, bmi: 26.83, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type",The patient is a 55-year-old white male with a BMI of 26.83. He is receiving the FOLFOX treatment arm and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer cells. The patient has a fully active performance status and his KRAS biomarker is wild-type.
2949,white,male,61,28.7,FOLFOX + Cetuximab,No,No,No,No,12,poorly differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 61, bmi: 28.7, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 61-year-old white male with a BMI of 28.7. He is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. His histology shows poorly differentiated cancer cells. Despite this, his performance status is fully active. Additionally, his KRAS biomarker status is wild-type."
2950,white,male,58,33.22,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,symptoms but ambulatory,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 58, bmi: 33.22, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type","The patient is a 58-year-old white male with a BMI of 33.22. He is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer. Despite experiencing symptoms, he is still able to be ambulatory. The KRAS biomarker analysis indicates that he has a wild-type KRAS status."
2951,white,male,43,33.24,FOLFOX,No,No,No,No,12,poorly differentiated,fully active,wild-type,No,No,No,No,No,1,"race: white, sex: male, age: 43, bmi: 33.24, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 43-year-old white male with a BMI of 33.24. He is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. His cancer histology is poorly differentiated. Despite his diagnosis, he has a fully active performance status. The KRAS biomarker testing revealed that he has a wild-type KRAS status."
2952,white,male,56,28.93,FOLFOX + Cetuximab,Yes,No,Yes,No,12,well differentiated,symptoms but ambulatory,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 56, bmi: 28.93, treatment arm: FOLFOX + Cetuximab, adherence: Yes, bowel obstruction: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type","The patient is a 56-year-old white male with a BMI of 28.93. He is receiving treatment with FOLFOX + Cetuximab and has been adherent to the treatment. He has experienced a bowel obstruction. The patient has completed 12 cycles of chemotherapy. Histologically, the cancer is well-differentiated. Despite experiencing symptoms, the patient is still ambulatory. The KRAS biomarker indicates that the cancer is wild-type."
2953,other,female,40,21.64,FOLFOX + Cetuximab,No,Yes,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: other, sex: female, age: 40, bmi: 21.64, treatment arm: FOLFOX + Cetuximab, serious adverse effect: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 40-year-old female of a race other than specified, with a BMI of 21.64. She is undergoing treatment with FOLFOX + Cetuximab and has experienced a serious adverse effect. She has completed 12 cycles of chemotherapy. The histology of her condition is well-differentiated, and her performance status is fully active. Additionally, her KRAS biomarker is wild-type."
2954,other,male,38,23.39,FOLFOX + Cetuximab,No,No,No,No,7,well differentiated,symptoms but ambulatory,mutant,No,No,No,No,No,0,"race: other, sex: male, age: 38, bmi: 23.39, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 7, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: mutant","The patient is a 38-year-old male of a race categorized as ""other"" with a BMI of 23.39. He is currently receiving treatment in the FOLFOX + Cetuximab treatment arm and has completed 7 cycles of chemotherapy. His histology shows well-differentiated characteristics. Despite experiencing symptoms, the patient is still able to be ambulatory. Additionally, the KRAS biomarker analysis indicates a mutant status."
2955,white,male,61,17.51,FOLFOX,Yes,No,No,Yes,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 61, bmi: 17.51, treatment arm: FOLFOX, adherence: Yes, bowel perforation: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 61-year-old white male with a BMI of 17.51. He is receiving the FOLFOX treatment arm and has been adherent to the treatment. He experienced a bowel perforation and has completed 12 cycles of chemotherapy. The histology shows well-differentiated cells. Despite the bowel perforation, his performance status is fully active. The KRAS biomarker indicates a wild-type status."
2956,white,female,43,25,FOLFOX,No,Yes,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 43, bmi: 25.0, treatment arm: FOLFOX, serious adverse effect: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 43-year-old white female with a BMI of 25.0. She is receiving treatment with FOLFOX chemotherapy regimen and has experienced a serious adverse effect. She has completed 12 cycles of chemotherapy. The histology of her cancer is well differentiated. Despite the adverse effect, her performance status is fully active. Her KRAS biomarker status is wild-type."
2957,white,male,36,20.76,FOLFOX + Cetuximab,No,No,No,No,11,well differentiated,fully active,wild-type,No,No,Yes,No,No,0,"race: white, sex: male, age: 36, bmi: 20.76, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 11, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type, adverse effect: diarrhea: Yes","The patient is a 36-year-old white male with a BMI of 20.76. He is receiving treatment with FOLFOX + Cetuximab and has completed 11 cycles of chemotherapy. His histology shows well-differentiated cancer, and his performance status is fully active. The KRAS biomarker testing indicates he has a wild-type KRAS status. The patient is experiencing diarrhea as an adverse effect of the treatment."
2958,white,female,55,26.37,FOLFOX,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: female, age: 55, bmi: 26.37, treatment arm: FOLFOX, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type",The patient is a 55-year-old white female with a BMI of 26.37. She is undergoing treatment with the FOLFOX chemotherapy regimen and has completed 12 cycles. The histology of her cancer is well-differentiated. She has a fully active performance status. The KRAS biomarker testing revealed that she has a wild-type KRAS status.
2959,white,male,60,23.23,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,symptoms but ambulatory,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 60, bmi: 23.23, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type","The patient is a 60-year-old white male with a BMI of 23.23. He is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer. Despite experiencing symptoms, he is still able to be ambulatory. The KRAS biomarker indicates that he has a wild-type status."
2960,white,female,73,22.04,FOLFOX + Cetuximab,Yes,Yes,No,No,4,poorly differentiated,symptoms but ambulatory,wild-type,No,No,No,No,No,1,"race: white, sex: female, age: 73, bmi: 22.04, treatment arm: FOLFOX + Cetuximab, adherence: Yes, serious adverse effect: Yes, chemotherapy cycles: 4, histology: poorly differentiated, performance status: symptoms but ambulatory, KRAS biomarker: wild-type","The patient is a 73-year-old white female with a BMI of 22.04. She is currently receiving treatment in the FOLFOX + Cetuximab treatment arm and has been adherent to her medication. However, she has experienced a serious adverse effect. She has completed 4 cycles of chemotherapy and her histology shows poorly differentiated cells. Despite experiencing symptoms, she is still able to be ambulatory. Her KRAS biomarker is wild-type."
2961,white,male,66,22.44,FOLFOX + Cetuximab,No,No,No,No,1,well differentiated,symptoms but ambulatory,mutant,No,No,No,No,No,0,"race: white, sex: male, age: 66, bmi: 22.44, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 1, histology: well differentiated, performance status: symptoms but ambulatory, KRAS biomarker: mutant","The patient is a 66-year-old white male with a BMI of 22.44. He is currently receiving treatment in the FOLFOX + Cetuximab treatment arm and has completed 1 cycle of chemotherapy. His histology shows well-differentiated cancer cells. Despite experiencing symptoms, the patient is still able to walk around (ambulatory). The KRAS biomarker analysis indicates a mutant status."
2962,white,male,67,34.88,FOLFOX + Cetuximab,No,No,No,No,9,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 67, bmi: 34.88, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 9, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type",The patient is a 67-year-old white male with a BMI of 34.88. He is receiving treatment with FOLFOX + Cetuximab and has completed 9 cycles of chemotherapy. His cancer histology is well-differentiated. The patient has a fully active performance status. His KRAS biomarker status is wild-type.
2963,white,male,64,29.62,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,fully active,mutant,No,No,No,No,No,0,"race: white, sex: male, age: 64, bmi: 29.62, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant",The patient is a 64-year-old white male with a BMI of 29.62. He is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. His cancer histology is well-differentiated. The patient has a fully active performance status. The KRAS biomarker analysis showed a mutant result.
2964,white,male,75,32.15,FOLFOX,No,No,No,No,11,poorly differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 75, bmi: 32.15, treatment arm: FOLFOX, chemotherapy cycles: 11, histology: poorly differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 75-year-old white male with a BMI of 32.15. He is receiving treatment with the FOLFOX chemotherapy regimen and has completed 11 cycles so far. His cancer histology is poorly differentiated. Despite his age, he has a fully active performance status. The KRAS biomarker testing revealed that he has a wild-type KRAS status."
2965,white,male,68,26.22,FOLFOX,Yes,Yes,No,No,1,well differentiated,fully active,mutant,No,No,No,No,No,0,"race: white, sex: male, age: 68, bmi: 26.22, treatment arm: FOLFOX, adherence: Yes, serious adverse effect: Yes, chemotherapy cycles: 1, histology: well differentiated, performance status: fully active, KRAS biomarker: mutant","The patient is a 68-year-old white male with a BMI of 26.22. He is receiving the FOLFOX treatment regimen and has been adherent to the prescribed treatment. However, he experienced a serious adverse effect after completing one cycle of chemotherapy. The histology shows that the cancer is well-differentiated. Despite the adverse effect, the patient's performance status is fully active. Additionally, the KRAS biomarker analysis revealed a mutant status."
2966,black,female,41,37.67,FOLFOX + Cetuximab,No,No,No,No,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: black, sex: female, age: 41, bmi: 37.67, treatment arm: FOLFOX + Cetuximab, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 41-year-old Black female with a BMI of 37.67. She is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cancer cells. Despite her cancer diagnosis, she has a fully active performance status. The KRAS biomarker analysis indicates that she has a wild-type KRAS gene."
2967,white,male,61,33.08,FOLFOX + Cetuximab,Yes,No,Yes,Yes,12,well differentiated,fully active,wild-type,No,No,No,No,No,0,"race: white, sex: male, age: 61, bmi: 33.08, treatment arm: FOLFOX + Cetuximab, adherence: Yes, bowel obstruction: Yes, bowel perforation: Yes, chemotherapy cycles: 12, histology: well differentiated, performance status: fully active, KRAS biomarker: wild-type","The patient is a 61-year-old white male with a BMI of 33.08 who is receiving treatment with FOLFOX + Cetuximab. He has been adherent to his treatment. The patient has experienced both a bowel obstruction and a bowel perforation. He has completed 12 cycles of chemotherapy. His histology shows well-differentiated cells. Despite the bowel issues, the patient's performance status is fully active. His KRAS biomarker is wild-type."
